Clustering O 0 0.0015183809446170926
of O 0 1.2150216207373887e-05
missense O 0 0.00774433882907033
mutations O 0 0.00022911425912752748
in O 0 8.432118647760944e-07
the O 0 2.9751984129688935e-06
ataxia B-Disease 1 0.9995531439781189
- I-Disease 1 0.9665979743003845
telangiectasia I-Disease 1 0.9995399713516235
gene O 0 1.4810234461037908e-05
in O 0 1.4816922089266882e-07
a O 0 3.3719274483701156e-07
sporadic B-Disease 0 8.850356243783608e-05
T I-Disease 1 0.7562330961227417
- I-Disease 1 0.5401539206504822
cell I-Disease 0 0.027273237705230713
leukaemia I-Disease 1 0.9686170220375061
. O 0 2.5709883630042896e-05

Ataxia B-Disease 1 0.9993361830711365
- I-Disease 1 0.9957915544509888
telangiectasia I-Disease 1 0.9993010759353638
( O 0 0.00010413434938527644
A B-Disease 0 7.256022217916325e-05
- I-Disease 1 0.7980445027351379
T I-Disease 1 0.9976730942726135
) O 0 1.6076041902124416e-06
is O 0 7.950585967364532e-08
a O 0 1.8903602949649212e-07
recessive B-Disease 0 0.00020468853472266346
multi I-Disease 0 0.0026137051172554493
- I-Disease 1 0.9937741756439209
system I-Disease 0 0.10132531821727753
disorder I-Disease 1 0.9986341595649719
caused O 0 0.0004337021673563868
by O 0 3.8433552163041895e-07
mutations O 0 2.4314508664247114e-06
in O 0 2.5523178237563116e-08
the O 0 3.892465727517447e-08
ATM O 0 1.1191574230906554e-05
gene O 0 7.448866767845175e-07
at O 0 2.612040077565325e-07
11q22 O 0 4.993918628315441e-05
- O 0 0.0002453461056575179
q23 O 0 0.00034518472966738045
( O 0 7.975074254318315e-07
ref O 0 0.001488859299570322
. O 0 1.3835514778293145e-07
3 O 0 8.961615094449371e-07
) O 0 9.882155609375332e-07
. O 0 2.5275176085415296e-06

The O 0 0.00010832004045369104
risk O 0 0.001657260349020362
of O 0 3.222286613890901e-05
cancer B-Disease 1 0.8991767764091492
, O 0 3.7021582102170214e-06
especially O 0 1.9221943148295395e-05
lymphoid B-Disease 0 0.16770590841770172
neoplasias I-Disease 0 0.09781104326248169
, O 0 5.046423439125647e-07
is O 0 7.671494728356265e-08
substantially O 0 8.319341304741101e-07
elevated O 0 6.189978194015566e-06
in O 0 1.1599518501270722e-07
A B-Disease 0 2.0887146092718467e-05
- I-Disease 1 0.9985502362251282
T I-Disease 1 0.9999833106994629
patients O 0 0.013796779327094555
and O 0 8.013972774278955e-07
has O 0 5.735648755944567e-07
long O 0 1.6139227227540687e-05
been O 0 5.214326392888324e-07
associated O 0 6.824847787356703e-06
with O 0 1.214430812979117e-05
chromosomal O 1 0.995870053768158
instability O 0 0.48336151242256165
. O 0 3.5057539207628e-05

By O 0 6.12725707469508e-05
analysing O 0 0.0036744619719684124
tumour B-Disease 1 0.9986477494239807
DNA O 0 0.0005623190081678331
from O 0 2.7748203592636855e-06
patients O 0 5.586872066487558e-05
with O 0 4.663045558572776e-07
sporadic B-Disease 0 4.405034633236937e-05
T I-Disease 0 0.21564345061779022
- I-Disease 0 0.06862984597682953
cell I-Disease 0 0.0029761865735054016
prolymphocytic I-Disease 1 0.6784467101097107
leukaemia I-Disease 1 0.9356497526168823
( O 0 5.415888608695241e-06
T B-Disease 0 0.014324569143354893
- I-Disease 0 0.005291744600981474
PLL I-Disease 0 0.047685202211141586
) O 0 2.803617178415152e-07
, O 0 4.484851601205264e-08
a O 0 7.159967907455211e-08
rare O 0 4.149545475229388e-06
clonal B-Disease 0 0.0027178374584764242
malignancy I-Disease 0 0.04861568659543991
with O 0 1.4361722833200474e-07
similarities O 0 1.5280133993655909e-06
to O 0 5.328230301415715e-08
a O 0 6.920762984918838e-08
mature B-Disease 0 8.14686791272834e-06
T I-Disease 0 0.038669854402542114
- I-Disease 0 0.021412692964076996
cell I-Disease 0 0.0014174289535731077
leukaemia I-Disease 0 0.3150288760662079
seen O 0 3.7216665305095376e-07
in O 0 4.023570454592118e-08
A B-Disease 0 1.6937696045715711e-06
- I-Disease 0 0.06309361755847931
T I-Disease 1 0.9857914447784424
, O 0 2.3529638326635904e-07
we O 0 2.7527899959522983e-08
demonstrate O 0 3.884692745259599e-08
a O 0 6.447684608446025e-09
high O 0 3.697881112429968e-08
frequency O 0 3.258678660245096e-08
of O 0 3.970343342984961e-08
ATM O 0 2.68917119683465e-05
mutations O 0 6.983681942074327e-06
in O 0 9.221466257258726e-07
T B-Disease 0 0.022976785898208618
- I-Disease 0 0.03588800132274628
PLL I-Disease 0 0.09623119235038757
. O 0 1.263362901227083e-05

In O 0 7.815089702489786e-06
marked O 0 8.929469913709909e-06
contrast O 0 3.2543205179536017e-06
to O 0 1.7590630818631325e-07
the O 0 1.051956388664621e-07
ATM O 0 4.4714321120409295e-05
mutation O 0 5.299064468999859e-06
pattern O 0 1.179321770905517e-06
in O 0 6.605488067634724e-08
A B-Disease 0 2.835258555933251e-06
- I-Disease 0 0.1328367292881012
T I-Disease 1 0.9887579679489136
, O 0 2.0035039938193222e-07
the O 0 2.7797831592124567e-08
most O 0 1.5200843250795515e-08
frequent O 0 2.9255809863570903e-07
nucleotide O 0 1.159902467406937e-06
changes O 0 1.3575031232448964e-07
in O 0 9.891304841858073e-08
this O 0 4.2891181806226086e-07
leukaemia B-Disease 0 0.3293928802013397
were O 0 1.3208996278990526e-06
missense O 0 0.0008101364364847541
mutations O 0 0.00012430534115992486
. O 0 6.983861112530576e-06

These O 0 3.7908666854491457e-06
clustered O 0 1.7725275029079057e-05
in O 0 2.8827767550865246e-07
the O 0 1.2475646826715092e-07
region O 0 4.855000952375121e-07
corresponding O 0 1.8110699784301687e-07
to O 0 3.150561767029103e-08
the O 0 3.451415864219598e-08
kinase O 0 8.157317097357009e-06
domain O 0 2.2425986401231057e-07
, O 0 2.8482396885465278e-08
which O 0 7.829261683411914e-09
is O 0 3.868630749082058e-09
highly O 0 1.0441239872704955e-08
conserved O 0 4.002933451374702e-08
in O 0 2.057909931352242e-08
ATM O 0 5.973488896415802e-06
- O 0 4.5103439333615825e-05
related O 0 9.680219363872311e-07
proteins O 0 1.6345373410331376e-07
in O 0 9.489469476875456e-08
mouse O 0 4.12932968174573e-06
, O 0 1.785975456414235e-07
yeast O 0 5.437784693640424e-06
and O 0 4.6887484472790675e-07
Drosophila O 0 9.82109850156121e-06
. O 0 4.5162751121097244e-06

The O 0 5.4230308705882635e-06
resulting O 0 5.103619059809716e-06
amino O 0 1.0502848226678907e-06
- O 0 4.159546733717434e-05
acid O 0 2.9951177111797733e-06
substitutions O 0 3.6598294173018076e-07
are O 0 3.2165885954782425e-08
predicted O 0 8.224739644902002e-07
to O 0 3.015446736753802e-08
interfere O 0 2.1599093713575712e-07
with O 0 1.1315859183014254e-07
ATP O 0 6.853616650914773e-05
binding O 0 6.852368983345514e-07
or O 0 3.483020520889113e-07
substrate O 0 2.1488329366547987e-05
recognition O 0 5.032960416428978e-06
. O 0 7.754317266517319e-06

Two O 0 3.866076895064907e-06
of O 0 1.018427269627864e-06
seventeen O 0 6.614316134800902e-06
mutated O 0 0.00011598136188695207
T B-Disease 0 0.06083150953054428
- I-Disease 0 0.009949637576937675
PLL I-Disease 0 0.055089667439460754
samples O 0 1.932997065523523e-06
had O 0 1.9332428280449676e-07
a O 0 6.857037249119458e-08
previously O 0 5.215833311922324e-07
reported O 0 1.838295816014579e-06
A B-Disease 0 4.541294856608147e-06
- I-Disease 0 0.1078406572341919
T I-Disease 1 0.9811143279075623
allele O 0 0.00010595283674774691
. O 0 1.7185524484375492e-05

In O 0 1.551270906929858e-05
contrast O 0 4.4711381633533165e-05
, O 0 2.3970098936842987e-06
no O 0 1.011368794934242e-06
mutations O 0 1.0837416084541474e-05
were O 0 7.180426564445952e-08
detected O 0 8.868232157510647e-07
in O 0 2.892977057911139e-08
the O 0 7.43239070288837e-08
p53 O 0 2.514429297661991e-06
gene O 0 6.947750534891384e-07
, O 0 7.82451721192956e-08
suggesting O 0 6.622019554924918e-07
that O 0 9.243763088306878e-08
this O 0 5.902302859794872e-07
tumour B-Disease 1 0.9773271679878235
suppressor O 0 7.575110794277862e-05
is O 0 8.06816871090632e-08
not O 0 3.719619101616445e-08
frequently O 0 1.747937545815148e-07
altered O 0 8.498665806655481e-07
in O 0 3.4920341818178713e-07
this O 0 1.93559640138119e-06
leukaemia B-Disease 1 0.8404739499092102
. O 0 2.6444855393492617e-05

Occasional O 0 0.000902409665286541
missense O 0 0.012775788083672523
mutations O 0 0.0003801468410529196
in O 0 1.0708437230277923e-06
ATM O 0 5.93390577705577e-05
were O 0 1.6565829241699248e-07
also O 0 1.651776244671055e-07
found O 0 1.7239592864370934e-07
in O 0 1.1365441423549782e-06
tumour B-Disease 1 0.9779344201087952
DNA O 0 3.221432416466996e-05
from O 0 2.96153501722074e-07
patients O 0 9.156450687441975e-06
with O 0 8.324803246750889e-08
B B-Disease 0 2.002757537411526e-05
- I-Disease 0 0.00016877983580343425
cell I-Disease 0 3.779095277423039e-05
non I-Disease 0 8.897442057786975e-06
- I-Disease 1 0.6076534390449524
Hodgkins I-Disease 1 0.9999127388000488
lymphomas I-Disease 1 0.9470348358154297
( O 0 6.00103419401421e-07
B B-Disease 0 4.32270644523669e-06
- I-Disease 0 1.928521305671893e-05
NHL I-Disease 0 1.168581775345956e-06
) O 0 2.025726608678724e-08
and O 0 8.871207768379463e-09
a O 0 2.855299996440408e-08
B B-Disease 0 2.1905077574047027e-06
- I-Disease 0 3.988870594184846e-05
NHL I-Disease 0 9.139045687334146e-06
cell O 0 8.510843144904356e-06
line O 0 5.094822427054169e-06
. O 0 3.993838163296459e-06

The O 0 6.2040317061473615e-06
evidence O 0 2.1917553567618597e-06
of O 0 9.735075678918292e-08
a O 0 8.567056397623674e-08
significant O 0 9.821408752941352e-08
proportion O 0 2.8931435736012645e-07
of O 0 5.433952665612196e-08
loss O 0 5.011977191315964e-05
- O 0 6.22580701019615e-05
of O 0 1.1965124713242403e-07
- O 0 0.0075195785611867905
function O 0 2.4649941678944742e-06
mutations O 0 2.1669479792763013e-06
and O 0 1.7209442759735794e-08
a O 0 1.628198376124601e-08
complete O 0 1.3464597259371658e-07
absence O 0 7.73610295823346e-08
of O 0 4.821573362789877e-09
the O 0 7.766170817546936e-09
normal O 0 3.180393903789991e-08
copy O 0 4.115437235441277e-08
of O 0 8.477019086683413e-09
ATM O 0 1.9266917661298066e-06
in O 0 1.480894784577913e-08
the O 0 1.2246248459746312e-08
majority O 0 8.072309043427595e-08
of O 0 1.5315775669932918e-07
mutated O 0 0.0002899910614360124
tumours B-Disease 1 0.7279382944107056
establishes O 0 1.4101568922342267e-05
somatic O 0 1.3033428331254981e-05
inactivation O 0 0.0001105930277844891
of O 0 2.2518584330555313e-08
this O 0 1.9706163811861188e-08
gene O 0 2.386619257777056e-07
in O 0 2.3472411569969154e-08
the O 0 3.500288769942017e-08
pathogenesis O 0 1.2282303941901773e-05
of O 0 5.7113215490289804e-08
sporadic B-Disease 0 1.5207621800072957e-05
T I-Disease 0 0.038460057228803635
- I-Disease 0 0.006052726414054632
PLL I-Disease 0 0.02682429365813732
and O 0 2.1726145860156976e-07
suggests O 0 6.012106723574107e-07
that O 0 3.961538297403422e-08
ATM O 0 5.9770386542368215e-06
acts O 0 1.9685676022618281e-07
as O 0 1.0939533723330896e-07
a O 0 2.3204895569506334e-06
tumour B-Disease 1 0.9807735085487366
suppressor O 0 0.0006667226552963257
. O 0 9.082311407837551e-06

As O 0 8.119728590827435e-06
constitutional O 0 1.0764786566141993e-05
DNA O 0 5.801320730824955e-05
was O 0 4.634375159184856e-07
not O 0 4.056953173403599e-08
available O 0 2.0871619099693817e-08
, O 0 4.8714557721041274e-08
a O 0 1.5617598592143622e-07
putative O 0 0.0002940933918580413
hereditary O 0 0.01402831170707941
predisposition O 0 0.0018302362877875566
to O 0 9.296627467847429e-07
T B-Disease 0 0.028370317071676254
- I-Disease 0 0.003850454930216074
PLL I-Disease 0 0.009961104020476341
will O 0 1.3440029533740017e-07
require O 0 1.6433888561095955e-07
further O 0 1.3758764794147282e-07
investigation O 0 1.8303659317098209e-06
. O 0 1.3356099088923656e-06
. O 0 3.447604512984981e-06

Myotonic B-Disease 1 0.9995125532150269
dystrophy I-Disease 1 0.9997926354408264
protein O 0 0.0025095478631556034
kinase O 0 0.001476406236179173
is O 0 4.4297325985098723e-07
involved O 0 1.1997758520010393e-07
in O 0 2.6081789172849312e-08
the O 0 1.8330855056092332e-08
modulation O 0 1.5457966640042287e-07
of O 0 2.3441989682737585e-08
the O 0 1.3070724946828705e-07
Ca2 O 0 4.448736581252888e-05
+ O 0 4.9316709919366986e-05
homeostasis O 0 0.00025594199541956186
in O 0 1.206053639180027e-06
skeletal O 0 0.021827248856425285
muscle O 0 0.004810083657503128
cells O 0 9.100107126869261e-05
. O 0 8.85527697391808e-06

Myotonic B-Disease 1 0.9997612833976746
dystrophy I-Disease 1 0.9999552965164185
( O 0 0.13225096464157104
DM B-Disease 1 0.9999047517776489
) O 0 3.0083063393249176e-05
, O 0 4.906129902337852e-07
the O 0 1.8354668895881332e-07
most O 0 3.396183956283494e-07
prevalent O 0 0.0011358227347955108
muscular B-Disease 1 0.9998125433921814
disorder I-Disease 1 0.9985764026641846
in O 0 1.093825812858995e-05
adults O 0 0.00013600080274045467
, O 0 1.5960843029461103e-06
is O 0 7.54362531552033e-07
caused O 0 2.312628203071654e-05
by O 0 1.7767915494459885e-07
( O 0 4.1155712438012415e-07
CTG O 0 0.00016757570847403258
) O 0 1.271386054213508e-07
n O 0 1.9073693238169653e-06
- O 0 1.6937381587922573e-05
repeat O 0 2.152669821953168e-06
expansion O 0 1.2972384411114035e-07
in O 0 6.5915033431451775e-09
a O 0 7.170241733689409e-09
gene O 0 4.304427037027381e-08
encoding O 0 3.8137294211537665e-08
a O 0 3.989259766967734e-08
protein O 0 6.488002100013546e-07
kinase O 0 1.909534512378741e-05
( O 0 6.662173177574005e-07
DM B-Disease 1 0.6678028106689453
protein O 0 2.1722119072364876e-06
kinase O 0 1.7784657757147215e-05
; O 0 5.015266424379661e-07
DMPK O 0 0.00016604179108981043
) O 0 6.605488067634724e-08
and O 0 2.107061369827079e-08
involves O 0 1.2851353403675603e-07
changes O 0 9.182504356886056e-08
in O 0 1.0528817284694014e-07
cytoarchitecture O 0 0.0001234067021869123
and O 0 1.0531545058256597e-06
ion O 0 5.711941048502922e-05
homeostasis O 0 0.002552639227360487
. O 0 1.1148505109304097e-05

To O 0 8.038390660658479e-06
obtain O 0 4.6187828957044985e-06
clues O 0 6.793612556066364e-06
to O 0 1.1137841937625126e-07
the O 0 5.9298248089589833e-08
normal O 0 2.3483748634589574e-07
biological O 0 2.742950471201766e-07
role O 0 7.963046044778821e-08
of O 0 4.138469122949573e-08
DMPK O 0 0.00016166275599971414
in O 0 1.2914247804474144e-07
cellular O 0 3.084943818976171e-05
ion O 0 3.706159259309061e-05
homeostasis O 0 0.0006657365593127906
, O 0 1.2578209407365648e-07
we O 0 2.1192860799601476e-08
have O 0 8.68897664929591e-09
compared O 0 3.4055236852736925e-08
the O 0 2.6818302245601444e-08
resting O 0 2.281793967995327e-06
[ O 0 1.917788040373125e-06
Ca2 O 0 9.0472994997981e-06
+ O 0 5.974480245640734e-06
] O 0 9.371337341690378e-07
i O 0 4.2114411513693994e-08
, O 0 4.234733452790351e-09
the O 0 3.4624914047043376e-09
amplitude O 0 2.9689346092709457e-08
and O 0 7.97470001145939e-09
shape O 0 8.447292287883101e-08
of O 0 1.8666888479401678e-08
depolarization O 0 6.808998023188906e-06
- O 0 4.5905129809398204e-05
induced O 0 0.00015217573672998697
Ca2 O 0 2.5425513740628958e-05
+ O 0 1.570299173181411e-05
transients O 0 1.020578019961249e-05
, O 0 1.3390001996071987e-08
and O 0 3.5078997484561114e-09
the O 0 2.289003431243941e-09
content O 0 4.596172775706009e-09
of O 0 6.017782716583042e-09
ATP O 0 6.029089036019286e-06
- O 0 4.311520115152234e-06
driven O 0 3.1421876656168024e-07
ion O 0 8.845755701258895e-07
pumps O 0 7.195946523097518e-07
in O 0 4.5630606848590105e-08
cultured O 0 5.429970315162791e-06
skeletal O 0 0.001087516313418746
muscle O 0 9.237512858817354e-05
cells O 0 4.095227836842241e-07
of O 0 2.2987350689618324e-08
wild O 0 9.183062843476364e-07
- O 0 3.81432801077608e-05
type O 0 9.135317782238417e-07
and O 0 1.6587787854405178e-07
DMPK O 0 0.00035683606984093785
[ O 0 4.102082129975315e-06
- O 0 4.868290852755308e-05
/ O 0 0.000140562784508802
- O 0 0.000945729436352849
] O 0 0.00015032281226012856
knockout O 0 0.000488823454361409
mice O 0 0.0001924530661199242
. O 0 6.0216934798518196e-06

In O 0 1.4905793250363786e-05
vitro O 0 0.0002060971746686846
- O 0 0.0004137552750762552
differentiated O 0 7.325323531404138e-05
DMPK O 0 0.004256627522408962
[ O 0 1.5043659004732035e-05
- O 0 0.0001410739787388593
/ O 0 0.00014083285350352526
- O 0 0.00030886707827448845
] O 0 1.6041465642047115e-05
myotubes O 0 6.061653039068915e-05
exhibit O 0 6.416060500669118e-07
a O 0 4.096703776212962e-08
higher O 0 1.1230829954911314e-07
resting O 0 2.9029818051640177e-06
[ O 0 2.801975824695546e-06
Ca2 O 0 1.4869858205202036e-05
+ O 0 4.741119028039975e-06
] O 0 7.979890028764203e-07
i O 0 5.683079251639356e-08
than O 0 7.776130850345453e-09
do O 0 4.302678746626043e-08
wild O 0 4.898466841041227e-07
- O 0 0.0001445851376047358
type O 0 5.243040959612699e-06
myotubes O 0 8.636133861728013e-05
because O 0 2.2136719124432602e-08
of O 0 4.665765551692402e-09
an O 0 1.0086697699307479e-08
altered O 0 1.4783499580062198e-07
open O 0 1.3569361101417599e-07
probability O 0 2.989596126212746e-08
of O 0 8.317879718333643e-09
voltage O 0 3.664907808342832e-07
- O 0 1.153693301603198e-05
dependent O 0 1.096789105758944e-06
l O 0 0.000244122464209795
- O 0 6.858259439468384e-05
type O 0 2.4066760033747414e-06
Ca2 O 0 3.724457656062441e-06
+ O 0 1.674052555244998e-06
and O 0 1.445542352485063e-07
Na O 0 0.00010119949001818895
+ O 0 1.2168571629445069e-05
channels O 0 3.879268660966773e-06
. O 0 3.676004325825488e-06

The O 0 2.4373559426749125e-05
mutant O 0 0.00014281863695941865
myotubes O 0 0.000701479846611619
exhibit O 0 5.281809535517823e-06
smaller O 0 6.497946856143244e-07
and O 0 1.451483910841489e-07
slower O 0 2.15250156543334e-06
Ca2 O 0 3.0691073334310204e-05
+ O 0 1.3230316653789487e-05
responses O 0 4.4662851905741263e-07
upon O 0 8.722073374656247e-08
triggering O 0 1.1660380323519348e-06
by O 0 1.0941953831888895e-07
acetylcholine O 0 1.694048296485562e-05
or O 0 1.9107945092855516e-07
high O 0 2.2937786070542643e-06
external O 0 7.23528455637279e-06
K O 0 7.215753430500627e-05
+ O 0 7.669887418160215e-05
. O 0 7.860417099436745e-06

In O 0 1.3465639312926214e-05
addition O 0 5.5490504564659204e-06
, O 0 7.232886218844214e-07
we O 0 1.458801506259988e-07
observed O 0 2.1775224468001397e-07
that O 0 2.5834728134555007e-08
these O 0 4.182917479056414e-08
Ca2 O 0 4.055913086631335e-05
+ O 0 9.003416198538616e-05
transients O 0 0.00011131035716971382
partially O 0 2.641653509272146e-06
result O 0 7.720979056102806e-08
from O 0 1.0464407118604413e-08
an O 0 8.766986248076591e-09
influx O 0 1.2075055622062791e-07
of O 0 1.4095695277660525e-08
extracellular O 0 5.077284868093557e-07
Ca2 O 0 2.82908672488702e-06
+ O 0 5.498440600604226e-07
through O 0 2.679038857422711e-08
the O 0 3.794993475025876e-08
l O 0 1.99087880901061e-05
- O 0 2.5861460017040372e-05
type O 0 5.3059511628816836e-06
Ca2 O 0 2.8068863684893586e-05
+ O 0 1.2853974112658761e-05
channel O 0 5.751369826612063e-06
. O 0 3.2917298540269258e-06

Neither O 0 3.453313547652215e-05
the O 0 1.155757331616769e-06
content O 0 3.1201591355056735e-07
nor O 0 1.8621960862219566e-07
the O 0 1.7341738711706967e-08
activity O 0 4.59634144078791e-08
of O 0 2.9211220109459646e-08
Na O 0 0.00021292448218446225
+ O 0 8.978631740319543e-06
/ O 0 9.912900168274064e-06
K O 0 2.166819967897027e-06
+ O 0 1.8691740706344717e-06
ATPase O 0 4.068669568368932e-06
and O 0 1.350461786842061e-07
sarcoplasmic O 0 3.7174366298131645e-05
reticulum O 0 5.1893443014705554e-05
Ca2 O 0 5.451451215776615e-06
+ O 0 5.153905021870742e-06
- O 0 3.754549834411591e-05
ATPase O 0 4.341117892181501e-05
are O 0 6.164935939523275e-08
affected O 0 8.7036409013308e-07
by O 0 4.7043894824128074e-07
DMPK O 0 0.0019328383496031165
absence O 0 2.421169301669579e-05
. O 0 7.909210580692161e-06

In O 0 6.260387181100668e-06
conclusion O 0 8.113049261737615e-06
, O 0 6.124701030785218e-07
our O 0 2.5014989546434663e-07
data O 0 6.313667881840956e-07
suggest O 0 1.013892983792175e-06
that O 0 8.744410706640338e-08
DMPK O 0 0.00017976693925447762
is O 0 2.4918053398437223e-08
involved O 0 3.311984642095922e-08
in O 0 1.613126165977974e-08
modulating O 0 2.8659724193857983e-06
the O 0 1.6699061688996153e-08
initial O 0 5.938155211993035e-08
events O 0 2.0816793622202567e-08
of O 0 1.764916746083145e-08
excitation O 0 8.908555173547938e-07
- O 0 9.937990398611873e-05
contraction O 0 0.00010615894279908389
coupling O 0 1.3759851754002739e-05
in O 0 1.1095631862190203e-06
skeletal O 0 0.015595143660902977
muscle O 0 0.001160557847470045
. O 0 2.1267628653731663e-06
. O 0 4.511449333222117e-06

Constitutional O 0 0.0006513625266961753
RB1 O 1 0.6705794334411621
- O 0 0.21204303205013275
gene O 0 0.0019681958947330713
mutations O 0 0.0008448661537840962
in O 0 5.81706717639463e-06
patients O 0 0.0005274905124679208
with O 0 6.429072982427897e-06
isolated O 0 0.000418986746808514
unilateral B-Disease 0 0.0002897655649576336
retinoblastoma I-Disease 0 0.18025754392147064
. O 0 4.1957009671023116e-05

In O 0 2.929242509708274e-05
most O 0 6.780383046134375e-06
patients O 0 0.0003621074720285833
with O 0 1.8015282421401935e-06
isolated O 0 9.25618878682144e-05
unilateral B-Disease 0 0.0001134714184445329
retinoblastoma I-Disease 1 0.7834329009056091
, O 0 5.2383482397999614e-05
tumor B-Disease 0 0.024605166167020798
development O 0 4.919055527352612e-07
is O 0 4.081518056864297e-08
initiated O 0 4.6902826511541207e-07
by O 0 4.1417699492285465e-08
somatic O 0 4.539035217021592e-06
inactivation O 0 4.0816852560965344e-05
of O 0 2.809515642354654e-08
both O 0 5.499673960684959e-08
alleles O 0 2.412093351722433e-07
of O 0 6.250349571246261e-08
the O 0 9.9955354926351e-07
RB1 O 0 0.006248710211366415
gene O 0 2.0175781173747964e-05
. O 0 4.273743343219394e-06

However O 0 2.9861830626032315e-05
, O 0 1.3013639090786455e-06
some O 0 1.7309972122347972e-07
of O 0 2.2862782600441278e-07
these O 0 5.488837473421881e-07
patients O 0 0.00018973261467181146
can O 0 1.3439841950457776e-06
transmit O 0 0.00022868363885208964
retinoblastoma B-Disease 0 0.17659607529640198
predisposition O 0 0.020264333114027977
to O 0 6.926890137037844e-07
their O 0 1.1029451343347318e-06
offspring O 0 3.722992551047355e-05
. O 0 7.0770029196864925e-06

To O 0 9.757429324963596e-06
determine O 0 2.023137767537264e-06
the O 0 1.507371081288511e-07
frequency O 0 1.9763872671774152e-07
and O 0 4.1890736213190394e-08
nature O 0 1.0602879285670497e-07
of O 0 2.433599988194146e-08
constitutional O 0 1.0987520226990455e-06
RB1 O 0 0.048381756991147995
- O 0 0.00973978266119957
gene O 0 2.9688510039704852e-05
mutations O 0 9.215222235070542e-06
in O 0 2.151560352103843e-07
patients O 0 1.2819451512768865e-05
with O 0 2.198702588884771e-07
isolated O 0 1.2598736248037312e-05
unilateral B-Disease 0 4.931192052026745e-06
retinoblastoma I-Disease 0 0.0007279435521923006
, O 0 9.322625516006156e-08
we O 0 2.7753648268458164e-08
analyzed O 0 2.1448181541927624e-07
DNA O 0 5.549990760300716e-07
from O 0 6.264982488346504e-08
peripheral O 0 0.00020696030696853995
blood O 0 3.083908450207673e-05
and O 0 4.232398396197823e-07
from O 0 3.9617307265871204e-06
tumor B-Disease 0 0.28928452730178833
tissue O 0 0.0020915300119668245
. O 0 1.15493057819549e-05

The O 0 7.2442048804077785e-06
analysis O 0 8.642641660117079e-06
of O 0 3.55569613930129e-06
tumors B-Disease 1 0.9799813628196716
from O 0 4.72729453804277e-07
54 O 0 6.223260697879596e-06
( O 0 4.321146604979731e-07
71 O 0 1.3083287058179849e-06
% O 0 6.143291386706551e-08
) O 0 3.385840940950402e-08
of O 0 2.8575827926147213e-08
76 O 0 1.0656017366272863e-05
informative O 0 1.8164777429774404e-05
patients O 0 0.00023579700791742653
showed O 0 5.679791229340481e-06
loss O 0 4.721343066194095e-05
of O 0 2.1608734357414505e-07
constitutional O 0 7.839267709641717e-06
heterozygosity O 1 0.5353829860687256
( O 0 6.475947884609923e-05
LOH O 1 0.9995991587638855
) O 0 3.2808015930640977e-06
at O 0 3.5569000829127617e-06
intragenic O 0 0.001355418935418129
loci O 0 6.182651122799143e-05
. O 0 7.370518687821459e-06

Three O 0 1.2722482097160537e-05
of O 0 4.953366897098022e-06
13 O 0 7.464172813342884e-05
uninformative O 0 0.49361512064933777
patients O 0 0.0049911849200725555
had O 0 5.974001396680251e-06
constitutional O 0 1.1856814126076642e-05
deletions O 0 0.00041363853961229324
. O 0 2.3674829208175652e-05

For O 0 7.69951475376729e-06
39 O 0 1.0855808795895427e-05
randomly O 0 3.004194923050818e-06
selected O 0 3.596988790377509e-06
tumors B-Disease 1 0.7182696461677551
, O 0 9.135126219916856e-07
SSCP O 0 0.0012152626877650619
, O 0 2.9616026608891843e-07
hetero O 0 0.0001727801572997123
- O 0 5.645818237098865e-05
duplex O 0 0.00010774037946248427
analysis O 0 1.7820114805999765e-07
, O 0 2.7787971035309056e-08
sequencing O 0 1.7704806509755144e-07
, O 0 2.0144989676396108e-08
and O 0 2.1603929312163928e-08
Southern O 0 2.478900000824069e-07
blot O 0 5.0042832299368456e-05
analysis O 0 1.1560457124915047e-07
were O 0 2.143539745702583e-08
used O 0 8.26657569064082e-08
to O 0 3.0009766760485945e-07
identify O 0 9.768900781637058e-06
mutations O 0 3.862406811094843e-05
. O 0 4.999907105229795e-06

Mutations O 0 0.003912331070750952
were O 0 3.0465573672699975e-06
detected O 0 1.0479373486305121e-05
in O 0 2.1495280577710218e-07
21 O 0 1.2883276667707833e-06
( O 0 4.257550472175353e-07
91 O 0 3.1454455893253908e-06
% O 0 1.3210377858285938e-07
) O 0 1.3446607738387684e-07
of O 0 2.956410583010438e-07
23 O 0 0.00021717573690693825
tumors B-Disease 1 0.9983046054840088
with O 0 9.405795572092757e-05
LOH O 1 0.9998078942298889
. O 0 5.237968798610382e-05

In O 0 1.597833397681825e-05
6 O 0 4.108682333026081e-05
( O 0 1.3304663752933266e-06
38 O 0 8.640258215564245e-07
% O 0 8.6245201202928e-08
) O 0 6.691310971973508e-08
of O 0 1.1019236723086578e-07
16 O 0 5.463515844894573e-05
tumors B-Disease 1 0.9973453879356384
without O 0 4.571773843053961e-06
LOH O 1 0.9998918771743774
, O 0 8.637094879304641e-07
one O 0 8.728980560590571e-08
mutation O 0 2.612306843730039e-06
was O 0 9.101180609150106e-08
detected O 0 7.191240456450032e-07
, O 0 1.3661910713835823e-08
and O 0 1.0317824816752363e-08
in O 0 1.857844367236794e-08
9 O 0 4.0575810089649167e-07
( O 0 1.0630336788608474e-07
56 O 0 3.184771060205094e-07
% O 0 4.485236715368046e-08
) O 0 3.9421067299372226e-08
of O 0 4.0437505788304406e-08
the O 0 2.8728081815643236e-06
tumors B-Disease 1 0.9949079155921936
without O 0 5.093690560897812e-06
LOH O 1 0.9998931884765625
, O 0 9.042088890964806e-07
both O 0 2.656115611898713e-07
mutations O 0 1.0669064067769796e-05
were O 0 1.794275590327743e-07
found O 0 1.476387410548341e-06
. O 0 4.723887286672834e-06

Thus O 0 2.144202335330192e-05
, O 0 9.269757583751925e-07
a O 0 1.2853647035626636e-07
total O 0 7.960403536344529e-08
of O 0 6.050932910284246e-08
45 O 0 8.453761211058008e-07
mutations O 0 1.857773713709321e-05
were O 0 1.6662576740600343e-07
identified O 0 2.799806907205493e-06
in O 0 3.1540605505142594e-06
tumors B-Disease 1 0.9813653826713562
of O 0 1.7501788533991203e-06
36 O 0 8.487244485877454e-05
patients O 0 0.0016204208368435502
. O 0 2.037979538727086e-05

Thirty O 0 2.994818532897625e-05
- O 0 6.833275256212801e-05
nine O 0 8.821232313493965e-07
of O 0 8.87933779836203e-08
the O 0 1.262772713062077e-07
mutations O 0 5.257400971458992e-06
- O 0 3.5410947020864114e-05
including O 0 1.539206522238601e-07
34 O 0 3.956717193887016e-07
small O 0 2.307087925146334e-07
mutations O 0 1.8224599216409842e-06
, O 0 3.8277065073089034e-08
2 O 0 2.446352027618559e-07
large O 0 4.774988155986648e-07
structural O 0 0.00011780142085626721
alterations O 0 1.0248684702673927e-05
, O 0 9.945372170250266e-08
and O 0 1.5426039112753642e-07
hypermethylation O 0 0.002191338688135147
in O 0 5.223394055065e-07
3 O 0 8.49449061206542e-05
tumors O 1 0.9955620765686035
- O 0 0.000924505467992276
were O 0 6.542293817801692e-08
not O 0 3.07216616590722e-08
detected O 0 3.1986084536583803e-07
in O 0 1.28779236163723e-08
the O 0 5.206748099340075e-08
corresponding O 0 1.192034687846899e-06
peripheral O 0 0.0008299441542476416
blood O 0 0.0002144360332749784
DNA O 0 6.967395165702328e-05
. O 0 9.526394023851026e-06

In O 0 1.0868715435208287e-05
6 O 0 1.6698189938324504e-05
( O 0 1.1351921784807928e-06
17 O 0 5.756795644629165e-07
% O 0 6.237332428327136e-08
) O 0 2.639477081345376e-08
of O 0 1.1577168557153072e-08
the O 0 8.161452313970585e-08
36 O 0 4.8969245654006954e-06
patients O 0 6.621524516958743e-05
, O 0 1.2520342806965346e-07
a O 0 1.3501114892733312e-07
mutation O 0 6.737723197147716e-06
was O 0 1.0366552061213952e-07
detected O 0 2.2227393969842524e-07
in O 0 1.0949340989441225e-08
constitutional O 0 1.1612911521297065e-07
DNA O 0 3.947369350498775e-06
, O 0 3.359805944569416e-08
and O 0 2.2941579302937498e-08
1 O 0 1.1700934265945762e-07
of O 0 5.3080444928355064e-08
these O 0 1.296109530812828e-07
mutations O 0 7.597370768053224e-06
is O 0 4.124473917954674e-08
known O 0 1.9231620740356448e-07
to O 0 4.4061167159270553e-08
be O 0 2.0592054283952166e-08
associated O 0 2.442272659664013e-07
with O 0 3.2212213341153983e-07
reduced O 0 1.0339679647586308e-05
expressivity O 0 0.054838553071022034
. O 0 1.5144044482440222e-05

The O 0 9.621559001971036e-06
presence O 0 3.5340667636774015e-06
of O 0 2.6684958243095025e-07
a O 0 4.2646496467568795e-07
constitutional O 0 6.153163667477202e-06
mutation O 0 4.6256769564934075e-05
was O 0 2.8589627731889777e-07
not O 0 4.76956714123844e-08
associated O 0 1.9046341037665115e-07
with O 0 4.664877550908386e-08
an O 0 8.524399675025052e-08
early O 0 1.3108691518937121e-06
age O 0 5.741248060076032e-06
at O 0 9.943597433448303e-06
treatment O 0 0.00018765547429211438
. O 0 1.159780458692694e-05

In O 0 2.0542589481920004e-05
1 O 0 2.5085179004236124e-05
patient O 0 0.00027316712657921016
, O 0 1.2573293588502565e-06
somatic O 0 0.00012725569831673056
mosaicism O 0 0.10209041833877563
was O 0 5.529180953089963e-07
demonstrated O 0 3.033257485185459e-07
by O 0 3.28017399908731e-08
molecular O 0 8.615754154561728e-07
analysis O 0 5.9425399712154103e-08
of O 0 1.770135504841619e-08
DNA O 0 5.820896262775932e-07
and O 0 8.505916326839724e-08
RNA O 0 1.549600369799009e-06
from O 0 5.237975528871175e-07
peripheral O 0 0.00045912337373010814
blood O 0 0.00014670786913484335
. O 0 7.059254585328745e-06

In O 0 5.6112516176654026e-05
2 O 0 0.0002888690505642444
patients O 0 0.000488357269205153
without O 0 4.487127966967819e-07
a O 0 4.5732770104223164e-07
detectable O 0 3.178863335051574e-05
mutation O 0 5.771963969891658e-06
in O 0 4.5724704023086815e-07
peripheral O 0 0.00356587884016335
blood O 0 0.00016520966892130673
, O 0 6.501009011117276e-07
mosaicism O 0 0.003178016748279333
was O 0 3.5562382549869653e-07
suggested O 0 3.8581512740165635e-07
because O 0 4.317434942890941e-08
1 O 0 8.038048093794714e-08
of O 0 6.598965285320446e-08
the O 0 1.9959586552431574e-06
patients O 0 0.0068192374892532825
showed O 0 0.0018027442274615169
multifocal O 1 0.9998762607574463
tumors B-Disease 1 0.9995243549346924
and O 0 1.5937540354116209e-07
the O 0 3.604586851224667e-08
other O 0 3.3564880652647844e-08
later O 0 2.4943713583525096e-07
developed O 0 4.800713213626295e-06
bilateral B-Disease 0 4.459032425074838e-05
retinoblastoma I-Disease 0 0.1320418119430542
. O 0 2.606814268801827e-05

In O 0 6.240763923415216e-06
conclusion O 0 5.812680683447979e-06
, O 0 4.7235539568646345e-07
our O 0 2.2686420209083735e-07
results O 0 5.083903147351521e-07
emphasize O 0 1.3642443263961468e-06
that O 0 3.2280510708915244e-08
the O 0 3.4153980976725506e-08
manifestation O 0 3.1923045753501356e-06
and O 0 1.0302018438324012e-07
transmissibility O 0 5.197069913265295e-05
of O 0 7.673675384012313e-08
retinoblastoma B-Disease 0 0.0003681052185129374
depend O 0 2.452605656344531e-07
on O 0 2.624742201362551e-08
the O 0 1.7096896343105072e-08
nature O 0 1.180103126330323e-07
of O 0 1.0304746389522279e-08
the O 0 1.9275352869385642e-08
first O 0 5.8510902789521424e-08
mutation O 0 5.296672043186845e-07
, O 0 1.1954695011695549e-08
its O 0 7.691930647979461e-09
time O 0 1.2397293858157354e-08
in O 0 1.401008375978563e-08
development O 0 1.0014888829346091e-07
, O 0 3.1115948928572834e-08
and O 0 1.0987038834286977e-08
the O 0 6.1255627237244425e-09
number O 0 7.452573669297635e-09
and O 0 1.9029869235964725e-08
types O 0 8.782119209627126e-08
of O 0 9.131435518838771e-08
cells O 0 1.4583297343051527e-05
that O 0 9.212941876057812e-08
are O 0 1.4055549968361447e-07
affected O 0 5.11267535330262e-06
. O 0 1.2142013474658597e-06
. O 0 6.24118683845154e-06

Hereditary B-Disease 1 0.9989997744560242
deficiency I-Disease 1 0.998485267162323
of I-Disease 0 2.137091314580175e-06
the I-Disease 0 6.415846769414202e-07
fifth I-Disease 0 2.6868256099987775e-06
component I-Disease 0 7.897090199548984e-07
of I-Disease 0 1.3140066812411533e-07
complement I-Disease 0 1.5935366945996066e-06
in O 0 7.506473025387095e-07
man O 0 2.2527605324285105e-05
. O 0 1.0324692084395792e-05

I O 0 0.0042076329700648785
. O 0 0.0005207160720601678

Clinical O 0 0.039340175688266754
, O 0 6.0968552133999765e-05
immunochemical O 0 0.0225294791162014
, O 0 7.3483192863932345e-06
and O 0 4.0645627450430766e-06
family O 0 3.850557186524384e-05
studies O 0 2.1326781279640272e-05
. O 0 1.235006311617326e-05

The O 0 1.2925566807098221e-05
first O 0 4.349403297965182e-06
recognized O 0 3.4782581224135356e-06
human O 0 4.703125341620762e-06
kindred O 0 0.003211001865565777
with O 0 9.94819201878272e-05
hereditary B-Disease 1 0.9969426989555359
deficiency I-Disease 1 0.9909955859184265
of I-Disease 0 1.1956068135532405e-07
the I-Disease 0 9.298953074221572e-08
fifth I-Disease 0 8.932715900300536e-07
component I-Disease 0 2.5375695145157806e-07
of I-Disease 0 5.872265163020529e-08
complement I-Disease 0 3.926306817447767e-06
( O 0 1.3096044995108969e-06
C5 O 0 0.00023777033493388444
) O 0 7.701107165303256e-07
is O 0 4.3133320559718413e-07
described O 0 7.3837663876474835e-06
. O 0 5.472114935400896e-06

The O 0 1.2127547961426899e-05
proband O 0 0.0007764247129671276
, O 0 5.899421466892818e-07
a O 0 1.4860876262901002e-07
20 O 0 2.1458882315528172e-07
- O 0 4.555881241685711e-05
year O 0 1.1252780041104415e-06
- O 0 0.0009784665890038013
old O 0 0.0001874635781859979
black O 0 0.000588734692428261
female O 0 0.0008176359697245061
with O 0 0.15927569568157196
systemic B-Disease 1 0.9999973773956299
lupus I-Disease 1 0.9999979734420776
erythematosus I-Disease 1 0.9999887943267822
since O 0 7.15960341040045e-05
age O 0 7.436555279127788e-06
11 O 0 3.184939714628854e-06
, O 0 1.2807031453121454e-06
lacked O 0 9.193557343678549e-05
serum O 0 0.016359791159629822
hemolytic O 1 0.9697242379188538
complement O 0 1.7595491499378113e-06
activity O 0 6.090649549150839e-07
, O 0 2.0502824327195412e-07
even O 0 5.464086711981508e-07
during O 0 3.960929916502209e-06
remission O 0 0.00046223265235312283
. O 0 8.451515896013007e-06

C5 O 0 0.02034829743206501
was O 0 2.8331875000731088e-05
undetectable O 0 0.00031513121211901307
in O 0 1.5605390899509075e-06
her O 0 5.667524874297669e-06
serum O 0 5.806623448734172e-05
by O 0 2.2154276280161866e-07
both O 0 3.812002375980228e-07
immunodiffusion O 0 0.009865936823189259
and O 0 2.6288957087672316e-05
hemolytic O 1 0.9982526898384094
assays O 0 0.00023116631200537086
. O 0 1.115594022849109e-05

Other O 0 3.16057321469998e-06
complement O 0 3.6586711757990997e-06
components O 0 1.4128230532151065e-06
were O 0 2.125628100202448e-07
normal O 0 7.580563305964461e-07
during O 0 2.0994627902837237e-06
remission O 0 0.0005434606573544443
of O 0 1.668363984208554e-05
lupus O 1 0.9999099969863892
, O 0 1.4164900221658172e-06
but O 0 4.040351200274017e-07
C1 O 0 0.0008062337874434888
, O 0 3.216601385247486e-07
C4 O 0 0.00013130797015037388
, O 0 5.226135044722469e-07
C2 O 0 0.00022368789359461516
, O 0 8.953314534210222e-08
and O 0 1.4525294034228864e-07
C3 O 0 0.0005746328388340771
levels O 0 2.3182553832157282e-06
fell O 0 3.8649715861538425e-05
during O 0 9.058150681084953e-06
exacerbations O 0 0.3751651644706726
. O 0 1.2717084246105514e-05

A O 0 1.665647141635418e-05
younger O 0 1.792922012100462e-05
half O 0 2.0356051209091675e-06
- O 0 0.00417565181851387
sister O 0 0.0006283323164097965
, O 0 2.352670207983465e-06
who O 0 2.678513283171924e-06
had O 0 3.5104965263599297e-06
no O 0 9.21553964872146e-06
underlying O 0 0.2338770031929016
disease O 1 0.7594322562217712
, O 0 6.261100224946858e-07
was O 0 2.0383721732741833e-07
also O 0 8.323247158159575e-08
found O 0 1.926366905991017e-07
to O 0 3.7925880747025076e-07
lack O 0 1.2650146345549729e-05
immunochemically O 0 0.02182893641293049
detectable O 0 0.00018070473743136972
C5 O 0 0.000966358813457191
. O 0 1.5963558325893246e-05

By O 0 0.0005780214560218155
hemolytic O 1 0.9992903470993042
assay O 0 0.0009401709539815784
, O 0 1.8566348671811284e-06
she O 0 7.686564913456095e-07
exhibited O 0 7.349303814407904e-07
1 O 0 1.7585264799890865e-07
- O 0 1.2170904483355116e-05
2 O 0 2.1403290872967773e-07
% O 0 2.0742163542308845e-08
of O 0 8.504695614419688e-09
the O 0 2.4038030232986785e-08
normal O 0 3.6028072258886823e-07
serum O 0 1.4132357136986684e-05
C5 O 0 1.475470435252646e-05
level O 0 6.660369678002098e-08
and O 0 3.0282304663842297e-08
normal O 0 1.20027479511009e-07
concentrations O 0 3.5649517826641386e-07
of O 0 1.7291073461933593e-08
other O 0 4.668099862215058e-08
complement O 0 7.882018735472229e-07
components O 0 2.0175807549094316e-06
. O 0 4.450550477486104e-06

C5 O 0 0.016729392111301422
levels O 0 1.7722062693792395e-05
of O 0 4.5725880681857234e-07
other O 0 1.0412010453819676e-07
family O 0 5.122291781844979e-07
members O 0 3.940911241784306e-08
were O 0 1.514689529358293e-08
either O 0 1.617559597377749e-08
normal O 0 5.0468226930888704e-08
or O 0 1.284564010717304e-08
approximately O 0 1.7950400277300105e-08
half O 0 6.539561780982694e-08
- O 0 7.989471487235278e-05
normal O 0 8.024832709452312e-07
, O 0 1.333049226559524e-07
consistent O 0 5.544853252104076e-07
with O 0 1.1958535424128058e-06
autosomal O 0 0.010776644572615623
codominant O 0 0.014697314240038395
inheritance O 0 1.5709658327978104e-05
of O 0 2.0458271876577783e-07
the O 0 1.2077698556822725e-06
gene O 0 6.296439096331596e-05
determining O 0 0.0003307673614472151
C5 B-Disease 1 0.9986854195594788
deficiency I-Disease 1 0.9997391104698181
. O 0 5.5674703617114574e-05

Normal O 0 0.005784295964986086
hemolytic O 1 0.9988266825675964
titers O 0 0.01132403127849102
were O 0 2.2046060621505603e-06
restored O 0 2.4159319309546845e-06
to O 0 1.5690392274336773e-07
both O 0 1.9233564785281487e-07
homozygous O 0 2.6198209525318816e-05
C5 B-Disease 1 0.6604601740837097
- I-Disease 1 0.9554327726364136
deficient I-Disease 1 0.9985791444778442
( O 0 3.4441673051333055e-05
C5D B-Disease 1 0.9951621890068054
) O 0 2.314356606802903e-06
sera O 0 4.5034583308734e-05
by O 0 3.022552519382771e-08
addition O 0 4.608860137977899e-08
of O 0 7.635802035110828e-08
highly O 0 1.3183449709686101e-06
purified O 0 2.712491186684929e-05
human O 0 6.542177288793027e-06
C5 O 0 0.0005563380545936525
. O 0 1.0151363312616013e-05

In O 0 1.722945125948172e-05
specific O 0 6.706645308440784e-06
C5 O 0 0.006691107992082834
titrations O 0 0.19915294647216797
, O 0 3.9140891203715e-06
however O 0 2.8679443175860797e-07
, O 0 8.198210110776927e-08
it O 0 2.4444066326623215e-08
was O 0 6.486901327207306e-08
noted O 0 1.0289372198712954e-07
that O 0 1.2497840096159507e-08
when O 0 1.808197858110816e-08
limited O 0 2.2004579491863296e-08
amounts O 0 2.5477119081074306e-08
of O 0 1.5453125001840817e-08
C5 O 0 1.7204267351189628e-05
were O 0 1.5410357434575417e-08
assayed O 0 4.1093903746514115e-07
in O 0 1.3499525941540469e-08
the O 0 9.40484845557421e-09
presence O 0 2.2559339285521673e-08
of O 0 1.5787694707114497e-08
low O 0 6.009768185322173e-07
dilutions O 0 1.050721311912639e-05
of O 0 4.4866482085126336e-08
either O 0 1.5722626756087266e-07
C5D B-Disease 0 0.24480703473091125
serum O 0 1.6105064787552692e-05
, O 0 2.133131360437801e-08
curving O 0 3.425929548939166e-07
rather O 0 1.4820306759588675e-08
than O 0 8.578448174034747e-09
linear O 0 8.567567419959232e-07
dose O 0 1.7391047322234954e-06
- O 0 3.055507113458589e-05
response O 0 2.6276282483195246e-07
plots O 0 2.9463086548275896e-07
were O 0 2.189205083880097e-08
consistently O 0 1.2965236351192289e-07
obtained O 0 7.222431008813146e-08
, O 0 7.272332425145578e-08
suggesting O 0 4.4764468043467787e-07
some O 0 7.657957468154564e-08
inhibitory O 0 8.212158718379214e-06
effect O 0 5.315589078236371e-06
. O 0 5.732723820983665e-06

Further O 0 2.49788754445035e-05
studies O 0 8.880657333065756e-06
suggested O 0 2.245535824840772e-06
that O 0 1.3250654262719763e-07
low O 0 1.8835664832295151e-06
dilutions O 0 0.000247731659328565
of O 0 7.470187028957298e-07
C5D B-Disease 1 0.9863625168800354
serum O 0 0.0004083005478605628
contain O 0 9.121206403506221e-07
a O 0 1.0783066528574636e-07
factor O 0 9.09382094960165e-07
( O 0 9.705319570230131e-08
or O 0 5.3269701538738445e-08
factors O 0 1.0627053370626527e-07
) O 0 2.5910033230047702e-08
interfering O 0 6.512538419656266e-08
at O 0 2.0134311995434473e-08
some O 0 5.183439455436201e-09
step O 0 8.461192635422776e-08
in O 0 4.5503629308996096e-08
the O 0 3.6433365835364384e-07
hemolytic O 1 0.969673752784729
assay O 0 3.5218233733758098e-06
of O 0 4.5869356313232856e-08
C5 O 0 8.484064164804295e-05
, O 0 4.949793819264414e-08
rather O 0 1.567075003094942e-08
than O 0 7.546666402902247e-09
a O 0 5.786718659805956e-08
true O 0 1.5368580079666572e-06
C5 O 0 0.0004173869383521378
inhibitor O 0 2.442444565531332e-05
or O 0 1.925901869981317e-06
inactivator O 0 0.0013566742418333888
. O 0 6.569455308635952e-06

Of O 0 1.7170910723507404e-05
clinical O 0 0.000992492539808154
interest O 0 3.472298885753844e-06
are O 0 2.853637397493003e-07
( O 0 4.117769663025683e-07
a O 0 1.19881278237699e-07
) O 0 1.3383764496666117e-07
the O 0 4.4989196368305784e-08
documentation O 0 1.2509881344158202e-06
of O 0 1.2338940678091603e-06
membranous O 1 0.9994693398475647
glomerulonephritis B-Disease 1 0.9999891519546509
, O 0 0.000919695186894387
vasculitis B-Disease 1 0.999935507774353
, O 0 6.212195876287296e-05
and O 0 0.0002851503959391266
arthritis B-Disease 1 0.9999845027923584
in O 0 9.64242417467176e-07
an O 0 1.4763182321075874e-07
individual O 0 3.723967267887929e-07
lacking O 0 5.226431767368922e-06
C5 O 0 0.00032245556940324605
( O 0 1.099016557759569e-07
and O 0 1.3431594503288125e-08
its O 0 1.6035274441605907e-08
biologic O 0 1.6310123100993223e-05
functions O 0 5.7158768385079384e-08
) O 0 4.9709488081361997e-08
, O 0 2.150731148731211e-08
and O 0 3.8052135664656817e-08
( O 0 1.9449041133157152e-07
b O 0 2.0816773940168787e-06
) O 0 5.069755459885528e-08
a O 0 2.984844016395982e-08
remarkable O 0 4.994455139240017e-06
propensity O 0 0.0009322885889559984
to O 0 1.3447095625451766e-05
bacterial B-Disease 1 0.7861815094947815
infections I-Disease 0 0.22879363596439362
in O 0 6.415424280703519e-08
the O 0 1.1109602127135076e-07
proband O 0 0.0004240145208314061
, O 0 4.706974365831229e-08
even O 0 1.3224187966898171e-08
during O 0 1.78368537717688e-08
periods O 0 6.547836761683357e-08
of O 0 8.940478579688715e-09
low O 0 5.979057959848433e-07
- O 0 2.4225944798672572e-05
dose O 0 1.1802713970610057e-06
or O 0 4.266451725243314e-08
alternate O 0 1.8348910657550732e-07
- O 0 6.014403697918169e-05
day O 0 6.12749772699317e-06
corticosteroid O 0 0.01654268614947796
therapy O 0 0.0003978245076723397
. O 0 8.964385415310971e-06

Other O 0 8.878396329237148e-06
observations O 0 2.731883250817191e-05
indicate O 0 6.113244580774335e-06
that O 0 1.9306909848637588e-07
the O 0 2.532997598336806e-07
C5D B-Disease 0 0.10215044021606445
state O 0 9.668035261256591e-08
is O 0 1.6056606710890264e-08
compatible O 0 5.062962671331661e-08
with O 0 4.045980261935256e-08
normal O 0 6.447293685596378e-07
coagulation O 0 2.9156170057831332e-05
function O 0 6.949864683747364e-08
and O 0 1.917809733242848e-08
the O 0 1.9882286039774044e-08
capacity O 0 1.5336121350628673e-07
to O 0 5.953578963158179e-08
mount O 0 3.956765340262791e-06
a O 0 1.3011231203563511e-06
neutrophilic O 1 0.6172892451286316
leukocytosis O 1 0.9385947585105896
during O 0 0.00022795502445660532
pyogenic B-Disease 1 0.9940040707588196
infection I-Disease 0 0.01448030211031437
. O 0 2.5160315999528393e-06
. O 0 7.4201907409587875e-06

Susceptibility O 1 0.8686409592628479
to O 0 0.002063752617686987
ankylosing B-Disease 1 0.9999303817749023
spondylitis I-Disease 1 0.9999769926071167
in O 0 0.0001389002427458763
twins O 0 0.17050553858280182
: O 0 2.905568862843211e-06
the O 0 6.219359249826084e-08
role O 0 1.1212678430183587e-07
of O 0 5.817661019591469e-08
genes O 0 1.67461780620215e-06
, O 0 7.416020935124834e-07
HLA O 0 0.058966878801584244
, O 0 2.2421667722483107e-07
and O 0 1.3609925986202143e-07
the O 0 3.5388288210924657e-07
environment O 0 1.2208593943796586e-05
. O 0 5.432420493889367e-06

OBJECTIVE O 0 7.918258052086458e-05
To O 0 2.471646439516917e-06
determine O 0 1.9097228687314782e-06
the O 0 1.9331598366534308e-07
relative O 0 1.6792523638287093e-06
effects O 0 4.224621534376638e-06
of O 0 2.1255146975818207e-07
genetic O 0 9.87629100563936e-05
and O 0 1.60054719344771e-06
environmental O 0 5.0128659495385364e-05
factors O 0 3.740518423001049e-06
in O 0 3.0333205813803943e-06
susceptibility O 0 0.3484853208065033
to O 0 0.00039112981176003814
ankylosing B-Disease 1 0.9999932050704956
spondylitis I-Disease 1 0.999997615814209
( O 0 0.00018570036627352238
AS B-Disease 0 3.6417393857846037e-05
) O 0 7.318282769119833e-06
. O 0 5.583347046922427e-06

METHODS O 0 0.0002930927148554474
Twins O 0 0.004665452521294355
with O 0 3.234179075661814e-06
AS B-Disease 0 3.2394543723057723e-06
were O 0 1.1515596298750097e-07
identified O 0 2.8749300895469787e-07
from O 0 3.797245540226868e-08
the O 0 1.1672413791075087e-07
Royal O 0 2.109662273142021e-05
National O 0 7.957300840644166e-05
Hospital O 0 0.15026257932186127
for O 0 0.00022252050985116512
Rheumatic B-Disease 1 0.9999791383743286
Diseases I-Disease 1 0.9957032799720764
database O 0 0.00029403058579191566
. O 0 1.5875308235990815e-05

Clinical O 0 0.00398786598816514
and O 0 1.652461287449114e-05
radiographic O 0 0.006302050314843655
examinations O 0 9.581280028214678e-05
were O 0 4.890633817922208e-07
performed O 0 2.4971018319774885e-06
to O 0 3.829971149116318e-07
establish O 0 2.7872223654412664e-05
diagnoses O 0 0.4139878749847412
, O 0 3.3947679185075685e-05
and O 0 0.000404562073526904
disease O 1 0.9970101118087769
severity O 0 0.08571009337902069
was O 0 4.650983100873418e-07
assessed O 0 5.669626830240304e-07
using O 0 2.2932436394285105e-08
a O 0 2.4900757011891983e-08
combination O 0 1.9621685964921198e-07
of O 0 3.904988332692483e-08
validated O 0 1.8749855144051253e-06
scoring O 0 5.525338337974972e-07
systems O 0 2.1410698536783457e-05
. O 0 5.9725202845584136e-06

HLA O 0 0.04245086386799812
typing O 0 0.00039478030521422625
for O 0 7.449943041137885e-06
HLA O 0 0.016378816217184067
- O 0 0.0007724686875008047
B27 O 0 0.00038705786573700607
, O 0 8.228631145357213e-07
HLA O 0 0.0009552284609526396
- O 0 5.622376556857489e-05
B60 O 0 3.817661490757018e-05
, O 0 1.10059403368723e-07
and O 0 1.3237821860911936e-07
HLA O 0 0.012150533497333527
- O 0 0.0006203856319189072
DR1 O 0 0.00218252744525671
was O 0 6.947744424223856e-08
performed O 0 7.32763680844073e-08
by O 0 1.8234922904980522e-08
polymerase O 0 2.030304585787235e-06
chain O 0 1.4917361568222987e-06
reaction O 0 7.551825120799549e-08
with O 0 1.1648089603966127e-08
sequence O 0 8.851774424556424e-08
- O 0 2.846442157533602e-06
specific O 0 3.9671107288086205e-08
primers O 0 1.0784933692775667e-06
, O 0 5.214400644604211e-08
and O 0 1.2075965116764564e-07
zygosity O 0 0.0002885882859118283
was O 0 1.5357430527274119e-07
assessed O 0 5.418054911388026e-07
using O 0 3.368028842487547e-07
microsatellite O 0 0.00013138724898453802
markers O 0 5.9104346291860566e-05
. O 0 5.638295533572091e-06

Genetic O 0 0.007287097163498402
and O 0 9.157900421996601e-06
environmental O 0 1.3755771760770585e-05
variance O 0 1.6662052075844258e-06
components O 0 5.214271823206218e-07
were O 0 5.138486258715602e-08
assessed O 0 1.6481870090956363e-07
with O 0 2.1555278451046433e-08
the O 0 3.009620641591937e-08
program O 0 1.8115157729425846e-07
Mx O 0 2.1332476535462774e-05
, O 0 1.7303740662555356e-08
using O 0 6.895606752266303e-09
data O 0 2.6817996712225067e-08
from O 0 7.875751606434278e-09
this O 0 5.904383204580199e-09
and O 0 2.4395998110549044e-08
previous O 0 1.0023985907992028e-07
studies O 0 1.022730771182978e-07
of O 0 6.73512730031689e-08
twins O 0 0.0006029810756444931
with O 0 1.2673019682551967e-06
AS B-Disease 0 1.2983853594050743e-05
. O 0 1.0632081284711603e-05

RESULTS O 0 9.273337491322309e-05
Six O 0 1.5924867966532474e-06
of O 0 5.504930982169753e-07
8 O 0 8.712279850442428e-06
monozygotic O 0 0.012086194008588791
( O 0 1.7247617506654933e-05
MZ O 1 0.9775925278663635
) O 0 4.2883843889285345e-06
twin O 0 0.0002917219535447657
pairs O 0 6.659646714979317e-06
were O 0 1.6121622365972144e-06
disease O 0 0.03613753244280815
concordant O 0 0.00023038544168230146
, O 0 1.906051636524353e-07
compared O 0 1.7003212349209207e-07
with O 0 4.128173003437041e-08
4 O 0 2.2289206924597238e-07
of O 0 5.366251798477606e-08
15 O 0 6.526098559334059e-07
B27 O 0 0.00017502081755083054
- O 0 0.00022578590142074972
positive O 0 9.475593856222986e-07
dizygotic O 0 0.0018917954294010997
( O 0 1.9538140350050526e-06
DZ O 0 0.13514530658721924
) O 0 5.569757490775373e-07
twin O 0 2.8431803002604283e-05
pairs O 0 3.9770932858118613e-07
( O 0 6.426115817248501e-08
27 O 0 1.203779191882859e-07
% O 0 2.4859899028228938e-08
) O 0 1.9615338686662653e-08
and O 0 1.3170949664242926e-08
4 O 0 7.195260565140416e-08
of O 0 2.983597724437459e-08
32 O 0 1.8952931668536621e-06
DZ O 0 0.4661916196346283
twin O 0 0.00037721797707490623
pairs O 0 1.2990686855118838e-06
overall O 0 1.7499268096798914e-06
( O 0 1.805696001611068e-07
12 O 0 1.4899205780238844e-07
. O 0 6.584607348258942e-08
5 O 0 4.688288299803389e-07
% O 0 5.188546765566571e-07
) O 0 1.3781642564936192e-06
. O 0 3.3079397780966247e-06

Nonsignificant O 0 0.06043858453631401
increases O 0 9.432886145077646e-05
in O 0 1.9628964764706325e-06
similarity O 0 1.3512013538274914e-05
with O 0 4.2273154576832894e-07
regard O 0 1.8779289803205756e-06
to O 0 1.005810304377519e-06
age O 0 2.8957187168998644e-05
at O 0 0.00019766975310631096
disease O 1 0.9739621877670288
onset O 0 0.3696829378604889
and O 0 2.341663503102609e-07
all O 0 2.3497497281255164e-08
of O 0 5.755687197961379e-07
the O 0 6.26448672846891e-05
disease O 1 0.9685488343238831
severity O 0 0.01920183189213276
scores O 0 8.69113500812091e-06
assessed O 0 4.076950517628575e-06
were O 0 7.673733648516645e-08
noted O 0 1.537884372737608e-06
in O 0 5.650923867506208e-06
disease O 0 0.3215322196483612
- O 0 0.12067684531211853
concordant O 0 0.4362408518791199
MZ O 1 0.9987743496894836
twins O 0 0.0234542079269886
compared O 0 7.965087206684984e-06
with O 0 4.603049092111178e-06
concordant O 0 0.03398880362510681
DZ O 1 0.9878589510917664
twins O 0 0.105159692466259
. O 0 2.7558546207728796e-05

HLA O 1 0.9199883937835693
- O 0 0.04540519043803215
B27 O 0 0.00448757316917181
and O 0 3.833204573311377e-06
B60 O 0 0.0006335627404041588
were O 0 2.825983926868503e-07
associated O 0 8.681854524184018e-07
with O 0 3.37837803954244e-07
the O 0 4.4171670197101776e-06
disease O 0 0.07471754401922226
in O 0 6.996001502557192e-07
probands O 0 0.017284059897065163
, O 0 1.996597376319187e-07
and O 0 7.67881402907733e-08
the O 0 9.505264841891403e-08
rate O 0 1.1686910283970064e-06
of O 0 9.490570960224431e-07
disease O 0 0.014613059349358082
concordance O 0 6.837322871433571e-05
was O 0 2.4337072090929723e-07
significantly O 0 5.801178417641495e-07
increased O 0 1.646510696673431e-07
among O 0 3.024790942163236e-07
DZ O 0 0.33196333050727844
twin O 0 8.429196168435737e-05
pairs O 0 1.38321638587513e-07
in O 0 1.3917611951796971e-08
which O 0 1.0726344257250275e-08
the O 0 3.7488209869707134e-08
co O 0 0.00011894880299223587
- O 0 0.010650013573467731
twin O 0 0.0005624262266792357
was O 0 1.141008283411793e-07
positive O 0 4.5522295266664514e-08
for O 0 1.886665756956063e-08
both O 0 1.3389868058766297e-07
B27 O 0 0.00012440720456652343
and O 0 2.3294981019716943e-06
DR1 O 0 0.012754376046359539
. O 0 1.2673474884650204e-05

Additive O 0 0.0006026308983564377
genetic O 0 0.0028906064108014107
effects O 0 5.737988249165937e-05
were O 0 2.4808960574773664e-07
estimated O 0 3.809655026998371e-07
to O 0 7.904800014557622e-08
contribute O 0 2.7894319032384374e-07
97 O 0 8.254820045294764e-07
% O 0 4.77060453363265e-08
of O 0 3.370164947114063e-08
the O 0 1.7114065542500612e-07
population O 0 7.64318883739179e-07
variance O 0 4.261541562300408e-06
. O 0 2.9928878575447015e-06

CONCLUSION O 0 0.00039279222255572677
Susceptibility O 0 0.010776828043162823
to O 0 2.2013789475749945e-06
AS B-Disease 0 9.755873406902538e-07
is O 0 5.970738214955418e-08
largely O 0 1.591749025919853e-07
genetically O 0 1.5919903262329171e-06
determined O 0 5.438342896013637e-07
, O 0 5.39377360553317e-08
and O 0 8.329186584887793e-08
the O 0 1.753597729248213e-07
environmental O 0 9.497374776401557e-06
trigger O 0 1.45335234265076e-05
for O 0 1.7875755986551667e-07
the O 0 3.8113153095764574e-06
disease O 0 0.060158416628837585
is O 0 5.400376039688126e-07
probably O 0 4.272329078958137e-06
ubiquitous O 0 3.573502181097865e-05
. O 0 9.825343113334384e-06

HLA O 1 0.9245274066925049
- O 0 0.030281225219368935
B27 O 0 0.0017798293847590685
accounts O 0 2.0496579509199364e-06
for O 0 1.4299443762411101e-07
a O 0 7.848552030509381e-08
minority O 0 3.098548120306077e-07
of O 0 6.394009233190445e-08
the O 0 2.4211669824580895e-07
overall O 0 2.223032061010599e-05
genetic O 0 0.000392494403058663
susceptibility O 0 0.001612311927601695
to O 0 6.633011366830033e-07
AS B-Disease 0 7.055647074594162e-06
. O 0 7.429055585816968e-06

Cell O 0 0.0007938354392535985
cycle O 0 0.00028947615646757185
- O 0 0.000835863989777863
dependent O 0 2.1625613953801803e-05
colocalization O 0 0.0006348895258270204
of O 0 9.29735392674047e-07
BARD1 O 0 0.0014472882030531764
and O 0 1.115037662202667e-06
BRCA1 O 0 9.897589188767597e-05
proteins O 0 3.2067967481452797e-07
in O 0 1.0397998551070486e-07
discrete O 0 2.2414726572606014e-06
nuclear O 0 1.1241464562772308e-05
domains O 0 1.629844518902246e-05
. O 0 7.07757635609596e-06

Germ O 0 0.007567651104182005
- O 0 0.001659552101045847
line O 0 2.1742678654845804e-05
mutations O 0 1.1162995178892743e-05
of O 0 1.238342548504079e-07
the O 0 4.917741875942738e-07
BRCA1 O 0 0.0004762129974551499
gene O 0 6.84696124153561e-06
predispose O 0 2.8204794944031164e-05
women O 0 1.8416650959807157e-07
to O 0 6.459960388838226e-08
early O 0 2.3583986603625817e-06
- O 1 0.8898590803146362
onset O 1 0.9998061060905457
breast B-Disease 1 0.9999103546142578
and I-Disease 1 0.865790069103241
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9998311996459961
by O 0 1.3732287698076107e-06
compromising O 0 3.2554315112065524e-05
the O 0 6.829951644249377e-07
genes O 0 1.1037785043299664e-05
presumptive O 0 0.0013433292042464018
function O 0 8.641098929729196e-07
as O 0 1.8345201624470064e-07
a O 0 2.187065774705843e-06
tumor B-Disease 0 0.018460657447576523
suppressor O 0 0.00019993948808405548
. O 0 7.610212833242258e-06

Although O 0 1.3062543985142838e-05
the O 0 1.4825870948698139e-06
biochemical O 0 2.0690398741862737e-05
properties O 0 2.7304045033815783e-06
of O 0 2.971397066175996e-07
BRCA1 O 0 0.0004404475330375135
polypeptides O 0 1.2400257219269406e-05
are O 0 5.70707499036871e-08
not O 0 2.7151566328598165e-08
understood O 0 1.1027983504163785e-07
, O 0 1.512639613565625e-08
their O 0 1.2817690020483496e-08
expression O 0 6.529677420985536e-08
pattern O 0 2.418067879261798e-07
and O 0 4.205725545602945e-08
subcellular O 0 1.392928993482201e-06
localization O 0 1.644122335164866e-06
suggest O 0 2.3563836748508038e-07
a O 0 2.1598820509893812e-08
role O 0 7.914032806866089e-08
in O 0 8.282974306439428e-08
cell O 0 1.300664462178247e-05
- O 0 0.0005581960431300104
cycle O 0 6.539220339618623e-05
regulation O 0 1.7842517991084605e-05
. O 0 5.170426902623149e-06

When O 0 6.660216604359448e-05
resting O 0 0.0004891763092018664
cells O 0 2.4765733542153612e-05
are O 0 2.621938506308652e-07
induced O 0 0.00017247942741960287
to O 0 1.8215669683740998e-07
proliferate O 0 5.776870693807723e-06
, O 0 1.9418973096207992e-08
the O 0 1.2151573081098377e-08
steady O 0 2.5332124664600997e-07
- O 0 4.0635936784383375e-06
state O 0 5.3612183137374814e-08
levels O 0 6.678484254507566e-08
of O 0 2.4043073310053842e-08
BRCA1 O 0 1.7180051145260222e-05
increase O 0 1.2778224345311173e-07
in O 0 2.3951166383540112e-08
late O 0 2.654783770594804e-07
G1 O 0 7.689278572797775e-05
and O 0 5.3802004629233124e-08
reach O 0 9.088689978398179e-08
a O 0 2.7681855030436964e-08
maximum O 0 1.0645473480508372e-07
during O 0 6.777756880183006e-07
S O 0 0.00013096359907649457
phase O 0 2.492628846084699e-05
. O 0 6.350664989440702e-06

Moreover O 0 0.00010325344192096964
, O 0 2.1790981463709613e-06
in O 0 7.111080435606709e-07
S O 0 0.0002503800205886364
phase O 0 3.931085666408762e-05
cells O 0 8.417330718657468e-06
, O 0 2.9322427508304827e-07
BRCA1 O 0 3.3617143344599754e-05
polypeptides O 0 1.8421761751596932e-06
are O 0 4.8183945722257704e-08
hyperphosphorylated O 0 5.1299364713486284e-05
and O 0 8.535674567156093e-08
accumulate O 0 2.0182967546134023e-06
into O 0 6.22781115566795e-08
discrete O 0 1.3365923905439558e-06
subnuclear O 0 0.0003275430644862354
foci O 0 7.282140722963959e-05
termed O 0 1.4518810530717019e-05
" O 0 2.2276465188042494e-06
BRCA1 O 0 9.008104825625196e-05
nuclear O 0 1.6684960428392515e-05
dots O 0 0.00018099597946275026
. O 0 1.1166082913405262e-05

" O 0 0.0003486326604615897
BRCA1 O 0 0.15081249177455902
associates O 0 0.020389990881085396
in O 0 3.2065204322861973e-06
vivo O 0 0.00033571061794646084
with O 0 5.232478201833146e-07
a O 0 5.701492113985296e-07
structurally O 0 7.163557893363759e-05
related O 0 1.4910585377947427e-05
protein O 0 2.0311748812673613e-05
termed O 0 0.00040640702354721725
BARD1 O 0 0.055056292563676834
. O 0 1.7284799469052814e-05

Here O 0 1.29169893625658e-05
we O 0 1.2568500551424222e-06
show O 0 4.458982232335984e-07
that O 0 2.712744340271911e-08
the O 0 2.6741787451101118e-08
steady O 0 4.71260705126042e-07
- O 0 7.868584361858666e-06
state O 0 7.677277125139881e-08
levels O 0 1.2564888152155618e-07
of O 0 4.611867154835636e-08
BARD1 O 0 0.0006597589235752821
, O 0 7.080683417370892e-08
unlike O 0 1.1705967750685886e-07
those O 0 1.2730464682420006e-08
of O 0 4.511422346809013e-08
BRCA1 O 0 0.00010193099296884611
, O 0 1.2915884894937335e-07
remain O 0 1.0681473128215657e-07
relatively O 0 1.2363211965293885e-07
constant O 0 5.907393756388046e-07
during O 0 7.714610887887829e-07
cell O 0 3.8257196138147265e-05
cycle O 0 7.699991692788899e-05
progression O 0 0.0004975299234502017
. O 0 6.048762770660687e-06

However O 0 4.2388372094137594e-05
, O 0 1.1694743079715408e-05
immunostaining O 0 0.010909497737884521
revealed O 0 5.782575317425653e-05
that O 0 7.002008715062402e-07
BARD1 O 0 0.0009843019070103765
resides O 0 4.369816906546475e-06
within O 0 1.7332403956515918e-07
BRCA1 O 0 1.3707213838642929e-05
nuclear O 0 9.668751772551332e-07
dots O 0 6.696508989989525e-06
during O 0 3.2551724871154875e-07
S O 0 1.4471452232101e-05
phase O 0 2.8973875032534124e-07
of O 0 7.39655137138584e-09
the O 0 2.9064887385743532e-08
cell O 0 2.6949012408294948e-06
cycle O 0 1.7546276467328425e-06
, O 0 2.745093041767177e-08
but O 0 1.0229468827560595e-08
not O 0 1.033308727471649e-08
during O 0 5.970908745212e-08
the O 0 1.6875075914413173e-07
G1 O 0 0.0005836616619490087
phase O 0 2.4456283426843584e-05
. O 0 4.81704410049133e-06

Nevertheless O 0 0.00016390108794439584
, O 0 1.2114844139432535e-05
BARD1 O 0 0.002447918988764286
polypeptides O 0 2.4755274353083223e-05
are O 0 1.1095752938672376e-07
found O 0 5.073673392530509e-08
exclusively O 0 2.88604393716696e-08
in O 0 1.1863314774984701e-08
the O 0 1.0478608203356998e-08
nuclear O 0 1.1086803652915478e-07
fractions O 0 8.057018874296773e-08
of O 0 1.2369115509613948e-08
both O 0 4.330878411451522e-08
G1 O 0 0.00010259154805680737
- O 0 3.391447535250336e-05
and O 0 4.2187292592643644e-07
S O 0 0.0001893689768621698
- O 0 0.0002980215067509562
phase O 0 4.459062256501056e-05
cells O 0 2.299988227605354e-05
. O 0 5.085123575554462e-06

Therefore O 0 3.1064326321939006e-05
, O 0 4.290535798645578e-06
progression O 0 0.0002593345125205815
to O 0 1.0983538913933444e-06
S O 0 0.0002343017258681357
phase O 0 6.91181867296109e-06
is O 0 6.595983137458461e-08
accompanied O 0 2.641628213950753e-07
by O 0 2.7040707450964874e-08
the O 0 2.7747297792757308e-08
aggregation O 0 5.297040956975252e-07
of O 0 6.936489427289416e-08
nuclear O 0 3.795399152295431e-06
BARD1 O 0 0.0001846844970714301
polypeptides O 0 3.2965929221973056e-06
into O 0 7.400011554636876e-07
BRCA1 O 0 6.722071702824906e-05
nuclear O 0 2.0882405806332827e-05
dots O 0 0.00018522203026805073
. O 0 1.033276021189522e-05

This O 0 5.0617832130228635e-06
cell O 0 3.549401299096644e-05
cycle O 0 3.9687001844868064e-05
- O 0 0.00024512046365998685
dependent O 0 5.200993655307684e-06
colocalization O 0 0.0001749250222928822
of O 0 4.1105073478320264e-07
BARD1 O 0 0.00508227851241827
and O 0 1.659932422626298e-06
BRCA1 O 0 0.0002700501645449549
indicates O 0 1.1441032938819262e-06
a O 0 2.9516963095943538e-08
role O 0 7.994120920784553e-08
for O 0 8.005107332564876e-08
BARD1 O 0 0.0005462429253384471
in O 0 7.108375257303123e-07
BRCA1 O 0 0.00046100231702439487
- O 0 0.013356970623135567
mediated O 0 0.004232967738062143
tumor B-Disease 0 0.045028675347566605
suppression O 0 8.295880979858339e-05
. O 0 9.286443855671678e-06

Ethnic O 0 4.0378748963121325e-05
differences O 0 4.2710391426226124e-05
in O 0 2.0683339698734926e-06
the O 0 2.0969116576452507e-06
HFE O 0 0.0049886987544596195
codon O 0 3.717422441695817e-05
282 O 0 4.5701930503128096e-05
( O 0 5.58254851057427e-06
Cys O 0 0.4391953945159912
/ O 0 0.0014981762506067753
Tyr O 0 0.00330162956379354
) O 0 4.961811555403983e-06
polymorphism O 0 4.2792824388016015e-05
. O 0 8.087895366770681e-06

Recent O 0 0.00011023400293197483
studies O 0 1.7668638975010253e-05
have O 0 2.0285258415242424e-06
shown O 0 3.7208828871371225e-06
that O 0 2.1388414097600617e-05
hereditary B-Disease 1 0.9998620748519897
hemochromatosis I-Disease 1 0.999998927116394
( O 0 0.058955565094947815
HH B-Disease 1 0.9999245405197144
) O 0 6.657843641733052e-06
is O 0 1.0139205386394678e-07
likely O 0 2.4634920237076585e-07
to O 0 6.916447858884567e-08
be O 0 3.3618189121398245e-08
caused O 0 2.9383077162492555e-06
by O 0 8.60562323623526e-08
homozygosity O 0 0.00012945703929290175
for O 0 6.774991589963975e-08
a O 0 2.3544181715351442e-07
Cys282Tyr O 0 0.00167859869543463
mutation O 0 2.919860435213195e-06
in O 0 1.0110856152323322e-07
the O 0 2.9630237463607045e-07
HFE O 0 0.0013343265745788813
gene O 0 3.028848595931777e-06
located O 0 1.7626916815061122e-06
4 O 0 4.452082976058591e-06
. O 0 5.095575488667237e-06

5 O 0 0.00013667943130712956
Mb O 0 0.001776537043042481
telomeric O 0 0.006428285501897335
to O 0 1.8226653992314823e-05
HLA O 0 0.11443586647510529
- O 0 0.0011537985410541296
A O 0 1.291253101953771e-05
. O 0 1.5909363355604e-05

Population O 0 2.2824166080681607e-05
studies O 0 3.7748993690911448e-06
of O 0 1.557577320454584e-07
this O 0 8.40956246861424e-08
polymorphism O 0 4.264200470061041e-06
are O 0 4.3038852481913636e-08
facilitated O 0 1.0144365205633221e-06
by O 0 4.390395957898363e-08
the O 0 3.796376546461033e-08
fact O 0 9.586085525370436e-08
that O 0 2.8620009473456776e-08
the O 0 1.2832921925109986e-07
Cys282Tyr O 0 0.0004764908808283508
mutation O 0 3.214459411537973e-06
creates O 0 1.0793606861625449e-06
a O 0 2.69284868181785e-07
Rsal O 0 0.00021405279403552413
restriction O 0 2.472749883963843e-06
site O 0 4.839647772314493e-06
. O 0 3.1109236715565203e-06

We O 0 1.1300267942715436e-05
have O 0 1.051792423822917e-06
studied O 0 1.4479696801572572e-06
the O 0 3.972616298142384e-07
codon O 0 7.401447874144651e-06
282 O 0 1.8501941667636856e-05
( O 0 4.192425421933876e-06
Cys O 0 0.14834587275981903
/ O 0 0.0004024633963126689
Tyr O 0 0.0005070549668744206
) O 0 2.3912579649731924e-07
polymorphism O 0 5.689911972694972e-07
in O 0 3.386945479633141e-08
different O 0 3.270883652817247e-08
ethnic O 0 3.159381094519631e-07
groups O 0 1.5722926036687568e-06
. O 0 6.338140337902587e-06

In O 0 4.1724501897988375e-06
agreement O 0 2.7741004942072323e-06
with O 0 3.9208447333294316e-07
previous O 0 5.095606070426584e-07
observations O 0 8.683651913088397e-07
the O 0 1.65533222684644e-07
Tyr O 0 0.000320237799314782
allele O 0 1.0993935575243086e-06
appeared O 0 1.4700871986406128e-07
to O 0 2.2958344558787758e-08
be O 0 9.586063498545627e-09
rare O 0 1.42828028515396e-07
or O 0 7.890670161714297e-08
absent O 0 5.735003014706308e-07
in O 0 1.2942408034177788e-07
Asiatic O 0 3.409945929888636e-05
( O 0 2.1852092402241396e-07
Indian O 0 4.668945905450528e-07
, O 0 1.444902864022879e-07
Chinese O 0 5.75530293644988e-07
) O 0 2.2513081603392493e-06
populations O 0 1.2061091183568351e-05
. O 0 5.280917775962735e-06

The O 0 8.810086001176387e-06
highest O 0 7.517486665165052e-06
allele O 0 8.151438123604748e-06
frequency O 0 2.1569176169577986e-06
( O 0 4.898765837424435e-07
7 O 0 5.617308147520816e-07
. O 0 4.941530207247524e-08
5 O 0 2.048623031214447e-07
% O 0 8.378230376138163e-08
) O 0 8.757830727290639e-08
was O 0 5.6176087781523165e-08
found O 0 1.4959275063120003e-07
in O 0 5.28704845237371e-07
Swedes O 0 0.00015879920101724565
. O 0 9.29843372432515e-06

Saamis O 0 0.0465272031724453
( O 0 1.3562943422584794e-05
2 O 0 3.341641786391847e-06
% O 0 4.178962456080626e-07
) O 0 1.730569749724964e-07
and O 0 1.442468686718712e-07
Mordvinians O 0 0.00015148604870773852
( O 0 1.2912929037156573e-07
1 O 0 9.351261809342759e-08
. O 0 2.4226377348668393e-08
8 O 0 1.3783876795514516e-07
% O 0 4.5513701252275496e-08
) O 0 4.6961059041450426e-08
had O 0 3.172693041619823e-08
significantly O 0 1.1436784319585058e-07
lower O 0 1.297320153526016e-07
frequencies O 0 6.713055711315974e-08
of O 0 7.746911734329842e-08
the O 0 7.447893608514278e-07
Tyr O 0 0.0015903806779533625
allele O 0 2.0293780835345387e-05
. O 0 5.990763384033926e-06

Comparisons O 0 6.189636769704521e-05
with O 0 2.4512964955647476e-06
allele O 0 4.959148100169841e-06
frequencies O 0 1.288384169129131e-06
based O 0 3.2963748708425555e-07
on O 0 3.3168845448017237e-07
prevalence O 0 0.00014729532995261252
estimates O 0 2.2979781988397008e-06
of O 0 2.440629032207653e-07
HH B-Disease 1 0.9570293426513672
showed O 0 1.4052362757865922e-06
some O 0 1.706340668761186e-08
disagreements O 0 1.6052861155912979e-06
with O 0 6.463903901021695e-08
the O 0 1.4255832070375618e-07
RFLP O 0 4.2149986256845295e-05
data O 0 2.800439915517927e-07
, O 0 1.2748670030759968e-07
particularly O 0 3.586130219446204e-07
in O 0 7.224606974887138e-07
Finns O 0 0.0002463450946379453
. O 0 6.462649253080599e-06

The O 0 1.3278527148941066e-05
newly O 0 2.413543188595213e-05
described O 0 2.8335009119473398e-05
HFE O 0 0.011697523295879364
marker O 0 1.7035743439919315e-05
provides O 0 2.684261914964736e-07
a O 0 3.9316841338177255e-08
new O 0 3.057131792161272e-08
approach O 0 5.702439409560611e-08
to O 0 1.7248021677573888e-08
the O 0 1.988801301422427e-08
screening O 0 2.9546376367761695e-07
of O 0 1.0856182086627086e-07
HH B-Disease 0 0.42923009395599365
as O 0 4.834984324020297e-08
well O 0 2.534794418806996e-08
as O 0 1.0127334526544018e-08
studies O 0 2.4944062815279722e-08
of O 0 1.2384389513897531e-08
the O 0 3.475342325032216e-08
relationship O 0 1.3929355873187887e-06
between O 0 2.866995600925293e-07
the O 0 8.170686669473071e-07
HFE O 0 0.3868977427482605
Tyr O 0 0.025715813040733337
allele O 0 6.108313755248673e-06
and O 0 8.26542304821487e-07
different O 0 1.9101673842669697e-06
disorders O 1 0.9534271955490112
including O 0 0.00017297813610639423
cancer B-Disease 1 0.9756585955619812

Autosomal B-Disease 1 0.9972718358039856
dominant I-Disease 1 0.9699530601501465
neurohypophyseal I-Disease 1 0.9996926784515381
diabetes I-Disease 1 0.9999687671661377
insipidus I-Disease 1 0.999589741230011
associated O 0 0.0001166599613497965
with O 0 9.638673645895324e-07
a O 0 4.965258995071054e-07
missense O 0 6.035513069946319e-05
mutation O 0 2.189436372646014e-06
encoding O 0 5.980107289360603e-07
Gly23 O 0 0.00014158013800624758
- O 0 0.0001160570391220972
- O 0 0.000440812116721645
> O 0 0.0006758531671948731
Val O 0 0.002574751852080226
in O 0 1.7769892792784958e-06
neurophysin O 0 0.00393391028046608
II O 0 0.00039533578092232347
. O 0 1.2141748811700381e-05

Autosomal B-Disease 1 0.9939870834350586
dominant I-Disease 1 0.8625873923301697
neurohypophyseal I-Disease 1 0.9995816349983215
diabetes I-Disease 1 0.9999382495880127
insipidus I-Disease 1 0.9996542930603027
( O 0 0.0016805479535833001
ADNDI B-Disease 1 0.9680147767066956
) O 0 2.834892802638933e-05
is O 0 3.908397047780454e-06
an O 0 6.518182635772973e-05
inherited B-Disease 1 0.9999890327453613
disease I-Disease 1 0.9999825954437256
caused O 0 0.014397145248949528
by O 0 2.3184634301287588e-06
progressive O 0 0.0009817134123295546
degeneration O 1 0.617324709892273
of O 0 1.4585245367015887e-07
the O 0 1.999297296606528e-07
magnocellular O 0 0.0006744260317645967
neurons O 0 3.602398919611005e-06
of O 0 2.3122437298184195e-08
the O 0 7.010160629761231e-08
hypothalamus O 0 1.0656413905962836e-05
leading O 0 3.1396237432090857e-07
to O 0 4.4119364162042984e-08
decreased O 0 8.441540444437123e-07
ability O 0 1.0970919106512156e-07
to O 0 2.3825046824299534e-08
produce O 0 6.356921034011975e-08
the O 0 1.1812167599600798e-07
hormone O 0 4.176112270215526e-06
arginine O 0 5.983592018310446e-06
vasopressin O 0 1.3586258319264743e-05
( O 0 1.6859951301739784e-06
AVP O 0 0.0001334928092546761
) O 0 2.1904891127633164e-06
. O 0 4.021126187581103e-06

Affected O 0 0.0014743611682206392
individuals O 0 1.8662403817870654e-05
are O 0 1.0808244041982107e-06
not O 0 1.0409444257675204e-06
symptomatic O 0 0.002804904244840145
at O 0 7.329919299081666e-06
birth O 0 0.0001119855442084372
, O 0 8.695261612956529e-07
but O 0 4.872868544225639e-07
usually O 0 3.954437943320954e-06
develop O 0 0.0012227268889546394
diabetes B-Disease 1 0.990666925907135
insipidus I-Disease 0 0.29363352060317993
at O 0 7.227314995361667e-07
1 O 0 8.584776196585153e-07
- O 0 0.0002179960283683613
6 O 0 2.8787742849090137e-05
yr O 0 0.08561882376670837
of O 0 9.266628353543638e-07
age O 0 1.0133082469110377e-05
. O 0 7.370659204752883e-06

The O 0 2.4634600777062587e-05
genetic O 0 0.0004251140635460615
locus O 0 8.250959945144132e-05
of O 0 1.1118628435724531e-06
the O 0 8.793247616267763e-06
disease O 0 0.030164606869220734
is O 0 8.420492036975702e-08
the O 0 1.3515169428046647e-07
AVP O 0 0.0010509092826396227
- O 0 0.010753975249826908
neurophysin O 0 0.12601156532764435
II O 0 0.0013355787377804518
( O 0 1.8364629568168311e-06
NPII O 0 0.00124663847964257
) O 0 2.5220683141924383e-07
gene O 0 4.886158535555296e-07
, O 0 7.334111273848976e-08
and O 0 2.877261522371555e-07
mutations O 0 2.5786694095586427e-05
that O 0 2.967152283872565e-07
cause O 0 2.657241748238448e-05
ADNDI B-Disease 0 0.007899858988821507
have O 0 4.499571915062006e-08
been O 0 9.887415330922522e-09
found O 0 7.609309626843697e-09
in O 0 4.703005096473589e-09
both O 0 3.6601901509669688e-09
the O 0 7.121828460299184e-09
signal O 0 4.154872357275963e-08
peptide O 0 8.528171946409202e-08
of O 0 7.34495664289625e-09
the O 0 3.6859592711380174e-08
prepro O 0 7.201736298156902e-05
- O 0 0.00014084305439610034
AVP O 0 0.0005859067314304411
- O 0 0.0004196686786599457
NPII O 0 0.0005111253703944385
precursor O 0 1.791428758224356e-06
and O 0 1.382185246256995e-07
within O 0 3.018819541011908e-07
NPII O 0 0.0003563507925719023
itself O 0 3.6784626900043804e-06
. O 0 4.1723783397173975e-06

An O 0 1.2602546121343039e-05
affected O 0 7.455857848981395e-05
girl O 0 0.00014701441978104413
who O 0 1.366008405057073e-06
presented O 0 6.185200618347153e-07
at O 0 3.281713816249976e-07
9 O 0 9.972656016543624e-07
months O 0 3.0762504366066423e-07
of O 0 5.860427165771398e-08
age O 0 1.0287247960150125e-06
and O 0 1.3579872870650433e-07
her O 0 3.248267830713303e-06
similarly O 0 1.3537215636461042e-05
affected O 0 9.723551556817256e-06
younger O 0 1.0804722478496842e-05
brother O 0 1.1939348951273132e-05
and O 0 2.390587212630635e-07
father O 0 1.6408423562097596e-06
were O 0 1.3459906966772905e-08
all O 0 7.3720731741389045e-09
found O 0 3.315284047289424e-08
to O 0 1.178166275650483e-08
have O 0 1.1002304844964783e-08
a O 0 3.0880514145792404e-08
novel O 0 1.142437213275116e-06
missense O 0 1.974107181013096e-05
mutation O 0 9.291414926337893e-07
( O 0 7.446353578188791e-08
G1758 O 0 3.899907824234106e-06
- O 0 1.2928993783134501e-05
- O 0 6.169417611090466e-05
> O 0 3.1144449167186394e-05
T O 0 6.01886204094626e-05
) O 0 1.839821273108555e-08
encoding O 0 1.9528693329107227e-08
the O 0 7.039743010750499e-09
amino O 0 3.936096248935428e-08
acid O 0 1.4719685736963584e-07
substitution O 0 1.2886430056369136e-07
Gly23 O 0 1.7371970898238942e-05
- O 0 3.7911770050413907e-05
- O 0 0.0006039781146682799
> O 0 0.00037338907714001834
Val O 0 0.0022145207040011883
within O 0 1.7667206293481286e-06
NPII O 0 0.000979165080934763
. O 0 7.148652912292164e-06

The O 0 5.2027677156729624e-05
mutation O 0 0.0003227895649615675
was O 0 2.282009518239647e-06
confirmed O 0 1.9261663055658573e-06
by O 0 4.6549499188586196e-07
restriction O 0 4.5829315240553115e-06
endonuclease O 0 0.0002430402091704309
analysis O 0 1.008551407721825e-05
. O 0 7.691141036048066e-06

A O 0 5.332269938662648e-05
T1 O 0 0.007988965138792992
- O 0 0.00016791783855296671
weighted O 0 8.332662218890619e-06
magnetic O 0 7.041227945592254e-06
resonance O 0 8.311551027873065e-06
imaging O 0 3.335859582875855e-05
of O 0 2.2449182779382681e-07
the O 0 9.75479451881256e-07
fathers O 0 0.0004410760593600571
pituitary O 0 0.13355320692062378
gland O 0 0.003201112151145935
demonstrates O 0 1.3795759514323436e-05
an O 0 6.427623588933784e-07
attenuated O 0 0.00037001355667598546
posterior O 0 0.012002034112811089
pituitary O 0 0.0180697962641716
bright O 0 8.518972754245624e-05
spot O 0 2.997267438331619e-05
. O 0 1.0929519703495316e-05

This O 0 2.010573007282801e-05
mutation O 0 0.0006234135362319648
may O 0 4.212142357573612e-06
be O 0 3.8584708761391084e-08
valuable O 0 9.912078979823491e-08
for O 0 4.2100516850496206e-08
developing O 0 4.7382351908709097e-07
models O 0 2.246205355049824e-07
of O 0 3.9246492633537855e-07
dominantly B-Disease 0 0.1929701268672943
inherited I-Disease 1 0.9905281066894531
neurodegeneration I-Disease 1 0.9999563694000244
, O 0 1.036378876051458e-06
as O 0 3.212511145989083e-08
the O 0 3.547275184700993e-08
early O 0 2.4774820417405863e-07
age O 0 7.536039561273356e-07
of O 0 5.965792411188886e-07
onset O 1 0.8042153120040894
of O 0 2.4902928998926654e-05
symptoms O 1 0.5445249676704407
suggests O 0 2.1547672076849267e-05
that O 0 1.7597527346424613e-07
this O 0 1.4676554371817474e-07
mutation O 0 1.7447580830776133e-05
may O 0 8.074601396401704e-07
be O 0 2.1516500581242326e-08
particularly O 0 2.6807163067132933e-07
deleterious O 0 4.774518856720533e-06
to O 0 9.741594908518891e-08
the O 0 3.655361240362254e-07
magnocellular O 0 0.003823106409981847
neuron O 0 0.0003872493689414114
. O 0 1.7513909824629081e-06
. O 0 3.7141005577723263e-06

Frequent O 0 0.002179988892748952
inactivation O 0 0.015444225631654263
of O 0 1.4090061085880734e-05
PTEN O 0 0.48013877868652344
/ O 0 0.03932945802807808
MMAC1 O 0 0.4638895094394684
in O 0 6.0569214838324115e-05
primary O 0 0.2069036066532135
prostate B-Disease 1 0.9999786615371704
cancer I-Disease 1 0.9995743632316589
. O 0 9.704551484901458e-05

Sporadic B-Disease 1 0.9968430995941162
prostate I-Disease 1 0.9999650716781616
carcinoma I-Disease 1 0.9999866485595703
is O 0 2.4321245291503146e-05
the O 0 2.64771392721741e-06
most O 0 1.2697287274932023e-06
common O 0 6.806396413594484e-05
male B-Disease 0 0.00045315115130506456
cancer I-Disease 0 0.07325660437345505
in O 0 9.293988512126816e-08
the O 0 4.3150311768158645e-08
Western O 0 2.369087752640553e-07
world O 0 5.802190798931406e-07
, O 0 5.962987614793747e-08
yet O 0 2.2903412499886144e-08
many O 0 4.668204489632899e-09
of O 0 9.238154241586471e-09
the O 0 6.46104396651026e-08
major O 0 2.024372861342272e-06
genetic O 0 7.865710358601063e-06
events O 0 1.2262684379038546e-07
involved O 0 5.567676453210879e-08
in O 0 2.2454079484646172e-08
the O 0 6.250504469562657e-08
progression O 0 2.34612452914007e-05
of O 0 7.242972088761235e-08
this O 0 5.606738113783649e-07
often O 0 5.065534060122445e-05
fatal O 1 0.9671885371208191
cancer B-Disease 1 0.6842339038848877
remain O 0 2.274070993735222e-06
to O 0 5.398187568061985e-07
be O 0 6.008438617755019e-07
elucidated O 0 0.00025833328254520893
. O 0 8.30461794976145e-06

Numerous O 0 0.00017053015471901745
cytogenetic O 0 0.027800528332591057
and O 0 3.7279165553627536e-05
allelotype O 0 0.04743685945868492
studies O 0 1.3606603715743404e-05
have O 0 1.0550513707130449e-06
reported O 0 6.636784746660851e-06
frequent O 0 1.0931427823379636e-05
loss O 0 9.425296593690291e-05
of O 0 3.2559239571128273e-07
heterozygosity O 0 0.003882106626406312
on O 0 2.6156574222113704e-06
chromosomal O 0 0.04538174346089363
arm O 0 0.0023749140091240406
10q O 0 0.004660508595407009
in O 0 1.620312104932964e-05
sporadic B-Disease 0 0.22788603603839874
prostate I-Disease 1 0.9999735355377197
cancer I-Disease 1 0.9996331930160522
. O 0 7.451102283084765e-05

Deletion O 0 0.00650442112237215
mapping O 0 0.0009181945933960378
studies O 0 2.7567037250264548e-05
have O 0 1.5603515066686668e-06
unambiguously O 0 4.035526580992155e-05
identified O 0 9.078587481781142e-07
a O 0 9.499628106368618e-08
region O 0 8.282308954221662e-07
of O 0 1.4872360054596356e-07
chromosome O 0 0.00027556769782677293
10q23 O 0 0.00042517692781984806
to O 0 5.1866273054201883e-08
be O 0 7.368080368053143e-09
the O 0 2.0619568275037636e-08
minimal O 0 5.236861966295692e-07
area O 0 3.294573787115951e-07
of O 0 3.1168460168373713e-07
loss O 0 0.0006280305096879601
. O 0 1.7336718883598223e-05

A O 0 4.4342126784613356e-05
new O 0 7.432430720655248e-05
tumor B-Disease 0 0.20618410408496857
suppressor O 0 0.0006978957680985332
gene O 0 1.7696072973194532e-05
, O 0 1.8621888102643425e-06
PTEN O 0 0.011393498629331589
/ O 0 0.0009105850476771593
MMAC1 O 0 0.00906699150800705
, O 0 3.023216095243697e-07
was O 0 1.1346029538117364e-07
isolated O 0 1.6576512962274137e-06
recently O 0 3.37914798365091e-07
at O 0 7.288635828217593e-08
this O 0 9.551387236683695e-09
region O 0 1.0238784398097778e-07
of O 0 4.035006284652809e-08
chromosome O 0 8.577860717196018e-05
10q23 O 0 0.00011445401469245553
and O 0 4.587722912674508e-08
found O 0 2.4463842507316258e-08
to O 0 1.2894735945678804e-08
be O 0 7.155787073997999e-09
inactivated O 0 3.404345818580623e-07
by O 0 6.515060846368215e-08
mutation O 0 3.4736006000457564e-06
in O 0 8.546154504074366e-07
three O 0 0.00017193166422657669
prostate B-Disease 1 0.9999868869781494
cancer I-Disease 1 0.9995437264442444
cell O 0 0.0007250336930155754
lines O 0 0.00012029409117531031
. O 0 2.103149745380506e-05

We O 0 5.322743527358398e-05
screened O 0 0.00033912647631950676
80 O 0 0.0010061148786917329
prostate B-Disease 1 0.9997804760932922
tumors I-Disease 1 0.9993719458580017
by O 0 1.0364748277424951e-06
microsatellite O 0 0.00017081234545912594
analysis O 0 4.815996703655401e-07
and O 0 1.6616921527656814e-07
found O 0 5.583074198511895e-07
chromosome O 0 5.431779209175147e-05
10q23 O 0 6.081884930608794e-05
to O 0 4.240231987751031e-08
be O 0 1.0992803112230831e-08
deleted O 0 3.403923471978487e-07
in O 0 1.8331228091028606e-07
23 O 0 2.73468367595342e-06
cases O 0 4.701726084022084e-06
. O 0 8.207640348700806e-06

We O 0 7.060546977299964e-06
then O 0 8.155023465405975e-07
proceeded O 0 1.0985634162352653e-06
with O 0 8.158899333920999e-08
sequence O 0 1.733496617362107e-07
analysis O 0 5.678322878566178e-08
of O 0 2.14208473181543e-08
the O 0 5.132756086823065e-08
entire O 0 7.947574545141833e-07
PTEN O 0 0.0030857583042234182
/ O 0 0.00020970623882021755
MMAC1 O 0 0.0018183559877797961
coding O 0 3.1748644687468186e-05
region O 0 8.224982934734726e-07
and O 0 1.0542864004037256e-07
tested O 0 3.5118821983814996e-07
for O 0 2.918448771538351e-08
homozygous O 0 1.6118162875500275e-06
deletion O 0 2.495549779268913e-06
with O 0 4.496337524528826e-08
new O 0 4.7523047896902426e-07
intragenic O 0 0.004387817811220884
markers O 0 1.598828748683445e-05
in O 0 6.337018731983335e-08
these O 0 3.473168419532158e-08
23 O 0 6.18137960373133e-07
cases O 0 4.5214926558401203e-07
with O 0 2.0970214791304898e-06
10q23 O 0 0.022423898801207542
loss O 0 0.0006939293816685677
of O 0 4.3196819206059445e-06
heterozygosity O 0 0.056501101702451706
. O 0 2.634859447425697e-05

The O 0 3.6881401683785953e-06
identification O 0 1.0613972563078278e-06
of O 0 1.0754618529063009e-07
the O 0 1.6909727662550722e-07
second O 0 1.0483794312676764e-06
mutational O 0 0.0004315382684580982
event O 0 1.2388048844513833e-06
in O 0 7.345015973214686e-08
10 O 0 1.9096685832664662e-07
( O 0 2.2407472499708092e-07
43 O 0 9.010549320009886e-07
% O 0 5.155013127478014e-07
) O 0 7.309612556127831e-06
tumors B-Disease 1 0.9330092668533325
establishes O 0 0.0002682198246475309
PTEN O 0 0.03469756990671158
/ O 0 0.00034796076943166554
MMAC1 O 0 0.0001921699586091563
as O 0 2.473946913994496e-08
a O 0 1.6806104952138412e-08
main O 0 2.319787313354027e-07
inactivation O 0 3.7958143366267905e-05
target O 0 1.1968114677074482e-07
of O 0 7.762471199157517e-08
10q O 0 0.001523887855000794
loss O 0 0.0009487224742770195
in O 0 1.9747116311918944e-05
sporadic B-Disease 1 0.844235360622406
prostate I-Disease 1 0.9999922513961792
cancer I-Disease 1 0.9996045231819153
. O 0 8.388338756049052e-06
. O 0 1.304249235545285e-05

Risk O 0 0.002298047300428152
reversals O 0 0.0005903699202463031
in O 0 5.324132871464826e-06
predictive O 0 0.0001430279662599787
testing O 0 0.00011924147111130878
for O 0 8.987684122985229e-05
Huntington B-Disease 1 0.9997405409812927
disease I-Disease 1 0.9994016885757446
. O 0 7.828559319023043e-05

The O 0 4.790039383806288e-06
first O 0 2.1118548829690553e-06
predictive O 0 3.2529547752346843e-05
testing O 0 3.870891669066623e-05
for O 0 4.025575253763236e-05
Huntington B-Disease 1 0.9999129772186279
disease I-Disease 1 0.9996452331542969
( O 0 4.028480361739639e-06
HD B-Disease 0 3.2341209589503706e-05
) O 0 9.73208642562895e-08
was O 0 1.3565500722734214e-08
based O 0 1.2460255938151477e-08
on O 0 8.219985581092715e-09
analysis O 0 2.331325887894309e-08
of O 0 1.2903051960222456e-08
linked O 0 1.8773829424389987e-06
polymorphic O 0 2.4164473870769143e-05
DNA O 0 6.714740720781265e-06
markers O 0 9.516350473859347e-06
to O 0 6.470169466865627e-08
estimate O 0 3.253450131524005e-07
the O 0 2.2680227473870218e-08
likelihood O 0 5.519823957911285e-07
of O 0 5.765675581415053e-08
inheriting O 0 2.1150308384676464e-05
the O 0 2.140090344937562e-07
mutation O 0 2.7514074645296205e-06
for O 0 4.4815982391810394e-07
HD B-Disease 0 0.00012871995568275452
. O 0 8.518866707163397e-06

Limits O 0 2.3567581592942588e-05
to O 0 8.704969332029577e-07
accuracy O 0 9.345768035018409e-07
included O 0 1.5101640826742369e-07
recombination O 0 1.1847439509438118e-06
between O 0 7.212545938273252e-08
the O 0 7.154547887466833e-08
DNA O 0 5.758219231211115e-06
markers O 0 7.23214543540962e-06
and O 0 5.3882004635852354e-08
the O 0 7.262283219233723e-08
mutation O 0 2.3533254989160923e-06
, O 0 1.0435012853804437e-07
pedigree O 0 3.113916318397969e-05
structure O 0 6.830543952673906e-07
, O 0 3.3184726078161475e-08
and O 0 3.208176124758211e-08
whether O 0 9.096044095713296e-08
DNA O 0 1.7233935523108812e-06
samples O 0 1.7440578403693507e-07
were O 0 1.3468586246290215e-08
available O 0 2.7346725772758873e-08
from O 0 6.656483719780226e-08
family O 0 1.4261926253311685e-06
members O 0 1.0033738817583071e-06
. O 0 6.845485586381983e-06

With O 0 4.509358859650092e-06
direct O 0 1.7401880541001447e-06
tests O 0 9.428702014702139e-07
for O 0 6.314120071237994e-08
the O 0 1.1125570154035813e-07
HD B-Disease 0 3.2404244848294184e-05
mutation O 0 5.251347374723991e-06
, O 0 1.0220794877113804e-07
we O 0 3.354837119218246e-08
have O 0 1.3016336453119948e-08
assessed O 0 8.37177722701199e-08
the O 0 8.274933627205883e-09
accuracy O 0 5.969986460740984e-08
of O 0 1.2789556969039495e-08
results O 0 1.8121048128705297e-07
obtained O 0 5.0730736944615273e-08
by O 0 2.650737762621702e-08
linkage O 0 3.822070993919624e-06
approaches O 0 3.164519455367554e-07
when O 0 4.2995203841655893e-08
requested O 0 9.7770744389436e-08
to O 0 3.0298483721935554e-08
do O 0 4.511413465024816e-08
so O 0 1.3939129850371046e-08
by O 0 1.9924273786386948e-08
the O 0 6.6024654188368e-08
test O 0 1.8985874703503214e-06
individuals O 0 9.922518984240014e-07
. O 0 2.8411238872649847e-06

For O 0 5.3819321692571975e-06
six O 0 2.122556225003791e-06
such O 0 6.166512775962474e-07
individuals O 0 8.152504165082064e-07
, O 0 2.825646845394658e-07
there O 0 1.4600038866774412e-07
was O 0 2.3858024178480264e-07
significant O 0 3.4209830346298986e-07
disparity O 0 2.1458450646605343e-05
between O 0 5.684710799869208e-07
the O 0 6.408367880794685e-07
tests O 0 1.1635071132332087e-05
. O 0 8.593158781877719e-06

Three O 0 6.940280400158372e-06
went O 0 3.810054295172449e-06
from O 0 3.2739865218900377e-07
a O 0 4.645636977329559e-07
decreased O 0 9.347319428343326e-05
risk O 0 1.3499236047209706e-05
to O 0 7.020383208100611e-08
an O 0 4.666924624530111e-08
increased O 0 1.0714300060499227e-06
risk O 0 5.6818985285644885e-06
, O 0 2.735564663680634e-08
while O 0 1.4711146079093851e-08
in O 0 1.708985308823685e-08
another O 0 5.0718643507252636e-08
three O 0 7.150060099547773e-08
the O 0 4.904543402517447e-07
risk O 0 1.9778743080678396e-05
was O 0 1.0309129265806405e-06
decreased O 0 4.344605258665979e-05
. O 0 6.580416084034368e-06

Knowledge O 0 1.491362854721956e-05
of O 0 1.4914743360350258e-06
the O 0 1.1341350045768195e-06
potential O 0 2.9167961201892467e-06
reasons O 0 2.2000659782861476e-07
for O 0 2.7816605907560188e-08
these O 0 1.8542122504072722e-08
changes O 0 3.439888374145994e-08
in O 0 2.9784462896031982e-08
results O 0 5.60093894819147e-07
and O 0 7.993770623215823e-08
impact O 0 6.948300210751768e-07
of O 0 3.342841381481776e-08
these O 0 1.1608737082724474e-07
risk O 0 9.837531251832843e-06
reversals O 0 1.8086111595039256e-05
on O 0 1.3163030132545828e-07
both O 0 3.6955864857191045e-07
patients O 0 5.198952931095846e-05
and O 0 1.0740514966300907e-07
the O 0 9.844514181622799e-08
counseling O 0 1.4722840205649845e-05
team O 0 2.460010364302434e-07
can O 0 3.348035448880182e-08
assist O 0 6.7202172715497e-08
in O 0 7.722831263379248e-09
the O 0 7.640067245517912e-09
development O 0 2.3137703308862e-08
of O 0 1.2206952781923519e-08
strategies O 0 1.2654854799620807e-06
for O 0 2.710623725477035e-08
the O 0 1.546001584529222e-07
prevention O 0 2.8758520784322172e-05
and O 0 9.613972906663548e-08
, O 0 1.1602129035281905e-07
where O 0 2.43940718291924e-07
necessary O 0 1.2789281811365072e-07
, O 0 6.471848479350228e-08
management O 0 5.637261324409337e-07
of O 0 2.3702847684603512e-08
a O 0 2.83087956631789e-07
risk O 0 1.6310277715092525e-05
reversal O 0 4.031670414406108e-06
in O 0 4.456328994706382e-08
any O 0 4.9108148658660866e-08
predictive O 0 2.4010753350012237e-06
testing O 0 1.3721527238885756e-06
program O 0 7.781577551213559e-07
. O 0 7.210152830339212e-07
. O 0 3.5341981856618077e-06

A O 0 3.970611942349933e-05
novel O 0 4.520247603068128e-05
common O 0 1.3179653251427226e-05
missense O 0 0.0004970118752680719
mutation O 0 2.512494393158704e-05
G301C O 0 2.970612513308879e-05
in O 0 6.912728878205598e-08
the O 0 7.726282547082519e-08
N O 0 1.1415004337322898e-05
- O 0 9.884102473733947e-05
acetylgalactosamine O 0 0.00042676585144363344
- O 0 9.565222717355937e-05
6 O 0 6.588585620193044e-06
- O 0 0.0013949208660051227
sulfate O 0 0.004135090857744217
sulfatase O 0 0.020344151183962822
gene O 0 7.324573743971996e-06
in O 0 1.813209337342414e-06
mucopolysaccharidosis B-Disease 0 0.00374204502440989
IVA I-Disease 0 0.17446215450763702
. O 0 1.8977740182890557e-05

Mucopolysaccharidosis B-Disease 1 0.9406331777572632
IVA I-Disease 1 0.9948766827583313
( O 0 0.0016594650223851204
MPS B-Disease 0 0.3963187336921692
IVA I-Disease 1 0.999789297580719
) O 0 3.608438419178128e-05
is O 0 1.2775094546668697e-06
an O 0 5.713489827030571e-06
autosomal B-Disease 1 0.9849302768707275
recessive I-Disease 1 0.9994113445281982
lysosomal I-Disease 1 0.9999681711196899
storage I-Disease 1 0.9990456700325012
disorder I-Disease 1 0.9998468160629272
caused O 0 0.0005628633080050349
by O 0 2.8929781592523796e-07
a O 0 8.218952416427783e-07
genetic B-Disease 0 0.008610377088189125
defect I-Disease 0 0.003622566582635045
in O 0 1.2806393101527647e-07
N O 0 2.5432524125790223e-05
- O 0 0.0001750858937157318
acetylgalactosamine O 0 0.0007044251542538404
- O 0 0.00028192115132696927
6 O 0 1.647842873353511e-05
- O 0 0.020256217569112778
sulfate O 0 0.04501965269446373
sulfatase O 1 0.5542474985122681
( O 0 6.686540928058093e-06
GALNS O 0 0.0015792398480698466
) O 0 3.3588212318136357e-06
. O 0 4.063857431901852e-06

In O 0 7.2932139119075146e-06
previous O 0 5.5755253924871795e-06
studies O 0 2.5225979243259644e-06
, O 0 3.335721316943818e-07
we O 0 9.434101855276822e-08
have O 0 2.9506550092150974e-08
found O 0 3.724467845245272e-08
two O 0 2.5489464761108138e-08
common O 0 8.906048947210365e-07
mutations O 0 4.46794410891016e-06
in O 0 1.1446016401350789e-07
Caucasians O 0 1.942984999914188e-05
and O 0 3.8258895074250177e-07
Japanese O 0 2.6414622880110983e-06
, O 0 1.3660253443958936e-06
respectively O 0 9.050389053300023e-06
. O 0 6.8967274273745716e-06

To O 0 1.5415731468237936e-05
characterize O 0 0.00011497710511321202
the O 0 1.3039939403824974e-06
mutational O 0 0.0001489103160565719
spectrum O 0 1.6951044017332606e-06
in O 0 8.856671485091283e-08
various O 0 1.7239404570545958e-08
ethnic O 0 1.0049178200688402e-07
groups O 0 1.4717004148678825e-07
, O 0 3.469441764991643e-07
mutations O 0 1.4410704807232833e-06
in O 0 3.1654700194394536e-08
the O 0 8.949012197945194e-08
GALNS O 0 0.00029199299751780927
gene O 0 8.138847533700755e-07
in O 0 9.73026814676814e-08
Colombian O 0 4.012315457657678e-06
MPS B-Disease 0 0.016922544687986374
IVA I-Disease 1 0.9999288320541382
patients O 0 0.022955985739827156
were O 0 3.3064435456253705e-07
investigated O 0 1.1770759556384291e-05
, O 0 1.8534367995926004e-07
and O 0 1.8182312544468004e-07
genetic O 0 5.858086296939291e-06
backgrounds O 0 6.046756766409089e-07
were O 0 2.0204595330142183e-08
extensively O 0 2.6108671136171324e-07
analyzed O 0 5.795013180431852e-07
to O 0 4.7400476432812866e-08
identify O 0 2.6569770739115484e-07
racial O 0 2.2182965153660916e-07
origin O 0 6.861917256628658e-08
, O 0 2.7803928048797388e-08
based O 0 7.683575375949658e-08
on O 0 8.940550344505027e-08
mitochondrial O 0 1.559381234983448e-05
DNA O 0 8.500428521074355e-06
( O 0 5.824266509080189e-07
mtDNA O 0 4.487137630349025e-06
) O 0 5.246709520179138e-07
lineages O 0 6.061056410544552e-06
. O 0 3.517966433719266e-06

Three O 0 3.345857112435624e-05
novel O 0 0.00010847178782569245
missense O 0 0.03085220418870449
mutations O 0 0.004182481672614813
never O 0 8.987000910565257e-06
identified O 0 8.436051643911924e-07
previously O 0 2.3115917713312228e-07
in O 0 4.511585771638238e-08
other O 0 4.572740763819638e-08
populations O 0 1.5820888847883907e-06
and O 0 7.526559642201391e-08
found O 0 4.0542921908581775e-08
in O 0 2.0712040083026295e-08
16 O 0 5.032077865507745e-08
out O 0 1.6948387582260693e-08
of O 0 3.192427300291456e-08
19 O 0 9.214556371262006e-07
Colombian O 0 2.7980024697171757e-06
MPS B-Disease 0 0.000805137911811471
IVA I-Disease 1 0.9971036314964294
unrelated O 0 0.00012085655180271715
alleles O 0 5.1822748901031446e-06
account O 0 6.766757678633439e-07
for O 0 3.92210523614267e-07
84 O 0 2.198386937379837e-05
. O 0 8.778693882049993e-06

2 O 0 4.0487677324563265e-05
% O 0 1.8896656683864421e-06
of O 0 4.123967300984077e-07
the O 0 5.732635486310755e-07
alleles O 0 3.2446673685626592e-06
in O 0 2.5212580112565774e-07
this O 0 4.529036345957138e-07
study O 0 9.162267815554515e-06
. O 0 7.606034159834962e-06

The O 0 3.9870457840152085e-05
G301C O 0 0.0022346621844917536
and O 0 1.1027612345060334e-05
S162F O 0 0.0044412012211978436
mutations O 0 8.468787564197555e-05
account O 0 1.3723072243010392e-06
for O 0 7.728521609351446e-07
68 O 0 2.6310226530767977e-05
. O 0 8.273898856714368e-06

4 O 0 8.566195901948959e-05
% O 0 1.0378158549428917e-05
and O 0 3.5769121495832223e-06
10 O 0 6.862270311103202e-06
. O 0 1.156091002485482e-05

5 O 0 3.729893433046527e-05
% O 0 2.212976824012003e-06
of O 0 4.3843209596161614e-07
mutations O 0 3.5329288948560134e-05
, O 0 2.2187704473708436e-07
respectively O 0 5.165568950360466e-07
, O 0 6.168652788574036e-08
whereas O 0 1.9808121010100876e-07
the O 0 4.205613279850695e-08
remaining O 0 1.7959071385575953e-07
F69V O 0 0.0003734559868462384
is O 0 3.3611648575515574e-08
limited O 0 4.4167524748672804e-08
to O 0 2.751283467716803e-08
a O 0 6.89858268287935e-08
single O 0 5.274025056678511e-07
allele O 0 6.70053350404487e-06
. O 0 4.116900072403951e-06

The O 0 1.753781361912843e-05
skewed O 0 0.00011509184696478769
prevalence O 0 0.0008357334299944341
of O 0 1.4232795138013898e-06
G301C O 0 0.000375919888028875
in O 0 3.4297605111532903e-07
only O 0 8.313188004649419e-08
Colombian O 0 5.008521384297637e-06
patients O 0 6.665884575340897e-05
and O 0 2.1007076611567754e-07
haplotype O 0 9.139370376942679e-05
analysis O 0 1.6669760327658878e-07
by O 0 2.295987755474016e-08
restriction O 0 9.154891955631683e-08
fragment O 0 9.512925771559821e-07
length O 0 4.5586071450998134e-07
polymorphisms O 0 5.169544238015078e-06
in O 0 3.7360578630796226e-08
the O 0 1.1593049009661627e-07
GALNS O 0 0.000982763827778399
gene O 0 1.4220936463971157e-06
suggest O 0 5.797599555990018e-07
that O 0 6.270624908211175e-08
G301C O 0 2.3376824174192734e-05
originated O 0 3.004608117862517e-07
from O 0 6.53438760878089e-08
a O 0 2.2204362437605596e-07
common O 0 1.738796186145919e-06
ancestor O 0 2.1328203729353845e-05
. O 0 8.216372407332528e-06

Investigation O 0 9.52096888795495e-05
of O 0 1.3226291457613115e-06
the O 0 1.0595889534670277e-06
genetic O 0 3.482817919575609e-05
background O 0 9.88234432952595e-07
by O 0 5.887068610377355e-08
means O 0 3.890068356326992e-08
of O 0 2.3939428217545355e-08
mtDNA O 0 1.9830549717880785e-06
lineages O 0 2.5870731406030245e-06
indicate O 0 4.2702620817181014e-07
that O 0 1.384010150928816e-08
all O 0 1.0145895679158912e-08
our O 0 3.891612720963167e-07
patients O 0 1.7888723959913477e-05
are O 0 2.4323513869717317e-08
probably O 0 1.4110105439613108e-07
of O 0 7.244173616527405e-08
native O 0 4.9634727474767715e-06
American O 0 1.2266688827367034e-05
descent O 0 0.0003731408796738833

Low O 0 5.886680446565151e-05
frequency O 0 1.7393405869370326e-05
of O 0 5.258734745439142e-06
BRCA1 O 0 0.004590084310621023
germline O 0 0.02717759646475315
mutations O 0 9.701932867756113e-05
in O 0 6.734003932251653e-07
45 O 0 9.075765774468891e-06
German O 0 0.1150304302573204
breast B-Disease 1 0.9999245405197144
/ I-Disease 1 0.9999452829360962
ovarian I-Disease 1 0.9999973773956299
cancer I-Disease 1 0.9999288320541382
families O 0 0.00034458335721865296
. O 0 3.2545220165047795e-05

In O 0 6.60646128380904e-06
this O 0 8.277381766674807e-07
study O 0 1.050250830303412e-06
we O 0 2.222981123622958e-07
investigated O 0 5.408105153037468e-06
45 O 0 3.060503331653308e-06
German O 0 0.028965285047888756
breast B-Disease 1 0.9998849630355835
/ I-Disease 1 0.9999731779098511
ovarian I-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999231100082397
families O 0 2.4190365365939215e-05
for O 0 1.8712108840190922e-06
germline O 0 0.07293186336755753
mutations O 0 5.336853428161703e-05
in O 0 2.439465447423572e-07
the O 0 1.6196919432331924e-06
BRCA1 O 0 0.0020430118311196566
gene O 0 2.90563257294707e-05
. O 0 4.431115485203918e-06

We O 0 1.8478542187949643e-05
identified O 0 8.315198101627175e-06
four O 0 1.1939424666707055e-06
germline O 0 0.02722361870110035
mutations O 0 0.00020811412832699716
in O 0 9.98212385638908e-07
three O 0 1.9909964976250194e-05
breast B-Disease 1 0.9989301562309265
cancer I-Disease 1 0.863088846206665
families O 0 4.473728949960787e-06
and O 0 5.558264319915907e-07
in O 0 1.145530291069008e-06
one O 0 5.197272912482731e-05
breast B-Disease 1 0.999936580657959
- I-Disease 1 0.9999970197677612
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999902248382568
family O 0 0.00016591644089203328
. O 0 2.660562472556194e-07
among O 0 6.624262738341713e-08
these O 0 1.3145425192817584e-08
were O 0 2.2722531412000535e-08
one O 0 6.713964495475011e-08
frameshift O 0 0.001146327005699277
mutation O 0 3.8451516957138665e-06
, O 0 3.31594165459137e-08
one O 0 2.3115823921671108e-08
nonsense O 0 7.661173185624648e-06
mutation O 0 1.357467112939048e-06
, O 0 2.7916851053078062e-08
one O 0 1.8885272012880705e-08
novel O 0 5.861360250491998e-07
splice O 0 3.381939677638002e-05
site O 0 1.494098114562803e-06
mutation O 0 1.2956179489265196e-06
, O 0 5.8638377709030465e-08
and O 0 1.2572726859616523e-07
one O 0 6.637085903093976e-07
missense O 0 0.00039246841333806515
mutation O 0 8.249314851127565e-05
. O 0 6.796016805310501e-06

The O 0 5.3265877795638517e-05
missense O 0 0.011522511020302773
mutation O 0 0.0004369389498606324
was O 0 1.0239639323117444e-06
also O 0 2.025329592925118e-07
found O 0 2.2549687628270476e-07
in O 0 2.663436191596702e-07
2 O 0 4.866176368523156e-06
. O 0 6.965510692680255e-06

8 O 0 3.6792054743273184e-05
% O 0 1.0041262612503488e-06
of O 0 1.6462736596167815e-07
the O 0 1.7833578169756947e-07
general O 0 9.543739452055888e-07
population O 0 3.25951248214551e-07
, O 0 2.1467255351126369e-07
suggesting O 0 2.01932675736316e-06
that O 0 9.299556325004232e-08
it O 0 9.393629341047927e-08
is O 0 5.429802172329801e-07
not O 0 3.864377958961995e-06
disease O 0 0.16073691844940186
associated O 0 3.230341462767683e-05
. O 0 1.3060538549325429e-05

The O 0 2.3333923309110105e-05
average O 0 7.954266766319051e-05
age O 0 2.941102320619393e-05
of O 0 1.4081503650231753e-05
disease O 1 0.9802300930023193
onset O 1 0.8519703149795532
in O 0 2.5794433895498514e-06
those O 0 2.8911567824252415e-06
families O 0 0.00012419729318935424
harbouring O 1 0.9736335873603821
causative O 1 0.8888777494430542
mutations O 0 0.00014994388038758188
was O 0 3.1099753527996654e-07
between O 0 8.884019280230859e-07
32 O 0 6.191442480485421e-06
. O 0 6.883446985739283e-06

3 O 0 0.0001289442734559998
and O 0 1.1431346138124354e-05
37 O 0 4.9604717787588015e-05
. O 0 2.6228157366858795e-05

4 O 0 8.734792936593294e-05
years O 0 5.787761438114103e-06
, O 0 8.279245093945065e-07
whereas O 0 1.8128824876839644e-06
the O 0 3.0658620175927354e-07
family O 0 6.689539077342488e-06
harbouring O 0 0.001093695405870676
the O 0 8.494622534271912e-07
missense O 0 0.0008682655170559883
mutation O 0 2.3069518647389486e-05
had O 0 2.3948842908794177e-07
an O 0 2.8014143893528853e-08
average O 0 7.195253601821605e-07
age O 0 3.125439320683654e-07
of O 0 1.2525836723398243e-07
onset O 0 0.0029436408076435328
of O 0 5.690210400643991e-07
51 O 0 3.8471436710096896e-05
. O 0 1.0094078788824845e-05

2 O 0 0.00028955176821909845
years O 0 9.96487433440052e-05
. O 0 0.0001028230763040483

These O 0 1.6180405509658158e-05
findings O 0 4.047860056743957e-05
show O 0 3.9199389902933035e-06
that O 0 7.199790843515075e-07
BRCA1 O 0 0.0002785050601232797
is O 0 1.5415700715948333e-07
implicated O 0 3.1679876428825082e-06
in O 0 3.788267832760539e-08
a O 0 3.0059375433211244e-08
small O 0 1.015800137338374e-07
fraction O 0 2.134823944288655e-06
of O 0 1.0151363312616013e-05
breast B-Disease 1 0.9998903274536133
/ I-Disease 1 0.9999778270721436
ovarian I-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999306201934814
families O 0 1.612745654711034e-05
suggesting O 0 5.077922196505824e-06
the O 0 7.851187433516316e-08
involvement O 0 1.2150063639637665e-06
of O 0 1.4691075023165467e-07
another O 0 7.136650765460217e-06
susceptibility O 0 0.03777872771024704
gene O 0 6.434745591832325e-05
( O 0 1.1136881767015439e-05
s O 0 0.0006145266816020012
) O 0 2.3399350538966246e-05

Paternal O 0 0.18684743344783783
transmission O 0 0.056333571672439575
of O 0 0.00855798739939928
congenital B-Disease 1 0.9999772310256958
myotonic I-Disease 1 0.9999743700027466
dystrophy I-Disease 1 0.9999691247940063
. O 0 0.005475581157952547

We O 0 2.6984478608937934e-05
report O 0 1.0629161806718912e-05
a O 0 1.6325742535627796e-06
rare O 0 9.532328476780094e-06
case O 0 6.315839073067764e-06
of O 0 1.2125143257435411e-05
paternally O 1 0.9888624548912048
transmitted O 1 0.9905727505683899
congenital B-Disease 1 0.9999911785125732
myotonic I-Disease 1 0.9999933242797852
dystrophy I-Disease 1 0.9999933242797852
( O 0 0.06110873445868492
DM B-Disease 1 0.9997891783714294
) O 0 8.796682232059538e-05
. O 0 1.334801345365122e-05

The O 0 1.8716995327849872e-05
proband O 0 0.0009487925563007593
is O 0 5.056458007857145e-07
a O 0 2.0211578544149233e-07
23 O 0 5.952284141130804e-07
year O 0 4.623431664185773e-07
old O 0 3.899356670444831e-05
, O 0 2.1013134755776264e-05
mentally B-Disease 1 0.9600357413291931
retarded I-Disease 1 0.9744652509689331
male O 0 0.015334510244429111
who O 0 0.04535958170890808
suffers O 1 0.9999322891235352
severe O 1 0.9996063113212585
muscular B-Disease 1 0.9996169805526733
weakness I-Disease 1 0.9553759694099426
. O 0 6.455513357650489e-05

He O 0 7.734912651358172e-05
presented O 0 4.755812915391289e-05
with O 0 0.00019940697529818863
respiratory O 1 0.9980157613754272
and O 0 3.441980152274482e-05
feeding O 0 0.000956791453063488
difficulties O 0 0.002476747613400221
at O 0 2.5764717065612786e-05
birth O 0 0.0005666820798069239
. O 0 2.3474360205000266e-05

His O 0 6.29012574790977e-05
two O 0 3.950194877688773e-05
sibs O 1 0.9904283285140991
suffer O 1 0.6027337908744812
from O 0 6.663717795163393e-05
childhood O 1 0.9175252914428711
onset O 1 0.9993785619735718
DM B-Disease 1 0.9998034834861755
. O 0 0.00028533616568893194

Their O 0 8.259778951469343e-06
late O 0 1.2170904483355116e-05
father O 0 1.804731073207222e-05
had O 0 4.008228415841586e-07
the O 0 8.386464145360151e-08
adult O 0 5.810496759295347e-07
type O 0 2.3854161099734483e-06
of O 0 5.741126756220183e-07
DM B-Disease 1 0.9996647834777832
, O 0 1.2238400586284115e-06
with O 0 9.25438826016034e-07
onset O 0 0.004517308436334133
around O 0 6.139566721685696e-07
30 O 0 1.321380977969966e-06
years O 0 3.2489961085957475e-06
. O 0 6.3204906837199815e-06

Only O 0 3.1085867249203147e-06
six O 0 1.035523382597603e-06
other O 0 1.7390337347933382e-07
cases O 0 5.722241098737868e-07
of O 0 4.583913835176645e-07
paternal O 0 0.00762019632384181
transmission O 0 0.0013868395471945405
of O 0 0.00017616400145925581
congenital B-Disease 1 0.9999946355819702
DM I-Disease 1 0.9999829530715942
have O 0 8.009565135580488e-06
been O 0 1.2837112990382593e-06
reported O 0 1.2058687389071565e-05
recently O 0 2.4226845198427327e-05
. O 0 1.3724060409003869e-05

We O 0 1.2756719115714077e-05
review O 0 9.382002644997556e-06
the O 0 5.803269687021384e-07
sex O 0 5.516926194104599e-06
related O 0 7.642382115591317e-06
effects O 0 2.0141022105235606e-05
on O 0 1.4089372371017816e-06
transmission O 0 0.0001539632212370634
of O 0 0.00011296679440420121
congenital B-Disease 1 0.9999629259109497
DM I-Disease 1 0.9998581409454346
. O 0 0.00028384439065121114

Decreased O 0 0.015876607969403267
fertility O 0 0.007325100712478161
of O 0 2.2896131213201443e-06
males O 0 6.107387889642268e-06
with O 0 1.722121965030965e-06
adult O 0 4.8947880713967606e-05
onset O 1 0.9883807897567749
DM B-Disease 1 0.9998608827590942
and O 0 3.567839712559362e-06
contraction O 0 9.410308121005073e-05
of O 0 5.647948952969273e-08
the O 0 1.5088338045643468e-07
repeat O 0 1.719824649626389e-05
upon O 0 1.825262359034241e-07
male O 0 7.603863423355506e-07
transmission O 0 1.8150933556171367e-06
contribute O 0 2.1367539204675268e-07
to O 0 2.491619888189689e-08
the O 0 2.3426165896012208e-08
almost O 0 6.785467121517286e-08
absent O 0 1.758146936481353e-06
occurrence O 0 8.06382013252005e-06
of O 0 4.571947158638068e-07
paternal O 0 0.0005925972363911569
transmission O 0 0.00030539403087459505
of O 0 6.934247358003631e-05
congenital B-Disease 1 0.9999608993530273
DM I-Disease 1 0.9998419284820557
. O 0 0.00024412828497588634

Also O 0 1.068634355760878e-05
the O 0 8.570370937377447e-07
fathers O 0 2.9249467843328603e-06
of O 0 1.3043879221186216e-07
the O 0 4.157037380991824e-07
reported O 0 2.0213969037286006e-05
congenitally O 0 0.017769349738955498
affected O 0 4.947772322339006e-05
children O 0 2.5074200493691023e-06
showed O 0 1.3408234735834412e-06
, O 0 3.7294437760238e-08
on O 0 4.779876405791583e-08
average O 0 4.83174403598241e-07
, O 0 1.224869379257143e-07
shorter O 0 2.36055234381638e-06
CTG O 0 0.0003669412690214813
repeat O 0 1.938579953275621e-05
lengths O 0 3.113010461675003e-05
and O 0 3.386316222986352e-07
hence O 0 3.2906909837038256e-06
less O 0 4.1105840864474885e-06
severe O 1 0.7327456474304199
clinical O 0 0.25697657465934753
symptoms O 0 0.048304930329322815
than O 0 1.09589763042095e-07
the O 0 3.5480644555718754e-07
mothers O 0 5.834137482452206e-05
of O 0 7.254847673721088e-07
children O 0 7.322746387217194e-05
with O 0 0.0011388541897758842
congenital B-Disease 1 0.9999771118164062
DM I-Disease 1 0.9998956918716431
. O 0 0.000360310630640015

We O 0 2.4078188289422542e-05
conclude O 0 0.00016361844609491527
that O 0 2.6812838314071996e-06
paternal O 0 0.0004051889118272811
transmission O 0 0.0004365546628832817
of O 0 0.00017429304716642946
congenital B-Disease 1 0.999995231628418
DM I-Disease 1 0.9999896287918091
is O 0 9.13000349100912e-06
rare O 0 1.3767700693279039e-05
and O 0 9.772522844286868e-07
preferentially O 0 1.303301723964978e-05
occurs O 0 7.316449455174734e-07
with O 0 2.941998786809563e-07
onset O 0 0.004696075804531574
of O 0 6.444896030188829e-07
DM B-Disease 1 0.9978917241096497
past O 0 1.0761600606201682e-06
30 O 0 1.6346777442777238e-07
years O 0 9.694884539612758e-08
in O 0 4.147920407149286e-08
the O 0 2.0079437490494456e-07
father O 0 8.427933607890736e-06
. O 0 9.844849273576983e-07
. O 0 3.740275815289351e-06

The O 0 9.892984962789342e-05
RB1 O 0 0.42062830924987793
gene O 0 0.0005281958729028702
mutation O 0 0.00010594980994937941
in O 0 9.657738928581239e-07
a O 0 1.1548946758921375e-06
child O 0 9.226104157278314e-05
with O 0 9.630092972656712e-05
ectopic B-Disease 1 0.9984700083732605
intracranial I-Disease 1 0.9991740584373474
retinoblastoma I-Disease 1 0.9148423075675964
. O 0 9.309540473623201e-05

The O 0 0.00010308392666047439
RB1 O 1 0.8225158452987671
gene O 0 0.0006437966949306428
mutation O 0 0.00025840423768386245
was O 0 8.931233992370835e-07
investigated O 0 2.000738504648325e-06
in O 0 1.1035221803012973e-07
a O 0 4.12848891073736e-07
child O 0 2.019358544202987e-05
with O 0 1.6866863006725907e-05
ectopic B-Disease 1 0.9912263751029968
intracranial I-Disease 1 0.9960105419158936
retinoblastoma I-Disease 0 0.010048449970781803
using O 0 2.4753117600084806e-07
DNA O 0 1.9118094769510208e-06
obtained O 0 7.13085697157112e-08
from O 0 1.3077030125430156e-08
both O 0 1.5406156350650235e-08
the O 0 1.313092070631683e-07
pineal B-Disease 0 0.001310354215092957
and I-Disease 0 8.695338692632504e-06
retinal I-Disease 1 0.9831063747406006
tumours I-Disease 1 0.9977203011512756
of O 0 8.744007686800614e-07
the O 0 4.457036538951797e-06
patient O 0 0.0005452610785141587
. O 0 1.1987744983343873e-05

A O 0 3.8766025681979954e-05
nonsense O 0 0.000377245363779366
mutation O 0 4.792142135556787e-05
in O 0 7.523407816734107e-07
exon O 0 9.141462942352518e-05
17 O 0 2.0536926967906766e-06
( O 0 2.3286845873826678e-07
codon O 0 7.784843205627112e-07
556 O 0 1.868575282060192e-06
) O 0 3.48735404998024e-08
of O 0 1.3373183449516546e-08
the O 0 9.614834795002025e-08
RB1 O 0 0.002364112064242363
gene O 0 1.1205318060092395e-06
was O 0 3.588856500869042e-08
found O 0 2.2116335429700484e-08
to O 0 1.3719306579673685e-08
be O 0 6.506204019984807e-09
present O 0 2.7178870709576586e-08
homozygously O 0 1.955661537067499e-05
in O 0 2.2794326426378575e-08
both O 0 2.367284857029972e-08
the O 0 1.5965302679887827e-07
retinal B-Disease 0 0.006265462376177311
and I-Disease 0 1.5318930763896788e-06
the I-Disease 0 6.956084234843729e-06
pineal I-Disease 0 0.46518391370773315
tumours I-Disease 1 0.9969897270202637
. O 0 2.0806646716664545e-05

The O 0 9.256990779249463e-06
same O 0 3.788379899560823e-06
mutation O 0 2.156522896257229e-05
was O 0 3.0088833113950386e-07
present O 0 1.7038469479757623e-07
heterozygously O 0 3.6888708564219996e-05
in O 0 4.7153847049230535e-08
the O 0 4.1608679168803064e-08
DNA O 0 7.224193154797831e-07
from O 0 1.9132938788857246e-08
the O 0 2.290860834364139e-08
constitutional O 0 2.1003629058213846e-07
cells O 0 8.883069995135884e-07
of O 0 4.632126149317628e-08
the O 0 4.834029709854804e-07
patient O 0 0.0001453386212233454
, O 0 3.8892343923180306e-07
proving O 0 1.2212099136377219e-05
it O 0 3.243752288994983e-08
to O 0 3.5069579240598614e-08
be O 0 1.8293727421792028e-08
of O 0 1.8192127981819795e-07
germline O 0 0.0008033651974983513
origin O 0 6.232829491636949e-06
. O 0 8.035700375330634e-06

The O 0 1.4685288078908343e-05
initial O 0 3.151170676574111e-05
mutation O 0 6.43404055153951e-05
was O 0 4.4977574020776956e-07
shown O 0 1.768234767496324e-07
to O 0 5.0122878292313544e-08
have O 0 4.839865397343601e-08
occurred O 0 2.2391067489024863e-07
in O 0 8.366413339899736e-08
the O 0 3.943652586713142e-07
paternally O 0 0.00023410191352013499
derived O 0 1.0720212230808102e-05
RB1 O 0 0.003189666662365198
allele O 0 2.092418617394287e-05
. O 0 7.404265033983393e-06

The O 0 2.686541665752884e-05
mutation O 0 0.00016270304331555963
is O 0 2.9525332934099424e-07
in O 0 7.581424910085843e-08
an O 0 2.490707728952657e-08
area O 0 6.189135604017793e-08
of O 0 1.0301464570261487e-08
the O 0 2.514209995752026e-08
gene O 0 1.2516761671577115e-07
that O 0 7.202411556050947e-09
encodes O 0 3.644837676120005e-08
the O 0 8.16917289370167e-09
protein O 0 6.834044086190261e-08
- O 0 8.567195436626207e-06
binding O 0 2.4243254870270903e-07
region O 0 2.860443828467396e-07
known O 0 1.0210467848992266e-07
as O 0 9.639418152573853e-09
the O 0 3.444431584398444e-08
pocket O 0 1.9648290617624298e-05
region O 0 7.240374202410749e-07
and O 0 6.591631773744666e-08
has O 0 5.325121321675397e-08
been O 0 4.216560967051919e-08
detected O 0 3.746040988517052e-07
in O 0 2.1110116321665373e-08
other O 0 3.599358677774944e-08
cases O 0 4.2482867002036073e-07
of O 0 6.919059956089768e-07
retinoblastoma B-Disease 0 0.06067763268947601
. O 0 3.4185311506007565e-06
. O 0 8.674954187881667e-06

Low O 0 7.049230771372095e-05
levels O 0 3.597627028284478e-06
of O 0 3.2168344432648155e-07
beta O 0 4.323617758927867e-06
hexosaminidase O 0 0.0006171353743411601
A O 0 5.072377007309115e-07
in O 0 5.950716968072811e-07
healthy O 0 2.3475478883483447e-05
individuals O 0 1.188596115753171e-06
with O 0 7.069656476232922e-06
apparent O 0 0.019852351397275925
deficiency O 1 0.8452234864234924
of O 0 3.0715102639078395e-07
this O 0 8.019485449040076e-07
enzyme O 0 6.0621678130701184e-05
. O 0 7.123738214431796e-06

Appreciable O 0 0.0009662426891736686
beta O 0 0.00027492790832184255
hexosaminidase O 0 0.0067641520872712135
A O 0 4.180487849225756e-06
( O 0 1.2236673683219124e-06
hex O 0 4.02468467655126e-05
A O 0 3.498040257454704e-07
) O 0 1.4798069969401695e-07
activity O 0 9.517147958604255e-08
has O 0 3.079646049286566e-08
been O 0 3.218079669409235e-08
detected O 0 5.088802481623134e-07
in O 0 1.0716327381032897e-07
cultured O 0 8.467350562568754e-05
skin O 0 0.20273183286190033
fibroblasts O 0 0.018990684300661087
and O 0 0.0009091746178455651
melanoma B-Disease 1 0.99993896484375
tissue O 0 0.24120035767555237
from O 0 2.083274011965841e-06
healthy O 0 5.263736238703132e-05
individuals O 0 7.787509730405873e-07
previously O 0 2.997858473463566e-06
reported O 0 4.609625648299698e-06
as O 0 4.812617362404126e-07
having O 0 1.8162387277698144e-05
deficiency B-Disease 0 0.2216268926858902
of I-Disease 0 6.367478277979899e-08
hex I-Disease 0 2.447303631925024e-05
A I-Disease 0 8.910826210239975e-08
activity O 0 8.541000084960615e-08
indistinguishable O 0 1.68790364796223e-07
from O 0 1.9235393722283334e-08
that O 0 1.927447002003646e-08
of O 0 1.3799895270949492e-07
patients O 0 0.00048578286077827215
with O 0 0.00010248751641483977
Tay B-Disease 1 0.9999961853027344
- I-Disease 1 0.9999822378158569
Sachs I-Disease 1 0.99998939037323
disease I-Disease 1 0.999100923538208
( O 0 7.61539486120455e-05
TSD B-Disease 1 0.5843106508255005
) O 0 7.804984306858387e-06
. O 0 6.44868623567163e-06

Identification O 0 4.728985368274152e-05
and O 0 3.8831703932373784e-06
quantitation O 0 0.00039337979978881776
of O 0 7.180810257523262e-07
hex O 0 0.00011711897241184488
A O 0 5.873726536265167e-07
, O 0 2.61047404137571e-07
amounting O 0 2.5983779323723866e-06
to O 0 4.1749433421500726e-07
3 O 0 5.142475401953561e-06
. O 0 8.379727660212666e-06

5 O 0 0.00017813484009820968
% O 0 2.5782514057937078e-05
- O 0 0.0013097720220685005
6 O 0 0.00011563583393581212
. O 0 2.9601211281260476e-05

9 O 0 3.143912545056082e-05
% O 0 8.193283633772808e-07
of O 0 1.588780946804036e-07
total O 0 3.4515610991547874e-07
beta O 0 3.7513500501518138e-06
hexosaminidase O 0 0.000527404248714447
activity O 0 4.0937359813142393e-07
, O 0 4.5231143275259456e-08
has O 0 2.137725552131542e-08
been O 0 9.991722116353685e-09
obtained O 0 3.073894916383324e-08
by O 0 4.9215046260542294e-08
cellulose O 0 1.3376825336308684e-05
acetate O 0 5.252078335615806e-05
gel O 0 0.00028007474611513317
electrophoresis O 0 3.266545900260098e-05
, O 0 1.0962614993559328e-07
DEAE O 0 2.5210460080415942e-05
- O 0 4.684892246586969e-06
cellulose O 0 7.944512617541477e-06
ion O 0 2.2278250071394723e-06
- O 0 1.4371014003700111e-05
exchange O 0 1.2634692438950879e-06
chromatography O 0 0.0001600051182322204
, O 0 4.1706582010192506e-07
radial O 0 3.912013562512584e-05
immunodiffusion O 0 0.00024359699455089867
, O 0 4.003705100785737e-07
and O 0 1.0843430118256947e-06
radioimmunoassay O 0 0.000972942856606096
. O 0 8.938834980654065e-06

Previous O 0 7.701695722062141e-05
family O 0 4.037855251226574e-05
studies O 0 4.636254743672907e-06
suggested O 0 2.9691070722037693e-06
that O 0 1.4847093154912727e-07
these O 0 7.734303153483779e-08
individuals O 0 3.264449048856477e-07
may O 0 4.923288656755176e-07
be O 0 1.410139560675816e-08
compound O 0 5.940125902270665e-07
heterozygotes O 0 1.594631976331584e-05
for O 0 2.8687452413578285e-08
the O 0 6.03547576361052e-08
common O 0 7.355319553425943e-07
mutant O 0 4.4923923269379884e-05
TSD B-Disease 0 0.07246778905391693
gene O 0 2.429469077469548e-06
and O 0 7.04971583331826e-08
a O 0 1.916395291345907e-07
rare O 0 3.761118477996206e-06
( O 0 1.0620968851071666e-06
allelic O 0 9.355345537187532e-05
) O 0 1.7011791442200774e-06
mutant O 0 1.9322162188473158e-05
gene O 0 8.064142093644477e-06
. O 0 4.514965894486522e-06

Thus O 0 2.207862416980788e-05
, O 0 1.5248893987518386e-06
the O 0 3.281282090483728e-07
postulated O 0 1.157924907602137e-05
rate O 0 1.3915986301071825e-06
mutant O 0 9.460926776228007e-06
gene O 0 9.8666089343169e-07
appears O 0 9.711614978868965e-08
to O 0 1.1702201874186358e-08
code O 0 1.3042728674861337e-08
for O 0 3.891929445387632e-09
the O 0 8.04311994784257e-09
expression O 0 3.50973508034258e-08
of O 0 2.0739236106237513e-08
low O 0 5.122354878039914e-07
amounts O 0 1.0775027448062247e-07
of O 0 1.0250606408135354e-07
hex O 0 7.372879917966202e-05
A O 0 1.9638664525700733e-06
. O 0 6.131326699687634e-06

Heterozygotes O 0 0.007175298873335123
for O 0 5.09124265590799e-06
the O 0 1.8391498315395438e-06
rare O 0 1.8296806956641376e-05
mutant O 0 8.359785715583712e-05
may O 0 1.3085608543406124e-06
be O 0 1.7310178179741342e-08
indistinguishable O 0 1.9150488128616416e-07
from O 0 5.715702755537677e-08
heterozygotes O 0 1.507735487393802e-05
for O 0 7.997461182185361e-08
the O 0 4.630367982372263e-07
common O 0 1.3286304238135926e-05
TSD B-Disease 0 0.31477659940719604
mutant O 0 0.0002842102258000523
. O 0 1.739755316521041e-05

However O 0 1.0179924174735788e-05
, O 0 6.502360747617786e-07
direct O 0 5.372447162699245e-07
visualization O 0 1.625397453608457e-05
and O 0 2.990423411119991e-07
quantitation O 0 0.00011120999261038378
of O 0 1.2492363055116584e-07
hex O 0 4.194180655758828e-05
A O 0 9.332730854794136e-08
by O 0 3.1487417118114536e-08
the O 0 3.72235149370681e-08
methods O 0 3.1076953632691584e-07
described O 0 3.7377869830379495e-06
may O 0 1.3366076245802105e-06
prevent O 0 3.6859637475572526e-06
false O 0 8.629569379081659e-07
- O 0 0.000843400601297617
positive O 0 3.649485279311193e-06
prenatal O 0 0.10424208641052246
diagnosis O 0 0.014980639331042767
of O 0 6.060133159735415e-07
TSD B-Disease 1 0.6950851678848267
in O 0 2.8610133995243814e-06
fetuses O 0 5.150710785528645e-05
having O 0 2.1581344356036425e-07
the O 0 4.907547079824326e-08
incomplete O 0 2.822906708388473e-06
hex B-Disease 0 0.0004741954617202282
A I-Disease 0 1.1430048289184924e-05
deficiency I-Disease 0 0.10346440225839615
of O 0 5.00647843182378e-08
the O 0 1.766096033861686e-07
type O 0 5.047543709224556e-06
described O 0 7.536427233389986e-07
in O 0 6.593278811806158e-08
the O 0 1.6426977822447952e-07
four O 0 1.133033379119297e-06
healthy O 0 6.975499127293006e-05
individuals O 0 1.9495628293952905e-05

The O 0 0.00013264748849906027
tumor B-Disease 0 0.1277918666601181
suppressor O 0 0.0009725508862175047
gene O 0 0.00012030545622110367
Smad4 O 0 0.01031784899532795
/ O 0 0.0004809138481505215
Dpc4 O 0 0.00028141686925664544
is O 0 6.004027852668514e-08
required O 0 3.690897898422918e-08
for O 0 3.344831256413272e-08
gastrulation O 0 6.479005241999403e-05
and O 0 1.4770604650493624e-07
later O 0 1.373369968860061e-07
for O 0 9.283411372962291e-08
anterior O 0 0.000162319207447581
development O 0 3.5261751918369555e-07
of O 0 1.0557150886825184e-07
the O 0 6.748230134689948e-07
mouse O 0 0.00010584095434751362
embryo O 0 3.6410001484910026e-05
. O 0 6.402145572792506e-06

Mutations O 0 0.0012266419362276793
in O 0 7.221794021461392e-06
the O 0 8.457748663204256e-06
SMAD4 O 0 0.16913488507270813
/ O 0 0.085442915558815
DPC4 O 1 0.9219579696655273
tumor B-Disease 0 0.09713145345449448
suppressor O 0 8.440263627562672e-05
gene O 0 1.5670487982788472e-06
, O 0 3.008897309086933e-08
a O 0 1.472728961005032e-08
key O 0 1.0037742725899079e-07
signal O 0 1.4567508799245843e-07
transducer O 0 2.1167750219319714e-06
in O 0 2.8251529116118945e-08
most O 0 2.786508801477794e-08
TGFbeta O 0 0.0004748535866383463
- O 0 0.0003501347091514617
related O 0 3.0331498237501364e-06
pathways O 0 6.539957212226e-06
, O 0 4.053967472827935e-08
are O 0 1.0770236258395016e-08
involved O 0 4.288234478622144e-08
in O 0 2.9750964358754572e-08
50 O 0 1.1526056198363221e-07
% O 0 4.7582275897184445e-07
of O 0 1.071734914148692e-05
pancreatic B-Disease 1 0.9995197057723999
cancers I-Disease 1 0.964383065700531
. O 0 4.126182830077596e-05

Homozygous O 0 0.006423082668334246
Smad4 O 0 0.4902910888195038
mutant O 0 0.015983957797288895
mice O 0 0.019798751920461655
die O 0 0.0007092843297868967
before O 0 1.1482865147627308e-06
day O 0 1.887364078356768e-06
7 O 0 9.115145076066256e-06
. O 0 6.928423772478709e-06

5 O 0 9.599964687367901e-05
of O 0 1.8202821593149565e-05
embryogenesis O 0 0.0017969203181564808
. O 0 0.0001176839869003743

Mutant O 0 0.0010223068529739976
embryos O 0 5.1314826123416424e-05
have O 0 1.4156878478388535e-06
reduced O 0 2.0689258235506713e-06
size O 0 2.933819359896006e-06
, O 0 6.951474915695144e-07
fail O 0 1.1418782378314063e-05
to O 0 1.8162641879371222e-07
gastrulate O 0 0.00014923738490324467
or O 0 1.1915237507764687e-07
express O 0 4.868288669968024e-07
a O 0 1.0497676328213856e-07
mesodermal O 0 0.0001760373852448538
marker O 0 1.2546352991193999e-05
, O 0 1.5321954549563088e-07
and O 0 2.5314952267763147e-07
show O 0 2.5854551495285705e-06
abnormal O 0 9.317586227552965e-05
visceral O 0 0.00016597259673289955
endoderm O 0 0.003413354977965355
development O 0 1.6015159417293034e-05
. O 0 1.163598062703386e-05

Growth B-Disease 0 0.4474770724773407
retardation I-Disease 1 0.9837814569473267
of O 0 2.3563752620248124e-06
the O 0 2.6624381916917628e-06
Smad4 O 0 0.10686048865318298
- O 0 0.05061296746134758
deficient O 0 0.006442517973482609
embryos O 0 2.0041168227180606e-06
results O 0 2.421522538043064e-07
from O 0 3.503454948372564e-08
reduced O 0 4.4188928427502105e-07
cell O 0 9.1761621661135e-06
proliferation O 0 3.9787769310350996e-06
rather O 0 7.168658555656293e-08
than O 0 1.1991662063337571e-07
increased O 0 1.6122252191053121e-06
apoptosis O 0 8.824205724522471e-05
. O 0 5.327653070708038e-06

Aggregation O 0 0.0003580793854780495
of O 0 1.1979495866398793e-05
mutant O 0 0.0004975603078491986
Smad4 O 0 0.0252678245306015
ES O 0 0.0008776580216363072
cells O 0 1.1483521120680962e-05
with O 0 3.6555704241436615e-07
wild O 0 6.935881174285896e-06
- O 0 0.000360405829269439
type O 0 1.4411596566787921e-05
tetraploid O 0 0.00014703950728289783
morulae O 0 0.0015091124223545194
rescues O 0 0.00018327025463804603
the O 0 2.146270162484143e-06
gastrulation B-Disease 0 0.002815374406054616
defect I-Disease 0 0.0019603578839451075
. O 0 1.3682555618288461e-05

These O 0 1.0999148798873648e-05
results O 0 2.4218112230300903e-05
indicate O 0 7.165635452111019e-06
that O 0 2.812551258557505e-07
Smad4 O 0 0.0003865499165840447
is O 0 9.082209118105311e-08
initially O 0 7.192434026137562e-08
required O 0 1.0945249151461667e-08
for O 0 4.026762479014678e-09
the O 0 7.485509989635375e-09
differentiation O 0 1.7905236404658353e-07
of O 0 1.2098936075233269e-08
the O 0 4.279295851006282e-08
visceral O 0 1.0298428605892695e-05
endoderm O 0 0.0003751398471649736
and O 0 1.0359455870911916e-07
that O 0 3.634202627722516e-08
the O 0 6.669230145917027e-08
gastrulation B-Disease 0 0.0004616368969436735
defect I-Disease 0 9.270949522033334e-05
in O 0 4.953410837060801e-08
the O 0 1.1461187909844739e-07
epiblast O 0 0.0013929496053606272
is O 0 3.29067653126458e-08
secondary O 0 8.552965624630815e-08
and O 0 3.347090427041621e-08
non O 0 3.9672480056651693e-07
- O 0 0.00016435713041573763
cell O 0 2.8154918254585937e-05
autonomous O 0 9.477253115619533e-06
. O 0 8.722588972887024e-06

Rescued O 0 0.004296740982681513
embryos O 0 0.0004339755396358669
show O 0 0.0003552539856173098
severe O 1 0.5810398459434509
anterior O 0 0.2639242708683014
truncations O 0 0.02045450545847416
, O 0 2.161293195968028e-06
indicating O 0 3.6702979286928894e-06
a O 0 5.633209809730033e-08
second O 0 1.0548134099508388e-07
important O 0 5.1865676198303845e-08
role O 0 2.198675304043718e-07
for O 0 1.4399918768503994e-07
Smad4 O 0 0.000635637785308063
in O 0 1.044944724526431e-06
anterior O 0 0.0027707256376743317
patterning O 0 0.003536670934408903
during O 0 2.4899534764699638e-05
embryogenesis O 0 0.001245531253516674
. O 0 2.5317338440800086e-05

Prevalence O 0 0.006512668915092945
of O 0 7.658695722057018e-06
p16 O 0 0.0004335690464358777
and O 0 7.854249815864023e-06
CDK4 O 0 0.11429156363010406
germline O 0 0.11890935897827148
mutations O 0 0.0001468821574235335
in O 0 1.1946121958317235e-06
48 O 0 0.00012550625251606107
melanoma B-Disease 1 0.9986754059791565
- O 0 0.26193463802337646
prone O 0 0.00547496834769845
families O 0 3.5370205750950845e-06
in O 0 9.967122878151713e-07
France O 0 2.5260756956413388e-05
. O 0 1.2366857845336199e-05

The O 0 0.00016346767370123416
French O 0 0.006307074800133705
Familial B-Disease 1 0.9993890523910522
Melanoma I-Disease 1 0.9996792078018188
Study O 0 0.0006174709997139871
Group O 0 0.0001535036863060668
. O 0 3.7785692256875336e-05

Germline O 1 0.8368588089942932
mutations O 0 0.00211751414462924
in O 0 2.1618370737996884e-06
the O 0 8.503570256834792e-07
p16 O 0 7.389857637463138e-05
and O 0 1.1248316695855465e-06
CDK4 O 0 0.030309300869703293
genes O 0 2.2719077605870552e-06
have O 0 5.0998693268411444e-08
been O 0 3.057224873259656e-08
reported O 0 1.1052811288436715e-07
in O 0 1.423103679343285e-08
a O 0 2.8116064143546282e-08
subset O 0 3.555163857527077e-06
of O 0 2.013978246395709e-06
melanoma B-Disease 1 0.9922584891319275
pedigrees O 0 0.0010791749227792025
, O 0 3.615056414218998e-07
but O 0 6.506281380325163e-08
their O 0 1.859207827692444e-07
prevalence O 0 0.00043896224815398455
is O 0 8.884826740995777e-08
not O 0 5.5863022652147265e-08
well O 0 2.599651907075895e-07
known O 0 4.526567863649689e-06
. O 0 6.024864433129551e-06

We O 0 9.482984751230106e-06
searched O 0 7.890037522884086e-06
for O 0 1.7050659550932323e-07
such O 0 3.3571322433090245e-07
germline O 0 0.0038672008085995913
mutations O 0 1.0645718248269986e-05
in O 0 1.337499924147778e-07
48 O 0 1.806627892619872e-06
French O 0 7.406465738313273e-05
melanoma B-Disease 1 0.9955822825431824
- O 0 0.29103270173072815
prone O 0 0.0049194470047950745
families O 0 7.468890430573083e-07
selected O 0 3.823561911531215e-08
according O 0 3.351338406787363e-08
to O 0 8.87388207360118e-09
two O 0 1.1761769336260386e-08
major O 0 2.7440287908575556e-07
criteria O 0 2.096396798378919e-07
families O 0 8.057111955395158e-08
with O 0 3.770390932800183e-08
at O 0 1.0596045285637956e-07
least O 0 1.2229931733998e-08
three O 0 2.7046175077316548e-08
affected O 0 2.6205134417978115e-07
members O 0 1.912892599875704e-08
( O 0 2.1621721657538728e-07
n O 0 5.222656182013452e-05
= O 0 9.121948824031278e-05
20 O 0 8.353863734100742e-08
) O 0 2.803921539396015e-08
or O 0 1.4997178610087758e-08
families O 0 4.7458918572829134e-08
with O 0 3.273536464121207e-08
two O 0 4.5013745619826295e-08
affected O 0 1.2353458487268654e-06
members O 0 2.8649065342278845e-08
, O 0 2.971364843062929e-08
one O 0 5.397846170041021e-09
of O 0 6.6969771950198265e-09
them O 0 2.0521989441135702e-08
affected O 0 3.5432492495601764e-07
before O 0 3.648551682999823e-08
the O 0 2.577163549233319e-08
age O 0 7.018107339717972e-08
of O 0 1.2582917818804162e-08
50 O 0 7.022767078979086e-08
( O 0 1.1317327164306334e-07
n O 0 1.541529127280228e-05
= O 0 4.33722379966639e-05
28 O 0 1.6149475356996845e-07
) O 0 2.211161032050768e-08
, O 0 1.1264635446650573e-08
and O 0 1.4519803137602594e-08
one O 0 2.5036438699999053e-08
additional O 0 1.85061608704018e-07
minor O 0 1.5621588318026625e-05
criterion O 0 6.125486106611788e-05
. O 0 1.0988412213919219e-05

Sixteen O 0 5.762961518485099e-05
different O 0 5.077506102679763e-06
p16 O 0 0.0007440565968863666
germline O 0 0.0901443362236023
mutations O 0 0.00019358679128345102
were O 0 1.2233705604103307e-07
found O 0 8.205969237451427e-08
in O 0 6.471848479350228e-08
21 O 0 3.513945898703241e-07
families O 0 1.883816622694212e-07
, O 0 4.863220937068036e-08
while O 0 6.824925691262251e-08
one O 0 8.20446715010803e-08
germline O 0 0.0010098229395225644
mutation O 0 1.6266396414721385e-05
, O 0 4.035499330257153e-07
Arg24His O 0 0.0005991680081933737
, O 0 1.91409384342478e-07
was O 0 1.09892219768426e-07
detected O 0 6.970893196012184e-07
in O 0 6.95547441864619e-08
the O 0 4.114048692827055e-07
CDK4 O 0 0.00559138273820281
gene O 0 2.1989782908349298e-05
. O 0 6.4911491790553555e-06

The O 0 4.847976924793329e-06
frequency O 0 1.9090052774117794e-06
of O 0 4.3021742612836533e-07
p16 O 0 5.5050779337761924e-05
gene O 0 5.193267043068772e-06
mutation O 0 1.292230649596604e-06
in O 0 2.9091509645695623e-08
our O 0 2.9841384474593724e-08
sample O 0 8.274242446759672e-08
( O 0 5.026686977771533e-08
44 O 0 9.787037669184429e-08
% O 0 5.3099988406302145e-08
) O 0 3.8770092913864573e-08
is O 0 5.899812638432422e-09
among O 0 1.0515708304126292e-08
the O 0 1.781923941734931e-08
highest O 0 2.8083860570404795e-07
rates O 0 3.9060580547811696e-07
yet O 0 9.192913807964942e-08
reported O 0 2.3115961766961846e-07
and O 0 2.81301719695648e-08
the O 0 1.1360722851350147e-07
CDK4 O 0 0.010455372743308544
mutation O 0 1.802741735446034e-06
is O 0 1.2059653720086772e-08
the O 0 1.842110641803174e-08
second O 0 2.902323785747285e-07
mutation O 0 3.226898797947797e-06
detected O 0 8.396569910473772e-07
in O 0 4.0776200194159173e-08
this O 0 7.797060419534318e-08
gene O 0 3.0966268695920007e-06
worldwide O 0 4.387129138194723e-06
. O 0 4.747045750264078e-06

In O 0 9.13242456590524e-06
summary O 0 1.765139131748583e-05
, O 0 7.46782973237714e-07
our O 0 4.842238467972493e-07
results O 0 1.0809027344294009e-06
show O 0 2.4854051616785e-07
frequent O 0 2.701790151604655e-07
involvement O 0 2.342972322821879e-07
of O 0 3.348342048070663e-08
the O 0 1.9871468737164832e-07
p16 O 0 5.610764492303133e-05
gene O 0 6.389081136148889e-06
in O 0 4.130428351345472e-06
familial B-Disease 1 0.9987553358078003
melanoma I-Disease 1 0.9996650218963623
and O 0 9.81942093858379e-07
confirm O 0 8.33511364817241e-07
the O 0 1.9212293977943773e-08
role O 0 3.2784349457415374e-08
of O 0 1.5482745752137816e-08
the O 0 1.2081771672001196e-07
CDK4 O 0 0.009080002084374428
gene O 0 2.574574864411261e-06
as O 0 1.4929743485936342e-07
a O 0 2.858261495930492e-06
melanoma B-Disease 1 0.9879395961761475
- O 0 0.15815962851047516
predisposing O 0 0.01917887292802334
gene O 0 1.0826795914908871e-05
. O 0 1.0640778782544658e-06
. O 0 3.017647486558417e-06

Progression O 0 0.0012336475774645805
of O 0 4.871483724855352e-06
somatic O 0 0.00022845700732432306
CTG O 0 0.014284337870776653
repeat O 0 0.000210341444471851
length O 0 6.781392130505992e-06
heterogeneity O 0 4.9561400373931974e-05
in O 0 2.661849123342108e-07
the O 0 5.672076213159016e-07
blood O 0 0.000131443259306252
cells O 0 8.418054494541138e-05
of O 0 4.041465217596851e-05
myotonic B-Disease 1 0.9999691247940063
dystrophy I-Disease 1 0.9999878406524658
patients O 1 0.8858070969581604
. O 0 0.00012238073395565152

The O 0 2.6559877369436435e-05
genetic O 0 0.00012667082773987204
basis O 0 3.1990889510780107e-06
of O 0 5.083181895315647e-05
myotonic B-Disease 1 0.9999856948852539
dystrophy I-Disease 1 0.9999974966049194
( O 0 0.05108164623379707
DM B-Disease 1 0.9999691247940063
) O 0 3.2983919027174124e-06
is O 0 3.084113586737658e-08
the O 0 1.3633122186718083e-08
expansion O 0 2.0919131316077255e-07
of O 0 3.968208162064002e-08
an O 0 1.651095828947291e-07
unstable O 0 0.00022745979367755353
CTG O 0 0.0018273444147780538
repeat O 0 4.390732556203147e-06
in O 0 1.7533109186729234e-08
the O 0 1.7871860436002862e-08
34 O 0 1.408633494293099e-07
UTR O 0 1.2514769878180232e-05
of O 0 2.6552919862865565e-08
the O 0 1.9075991986028384e-07
DM B-Disease 1 0.9504381418228149
protein O 0 6.252762432268355e-06
kinase O 0 3.359019319759682e-05
gene O 0 1.5076514046086231e-06
on O 0 5.534657248063013e-07
chromosome O 0 7.682008435949683e-05
19 O 0 7.581013505841838e-06
. O 0 4.731705757876625e-06

One O 0 3.2870871109480504e-06
of O 0 4.509757900450495e-07
the O 0 2.530305494019558e-07
principal O 0 4.557581121389376e-07
features O 0 1.8217198771708354e-07
of O 0 1.3010011912228947e-07
the O 0 1.781506284714851e-06
DM B-Disease 1 0.9998977184295654
mutation O 0 7.720675057498738e-05
is O 0 5.588305640458202e-08
an O 0 2.199761262033917e-08
extraordinarily O 0 1.5297484878828982e-06
high O 0 1.5983920320650213e-07
level O 0 3.951064186935582e-08
of O 0 3.116310764994523e-08
somatic O 0 9.772609701030888e-06
mosaicism O 0 0.012873213738203049
, O 0 2.6256668661517324e-07
due O 0 2.6793077267939225e-07
to O 0 2.4597280656735165e-08
an O 0 1.1776990049838787e-08
extremely O 0 9.356936203630539e-08
high O 0 5.3812371447747864e-08
degree O 0 4.184074953172967e-08
of O 0 3.4322336972536505e-08
somatic O 0 1.147665625467198e-05
instability O 0 8.404849722865038e-06
both O 0 2.0134695688511783e-08
within O 0 2.0650306353786618e-08
and O 0 4.4146467814698553e-08
between O 0 2.3276342631106672e-07
different O 0 2.926973365902086e-07
tissues O 0 0.00010047743853647262
. O 0 8.337734470842406e-06

This O 0 1.8642500435817055e-05
instability O 0 0.00036440015537664294
appears O 0 5.063091521151364e-06
to O 0 1.2207051724999474e-07
be O 0 1.9468036072112227e-08
biased O 0 7.60733911420175e-08
towards O 0 2.206724580844366e-08
further O 0 1.399675664259803e-08
expansion O 0 7.834971427200799e-08
and O 0 1.6541511271839227e-08
continuous O 0 1.4259407521421963e-07
throughout O 0 3.529693870518713e-08
the O 0 1.9061582534618537e-08
life O 0 5.904341549012315e-08
of O 0 1.3290692990608477e-08
an O 0 2.2332692140025756e-08
individual O 0 5.166494787545162e-08
, O 0 7.384854683323283e-08
features O 0 2.723533896187291e-07
that O 0 4.414158638610388e-08
could O 0 6.226314042123704e-08
be O 0 9.50353928885761e-09
associated O 0 5.291678562002744e-08
with O 0 2.1312320797051143e-08
the O 0 8.805466933381467e-08
progressive O 0 1.6434216377092525e-05
nature O 0 1.7284054365518386e-06
of O 0 2.921747181972023e-07
the O 0 1.3132917956681922e-05
disease O 0 0.36703234910964966
. O 0 1.0297916560375597e-05

Although O 0 2.0482437321334146e-05
increasing O 0 1.0572406608844176e-05
measured O 0 7.156934316299157e-06
allele O 0 5.693891580449417e-06
size O 0 5.330483418219956e-06
between O 0 6.394109732354991e-06
patients O 0 0.00015038918354548514
clearly O 0 7.192077191575663e-07
correlates O 0 1.2396828424243722e-05
with O 0 1.813700691855047e-07
an O 0 2.3498556345202815e-07
increased O 0 9.28410554479342e-06
severity O 0 0.01441508810967207
of O 0 3.195021690771682e-06
symptoms O 0 0.02674674242734909
and O 0 2.8653090566876926e-07
an O 0 7.26714688426e-08
earlier O 0 1.5805915154487593e-06
age O 0 1.8149999050365295e-06
of O 0 4.2720421333797276e-07
onset O 0 0.2564981281757355
, O 0 3.0364643066604913e-07
this O 0 2.520447139886528e-08
correlation O 0 1.4367041103469091e-06
is O 0 1.8711018512362898e-08
not O 0 8.47750314392215e-09
precise O 0 4.854814861232626e-08
and O 0 2.2558650059067986e-08
measured O 0 2.501558356016176e-07
allele O 0 2.1810224382079468e-07
length O 0 4.275102867268288e-07
cannot O 0 7.284438652277458e-08
be O 0 3.7479468417700446e-09
used O 0 9.932931810396894e-09
as O 0 9.003659151574084e-09
an O 0 1.8576352900367965e-08
accurate O 0 6.007595629853313e-07
predictor O 0 4.007332245237194e-05
of O 0 1.1848066350239606e-07
age O 0 1.6849488702064264e-06
of O 0 1.372201154481445e-06
onset O 0 0.20917412638664246
. O 0 2.443220182613004e-05

In O 0 9.221622349286918e-06
order O 0 1.727144990582019e-06
to O 0 2.4300729251081066e-07
further O 0 1.9549831620224722e-07
characterize O 0 5.444810994958971e-06
the O 0 1.517188366051414e-07
dynamics O 0 1.8745686247712e-05
of O 0 1.2389135690682451e-06
DM B-Disease 1 0.999406099319458
CTG O 0 0.17036032676696777
repeat O 0 0.00015540678577963263
somatic O 0 2.331132782273926e-05
instability O 0 2.375085932726506e-05
, O 0 6.280608033648605e-08
we O 0 2.2301362534449254e-08
have O 0 1.7815432684642474e-08
studied O 0 1.1531937360587108e-07
repeat O 0 2.768423655652441e-06
length O 0 1.9843629672777752e-07
changes O 0 4.0052171357274347e-08
over O 0 3.247701840791706e-08
time O 0 7.058784490254766e-08
in O 0 3.804230459536484e-07
111 O 0 0.025018105283379555
myotonic B-Disease 1 0.9999938011169434
dystrophy I-Disease 1 0.999996542930603
patients O 0 0.22823645174503326
with O 0 1.9094679828413064e-06
varying O 0 1.0271336577716284e-05
clinical O 0 0.0073350477032363415
severity O 0 0.0030622752383351326
and O 0 4.453835344975232e-07
CTG O 0 0.0019582374952733517
repeat O 0 4.560286470223218e-06
size O 0 1.1159212220945847e-07
over O 0 2.430964585187212e-08
time O 0 1.4218366040097408e-08
intervals O 0 6.599317714517383e-08
of O 0 1.0138505146528587e-08
1 O 0 3.090582652021112e-07
- O 0 7.69817124819383e-05
7 O 0 4.891515345661901e-06
years O 0 3.0739181511307834e-06
. O 0 5.006463197787525e-06

We O 0 1.0463853868714068e-05
have O 0 6.07397907970153e-07
found O 0 1.2660235881867266e-07
a O 0 3.6808938119747836e-08
direct O 0 7.444819516422285e-08
progression O 0 6.087878318794537e-06
of O 0 1.5761337124331476e-08
the O 0 3.6516013324217056e-08
size O 0 4.911836413157289e-07
heterogeneity O 0 8.180547411029693e-06
over O 0 7.083519903972046e-08
time O 0 3.4502178891671065e-08
related O 0 1.2552324335501908e-07
to O 0 4.202486181270615e-08
initial O 0 6.64203753331094e-07
CTG O 0 0.0004068237612955272
repeat O 0 5.905922989768442e-06
size O 0 1.588453812928492e-07
and O 0 1.0879975143041065e-08
the O 0 8.770029147342484e-09
time O 0 2.5704672168558318e-08
interval O 0 2.9097429887769977e-07
and O 0 3.6752041410181846e-08
always O 0 9.304471149107485e-08
biased O 0 3.2682370942893613e-07
towards O 0 1.249846377504582e-07
further O 0 2.93918020588535e-07
expansion O 0 6.0723091337422375e-06
. O 0 6.078236310713692e-06

Attempts O 0 9.107607911573723e-05
to O 0 3.3187116059707478e-06
mathematically O 0 5.202675765758613e-06
model O 0 7.968802151481214e-07
the O 0 1.6007808767426468e-07
dynamics O 0 2.842486537701916e-05
have O 0 1.0530745697678867e-07
proved O 0 5.84306008022395e-07
only O 0 2.1615305101363447e-08
partially O 0 1.670956635280163e-06
successful O 0 5.238430276222061e-07
suggesting O 0 6.828629466326674e-07
that O 0 2.367320917073812e-08
individual O 0 4.325719160647168e-08
specific O 0 6.364782478840425e-08
genetic O 0 1.0055588973045815e-05
and O 0 5.684997859134455e-07
/ O 0 0.0006942889303900301
or O 0 1.2048466260239366e-06
environmental O 0 8.375221113965381e-06
factors O 0 1.6234979227647273e-07
also O 0 1.3425292877400352e-08
play O 0 2.669184873127506e-08
a O 0 3.9698889509054425e-08
role O 0 2.788641779716272e-07
in O 0 2.6073465164699883e-07
somatic O 0 5.936820525676012e-05
mosaicism O 0 0.017376022413372993
. O 0 2.4587066036474425e-06
. O 0 6.465792921517277e-06

Aspartylglucosaminuria B-Disease 1 0.847835123538971
among O 0 0.00011611781519604847
Palestinian O 0 0.00017632113303989172
Arabs O 0 0.00023814651649445295
. O 0 7.839795580366626e-05

Aspartylglucosaminuria B-Disease 1 0.9964660406112671
( O 0 0.0024188936222344637
AGU B-Disease 1 0.9984738230705261
) O 0 1.1372563676559366e-05
is O 0 3.3333742521790555e-07
a O 0 1.0533211707297596e-06
rare O 0 0.00015730361337773502
disorder B-Disease 1 0.6919171810150146
of I-Disease 0 3.0877329209033633e-06
glycoprotein I-Disease 1 0.5445330142974854
metabolism I-Disease 0 0.019642386585474014
caused O 0 0.00010149183071916923
by O 0 5.265492291073315e-07
the O 0 2.8969088816666044e-06
deficiency B-Disease 0 0.3406359553337097
of I-Disease 0 1.4955379867842566e-07
the I-Disease 0 1.9545352643035585e-06
lysosomal I-Disease 1 0.7227668762207031
enzyme I-Disease 0 0.00032812569406814873
aspartylglucosaminidase I-Disease 0 0.024437107145786285
( O 0 3.7536367472057464e-06
AGA O 0 0.000413636356825009
) O 0 2.7763924208557e-06
. O 0 3.3443548090872355e-06

AGU B-Disease 1 0.9988797307014465
is O 0 0.0007152794860303402
inherited O 1 0.5291298031806946
as O 0 1.0780299817270134e-05
an O 0 1.9316137695568614e-05
autosomal O 1 0.9763591289520264
recessive O 1 0.9488033056259155
trait O 0 0.002444242360070348
and O 0 1.8894405684477533e-06
occurs O 0 8.951775498644565e-07
with O 0 6.598059343332352e-08
a O 0 6.370004967948262e-08
high O 0 4.7010840376060514e-07
frequency O 0 2.0945583401044132e-07
in O 0 5.257703961092375e-08
Finland O 0 1.8585799352877075e-06
because O 0 6.921990802766231e-08
of O 0 3.810297144468677e-08
a O 0 2.9458112749125576e-07
founder O 0 6.293882324825972e-05
effect O 0 9.795170626603067e-06
. O 0 6.147948624857236e-06

While O 0 2.208843761764001e-05
very O 0 4.9236355152970646e-06
few O 0 7.224431556096533e-06
patients O 0 0.0008794679306447506
with O 0 1.3488041076925583e-05
AGU B-Disease 1 0.9994181394577026
have O 0 9.982627489080187e-07
been O 0 9.17291131941056e-08
reported O 0 2.3648823344046832e-07
from O 0 2.0154367064151302e-08
non O 0 2.2381011888228386e-07
- O 0 0.00011351524881320074
Finnish O 0 7.730185461696237e-05
origin O 0 1.776049089130538e-06
, O 0 2.913321168307448e-06
we O 0 1.8311309759155847e-05
diagnosed O 1 0.8140915632247925
the O 0 6.325978574750479e-06
disorder O 0 0.24502325057983398
in O 0 3.500847185478051e-07
8 O 0 1.3743812814936973e-05
patients O 0 2.952131580968853e-05
originating O 0 2.66493771050591e-07
from O 0 5.7806072817356835e-08
3 O 0 1.255509459952009e-06
unrelated O 0 3.858633135678247e-06
families O 0 8.635859671812796e-07
, O 0 5.5839475265884175e-08
all O 0 1.0409523021337463e-08
Palestinian O 0 2.1281068995904207e-07
Arabs O 0 1.7093773863052775e-07
from O 0 1.9455601574236425e-08
the O 0 3.128304726374154e-08
region O 0 3.391839982214151e-07
of O 0 1.8253145128710457e-07
Jerusalem O 0 2.687410233193077e-05
. O 0 6.303004738583695e-06

The O 0 0.000254554848652333
clinical O 0 0.2429366111755371
diagnosis O 1 0.9039602279663086
of O 0 2.3417167540173978e-05
AGU B-Disease 1 0.9996765851974487
is O 0 4.826014901482267e-06
often O 0 1.2717840718323714e-06
difficult O 0 2.714209358600783e-06
, O 0 5.25085894764743e-08
in O 0 2.1502224001324066e-08
particular O 0 3.3808010613256556e-08
early O 0 3.712191087856809e-08
in O 0 1.7841346178215645e-08
the O 0 4.275754861282621e-08
course O 0 1.1957941978835152e-06
of O 0 1.56938938289386e-07
the O 0 3.727257535501849e-06
disease O 0 0.027472026646137238
, O 0 1.259891746485664e-07
and O 0 4.088967386906006e-08
most O 0 1.806095184520018e-08
of O 0 1.286870912053928e-07
the O 0 7.008963166299509e-06
patients O 0 0.009291787631809711
are O 0 3.696284693432972e-06
diagnosed O 1 0.7871670722961426
after O 0 3.706507186507224e-06
the O 0 2.2719893877365394e-07
age O 0 5.157058353688626e-07
of O 0 9.914840148894655e-08
5 O 0 3.979019766120473e-06
years O 0 4.2622896216926165e-06
. O 0 7.395824468403589e-06

However O 0 3.927717261831276e-05
, O 0 3.7929348764009774e-06
since O 0 2.58263594332675e-06
these O 0 6.158625751595537e-07
patients O 0 8.576201071264222e-05
excrete O 0 2.383917490078602e-05
early O 0 1.139873901934152e-07
large O 0 7.439481919391255e-08
amounts O 0 6.364393811963964e-08
of O 0 3.4603143461708896e-08
aspartylglucosamine O 0 0.0001903320080600679
in O 0 1.302527010693666e-07
urine O 0 1.2637223107958562e-06
, O 0 8.671166540352715e-08
biochemical O 0 1.6916806089284364e-06
screening O 0 4.96708196351392e-07
is O 0 3.01830098692335e-08
easy O 0 2.751121712663007e-07
by O 0 1.4257979330523085e-07
urine O 0 4.4963044274481945e-06
chromatography O 0 0.0003342718700878322
. O 0 1.0084620498673758e-06
. O 0 4.724729933514027e-06

Detection O 0 0.0002931673370767385
of O 0 4.247802735335426e-06
heterozygous O 0 2.421818317088764e-05
carriers O 0 1.0687403118936345e-05
of O 0 5.196053507461329e-07
the O 0 4.763485321745975e-06
ataxia B-Disease 1 0.9996869564056396
- I-Disease 1 0.9810132384300232
telangiectasia I-Disease 1 0.9997729659080505
( O 0 5.009309916204074e-06
ATM O 0 4.177854134468362e-05
) O 0 2.9457046935021935e-07
gene O 0 4.703685192453122e-07
by O 0 1.4952685489788564e-07
G2 O 0 0.0004916230100207031
phase O 0 1.0848169949895237e-05
chromosomal O 0 0.0007343572797253728
radiosensitivity O 0 0.00043548893881961703
of O 0 8.655788406031206e-07
peripheral O 0 0.012025352567434311
blood O 0 0.0015439498238265514
lymphocytes O 0 0.011497169733047485
. O 0 1.2250859072082676e-05

In O 0 0.00021170562831684947
ataxia B-Disease 1 0.9996179342269897
- I-Disease 1 0.9950166344642639
telangiectasia I-Disease 1 0.9996823072433472
( O 0 5.1928680477431044e-05
A B-Disease 0 0.00010411925904918462
- I-Disease 1 0.9948437213897705
T I-Disease 1 0.9999551773071289
) O 0 0.00010885165102081373
patients O 0 0.0003467457718215883
, O 0 5.455760856420966e-07
mutations O 0 3.4311321996938204e-06
in O 0 1.8490171171947622e-08
a O 0 3.610890075833595e-08
single O 0 1.7816749675603205e-07
gene O 0 8.433042921751621e-07
, O 0 9.415963120318338e-08
ATM O 0 1.875940324680414e-05
, O 0 1.9356981795226602e-07
result O 0 1.3462392871588236e-06
in O 0 1.5564309023829992e-06
an O 0 0.00011123417789349332
autosomal B-Disease 1 0.9999802112579346
recessive I-Disease 1 0.999987006187439
syndrome I-Disease 1 0.9999984502792358
that O 0 2.1872870092920493e-06
embraces O 0 1.4772924259887077e-05
a O 0 9.119304422711139e-08
variety O 0 1.2715314312572445e-07
of O 0 9.708355719340034e-08
clinical O 0 4.440619159140624e-05
features O 0 1.1773709047702141e-06
and O 0 6.083874950491008e-07
manifests O 0 4.818680099560879e-05
extreme O 0 1.875793532235548e-05
radiosensitivity O 0 0.0003416540857870132
and O 0 4.691074551033125e-08
a O 0 2.7683542569434394e-08
strong O 0 1.8830370152045361e-07
pre O 0 1.7435471818316728e-05
- O 0 0.001397264888510108
disposition O 0 0.00030429341131821275
to O 0 4.925688244838966e-06
malignancy B-Disease 0 0.05725051462650299
. O 0 7.873298272897955e-06

Heterozygotes O 0 0.0012776331277564168
for O 0 3.102177970504272e-06
the O 0 8.790177616901929e-07
ATM O 0 0.00015810165496077389
gene O 0 1.107425669033546e-05
have O 0 1.3994466030453623e-07
no O 0 1.0530283134357887e-07
clinical O 0 1.710502260721114e-06
expression O 0 5.803563496442621e-08
of O 0 3.471810927635488e-08
A B-Disease 0 1.1109777915407903e-05
- I-Disease 1 0.8855442404747009
T I-Disease 1 0.9996976852416992
but O 0 8.404665095440578e-06
may O 0 3.2473792089149356e-05
be O 0 1.6630159507258213e-06
cancer B-Disease 0 0.17492999136447906
prone O 0 8.009532757569104e-05
with O 0 1.253539778645063e-07
a O 0 1.0785843329585987e-07
moderate O 0 4.11942892242223e-06
increase O 0 2.838651766978728e-07
in O 0 1.3623002814711072e-07
in O 0 9.083965437639563e-07
vitro O 0 0.0005708453827537596
radiosensitivity O 0 0.010226579383015633
. O 0 1.4526372979162261e-05

We O 0 2.068881985906046e-05
performed O 0 7.72376915847417e-06
a O 0 8.211313797801267e-07
blind O 0 2.3108756067813374e-05
chromosomal O 0 7.92296341387555e-05
analysis O 0 4.2451199533388717e-07
on O 0 1.2861777065609203e-07
G2 O 0 0.000478690693853423
- O 0 0.0002159391005989164
phase O 0 2.3928847440402023e-05
lymphocytes O 0 0.00029937137151136994
from O 0 8.100828097212798e-08
7 O 0 6.095205549172533e-07
unrelated O 0 2.792007762764115e-06
A B-Disease 0 3.5698678402695805e-05
- I-Disease 1 0.9956297874450684
T I-Disease 1 0.9999499320983887
patients O 0 0.007131205406039953
, O 0 3.9908547933009686e-07
13 O 0 5.876987643205211e-07
obligate O 0 1.0788969120767433e-05
A B-Disease 0 1.2477432392188348e-05
- I-Disease 1 0.5867062211036682
T I-Disease 1 0.9994239807128906
heterozygotes O 0 0.005804386455565691
( O 0 6.88645400259702e-07
parents O 0 2.5608031251067587e-07
of O 0 4.796955366259681e-08
the O 0 1.0899436801992124e-06
patients O 0 6.196658068802208e-05
) O 0 1.3325306724709662e-07
, O 0 2.4563245659692257e-08
and O 0 2.321320202725019e-08
14 O 0 4.971963107891497e-08
normal O 0 5.158469917887487e-08
controls O 0 1.0151241980338455e-07
following O 0 7.97552459630424e-08
X O 0 1.8789749447023496e-05
- O 0 1.9146491467836313e-05
irradiation O 0 7.788809739395219e-07
with O 0 2.846974211934139e-08
1 O 0 2.654624040587805e-07
Gy O 0 0.0083823436871171
in O 0 4.0953523239295464e-08
order O 0 6.109637951112745e-08
to O 0 3.582441365779232e-08
evaluate O 0 8.286978641081078e-07
this O 0 3.332915810005943e-08
cytogenetic O 0 3.528383604134433e-05
method O 0 7.333090223937688e-08
as O 0 1.1747443018350623e-08
a O 0 2.0543568624020736e-08
tool O 0 3.535485575412167e-07
for O 0 4.1103771053485616e-08
detection O 0 2.8259019018150866e-06
of O 0 3.3663624776636425e-07
ATM O 0 0.00018932673265226185
carriers O 0 6.803061114624143e-05
. O 0 7.269097750395304e-06

Both O 0 1.5386869563371874e-05
A B-Disease 0 6.23358937446028e-05
- I-Disease 0 0.3728598654270172
T I-Disease 1 0.9964019060134888
homozygotes O 0 0.019515493884682655
and O 0 2.9976124551467365e-06
heterozygotes O 0 0.00029676573467440903
showed O 0 2.877834731407347e-06
significantly O 0 7.713580885138072e-07
increased O 0 1.530247573100496e-07
levels O 0 1.8417792091440788e-07
of O 0 1.3368877205266472e-07
radiation O 0 0.000601575244218111
- O 0 0.03854356333613396
induced O 0 0.17047369480133057
chromatid O 1 0.8063817024230957
damage O 0 0.0002797816996462643
relative O 0 8.112523346426315e-07
to O 0 3.976391127480383e-08
that O 0 2.8507127325383408e-08
of O 0 5.646914758017374e-08
normal O 0 1.4021640026840032e-06
controls O 0 4.983193775842665e-06
. O 0 4.240137059241533e-06

These O 0 9.951280844688881e-06
results O 0 5.155532562639564e-06
show O 0 6.888010943839618e-07
that O 0 7.587457417912447e-08
the O 0 2.042651487954572e-07
G2 O 0 0.0015358405653387308
- O 0 0.0007268559420481324
phase O 0 9.891503577819094e-05
chromosomal O 0 0.0091926334425807
radiosensitivity O 0 0.003618336748331785
assay O 0 1.2984967725060415e-05
can O 0 3.7071533398602696e-08
be O 0 3.5604508230591136e-09
used O 0 4.931425046095228e-09
for O 0 5.003077507836906e-09
the O 0 1.4700767714259655e-08
detection O 0 4.5158429884395446e-07
of O 0 6.124198392853941e-08
A B-Disease 0 9.162800779449753e-06
- I-Disease 0 0.3241933286190033
T I-Disease 1 0.9978721141815186
heterozygotes O 0 0.024792354553937912
. O 0 2.0927100194967352e-05

In O 0 1.338979200227186e-05
combination O 0 2.059735925286077e-05
with O 0 1.46822264923685e-06
molecular O 0 0.0002379320649197325
genetic O 0 0.00016009989485610276
analyses O 0 4.899017312709475e-06
, O 0 1.057742764487557e-07
this O 0 3.2923843207299797e-08
test O 0 7.559057735306851e-07
may O 0 1.1782071851484943e-07
be O 0 2.658427478152703e-09
of O 0 4.087304272815118e-09
value O 0 1.2478331257170794e-08
in O 0 2.1310329501034175e-08
studies O 0 1.353809437887321e-07
of O 0 1.3656081421231647e-07
familial B-Disease 0 0.3236370086669922
and I-Disease 0 3.6911592360411305e-06
sporadic I-Disease 0 0.00036767509300261736
cancers I-Disease 0 0.07458257675170898
aimed O 0 1.8091899391947663e-06
at O 0 3.869755289542809e-07
determination O 0 1.128857320509269e-06
of O 0 1.4259211589262577e-08
the O 0 3.9691393283192156e-08
potential O 0 2.073787754852674e-07
involvement O 0 5.830808049722691e-07
of O 0 1.8312968563805043e-07
ATM O 0 0.004022462759166956
mutations O 0 0.0002968324988614768
in O 0 1.0691337593016215e-05
tumor B-Disease 1 0.7892052531242371
risk O 0 2.5285175070166588e-05
or O 0 3.90542084005574e-07
development O 0 2.0970614968973678e-06
. O 0 1.4058756505619385e-06
. O 0 5.287837211653823e-06

Ataxia B-Disease 1 0.9992071986198425
- I-Disease 1 0.9918906688690186
telangiectasia I-Disease 1 0.9990298748016357
: O 0 5.8621273637982085e-05
identification O 0 3.1639960980101023e-06
and O 0 3.7945343933643016e-07
detection O 0 1.8908898482550285e-06
of O 0 6.142975195189138e-08
founder O 0 2.3277874788618647e-05
- O 0 0.0010932737495750189
effect O 0 3.057078629353782e-06
mutations O 0 1.9018785906155244e-06
in O 0 2.4428219447258925e-08
the O 0 4.4212871586069014e-08
ATM O 0 6.682964340143371e-06
gene O 0 6.172667212922534e-07
in O 0 1.0002785444385154e-07
ethnic O 0 1.1181300578755327e-06
populations O 0 2.2980302674113773e-05
. O 0 5.809555204905337e-06

To O 0 1.0026995369116776e-05
facilitate O 0 6.473054781963583e-06
the O 0 4.908029040961992e-07
evaluation O 0 1.2890502603113418e-06
of O 0 1.4271243742314255e-07
ATM O 0 0.00011157187691424042
heterozygotes O 0 0.0003074151754844934
for O 0 7.781362683090265e-07
susceptibility O 0 0.003104157280176878
to O 0 9.45441740896058e-07
other O 0 1.549999410599412e-06
diseases O 0 0.35327762365341187
, O 0 4.5827121653019276e-07
such O 0 8.195760869966762e-07
as O 0 3.1815292459214106e-05
breast B-Disease 1 0.9996366500854492
cancer I-Disease 1 0.9455388784408569
, O 0 8.432576805716963e-07
we O 0 6.851768574733796e-08
have O 0 1.994084897205539e-08
attempted O 0 3.859877324430272e-07
to O 0 2.0914896481372125e-08
define O 0 3.994293251707859e-07
the O 0 1.954971295958785e-08
most O 0 1.945920224954989e-08
common O 0 2.568213517406548e-07
mutations O 0 7.53823883314908e-07
and O 0 1.493882351155662e-08
their O 0 2.5367533851294866e-08
frequencies O 0 1.283961950093726e-07
in O 0 6.871156301713199e-07
ataxia B-Disease 1 0.9990667700767517
- I-Disease 1 0.9641904234886169
telangiectasia I-Disease 1 0.9997453093528748
( O 0 5.784588665846968e-06
A B-Disease 0 6.8494168772303965e-06
- I-Disease 0 0.29105624556541443
T I-Disease 1 0.9882787466049194
) O 0 1.198423433379503e-06
homozygotes O 0 3.9587892388226464e-05
from O 0 6.858358148065236e-08
10 O 0 2.2494637619274727e-07
ethnic O 0 9.626180599298095e-07
populations O 0 1.6643894923618063e-05
. O 0 6.9773509494552854e-06

Both O 0 1.618224268895574e-05
genomic O 0 0.0004593508201651275
mutations O 0 0.0001349162048427388
and O 0 3.7609896708090673e-07
their O 0 1.6597805085893924e-07
effects O 0 1.5176817669271259e-06
on O 0 1.6898943044907355e-07
cDNA O 0 3.0059777600399684e-06
were O 0 5.056111263002094e-07
characterized O 0 4.704085222329013e-05
. O 0 8.06337357062148e-06

Protein O 0 5.339266135706566e-05
- O 0 0.00015041156439110637
truncation O 0 9.01640669326298e-05
testing O 0 1.1870454272866482e-06
of O 0 4.4998465398293774e-08
the O 0 3.3538963606360994e-08
entire O 0 1.3433765388981556e-07
ATM O 0 2.5771591936063487e-06
cDNA O 0 1.263353624381125e-06
detected O 0 6.826421667938121e-07
92 O 0 4.943656222167192e-07
( O 0 8.166746567894734e-08
66 O 0 4.420646746439161e-07
% O 0 1.1985888193066785e-07
) O 0 3.0606852874370816e-07
truncating O 0 4.232383071212098e-05
mutations O 0 2.6018892640422564e-06
in O 0 8.945599461185338e-08
140 O 0 8.707792176210205e-07
mutant O 0 1.3923810911364853e-05
alleles O 0 8.340253771166317e-06
screened O 0 1.168678227259079e-05
. O 0 4.623335371434223e-06

The O 0 1.8997079678229056e-05
haplotyping O 0 0.018926456570625305
of O 0 7.712941624049563e-06
patients O 0 0.0006737931980751455
with O 0 1.1813659739345894e-06
identical O 0 3.1091771234059706e-05
mutations O 0 0.00013902918726671487
indicates O 0 2.843596121238079e-06
that O 0 1.5538541120463378e-08
almost O 0 6.40836539389511e-09
all O 0 2.8646101046803096e-09
of O 0 1.0467162248062323e-08
these O 0 1.8859532602277795e-08
represent O 0 1.3768359963250987e-07
common O 0 1.4727619372933987e-06
ancestry O 0 8.135983080137521e-06
and O 0 1.9653036531508405e-07
that O 0 7.331901485940762e-08
very O 0 1.338269299822059e-07
few O 0 5.212173164181877e-07
spontaneously O 0 3.999402542831376e-05
recurring O 0 0.00030869219335727394
ATM O 0 0.0017665209015831351
mutations O 0 0.0001223739527631551
exist O 0 5.81178846914554e-06
. O 0 7.857381206122227e-06

Assays O 0 0.00043420225847512484
requiring O 0 2.7342735847923905e-05
minimal O 0 8.89142756932415e-06
amounts O 0 1.0095399147758144e-06
of O 0 1.5637196781881357e-07
genomic O 0 8.411665476160124e-06
DNA O 0 3.260014409534051e-06
were O 0 4.993194124836009e-08
designed O 0 2.984938589634112e-07
to O 0 3.3270030286303154e-08
allow O 0 9.129154676656981e-08
rapid O 0 4.743597855849657e-06
screening O 0 1.4358863609231776e-06
for O 0 1.0974225261861648e-07
common O 0 1.211047674587462e-06
ethnic O 0 4.514479314821074e-06
mutations O 0 0.00018575279682409018
. O 0 8.904638889362104e-06

These O 0 1.6851588952704333e-05
rapid O 0 0.00020755433070007712
assays O 0 0.00010265849414281547
detected O 0 3.415039464016445e-05
mutations O 0 7.313189144042553e-06
in O 0 7.497116172316964e-08
76 O 0 9.956643225450534e-07
% O 0 4.573290013354381e-08
of O 0 5.010375758729424e-08
Costa O 0 2.461973599565681e-05
Rican O 0 9.718599903862923e-05
patients O 0 0.00021739181829616427
( O 0 2.927732793978066e-07
3 O 0 4.1562725527910516e-07
) O 0 8.115736704894516e-08
, O 0 1.994393095117175e-08
50 O 0 2.327274017943637e-08
% O 0 2.1083517154352194e-08
of O 0 3.801107695267092e-08
Norwegian O 0 0.00015864829765632749
patients O 0 6.998873868724331e-05
( O 0 1.6877635289347381e-07
1 O 0 2.17781533251582e-07
) O 0 6.552333786657982e-08
, O 0 1.7305159971670037e-08
25 O 0 1.913804759112736e-08
% O 0 1.8437768645185315e-08
of O 0 4.841323786308749e-08
Polish O 0 0.0004778486327268183
patients O 0 0.00013798750296700746
( O 0 3.320863299904886e-07
4 O 0 5.248601269158826e-07
) O 0 6.664537721690067e-08
, O 0 1.5225564808929448e-08
and O 0 1.6803733515757813e-08
14 O 0 1.0280779605409407e-07
% O 0 3.0441157150562503e-08
of O 0 7.656175426973277e-08
Italian O 0 0.0001053453452186659
patients O 0 9.850266360444948e-05
( O 0 2.4038058654696215e-07
1 O 0 4.094571579571493e-07
) O 0 1.0793952043286481e-07
, O 0 2.2411891009710416e-08
as O 0 6.920588990766419e-09
well O 0 1.1510518760360355e-08
as O 0 1.2988881969988597e-08
in O 0 7.563659920606369e-08
patients O 0 3.3631163205427583e-06
of O 0 7.784770872376612e-08
Amish O 0 0.00028977327747270465
/ O 0 0.0003370194463059306
Mennonite O 0 0.00018643630028236657
and O 0 5.176664785722096e-07
Irish O 0 4.605710273608565e-06
English O 0 1.3038435326961917e-06
backgrounds O 0 1.0538001333770808e-05
. O 0 7.366274530795636e-06

Additional O 0 4.38668648712337e-05
mutations O 0 0.00014507512969430536
were O 0 3.229695835216262e-07
observed O 0 4.902528303318832e-07
in O 0 7.998895057426125e-08
Japanese O 0 6.300074915088771e-07
, O 0 1.2810558303044672e-07
Utah O 0 3.5311929877934745e-06
Mormon O 0 1.0658899327609106e-06
, O 0 1.555315236601018e-07
and O 0 2.326469257241115e-07
African O 0 3.166625447192928e-06
American O 0 1.843974314397201e-05
patients O 0 0.0009227163391187787
. O 0 1.3911096175434068e-05

These O 0 9.957791917258874e-06
assays O 0 2.5548308258294128e-05
should O 0 8.341825150637305e-07
facilitate O 0 1.4415695659408811e-06
screening O 0 1.4676962791781989e-06
for O 0 9.792602639890902e-08
A B-Disease 0 6.0487855080282316e-06
- I-Disease 0 0.47169336676597595
T I-Disease 1 0.9983170032501221
heterozygotes O 0 0.0006748317391611636
in O 0 2.878864222566335e-07
the O 0 2.611300544685946e-07
populations O 0 3.2493865091964835e-06
studied O 0 1.5562928865620052e-06
. O 0 1.034419938150677e-06
. O 0 4.041618012706749e-06

The O 0 0.00013712825602851808
von B-Disease 1 0.8288565874099731
Hippel I-Disease 1 0.9884682297706604
- I-Disease 1 0.9307577610015869
Lindau I-Disease 1 0.9990909099578857
tumor I-Disease 1 0.8035404086112976
suppressor O 0 0.0003190149727743119
gene O 0 3.6232197544450173e-06
is O 0 6.652853556943228e-08
required O 0 5.1606548367999494e-08
for O 0 5.308368855594381e-08
cell O 0 4.819005880563054e-06
cycle O 0 5.047245394962374e-06
exit O 0 4.840312612941489e-06
upon O 0 1.0442613529448863e-06
serum O 0 8.143316517816857e-05
withdrawal O 0 1.9987468476756476e-05
. O 0 9.846362445387058e-06

The O 0 3.333292988827452e-05
inactivation O 0 0.001179494196549058
of O 0 2.1277326140989317e-06
the O 0 5.289502041705418e-06
von B-Disease 1 0.6567290425300598
Hippel I-Disease 1 0.9879701733589172
- I-Disease 1 0.5917202234268188
Lindau I-Disease 1 0.9927377104759216
( I-Disease 0 3.66870553989429e-05
VHL I-Disease 0 0.19207054376602173
) I-Disease 0 7.44849376133061e-06
tumor I-Disease 0 0.0012198048643767834
suppressor O 0 6.988896348048002e-05
gene O 0 1.0997606295859441e-05
predisposes O 0 0.0006120486650615931
affected O 0 4.821074526262237e-06
individuals O 0 1.6837024929827749e-07
to O 0 1.7014373554502527e-07
the O 0 2.4024611775530502e-06
human O 0 0.013960986398160458
VHL B-Disease 1 0.99998939037323
cancer I-Disease 1 0.9999879598617554
syndrome I-Disease 1 0.9999666213989258
and O 0 1.3248067034510314e-06
is O 0 2.5266763259423897e-07
associated O 0 1.2016117807434057e-06
with O 0 1.0102709211423644e-06
sporadic B-Disease 0 0.006018097512423992
renal I-Disease 1 0.999897837638855
cell I-Disease 1 0.7174593210220337
carcinomas I-Disease 1 0.9999579191207886
( O 0 0.00019669435278046876
RCC B-Disease 1 0.9744002819061279
) O 0 4.954591076966608e-06
and O 0 5.0101743909181096e-06
brain B-Disease 0 0.025844013318419456
hemangioblastomas I-Disease 0 0.019752956926822662
. O 0 1.5139669812924694e-05

VHL O 0 0.21295927464962006
- O 0 0.002366409869864583
negative O 0 4.412051566760056e-05
786 O 0 0.000635073462035507
- O 0 0.0009300949168391526
0 O 0 0.00011648911458905786
RCC B-Disease 0 0.07623406499624252
cells O 0 1.174978751805611e-05
are O 0 9.177426818496315e-08
tumorigenic O 0 0.0002413915644865483
in O 0 3.1628178476239555e-07
nude O 0 5.152759695192799e-05
mice O 0 4.7131423343671486e-05
which O 0 4.582930301921806e-08
is O 0 3.721698149661279e-08
suppressed O 0 5.339661015568709e-07
by O 0 5.2222635105181325e-08
the O 0 1.2627714340851526e-07
reintroduction O 0 1.7825102986535057e-05
of O 0 2.376304109930061e-06
VHL B-Disease 0 0.07055003196001053
. O 0 1.7775058950064704e-05

Remarkably O 0 0.0010888043325394392
, O 0 7.999572517292108e-06
this O 0 7.203485665741027e-07
occurs O 0 1.3148330708645517e-06
without O 0 1.4644118095930025e-07
affecting O 0 1.930701500896248e-06
the O 0 1.357804677581953e-07
growth O 0 2.200539483965258e-06
rate O 0 3.5523405017556797e-07
and O 0 9.680952217649974e-08
cell O 0 7.684405318286736e-06
cycle O 0 3.75379772776796e-06
profile O 0 5.331076522452349e-07
of O 0 3.380169033562197e-08
these O 0 5.10816384746704e-08
cells O 0 9.691664217825746e-07
in O 0 2.0743951267832017e-07
culture O 0 3.150669499518699e-06
. O 0 5.519920705410186e-06

The O 0 1.0169928827963304e-05
786 O 0 0.0001901457435451448
- O 0 0.00021083762112539262
0 O 0 1.2028698620270006e-05
cell O 0 7.885982995503582e-06
line O 0 9.663616538091446e-07
, O 0 1.370104740772149e-07
like O 0 1.7431511878385209e-06
many O 0 1.7803361060941825e-06
cancer B-Disease 0 0.12145823985338211
cells O 0 1.0250453669868875e-05
, O 0 3.1542933243144944e-07
fails O 0 1.8735966023086803e-06
to O 0 2.4861417813326625e-08
exit O 0 2.6718470280684414e-07
the O 0 4.225158889425984e-08
cell O 0 2.6510113002586877e-06
cycle O 0 3.886337708536303e-06
upon O 0 6.230876010704378e-07
serum O 0 8.163032907759771e-05
withdrawal O 0 1.2994394637644291e-05
. O 0 5.89902219871874e-06

Here O 0 3.490831659291871e-05
, O 0 2.764816827038885e-06
it O 0 2.2045922776214866e-07
is O 0 7.371063759364915e-08
shown O 0 8.183211974710503e-08
that O 0 1.993807252631541e-08
reintroduction O 0 6.98478800131852e-07
of O 0 2.356086525878709e-08
the O 0 6.649618455867312e-08
wild O 0 4.251668997312663e-06
- O 0 0.0008237528963945806
type O 0 2.5910441763699055e-05
VHL B-Disease 0 0.0013797900173813105
gene O 0 8.419301593676209e-07
restores O 0 1.1398863080103183e-06
the O 0 3.3120603148972805e-08
ability O 0 7.572855054149841e-08
of O 0 6.952834752382842e-08
VHL O 0 0.003662991803139448
- O 0 0.009037664160132408
negative O 0 4.887045724899508e-05
RCC B-Disease 1 0.9157848954200745
cancer I-Disease 0 0.040151197463274
cells O 0 1.0273188308929093e-06
to O 0 3.3425671119857725e-08
exit O 0 2.9776123255942366e-07
the O 0 2.896510586936074e-08
cell O 0 1.161767954727111e-06
cycle O 0 8.112082241495955e-07
and O 0 7.345996522190035e-08
enter O 0 8.205270773942175e-07
G0 O 0 0.0006213871529325843
/ O 0 6.1800230469089e-05
quiescence O 0 0.0001500564394518733
in O 0 5.567914627135906e-07
low O 0 2.1877727704122663e-05
serum O 0 0.0002104020386468619
. O 0 6.091589057177771e-06

Both O 0 3.683014801936224e-05
VHL O 0 0.047744713723659515
- O 0 0.0012699369108304381
positive O 0 3.1641561690776143e-06
and O 0 1.0407517265775823e-06
VHL O 0 0.009052539244294167
- O 0 0.0008257215959019959
negative O 0 6.974197276576888e-06
RCC B-Disease 0 0.0050420090556144714
cells O 0 3.550681185515714e-06
exit O 0 9.062496815204213e-07
the O 0 6.356411574870435e-08
cell O 0 2.253834509247099e-06
cycle O 0 1.5505198689425015e-06
by O 0 1.8062075923808152e-07
contact O 0 3.7652923765563173e-06
inhibition O 0 1.7095229850383475e-05
. O 0 6.4363484852947295e-06

The O 0 1.4301561350293923e-05
cyclin O 0 0.0028396740090101957
- O 0 0.0004920714418403804
dependent O 0 1.7692580513539724e-05
kinase O 0 0.0001239646808244288
inhibitor O 0 1.6917318134801462e-05
, O 0 2.134020888888699e-07
p27 O 0 3.173883669660427e-05
, O 0 1.3884672966923972e-07
accumulates O 0 4.288486707082484e-06
upon O 0 1.295688036861975e-07
serum O 0 1.312151289312169e-05
withdrawal O 0 5.935663125455903e-07
, O 0 1.6648209921754642e-08
only O 0 2.885288230558558e-09
in O 0 4.267743491936926e-09
the O 0 9.814401735752654e-09
presence O 0 4.01880733136295e-08
of O 0 5.4125816717487396e-08
VHL B-Disease 0 0.006995373405516148
, O 0 6.654198614342022e-08
as O 0 7.867073215095388e-09
a O 0 1.4715805463083598e-08
result O 0 2.7187425644115137e-08
of O 0 7.93160470635712e-09
the O 0 2.2379083475243533e-08
stabilization O 0 7.525704859290272e-07
of O 0 5.921653212226374e-08
the O 0 4.544443470422266e-07
protein O 0 6.595733793801628e-06
. O 0 4.877685114479391e-06

We O 0 1.5048552086227573e-05
propose O 0 3.18539678119123e-05
that O 0 4.7502115307906934e-07
the O 0 2.8791663453375804e-07
loss O 0 2.1478146663866937e-05
of O 0 1.6852978035331034e-07
wild O 0 2.5877521693473682e-05
- O 0 0.0235682874917984
type O 0 0.00025238562375307083
VHL B-Disease 0 0.07875771820545197
gene O 0 3.4039082947856514e-06
results O 0 2.3509360858042783e-07
in O 0 1.59399196064669e-08
a O 0 2.2555552092740072e-08
specific O 0 5.7402846920240336e-08
cellular O 0 4.308404459152371e-05
defect O 0 0.0002973724331241101
in O 0 3.9632507764508773e-07
serum O 0 0.00016531998699065298
- O 0 0.0003481237217783928
dependent O 0 4.131409241381334e-06
growth O 0 3.052598003705498e-06
control O 0 5.822583943881909e-07
, O 0 1.2731076992622548e-07
which O 0 1.8383660460585816e-07
may O 0 4.525337772065541e-06
initiate O 0 0.00011372055450920016
tumor B-Disease 0 0.02680235169827938
formation O 0 6.070909512345679e-05
. O 0 1.0310181096429005e-05

This O 0 1.1627650565060321e-05
is O 0 1.898714231174381e-06
corrected O 0 1.9912755305995233e-05
by O 0 6.879844960394621e-08
the O 0 3.4131449666574554e-08
reintroduction O 0 1.339895334240282e-06
of O 0 6.842652311433994e-08
wild O 0 1.1414274922572076e-05
- O 0 0.024302907288074493
type O 0 0.00018921878654509783
VHL B-Disease 0 0.06275440007448196
, O 0 5.715358497582201e-07
implicating O 0 0.00022419437300413847
VHL B-Disease 0 0.003808740060776472
as O 0 4.433700695471998e-08
the O 0 5.017271220708608e-08
first O 0 6.007051638334815e-07
tumor B-Disease 0 0.0010267136385664344
suppressor O 0 4.753714620164828e-06
involved O 0 3.14913783938664e-08
in O 0 9.827007652063457e-09
the O 0 9.010564738787252e-09
regulation O 0 8.419095109957198e-08
of O 0 1.3097547935103648e-08
cell O 0 5.330417479854077e-06
cycle O 0 5.4449878916784655e-06
exit O 0 2.1289258711476577e-06
, O 0 4.298823341741809e-08
which O 0 1.340270205929528e-08
is O 0 6.516189365868286e-09
consistent O 0 2.513270302983983e-08
with O 0 1.1721927428709478e-08
its O 0 4.318933832792027e-08
gatekeeper O 0 0.0001275324320886284
function O 0 2.951888689040061e-07
in O 0 2.508257068711828e-07
the O 0 2.897607828344917e-06
kidney O 0 0.17396610975265503
. O 0 2.6255793272866867e-06
. O 0 8.958540092862677e-06

Piebaldism B-Disease 1 0.9927467703819275
with O 0 0.0018161875195801258
deafness B-Disease 1 0.9998968839645386
: O 0 0.0004621190018951893
molecular O 0 0.0008934544748626649
evidence O 0 9.009843779494986e-06
for O 0 7.11384075202659e-07
an O 0 2.5686131266411394e-06
expanded O 0 0.0011828324059024453
syndrome O 1 0.999769389629364
. O 0 4.859825276071206e-05

In O 0 4.095972144568805e-06
a O 0 9.741016810949077e-07
South O 0 1.262546675206977e-06
African O 0 7.870406761867343e-07
girl O 0 4.637289293896174e-06
of O 0 1.6979959127638722e-07
Xhosa O 0 0.01364145427942276
stock O 0 0.00013882647908758372
with O 0 1.9935197997256182e-05
severe O 1 0.738670289516449
piebaldism B-Disease 1 0.8531224727630615
and O 0 7.88344259490259e-05
profound O 1 0.7996565103530884
congenital O 1 0.9999967813491821
sensorineural B-Disease 1 0.9999946355819702
deafness I-Disease 1 0.9999982118606567
we O 0 3.705109338625334e-05
identified O 0 1.995197635551449e-06
a O 0 8.117176264477166e-08
novel O 0 6.201164524100022e-07
missense O 0 3.1998670237953775e-06
substitution O 0 8.31927948752309e-08
at O 0 3.966339434668953e-08
a O 0 2.1549851680902066e-08
highly O 0 4.1313001020171214e-08
conserved O 0 1.3537305676436517e-07
residue O 0 1.4580002982711449e-07
in O 0 9.46695788428542e-09
the O 0 2.2611549965745326e-08
intracellular O 0 1.3846961337549146e-06
kinase O 0 1.092372485800297e-06
domain O 0 5.64941409209041e-08
of O 0 1.543318361996171e-08
the O 0 1.0130487027026902e-07
KIT O 0 0.00011877844372065738
proto O 0 0.005156045779585838
- O 0 0.005151102785021067
oncogene O 0 0.005207451060414314
, O 0 4.697790700447513e-06
R796G O 0 0.00041664752643555403
. O 0 9.632457476982381e-06

Though O 0 0.0005651324172504246
auditory B-Disease 0 0.24897529184818268
anomalies I-Disease 1 0.5412126779556274
have O 0 2.173419716200442e-06
been O 0 4.842935936721915e-07
observed O 0 7.536779662586923e-07
in O 0 1.7918458183885377e-07
mice O 0 4.580167296808213e-05
with O 0 4.757383749165456e-07
dominant O 0 2.951658643723931e-05
white O 0 0.00016461859922856092
spotting O 0 0.007439131382852793
( O 0 5.747488103224896e-06
W O 0 0.3466455638408661
) O 0 4.710957739462174e-07
due O 0 4.7390349777742813e-07
to O 0 3.4358529887867917e-07
KIT O 0 0.01748236082494259
mutations O 0 0.00018246244871988893
, O 0 4.372597686597146e-06
deafness B-Disease 1 0.9996992349624634
is O 0 4.440378518211219e-07
not O 0 6.831802323858938e-08
typical O 0 1.0091432613990037e-06
in O 0 5.298097107697686e-07
human O 0 9.05589695321396e-06
piebaldism B-Disease 0 0.007093673571944237
. O 0 1.134661852120189e-05

Thus O 0 3.212535739294253e-05
, O 0 3.733202220246312e-06
the O 0 9.056345788849285e-07
occurrence O 0 3.3307482226518914e-05
of O 0 3.745262574739172e-06
sensorineural B-Disease 1 0.9998980760574341
deafness I-Disease 1 0.9999911785125732
in O 0 2.6232235541101545e-05
this O 0 1.7462010646340786e-06
patient O 0 7.18147202860564e-05
extends O 0 2.84050088339427e-06
considerably O 0 3.4647101188056695e-07
the O 0 3.286273297931075e-08
phenotypic O 0 3.809807367360918e-07
range O 0 6.869080237947855e-08
of O 0 6.001966568192074e-08
piebaldism B-Disease 0 0.000301635533105582
due O 0 6.011539426253876e-07
to O 0 1.1616023698479694e-07
KIT O 0 0.0001444669032935053
gene O 0 5.208911261433968e-06
mutation O 0 1.7325558019365417e-06
in O 0 5.712770345667195e-08
humans O 0 2.1675627692729904e-07
and O 0 6.528382812120981e-08
tightens O 0 0.00015609542606398463
the O 0 1.4525723202041263e-07
clinical O 0 1.162585431302432e-05
similarity O 0 2.3883299036242533e-06
between O 0 3.8932867596486176e-07
piebaldism B-Disease 0 0.0005850032903254032
and O 0 6.710226330142177e-08
the O 0 4.304427037027381e-08
various O 0 5.638691646936422e-08
forms O 0 3.215599690520321e-06
of O 0 9.768661402631551e-05
Waardenburg B-Disease 1 0.9999594688415527
syndrome I-Disease 1 0.9999533891677856
. O 0 1.3989629223942757e-05
. O 0 1.6944846720434725e-05

Cycloheximide O 0 0.006297360640019178
facilitates O 0 7.27842707419768e-05
the O 0 8.179449082490464e-07
identification O 0 3.875047127621656e-07
of O 0 9.686124258223572e-08
aberrant O 0 1.4689868294226471e-05
transcripts O 0 4.2556607695587445e-06
resulting O 0 4.7062786734386464e-07
from O 0 2.4070970994216623e-08
a O 0 3.508235835170126e-08
novel O 0 4.3388661197241163e-07
splice O 0 3.575915252440609e-05
- O 0 0.00012302813411224633
site O 0 1.3713939779336215e-06
mutation O 0 7.321503403545648e-07
in O 0 7.827980397223655e-08
COL17A1 O 0 0.0003407449694350362
in O 0 2.2170380020725133e-07
a O 0 1.1785234619310359e-06
patient O 0 0.00033036680542863905
with O 0 2.1531219317694195e-05
generalized O 0 0.3722580373287201
atrophic B-Disease 1 0.999752938747406
benign I-Disease 1 0.9940232634544373
epidermolysis I-Disease 1 0.9986761212348938
bullosa I-Disease 1 0.9946739673614502
. O 0 0.00011151858052471653

Patients O 1 0.7750009298324585
with O 0 0.0006279210792854428
generalized O 1 0.8814036846160889
atrophic B-Disease 1 0.9998389482498169
benign I-Disease 1 0.9978271126747131
epidermolysis I-Disease 1 0.9991818070411682
bullosa I-Disease 1 0.9957484602928162
often O 0 9.207597940985579e-06
show O 0 1.9713659185072174e-06
decreased O 0 2.7174573915544897e-06
expression O 0 3.1083948215382406e-07
of O 0 1.9483198343550612e-07
type O 0 4.121153324376792e-05
XVII O 1 0.7064959406852722
collagen O 0 0.0005979160778224468
, O 0 3.078654344790266e-07
a O 0 1.6991540974231611e-07
transmembrane O 0 0.00014501855184789747
hemidesmosomal O 0 0.00014020511298440397
protein O 0 6.354878223646665e-07
encoded O 0 4.467661085527652e-07
by O 0 7.913072295195889e-07
COL17A1 O 0 0.00091996428091079
. O 0 8.886680916475598e-06

This O 0 6.07827132625971e-06
report O 0 1.8961194427902228e-06
documents O 0 4.363901666692982e-07
a O 0 1.5326851610097947e-07
novel O 0 1.0590433703328017e-06
splice O 0 7.234590884763747e-05
- O 0 0.00036078496486879885
site O 0 3.7941686059639324e-06
mutation O 0 1.3959145235276083e-06
in O 0 1.0435092434590842e-07
COL17A1 O 0 0.0013024582294747233
in O 0 2.8155034215160413e-07
a O 0 9.500387250227504e-07
patient O 0 0.0007848177338019013
with O 0 1.819862336560618e-05
generalized O 1 0.6234073042869568
atrophic B-Disease 1 0.999941349029541
benign I-Disease 1 0.9916501045227051
epidermolysis I-Disease 1 0.9995096921920776
bullosa I-Disease 1 0.9913617968559265
, O 0 1.2650776852751733e-06
and O 0 9.093892572309414e-08
applies O 0 1.4036073991974263e-07
a O 0 4.10816696216898e-08
new O 0 7.285382963573284e-08
methodology O 0 3.377678865490452e-07
to O 0 3.5620146832116006e-08
define O 0 6.06156049798301e-07
and O 0 1.0036803388402404e-07
characterize O 0 4.40893472841708e-06
the O 0 7.467588147846982e-08
resulting O 0 4.1459756516815105e-07
mRNA O 0 1.2827200635001645e-06
splice O 0 3.1741288694320247e-05
variants O 0 6.924235549377045e-06
. O 0 5.581222922046436e-06

Mutational O 0 0.0033336288761347532
analysis O 0 3.692115569720045e-05
of O 0 3.23389235745708e-06
COL17A1 O 0 0.009335551410913467
identified O 0 3.7360975966294063e-06
a O 0 5.901093231841514e-07
maternally O 0 0.00010639709216775373
inherited O 0 0.0011009114095941186
G O 0 0.0006138181197457016
- O 0 7.622158591402695e-05
to O 0 3.154016496864642e-07
- O 0 0.0003045450721401721
T O 0 0.005237780511379242
transversion O 0 6.658057100139558e-05
at O 0 5.516525192206245e-08
the O 0 1.548593608902138e-08
- O 0 2.405104396530078e-06
1 O 0 9.184098104242366e-08
position O 0 6.334263957796793e-08
of O 0 7.851217276311218e-08
exon O 0 5.304209116729908e-05
32 O 0 7.777076461934485e-06
. O 0 6.065190518711461e-06

This O 0 7.379204816970741e-06
acceptor O 0 4.0574916056357324e-05
splice O 0 0.0008128830813802779
- O 0 0.0013773915125057101
site O 0 7.4693280112114735e-06
mutation O 0 4.101499143871479e-06
led O 0 3.557011893917661e-07
to O 0 2.4544979382312704e-08
the O 0 1.755432421646219e-08
formation O 0 1.7910565475176554e-07
of O 0 3.523747338363137e-08
aberrant O 0 6.9100656219234224e-06
transcripts O 0 3.8560101529583335e-06
present O 0 2.627004391797527e-07
at O 0 5.525428150576772e-07
extremely O 0 1.8347158174947253e-06
low O 0 4.5498914005293045e-06
levels O 0 5.42591214980348e-06
. O 0 4.956953944201814e-06

Based O 0 1.5736062778159976e-05
on O 0 1.6731107734813122e-06
our O 0 7.294586907846679e-07
recent O 0 9.139570238403394e-07
finding O 0 9.555960787110962e-07
that O 0 3.3138744015559496e-07
cycloheximide O 0 0.0005083524738438427
stabilized O 0 6.782288255635649e-05
mutant O 0 8.38275627756957e-06
COL17A1 O 0 0.00019766090554185212
transcripts O 0 2.0997013052692637e-06
in O 0 9.757252428244101e-08
keratinocytes O 0 4.345834895502776e-05
homozygous O 0 1.7613439240449225e-06
for O 0 3.46792603522772e-08
a O 0 1.7485344017131865e-07
frameshift O 0 0.0014512642519548535
mutation O 0 3.6336145967652556e-06
, O 0 3.903305412222835e-08
the O 0 2.3316770736414583e-08
effects O 0 1.5791223972883017e-07
of O 0 8.303993048741631e-09
the O 0 3.086861966039578e-08
splice O 0 2.95441277557984e-05
- O 0 7.936597103253007e-05
site O 0 6.519013595607248e-07
mutation O 0 1.3080739336146507e-07
on O 0 6.666175611513836e-09
splicing O 0 1.8293121684109792e-07
of O 0 2.7701819504954983e-08
COL17A1 O 0 3.746152651729062e-05
transcripts O 0 3.7394127616607875e-07
were O 0 2.0980262860348375e-08
determined O 0 5.137565040058689e-08
using O 0 2.499311690939976e-08
reverse O 0 9.95320647234621e-07
transcriptase O 0 8.329269803653006e-06
polymerase O 0 3.5323482734384015e-06
chain O 0 1.0373253189754905e-06
reaction O 0 3.8331055662865765e-08
of O 0 8.61010196473444e-09
total O 0 4.059058866801024e-08
RNA O 0 3.4570757634355687e-07
from O 0 6.611413283508227e-08
keratinocytes O 0 1.6700356354704127e-05
incubated O 0 3.5662203572428552e-06
for O 0 1.8035500204405253e-07
2 O 0 3.0201551908248803e-06
. O 0 4.4315384002402425e-06

5 O 0 0.00011451328464318067
h O 0 0.0007476758328266442
in O 0 5.368375468606246e-07
the O 0 1.767717066059049e-07
presence O 0 4.0625755559631216e-07
or O 0 1.655107979559034e-07
absence O 0 5.690155830961885e-07
of O 0 1.2742141564103804e-07
10 O 0 1.2724938187602675e-06
microg O 0 0.0037095854058861732
cycloheximide O 0 0.001463567721657455
per O 0 1.7869086832433823e-06
ml O 0 0.0001109608419938013
. O 0 7.5439302236191e-06

Using O 0 7.286407708306797e-06
this O 0 7.595397732984566e-07
approach O 0 8.036819281187491e-07
, O 0 2.1226586000011594e-07
an O 0 9.929108557571453e-08
abnormally O 0 9.058850992005318e-05
spliced O 0 3.608448605518788e-05
transcript O 0 2.423856312816497e-05
was O 0 3.0126216188364197e-07
identified O 0 1.3253144004465867e-07
that O 0 8.135835116718226e-09
contains O 0 1.4615328502998182e-08
an O 0 5.796336743912889e-09
extra O 0 2.874397431185116e-08
264 O 0 1.905042950056668e-07
bases O 0 8.904200399229012e-08
upstream O 0 1.764246064794861e-07
from O 0 1.6379978262648365e-08
exon O 0 1.4470170981439878e-06
32 O 0 1.1267540855897096e-07
, O 0 3.435901518855644e-08
resulting O 0 9.211870377612286e-08
in O 0 2.4594935865707157e-08
a O 0 1.0877157308186725e-07
premature O 0 4.382948100101203e-05
termination O 0 1.9310629795654677e-05
codon O 0 2.072083134407876e-06
27 O 0 7.182796366578259e-07
bp O 0 4.7416301640623715e-06
downstream O 0 5.517703129953588e-07
from O 0 5.8618358167450424e-08
the O 0 2.245256638389037e-07
cryptic O 0 3.849228232866153e-05
splice O 0 0.0003202799416612834
site O 0 1.8308150174561888e-05
. O 0 7.6140759119880386e-06

Three O 0 4.950576112605631e-06
other O 0 5.468601216307434e-07
splice O 0 6.650176510447636e-05
variants O 0 2.1072298750368645e-06
, O 0 1.2649579161916336e-07
including O 0 3.5375119722402815e-08
one O 0 1.3777101237621991e-08
derived O 0 2.476638272241871e-08
from O 0 7.661591361340925e-09
the O 0 8.619780444973912e-09
skipping O 0 1.0963952945530764e-07
of O 0 2.5225777022797047e-08
exon O 0 2.361541373829823e-05
32 O 0 6.492334705399117e-07
, O 0 1.0204120570733721e-07
were O 0 7.489541076211026e-08
also O 0 4.2948119016728015e-07
identified O 0 4.633081516658422e-06
. O 0 4.837806955038104e-06

These O 0 1.5754862033645622e-05
results O 0 1.876248097687494e-05
indicate O 0 3.3798387448769063e-06
the O 0 1.8000858403866005e-07
usefulness O 0 4.205960976833012e-06
of O 0 3.7727653534602723e-07
cycloheximide O 0 0.1507466733455658
treatment O 0 2.4682292860234156e-05
in O 0 9.491859032095817e-08
evaluating O 0 1.2620470215551904e-06
the O 0 4.790756236161542e-08
abnormal O 0 1.2818688901461428e-06
processing O 0 5.8218123655251475e-08
of O 0 1.2609874922020481e-08
mRNA O 0 1.478994278159007e-07
due O 0 1.0863390542681373e-07
to O 0 3.646242419108603e-08
splice O 0 3.921141251339577e-05
- O 0 0.0003468691138550639
site O 0 6.677645160380052e-06
mutations O 0 6.642508196819108e-06
, O 0 1.0398950678336405e-07
because O 0 1.1558208967699102e-07
( O 0 1.0638004965812797e-07
i O 0 1.8287018122009613e-07
) O 0 5.537545888500972e-08
aberrant O 0 1.2224787724335329e-06
splicing O 0 6.314661504802643e-07
often O 0 3.5266925380028624e-08
generates O 0 6.808166830296614e-08
a O 0 5.905253530613663e-08
premature O 0 9.710940503282472e-06
termination O 0 7.961389201227576e-06
codon O 0 1.0574680118224933e-06
, O 0 7.801924795103332e-08
( O 0 8.458707156933087e-08
ii O 0 1.532292003503244e-06
) O 0 5.113711054605119e-08
transcripts O 0 3.08396977288794e-07
with O 0 1.4055363806164678e-07
premature O 0 0.0001070164653356187
termination O 0 2.709848922677338e-05
codons O 0 5.5463788157794625e-06
can O 0 4.5092029665738664e-08
occur O 0 8.477314139554437e-08
at O 0 6.404115282521161e-08
low O 0 9.295669087805436e-07
or O 0 1.939636291581337e-07
undetectable O 0 1.1407810234231874e-05
levels O 0 9.942469603174686e-08
due O 0 4.230489381029656e-08
to O 0 1.3313248281576762e-08
nonsense O 0 4.350177107426134e-07
- O 0 3.299631543995929e-06
mediated O 0 7.578127565466275e-07
mRNA O 0 1.24753370300823e-07
decay O 0 7.417322080982558e-07
, O 0 3.8648860112289185e-08
and O 0 4.83686584118459e-08
( O 0 2.6727286694949726e-07
iii O 0 2.8180869776406325e-05
) O 0 3.9190162226532266e-08
the O 0 7.813000912904045e-09
levels O 0 1.5434448386031363e-08
of O 0 3.815764593184667e-09
these O 0 7.943792290632246e-09
transcripts O 0 4.6151058086252306e-07
can O 0 3.798556491574345e-08
be O 0 1.211205091777856e-08
increased O 0 1.8167007453939732e-07
by O 0 5.06675974065729e-07
cycloheximide O 0 0.001284364378079772
. O 0 8.227334546972997e-06

A O 0 6.858658161945641e-05
deletion O 0 0.0027418152894824743
mutation O 0 8.363285451196134e-05
in O 0 1.1589604582695756e-06
COL17A1 O 0 0.001102231559343636
in O 0 3.7574261568806833e-07
five O 0 4.674448348396254e-07
Austrian O 0 0.0002220980532001704
families O 0 1.4269790881371591e-05
with O 0 2.024952664214652e-05
generalized O 1 0.721934974193573
atrophic B-Disease 1 0.9999402761459351
benign I-Disease 1 0.98478102684021
epidermolysis I-Disease 1 0.9989293217658997
bullosa I-Disease 1 0.9792910218238831
represents O 0 1.0689207556424662e-05
propagation O 0 2.1109526642248966e-06
of O 0 8.690919628406846e-08
an O 0 1.5510433115650812e-07
ancestral O 0 5.90586569160223e-05
allele O 0 2.0101895643165335e-05
. O 0 6.6793072619475424e-06

Patients O 1 0.5842523574829102
with O 0 0.0006200085044838488
generalized O 1 0.9486979246139526
atrophic B-Disease 1 0.9997811913490295
benign I-Disease 1 0.998335063457489
epidermolysis I-Disease 1 0.9990580677986145
bullosa I-Disease 1 0.994616687297821
, O 0 6.475666850747075e-06
a O 0 4.6438648837465735e-07
usually O 0 3.3846987435026676e-07
nonlethal O 0 3.5506911899574334e-06
form O 0 5.381590426623006e-07
of O 0 1.5310664593926049e-06
junctional B-Disease 1 0.9849011301994324
epidermolysis I-Disease 1 0.9983651041984558
bullosa I-Disease 1 0.9388107061386108
, O 0 2.127121888406691e-06
have O 0 5.438135417534795e-07
generalized O 0 5.497434540302493e-05
blistering B-Disease 0 0.0006985384970903397
, O 0 1.6813160982565023e-05
nail B-Disease 1 0.9985122084617615
dystrophy I-Disease 1 0.9998952150344849
, O 0 0.00022145437833387405
patchy B-Disease 1 0.999221682548523
alopecia I-Disease 1 0.9999812841415405
, O 0 0.00010535660112509504
and O 0 0.0001718257844913751
dental B-Disease 1 0.9993293285369873
abnormalities I-Disease 1 0.9983886480331421
. O 0 6.794911314500496e-05

Skin B-Disease 1 0.9947541952133179
fragility I-Disease 1 0.868579626083374
in O 0 1.4861280760669615e-05
most O 0 1.2029234994770377e-06
cases O 0 3.5170539831597125e-06
is O 0 4.020671440230217e-07
due O 0 2.9040729714324698e-06
to O 0 2.403677399342996e-07
mutations O 0 2.1997420844854787e-06
in O 0 4.162820843589543e-08
the O 0 4.63325697808159e-08
gene O 0 9.386041597281292e-07
encoding O 0 1.7189436221087817e-06
type O 0 8.928451279643923e-05
XVII O 1 0.790938675403595
collagen O 0 0.013044017367064953
( O 0 1.2603290997503791e-05
COL17A1 O 0 0.0030662929639220238
) O 0 3.19060632136825e-06
. O 0 3.5637519886222435e-06

Recently O 0 0.0002436318463878706
, O 0 5.070658517070115e-06
we O 0 1.1458984090495505e-06
reported O 0 1.604185854375828e-06
five O 0 4.4579235236597015e-07
Austrian O 0 0.00022828827786725014
families O 0 8.724369763513096e-06
with O 0 2.5482340788585134e-05
generalized O 1 0.5894411206245422
atrophic B-Disease 1 0.9999041557312012
benign I-Disease 1 0.9662958979606628
epidermolysis I-Disease 1 0.9990496039390564
bullosa I-Disease 1 0.9893252849578857
who O 0 2.531222662582877e-06
share O 0 6.202134841259976e-07
the O 0 2.19064261841595e-07
same O 0 9.809798484639032e-07
COL17A1 O 0 0.04329817369580269
mutation O 0 0.00010912102152360603
. O 0 8.499707291775849e-06

Affected O 0 0.0004989307490177453
individuals O 0 3.3434587294323137e-06
in O 0 2.989091854033177e-07
three O 0 1.8389290801223979e-07
families O 0 9.039829933499277e-07
are O 0 6.52079137353212e-08
homozygous O 0 2.053837533821934e-06
for O 0 1.3677299648406915e-07
4003delTC O 0 0.00015886491746641695
, O 0 1.0498116864710028e-07
whereas O 0 1.586305700129742e-07
those O 0 1.1108623354516567e-08
in O 0 1.5279063347861666e-08
two O 0 3.829437034141847e-08
others O 0 2.4184231506296783e-07
are O 0 2.1933057325895788e-07
compound O 0 1.8944543626275845e-05
heterozygotes O 0 0.000567995070014149
. O 0 9.76051978796022e-06

To O 0 1.6649642930133268e-05
determine O 0 5.283663540467387e-06
if O 0 2.5399785386071017e-07
the O 0 8.614853186372784e-08
occurrence O 0 1.92170978152717e-06
of O 0 1.1674183753029865e-07
4003delTC O 0 0.00012232626613695174
in O 0 8.432868270347171e-08
these O 0 4.6103547646225707e-08
unrelated O 0 1.6530857465113513e-06
families O 0 4.3533353277780407e-07
signifies O 0 2.213247171312105e-06
propagation O 0 4.914483611173637e-07
of O 0 1.843896590969507e-08
an O 0 2.4329919412480194e-08
ancestral O 0 6.877292435092386e-06
allele O 0 4.805710887012538e-07
or O 0 4.6494925243223406e-08
a O 0 6.561951693129231e-08
mutational O 0 6.324674905044958e-05
hot O 0 3.628475724326563e-06
spot O 0 5.866091328243783e-07
, O 0 9.505627929229377e-08
haplotypes O 0 1.0686791938496754e-05
were O 0 3.035470896861625e-08
determined O 0 1.676690715157747e-07
for O 0 3.560622019449511e-08
polymorphisms O 0 5.683215022145305e-06
both O 0 5.0522451999768236e-08
within O 0 1.0559286067746143e-07
and O 0 6.810834634052298e-07
flanking O 0 0.0005344956298358738
COL17A1 O 0 0.06368253380060196
. O 0 2.4000244593480602e-05

Five O 0 5.430256715044379e-05
intragenic O 0 0.009894219227135181
polymorphisms O 0 0.0004885311936959624
were O 0 5.608443416349473e-07
chosen O 0 2.7128513124807796e-07
based O 0 2.1962424057164753e-07
on O 0 2.294898138188728e-07
their O 0 9.190036394102208e-07
informativeness O 0 0.0030238418839871883
. O 0 1.05893986983574e-05

One O 0 2.6394022825115826e-06
of O 0 4.5865726860938594e-07
these O 0 1.6923684142966522e-07
, O 0 1.451720521572497e-07
not O 0 3.617956423340729e-08
previously O 0 2.9641287824233586e-07
reported O 0 5.127922122483142e-07
, O 0 6.401587171467327e-08
was O 0 9.411169088480165e-08
2988 O 0 8.388901187572628e-05
A O 0 9.086247132472636e-08
or O 0 1.048562978667178e-07
C O 0 4.498444923228817e-06
that O 0 1.2969844753740745e-08
introduces O 0 1.846661774607128e-07
a O 0 2.147795896689786e-08
new O 0 6.606382640939046e-08
restriction O 0 2.0306769954459014e-07
site O 0 4.2247242504345195e-07
for O 0 1.789779275895853e-07
Eco0109 O 0 0.0002445016580168158
I O 0 1.1166828699060716e-05
. O 0 4.7592257033102214e-06

All O 0 6.460566510213539e-06
the O 0 2.4696814762137365e-06
4003delTC O 0 0.0003715819912031293
alleles O 0 8.044440619414672e-06
showed O 0 1.608399998076493e-06
the O 0 6.58242242934648e-08
same O 0 6.850474676411977e-08
haplotype O 0 2.9904578696005046e-05
for O 0 6.668771845852461e-08
these O 0 7.147251324113313e-08
five O 0 6.756040988875611e-07
polymorphic O 0 0.0002606624038890004
markers O 0 0.00029996701050549746
. O 0 1.2640040040423628e-05

Fourteen O 0 0.00011827731941593811
microsatellite O 0 0.0010093220043927431
polymorphisms O 0 0.00037478847661986947
were O 0 3.2193941024161177e-07
selected O 0 1.0463572408525579e-07
based O 0 5.106751288508349e-08
on O 0 2.6840920597237528e-08
their O 0 5.638734990043304e-08
high O 0 1.1706531495292438e-06
heterozygosity O 0 0.00023717306612525135
and O 0 6.244177086500713e-08
their O 0 3.9557694009317856e-08
location O 0 2.1742147282566293e-07
within O 0 1.1000630451007964e-07
10q23 O 0 9.753750055097044e-05
- O 0 0.00043442792957648635
q25 O 0 0.0006702374084852636
near O 0 2.6605888706399128e-05
COL17A1 O 0 0.002899161772802472
. O 0 1.4812225344940089e-05

Three O 0 1.3641021723742597e-05
families O 0 1.386513849865878e-05
shared O 0 8.79435447131982e-06
microsatellite O 0 0.001388318371027708
polymorphisms O 0 0.0006045696209184825
covering O 0 2.2082687792135403e-05
at O 0 9.757770840224111e-07
most O 0 1.3485775696153723e-07
19 O 0 2.0386455616971944e-06
cM O 0 5.2373648941284046e-05
, O 0 1.266683113954059e-07
whereas O 0 1.7023543819050246e-07
the O 0 3.278522697769404e-08
others O 0 4.132710529347605e-08
shared O 0 6.815324837816661e-08
smaller O 0 7.457212092276677e-08
regions O 0 1.2545251593110152e-07
consistent O 0 4.799792918674939e-08
with O 0 8.941450246879867e-09
cross O 0 1.3063473147667537e-07
- O 0 7.354291938099777e-06
over O 0 5.407153835790268e-08
events O 0 4.014524890294524e-08
during O 0 3.012618421394109e-08
passage O 0 4.3337376354202206e-08
of O 0 9.801306433132595e-09
this O 0 1.9642106607875576e-08
mutation O 0 3.9143964158938616e-07
through O 0 5.5153254407969143e-08
several O 0 1.4475732257324125e-07
generations O 0 8.076010090007912e-06
. O 0 4.695237294072285e-06

These O 0 1.2304169104027096e-05
results O 0 2.2834616174804978e-05
indicate O 0 6.547689281433122e-06
that O 0 4.388123215903761e-07
4003delTC O 0 0.0005527322646230459
occurs O 0 5.679941637026786e-07
on O 0 4.087072369429734e-08
a O 0 8.040561993993833e-08
single O 0 9.98815153252508e-07
ancestral O 0 0.0001525962579762563
allele O 0 1.0408400157757569e-05
. O 0 1.8034536424238468e-06
. O 0 6.156186373118544e-06

The O 0 3.603486766223796e-05
haptoglobin O 0 0.003640174400061369
- O 0 0.004038662649691105
gene O 0 0.00013863388448953629
deletion O 0 0.00028006514185108244
responsible O 0 9.00558279681718e-06
for O 0 2.612551043057465e-06
anhaptoglobinemia B-Disease 0 0.01035792101174593
. O 0 2.0323665012256242e-05

We O 0 1.2530498679552693e-05
have O 0 5.678722914126411e-07
found O 0 2.313649503093984e-07
an O 0 7.341066066146595e-08
allelic O 0 2.2323327357298695e-05
deletion O 0 1.0873619430640247e-05
of O 0 5.305018291323904e-08
the O 0 2.3575412910759042e-07
haptoglobin O 0 0.0002770526916719973
( O 0 5.31807756942726e-07
Hp O 0 6.9168104346317705e-06
) O 0 1.4595096331504465e-07
gene O 0 2.452505043493147e-07
from O 0 2.3298010631833677e-08
an O 0 2.6092537908084523e-08
individual O 0 1.5411525566833006e-07
with O 0 1.2911860949316178e-06
anhaptoglobinemia B-Disease 0 0.011162924580276012
. O 0 1.4392177945410367e-05

The O 0 1.3716537068830803e-05
Hp O 0 7.256534445332363e-05
gene O 0 1.8188402464147657e-05
cluster O 0 6.5009862737497315e-06
consists O 0 1.8494745290809078e-07
of O 0 5.6924633895505394e-08
coding O 0 2.8853753519797465e-06
regions O 0 1.1358144291762073e-07
of O 0 1.3425087708185401e-08
the O 0 2.4041696633503307e-08
alpha O 0 4.016922900973441e-07
chain O 0 1.5931871075736126e-06
and O 0 4.416196475176548e-08
beta O 0 2.3184423980637803e-07
chain O 0 6.552753575306269e-07
of O 0 1.8547746449826263e-08
the O 0 6.880422631638794e-08
haptoglobin O 0 8.615898696007207e-05
gene O 0 1.3105466223350959e-06
( O 0 1.21857539170378e-07
Hp O 0 9.876428066490917e-07
) O 0 1.8326765882648033e-08
and O 0 3.6008469539439147e-09
of O 0 3.6230647371127134e-09
the O 0 1.022669859906955e-08
alpha O 0 2.4470966764056357e-07
chain O 0 9.282027235713031e-07
and O 0 2.1541469052976936e-08
beta O 0 1.1397489174669317e-07
chain O 0 2.4140609866663e-07
of O 0 1.001771288144937e-08
the O 0 3.4714599195240226e-08
haptoglobin O 0 3.688058495754376e-05
- O 0 7.055256719468161e-05
related O 0 2.7944211069552694e-06
gene O 0 3.177785629304708e-06
( O 0 2.923090391959704e-07
Hpr O 0 5.223234256845899e-05
) O 0 4.8927986995295214e-08
, O 0 1.721558184897276e-08
in O 0 1.8420440284216966e-08
tandem O 0 5.747930913457822e-07
from O 0 2.7468212593362296e-08
the O 0 6.290078857773551e-08
5 O 0 7.799007448738848e-07
side O 0 3.5735740766540403e-06
. O 0 5.681643870047992e-06

Southern O 0 9.991582919610664e-05
blot O 0 0.0015318385558202863
and O 0 3.894916517310776e-06
PCR O 0 4.885694579570554e-05
analyses O 0 7.230593837448396e-06
have O 0 1.330098058360818e-07
indicated O 0 4.4335615712043364e-07
that O 0 1.473881106051067e-08
the O 0 1.612876765477722e-08
individual O 0 2.8408663865775452e-08
with O 0 2.081473695625391e-07
anhaptoglobinemia B-Disease 0 0.004651006776839495
was O 0 1.977237644723573e-07
homozygous O 0 4.2307274839004094e-07
for O 0 9.082794960590945e-09
the O 0 2.2845384251013456e-08
gene O 0 6.789854865019151e-07
deletion O 0 3.0626904390373966e-06
and O 0 2.9811232593601744e-08
that O 0 1.4249126323306882e-08
the O 0 4.1036482656409135e-08
gene O 0 1.0548250202191412e-06
deletion O 0 5.268659151624888e-06
was O 0 4.371469941588657e-08
included O 0 3.712297313995805e-08
at O 0 5.3773483443819714e-08
least O 0 1.0525621263468565e-08
from O 0 1.9311636734187232e-08
the O 0 4.4125169296194144e-08
promoter O 0 6.883224159537349e-06
region O 0 2.7745264219447563e-07
of O 0 3.2969463603649274e-08
Hp O 0 2.756894218691741e-06
to O 0 1.0379233827961798e-07
Hpr O 0 4.21879485656973e-05
alpha O 0 5.531264264391211e-07
but O 0 2.2924520948208738e-08
not O 0 1.248228276296004e-08
to O 0 6.863409396373754e-08
Hpr O 0 0.00010748937347671017
beta O 0 3.4545025755505776e-06
( O 0 1.968632432181039e-06
Hpdel O 0 0.0003574553702492267
) O 0 2.6590278139337897e-06
. O 0 3.0882690680300584e-06

In O 0 1.0243497854389716e-05
addition O 0 4.173365141468821e-06
, O 0 9.307183290729881e-07
we O 0 3.0290254926512716e-07
found O 0 1.370935933664441e-07
seven O 0 1.2139160787683068e-07
individuals O 0 7.648279165550775e-08
with O 0 1.1194941862413543e-07
hypohaptoglobinemia B-Disease 0 0.0002690158144105226
in O 0 5.614245424112596e-08
three O 0 4.357176663916107e-08
families O 0 2.795684679313126e-07
, O 0 4.519759499999054e-08
and O 0 2.5165801886828376e-08
the O 0 3.2801551697048126e-08
genotypes O 0 1.6211522506637266e-06
of O 0 6.095551174922775e-09
six O 0 1.1413996858777864e-08
of O 0 9.207598239413528e-09
the O 0 2.468860849091925e-08
seven O 0 1.036461512171627e-07
individuals O 0 4.4679293154104016e-08
were O 0 2.0268320355398828e-08
found O 0 8.256144212737127e-08
to O 0 8.162712816783824e-08
be O 0 2.7276928449282423e-07
Hp2 O 0 0.0020468984730541706
/ O 0 0.000865374633576721
Hpdel O 0 0.0018068513600155711
. O 0 8.949018592829816e-06

The O 0 2.4634036890347488e-05
phenotypes O 0 0.00047493824968114495
and O 0 1.5795908439031336e-06
genotypes O 0 0.00011892680049641058
in O 0 5.417301451871026e-08
one O 0 1.4831336159204511e-08
of O 0 1.0436820296888527e-08
these O 0 1.00577270956137e-08
three O 0 1.8549304314774417e-08
families O 0 2.1725857379806257e-07
showed O 0 4.7562178906446206e-07
the O 0 4.0977663928742913e-08
father O 0 9.214662100021087e-07
to O 0 4.108707685190893e-08
be O 0 2.8593818868216658e-08
hypohaptoglobinemic B-Disease 0 0.00016874588618520647
( O 0 2.5174907136715774e-07
Hp2 O 0 3.9544196624774486e-05
) O 0 4.6662304242772734e-08
and O 0 4.453660906733603e-08
Hp2 O 0 0.00019010945106856525
/ O 0 7.112065213732421e-05
Hpdel O 0 9.694950858829543e-05
, O 0 3.78406461720715e-08
the O 0 2.02212504518684e-08
mother O 0 5.400370923780429e-07
to O 0 9.332851824694899e-09
be O 0 6.073697544906054e-09
Hp2 O 0 6.368751201080158e-06
- O 0 6.358258360705804e-06
1 O 0 2.760817494618095e-07
and O 0 2.263809477653922e-07
Hp1 O 0 0.001991485944017768
/ O 0 0.00019309934577904642
Hp2 O 0 0.00021020389976911247
, O 0 2.508978802495676e-08
one O 0 3.2775582248234514e-09
of O 0 3.86468546054175e-09
the O 0 8.177373445050762e-09
two O 0 1.5786641327508733e-08
children O 0 1.7614905800655833e-07
to O 0 5.6412734039668067e-08
be O 0 3.594261599459969e-08
hypohaptoglobinemic B-Disease 0 0.00039191884570755064
( O 0 4.779105893248925e-07
Hp2 O 0 8.983485167846084e-05
) O 0 7.30363680645496e-08
and O 0 6.436665245246331e-08
Hp2 O 0 0.00025827717036008835
/ O 0 9.959648741642013e-05
Hpdel O 0 9.240138751920313e-05
, O 0 2.9655726763166967e-08
and O 0 1.1163997726271191e-08
the O 0 8.760666858620425e-09
other O 0 1.559590678823497e-08
child O 0 8.217996310122544e-07
to O 0 3.699990358541072e-08
be O 0 1.5552894083725732e-08
Hp1 O 0 3.585367085179314e-05
and O 0 2.6990937840309925e-07
Hp1 O 0 0.0015954882837831974
/ O 0 0.00025944432127289474
Hpdel O 0 0.0003467983624432236
, O 0 1.4026413452938868e-07
showing O 0 4.785578084920417e-07
an O 0 3.624158750881179e-08
anomalous O 0 1.8049169739242643e-05
inheritance O 0 8.268022611446213e-06
of O 0 2.0179356852167984e-07
Hp O 0 0.00011172881204402074
phenotypes O 0 4.2381179810035974e-05
in O 0 1.1056163629064031e-07
the O 0 1.5869137826030055e-07
child O 0 4.741295470012119e-06
with O 0 3.7884776702412637e-06
Hp1 O 0 0.029349878430366516
. O 0 1.7498619854450226e-05

The O 0 3.771563569898717e-05
Hp2 O 0 0.04418299347162247
/ O 0 0.020562274381518364
Hpdel O 0 0.03427433967590332
individuals O 0 1.695518335509405e-06
had O 0 1.822465378609195e-07
an O 0 1.6649480016894813e-08
extremely O 0 1.5015288568065444e-07
low O 0 2.4738037041061034e-07
level O 0 3.058122999277657e-08
of O 0 1.7653510653303783e-08
Hp O 0 1.8818428770828177e-06
( O 0 8.298044207322164e-08
mean O 0 1.9251952210197487e-07
+ O 0 2.7260048227617517e-06
/ O 0 3.888988885591971e-06
- O 0 1.3675145055458415e-05
SD O 0 4.037439794046804e-05
= O 0 6.796956768084783e-06
0 O 0 2.82729388345615e-07
. O 0 3.3339841110091584e-08
049 O 0 8.661132596898824e-06
+ O 0 1.6149627981576486e-06
/ O 0 2.7951300580753013e-06
- O 0 4.68561620436958e-06
0 O 0 6.294639547377301e-07
. O 0 6.023182663739135e-08
043 O 0 1.5357563825091347e-05
mg O 0 5.214587417867733e-06
/ O 0 8.471238288620953e-06
ml O 0 6.783888693462359e-06
; O 0 1.846918848968926e-07
n O 0 7.1994254540186375e-06
= O 0 1.096547748602461e-05
6 O 0 1.7343580793749425e-07
) O 0 1.5711691503383918e-08
, O 0 5.561719529367792e-09
compared O 0 1.4348015220377874e-08
with O 0 5.134163316711238e-09
the O 0 7.775627253181483e-09
level O 0 2.59679175940164e-08
( O 0 2.3269322468877363e-08
1 O 0 2.6753827597758573e-08
. O 0 1.2012110417458643e-08
64 O 0 7.197594698027387e-08
+ O 0 2.247018301204662e-06
/ O 0 3.006195584021043e-06
- O 0 4.4254061322135385e-06
1 O 0 1.15755710794474e-07
. O 0 2.8317453271142767e-08
07 O 0 2.8068700430594618e-06
mg O 0 6.2631220316689e-06
/ O 0 1.1831443771370687e-05
ml O 0 4.811507551494287e-06
) O 0 3.476508680932966e-08
obtained O 0 1.398973648036872e-08
from O 0 9.721656368810727e-09
52 O 0 2.765093825018994e-07
healthy O 0 6.575056090696307e-07
volunteers O 0 7.216749509098008e-07
having O 0 4.0497295117347676e-07
phenotype O 0 1.822533340600785e-05
Hp2 O 0 6.149295222712681e-05
, O 0 4.823442978363346e-08
whereas O 0 7.011765035258577e-08
the O 0 4.311674572932134e-08
serum O 0 3.6416731745703146e-06
Hp O 0 4.527494752437633e-07
level O 0 1.5359034932771465e-08
of O 0 4.416531140805091e-09
an O 0 1.0602127176184695e-08
individual O 0 4.901709615978689e-08
with O 0 3.4033752172035747e-07
Hp1 O 0 0.011832300573587418
/ O 0 0.0010422152699902654
Hpdel O 0 0.001049962593242526
was O 0 1.1928681260542362e-06
0 O 0 1.217876524606254e-05
. O 0 4.075407105119666e-06

50 O 0 2.9464306862792e-05
mg O 0 0.0006445161416195333
/ O 0 0.0007133991457521915
ml O 0 0.00016414928541053087
, O 0 1.7428706655664428e-07
which O 0 1.8572881899103777e-08
was O 0 1.0294393781862254e-08
approximately O 0 1.0370503567003198e-08
half O 0 9.29446386521704e-09
the O 0 6.790513484844496e-09
level O 0 1.7025888254806887e-08
of O 0 1.7781689010121227e-08
Hp O 0 1.4229076441552024e-06
in O 0 5.1857171001756797e-08
control O 0 5.319695333128038e-07
sera O 0 1.5150256331253331e-05
from O 0 1.8096883991347568e-08
the O 0 8.838328824367636e-08
Hp1 O 0 0.0012756655924022198
phenotype O 0 1.7900294551509432e-05
( O 0 2.8094621740137882e-08
1 O 0 2.7563046955947357e-08
. O 0 9.638278619661378e-09
26 O 0 9.742134210455333e-08
+ O 0 1.8081843791151186e-06
/ O 0 4.864074526267359e-06
- O 0 7.799775630701333e-06
0 O 0 4.203825199056155e-07
. O 0 1.5295626099032233e-08
33 O 0 9.653643928686506e-08
mg O 0 2.57544911619334e-06
/ O 0 7.739238753856625e-06
ml O 0 5.620369847747497e-06
; O 0 1.1932522170354787e-07
n O 0 4.100721071154112e-06
= O 0 4.6258801376097836e-06
9 O 0 1.285255564198451e-07
) O 0 1.7042980360315596e-08
, O 0 8.228079551031442e-09
showing O 0 6.90911718947973e-08
a O 0 4.252445506836011e-08
gene O 0 1.958421989911585e-06
- O 0 0.0003496537101455033
dosage O 0 3.685657065943815e-05
effect O 0 3.856591320072766e-06
. O 0 4.985993655282073e-06

The O 0 6.4912851485132705e-06
other O 0 9.118448929257283e-07
allele O 0 8.79596518643666e-06
( O 0 1.393372826896666e-06
Hp2 O 0 0.0002006443974096328
) O 0 1.0808867756395557e-07
of O 0 1.858347609129396e-08
individuals O 0 6.046456491048957e-08
with O 0 2.5663800329311925e-07
Hp2 O 0 0.04395294189453125
/ O 0 0.004402858670800924
Hpdel O 0 0.0034606135450303555
was O 0 1.0129347316478743e-07
found O 0 2.6682227982632867e-08
to O 0 1.5316675927579126e-08
have O 0 7.742151808542985e-09
, O 0 6.83940104551084e-09
in O 0 6.0428804182777185e-09
all O 0 8.17012324461075e-09
exons O 0 1.1417638233979233e-05
, O 0 2.187646686024891e-07
no O 0 1.8436877269323304e-07
mutation O 0 1.2632957577807247e-06
, O 0 7.595884454758561e-08
by O 0 1.407051826163297e-07
DNA O 0 7.179055501183029e-06
sequencing O 0 1.2341456567810383e-05
. O 0 4.7607877604605164e-06

On O 0 3.475777930361801e-06
the O 0 5.228766895015724e-07
basis O 0 1.42748092457623e-07
of O 0 5.157702531732866e-08
the O 0 5.438939965074496e-08
present O 0 1.3428449108232599e-07
study O 0 2.170860398109653e-07
, O 0 2.8852953803948367e-08
the O 0 1.4192139019542083e-08
mechanism O 0 1.2159901530139905e-07
of O 0 2.8641306215604345e-08
anhaptoglobinemia B-Disease 0 0.00011761374480556697
and O 0 4.7350866339002096e-08
the O 0 2.7864983209724414e-08
mechanism O 0 2.509501371150691e-07
of O 0 5.580785611414285e-08
anomalous O 0 2.1432822904898785e-05
inheritance O 0 5.818243153044023e-06
of O 0 2.3504405533003592e-07
Hp O 0 0.00015367341984529048
phenotypes O 0 7.038611511234194e-05
were O 0 9.801627953720526e-08
well O 0 5.438814696390182e-07
explained O 0 6.710886736982502e-06
. O 0 4.572419129544869e-06

However O 0 2.428286461508833e-05
, O 0 2.5896749775711214e-06
the O 0 9.015706154968939e-07
mechanism O 0 3.5124858186463825e-06
of O 0 2.1550465589825762e-06
hypohaptoglobinemia B-Disease 0 0.04385516420006752
remains O 0 5.2306462748674676e-05
unknown O 0 5.375083492253907e-05

ATM O 0 0.02279922552406788
mutations O 0 0.007301129400730133
and O 0 1.4645595911133569e-05
phenotypes O 0 0.0013182585826143622
in O 0 1.745185727486387e-05
ataxia B-Disease 1 0.9999034404754639
- I-Disease 1 0.9983946681022644
telangiectasia I-Disease 1 0.9998793601989746
families O 0 2.5114020900218748e-05
in O 0 1.9070917289809586e-07
the O 0 7.178811500807569e-08
British O 0 4.958785098096996e-07
Isles O 0 6.103096438891953e-06
: O 0 7.949494573722404e-08
expression O 0 2.739527538153652e-08
of O 0 1.186962883537035e-08
mutant O 0 1.022102310344053e-06
ATM O 0 4.245291620463831e-06
and O 0 6.009756248204212e-08
the O 0 1.3262879861031251e-07
risk O 0 2.084179868688807e-05
of O 0 4.081579845660599e-06
leukemia B-Disease 1 0.9999452829360962
, O 0 0.004372990690171719
lymphoma B-Disease 1 0.9999969005584717
, O 0 0.0002247604716103524
and O 0 0.0012366698356345296
breast B-Disease 1 0.9996583461761475
cancer I-Disease 1 0.9842573404312134
. O 0 4.147655636188574e-05

We O 0 7.1845897764433175e-06
report O 0 1.0364748277424951e-06
the O 0 1.2824199302485795e-07
spectrum O 0 3.3389579812137526e-07
of O 0 7.76735902263681e-08
59 O 0 7.625564649060834e-06
ATM O 0 0.00024061487056314945
mutations O 0 2.286987546540331e-05
observed O 0 7.141963465073786e-07
in O 0 5.842781547471532e-07
ataxia B-Disease 1 0.9986306428909302
- I-Disease 1 0.9185665845870972
telangiectasia I-Disease 1 0.9995549321174622
( O 0 4.60404544355697e-06
A B-Disease 0 2.071067319775466e-05
- I-Disease 1 0.8690972924232483
T I-Disease 1 0.9997343420982361
) O 0 2.622770807647612e-05
patients O 0 2.5304785594926216e-05
in O 0 1.129073226024957e-07
the O 0 2.790940527575003e-07
British O 0 8.938783139456064e-06
Isles O 0 0.00027459734701551497
. O 0 8.225671081163455e-06

Of O 0 9.07029698282713e-06
51 O 0 0.00012960933963768184
ATM O 0 0.00411792891100049
mutations O 0 0.00042429505265317857
identified O 0 1.4553720575349871e-06
in O 0 1.1688108259022556e-07
families O 0 4.4245055619285267e-07
native O 0 4.1891215118994296e-07
to O 0 5.194150887177784e-08
the O 0 3.489875766149453e-08
British O 0 5.499767326000438e-07
Isles O 0 1.8709537471295334e-05
, O 0 1.0425802088320779e-07
11 O 0 2.0666448108386248e-07
were O 0 4.236036588167735e-08
founder O 0 2.2021868062438443e-05
mutations O 0 4.552647624223027e-06
, O 0 3.6008419357358434e-08
and O 0 1.6722042417427474e-08
2 O 0 7.893997633345862e-08
of O 0 1.5340823722453933e-08
these O 0 3.4223170075620146e-08
11 O 0 4.7514484435851045e-07
conferred O 0 2.376005113546853e-06
a O 0 3.4532766335360066e-07
milder O 0 8.311274723382667e-05
clinical O 0 0.000302638829452917
phenotype O 0 3.992863275925629e-05
with O 0 9.220519103791958e-08
respect O 0 1.5057317170885653e-07
to O 0 1.2696752094143449e-07
both O 0 4.513548219620134e-07
cerebellar B-Disease 0 0.47770968079566956
degeneration I-Disease 1 0.9813073873519897
and O 0 4.2356023186584935e-06
cellular O 0 0.00021149317035451531
features O 0 2.5690767870401032e-05
. O 0 1.3630461580760311e-05

We O 0 1.3249823496153113e-05
report O 0 2.7070384476246545e-06
, O 0 1.1827858514834588e-07
in O 0 2.5555815241773416e-08
two O 0 3.956660066251061e-08
A B-Disease 0 3.4283714285265887e-06
- I-Disease 0 0.30116456747055054
T I-Disease 1 0.9961840510368347
families O 0 3.959554760513129e-06
, O 0 9.901837216830245e-08
an O 0 2.922883091116546e-08
ATM O 0 2.342893640161492e-05
mutation O 0 1.9796896140178433e-06
( O 0 8.732177292358756e-08
7271T O 0 1.0774913789646234e-05
- O 0 5.732359932153486e-05
- O 0 0.0031304594594985247
> O 0 0.004397805314511061
G O 0 0.004194237757474184
) O 0 1.4193281572261185e-07
that O 0 2.8066716950547743e-08
may O 0 1.6644948175326135e-07
be O 0 4.978460754756497e-09
associated O 0 5.827022775406476e-08
with O 0 2.593722925325892e-08
an O 0 6.160622234574475e-08
increased O 0 2.6309382974432083e-06
risk O 0 6.184149242471904e-05
of O 0 1.5883304513408802e-05
breast B-Disease 1 0.9996392726898193
cancer I-Disease 1 0.8260135054588318
in O 0 3.8713645267307584e-07
both O 0 5.657420274474134e-07
homozygotes O 0 0.008413657546043396
and O 0 1.966147010534769e-06
heterozygotes O 0 0.0009973803535103798
( O 0 1.525149741610221e-06
relative O 0 3.3245053145947168e-06
risk O 0 1.611747052265855e-06
12 O 0 9.432050518398682e-08
. O 0 3.124321068526115e-08
7 O 0 4.088129799129092e-07
; O 0 8.656721206534712e-07
P O 0 0.002130727982148528
= O 0 6.940413732081652e-05
. O 0 1.4291046568359889e-07
0025 O 0 0.0003285773564130068
) O 0 7.15794712391471e-08
, O 0 1.932165716311829e-08
although O 0 1.0225801538865653e-08
there O 0 5.754663856549769e-09
is O 0 6.229388116452128e-09
a O 0 2.8405304774992146e-08
less O 0 1.5230639860419615e-07
severe O 0 0.0005256709991954267
A B-Disease 0 1.0018411558121443e-05
- I-Disease 1 0.6986411213874817
T I-Disease 1 0.999620795249939
phenotype O 0 0.00024921566364355385
in O 0 3.31170681988624e-08
terms O 0 2.869878024114314e-08
of O 0 1.4333135567312638e-08
the O 0 5.0057334277653354e-08
degree O 0 7.805182917763887e-07
of O 0 3.040355068151257e-06
cerebellar B-Disease 1 0.9939895868301392
degeneration I-Disease 1 0.9992231130599976
. O 0 9.36200303840451e-05

This O 0 1.2179508303233888e-05
mutation O 0 6.157562893349677e-05
( O 0 1.6804362985567423e-06
7271T O 0 7.780749001540244e-05
- O 0 0.00011136790999444202
- O 0 0.0007209214963950217
> O 0 0.0007002615602687001
G O 0 0.00014634306717198342
) O 0 3.35219532132669e-08
also O 0 4.648985196809008e-09
allows O 0 5.536381575410587e-09
expression O 0 5.38555733342605e-09
of O 0 2.8289151021709813e-09
full O 0 2.642101115668538e-08
- O 0 7.086511232046178e-06
length O 0 3.8143483038766135e-07
ATM O 0 2.964481154776877e-06
protein O 0 1.2118606207423e-07
at O 0 2.266422782781774e-08
a O 0 1.2673434746091061e-08
level O 0 3.659075176187798e-08
comparable O 0 1.2766943768838246e-07
with O 0 4.5184407326814835e-08
that O 0 7.964731452148044e-08
in O 0 5.499237545336655e-07
unaffected O 0 0.0001520485384389758
individuals O 0 2.8837962418037932e-06
. O 0 5.693142156815156e-06

In O 0 8.852904102241155e-06
addition O 0 1.9642277493403526e-06
, O 0 4.393692734083743e-07
we O 0 8.324899170020217e-08
have O 0 3.21903748101704e-08
studied O 0 2.5221356736437883e-07
18 O 0 4.1457894894847414e-07
A B-Disease 0 1.737133970891591e-05
- I-Disease 1 0.9862812161445618
T I-Disease 1 0.9999445676803589
patients O 0 0.0020699126180261374
, O 0 1.0083758184009639e-07
in O 0 5.775669364993519e-08
15 O 0 1.956596520358289e-07
families O 0 6.65007462430367e-07
, O 0 8.413377940996725e-07
who O 0 8.847376193443779e-06
developed O 0 0.004203788470476866
leukemia B-Disease 1 0.999914288520813
, O 0 0.00016794889234006405
lymphoma B-Disease 1 0.9999798536300659
, O 0 5.1127631195413414e-06
preleukemic O 0 0.03964156284928322
T O 0 0.11981182545423508
- O 0 0.005225226748734713
cell O 0 0.00013818185834679753
proliferation O 0 0.0001798017037799582
, O 0 5.634521585307084e-06
or O 0 0.00039283488877117634
Hodgkin B-Disease 1 0.9999876022338867
lymphoma I-Disease 1 0.9999934434890747
, O 0 4.426647137734108e-06
mostly O 0 9.611311497792485e-07
in O 0 2.2737458493793383e-06
childhood O 0 0.0022237792145460844
. O 0 1.8457654732628725e-05

A O 0 1.509640242147725e-05
wide O 0 6.947478595975554e-06
variety O 0 1.3412391126621515e-06
of O 0 3.999717250735557e-07
ATM O 0 0.00028837486752308905
mutation O 0 2.4365888748434372e-05
types O 0 8.283936381303647e-07
, O 0 1.0786604320855986e-07
including O 0 1.7085413617223821e-07
missense O 0 0.00011368748528184369
mutations O 0 3.5614111766335554e-06
and O 0 3.77485918079401e-08
in O 0 5.670443670169334e-08
- O 0 9.046618652064353e-05
frame O 0 1.953635182871949e-05
deletions O 0 8.080586667347234e-06
, O 0 9.97158338122972e-08
were O 0 3.770088952137485e-08
seen O 0 2.9287519964782405e-07
in O 0 2.7727887186301814e-07
these O 0 1.0816926305778907e-06
patients O 0 0.00032030403963290155
. O 0 8.639857696834952e-06

We O 0 1.1021083082596306e-05
also O 0 1.0091230251418892e-06
show O 0 4.681099596837157e-07
that O 0 4.0876184215221656e-08
25 O 0 3.319453867334232e-08
% O 0 1.1901866159291785e-08
of O 0 5.067094743793632e-09
all O 0 1.4442025353389454e-08
A B-Disease 0 5.203400178288575e-06
- I-Disease 1 0.8028207421302795
T I-Disease 1 0.9997544884681702
patients O 0 0.00010073974408442155
carried O 0 9.13373483513169e-08
in O 0 2.279584876418994e-08
- O 0 2.0918243535561487e-05
frame O 0 9.224508175975643e-06
deletions O 0 8.550168786314316e-06
or O 0 4.138272515774588e-07
missense O 0 0.00015869778872001916
mutations O 0 6.814754215156427e-06
, O 0 2.124020781479885e-08
many O 0 4.056757596515581e-09
of O 0 7.845884830715022e-09
which O 0 2.7237721411665916e-08
were O 0 1.9229229764050615e-08
also O 0 4.975520795369448e-08
associated O 0 9.537627221334333e-08
with O 0 2.5335715747587528e-08
expression O 0 1.361202777161452e-07
of O 0 7.802832868719634e-08
mutant O 0 9.772357770998497e-06
ATM O 0 4.320928928791545e-05
protein O 0 6.0551460592250805e-06
. O 0 3.942207968066214e-06

The O 0 3.702810136019252e-05
DMPK O 0 0.018615150824189186
gene O 0 8.873704791767523e-05
of O 0 1.643059658817947e-05
severely O 1 0.7133433222770691
affected O 1 0.6031433939933777
myotonic B-Disease 1 0.9999935626983643
dystrophy I-Disease 1 0.9999973773956299
patients O 1 0.9826206564903259
is O 0 1.88271478691604e-05
hypermethylated O 0 0.3334816098213196
proximal O 0 0.002444928279146552
to O 0 3.0998160127637675e-07
the O 0 1.404312968134036e-07
largely O 0 5.500958195625572e-07
expanded O 0 4.827023076359183e-06
CTG O 0 0.0038352645933628082
repeat O 0 0.00017432095773983747
. O 0 8.525124030711595e-06

Using O 0 1.56252699525794e-05
methylation O 0 5.973392762825824e-05
- O 0 0.00020303341443650424
sensitive O 0 1.0910606761171948e-05
restriction O 0 3.1666374979977263e-06
enzymes O 0 8.488382263749372e-06
, O 0 1.3332818582512118e-07
we O 0 5.598120722538624e-08
characterized O 0 6.149106184238917e-07
the O 0 2.1863009180833615e-08
methylation O 0 1.0341742608943605e-06
pattern O 0 3.7863577517782687e-07
on O 0 1.9205590007231876e-08
the O 0 1.5715707846197802e-08
5 O 0 7.464128515266566e-08
side O 0 3.948186844127122e-08
of O 0 1.4586922780779332e-08
the O 0 9.556711688674113e-08
CTG O 0 0.0004884476657025516
repeat O 0 2.3800191684131278e-06
in O 0 1.6275185643621626e-08
the O 0 2.8970079668511062e-08
DMPK O 0 7.747609197394922e-05
gene O 0 1.0047223497622326e-07
of O 0 1.0889483093023955e-08
normal O 0 1.6570001548643631e-07
individuals O 0 3.8161303450579e-08
and O 0 4.700962819015331e-08
of O 0 8.13981728242652e-07
patients O 0 0.0037928372621536255
affected O 0 4.810594327864237e-05
with O 0 0.00019586380221880972
myotonic B-Disease 1 0.9999940395355225
dystrophy I-Disease 1 0.9999884366989136
, O 0 5.4802667364128865e-06
showing O 0 5.427154519566102e-06
expansions O 0 8.813439308141824e-06
of O 0 1.5181855417267798e-07
the O 0 5.428041731647681e-07
repetitive O 0 0.00040099085890688
sequence O 0 1.1606024600041565e-05
. O 0 7.857201126171276e-06

The O 0 1.134207377617713e-05
gene O 0 1.3997810128785204e-05
segment O 0 8.955994417192414e-06
analyzed O 0 2.6551863356871763e-06
corresponds O 0 6.809282808717398e-07
to O 0 7.884833053140028e-08
the O 0 1.0314857235016461e-07
genomic O 0 6.193722583702765e-06
SacI O 0 0.0001621921983314678
- O 0 9.517166472505778e-05
HindIII O 0 8.139231795212254e-05
fragment O 0 1.6663085489199148e-06
carrying O 0 1.666624740437328e-07
exons O 0 5.140102075529285e-06
11 O 0 1.5299673350455123e-06
- O 0 7.484265370294452e-05
15 O 0 4.682971393776825e-06
. O 0 6.365951776388101e-06

There O 0 6.102148290665355e-06
is O 0 9.889839702736936e-07
constitutive O 0 1.0045831004390493e-05
methylation O 0 1.1589026144065429e-05
in O 0 2.645672054768511e-07
intron O 0 0.0003115168074145913
12 O 0 3.119430402875878e-07
at O 0 7.080683417370892e-08
restriction O 0 8.179607391411992e-08
sites O 0 3.7347401615761555e-08
of O 0 2.458640047109384e-08
SacII O 0 5.342159420251846e-05
and O 0 1.7237637450762122e-07
HhaI O 0 0.00010834452405106276
, O 0 7.95858170477004e-08
localized O 0 9.15269708912092e-07
1 O 0 8.582446042737502e-08
, O 0 3.179520646767742e-08
159 O 0 7.127973162823764e-07
- O 0 1.870222513389308e-05
1 O 0 1.8019237302269175e-07
, O 0 3.248216273732396e-08
232 O 0 5.277024115457607e-07
bp O 0 3.095915417361539e-06
upstream O 0 1.4239186896247702e-07
of O 0 9.899284059144975e-09
the O 0 5.3548621536947394e-08
CTG O 0 0.00022208833252079785
repeat O 0 5.9426806728879455e-06
, O 0 4.7153132953781096e-08
whereas O 0 1.1213342077098787e-07
most O 0 1.027571805423122e-08
, O 0 2.4734564618711374e-08
if O 0 1.2479855371339e-08
not O 0 2.1781583203761556e-09
all O 0 1.5776127071376322e-09
, O 0 5.451618267926506e-09
of O 0 3.569337714282028e-09
the O 0 8.324958500338653e-09
other O 0 4.397433528424699e-09
sites O 0 2.991558289977547e-08
of O 0 2.24963478956397e-08
SacII O 0 0.00031288713216781616
, O 0 2.648310157837841e-07
HhaI O 0 9.76891242316924e-05
, O 0 5.414058179553649e-08
and O 0 3.930409420149772e-08
HpaII O 0 2.9988081223564222e-05
in O 0 1.872437138672467e-08
this O 0 8.724481581623422e-09
region O 0 1.522178223467563e-07
are O 0 2.1800630634061235e-08
unmethylated O 0 6.0923157434444875e-05
, O 0 6.032805544009534e-08
in O 0 4.620866178584038e-08
normal O 0 3.818158802459948e-07
individuals O 0 3.786577451592166e-08
and O 0 2.818392985659557e-08
most O 0 1.6816011694231747e-08
of O 0 9.399902722861952e-08
the O 0 4.039213763462612e-06
patients O 0 0.0006655941251665354
. O 0 1.2273932043171953e-05

In O 0 3.597414206524263e-06
a O 0 1.0007477158069378e-06
number O 0 1.9667756134822412e-07
of O 0 2.0894010788197193e-07
young O 0 2.6687153876991943e-05
and O 0 1.60655181389302e-05
severely O 0 0.2370571494102478
affected O 0 0.0028597083874046803
patients O 0 0.0019372348906472325
, O 0 2.615407765915734e-07
however O 0 4.1932942451694544e-08
, O 0 2.4801078524205877e-08
complete O 0 1.5499327332690882e-07
methylation O 0 7.173500193857762e-07
of O 0 1.0006197648237958e-08
these O 0 9.609789408671077e-09
restriction O 0 7.172953075951227e-08
sites O 0 5.049181694971594e-08
was O 0 3.2435234942340685e-08
found O 0 3.143089344348482e-08
in O 0 6.792472362349145e-08
the O 0 3.2627997370582307e-07
mutated O 0 2.711467277549673e-05
allele O 0 1.2152070667070802e-05
. O 0 5.351142590370728e-06

In O 0 2.892414386224118e-06
most O 0 4.134844289183093e-07
of O 0 2.928123592482734e-07
these O 0 1.1953962939514895e-06
patients O 0 0.00011327261745464057
, O 0 4.6643754103570245e-07
the O 0 1.019050046124903e-06
onset O 0 0.19580528140068054
of O 0 2.4442981612082804e-06
the O 0 0.0001692321675363928
disease O 1 0.9984689354896545
was O 0 0.0005244988715276122
congenital O 1 0.9998799562454224
. O 0 0.00013221106200944632

Preliminary O 0 0.00012277545465622097
in O 0 8.588758646510541e-06
vivo O 0 0.0009052033419720829
footprinting O 0 0.021645909175276756
data O 0 3.022583996425965e-06
gave O 0 4.4104348262408166e-07
evidence O 0 1.431336187351917e-07
for O 0 3.275353677167914e-08
protein O 0 3.599084550387488e-07
- O 0 5.6669632613193244e-05
DNA O 0 3.956157797802007e-06
contact O 0 5.452026243801811e-07
in O 0 4.539293385619203e-08
normal O 0 3.366529313097999e-07
genes O 0 1.7289382014951116e-07
at O 0 5.579295603297396e-08
an O 0 2.8514413941138628e-08
Sp1 O 0 4.1991836042143404e-05
consensus O 0 8.846036081422426e-08
binding O 0 8.410540885961382e-08
site O 0 5.7196828606720374e-08
upstream O 0 8.163694076301908e-08
of O 0 1.0767401192879333e-08
the O 0 5.39871400917491e-08
CTG O 0 0.00016603861877229065
repeat O 0 4.134077698836336e-06
and O 0 1.9915535887093938e-08
for O 0 7.599794571433449e-09
a O 0 1.572122521054098e-08
significant O 0 4.321142199614769e-08
reduction O 0 1.7568501675668813e-07
of O 0 1.0566252761634587e-08
this O 0 1.391453263721587e-08
interaction O 0 8.422323105605756e-08
in O 0 3.2208919975573735e-08
cells O 0 4.1360789282407495e-07
with O 0 6.916356198871654e-08
a O 0 7.705324378548539e-07
hypermethylated O 0 0.09425239264965057
DMPK O 0 0.16555094718933105
gene O 0 1.029928262141766e-05
. O 0 7.181433261393977e-07
. O 0 4.1534849515301175e-06

The O 0 8.519452239852399e-05
hemochromatosis B-Disease 1 0.9983762502670288
gene O 0 0.0001181734842248261
product O 0 2.7933581350225722e-06
complexes O 0 4.991150490241125e-06
with O 0 1.347253544281557e-07
the O 0 1.6200102948005224e-07
transferrin O 0 0.00024854482035152614
receptor O 0 3.560304321581498e-06
and O 0 1.248769336825717e-07
lowers O 0 8.787286787992343e-06
its O 0 1.1514585906979846e-07
affinity O 0 1.2070444199707708e-06
for O 0 2.164951524719072e-07
ligand O 0 1.4564589037036058e-05
binding O 0 7.541038030467462e-06
. O 0 9.324541679234244e-06

We O 0 2.697521631489508e-05
recently O 0 2.2115962565294467e-05
reported O 0 2.2195818019099534e-06
the O 0 1.9695234243499726e-07
positional O 0 2.503917130525224e-06
cloning O 0 3.199406137355254e-06
of O 0 8.650154370570817e-08
a O 0 1.97156438730417e-07
candidate O 0 1.0463847956998507e-06
gene O 0 8.940897714637686e-06
for O 0 6.224353001016425e-06
hereditary B-Disease 1 0.9971394538879395
hemochromatosis I-Disease 1 0.9999822378158569
called O 0 0.0022672044578939676
HFE O 1 0.8700202107429504
. O 0 3.230501533835195e-05

The O 0 1.14634312922135e-05
gene O 0 2.0055633285664953e-05
product O 0 1.8760246121019009e-06
, O 0 1.5901254357686412e-07
a O 0 3.843728535457558e-08
member O 0 5.666335312071169e-08
of O 0 2.0394972821691226e-08
the O 0 8.066106715887145e-08
major O 0 1.9034389424632536e-06
histocompatibility O 0 0.014926849864423275
complex O 0 4.843558599532116e-06
class O 0 3.882792043441441e-06
I O 0 2.8027507141814567e-06
- O 0 6.771663902327418e-05
like O 0 1.1337338037265e-06
family O 0 1.4064885363040958e-06
, O 0 9.166861048015562e-08
was O 0 3.444352714154775e-08
found O 0 1.7178450661958777e-08
to O 0 1.2015593853220707e-08
have O 0 7.033662985378442e-09
a O 0 2.3863250930844515e-08
mutation O 0 5.351513436835376e-07
, O 0 6.679032082956837e-08
Cys O 0 0.00041809541289694607
- O 0 1.7990691048908047e-05
282 O 0 4.327651822677581e-06
- O 0 0.000157440168550238
- O 0 0.0007119789952412248
> O 0 0.0003853646048810333
Tyr O 0 0.0018813654314726591
( O 0 4.994784603695734e-07
C282Y O 0 1.4841352822259068e-05
) O 0 4.260466468508639e-08
, O 0 1.3102395612918372e-08
in O 0 1.82407333682022e-08
85 O 0 1.7952015696209855e-07
% O 0 9.470375061937375e-08
of O 0 2.970796231238637e-07
patient O 0 0.00029467264539562166
chromosomes O 0 7.8276039857883e-05
. O 0 8.312636964546982e-06

This O 0 1.1665869351418223e-05
mutation O 0 4.147557046962902e-05
eliminates O 0 2.5085466404561885e-05
the O 0 3.707086762005929e-07
ability O 0 4.2414291101522394e-07
of O 0 1.1281184697509161e-07
HFE O 0 0.0011004406260326505
to O 0 1.0704928854465834e-07
associate O 0 2.9099317089276155e-07
with O 0 1.336844519528313e-07
beta2 O 0 0.002464440418407321
- O 0 0.004733229987323284
microglobulin O 0 0.020629575476050377
( O 0 1.3721985396841774e-06
beta2m O 0 0.00010786261555040255
) O 0 7.070912033668719e-08
and O 0 2.73599773947808e-08
prevents O 0 8.858291380420269e-07
cell O 0 4.02815749112051e-06
- O 0 0.00010560101509327069
surface O 0 1.4412010386877228e-05
expression O 0 5.397078894020524e-06
. O 0 4.630470812116982e-06

A O 0 2.9186576284701005e-05
second O 0 1.582089862495195e-05
mutation O 0 3.887245838996023e-05
that O 0 1.3395678877259343e-07
has O 0 6.57859473562894e-08
no O 0 4.089794103379063e-08
effect O 0 1.1668874577708266e-07
on O 0 1.1447969683331394e-07
beta2m O 0 0.0038969095330685377
association O 0 1.0946522706944961e-05
, O 0 1.111288270294608e-06
H63D O 0 0.015475501306355
, O 0 1.364352044674888e-07
was O 0 4.306298961864741e-08
found O 0 1.4990400032388607e-08
in O 0 9.213413143527305e-09
eight O 0 2.0016184265614356e-08
out O 0 1.5457398916396414e-08
of O 0 3.313690655204482e-08
nine O 0 1.3814317298965761e-06
patients O 0 3.4660817618714646e-05
heterozygous O 0 5.39566599400132e-07
for O 0 6.016591669322224e-08
the O 0 6.672333938695374e-07
C282Y O 0 0.0006700943340547383
mutant O 0 5.9575948398560286e-05
. O 0 6.78483320371015e-06

In O 0 1.1984110642515589e-05
this O 0 1.3193574659453589e-06
report O 0 9.837023071668227e-07
, O 0 1.0516995274656438e-07
we O 0 4.344795101474119e-08
demonstrate O 0 1.5674673647936288e-07
in O 0 3.807536685940249e-08
cultured O 0 2.646992243171553e-06
293 O 0 1.1444838492025156e-05
cells O 0 3.2450388971483335e-06
overexpressing O 0 0.00010454876610310748
wild O 0 1.2776570201822324e-06
- O 0 5.640743620460853e-05
type O 0 1.5412805396408658e-06
or O 0 1.422984752252887e-07
mutant O 0 7.776558049954474e-06
HFE O 0 0.0003766687586903572
proteins O 0 5.913740963592318e-08
that O 0 6.5640648472253815e-09
both O 0 6.4316800774122385e-09
the O 0 1.778813363273457e-08
wild O 0 7.21568312656018e-07
- O 0 4.4032880396116525e-05
type O 0 2.227038976343465e-06
and O 0 2.9029993697804457e-07
H63D O 0 0.0027586990036070347
HFE O 0 0.0017704631900414824
proteins O 0 3.8470298591164465e-07
form O 0 1.1601643024050645e-07
stable O 0 6.49260698537546e-07
complexes O 0 2.6417444587423233e-06
with O 0 1.0235640246492039e-07
the O 0 5.78892070279835e-07
transferrin O 0 0.0026777517050504684
receptor O 0 6.0217673308216035e-05
( O 0 4.241160240781028e-06
TfR O 0 0.0009373248904012144
) O 0 2.9346167593757855e-06
. O 0 4.562331469060155e-06

The O 0 4.14733549405355e-05
C282Y O 0 0.007050900720059872
mutation O 0 0.00015073560643941164
nearly O 0 1.7669379985818523e-06
completely O 0 1.7513192460683058e-06
prevents O 0 2.2138337953947484e-06
the O 0 1.068461159547951e-07
association O 0 4.465999836611445e-07
of O 0 3.935277703703832e-08
the O 0 1.8336595530854538e-07
mutant O 0 3.3349784644087777e-05
HFE O 0 0.003052191808819771
protein O 0 1.0255226925437455e-06
with O 0 3.26628963875919e-07
the O 0 1.3726161114391289e-06
TfR O 0 0.004205471370369196
. O 0 9.523986591375433e-06

Studies O 0 3.521546386764385e-05
on O 0 2.6162811082031112e-06
cell O 0 4.17248229496181e-05
- O 0 0.0005798020865768194
associated O 0 6.110096819611499e-06
transferrin O 0 5.955481174169108e-05
at O 0 2.013458413330227e-07
37 O 0 2.969346155623498e-07
degrees O 0 3.714613967531477e-07
C O 0 1.3085148566460703e-05
suggest O 0 3.197309013103222e-07
that O 0 1.681553207788511e-08
the O 0 3.8568153115647874e-08
overexpressed O 0 5.951199000264751e-06
wild O 0 1.3867286270397017e-06
- O 0 0.00011923033162020147
type O 0 6.956389370316174e-06
HFE O 0 0.0003492712276056409
protein O 0 2.734383883762348e-07
decreases O 0 2.6113775675185025e-07
the O 0 1.5389561625056558e-08
affinity O 0 1.4486600719010312e-07
of O 0 3.82891869321611e-08
the O 0 2.2652757536434365e-07
TfR O 0 0.00020283315097913146
for O 0 9.301912768933107e-07
transferrin O 0 0.0004899156629107893
. O 0 9.000431418826338e-06

The O 0 4.8808844439918175e-05
overexpressed O 0 0.003933521918952465
H63D O 0 0.05745279788970947
protein O 0 1.6053034414653666e-05
does O 0 8.817699495011766e-07
not O 0 3.796825254198666e-08
have O 0 1.5038741807416045e-08
this O 0 1.1293161072956082e-08
effect O 0 7.459801310005787e-08
, O 0 1.7656340389748948e-08
providing O 0 2.8171408317234636e-08
the O 0 1.185994324970352e-08
first O 0 1.7166495780429614e-08
direct O 0 2.7135413915857498e-08
evidence O 0 8.141566354424867e-08
for O 0 1.2974669338916556e-08
a O 0 4.3947697037083344e-08
functional O 0 7.96906078903703e-07
consequence O 0 1.3465166830428643e-06
of O 0 1.2486823663948599e-07
the O 0 1.7637005385040538e-06
H63D O 0 0.1334235966205597
mutation O 0 0.0001449115516152233
. O 0 1.2944513400725555e-05

Addition O 0 1.5115678252186626e-05
of O 0 2.901371090047178e-06
soluble O 0 0.0002616394485812634
wild O 0 3.8362995837815106e-05
- O 0 0.0012241313233971596
type O 0 8.244163473136723e-05
HFE O 0 0.020449189469218254
/ O 0 0.00023088327725417912
beta2m O 0 0.0008227715734392405
heterodimers O 0 0.0007690485217608511
to O 0 2.5071949494304135e-07
cultured O 0 1.0260821909469087e-05
cells O 0 2.5509975785098504e-06
also O 0 5.695645555192641e-08
decreased O 0 9.692580533737782e-07
the O 0 4.206014381225032e-08
apparent O 0 6.126833227426687e-07
affinity O 0 2.1855612430954352e-07
of O 0 1.7979013833269164e-08
the O 0 4.303326761601056e-08
TfR O 0 2.2914719011168927e-05
for O 0 6.333838342698073e-09
its O 0 1.0172927389362485e-08
ligand O 0 2.168631709764668e-07
under O 0 2.396903475698764e-08
steady O 0 4.445759600457677e-07
- O 0 1.7736283552949317e-05
state O 0 1.6949009307154483e-07
conditions O 0 2.6201589662377955e-06
, O 0 1.9785440841246782e-08
both O 0 9.606948125906456e-09
in O 0 5.254816315414246e-08
293 O 0 1.1538418220879976e-05
cells O 0 1.5158952919591684e-06
and O 0 1.1220723905580599e-07
in O 0 9.568636869516922e-07
HeLa O 0 0.019741341471672058
cells O 0 3.934724009013735e-05
. O 0 5.547658929572208e-06

Furthermore O 0 3.674608888104558e-05
, O 0 1.1326497997288243e-06
at O 0 3.648962945135281e-07
4 O 0 3.051970338674437e-07
degrees O 0 3.750720338757674e-07
C O 0 6.658376605628291e-06
, O 0 3.27057811944087e-08
the O 0 3.484833754896499e-08
added O 0 1.1829922641481971e-07
soluble O 0 2.571767709014239e-06
complex O 0 4.201544641091459e-07
of O 0 1.796503283912898e-07
HFE O 0 0.03698670491576195
/ O 0 0.00023726443760097027
beta2m O 0 0.00020646183111239225
inhibited O 0 1.5079907598192221e-06
binding O 0 7.351884079298543e-08
of O 0 2.4573553858431296e-08
transferrin O 0 1.7268537703785114e-05
to O 0 1.470959603011579e-07
HeLa O 0 0.00019269765471108258
cell O 0 5.246121418167604e-06
TfR O 0 3.18463753501419e-05
in O 0 4.9198337848110896e-08
a O 0 1.127083990581923e-07
concentration O 0 6.0924608987988904e-05
- O 0 0.0004911119467578828
dependent O 0 9.494792720943224e-06
manner O 0 3.7602144402626436e-06
. O 0 5.0618509703781456e-06

Scatchard O 0 0.0005386978155001998
plots O 0 2.4485430913046002e-05
of O 0 8.713607257959666e-07
these O 0 2.1606777522720222e-07
data O 0 6.584311904589413e-07
indicate O 0 4.884640247837524e-07
that O 0 2.8901421700311403e-08
the O 0 2.3693266015811787e-08
added O 0 1.4277873106038896e-07
heterodimer O 0 3.9175680285552517e-05
substantially O 0 5.287572548695607e-07
reduced O 0 8.196614942335145e-08
the O 0 1.9037710075053837e-08
affinity O 0 3.260056189446914e-07
of O 0 1.861237421962869e-07
TfR O 0 0.0006164927617646754
for O 0 1.413091126778454e-06
transferrin O 0 0.0011759771732613444
. O 0 1.0982619642163627e-05

These O 0 9.0455041572568e-06
results O 0 7.977097993716598e-06
establish O 0 1.754669483489124e-06
a O 0 1.6564486315928661e-07
molecular O 0 1.0264805496262852e-05
link O 0 1.2160555343143642e-05
between O 0 7.976223059813492e-07
HFE O 0 0.0063668545335531235
and O 0 8.377080007448967e-08
a O 0 3.151397365286357e-08
key O 0 1.5646773476873932e-07
protein O 0 1.2198265153529064e-07
involved O 0 3.9732977796802516e-08
in O 0 5.610991138382815e-08
iron O 0 8.977884863270447e-05
transport O 0 1.9713245364982868e-06
, O 0 8.10854174915221e-08
the O 0 7.046381256259338e-08
TfR O 0 0.00028023848426528275
, O 0 6.409883468450062e-08
and O 0 2.7473715746850758e-08
raise O 0 2.714075151288853e-07
the O 0 2.7420943737865855e-08
possibility O 0 2.429071912501968e-07
that O 0 4.8121123086275475e-08
alterations O 0 1.6343814195352024e-06
in O 0 2.8908369031910297e-08
this O 0 3.12249852640889e-08
regulatory O 0 3.415741730350419e-06
mechanism O 0 7.625561693203053e-07
may O 0 1.5723722412985808e-07
play O 0 2.2998316140387942e-08
a O 0 2.28196022078464e-08
role O 0 9.983344995134757e-08
in O 0 8.148619912162758e-08
the O 0 4.486387581437157e-07
pathogenesis O 0 0.006367977242916822
of O 0 2.906877125496976e-05
hereditary B-Disease 1 0.9998084902763367
hemochromatosis I-Disease 1 0.999988317489624
. O 0 4.960126170772128e-05
. O 0 1.8255916074849665e-05

Genomic O 0 0.0005230460083112121
organization O 0 1.178778984467499e-05
of O 0 1.18685522920714e-06
the O 0 1.438478193449555e-06
UBE3A O 0 0.0033276048488914967
/ O 0 0.0005354078602977097
E6 O 0 0.001311911386437714
- O 0 0.003564711892977357
AP O 0 0.00028612915775738657
gene O 0 4.902092314296169e-06
and O 0 7.526400622737128e-07
related O 0 8.457369403913617e-06
pseudogenes O 0 0.000166761499713175
. O 0 1.476526176702464e-05

The O 0 4.299841748434119e-05
UBE3A O 0 0.002086915308609605
gene O 0 2.063083775283303e-05
encodes O 0 4.3344175537640695e-06
the O 0 4.0643348597768636e-07
E6 O 0 8.572186197852716e-05
- O 0 0.00019472937856335193
AP O 0 2.7538422727957368e-05
ubiquitin O 0 1.9036286175833084e-05
- O 0 3.1591320293955505e-05
protein O 0 5.773812858933525e-07
ligase O 0 5.62549075766583e-06
and O 0 8.374779270070576e-08
has O 0 4.8835218535714375e-08
recently O 0 2.589966356936202e-07
been O 0 1.8697853931826103e-08
shown O 0 2.8565311893657963e-08
to O 0 3.865254782908778e-08
be O 0 1.0233044633878308e-07
mutated O 0 0.00023569313634652644
in O 0 0.004059335682541132
Angelman B-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999996423721313
patients O 1 0.6492927670478821
who O 0 1.1609600733208936e-05
lack O 0 2.7251464416622184e-05
15q11 O 0 0.003255261341109872
- O 0 0.003998950589448214
q13 O 0 0.0012097693979740143
deletions O 0 1.7471589671913534e-05
or O 0 1.205760440825543e-06
chromosome O 0 9.995909204008058e-05
15 O 0 4.497895588428946e-06
paternal O 0 0.0004532202146947384
uniparental B-Disease 1 0.745536208152771
disomy I-Disease 0 0.029518546536564827
. O 0 2.425962702545803e-05

Previous O 0 0.00013043715443927795
UBE3A O 0 0.0019113526213914156
cDNA O 0 5.829665678902529e-05
analysis O 0 6.07492165727308e-06
has O 0 4.567959308587888e-07
shown O 0 3.162335246997827e-07
a O 0 1.6997003626784135e-07
coding O 0 7.738442036497872e-06
region O 0 8.453407076558506e-07
of O 0 9.450796767396241e-08
approximately O 0 8.371072226509568e-07
2 O 0 4.780642939294921e-06
. O 0 6.783015578548657e-06

6 O 0 0.00014807010302320123
kb O 0 0.0010014247382059693
and O 0 8.411902285843098e-07
a O 0 2.8180687650092295e-07
3 O 0 1.5428613551193848e-06
- O 0 0.00033989292569458485
untranslated O 0 0.005320485681295395
region O 0 1.2535158930404577e-05
( O 0 6.929030860192142e-07
UTR O 0 0.00016710467753000557
) O 0 6.925794338030755e-08
of O 0 2.7441611649692277e-08
< O 0 1.414708276570309e-05
50 O 0 1.0285211970995078e-07
bp O 0 3.3436053854529746e-06
, O 0 2.7217726739081627e-08
whereas O 0 3.9509362892431454e-08
Northern O 0 2.755080252825337e-08
analysis O 0 2.9288880654121385e-08
has O 0 1.1307516700753695e-08
indicated O 0 4.472823533774317e-08
mRNA O 0 3.4524692438253624e-08
sizes O 0 6.3187577836743e-08
of O 0 1.6923321410899916e-08
5 O 0 3.0346723178809043e-07
- O 0 4.533695027930662e-05
8 O 0 5.666903234669007e-06
kb O 0 0.0010772407986223698
. O 0 9.052288078237325e-06

We O 0 6.648047019552905e-06
have O 0 4.37554945165175e-07
analyzed O 0 6.680994033558818e-07
additional O 0 1.08438690915591e-07
cDNA O 0 9.607215361029375e-07
clones O 0 4.997028099751333e-06
and O 0 1.1289127144209488e-07
provide O 0 1.2278529482045997e-07
evidence O 0 1.6835581106988684e-07
for O 0 3.358044153856099e-08
an O 0 6.434725463577706e-08
additional O 0 5.882741334062302e-07
0 O 0 3.793976429733448e-05
. O 0 9.010411304188892e-06

5 O 0 4.162927871220745e-05
kb O 0 0.0002159339637728408
of O 0 7.786863420733425e-07
5 O 0 1.3760420642938698e-06
- O 0 4.573951446218416e-05
UTR O 0 0.00020133658836130053
and O 0 1.9027243070013355e-07
> O 0 5.395185326051433e-06
2 O 0 3.9286186392928357e-07
kb O 0 3.4567074180813506e-05
of O 0 1.448390634095631e-07
3 O 0 3.4187205528724007e-06
- O 0 0.0010270237689837813
UTR O 0 0.007107860874384642
. O 0 1.1507187991810497e-05

We O 0 7.4626350397011265e-06
have O 0 5.841616825819074e-07
established O 0 3.020400640707521e-07
the O 0 1.1011820078010714e-07
genomic O 0 2.592692226244253e-06
organization O 0 2.404746055617579e-07
of O 0 1.0461696575703172e-07
UBE3A O 0 9.949179366230965e-05
and O 0 4.479004545032694e-08
the O 0 3.270715254188872e-08
sequence O 0 1.320193945275605e-07
of O 0 1.1767708940624289e-07
intron O 0 0.0009685843251645565
- O 0 0.0008065035217441618
exon O 0 0.000340440368745476
borders O 0 5.009014785173349e-05
. O 0 1.3788394426228479e-05

We O 0 8.383508429687936e-06
have O 0 5.45710292954027e-07
also O 0 1.3537305676436517e-07
mapped O 0 6.89746400439617e-07
two O 0 2.344046912128306e-08
highly O 0 1.1494979901272018e-07
homologous O 0 1.2598139846886625e-06
processed O 0 2.1690186713385629e-07
pseudogenes O 0 2.2063620690460084e-06
, O 0 1.6619806331164e-07
UBE3AP1 O 0 0.00023899521329440176
and O 0 2.564305248142773e-07
UBE3AP2 O 0 0.0003059999435208738
, O 0 4.074898640737956e-08
to O 0 1.9083337576830672e-08
chromosomes O 0 2.3315867281326064e-07
2 O 0 1.053221154734274e-07
and O 0 3.4410039262411374e-08
21 O 0 1.6263726365650655e-07
, O 0 4.508187956275833e-08
respectively O 0 1.3182993541249743e-07
, O 0 2.953013833462137e-08
and O 0 4.013636711874824e-08
determined O 0 2.1044412790161005e-07
their O 0 8.44861318682888e-08
genomic O 0 2.0073506675544195e-05
organization O 0 3.997607109340606e-06
. O 0 3.2511502467968967e-06

These O 0 5.904143563384423e-06
results O 0 5.930100996920373e-06
will O 0 1.8718841943154985e-07
form O 0 9.976987058735176e-08
the O 0 2.4139017895663528e-08
basis O 0 3.0198787470681054e-08
for O 0 2.7132513125138757e-08
studies O 0 1.2030068319290876e-07
of O 0 7.892175801771373e-08
mutation O 0 4.142760644754162e-06
and O 0 2.8564582521539705e-07
imprinting O 0 9.138177119893953e-05
of O 0 2.676659505596035e-06
UBE3A O 0 0.03220384940505028
. O 0 1.111822530219797e-05

Mutation O 0 0.00047411140985786915
spectrum O 0 3.8078444049460813e-05
and O 0 6.492424290627241e-06
genotype O 0 0.0008378927013836801
- O 0 0.013721887022256851
phenotype O 0 0.0010238317772746086
analyses O 0 2.991127985296771e-05
in O 0 8.933090612117667e-06
Cowden B-Disease 1 0.9973927736282349
disease I-Disease 1 0.6790748834609985
and O 0 1.219500154547859e-05
Bannayan B-Disease 1 0.8771696090698242
- I-Disease 1 0.9992528557777405
Zonana I-Disease 1 0.999880313873291
syndrome I-Disease 1 0.9999300241470337
, O 0 5.845819032401778e-06
two O 0 1.1721428563760128e-05
hamartoma B-Disease 1 0.9974985718727112
syndromes I-Disease 1 0.9980667233467102
with O 0 5.835622505401261e-05
germline O 1 0.8472080826759338
PTEN O 1 0.8673493266105652
mutation O 0 0.0006857931730337441
. O 0 2.3004358808975667e-05

The O 0 0.0005225407076068223
tumour B-Disease 1 0.99605393409729
suppressor O 0 0.011300922371447086
gene O 0 0.00023319429601542652
PTEN O 0 0.002810658188536763
, O 0 1.228448468282295e-06
which O 0 2.5417571691832563e-07
maps O 0 3.2867076242837356e-06
to O 0 1.288821522393846e-06
10q23 O 0 0.00035890162689611316
. O 0 9.203919034916908e-06

3 O 0 3.326015576021746e-05
and O 0 1.7348937717542867e-06
encodes O 0 3.2525861115573207e-06
a O 0 3.308364284748677e-07
403 O 0 1.6625830312477774e-06
amino O 0 4.0347987351196934e-07
acid O 0 7.626100000379665e-07
dual O 0 6.05465061198629e-07
specificity O 0 8.489742867823225e-06
phosphatase O 0 0.002608231268823147
( O 0 2.3436473384208512e-07
protein O 0 3.612488796989055e-07
tyrosine O 0 4.685133262682939e-06
phosphatase O 0 0.0008745151571929455
; O 0 6.210397600625583e-07
PTPase O 0 8.846161654219031e-05
) O 0 6.72711664151393e-08
, O 0 2.23687575129361e-08
was O 0 1.2887039879672102e-08
shown O 0 2.7046537454111785e-08
recently O 0 1.0515892512330538e-07
to O 0 1.913505442985297e-08
play O 0 2.8668635465578518e-08
a O 0 3.25854223603983e-08
broad O 0 1.5016448742244393e-06
role O 0 1.2118425729568116e-06
in O 0 1.5757527762616519e-06
human O 0 3.223110252292827e-05
malignancy B-Disease 0 0.3759201467037201
. O 0 1.5842006177990697e-05

Somatic O 0 0.010305473580956459
PTEN O 1 0.7130805850028992
deletions O 0 0.0025258485693484545
and O 0 2.0320023395470344e-05
mutations O 0 9.142570343101397e-05
were O 0 1.7202214053213538e-07
observed O 0 6.267785011004889e-07
in O 0 2.7032282901018334e-07
sporadic B-Disease 0 0.00019877160957548767
breast I-Disease 1 0.8643177151679993
, I-Disease 0 0.0001052768639056012
brain I-Disease 1 0.9421759247779846
, I-Disease 0 0.00041525697452016175
prostate I-Disease 1 0.9998364448547363
and I-Disease 0 0.013705621473491192
kidney I-Disease 1 0.9998631477355957
cancer I-Disease 1 0.9065812230110168
cell O 0 3.6066492612008005e-05
lines O 0 2.7385513021727093e-06
and O 0 8.901007930717242e-08
in O 0 5.8370009270447554e-08
several O 0 1.9265654316313885e-07
primary O 0 6.880079308757558e-05
tumours B-Disease 1 0.9851536750793457
such O 0 1.8029514876616304e-06
as O 0 2.3253091057995334e-05
endometrial B-Disease 1 0.9996225833892822
carcinomas I-Disease 1 0.9999915361404419
, O 1 0.9790322780609131
malignant B-Disease 1 0.999998927116394
melanoma I-Disease 1 0.9999971389770508
and O 1 0.6080933809280396
thyroid B-Disease 1 0.9999690055847168
tumours I-Disease 1 0.9997811913490295
. O 0 0.0001268413761863485

In O 0 1.3272956493892707e-05
addition O 0 5.386363227444235e-06
, O 0 3.8981343095656484e-06
PTEN O 0 0.01576109603047371
was O 0 8.745543027544045e-07
identified O 0 4.164926394878421e-07
as O 0 4.457612590158533e-08
the O 0 1.748724542949276e-07
susceptibility O 0 0.0001992343895835802
gene O 0 3.055120032513514e-06
for O 0 4.678841207805817e-07
two O 0 3.7516438169404864e-05
hamartoma B-Disease 1 0.9999028444290161
syndromes I-Disease 1 0.9999877214431763
Cowden B-Disease 1 0.9999639987945557
disease I-Disease 1 0.9393671751022339
( O 0 7.656889806639811e-07
CD B-Disease 0 3.4513152513682144e-06
; O 0 2.247406200694968e-06
MIM O 0 0.005624718032777309
158350 O 0 0.00014518485113512725
) O 0 1.232483413105001e-07
and O 0 8.898835091031287e-08
Bannayan B-Disease 0 0.00013132097956258804
- I-Disease 0 0.00043164551607333124
Zonana I-Disease 0 0.0024749431759119034
( I-Disease 0 4.901606871499098e-07
BZS I-Disease 0 0.00011498203821247444
) I-Disease 0 1.5303614020467649e-07
or I-Disease 0 1.7562052789799054e-07
Ruvalcaba I-Disease 0 0.0005815520999021828
- I-Disease 0 0.003165485570207238
Riley I-Disease 0 0.0005108959157951176
- I-Disease 1 0.7354057431221008
Smith I-Disease 0 0.33841562271118164
syndrome I-Disease 1 0.9998685121536255
( O 0 3.109070530626923e-05
MIM O 0 0.3955574035644531
153480 O 0 0.0019626887515187263
) O 0 6.410717560356716e-06
. O 0 5.502985914063174e-06

Constitutive O 0 0.0006302842521108687
DNA O 0 0.00010284347808919847
from O 0 1.0697004881876637e-06
37 O 0 1.9043415022679255e-06
CD B-Disease 0 2.7987816793029197e-06
families O 0 1.0559321026448742e-06
and O 0 2.266831700126204e-07
seven O 0 1.057415488503466e-06
BZS B-Disease 0 0.005810506176203489
families O 0 3.7035110835859086e-06
was O 0 4.515511591307586e-07
screened O 0 5.119154593558051e-06
for O 0 1.4179943264025496e-06
germline O 0 0.14628121256828308
PTEN O 1 0.579719603061676
mutations O 0 0.000225788913667202
. O 0 7.826053661119658e-06

PTEN O 1 0.991615355014801
mutations O 0 0.022921796888113022
were O 0 1.6416624930570833e-06
identified O 0 7.234576173686946e-07
in O 0 6.130765939360572e-08
30 O 0 8.239689464062394e-08
of O 0 3.9050924272032717e-08
37 O 0 9.70224391494412e-07
( O 0 4.05734482455955e-07
81 O 0 1.200855763272557e-06
% O 0 7.246606514854648e-08
) O 0 5.37996456273504e-08
CD B-Disease 0 5.232129183241341e-07
families O 0 2.08770600806929e-07
, O 0 4.737037784252607e-08
including O 0 8.429152842381882e-08
missense O 0 1.2868988051195629e-05
and O 0 1.1905662944400319e-07
nonsense O 0 5.01353451909381e-06
point O 0 7.871262255321199e-07
mutations O 0 1.9355391032149782e-06
, O 0 5.641338418627129e-08
deletions O 0 1.0081447499032947e-06
, O 0 5.585598827906324e-08
insertions O 0 2.357566700084135e-06
, O 0 5.516777790148808e-08
a O 0 6.764506821355099e-08
deletion O 0 1.7430800653528422e-05
/ O 0 3.526122964103706e-05
insertion O 0 5.502518888533814e-06
and O 0 5.168412258171884e-07
splice O 0 0.00032629858469590545
site O 0 2.4324261175934225e-05
mutations O 0 6.858508277218789e-05
. O 0 5.500667157321004e-06

These O 0 1.3492788639268838e-05
mutations O 0 5.564275124925189e-05
were O 0 1.1758487516999594e-07
scattered O 0 2.5779090151445416e-07
over O 0 5.248365653187648e-08
the O 0 2.8388786432742563e-08
entire O 0 9.11281858861912e-08
length O 0 1.9606331136401423e-07
of O 0 5.015577286826556e-08
PTEN O 0 0.0007765574846416712
, O 0 4.534793518473634e-08
with O 0 1.8169547644220074e-08
the O 0 1.3878379334641977e-08
exception O 0 4.3664780235985745e-08
of O 0 7.696772996723666e-09
the O 0 1.3469974469160206e-08
first O 0 3.4700565976208964e-08
, O 0 4.724612878703738e-08
fourth O 0 4.696795485870098e-07
and O 0 1.421330040329849e-07
last O 0 1.5933406984913745e-06
exons O 0 0.00011221966269658878
. O 0 5.382743438531179e-06

A O 0 2.1929197828285396e-05
hot O 0 5.635630077449605e-05
spot O 0 9.25905624171719e-06
for O 0 9.104215905608726e-07
PTEN O 0 0.001471512601710856
mutation O 0 4.022963366878685e-06
in O 0 7.3339428752206e-08
CD B-Disease 0 9.506785545454477e-07
was O 0 9.583233406829095e-08
identified O 0 8.528579087396793e-08
in O 0 2.411081112541069e-08
exon O 0 8.203078323276713e-06
5 O 0 1.7068622071292339e-07
that O 0 1.018591611057218e-08
contains O 0 1.3197026582645321e-08
the O 0 2.2115743902872964e-08
PTPase O 0 1.3965195648779627e-05
core O 0 4.5037364770905697e-07
motif O 0 6.346932082124113e-07
, O 0 1.9602623524406226e-08
with O 0 1.5361086624920972e-08
13 O 0 6.087351067662894e-08
of O 0 1.926682635655652e-08
30 O 0 1.569352008345959e-07
( O 0 1.5090886051893904e-07
43 O 0 4.659511319005105e-07
% O 0 1.0265672045761676e-07
) O 0 1.5377729312149313e-07
CD B-Disease 0 4.3970685510430485e-06
mutations O 0 7.5067978286824655e-06
identified O 0 2.5975950279644167e-07
in O 0 9.111845145071129e-08
this O 0 3.008495923495502e-07
exon O 0 0.00011225967318750918
. O 0 8.275651453004684e-06

Seven O 0 7.504585482820403e-06
of O 0 6.85493091623357e-07
30 O 0 1.1978646625721012e-06
( O 0 5.120606374475756e-07
23 O 0 7.099087042661267e-07
% O 0 8.114327698649504e-08
) O 0 2.72255658018139e-08
were O 0 2.6536806085886155e-09
within O 0 3.2458924437150927e-09
the O 0 6.8675576336829636e-09
core O 0 2.351142427414743e-07
motif O 0 6.411467552425165e-07
, O 0 2.5374356837915002e-08
the O 0 1.3693060907371546e-08
majority O 0 7.843164695486848e-08
( O 0 2.795873399463744e-08
five O 0 5.575622186171358e-09
of O 0 7.059225648475831e-09
seven O 0 5.941916469964781e-08
) O 0 2.8300661369939917e-08
of O 0 9.568709380403106e-09
which O 0 2.684194555513386e-08
were O 0 6.863330526130085e-08
missense O 0 8.940634870668873e-05
mutations O 0 1.0456710697326344e-05
, O 0 1.3011947430641158e-07
possibly O 0 2.2173279035087035e-07
pointing O 0 3.283645355622866e-07
to O 0 1.7048767730898362e-08
the O 0 1.3387142061560553e-08
functional O 0 1.6443514994080033e-07
significance O 0 2.3366150969650334e-07
of O 0 1.0220092860890873e-07
this O 0 3.253558702454029e-07
region O 0 1.081600203178823e-05
. O 0 7.570848083560122e-06

Germline O 1 0.9806077480316162
PTEN O 1 0.992223858833313
mutations O 0 0.01109042763710022
were O 0 8.712119665688078e-07
identified O 0 5.508097729034489e-07
in O 0 2.929206566193443e-08
four O 0 2.1678724593243714e-08
of O 0 2.493236372913543e-08
seven O 0 1.9497993264394609e-07
( O 0 2.1170929187519505e-07
57 O 0 8.556609145671246e-07
% O 0 3.101406775840587e-07
) O 0 1.1297770470264368e-06
BZS B-Disease 0 0.0010026083327829838
families O 0 5.18341130373301e-06
studied O 0 1.0360664418840315e-05
. O 0 9.166925337922294e-06

Interestingly O 0 0.0017531301127746701
, O 0 7.259704034368042e-06
none O 0 1.2815241916541709e-06
of O 0 1.7130916774021898e-07
these O 0 2.503797418285103e-07
mutations O 0 9.675996807345655e-06
was O 0 1.0375057968303736e-07
observed O 0 1.207176296702528e-07
in O 0 5.8374570954811134e-08
the O 0 2.3466867560273386e-07
PTPase O 0 0.00026608584448695183
core O 0 1.1243726476095617e-05
motif O 0 4.6401684812735766e-05
. O 0 7.441130946972407e-06

It O 0 5.891578439332079e-06
is O 0 5.364557296161365e-07
also O 0 1.927282085034676e-07
worthy O 0 2.9775469556625467e-07
of O 0 4.177742951583241e-08
note O 0 6.264880880735291e-07
that O 0 1.7878509339652737e-08
a O 0 2.1572304831352085e-08
single O 0 7.78725137706715e-08
nonsense O 0 4.834190804103855e-06
point O 0 4.25770082301824e-07
mutation O 0 1.838499201767263e-06
, O 0 1.0003434169902903e-07
R233X O 0 5.0662103603826836e-05
, O 0 3.702609419065084e-08
was O 0 1.935219451354442e-08
observed O 0 2.555547595761709e-08
in O 0 5.668364444488816e-09
the O 0 1.4705198836395539e-08
germline O 0 3.6875237128697336e-05
DNA O 0 9.28818167267309e-07
from O 0 1.22446834893708e-08
two O 0 1.2433050144977642e-08
unrelated O 0 5.772007511950505e-07
CD B-Disease 0 2.125955688825343e-06
families O 0 7.536369821536937e-07
and O 0 2.5604467168705014e-07
one O 0 6.52726214411814e-07
BZS B-Disease 0 0.026797393336892128
family O 0 4.050671850563958e-05
. O 0 1.2390043593768496e-05

Genotype O 0 0.024237463250756264
- O 0 0.1150197982788086
phenotype O 0 0.007573090493679047
studies O 0 5.578870968747651e-06
were O 0 1.2319004838445835e-07
not O 0 3.1768351504979364e-08
performed O 0 1.1912886321852056e-07
on O 0 1.7820395825651758e-08
this O 0 9.935527067739258e-09
small O 0 8.002740514712059e-08
group O 0 4.525616930095566e-07
of O 0 5.015893407289695e-07
BZS B-Disease 0 0.0948392003774643
families O 0 2.6083262127940543e-05
. O 0 9.91214437817689e-06

However O 0 2.2126638214103878e-05
, O 0 5.730701559514273e-06
genotype O 0 0.0002831359743140638
- O 0 0.00936043355613947
phenotype O 0 0.00047802538028918207
analysis O 0 1.391496311953233e-06
inthe O 0 3.491960160317831e-05
group O 0 4.064145286974963e-07
of O 0 3.461046915731458e-08
CD B-Disease 0 3.0227022307371954e-06
families O 0 1.7804295566747896e-06
revealed O 0 2.527081278458354e-06
two O 0 3.255839331472998e-08
possible O 0 1.0604051681184501e-07
associations O 0 1.7875960622859566e-07
worthy O 0 1.355571441763459e-07
of O 0 2.1880989464762024e-08
follow O 0 1.5373798589735088e-07
- O 0 1.0076592843688559e-05
up O 0 1.601613064394769e-07
in O 0 8.751652558203205e-08
independent O 0 3.980128440161934e-07
analyses O 0 6.226407094800379e-06
. O 0 3.569861519281403e-06

The O 0 7.684009688091464e-06
first O 0 2.4488781491527334e-06
was O 0 5.444305202217947e-07
an O 0 1.093790586992327e-07
association O 0 3.451660859354888e-06
noted O 0 3.537634256645106e-07
in O 0 2.680735988747074e-08
the O 0 2.661107245671701e-08
group O 0 1.317908271403212e-07
of O 0 4.4791583775349864e-08
CD B-Disease 0 8.35248010844225e-06
families O 0 2.2815440388512798e-05
with O 0 0.000344777072314173
breast B-Disease 1 0.9997184872627258
disease I-Disease 1 0.9871554374694824
. O 0 5.527866960619576e-05

A O 0 1.7631067748880014e-05
correlation O 0 4.118210563319735e-05
was O 0 6.63702280689904e-07
observed O 0 5.726395215788216e-07
between O 0 1.390380646171252e-07
the O 0 1.490965217953999e-07
presence O 0 1.9905830868083285e-06
/ O 0 0.0001381704059895128
absence O 0 7.409566364913189e-07
of O 0 4.8742251124167524e-08
a O 0 4.862827154283877e-07
PTEN O 0 0.026547806337475777
mutation O 0 5.235286153038032e-06
and O 0 6.040669831008927e-08
the O 0 6.556922471645521e-08
type O 0 2.3854433948145015e-06
of O 0 4.157707849117287e-07
breast O 0 0.15961924195289612
involvement O 0 4.9208709242520854e-05
( O 0 3.4853173929150216e-06
unaffected O 0 0.0002142731100320816
versus O 0 0.0003526141808833927
benign O 0 0.042904336005449295
versus O 0 0.021124020218849182
malignant O 1 0.9803928732872009
) O 0 9.180810593534261e-06
. O 0 6.96662664267933e-06

Specifically O 0 3.0878254619892687e-05
and O 0 8.458544016320957e-07
more O 0 8.897087155901318e-08
directly O 0 1.2661612913689169e-07
, O 0 7.602769613868077e-08
an O 0 2.9619773300737506e-08
association O 0 2.330960569452145e-06
was O 0 1.5185953827767662e-07
also O 0 5.7432412603475314e-08
observed O 0 9.824069024944038e-08
between O 0 2.7998650509175604e-08
the O 0 2.195418957740003e-08
presence O 0 8.424604658330281e-08
of O 0 3.682839277985295e-08
a O 0 1.081632831301249e-06
PTEN O 1 0.6748942732810974
mutation O 0 0.0019044434884563088
and O 0 0.003242745064198971
malignant B-Disease 1 0.9999579191207886
breast I-Disease 1 0.9998063445091248
disease I-Disease 1 0.9821043610572815
. O 0 5.028690429753624e-05

Secondly O 0 0.008948626928031445
, O 0 5.813467851112364e-06
there O 0 5.443645818559162e-07
appeared O 0 8.144600656123657e-07
to O 0 7.899373599684623e-08
be O 0 1.209884459285604e-08
an O 0 2.643265517576765e-08
interdependent O 0 7.591322355438024e-05
association O 0 4.768776307173539e-06
between O 0 9.501437716608052e-07
mutations O 0 1.4418636055779643e-05
upstream O 0 9.407630159330438e-07
and O 0 1.9494159175792447e-08
within O 0 1.5491607996409584e-08
the O 0 3.072869247944254e-08
PTPase O 0 2.754049637587741e-05
core O 0 7.943982609504019e-07
motif O 0 6.89194678216154e-07
, O 0 1.6989881501672244e-08
the O 0 7.394718171127579e-09
core O 0 1.5957721188897267e-07
motif O 0 3.0059294431339367e-07
containing O 0 3.3034297075573704e-08
the O 0 1.0349162415934643e-08
majority O 0 5.058483765196797e-08
of O 0 5.7196938740844416e-08
missense O 0 0.00013732636580243707
mutations O 0 5.6184780987678096e-06
, O 0 4.126803077042496e-08
and O 0 2.0345165552271283e-08
the O 0 1.1170024905027276e-08
involvement O 0 1.4054209884761804e-07
of O 0 9.058452654642224e-09
all O 0 1.1635121310860086e-08
major O 0 1.7799881106839166e-06
organ O 0 0.0001284925965592265
systems O 0 2.8106871468480676e-05
( O 0 3.5803074638351973e-07
central O 0 8.835140761220828e-07
nervous O 0 0.0008438226650469005
system O 0 2.6465493647265248e-05
, O 0 5.547903856495395e-05
thyroid O 1 0.9995684027671814
, O 0 0.00013654654321726412
breast O 1 0.9937885403633118
, O 0 0.0001998649531742558
skin O 1 0.9924429059028625
and O 0 0.0038105060812085867
gastrointestinal O 1 0.9997959733009338
tract O 1 0.9846787452697754
) O 0 3.0139834052533843e-05
. O 0 1.4372713849297725e-05

However O 0 2.773603773675859e-05
, O 0 2.304023837496061e-06
these O 0 1.8028998738373048e-07
observations O 0 1.7527511317894096e-06
would O 0 9.857968308324416e-08
need O 0 1.1810556088676094e-07
to O 0 3.8931119661356206e-08
be O 0 1.1266461541481476e-08
confirmed O 0 5.7943829290252324e-08
by O 0 9.747521012570814e-09
studying O 0 4.6430415068243747e-08
a O 0 2.6490900140174745e-08
larger O 0 6.976467403774222e-08
number O 0 2.7296904292484214e-08
of O 0 5.782338519111363e-08
CD B-Disease 0 7.831914444977883e-06
families O 0 1.606671321496833e-05
. O 0 1.128236181102693e-05

Molecular O 0 0.4831021726131439
defects O 1 0.9672108292579651
leading O 0 5.349703860701993e-05
to O 0 1.0721536227720208e-06
human O 0 1.0477407386133564e-06
complement B-Disease 0 7.753504178253934e-06
component I-Disease 0 0.000211911610676907
C6 I-Disease 1 0.999934196472168
deficiency I-Disease 1 0.9998331069946289
in O 0 3.4219914368804893e-07
an O 0 1.1269346344988662e-07
African O 0 1.713877509246231e-06
- O 0 0.0003358828544151038
American O 0 8.244842319982126e-06
family O 0 4.198262467980385e-05
. O 0 1.1275273209321313e-05

Complement B-Disease 0 0.0012375189689919353
component I-Disease 0 0.023868683725595474
C6 I-Disease 1 0.9998784065246582
deficiency I-Disease 1 0.9999711513519287
( O 0 0.0003910567320417613
C6D B-Disease 1 0.9535662531852722
) O 0 2.0248775399522856e-05
was O 0 4.426055966177955e-06
diagnosed O 0 0.002850309479981661
in O 0 2.4336230808330583e-08
a O 0 2.089201167621013e-08
16 O 0 7.627593134884592e-08
- O 0 1.0074853889818769e-05
year O 0 9.69516236182244e-08
- O 0 2.6121397240785882e-05
old O 0 5.030944976169849e-06
African O 0 6.981564979469113e-07
- O 0 0.00014064859715290368
American O 0 2.1595685666397912e-06
male O 0 6.061749900254654e-06
with O 0 1.4445543456531595e-05
meningococcal B-Disease 1 0.9945534467697144
meningitis I-Disease 1 0.9782630801200867
. O 0 3.5052289604209363e-05

The O 0 0.0001578886149218306
patients O 0 0.010627112351357937
father O 0 1.775413693394512e-05
and O 0 4.5443871954375936e-07
two O 0 2.654019226611126e-07
brothers O 0 0.00021820771507918835
also O 0 5.228746999819123e-07
had O 0 1.3736112123297062e-06
C6D B-Disease 0 0.014815637841820717
, O 0 2.0731036443066841e-07
but O 0 4.59721789525247e-08
gave O 0 1.7725773204801953e-07
no O 0 3.738837861533284e-08
history O 0 2.728259858031379e-07
of O 0 4.4828379941463936e-07
meningitis B-Disease 1 0.7043710350990295
or O 0 5.261443220661022e-06
other O 0 6.816541826992761e-06
neisserial B-Disease 1 0.974741518497467
infection I-Disease 0 0.32333648204803467
. O 0 2.300106643815525e-05

By O 0 3.514016725603142e-06
using O 0 1.5000346138549503e-06
exon O 0 4.0924503991845995e-05
- O 0 9.244404645869508e-05
specific O 0 6.969988817218109e-07
polymerase O 0 2.9564307624241337e-05
chain O 0 9.08278798306128e-06
reaction O 0 7.258557275235944e-07
( O 0 1.3278915389491885e-07
PCR O 0 1.575321448399336e-06
) O 0 6.694745025015436e-08
/ O 0 6.261255407480348e-07
single O 0 3.4352069633314386e-08
- O 0 1.6820588371047052e-06
strand O 0 1.0226502809018712e-06
conformation O 0 4.383104226235446e-07
polymorphism O 0 3.8592921214331e-07
as O 0 9.630854336251105e-09
a O 0 1.104132252294221e-08
screening O 0 1.4488064437045978e-07
step O 0 4.943820997027615e-08
and O 0 1.1088640228251734e-08
nucleotide O 0 1.7736122970291035e-07
sequencing O 0 7.742568897128876e-08
of O 0 7.638479182503488e-09
target O 0 4.292457234100766e-08
exons O 0 9.658087947173044e-07
, O 0 4.886056004238526e-08
we O 0 1.8899216414069997e-08
determined O 0 4.212742510389944e-08
that O 0 6.100017380106237e-09
the O 0 2.222128259177225e-08
proband O 0 6.621360080316663e-05
was O 0 4.223088367893979e-08
a O 0 3.7726639590118793e-08
compound O 0 7.786580908941687e-07
heterozygote O 0 8.285964213428088e-06
for O 0 6.836103949581229e-08
two O 0 6.042035920472699e-07
C6 O 0 0.1848217099905014
gene O 0 0.00013054654118604958
mutations O 0 0.00011783871741499752
. O 0 7.5020957410742994e-06

The O 0 4.365897439129185e-06
first O 0 1.091960029953043e-06
, O 0 3.151665453060559e-07
1195delC O 0 2.1896074031246826e-05
located O 0 2.9854226113457116e-07
in O 0 3.528010950049065e-08
exon O 0 1.4333772014651913e-05
7 O 0 1.2288925290704356e-06
, O 0 8.108170135301407e-08
is O 0 1.7734134161173642e-08
a O 0 3.242224622113099e-08
novel O 0 7.133903068279324e-07
mutation O 0 8.894980396689789e-07
, O 0 1.4854494523319772e-08
while O 0 8.757793601432695e-09
the O 0 8.08523381579107e-09
second O 0 5.8934499946872165e-08
, O 0 4.020179744657071e-08
1936delG O 0 7.260825896082679e-06
in O 0 2.450349079197167e-08
exon O 0 7.815827302692924e-06
12 O 0 2.0594144700680772e-07
, O 0 4.8696161769612445e-08
has O 0 2.0111167842173927e-08
been O 0 1.6377603273554087e-08
described O 0 2.5903369760271744e-07
before O 0 9.167140291310716e-08
to O 0 1.5725221658158262e-07
cause O 0 5.549320121644996e-06
C6D B-Disease 0 0.00030416090157814324
in O 0 4.4259781617483895e-08
an O 0 2.5861154995254765e-08
unrelated O 0 9.006064374261769e-07
African O 0 5.232498097029747e-07
- O 0 0.0001342249452136457
American O 0 2.251052592328051e-06
individual O 0 1.625674485694617e-06
. O 0 5.971381142444443e-06

Both O 0 5.04914132761769e-05
mutations O 0 0.0011719369795173407
result O 0 1.17401896204683e-05
in O 0 3.0369762953341706e-06
premature O 0 0.0012349736643955112
termination O 0 0.0011779660126194358
codons O 0 0.00011611526133492589
and O 0 6.32998535365914e-06
C6 O 0 0.3041192293167114
null O 0 0.00026733597042039037
alleles O 0 6.939750892343e-05
. O 0 1.0167970685870387e-05

Allele O 0 0.00012051924568368122
- O 0 0.00016278015391435474
specific O 0 2.434998577882652e-06
PCR O 0 2.519791632948909e-05
indicated O 0 1.3655733255291125e-06
that O 0 5.1288708391439286e-08
the O 0 8.341014989809992e-08
probands O 0 0.0001525785046396777
two O 0 1.4350948163155408e-07
brothers O 0 6.656965706497431e-05
also O 0 6.708357886964222e-07
inherited O 0 0.00014636959531344473
the O 0 1.7173594812902593e-07
1195delC O 0 0.0005885742721147835
mutation O 0 1.4913932773197303e-06
from O 0 1.8838825610600907e-08
their O 0 4.90674203490471e-08
heterozygous O 0 1.179691821562301e-06
mother O 0 2.1787386685900856e-06
and O 0 5.226727850526913e-08
the O 0 1.607953805660145e-07
1936delG O 0 0.000600922794546932
mutation O 0 2.691549525479786e-06
from O 0 5.584011830706004e-08
their O 0 2.1862011578832607e-07
homozygous O 0 1.3330851288628764e-05
father O 0 9.408937330590561e-06
. O 0 1.3920870287620346e-06
. O 0 5.430291821539868e-06

PAX6 O 1 0.9464503526687622
mutations O 0 0.10389386117458344
reviewed O 0 0.00105712388176471
. O 0 0.00020829893765039742

Mutations O 0 0.004990990739315748
in O 0 1.874180816230364e-05
PAX6 O 0 0.11110439896583557
are O 0 1.0603015425658668e-06
responsible O 0 2.9804464247717988e-06
for O 0 4.052352835515194e-07
human O 0 4.767466634802986e-06
aniridia B-Disease 1 0.8954271674156189
and O 0 7.488196729354968e-07
have O 0 1.5576767964375904e-07
also O 0 1.260988113926942e-07
been O 0 9.150893731657561e-08
found O 0 2.691336362659058e-07
in O 0 1.4800441476836568e-06
patients O 0 0.0013299513375386596
with O 0 2.7991769457003102e-05
Peters B-Disease 1 0.9979193806648254
anomaly I-Disease 1 0.9975278973579407
, O 0 0.00011920827091671526
with O 0 0.03917635232210159
congenital B-Disease 1 0.999998927116394
cataracts I-Disease 1 0.9999921321868896
, O 0 8.625566260889173e-05
with O 0 0.00012877423432655632
autosomal B-Disease 1 0.8874745965003967
dominant I-Disease 0 0.007184377405792475
keratitis I-Disease 1 0.9877234697341919
, O 0 3.441780108914827e-06
and O 0 1.3249496078060474e-06
with O 0 1.2776235962519422e-05
isolated B-Disease 0 0.018834605813026428
foveal I-Disease 1 0.9983838796615601
hypoplasia I-Disease 1 0.9994518160820007
. O 0 8.118016558000818e-05

No O 0 5.268014865578152e-05
locus O 0 7.208771421574056e-05
other O 0 4.7539955971842573e-07
than O 0 3.091018925260869e-07
chromosome O 0 0.0001984269911190495
11p13 O 0 0.0005352517473511398
has O 0 1.94980685819246e-07
been O 0 7.117458977745628e-08
implicated O 0 5.093223990115803e-06
in O 0 4.6430901079475007e-07
aniridia B-Disease 1 0.7686778903007507
, O 0 6.225067750165181e-07
and O 0 8.65562356011651e-07
PAX6 O 0 0.01936359889805317
is O 0 9.70496785157593e-08
clearly O 0 1.1668663546515745e-07
the O 0 2.5219714316904174e-08
major O 0 2.729675543378107e-07
, O 0 6.951601250193562e-08
if O 0 2.7413884495786078e-08
not O 0 1.0850775389315004e-08
only O 0 1.9650276072979977e-08
, O 0 1.7751503378349298e-07
gene O 0 3.8951502574491315e-06
responsible O 0 4.481094492803095e-06
. O 0 5.943757514614845e-06

Twenty O 0 3.330779873067513e-05
- O 0 0.00018920455477200449
eight O 0 1.9889168925146805e-06
percent O 0 2.0118397969781654e-06
of O 0 3.1641181408303964e-07
identified O 0 8.739924851397518e-06
PAX6 O 0 0.0568571537733078
mutations O 0 1.7094494978664443e-05
are O 0 6.208597369550262e-08
C O 0 1.9205815988243558e-05
- O 0 0.000441524141933769
T O 0 0.002024437068030238
changes O 0 2.0101451525533776e-07
at O 0 1.6227131993673538e-07
CpG O 0 2.411429159110412e-05
dinucleotides O 0 7.909149280749261e-05
, O 0 3.664718661866573e-08
20 O 0 2.5178811924320144e-08
% O 0 1.760435175413022e-08
are O 0 8.351868530098727e-09
splicing O 0 1.3025049838688574e-06
errors O 0 2.4663861495355377e-06
, O 0 1.7112620653847443e-08
and O 0 1.0573712572181648e-08
more O 0 3.5010481180819397e-09
than O 0 8.416233043817556e-09
30 O 0 3.273773430123583e-08
% O 0 4.723711555243426e-08
are O 0 3.6641594647335296e-08
deletion O 0 8.125190106511582e-06
or O 0 3.6650232004831196e-07
insertion O 0 1.9685183360707015e-05
events O 0 3.5847019717039075e-06
. O 0 5.842018254043069e-06

There O 0 6.794616638217121e-06
is O 0 6.515787731586897e-07
a O 0 3.07627999518445e-07
noticeably O 0 6.204611509019742e-06
elevated O 0 2.725525882851798e-05
level O 0 1.7498206261734595e-07
of O 0 5.396572788640697e-08
mutation O 0 1.2671665672314703e-06
in O 0 2.4182796209970547e-08
the O 0 3.57296308095556e-08
paired O 0 1.582012032486091e-06
domain O 0 3.704238338286814e-07
compared O 0 1.4483630650374835e-07
with O 0 2.8495708903619743e-08
the O 0 2.941765053776635e-08
rest O 0 1.0429779706555564e-07
of O 0 6.340984981534348e-08
the O 0 6.050806291568733e-07
gene O 0 1.3468683391693048e-05
. O 0 5.682792561856331e-06

Increased O 0 5.458058512886055e-05
mutation O 0 4.889586489298381e-05
in O 0 5.078384219814325e-07
the O 0 3.4318415487177845e-07
homeodomain O 0 0.0001598020171513781
is O 0 8.033495646486699e-08
accounted O 0 2.3690152772815054e-07
for O 0 2.2775987318368607e-08
by O 0 3.694151828881331e-08
the O 0 1.3477252025495545e-07
hypermutable O 0 0.0003769038594327867
CpG O 0 8.043716661632061e-05
dinucleotide O 0 2.45653027377557e-05
in O 0 3.7570927702290646e-07
codon O 0 5.192692242417252e-06
240 O 0 4.553203325485811e-06
. O 0 3.7759723454655614e-06

Very O 0 1.1445930795161985e-05
nearly O 0 2.529367066017585e-06
all O 0 5.189135663385969e-07
mutations O 0 8.082685235422105e-05
appear O 0 3.0119576877041254e-06
to O 0 1.1253478078288026e-06
cause O 0 4.140028977417387e-05
loss O 0 5.079242691863328e-05
of O 0 3.9882554148107374e-08
function O 0 6.771529115212616e-08
of O 0 1.1745987293920734e-08
the O 0 3.5197437853184965e-08
mutant O 0 3.783722377193044e-06
allele O 0 2.2579985170523287e-07
, O 0 1.682136918645938e-08
and O 0 4.715274837252537e-09
more O 0 2.222415362851393e-09
than O 0 3.907064893837742e-09
80 O 0 2.4688562305641426e-08
% O 0 1.9558813235676098e-08
of O 0 3.8431789306514474e-08
exonic O 0 0.00035515273339115083
substitutions O 0 1.0826132665897603e-06
result O 0 3.9843857280175143e-07
in O 0 2.6066950908898434e-07
nonsense O 0 3.110876787104644e-05
codons O 0 2.8210335585754365e-05
. O 0 4.803305273526348e-06

In O 0 8.20311743154889e-06
a O 0 2.8440679216146236e-06
gene O 0 6.537244189530611e-06
with O 0 3.619250890096737e-07
such O 0 1.9316836130656156e-07
extraordinarily O 0 1.6428419257863425e-05
high O 0 9.853425808614702e-07
sequence O 0 3.7060476643091533e-07
conservation O 0 4.3961529172520386e-07
throughout O 0 4.427920075045222e-08
evolution O 0 2.0709163095489203e-07
, O 0 5.6726072727997234e-08
there O 0 3.797194736421261e-08
are O 0 7.002489610385965e-08
presumed O 0 1.772081304807216e-05
undiscovered O 0 0.003165043191984296
missense O 0 0.0022885033395141363
mutations O 0 3.0095434340182692e-05
, O 0 7.159708559356659e-08
these O 0 1.6955112869254663e-08
are O 0 1.928300008557926e-08
hypothesized O 0 2.4847347503964556e-06
to O 0 2.7123666868078544e-08
exist O 0 5.594694130195421e-08
in O 0 1.50446233249113e-08
as O 0 5.113867018735618e-08
- O 0 0.00019530282588675618
yet O 0 2.3858892745920457e-06
unidentified O 0 1.1699562492140103e-05
phenotypes O 0 9.843637235462666e-05
. O 0 1.1122509704364347e-06
. O 0 4.550642188405618e-06

Genetic O 0 0.012691080570220947
heterogeneity O 0 0.003271472407504916
and O 0 5.823927949677454e-06
penetrance O 0 0.00039892163476906717
analysis O 0 7.792197607159324e-07
of O 0 1.1022495272072774e-07
the O 0 3.258716674281459e-07
BRCA1 O 0 0.00023985990264918655
and O 0 2.6978993901138892e-06
BRCA2 O 0 0.005311388522386551
genes O 0 3.382433351362124e-05
in O 0 6.187228427734226e-05
breast B-Disease 1 0.9993875026702881
cancer I-Disease 1 0.9780979156494141
families O 0 0.00012948135554324836
. O 0 2.7968446374870837e-05

The O 0 0.009069127961993217
Breast B-Disease 1 0.999416708946228
Cancer I-Disease 1 0.9988617897033691
Linkage O 0 0.04941929131746292
Consortium O 0 0.0026666875928640366
. O 0 6.865607429062948e-05

The O 0 8.513392458553426e-06
contribution O 0 6.926586593181128e-06
of O 0 1.7254656086151954e-06
BRCA1 O 0 0.013128979131579399
and O 0 2.296153070346918e-05
BRCA2 O 1 0.6578639149665833
to O 0 0.002791173290461302
inherited B-Disease 1 0.9999872446060181
breast I-Disease 1 0.99998939037323
cancer I-Disease 1 0.9998801946640015
was O 0 2.418966005279799e-06
assessed O 0 1.4861927866149927e-06
by O 0 5.751320131253124e-08
linkage O 0 9.880151083052624e-06
and O 0 1.5224351557208138e-07
mutation O 0 1.1854898502861033e-06
analysis O 0 6.195536883524255e-08
in O 0 1.863888954289905e-08
237 O 0 1.3486384204952628e-06
families O 0 2.272000187986123e-07
, O 0 3.323108899166982e-08
each O 0 4.2071759409623155e-09
with O 0 2.0628537100719768e-08
at O 0 9.498958064568797e-08
least O 0 1.6984696316058034e-08
four O 0 9.916977461443821e-08
cases O 0 3.1068084354046732e-06
of O 0 2.9971444746479392e-05
breast B-Disease 1 0.9998849630355835
cancer I-Disease 1 0.9276968836784363
, O 0 1.2705245353572536e-06
collected O 0 8.024190378819185e-07
by O 0 1.2980879091628594e-06
the O 0 6.319224485196173e-05
Breast B-Disease 1 0.9999063014984131
Cancer I-Disease 1 0.9987117052078247
Linkage O 0 0.002014696830883622
Consortium O 0 0.0003031976521015167
. O 0 1.2285244338272605e-05

Families O 0 5.163403693586588e-05
were O 0 8.477231290271448e-07
included O 0 5.355020675779087e-07
without O 0 1.1216679496328652e-07
regard O 0 2.0728329275243595e-07
to O 0 5.418428017378574e-08
the O 0 1.3585896851964208e-07
occurrence O 0 4.3144314986420795e-05
of O 0 5.424996288638795e-06
ovarian B-Disease 1 0.9987527132034302
or I-Disease 0 1.3283631233207416e-05
other I-Disease 0 8.794362656772137e-06
cancers I-Disease 1 0.6883867979049683
. O 0 2.1911364456173033e-05

Overall O 0 0.018813569098711014
, O 0 0.0008914706413634121
disease O 1 0.776590883731842
was O 0 2.042524101852905e-06
linked O 0 2.8012733309878968e-05
to O 0 7.620000701535901e-07
BRCA1 O 0 0.00015696245827712119
in O 0 6.88430787931793e-08
an O 0 2.2692862700068872e-08
estimated O 0 1.5409115405873308e-07
52 O 0 2.062287904891491e-07
% O 0 2.2457248505247662e-08
of O 0 1.4305332030062345e-08
families O 0 3.182676096002979e-07
, O 0 9.650164400909489e-08
to O 0 9.765928865590467e-08
BRCA2 O 0 6.684443633275805e-06
in O 0 2.2220181250531823e-08
32 O 0 9.62142010507705e-08
% O 0 2.0211340157061386e-08
of O 0 1.591528153710442e-08
families O 0 3.462992310687696e-07
, O 0 5.6879702725609604e-08
and O 0 3.865424247351257e-08
to O 0 3.3354531581153424e-08
neither O 0 1.5695121646785992e-07
gene O 0 1.404002460958509e-07
in O 0 1.3149839439563493e-08
16 O 0 8.6534384990955e-08
% O 0 4.900513417283037e-08
( O 0 3.7280141640394504e-08
95 O 0 5.333182073741227e-08
% O 0 3.954962224383962e-08
confidence O 0 8.536795235158934e-07
interval O 0 2.013094899666612e-06
[ O 0 5.473712008097209e-06
CI O 0 0.016857678070664406
] O 0 3.0049257020436926e-06
6 O 0 1.9982945786978235e-07
% O 0 6.788224027332035e-08
- O 0 3.3592499676160514e-05
28 O 0 5.382185577218479e-07
% O 0 1.1208252459482537e-07
) O 0 1.497847392784024e-07
, O 0 1.2618831135569053e-07
suggesting O 0 1.3589877880804124e-06
other O 0 4.0190764138969826e-07
predisposition O 0 0.0011634756810963154
genes O 0 2.1337746147764847e-05
. O 0 8.857946340867784e-06

The O 0 5.832332135469187e-06
majority O 0 6.10756296737236e-06
( O 0 1.3359832564674434e-06
81 O 0 2.541202320571756e-06
% O 0 1.1826166002038008e-07
) O 0 4.289069011065294e-08
of O 0 3.441443752194573e-08
the O 0 4.353370059106965e-06
breast B-Disease 1 0.9996715784072876
- I-Disease 1 0.9999874830245972
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999513626098633
families O 0 1.6072628568508662e-05
were O 0 1.712199946268811e-07
due O 0 9.675318324298132e-07
to O 0 3.203685139396839e-07
BRCA1 O 0 8.166435145540163e-05
, O 0 8.87906637103697e-08
with O 0 5.3245834408244264e-08
most O 0 4.7436017780455586e-08
others O 0 1.8820335867530957e-07
( O 0 2.556140543674701e-07
14 O 0 3.6535280401039927e-07
% O 0 2.1281495321545663e-07
) O 0 4.4838850499218097e-07
due O 0 1.1147931218147278e-06
to O 0 1.5246072280206135e-06
BRCA2 O 0 0.0005438453517854214
. O 0 6.823936473665526e-06

Conversely O 0 0.0004613276105374098
, O 0 4.092294602742186e-06
the O 0 3.910001282747544e-07
majority O 0 4.4007126120959583e-07
of O 0 1.2979401731172402e-07
families O 0 2.718898485909449e-06
with O 0 2.2506812911160523e-06
male B-Disease 0 2.4440685592708178e-05
and I-Disease 0 1.832488487707451e-05
female I-Disease 0 0.017869848757982254
breast I-Disease 1 0.9998956918716431
cancer I-Disease 1 0.9520151019096375
were O 0 5.536573439712811e-07
due O 0 4.516468834481202e-06
to O 0 1.123343736253446e-06
BRCA2 O 0 0.0008127352339215577
( O 0 1.1793464409493026e-06
76 O 0 6.011440746078733e-06
% O 0 8.235461450567527e-07
) O 0 1.8834030015568715e-06
. O 0 3.1257779937732266e-06

The O 0 8.38279720483115e-06
largest O 0 1.7300020772381686e-05
proportion O 0 1.6555230104131624e-05
( O 0 1.0886326435866067e-06
67 O 0 2.8977349302294897e-06
% O 0 1.5939471609272005e-07
) O 0 8.000969842214545e-08
of O 0 3.1152588064742304e-08
families O 0 5.437119057205564e-07
due O 0 5.491449996952724e-07
to O 0 4.667022679427646e-08
other O 0 2.092495243743997e-08
genes O 0 3.2607186994937365e-07
was O 0 3.893000410926106e-08
found O 0 2.302658153041648e-08
in O 0 1.539023664065553e-08
families O 0 9.957386026826498e-08
with O 0 5.5850875924079446e-08
four O 0 8.817499974611565e-08
or O 0 1.8338764107284078e-07
five O 0 1.5911858497474896e-07
cases O 0 8.361498089470842e-07
of O 0 2.3459399471903453e-06
female O 0 0.04541652277112007
breast B-Disease 1 0.9996964931488037
cancer I-Disease 1 0.9147053360939026
only O 0 1.5977351495166658e-06
. O 0 1.2323440387262963e-05

These O 0 1.031092779157916e-05
estimates O 0 1.4438258403970394e-05
were O 0 3.2093794288812205e-07
not O 0 1.0669277372699071e-07
substantially O 0 1.2866184988524765e-06
affected O 0 6.499329288089939e-07
either O 0 4.1087155011609866e-08
by O 0 3.506556822685525e-08
changing O 0 2.2562613821719424e-07
the O 0 6.408636465948803e-08
assumed O 0 1.0317293117623194e-06
penetrance O 0 4.378786979941651e-05
model O 0 3.536217150212906e-07
for O 0 1.1988917947292066e-07
BRCA1 O 0 7.718231063336134e-05
or O 0 1.0154301577358638e-07
by O 0 5.044647721774709e-08
including O 0 1.1484952722184971e-07
or O 0 4.956893917551497e-07
excluding O 0 2.6913030524156056e-05
BRCA1 O 0 0.005360216833651066
mutation O 0 3.2740274036768824e-05
data O 0 7.898620424384717e-06
. O 0 8.333894584211521e-06

Among O 0 3.7072692066431046e-05
those O 0 6.09512835580972e-06
families O 0 3.132692654617131e-05
with O 0 0.0002767182304523885
disease O 1 0.9833202958106995
due O 0 4.394541247165762e-05
to O 0 2.6824652650248026e-06
BRCA1 O 0 0.0008643429027870297
that O 0 1.216686058569394e-07
were O 0 4.864937253046264e-08
tested O 0 2.8073176849829906e-07
by O 0 1.0999304578263036e-08
one O 0 6.626483806115857e-09
of O 0 9.92550841516504e-09
the O 0 2.7639224242648197e-08
standard O 0 3.2137131711351685e-07
screening O 0 1.7866411781142233e-06
methods O 0 3.365069005667465e-07
, O 0 2.145137472098213e-07
mutations O 0 2.4210917217715178e-06
were O 0 2.6961501475852856e-08
detected O 0 1.6121947510328027e-07
in O 0 9.700873881968164e-09
the O 0 1.8786437294693314e-08
coding O 0 1.149181571236113e-06
sequence O 0 1.1785330400471139e-07
or O 0 2.6895962790263184e-08
splice O 0 1.907669684442226e-06
sites O 0 3.876240484146365e-08
in O 0 8.097163828324483e-09
an O 0 5.6821551908115e-09
estimated O 0 9.812607970616227e-08
63 O 0 6.098734957049601e-07
% O 0 4.751462157059905e-08
( O 0 4.1726941901742975e-08
95 O 0 1.1015580980711093e-07
% O 0 2.1525742965877726e-07
CI O 0 0.0028328029438853264
51 O 0 7.02639795235882e-07
% O 0 1.6606482233783026e-07
- O 0 7.519311475334689e-05
77 O 0 7.54996835894417e-06
% O 0 1.0045505405287258e-06
) O 0 2.5568601813574787e-06
. O 0 3.2352311336580897e-06

The O 0 1.6011968909879215e-05
estimated O 0 1.1342322977725416e-05
sensitivity O 0 8.907212759368122e-06
was O 0 3.266700900894648e-07
identical O 0 2.876951441521669e-07
for O 0 4.7843094819199905e-08
direct O 0 8.17472596281732e-08
sequencing O 0 7.713831564615248e-07
and O 0 1.0178870013533015e-07
other O 0 1.5859637869652943e-07
techniques O 0 6.591759756702231e-06
. O 0 5.4548368098039646e-06

The O 0 1.773357689671684e-05
penetrance O 0 0.0032509395387023687
of O 0 4.6428831410594285e-06
BRCA2 O 0 0.003960448782891035
was O 0 5.898859285480285e-07
estimated O 0 3.004496420544456e-07
by O 0 5.6783878932265e-08
maximizing O 0 1.2117477581341518e-06
the O 0 1.2481204691994208e-07
LOD O 0 0.0001964237162610516
score O 0 1.4522052538268326e-07
in O 0 1.0102412062451549e-07
BRCA2 O 0 0.00011058554810006171
- O 0 0.0006284617120400071
mutation O 0 5.09315577801317e-06
families O 0 1.9064259504375514e-07
, O 0 2.695594858437289e-08
over O 0 4.878689807696901e-08
all O 0 3.9722142020082174e-08
possible O 0 8.785534646449378e-07
penetrance O 0 0.00023788576072547585
functions O 0 1.9918250018235995e-06
. O 0 4.810158316104207e-06

The O 0 5.17407497682143e-05
estimated O 0 6.843552546342835e-05
cumulative O 0 0.0011955086374655366
risk O 0 0.0006768993334844708
of O 0 1.8955635823658668e-05
breast B-Disease 1 0.99920254945755
cancer I-Disease 1 0.8701234459877014
reached O 0 2.1890857624384807e-06
28 O 0 5.238779294813867e-07
% O 0 8.94553053853997e-08
( O 0 5.151862580987654e-08
95 O 0 1.3453919223138655e-07
% O 0 1.5578683587591513e-07
CI O 0 0.00557955214753747
9 O 0 3.276404072494188e-07
% O 0 4.337558223710403e-08
- O 0 2.8319340344751254e-05
44 O 0 4.0675496393305366e-07
% O 0 8.414744456786138e-08
) O 0 3.365514089637145e-08
by O 0 1.5886865156744534e-08
age O 0 8.3484643198517e-08
50 O 0 2.456741476919433e-08
years O 0 3.215263788547418e-08
and O 0 2.496110163008325e-08
84 O 0 5.52016103938513e-07
% O 0 4.876624615235414e-08
( O 0 6.594574131213449e-08
95 O 0 1.693913560529836e-07
% O 0 9.74326752611887e-08
CI O 0 0.0029252334497869015
43 O 0 3.137357964533294e-07
% O 0 4.926162588958505e-08
- O 0 1.0364004992879927e-05
95 O 0 4.0862005334929563e-07
% O 0 7.460853623797448e-08
) O 0 5.6343168353123474e-08
by O 0 4.833841060758459e-08
age O 0 3.704920175096049e-07
70 O 0 5.979759407637175e-07
years O 0 1.5594055184919853e-06
. O 0 3.773545813601231e-06

The O 0 0.0008636884740553796
corresponding O 1 0.9027535319328308
ovarian B-Disease 1 0.999995231628418
cancer I-Disease 1 0.999967098236084
risks O 0 0.029945215210318565
were O 0 4.298447947803652e-06
0 O 0 0.0001109724908019416
. O 0 1.9469731341814622e-05

4 O 0 3.554350769263692e-05
% O 0 1.6361701682399143e-06
( O 0 4.718984314422414e-07
95 O 0 3.4648587643459905e-07
% O 0 2.9607980422952096e-07
CI O 0 0.007524231914430857
0 O 0 1.4064241895539453e-06
% O 0 5.9017519760118375e-08
- O 0 1.6421823602286167e-05
1 O 0 2.8170583732389787e-07
% O 0 8.721873712147499e-08
) O 0 5.8748646836193075e-08
by O 0 1.81965997825273e-08
age O 0 6.510029493256297e-08
50 O 0 2.820673117298611e-08
years O 0 3.3747063810096734e-08
and O 0 2.202112270310863e-08
27 O 0 1.6365760302505805e-07
% O 0 3.358486111437742e-08
( O 0 3.6136047043555664e-08
95 O 0 8.070800561199576e-08
% O 0 1.1403642474761e-07
CI O 0 0.008822919800877571
0 O 0 9.200006729770394e-07
% O 0 5.5671772969390076e-08
- O 0 1.999341657210607e-05
47 O 0 1.3870276234229095e-06
% O 0 1.1190395099447414e-07
) O 0 1.1692111456795828e-07
by O 0 7.090738307624633e-08
age O 0 4.964671234120033e-07
70 O 0 7.720454959780909e-07
years O 0 2.5508247745165136e-06
. O 0 5.281724043015856e-06

The O 0 0.00012751515896525234
lifetime O 0 0.0034565082751214504
risk O 0 0.0030906102620065212
of O 0 0.00014719803584739566
breast B-Disease 1 0.9998388290405273
cancer I-Disease 1 0.977275550365448
appears O 0 4.2929505070787854e-06
similar O 0 2.3239213930992264e-07
to O 0 1.3066787118987122e-07
the O 0 2.019916962581192e-07
risk O 0 5.92692913414794e-06
in O 0 4.111750229185418e-07
BRCA1 O 0 0.005288595799356699
carriers O 0 2.5604673282941803e-05
, O 0 1.8248863398184767e-07
but O 0 2.9689230629514896e-08
there O 0 9.100586950694378e-09
was O 0 1.2379334890511018e-08
some O 0 4.353901683629147e-09
suggestion O 0 5.914823830721616e-08
of O 0 1.0319674892400599e-08
a O 0 7.868817419875995e-08
lower O 0 1.1556511708477046e-05
risk O 0 1.2734911251754966e-05
in O 0 2.298652503895937e-07
BRCA2 O 0 0.00030800781678408384
carriers O 0 8.805012839729898e-06
< O 0 3.2295589335262775e-05
50 O 0 1.2581591590787866e-07
years O 0 1.1797881427355605e-07
of O 0 1.5859743029977835e-07
age O 0 7.421690952469362e-06
. O 0 6.718013992212946e-06

Eye B-Disease 0 0.47135868668556213
movement I-Disease 0 0.001390827470459044
abnormalities I-Disease 1 0.9085121750831604
correlate O 0 0.0004240809939801693
with O 0 9.779117135622073e-06
genotype O 0 0.002925141714513302
in O 0 1.659824738453608e-05
autosomal O 0 0.18525686860084534
dominant O 0 0.004415163770318031
cerebellar B-Disease 1 0.9989221096038818
ataxia I-Disease 1 0.9998239874839783
type I-Disease 0 0.0598379485309124
I I-Disease 0 0.0003377595858182758
. O 0 2.4463419322273694e-05

We O 0 2.319276063644793e-05
compared O 0 1.3042043974564876e-05
horizontal O 0 0.00010956687037833035
eye O 0 0.0006210582796484232
movements O 0 3.3309668197034625e-06
( O 0 7.367436865024501e-07
visually O 0 2.480676585037145e-06
guided O 0 2.0129566564719426e-06
saccades O 0 0.001956785097718239
, O 0 6.34630850981921e-07
antisaccades O 0 0.00018994692072737962
, O 0 7.223643194720353e-08
and O 0 2.9311177485169537e-08
smooth O 0 1.5836180864425842e-06
pursuit O 0 3.481676458250149e-06
) O 0 6.459713119966182e-08
in O 0 1.7439722554968284e-08
control O 0 6.263692142738364e-08
subjects O 0 9.745051698928364e-08
( O 0 1.2308719021802972e-07
n O 0 2.454422792652622e-05
= O 0 6.741844117641449e-05
14 O 0 4.914136866318586e-07
) O 0 2.391230395915045e-07
and O 0 2.7611727659859753e-07
patients O 0 6.865484010631917e-06
with O 0 4.760624250366163e-08
three O 0 5.4110746106061924e-08
forms O 0 4.465424865429668e-07
of O 0 8.524917234353779e-07
autosomal O 0 0.02583310194313526
dominant O 0 0.00017029274022206664
cerebellar B-Disease 1 0.8870670199394226
ataxias I-Disease 1 0.9520558714866638
type I-Disease 0 0.000357291370164603
I I-Disease 0 2.7754373149946332e-05
spinocerebellar B-Disease 0 0.374832421541214
ataxias I-Disease 0 0.0003682996321003884
1 I-Disease 0 1.8269653878633108e-07
and I-Disease 0 4.1370956438413486e-08
2 I-Disease 0 3.606657514865219e-07
( O 0 3.218513029423775e-07
SCA1 B-Disease 0 0.0001605767320143059
, O 0 1.0463812571970266e-07
n O 0 1.2546521247713827e-05
= O 0 1.5711244486737996e-05
11 O 0 2.117769355436394e-07
; O 0 1.0547611140054869e-07
SCA2 B-Disease 0 4.777941285283305e-05
, O 0 6.571935529109396e-08
n O 0 4.303665718907723e-06
= O 0 5.385618351283483e-06
10 O 0 3.4859642283890935e-08
) O 0 3.648572644010528e-08
and O 0 9.966259995053406e-08
SCA3 B-Disease 0 0.3391086757183075
/ O 0 0.00035504120751284063
Machado B-Disease 0 0.00027022528229281306
- I-Disease 0 0.038551658391952515
Joseph I-Disease 0 0.010802049189805984
disease I-Disease 0 0.10859142243862152
( O 0 2.5317513063782826e-06
MJD B-Disease 1 0.6733519434928894
) O 0 6.080690582166426e-07
( O 0 3.0437735176747083e-07
n O 0 1.6279913324979134e-05
= O 0 1.936639819177799e-05
16 O 0 5.316769033925084e-07
) O 0 1.1147718623760738e-06
. O 0 1.9957494714617496e-06

In O 0 3.106106669292785e-05
SCA1 B-Disease 0 0.004718942567706108
, O 0 6.083246717025759e-06
saccade O 0 0.0001898339542094618
amplitude O 0 1.0209400898020249e-05
was O 0 6.288333906923071e-07
significantly O 0 1.0107863772645942e-06
increased O 0 3.64435493338533e-07
, O 0 2.3469664256481337e-07
resulting O 0 1.6501811614944017e-06
in O 0 1.3546414265874773e-06
hypermetria B-Disease 0 0.0019748227205127478
. O 0 1.1991118299192749e-05

The O 0 1.507400520495139e-05
smooth O 0 6.576522719115019e-05
pursuit O 0 7.009286491665989e-05
gain O 0 3.275923154433258e-05
was O 0 4.161998276686063e-06
decreased O 0 6.859482527943328e-05
. O 0 1.612776395631954e-05

In O 0 5.1861930842278525e-05
SCA2 B-Disease 0 0.01005326583981514
, O 0 7.755013029964175e-06
saccade O 0 0.000297482474707067
velocity O 0 2.1197538444539532e-05
was O 0 2.94586902782612e-06
markedly O 0 2.9007656848989427e-05
decreased O 0 6.277176726143807e-05
. O 0 1.1658684343274217e-05

The O 0 8.393675670959055e-06
percentage O 0 9.939775736711454e-06
of O 0 6.139367769719684e-07
errors O 0 4.080688813701272e-05
in O 0 7.154533818720665e-07
antisaccades O 0 0.0037628549616783857
was O 0 3.144643017094495e-07
greatly O 0 3.7525055063269974e-07
increased O 0 1.0375176628940608e-07
and O 0 4.390748031823932e-08
was O 0 1.0333071998047672e-07
significantly O 0 6.039155664439022e-07
correlated O 0 4.133588845434133e-06
with O 0 1.0351591299695428e-06
age O 0 5.9299574786564335e-05
at O 0 0.00034785180469043553
disease O 1 0.9889340996742249
onset O 1 0.9344088435173035
. O 0 3.587487663025968e-05

In O 0 8.800529030850157e-06
addition O 0 2.2104181880422402e-06
, O 0 2.594787247289787e-07
a O 0 9.782409904346423e-08
correlation O 0 7.388242124761746e-07
between O 0 1.4563062222805456e-07
smooth O 0 3.8040273011574754e-06
pursuit O 0 6.301682333287317e-06
gain O 0 1.0322942216589581e-06
and O 0 3.687885907766031e-08
the O 0 1.7401211138690087e-08
number O 0 2.3239605795311036e-08
of O 0 1.7497637827545987e-07
trinucleotide O 0 0.046118658035993576
repeats O 0 3.250291047152132e-05
was O 0 1.0329657698093797e-06
found O 0 2.201687493652571e-06
. O 0 7.118562734831357e-06

In O 0 7.12374021532014e-05
SCA3 B-Disease 1 0.6553627848625183
, O 0 9.412716281076428e-06
gaze B-Disease 0 0.0004004955990239978
- I-Disease 0 0.018013518303632736
evoked I-Disease 0 0.003449511481449008
nystagmus I-Disease 0 0.19186775386333466
was O 0 1.001979740067327e-06
often O 0 1.430288136816671e-07
present O 0 6.710968847301046e-08
as O 0 3.720257524264525e-08
was O 0 1.1201349536804628e-07
saccade O 0 2.1970707166474313e-05
hypometria O 0 7.16267604730092e-05
and O 0 7.9754642001717e-08
smooth O 0 1.6315347011186532e-06
pursuit O 0 4.156436716584722e-06
gain O 0 1.7493845234639593e-06
was O 0 4.247938534263085e-07
markedly O 0 6.551586466230219e-06
decreased O 0 2.0465584384510294e-05
. O 0 6.661444786004722e-06

Three O 0 1.7438580471207388e-05
major O 0 1.4471245776803698e-05
criteria O 0 3.117510914307786e-06
, O 0 6.07385686635098e-07
saccade O 0 2.1378136807470582e-05
amplitude O 0 1.1416705092415214e-06
, O 0 1.3983606095280265e-07
saccade O 0 8.169086868292652e-06
velocity O 0 3.974374749304843e-07
, O 0 2.0979943116117283e-08
and O 0 1.462475385238804e-08
presence O 0 3.499340550661145e-08
of O 0 2.7935387336697204e-08
gaze B-Disease 0 9.250627044821158e-06
- I-Disease 0 0.0002924164291471243
evoked I-Disease 0 0.00019183565746061504
nystagmus I-Disease 0 0.0022751723881810904
, O 0 4.567135647448595e-08
permitted O 0 2.2315999714805912e-08
the O 0 1.2610549049441033e-08
correct O 0 9.121583133264721e-08
assignment O 0 3.473307685908367e-08
of O 0 3.324089892231541e-09
90 O 0 1.2025842544005627e-08
% O 0 7.745076580079058e-09
of O 0 6.265721275156011e-09
the O 0 2.2618236172888828e-08
SCA1 B-Disease 0 0.00010861027840292081
, O 0 1.9781440485644453e-08
90 O 0 1.594688292527735e-08
% O 0 8.638674664496193e-09
of O 0 7.925116563001211e-09
the O 0 2.896472039992659e-08
SCA2 B-Disease 0 0.00014130244380794466
, O 0 3.6015908477793346e-08
and O 0 3.595728870209314e-08
93 O 0 7.888561412983108e-07
% O 0 2.334044246765643e-08
of O 0 2.127418419206606e-08
the O 0 2.931851383891626e-07
patients O 0 3.739798557944596e-05
with O 0 1.2382921568132588e-06
SCA3 B-Disease 1 0.9698972105979919
to O 0 2.0687626545168314e-07
their O 0 1.2317362063640758e-07
genetically O 0 4.814201474800939e-06
confirmed O 0 3.2656591884006048e-06
patient O 0 1.7480757378507406e-05
group O 0 6.936713816685369e-07
and O 0 1.0081238599468634e-07
, O 0 1.3136106247202406e-07
therefore O 0 5.7781488038699536e-08
, O 0 9.006341628037262e-08
may O 0 4.673266857935232e-07
help O 0 1.3030467016506009e-06
orient O 0 0.0002817964705172926
diagnoses O 0 0.0006611177232116461
of O 0 1.8333342666210228e-07
SCA1 B-Disease 0 0.028229419142007828
, O 0 6.458511734308559e-07
SCA2 B-Disease 0 0.0022147379349917173
, O 0 1.9444088650288904e-07
and O 0 2.9340915830289305e-07
SCA3 B-Disease 0 0.3653411269187927
at O 0 5.632924171550258e-07
early O 0 6.484544883278431e-07
clinical O 0 2.5730243578436784e-05
stages O 0 3.36934749611828e-06
of O 0 2.7584198392105463e-07
the O 0 6.460369149863254e-06
diseases O 0 0.4107998013496399
. O 0 2.285616346853203e-06
. O 0 9.604525075701531e-06

Genetic O 0 0.0006052003591321409
basis O 0 7.771093805786222e-06
and O 0 5.4204351727094036e-06
molecular O 0 0.0005379708018153906
mechanism O 0 0.00041819942998699844
for O 0 0.0005356064066290855
idiopathic B-Disease 1 0.9999814033508301
ventricular I-Disease 1 0.9998183846473694
fibrillation I-Disease 1 0.9997705817222595
. O 0 0.000565274094697088

Ventricular B-Disease 1 0.9990228414535522
fibrillation I-Disease 1 0.9989823698997498
causes O 0 0.0008781926007941365
more O 0 1.4697339167923928e-07
than O 0 8.554564345786275e-08
300 O 0 1.8735647699941183e-07
, O 0 2.550856095240306e-07
000 O 0 3.837315944110742e-06
sudden O 0 0.00019364991749171168
deaths O 0 7.077050213410985e-06
each O 0 2.2470359795079276e-08
year O 0 9.584495330727805e-08
in O 0 8.798331663228964e-08
the O 0 4.3344860500837967e-07
USA O 0 4.902160071651451e-05
alone O 0 1.1156397704326082e-05
. O 0 5.860175861016614e-06

In O 0 6.368642061715946e-06
approximately O 0 2.3732989120617276e-06
5 O 0 2.9752295631624293e-06
- O 0 0.00017312415002379566
12 O 0 9.493512607150478e-07
% O 0 8.361563175185438e-08
of O 0 2.6288153875952958e-08
these O 0 3.733785547410662e-08
cases O 0 3.3915196695488703e-07
, O 0 1.5074932946390618e-07
there O 0 6.225697291029064e-08
are O 0 4.4612530558652e-08
no O 0 6.784463266740204e-07
demonstrable O 0 0.025543034076690674
cardiac O 0 0.444333553314209
or O 0 2.0576765109581174e-06
non O 0 9.700933151179925e-05
- O 1 0.9934889078140259
cardiac O 1 0.9976252913475037
causes O 0 0.00011610042565735057
to O 0 7.825890691037785e-08
account O 0 1.0418208518103711e-07
for O 0 1.4513157786666397e-08
the O 0 4.165163858260712e-08
episode O 0 8.552922281523934e-07
, O 0 5.565541982832656e-08
which O 0 3.274191939794946e-08
is O 0 6.280021125348867e-08
therefore O 0 2.8970640642000944e-07
classified O 0 4.7576544602634385e-05
as O 0 0.00017171638319268823
idiopathic B-Disease 1 0.9999914169311523
ventricular I-Disease 1 0.9998956918716431
fibrillation I-Disease 1 0.9999459981918335
( O 0 0.001062603434547782
IVF B-Disease 1 0.900608479976654
) O 0 1.9292700017103925e-05
. O 0 1.167189020634396e-05

A O 0 1.4632876627729274e-05
distinct O 0 6.94512709742412e-06
group O 0 1.8647051547304727e-05
of O 0 1.1925704711757135e-05
IVF B-Disease 1 0.9997885823249817
patients O 0 0.05752558633685112
has O 0 7.787925255797745e-07
been O 0 8.865020362236464e-08
found O 0 5.2200128664026124e-08
to O 0 2.6823162357914043e-08
present O 0 2.5582687968039863e-08
with O 0 7.21070279041669e-08
a O 0 4.39196242041362e-07
characteristic O 0 4.3107302190037444e-05
electrocardiographic O 0 0.053537338972091675
pattern O 0 0.0001461642823414877
. O 0 9.523505468678195e-06

Because O 0 5.471164968184894e-06
of O 0 1.874503112730963e-07
the O 0 8.356875724757629e-08
small O 0 1.081938663105575e-07
size O 0 2.1804108030210045e-07
of O 0 2.5940492420772898e-08
most O 0 3.7486707071821e-08
pedigrees O 0 2.4194196157623082e-05
and O 0 1.1687986045672005e-07
the O 0 1.247074550292382e-07
high O 0 9.415777640242595e-06
incidence O 0 0.002727293875068426
of O 0 1.7449724509788211e-06
sudden B-Disease 0 0.03430118039250374
death I-Disease 0 1.7606720575713553e-05
, O 0 2.53951355944082e-07
however O 0 1.269154665806127e-07
, O 0 1.5736023328827287e-07
molecular O 0 3.7859059375477955e-05
genetic O 0 2.1669440684490837e-05
studies O 0 3.9465837176067e-07
of O 0 2.2912091424132086e-07
IVF B-Disease 0 0.2364111691713333
have O 0 1.6887021558886772e-07
not O 0 4.3367474944489004e-08
yet O 0 1.8911607924110285e-07
been O 0 2.139322958782941e-07
done O 0 1.7053553165169433e-06
. O 0 3.6874400848319056e-06

Because O 0 0.016111798584461212
IVF B-Disease 1 0.9988976716995239
causes O 1 0.8085668087005615
cardiac O 1 0.9946920275688171
rhythm O 0 0.0657581090927124
disturbance O 0 0.003689646953716874
, O 0 1.2637524378078524e-06
we O 0 3.242639365907962e-07
investigated O 0 3.623855718615232e-06
whether O 0 3.714132219556632e-07
malfunction O 0 8.029898890526965e-05
of O 0 3.387546243516226e-08
ion O 0 6.6249908741156105e-06
channels O 0 1.1981709349129233e-06
could O 0 1.0756849633253296e-06
cause O 0 1.056206656357972e-05
the O 0 7.232065399875864e-07
disorder O 0 0.030017895624041557
by O 0 1.515276721875125e-07
studying O 0 1.2699636044999352e-06
mutations O 0 8.385811270272825e-06
in O 0 1.0493231883401677e-07
the O 0 4.4341450688989426e-07
cardiac O 0 0.003225012682378292
sodium O 0 4.9281175051874015e-06
channel O 0 6.979048066568794e-06
gene O 0 2.5495561203570105e-05
SCN5A O 0 0.0014086738228797913
. O 0 8.656715181132313e-06

We O 0 2.0645029508159496e-05
have O 0 1.5436502280863351e-06
now O 0 8.654591283629998e-07
identified O 0 9.105631875172548e-07
a O 0 3.0473606216219196e-07
missense O 0 0.0001355696440441534
mutation O 0 4.880681899521733e-06
, O 0 7.876536045614557e-08
a O 0 5.3422528623059407e-08
splice O 0 0.0001850100525189191
- O 0 0.017735693603754044
donor O 0 5.5013777455314994e-05
mutation O 0 2.2425288079830352e-06
, O 0 4.198864544946446e-08
and O 0 2.5846754070357747e-08
a O 0 9.165881209582949e-08
frameshift O 0 0.00021164427744224668
mutation O 0 8.490305845043622e-07
in O 0 1.3632133644136957e-08
the O 0 2.0394468336348837e-08
coding O 0 2.052780246231123e-06
region O 0 2.611365061966353e-07
of O 0 6.062172985821235e-08
SCN5A O 0 0.000974369584582746
in O 0 3.188457355918217e-07
three O 0 8.755197313803365e-07
IVF B-Disease 0 0.2499927580356598
families O 0 2.1888516130275093e-05
. O 0 9.75218335952377e-06

We O 0 6.614896847167984e-06
show O 0 1.7132695120380959e-06
that O 0 1.1650426756659726e-07
sodium O 0 2.3812697236280655e-07
channels O 0 1.1156147650126513e-07
with O 0 3.827487660146289e-08
the O 0 8.351840818932033e-08
missense O 0 7.194570207502693e-05
mutation O 0 1.2224401871208102e-05
recover O 0 2.391050657024607e-05
from O 0 6.906376626147903e-08
inactivation O 0 5.809908179799095e-05
more O 0 1.2228019485860386e-08
rapidly O 0 1.3768281803550053e-07
than O 0 5.896719557085817e-09
normal O 0 3.4798656400880645e-08
and O 0 1.3495072614944092e-08
that O 0 1.2399421045472536e-08
the O 0 8.493709202639366e-08
frameshift O 0 0.0020465536508709192
mutation O 0 8.80845618667081e-06
causes O 0 4.3102519953208684e-07
the O 0 9.365002995309624e-09
sodium O 0 1.0359516267044455e-07
channel O 0 8.067122081456546e-08
to O 0 8.816756214002908e-09
be O 0 6.5315188813031e-09
non O 0 1.509196607685226e-07
- O 0 5.5540542234666646e-05
functional O 0 1.0175886927754618e-05
. O 0 5.454519396153046e-06

Our O 0 3.284998456365429e-05
results O 0 3.496825593174435e-05
indicate O 0 1.062423598341411e-05
that O 0 6.272867949519423e-07
mutations O 0 1.8250015273224562e-05
in O 0 4.1351756863150513e-07
cardiac O 0 0.0032079829834401608
ion O 0 1.0617955922498368e-05
- O 0 0.00017279054736718535
channel O 0 1.6912757700993097e-06
genes O 0 3.7449729006766574e-07
contribute O 0 1.2955213435361657e-07
to O 0 3.077585120081494e-08
the O 0 5.990815310497055e-08
risk O 0 1.2080129181413213e-06
of O 0 1.4760324518192647e-07
developing O 0 3.124577415292151e-05
IVF B-Disease 0 0.20872192084789276
. O 0 2.931953531515319e-06
. O 0 9.227491318597458e-06

Molecular O 0 0.0016842513578012586
heterogeneity O 0 0.002169301500543952
in O 0 1.2034504834446125e-05
mucopolysaccharidosis B-Disease 0 0.01991516351699829
IVA I-Disease 0 0.38101911544799805
in O 0 1.6792428141343407e-06
Australia O 0 7.035154112600139e-07
and O 0 1.0471120504007558e-07
Northern O 0 3.818591949311667e-07
Ireland O 0 1.2364301937850541e-06
: O 0 6.318047098829993e-07
nine O 0 3.2769571589597035e-07
novel O 0 2.0635029613913503e-06
mutations O 0 3.5217328786529833e-06
including O 0 2.3632973977782967e-07
T312S O 0 0.00023009807046037167
, O 0 1.1146534006911679e-07
a O 0 5.614630893546746e-08
common O 0 3.043793697088404e-07
allele O 0 8.367169357370585e-07
that O 0 1.1834064395088717e-07
confers O 0 6.3219922594726086e-06
a O 0 1.8572652606962947e-06
mild O 0 0.0027961628511548042
phenotype O 0 0.00268961931578815
. O 0 1.0941116670437623e-05

Mucopolysaccharidosis B-Disease 1 0.8740400671958923
IVA I-Disease 1 0.9919891953468323
( O 0 0.0009510519448667765
MPS B-Disease 0 0.2629602551460266
IVA I-Disease 1 0.9997771382331848
) O 0 2.939932710432913e-05
is O 0 1.6526474837519345e-06
an O 0 5.667919140250888e-06
autosomal B-Disease 1 0.9801878333091736
recessive I-Disease 1 0.9987518787384033
lysosomal I-Disease 1 0.9999685287475586
storage I-Disease 1 0.9981943964958191
disorder I-Disease 1 0.9998364448547363
caused O 0 0.001002047793008387
by O 0 3.325379225316283e-07
a O 0 1.0538958576944424e-06
genetic B-Disease 0 0.020311865955591202
defect I-Disease 0 0.008363661356270313
in O 0 1.2483573641475232e-07
N O 0 4.596737926476635e-05
- O 0 0.0002244951028842479
acetylgalactosamine O 0 0.0012349443277344108
- O 0 0.00037530972622334957
6 O 0 1.6487827451783232e-05
- O 0 0.012321347370743752
sulfate O 0 0.1045517548918724
sulfatase O 1 0.697131872177124
( O 0 8.563110895920545e-06
GALNS O 0 0.0013599444646388292
) O 0 3.473385504548787e-06
. O 0 4.897966391581576e-06

Previous O 0 5.990037607261911e-05
studies O 0 1.1092658496636432e-05
of O 0 1.4834469084235025e-06
patients O 0 6.532880797749385e-05
from O 0 5.809389236333118e-08
a O 0 1.266848528302944e-07
British O 0 3.5366190331842517e-06
- O 0 0.0036884488072246313
Irish O 0 2.6268535293638706e-05
population O 0 3.6523155699796916e-07
showed O 0 5.240868290457001e-07
that O 0 2.2280188360923603e-08
the O 0 7.602842089227124e-08
I113F O 0 0.00033267340040765703
mutation O 0 2.6087716378242476e-06
is O 0 1.314113884376411e-08
the O 0 1.2998300213951097e-08
most O 0 1.4024895911290969e-08
common O 0 2.834683243690961e-07
single O 0 7.417477831950237e-07
mutation O 0 1.6555799447814934e-05
among O 0 3.153889110762975e-06
MPS B-Disease 0 0.07609529048204422
IVA I-Disease 1 0.9999527931213379
patients O 0 0.023368488997220993
and O 0 1.892726572805259e-06
produces O 0 1.3693324945052154e-05
a O 0 4.2490930354688317e-05
severe O 1 0.7877583503723145
clinical O 0 0.03816864639520645
phenotype O 0 0.013553118333220482
. O 0 1.9952163711423054e-05

We O 0 3.2409283448942006e-05
studied O 0 1.8793349227053113e-05
mutations O 0 3.846123945550062e-05
in O 0 2.118532904660242e-07
the O 0 2.673738492831035e-07
GALNS O 0 0.0009278869838453829
gene O 0 1.165946855508082e-06
from O 0 3.92958519057629e-08
23 O 0 3.4337503507231304e-07
additional O 0 2.9136748480596e-07
MPS B-Disease 0 0.005236320197582245
IVA I-Disease 1 0.9999090433120728
patients O 0 0.005829712841659784
( O 0 2.409645105672098e-07
15 O 0 3.999529951670411e-08
from O 0 1.031798291251107e-08
Australia O 0 3.987494778812106e-08
, O 0 1.1098161500910919e-08
8 O 0 5.338860731285422e-08
from O 0 9.146353008304686e-09
Northern O 0 6.769541016637959e-08
Ireland O 0 2.0670765366048727e-07
) O 0 7.735423679378073e-08
, O 0 1.8433057746847226e-08
with O 0 4.104555983985847e-08
various O 0 1.7587679224106978e-07
clinical O 0 0.009773445315659046
phenotypes O 0 0.03396314010024071
( O 0 1.5106065802683588e-05
severe O 0 0.0018707579001784325
, O 0 2.3151548589339654e-07
16 O 0 4.0626221675665874e-07
cases O 0 2.9209894591986085e-07
; O 0 4.853741302213166e-07
intermediate O 0 8.945578997554549e-07
, O 0 1.1450764958453874e-07
4 O 0 1.8699496422414086e-06
cases O 0 3.311882210255135e-06
; O 0 1.988032818189822e-05
mild O 0 0.001284048892557621
, O 0 1.5156076642597327e-06
3 O 0 1.1375415851944126e-05
cases O 0 5.3388630476547405e-06
) O 0 4.6529444261977915e-06
. O 0 6.009904609527439e-06

We O 0 1.8225629901280627e-05
found O 0 2.00884119294642e-06
two O 0 3.085923481194186e-07
common O 0 2.2981776055530645e-06
mutations O 0 8.033500307647046e-06
that O 0 2.7725604923034552e-08
together O 0 4.647294105097899e-08
accounted O 0 1.237827689237747e-07
for O 0 1.2709624463980163e-08
32 O 0 5.259719770833726e-08
% O 0 1.3945140153737157e-08
of O 0 8.504776438655881e-09
the O 0 4.246998486223674e-08
44 O 0 4.896920700048213e-07
unrelated O 0 6.386918357748073e-06
alleles O 0 2.877409315260593e-06
in O 0 4.4896106032865646e-07
these O 0 1.1746421932912199e-06
patients O 0 0.00029218208510428667
. O 0 1.112373956857482e-05

One O 0 7.963781172293238e-06
is O 0 1.2350725455689826e-06
the O 0 8.468778673886845e-07
T312S O 0 0.001483294414356351
mutation O 0 2.6620178687153384e-05
, O 0 1.9979954402060685e-07
a O 0 1.364392261393732e-07
novel O 0 1.6655172885293723e-06
mutation O 0 2.4818573365337215e-06
found O 0 1.3126175701927423e-07
exclusively O 0 2.497922935162933e-07
in O 0 1.2412243677317747e-06
milder O 0 0.0012044711038470268
patients O 0 0.0010961039224639535
. O 0 1.3103643141221255e-05

The O 0 6.36326285530231e-06
other O 0 4.6393938646360766e-07
is O 0 1.4247839885683788e-07
the O 0 1.2510865587955777e-07
previously O 0 8.646127298561623e-07
described O 0 6.509075774374651e-06
I113F O 0 0.0005318225594237447
that O 0 3.266504506882484e-07
produces O 0 3.4223053262394387e-06
a O 0 7.356789410550846e-06
severe O 0 0.1447148621082306
phenotype O 0 0.007597513496875763
. O 0 1.6938802218646742e-05

The O 0 1.7831682271207683e-05
I113F O 0 0.0007649685139767826
and O 0 5.118129593029153e-06
T312S O 0 0.0025847686920315027
mutations O 0 3.260240555391647e-05
accounted O 0 1.5152838841459015e-06
for O 0 7.854288242015173e-08
8 O 0 1.019999103846203e-06
( O 0 1.7578774702542432e-07
18 O 0 1.1836377922236352e-07
% O 0 4.437034206716817e-08
) O 0 4.719974100453328e-08
and O 0 4.17738448277305e-08
6 O 0 7.334705287576071e-07
( O 0 1.0630215996343395e-07
14 O 0 1.0850013865137953e-07
% O 0 3.0300970621510714e-08
) O 0 3.925749325617289e-08
of O 0 2.207191762693128e-08
44 O 0 6.213999199644604e-07
unrelated O 0 4.675327090808423e-06
alleles O 0 3.137500470984378e-06
, O 0 5.897188657399965e-07
respectively O 0 5.0018197725876234e-06
. O 0 4.349154551164247e-06

The O 0 9.799085091799498e-06
relatively O 0 4.979108780389652e-06
high O 0 5.442371275421465e-06
residual O 0 8.5926876636222e-05
GALNS O 0 0.0008569230558350682
activity O 0 1.2697407782980008e-06
seen O 0 3.5296002920404135e-07
when O 0 7.870109186569607e-08
the O 0 4.860374147597213e-08
T312S O 0 6.461231805587886e-06
mutant O 0 8.176641586032929e-07
cDNA O 0 3.130743380097556e-07
is O 0 2.709915492005166e-08
overexpressed O 0 1.763360728546104e-06
in O 0 3.993720909534204e-08
mutant O 0 3.202068000973668e-06
cells O 0 7.83335565301968e-07
provides O 0 6.858986267843648e-08
an O 0 9.699541614338614e-09
explanation O 0 4.90376734774145e-08
for O 0 2.0967581448871897e-08
the O 0 3.096367890975671e-07
mild O 0 0.0009527975344099104
phenotype O 0 0.0007010728004388511
in O 0 1.337652065558359e-06
patients O 0 5.548030821955763e-05
with O 0 3.072869674269896e-07
this O 0 5.010595600651868e-07
mutation O 0 3.255487172282301e-05
. O 0 4.371205250208732e-06

The O 0 5.081274593976559e-06
distribution O 0 1.684807330093463e-06
and O 0 1.793098789448777e-07
relative O 0 2.937283340997965e-07
frequencies O 0 7.360597464867169e-08
of O 0 2.2384464060110076e-08
the O 0 4.7585178464260025e-08
I113F O 0 3.509825182845816e-05
and O 0 3.3187325243488885e-07
T312S O 0 0.00031183590181171894
mutations O 0 2.6424297630001092e-06
in O 0 3.933941883360603e-08
Australia O 0 1.3869043868908193e-07
corresponded O 0 2.9207109264461906e-07
to O 0 2.5859280938789198e-08
those O 0 1.4765062950061747e-08
observed O 0 3.8693116266586e-08
in O 0 1.049729192459381e-08
Northern O 0 4.060545677475602e-08
Ireland O 0 1.3373289675655542e-07
and O 0 5.045071205245222e-08
are O 0 1.0785283777181576e-08
unique O 0 3.483199151332883e-08
to O 0 2.2533795274171098e-08
these O 0 1.0496590263642247e-08
two O 0 3.578214347044195e-08
populations O 0 2.1063237909402233e-06
, O 0 9.622631580441521e-08
suggesting O 0 6.562965495504614e-07
that O 0 2.066342474904559e-08
both O 0 5.317935247717287e-08
mutations O 0 2.9468947104760446e-06
were O 0 1.6764932553314793e-08
probably O 0 7.899976850467283e-08
introduced O 0 4.6808317222257756e-08
to O 0 1.9739340828550667e-08
Australia O 0 4.178627577289262e-08
by O 0 1.5952146270592493e-08
Irish O 0 3.4938292969854956e-07
migrants O 0 1.9553337438082963e-07
during O 0 7.121423806211169e-08
the O 0 5.964545835013269e-08
19th O 0 1.3480198504112195e-06
century O 0 4.693093160312856e-06
. O 0 5.671412054653047e-06

Haplotype O 0 0.013905497267842293
analysis O 0 4.037674079881981e-05
using O 0 3.521843609632924e-06
6 O 0 9.138261702901218e-06
RFLPs O 0 0.0002229252568213269
provides O 0 3.8664830981360865e-07
additional O 0 8.282563612738159e-08
data O 0 1.5359789529156842e-07
that O 0 2.4626197969723762e-08
the O 0 7.216619479777364e-08
I113F O 0 0.0001883276563603431
mutation O 0 3.2480697882419918e-06
originated O 0 2.2823286371931317e-07
from O 0 3.5517231822268513e-08
a O 0 1.995457097336839e-07
common O 0 2.542719812481664e-06
ancestor O 0 2.952979048131965e-05
. O 0 8.682470252097119e-06

The O 0 5.519541900866898e-06
other O 0 7.569640274596168e-07
9 O 0 7.415705567836994e-06
novel O 0 1.842912388383411e-05
mutations O 0 4.571709723677486e-05
identified O 0 5.585784492723178e-07
in O 0 5.768403710249004e-08
these O 0 6.71432331955657e-08
23 O 0 3.3910455385921523e-06
patients O 0 1.172493830381427e-05
were O 0 1.1752373296758378e-08
each O 0 9.413984258799246e-09
limited O 0 8.823506192356945e-08
to O 0 4.292670041650126e-08
a O 0 1.11920599010773e-07
single O 0 9.026941825140966e-07
family O 0 1.1509032447065692e-05
. O 0 1.0630824363033753e-05

These O 0 6.984354513406288e-06
data O 0 5.109589892526856e-06
provide O 0 1.283531332774146e-06
further O 0 2.9337644491533865e-07
evidence O 0 4.735908873954031e-07
for O 0 8.488299840792024e-08
extensive O 0 2.386849700997118e-06
allelic O 0 0.00010616855433909222
heterogeneity O 0 0.00029842896037735045
in O 0 1.0655421647243202e-06
MPS B-Disease 0 0.00037659102235920727
IVA I-Disease 1 0.9124533534049988
in O 0 9.339851203549188e-07
British O 0 1.576592512719799e-05
- O 0 0.0896867886185646
Irish O 0 0.0007194619392976165
patients O 0 0.00011660992458928376
and O 0 1.1227403007296743e-07
provide O 0 1.243680287643656e-07
evidence O 0 7.592987572024867e-08
for O 0 1.2355180878387273e-08
their O 0 2.586209113530913e-08
transmission O 0 9.061598689186212e-07
to O 0 3.235602363815815e-08
Australia O 0 5.46560379177663e-08
by O 0 2.206661520176567e-08
British O 0 1.9555592700726265e-07
- O 0 3.267938518547453e-05
Irish O 0 3.2190516776609e-06
migrants O 0 1.4481685184364324e-06
. O 0 5.56099507775798e-07
. O 0 2.9463637929438846e-06

Identification O 0 2.4001663405215368e-05
of O 0 2.3706184038019273e-06
constitutional O 0 2.2896958398632705e-05
WT1 O 1 0.8369351625442505
mutations O 0 0.0014826453989371657
, O 0 1.4553429537045304e-06
in O 0 2.146415454262751e-06
patients O 0 0.000760912022087723
with O 0 1.68531623785384e-05
isolated O 0 0.06840657442808151
diffuse B-Disease 1 0.9989398121833801
mesangial I-Disease 1 0.9999897480010986
sclerosis I-Disease 1 0.9999909400939941
, O 0 2.0140416836511577e-06
and O 0 1.5869410674440587e-07
analysis O 0 2.779937915420305e-07
of O 0 2.510731746951933e-07
genotype O 0 0.0008224013145081699
/ O 0 0.001059758709743619
phenotype O 0 5.996638719807379e-05
correlations O 0 2.6893069389188895e-06
by O 0 1.6431014771001173e-08
use O 0 1.9675630014148737e-08
of O 0 3.285395777652411e-08
a O 0 3.5875328308065946e-07
computerized O 0 0.0002793352759908885
mutation O 0 4.297316991141997e-05
database O 0 2.0343541109468788e-05
. O 0 5.495397545018932e-06

Constitutional O 0 0.0001732305099721998
mutations O 0 0.00014230234955903143
of O 0 8.556813781979145e-07
the O 0 6.127166329861211e-07
WT1 O 0 0.0009032505913637578
gene O 0 1.9038965319850831e-06
, O 0 6.642658689770542e-08
encoding O 0 9.538792511420979e-08
a O 0 1.0723708498971973e-07
zinc O 0 0.0005355517496354878
- O 0 0.0011933805653825402
finger O 0 0.00019806876662187278
transcription O 0 2.4134742488968186e-05
factor O 0 1.6578804888922605e-06
involved O 0 2.8822847752962844e-07
in O 0 7.581865020256373e-07
renal O 1 0.9665083289146423
and O 0 3.343997605043114e-06
gonadal O 1 0.7029475569725037
development O 0 2.3386755856336094e-06
, O 0 1.9261483430454973e-07
are O 0 2.1314150444595725e-08
found O 0 7.449151695482215e-08
in O 0 6.685570497211302e-08
most O 0 2.6277561460119614e-07
patients O 0 9.456058614887297e-05
with O 0 1.3795101949654054e-05
Denys B-Disease 1 0.999138355255127
- I-Disease 1 0.9999281167984009
Drash I-Disease 1 0.9999667406082153
syndrome I-Disease 1 0.9999878406524658
( O 0 9.858798875939101e-05
DDS B-Disease 1 0.9995966553688049
) O 0 4.461101980268722e-06
, O 0 1.256204086530488e-06
or O 0 1.6552547094761394e-05
diffuse B-Disease 1 0.9830174446105957
mesangial I-Disease 1 0.999984622001648
sclerosis I-Disease 1 0.9999961853027344
( O 0 0.0005232873954810202
DMS B-Disease 1 0.9923600554466248
) O 0 1.3293984011397697e-06
associated O 0 7.581394356748206e-07
with O 0 5.457150109577924e-07
pseudohermaphroditism B-Disease 1 0.9357580542564392
and O 0 4.9187733566213865e-06
/ O 0 0.025104358792304993
or O 0 0.00020043420954607427
Wilms B-Disease 1 0.9998852014541626
tumor I-Disease 1 0.9710425138473511
( O 0 4.892324432148598e-05
WT B-Disease 1 0.9216180443763733
) O 0 7.955165528983343e-06
. O 0 8.119287485897075e-06

Most O 0 3.5781838960247114e-05
mutations O 0 0.002811160869896412
in O 0 6.709282024530694e-05
DDS B-Disease 1 0.9999544620513916
patients O 0 0.21392834186553955
lie O 0 0.0001272384834010154
in O 0 1.2203919652620243e-07
exon O 0 2.006257818720769e-05
8 O 0 6.284334403972025e-07
or O 0 5.385754775488749e-08
exon O 0 3.7863464967813343e-06
9 O 0 1.3624445216464665e-07
, O 0 1.744604283260287e-08
encoding O 0 1.1230315521970624e-07
zinc O 0 8.543606963939965e-05
finger O 0 1.8878768969443627e-05
2 O 0 3.8396916579586104e-07
or O 0 2.3425680240052316e-07
zinc O 0 0.0006557306624017656
finger O 0 5.362145748222247e-05
3 O 0 3.191578628047864e-07
, O 0 3.581799035146105e-08
respectively O 0 9.354472751965659e-08
, O 0 1.3008221166899148e-08
with O 0 1.1096870089488675e-08
a O 0 3.6597729291543146e-08
hot O 0 6.39313429928734e-06
spot O 0 3.1004742595541757e-06
( O 0 4.3131510096827697e-07
R394W O 0 2.6352588974987157e-05
) O 0 1.398880726810603e-07
in O 0 1.8541102519975539e-07
exon O 0 3.2258962164632976e-05
9 O 0 1.0435970580147114e-05
. O 0 7.208535407698946e-06

We O 0 8.578567758377176e-06
analyzed O 0 5.836510354129132e-06
a O 0 3.03803716406037e-07
series O 0 4.7429415417354903e-07
of O 0 1.463247514266186e-07
24 O 0 4.8892579798121005e-06
patients O 0 5.4391814046539366e-05
, O 0 1.4460884756317682e-07
10 O 0 1.4289969385572476e-07
with O 0 7.834535722395231e-07
isolated B-Disease 0 0.0020689505618065596
DMS I-Disease 1 0.9975530505180359
( O 0 1.2036076441290788e-05
IDMS B-Disease 0 0.1822366714477539
) O 0 1.608231343652733e-07
, O 0 3.195113862375365e-08
10 O 0 4.545062992633575e-08
with O 0 1.9684625840454828e-07
DDS B-Disease 1 0.9800730347633362
, O 0 2.443931634843466e-07
and O 0 1.2717498520942172e-07
4 O 0 2.7334085643815342e-06
with O 0 1.2808735846192576e-05
urogenital B-Disease 1 0.9994575381278992
abnormalities I-Disease 1 0.9317882061004639
and O 0 8.493889254168607e-06
/ O 0 0.008257818408310413
or O 0 2.6534509743214585e-05
WT B-Disease 1 0.9745326042175293
. O 0 3.19565660902299e-05

We O 0 3.366510645719245e-05
report O 0 2.9450457077473402e-05
WT1 O 0 0.023692648857831955
heterozygous O 0 5.0306472985539585e-05
mutations O 0 4.842482303502038e-05
in O 0 5.046158548793755e-07
16 O 0 8.584051101934165e-06
patients O 0 0.0001303666504099965
, O 0 1.9363241676728649e-07
4 O 0 5.2943340733691e-07
of O 0 1.4353111055243062e-07
whom O 0 2.8083400138712022e-06
presented O 0 2.528855702621513e-06
with O 0 1.1114770131825935e-05
IDMS B-Disease 1 0.9365746378898621
. O 0 2.0609186321962625e-05

One O 0 2.1039360944996588e-05
male O 0 2.111457615683321e-05
and O 0 2.257691676277318e-06
two O 0 2.336557827220531e-06
female O 0 0.0005579768912866712
IDMS B-Disease 1 0.9992969036102295
patients O 0 0.028461046516895294
with O 0 6.954505806788802e-05
WT1 O 1 0.9982954859733582
mutations O 0 0.038367390632629395
underwent O 0 0.022565461695194244
normal O 0 8.178398275049403e-05
puberty O 0 0.0024479818530380726
. O 0 2.1162955817999318e-05

Two O 0 2.7993371986667626e-05
mutations O 0 0.004092943388968706
associated O 0 1.8290875232196413e-05
with O 0 3.99456166633172e-06
IDMS B-Disease 1 0.5637704730033875
are O 0 6.959110265825075e-08
different O 0 1.6927195645166648e-08
from O 0 6.168959032493149e-08
those O 0 1.8411732582990226e-07
described O 0 8.894888196664397e-06
in O 0 2.0772844436578453e-05
DDS B-Disease 1 0.9999330043792725
patients O 0 0.3565021753311157
. O 0 2.7916088583879173e-05

No O 0 0.0002712352725211531
WT1 O 0 0.3901103734970093
mutations O 0 0.0007132486789487302
were O 0 9.30452131342463e-07
detected O 0 3.0919466098566772e-06
in O 0 9.706652548402417e-08
the O 0 8.249313054875529e-08
six O 0 8.119860694932868e-07
other O 0 4.008257747045718e-06
IDMS B-Disease 1 0.9997329115867615
patients O 0 0.006749015301465988
, O 0 1.9874814825016074e-06
suggesting O 0 4.147193249082193e-05
genetic O 0 0.00012499187141656876
heterogeneity O 0 0.0002848881995305419
of O 0 9.841395467447e-07
this O 0 9.346478691441007e-06
disease O 0 0.20475095510482788
. O 0 1.563694058859255e-05

We O 0 4.9258054787060246e-05
analyzed O 0 0.00010999984806403518
genotype O 0 0.001140862819738686
/ O 0 0.002355347154662013
phenotype O 0 0.0006323628476820886
correlations O 0 4.431718843989074e-05
, O 0 6.449371880989929e-08
on O 0 1.4987255880782868e-08
the O 0 6.099621696620261e-09
basis O 0 6.395360685473861e-09
of O 0 6.546460706857715e-09
the O 0 1.3990590908008471e-08
constitution O 0 2.457739789463176e-08
of O 0 1.4118943347796176e-08
a O 0 1.5357957749984052e-07
WT1 O 0 0.013184457086026669
mutation O 0 1.4932862768546329e-06
database O 0 1.461798433410877e-07
of O 0 2.410616595227566e-08
84 O 0 2.0552249679894885e-06
germ O 0 0.00029325595824047923
- O 0 0.0005642588366754353
line O 0 6.813395884819329e-06
mutations O 0 5.372963187255664e-06
, O 0 3.040941365384242e-08
to O 0 1.7479518277241368e-08
compare O 0 2.5184294827340636e-07
the O 0 9.10558739519729e-09
distribution O 0 4.2157004997989134e-08
and O 0 5.042704387392405e-08
type O 0 7.279659257619642e-07
of O 0 8.473143253695525e-08
mutations O 0 1.2796002010873053e-05
, O 0 9.953265589501825e-08
according O 0 6.24596410148115e-08
to O 0 4.200194325676421e-08
the O 0 1.5234547845466295e-07
different O 0 6.019846523486194e-07
symptoms O 0 0.002380899153649807
. O 0 8.388346941501368e-06

This O 0 6.9257021095836535e-06
demonstrated O 0 1.915752363856882e-05
( O 0 9.669673772805254e-07
1 O 0 4.5041355178909726e-07
) O 0 9.62619282063315e-08
the O 0 2.8988429434662066e-08
association O 0 2.515928088087094e-07
between O 0 1.91132301097241e-07
mutations O 0 2.5280817226303043e-06
in O 0 2.420097544586497e-08
exons O 0 3.1976489935914287e-06
8 O 0 3.033266295915382e-07
and O 0 7.135740531793999e-08
9 O 0 1.1478015267130104e-06
and O 0 9.376325920129602e-07
DMS B-Disease 1 0.6850300431251526
; O 0 2.7544685963221127e-06
( O 0 3.471486991202255e-07
2 O 0 1.2727936109513394e-06
) O 0 4.753179894123605e-07
among O 0 6.406253874047252e-07
patients O 0 3.4864166082115844e-05
with O 0 8.382432383768901e-07
DMS B-Disease 1 0.6569353342056274
, O 0 6.365778659755961e-08
a O 0 1.5666895336607922e-08
higher O 0 3.311517104975792e-08
frequency O 0 3.213393640066897e-08
of O 0 1.2303022600690383e-08
exon O 0 1.6268242688965984e-05
8 O 0 3.24218990499503e-06
mutations O 0 7.76917386247078e-06
among O 0 1.574953358840503e-07
46 O 0 2.6022144083981402e-06
, O 0 4.332405296736397e-06
XY O 1 0.6502869725227356
patients O 0 0.00012679118663072586
with O 0 5.5831537792983e-07
female O 0 5.159738066140562e-06
phenotype O 0 2.267373747599777e-05
than O 0 2.263852039163794e-08
among O 0 1.2080987232820917e-07
46 O 0 3.58258967025904e-06
, O 0 9.574274372425862e-06
XY O 1 0.9145404696464539
patients O 0 0.00013024848885834217
with O 0 2.9103674137331836e-07
sexual O 0 2.5256019853259204e-06
ambiguity O 0 1.1517167877173051e-05
or O 0 1.7919036281455192e-06
male O 0 3.123865099041723e-05
phenotype O 0 0.0007566772401332855
; O 0 4.3623870737974357e-07
and O 0 9.201509953982168e-08
( O 0 1.1288589263358517e-07
3 O 0 3.420014138555416e-07
) O 0 9.688267255114624e-08
statistically O 0 5.728362495460715e-08
significant O 0 4.225634597787575e-08
evidence O 0 1.0386978033238847e-07
that O 0 4.2619703322088753e-08
mutations O 0 3.816964522229682e-07
in O 0 1.7998225132487278e-08
exons O 0 2.3251213860930875e-06
8 O 0 2.3382715141906374e-07
and O 0 4.228617811463664e-08
9 O 0 4.825656105822418e-07
preferentially O 0 4.62653247268463e-07
affect O 0 1.1773333596920565e-07
amino O 0 4.919486684684671e-08
acids O 0 4.268665776407943e-08
with O 0 9.856422344967086e-09
different O 0 1.2676336424988222e-08
functions O 0 1.1382607567611558e-07
. O 0 4.241752833422652e-07
. O 0 4.48187665824662e-06

The O 0 6.869235949125141e-05
185delAG O 0 0.029203372076153755
BRCA1 O 0 0.042155928909778595
mutation O 0 5.638173024635762e-05
originated O 0 1.1130020993732614e-06
before O 0 1.1194515536772087e-07
the O 0 3.5912599116727506e-08
dispersion O 0 6.897891466906003e-07
of O 0 2.5723014829281965e-08
Jews O 0 1.844181838350778e-07
in O 0 3.205350296298093e-08
the O 0 4.2322891857793365e-08
diaspora O 0 2.2809913389210124e-06
and O 0 6.661944951247278e-08
is O 0 3.20079251991956e-08
not O 0 2.761166761899858e-08
limited O 0 2.255951585539151e-07
to O 0 5.251234824754647e-07
Ashkenazim O 0 0.00021864192967768759
. O 0 7.05915999787976e-06

The O 0 4.585726128425449e-05
185delAG O 0 0.007227848283946514
mutation O 0 0.0002787773555610329
in O 0 2.5876211111608427e-06
BRCA1 O 0 0.0007349327206611633
is O 0 2.7452691142570984e-07
detected O 0 1.7521394966024673e-06
in O 0 1.4151112281979294e-07
Ashkenazi O 0 2.0603272787411697e-05
Jews O 0 8.461399829684524e-07
both O 0 2.970481887132337e-07
in O 0 1.217656972585246e-05
familial B-Disease 1 0.9999120235443115
breast I-Disease 1 0.9999727010726929
and I-Disease 1 0.975896954536438
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999197721481323
and O 0 1.5363466445705853e-06
in O 0 3.441211333665706e-07
the O 0 4.318007427173143e-07
general O 0 4.074637672601966e-06
population O 0 4.304330559534719e-06
. O 0 4.765271114592906e-06

All O 0 1.1433220606704708e-05
tested O 0 8.151947258738801e-05
Ashkenazi O 0 0.00042359752114862204
mutation O 0 3.860447759507224e-05
carriers O 0 5.429628799902275e-06
share O 0 4.874848400504561e-07
the O 0 7.700359816453783e-08
same O 0 1.1415285428029165e-07
allelic O 0 1.8534507034928538e-05
pattern O 0 6.796075012971414e-06
at O 0 1.0083409733852022e-06
the O 0 1.8286561953573255e-06
BRCA1 O 0 0.0014040193054825068
locus O 0 0.00017453152395319194
. O 0 1.454392167943297e-05

Our O 0 1.4342140275402926e-05
previous O 0 5.589271040662425e-06
study O 0 3.3899104892043397e-06
showed O 0 1.953786068042973e-06
that O 0 8.712944321587202e-08
this O 0 1.2050288944465137e-07
Ashkenazi O 0 0.00013929004489909858
mutation O 0 1.2963006156496704e-05
also O 0 1.2191927112326084e-07
occurs O 0 1.1258411092285314e-07
in O 0 2.5649624646462144e-08
Iraqi O 0 8.558220798704497e-08
Jews O 0 2.2228009299851692e-07
with O 0 4.9086704478895626e-08
a O 0 1.0888740575865086e-07
similar O 0 1.0133613841389888e-06
allelic O 0 0.00028282791026867926
pattern O 0 9.593650611350313e-05
. O 0 1.0509959793125745e-05

We O 0 6.747909537807573e-06
extended O 0 2.191090743508539e-06
our O 0 3.012403340107994e-07
analysis O 0 1.3894381822865398e-07
to O 0 2.51017553409838e-08
other O 0 1.4503473089177987e-08
non O 0 2.1691241158805497e-07
- O 0 5.703276110580191e-05
Ashkenazi O 0 1.5475443433388136e-05
subsets O 0 2.5843235107458895e-06
354 O 0 1.069021209332277e-06
of O 0 2.7922389733703312e-08
Moroccan O 0 8.189479103748454e-07
origin O 0 7.845513749771271e-08
, O 0 3.86380989425561e-08
200 O 0 7.301311200080818e-08
Yemenites O 0 7.066731086524669e-06
and O 0 6.205400637782077e-08
150 O 0 2.6586019430396846e-07
Iranian O 0 9.470660984334245e-07
Jews O 0 4.0115005504048895e-06
. O 0 4.944749434798723e-06

Heteroduplex O 0 0.004202449694275856
analysis O 0 2.429222149658017e-05
complemented O 0 9.182193934975658e-06
by O 0 3.4699843354246696e-07
direct O 0 3.5878133530786727e-07
DNA O 0 1.9432202407188015e-06
sequencing O 0 1.7040239299603854e-06
of O 0 3.0125355010568455e-07
abnormally O 0 0.0001983749825740233
migrating O 0 5.275285275274655e-06
bands O 0 3.2988227758323774e-06
were O 0 3.836130417766981e-07
employed O 0 7.184822607086971e-06
. O 0 6.56998781778384e-06

Four O 0 4.184089448244777e-06
of O 0 4.840354677071446e-07
Moroccan O 0 9.544281056150794e-06
origin O 0 5.147717843101418e-07
( O 0 2.0658565347275726e-07
1 O 0 1.1874445959847435e-07
. O 0 3.251098590340007e-08
1 O 0 1.4529531711104937e-07
% O 0 7.214995889626152e-08
) O 0 5.248245571465304e-08
and O 0 1.522283632482413e-08
none O 0 1.876323096894339e-08
of O 0 6.631971416481974e-09
the O 0 3.111867741267815e-08
Yemenites O 0 2.4393786588916555e-05
or O 0 3.759396705049767e-08
Iranians O 0 4.284800780851583e-08
was O 0 1.7764129722763755e-08
a O 0 1.4564320416354803e-08
carrier O 0 7.114580284905969e-07
of O 0 5.213068021703293e-08
the O 0 6.282213576014328e-07
185delAG O 0 0.001218915218487382
mutation O 0 4.1584280552342534e-05
. O 0 5.9610370044538286e-06

BRCA1 O 0 0.20926737785339355
allelic O 0 0.008338246494531631
patterns O 0 0.0002784745011013001
were O 0 8.053990541156963e-07
determined O 0 6.310243065854593e-07
for O 0 3.2773034064348394e-08
four O 0 3.0677391293920664e-08
of O 0 2.4303668411107537e-08
these O 0 2.2854012016182423e-08
individuals O 0 3.6327818975223636e-08
and O 0 2.1104844094566033e-08
for O 0 1.088520562575468e-08
12 O 0 4.191255342789191e-08
additional O 0 2.2849087955023606e-08
non O 0 4.58481025589208e-07
- O 0 0.0014541971031576395
Ashkenazi O 0 0.0007917767507024109
185delAG O 0 0.0037717404775321484
mutation O 0 1.9560271539376117e-05
carriers O 0 1.4056522559258156e-05
who O 0 6.7638234213518444e-06
had O 0 0.00013381395547185093
breast B-Disease 1 0.999569833278656
/ I-Disease 1 0.9998729228973389
ovarian I-Disease 1 0.9999946355819702
cancer I-Disease 1 0.9997578263282776
. O 0 0.0001127228606492281

Six O 0 1.7656308045843616e-05
non O 0 3.1922634661896154e-05
- O 0 0.01883736066520214
Ashkenazi O 0 0.0014353031292557716
individuals O 0 8.208503459172789e-07
shared O 0 5.598023449238099e-07
the O 0 2.067861260002246e-07
common O 0 3.286171704530716e-06
Ashkenazi O 0 0.0006653026794083416
haplotype O 0 0.00159803859423846
, O 0 1.746879405573054e-07
four O 0 3.7956233711611276e-08
had O 0 4.5444043195175254e-08
a O 0 3.138811877079206e-08
closely O 0 4.6019428623367276e-07
related O 0 5.661684099322883e-07
pattern O 0 3.7607956073770765e-06
, O 0 6.549110764808574e-08
and O 0 3.228149481060427e-08
the O 0 4.038547629647837e-08
rest O 0 2.0604103667665186e-07
( O 0 2.8890875114484516e-07
n O 0 4.012333374703303e-05
= O 0 6.0073420172557235e-05
6 O 0 6.794823548261775e-07
) O 0 7.103963639565336e-08
displayed O 0 9.284084256933056e-08
a O 0 1.0003434169902903e-07
distinct O 0 1.8030924593404052e-06
BRCA1 O 0 0.0004079868958797306
allelic O 0 0.0002951565256807953
pattern O 0 8.179076394299045e-05
. O 0 1.1884049854415935e-05

We O 0 2.0636918634409085e-05
conclude O 0 4.807173536391929e-05
that O 0 9.37032780257141e-07
the O 0 9.500142255092214e-07
185delAG O 0 0.02602727711200714
BRCA1 O 0 0.005330690182745457
mutation O 0 1.5642937796656042e-05
occurs O 0 2.090664708020995e-07
in O 0 1.55332671170072e-08
some O 0 1.0292665386657518e-08
non O 0 7.751055477456248e-07
- O 0 0.005875322502106428
Ashkenazi O 0 0.0004130216548219323
populations O 0 2.5169149466819363e-06
at O 0 1.2590618325702962e-07
rates O 0 2.4732588599363226e-07
comparable O 0 1.806319573915971e-07
with O 0 5.113252399269186e-08
that O 0 6.972888400014199e-08
of O 0 6.101730605223565e-07
Ashkenazim O 0 0.0007971138111315668
. O 0 1.3064387530903332e-05

The O 0 8.049206371651962e-06
majority O 0 3.5872462831321172e-06
of O 0 9.455102372157853e-07
Jewish O 0 3.7974579754518345e-05
185delAG O 0 0.022137977182865143
mutation O 0 7.734551036264747e-05
carriers O 0 9.41737562243361e-06
have O 0 9.020318003649663e-08
a O 0 7.473045826600355e-08
common O 0 4.2472296968298906e-07
allelic O 0 4.880954293184914e-05
pattern O 0 1.5873447409830987e-05
, O 0 1.0671413974705501e-07
supporting O 0 1.7565335497238266e-07
the O 0 4.7740819297814596e-08
founder O 0 4.096956672583474e-06
effect O 0 2.1886630463541223e-07
notion O 0 3.426841033160599e-07
, O 0 7.97760932869096e-08
but O 0 4.080591864408234e-08
dating O 0 1.4521597222483251e-06
the O 0 1.5267622188730456e-07
mutations O 0 3.873354671668494e-06
origin O 0 5.068972797062088e-08
to O 0 2.1891718660072e-08
an O 0 1.3519625419178283e-08
earlier O 0 1.256472188515545e-07
date O 0 1.4669039671844075e-07
than O 0 5.4677517624668326e-08
currently O 0 5.080074743091245e-07
estimated O 0 5.512151346920291e-06
. O 0 6.82110658090096e-06

However O 0 1.1905556675628759e-05
, O 0 7.983825867086125e-07
the O 0 1.5462786961961683e-07
different O 0 6.92457859940987e-08
allelic O 0 1.610676736163441e-05
pattern O 0 8.221044481615536e-06
at O 0 5.308257300384867e-07
the O 0 4.936876507599663e-07
BRCA1 O 0 0.0006254237960092723
locus O 0 1.2335809515207075e-05
even O 0 7.307580318638429e-08
in O 0 2.811375843236874e-08
some O 0 1.9349981172922526e-08
Jewish O 0 1.5982089962562895e-06
mutation O 0 7.856931915739551e-06
carriers O 0 7.0946384767012205e-06
, O 0 2.966504268897552e-07
might O 0 3.0552931207239453e-07
suggest O 0 3.349725545831461e-07
that O 0 2.607522375797089e-08
the O 0 1.1686157819212895e-07
mutation O 0 5.899168172618374e-06
arose O 0 3.8044772736611776e-06
independently O 0 5.30304077983601e-07
. O 0 5.412611585597915e-07
. O 0 3.456882041064091e-06

Crystal O 0 0.0009150372934527695
structure O 0 1.9926796085201204e-05
of O 0 7.503344932047185e-07
the O 0 2.9022953640378546e-06
hemochromatosis B-Disease 1 0.9995817542076111
protein O 0 3.9157905121101066e-05
HFE O 0 0.008690577000379562
and O 0 2.089504533842046e-07
characterization O 0 1.1783178024415975e-06
of O 0 2.3910907032131945e-08
its O 0 7.580918293115246e-08
interaction O 0 8.592033395871113e-07
with O 0 1.067509401764255e-06
transferrin O 0 0.001718435320071876
receptor O 0 7.912905857665464e-05
. O 0 1.1104980330856051e-05

HFE O 0 0.03616812452673912
is O 0 6.881773515488021e-06
an O 0 1.4102089380685356e-06
MHC O 0 0.0010279283160343766
- O 0 0.0003787877212744206
related O 0 2.996363491547527e-06
protein O 0 6.623933472837962e-07
that O 0 2.9022730885230885e-08
is O 0 2.1780763859169383e-08
mutated O 0 4.582462906910223e-07
in O 0 4.2144943535049606e-08
the O 0 5.602477699540032e-07
iron B-Disease 1 0.520504355430603
- I-Disease 1 0.9995515942573547
overload I-Disease 1 0.9998825788497925
disease I-Disease 1 0.999778687953949
hereditary B-Disease 1 0.9997069239616394
hemochromatosis I-Disease 1 0.9999696016311646
. O 0 0.0006592256249859929

HFE O 0 0.03430724889039993
binds O 0 0.0001970469020307064
to O 0 9.929581210599281e-06
transferrin O 0 0.0014708065427839756
receptor O 0 0.00010241913696518168
( O 0 1.5793483498782734e-06
TfR O 0 0.00019964593229815364
) O 0 1.689950721583955e-07
and O 0 3.921707758536286e-08
reduces O 0 3.021451959739352e-07
its O 0 2.776725516184797e-08
affinity O 0 3.248151756451989e-07
for O 0 5.422573678970366e-08
iron O 0 3.8431433495134115e-05
- O 0 6.350892363116145e-05
loaded O 0 2.0720001430163393e-06
transferrin O 0 0.00013150006998330355
, O 0 4.340521400081343e-07
implicating O 0 0.0002632463292684406
HFE O 0 0.01456294022500515
in O 0 2.0607851638487773e-06
iron O 0 0.0008203783654607832
metabolism O 0 0.0002744290104601532
. O 0 7.895750968600623e-06

The O 0 8.620008884463459e-05
2 O 0 0.00013307631888892502
. O 0 5.1788978453259915e-05

6 O 0 8.581788279116154e-05
A O 0 6.533916348416824e-06
crystal O 0 0.00014426137204281986
structure O 0 7.560574431408895e-06
of O 0 5.846738986292621e-07
HFE O 0 0.14421603083610535
reveals O 0 3.88087828468997e-05
the O 0 1.1591998116955438e-07
locations O 0 3.591723043427919e-07
of O 0 8.700661737748305e-07
hemochromatosis B-Disease 1 0.9999364614486694
mutations O 0 0.0003107893862761557
and O 0 2.532192979742831e-07
a O 0 2.3635857360204682e-07
patch O 0 0.009379174560308456
of O 0 3.4537606552476063e-07
histidines O 0 0.013250605203211308
that O 0 6.719678680155994e-08
could O 0 3.555464545001996e-08
be O 0 4.534202791006692e-09
involved O 0 5.413160053535648e-08
in O 0 1.3453725955514528e-07
pH O 0 0.0002038955281022936
- O 0 0.00030066221370361745
dependent O 0 9.346558726974763e-06
interactions O 0 9.55785253609065e-06
. O 0 6.2765643633611035e-06

We O 0 1.790978785720654e-05
also O 0 1.7871165027827374e-06
demonstrate O 0 4.219572474539746e-06
that O 0 5.646989507113176e-07
soluble O 0 5.624816913041286e-05
TfR O 0 0.001172417076304555
and O 0 1.6913064655454946e-06
HFE O 0 0.019111068919301033
bind O 0 1.4458361874858383e-05
tightly O 0 1.446502437829622e-06
at O 0 9.058680205953351e-08
the O 0 2.0992432681055107e-08
basic O 0 1.246072542926413e-07
pH O 0 4.803204774361802e-06
of O 0 1.2550704475700059e-08
the O 0 4.4654417052925055e-08
cell O 0 6.272686277952744e-06
surface O 0 5.336567028280115e-06
, O 0 4.083823412770471e-08
but O 0 1.3816101152031024e-08
not O 0 7.935478052445433e-09
at O 0 4.332753889002561e-08
the O 0 1.0006697692688249e-07
acidic O 0 7.035832823021337e-05
pH O 0 2.3731319743092172e-05
of O 0 3.106848112111038e-07
intracellular O 0 7.152820035116747e-05
vesicles O 0 0.00035696991835720837
. O 0 1.1999995876976755e-05

TfR O 1 0.5361982583999634
HFE O 1 0.6596402525901794
stoichiometry O 0 0.0029013734310865402
( O 0 1.2697487363766413e-05
2 O 0 2.3296915969694965e-06
1 O 0 6.875633289382677e-07
) O 0 1.7813113117881585e-07
differs O 0 3.07297824519992e-07
from O 0 1.4053324548513046e-07
TfR O 0 0.0006064024637453258
transferrin O 0 0.00017466122517362237
stoichiometry O 0 1.1010272828571033e-05
( O 0 8.707495169346657e-08
2 O 0 1.3036614632255805e-07
2 O 0 1.9595694311647094e-07
) O 0 6.31416767760129e-08
, O 0 2.3813962357621676e-08
implying O 0 1.38879698852179e-07
a O 0 5.452689411100664e-09
different O 0 2.4286881394885995e-09
mode O 0 2.3828455653074343e-08
of O 0 6.956479836617291e-09
binding O 0 6.264504293085338e-08
for O 0 3.66033177101599e-08
HFE O 0 0.00013489033153746277
and O 0 1.3718685920593998e-07
transferrin O 0 6.17299010627903e-05
to O 0 1.690611668436759e-07
TfR O 0 0.00015135637659113854
, O 0 4.3955573403309245e-08
consistent O 0 4.518414797871628e-08
with O 0 1.4326738906333958e-08
our O 0 3.1280478651751764e-08
demonstration O 0 2.870837079171906e-07
that O 0 7.898891851709777e-08
HFE O 0 0.0005138879059813917
, O 0 3.47242433917927e-07
transferrin O 0 6.463423051172867e-05
, O 0 1.6005824932108226e-07
and O 0 2.150464979422395e-07
TfR O 0 0.00022772628290113062
form O 0 4.4364716700329154e-07
a O 0 7.013128993094142e-07
ternary O 0 0.00043386637116782367
complex O 0 0.00012306041026022285
. O 0 1.6475300071761012e-05

Identification O 0 1.6179448721231893e-05
of O 0 1.061792090695235e-06
three O 0 6.051164405107556e-07
novel O 0 9.174946171697229e-06
mutations O 0 1.2074521691829432e-05
and O 0 4.4628357898091053e-08
a O 0 2.1218747647822056e-08
high O 0 1.1301504798666429e-07
frequency O 0 3.7595185631289496e-08
of O 0 1.0786251003480629e-08
the O 0 6.38374899608607e-08
Arg778Leu O 0 0.0002989688946399838
mutation O 0 2.825336196110584e-06
in O 0 1.743191404557365e-07
Korean O 0 5.110083657200448e-05
patients O 0 0.001204065978527069
with O 0 4.6412744268309325e-05
Wilson B-Disease 0 0.4328662157058716
disease I-Disease 1 0.9204047918319702
. O 0 2.7708971174433827e-05

Four O 0 2.3364476874121465e-05
mutations O 0 0.00019219046225771308
- O 0 0.0007076898473314941
- O 0 0.000834954553283751
R778L O 0 0.0004550666199065745
, O 0 4.714575823072664e-07
A874V O 0 2.478000351402443e-05
, O 0 1.306613910401211e-07
L1083F O 0 5.57158091396559e-06
, O 0 2.878292626462553e-08
and O 0 2.5646690104963454e-08
2304delC O 0 1.019112369249342e-05
- O 0 1.4604604075429961e-05
- O 0 5.984294148220215e-06
in O 0 1.6700656857437934e-08
the O 0 1.8305874149859847e-08
copper O 0 8.92851676326245e-06
- O 0 4.0213893953477964e-05
transporting O 0 1.7035461041814415e-06
enzyme O 0 3.050930445169797e-06
, O 0 2.2250912934396183e-07
P O 0 0.0002849666925612837
- O 0 0.0001733941026031971
type O 0 1.722421256999951e-05
ATPase O 0 0.00019969296408817172
( O 0 5.749608362748404e-07
ATP7B O 0 0.0002663902414496988
) O 0 9.007440837649483e-08
, O 0 1.8141465218945996e-08
were O 0 1.4854834695654517e-08
identified O 0 1.3343058924419893e-07
in O 0 2.166864163655191e-07
Korean O 0 0.00011216713028261438
Patients O 0 0.0011075552320107818
with O 0 3.7478173908311874e-05
Wilson B-Disease 1 0.5392744541168213
disease I-Disease 1 0.91759192943573
. O 0 3.117814412689768e-05

Arg778Leu O 0 0.0721716657280922
, O 0 1.0557917448750231e-05
the O 0 7.347186965489527e-07
most O 0 2.541669914535305e-07
frequently O 0 1.0870453479583375e-06
reported O 0 2.448565055601648e-06
mutation O 0 1.0869541711144848e-06
of O 0 2.4433903789145006e-08
this O 0 6.214687431338461e-08
enzyme O 0 3.2188306704483693e-06
, O 0 5.3311172365511084e-08
was O 0 2.298402002054445e-08
found O 0 9.267379752486704e-09
in O 0 6.528405815942051e-09
six O 0 1.841225483190101e-08
of O 0 2.882836369622055e-08
eight O 0 1.1125862329208758e-06
unrelated O 0 0.00016297974798362702
patients O 0 0.000234927429119125
studied O 0 8.786254852566344e-07
, O 0 1.098809079280727e-07
an O 0 3.343224008744983e-08
allele O 0 3.8550251701963134e-07
frequency O 0 1.4019538241427654e-07
of O 0 1.1994498549938726e-07
37 O 0 6.62629872749676e-06
. O 0 7.02442002875614e-06

5 O 0 5.426545249065384e-05
% O 0 2.116684072461794e-06
, O 0 3.4766458156809676e-07
which O 0 7.389025569182195e-08
is O 0 4.592765989741565e-08
considerably O 0 1.9411849905281997e-07
higher O 0 7.369855126171387e-08
than O 0 1.5382841667133107e-08
those O 0 2.4100465623178025e-08
in O 0 6.596260249125407e-08
other O 0 1.6310619344039878e-07
Asian O 0 1.204350519401487e-05
populations O 0 3.363821087987162e-05
. O 0 9.674926332081668e-06

The O 0 9.4857523436076e-06
novel O 0 6.608326202695025e-06
single O 0 1.29945408389176e-06
nucleotide O 0 6.2134163272276055e-06
deletion O 0 5.25263421877753e-05
, O 0 6.142495294625405e-07
2304delC O 0 0.0002576384285930544
, O 0 1.8790385070133198e-07
was O 0 8.339520007893952e-08
found O 0 6.7359501088049e-08
in O 0 1.1007305289467695e-07
one O 0 7.218498012662167e-07
patient O 0 0.00028962467331439257
. O 0 1.2506297935033217e-05

Since O 0 2.4490265786880627e-05
a O 0 1.94248082152626e-06
mutation O 0 5.820152182423044e-06
at O 0 7.56160261516925e-07
cDNA O 0 4.56613543065032e-06
nucleotide O 0 2.7075006073573604e-05
2302 O 0 0.12014283239841461
( O 0 1.9812118807749357e-06
2302insC O 0 0.00018500193255022168
) O 0 2.7156002602168883e-07
had O 0 9.325044203478683e-08
been O 0 2.953475863876065e-08
previously O 0 1.4523436675517587e-07
described O 0 4.121282302094187e-07
, O 0 2.716037172945107e-08
this O 0 8.935415074518005e-09
region O 0 1.104697346931971e-07
of O 0 1.8018218028714728e-08
the O 0 1.7632603999118146e-07
ATP7B O 0 0.041025154292583466
gene O 0 1.6713467630324885e-05
may O 0 1.3019013067605556e-06
be O 0 6.271989150263835e-08
susceptible O 0 2.0228084395057522e-05
to O 0 4.749219328914478e-07
gene O 0 2.6599900593282655e-05
rearrangements O 0 0.010072384029626846
causing O 0 0.02225768379867077
Wilson B-Disease 0 0.060942426323890686
disease I-Disease 0 0.4691615104675293
. O 0 2.3115897420211695e-05

Disruption O 0 0.0006151839043013752
of O 0 4.603352408594219e-06
splicing O 0 2.8764994567609392e-05
regulated O 0 6.049252988304943e-06
by O 0 3.6080299992136133e-07
a O 0 3.307702058918949e-07
CUG O 0 0.00041458336636424065
- O 0 7.994416228029877e-05
binding O 0 4.399068984639598e-06
protein O 0 7.915881724329665e-06
in O 0 2.866703835024964e-05
myotonic B-Disease 1 0.9995156526565552
dystrophy I-Disease 1 0.9998175501823425
. O 0 0.00022677940432913601

Myotonic B-Disease 1 0.9998389482498169
dystrophy I-Disease 1 0.9999698400497437
( O 1 0.752555251121521
DM B-Disease 1 0.9999489784240723
) O 0 0.0002004839334404096
is O 0 1.2071479886799352e-06
caused O 0 5.602095370704774e-06
by O 0 3.9779386895588686e-08
a O 0 5.434232264178718e-08
CTG O 0 9.046791819855571e-05
expansion O 0 4.944325837641372e-07
in O 0 2.574313917591553e-08
the O 0 2.7261835455760774e-08
3 O 0 4.1163994524140435e-07
untranslated O 0 0.00020732745178975165
region O 0 1.3327827446119045e-06
of O 0 2.8295434617575665e-07
the O 0 4.700837962445803e-06
DM B-Disease 1 0.9992790818214417
gene O 0 0.00014647025091107935
. O 0 1.0683958862500731e-05

One O 0 9.045978913491126e-06
model O 0 1.7376907635480165e-05
of O 0 8.155217074090615e-06
DM B-Disease 1 0.9996966123580933
pathogenesis O 0 0.39053964614868164
suggests O 0 1.9576040358515456e-05
that O 0 1.4390225544502755e-07
RNAs O 0 5.810059064970119e-06
from O 0 1.7560051190912418e-08
the O 0 1.8525648570744124e-08
expanded O 0 9.595103733772703e-08
allele O 0 1.1673649424892574e-07
create O 0 3.8343706876275974e-08
a O 0 2.1161920216172803e-08
gain O 0 1.915357614734603e-07
- O 0 4.022721441288013e-06
of O 0 4.898457106605747e-08
- O 0 0.00010327176278224215
function O 0 4.434720324297814e-07
mutation O 0 3.471566287771566e-07
by O 0 6.731785795466294e-09
the O 0 1.0137287453915178e-08
inappropriate O 0 6.99015956229232e-08
binding O 0 4.326948399580033e-08
of O 0 2.0159326652446907e-08
proteins O 0 1.408883179010445e-07
to O 0 5.9500596449879595e-08
the O 0 3.612736634295288e-07
CUG O 0 0.0021097999997437
repeats O 0 7.54097563913092e-05
. O 0 7.286331310751848e-06

Data O 0 4.267211625119671e-05
presented O 0 7.88360648584785e-06
here O 0 1.5169496236921987e-06
indicate O 0 2.139385287591722e-06
that O 0 5.763652666246344e-08
the O 0 4.6636678519007546e-08
conserved O 0 4.271137754585652e-07
heterogeneous O 0 3.828009994322201e-06
nuclear O 0 2.7698206395143643e-06
ribonucleoprotein O 0 0.00011956231173826382
, O 0 2.9942731316623394e-07
CUG O 0 7.503310189349577e-05
- O 0 9.89753971225582e-06
binding O 0 3.147145264392748e-07
protein O 0 2.9946528457003296e-07
( O 0 8.661116623898124e-08
CUG O 0 8.222752512665465e-05
- O 0 0.00010652074706740677
BP O 0 7.487671246053651e-05
) O 0 7.620467101787654e-08
, O 0 3.2566529029054436e-08
may O 0 7.615497565893747e-08
mediate O 0 1.118501131713856e-06
the O 0 2.5758856381230544e-08
trans O 0 4.476272806641646e-06
- O 0 0.00011004958651028574
dominant O 0 1.1489810276543722e-06
effect O 0 1.2413482863848913e-07
of O 0 4.997586700028478e-08
the O 0 3.5882206361748104e-07
RNA O 0 8.839077054290101e-06
. O 0 4.7445341806451324e-06

CUG O 1 0.6722161173820496
- O 0 0.1017291247844696
BP O 0 0.011898456141352654
was O 0 2.0133579710091e-06
found O 0 3.265570001076412e-07
to O 0 1.0047875775853754e-07
bind O 0 2.0480754301388515e-06
to O 0 6.886146763918077e-08
the O 0 2.0874711026408477e-07
human O 0 9.081522875931114e-06
cardiac O 0 0.22657975554466248
troponin O 1 0.8695296049118042
T O 0 0.15601354837417603
( O 0 4.869100962423545e-07
cTNT O 0 1.2430022252374329e-05
) O 0 7.570645266241627e-08
pre O 0 6.013787015035632e-07
- O 0 3.5947321066487348e-06
messenger O 0 6.907040983605839e-07
RNA O 0 1.8604814044920204e-07
and O 0 3.8109515543283123e-08
regulate O 0 3.3528417020534107e-07
its O 0 7.175197680453493e-08
alternative O 0 4.833877369492257e-07
splicing O 0 1.5217473446682561e-05
. O 0 5.160588898434071e-06

Splicing O 0 0.00040147893014363945
of O 0 1.54480312630767e-05
cTNT O 0 0.0024301218800246716
was O 0 4.391319180285791e-06
disrupted O 0 7.803784683346748e-05
in O 0 5.389667421695776e-06
DM B-Disease 1 0.9995970129966736
striated O 1 0.790142834186554
muscle O 0 0.0009051355882547796
and O 0 2.2349742323513055e-07
in O 0 1.7418803111013403e-07
normal O 0 1.0588797749733203e-06
cells O 0 3.362452389410464e-06
expressing O 0 8.427294915236416e-07
transcripts O 0 2.0348793441371527e-06
that O 0 2.1286103901729803e-07
contain O 0 4.456186616152991e-06
CUG O 0 0.0038672781083732843
repeats O 0 8.640797022962943e-05
. O 0 7.880750672484282e-06

Altered O 0 0.00020823939121328294
expression O 0 1.1468821867310908e-05
of O 0 9.030403589349589e-07
genes O 0 2.638602154547698e-06
regulated O 0 3.1848060189076932e-06
posttranscriptionally O 0 0.00036035323864780366
by O 0 8.244741707130743e-07
CUG O 0 0.006091435439884663
- O 0 0.004149512853473425
BP O 0 0.0008379590581171215
therefore O 0 6.08665516210749e-07
may O 0 8.577394510211889e-07
contribute O 0 1.366672904623556e-06
to O 0 2.649984935487737e-06
DM B-Disease 1 0.9989606142044067
pathogenesis O 0 0.2429366111755371
. O 0 6.215799203346251e-06
. O 0 9.392029824084602e-06

Identification O 0 1.7218630091520026e-05
of O 0 8.831106015350088e-07
a O 0 7.181515684351325e-07
novel O 0 3.4766794669849332e-06
nonsense O 0 2.609756847959943e-05
mutation O 0 1.942940343724331e-06
and O 0 2.7647871547742398e-08
a O 0 2.8071429625242672e-08
missense O 0 1.385336759085476e-06
substitution O 0 3.986490781926477e-08
in O 0 1.1110022235527595e-08
the O 0 2.690909894909055e-08
vasopressin O 0 1.7428004639441497e-06
- O 0 0.0001740590378176421
neurophysin O 0 0.002580850152298808
II O 0 6.160029442980886e-05
gene O 0 3.639374313024746e-07
in O 0 2.240402707798239e-08
two O 0 5.3268784938609315e-08
Spanish O 0 1.1579086276469752e-06
kindreds O 0 0.0003023178142029792
with O 0 2.5151673980872147e-05
familial B-Disease 1 0.9985640645027161
neurohypophyseal I-Disease 1 0.9996203184127808
diabetes I-Disease 1 0.9997808337211609
insipidus I-Disease 1 0.9942690134048462
. O 0 4.7434969019377604e-05

Familial B-Disease 1 0.9991024732589722
neurohypophyseal I-Disease 1 0.9995556473731995
diabetes I-Disease 1 0.9999446868896484
insipidus I-Disease 1 0.9997579455375671
( O 0 0.04192423075437546
FNDI B-Disease 1 0.9994943141937256
) O 0 3.9152528188424185e-05
is O 0 1.8603781199999503e-06
an O 0 7.451562396454392e-06
autosomal B-Disease 1 0.9872849583625793
dominant I-Disease 1 0.9783782362937927
disease I-Disease 1 0.9999057054519653
caused O 0 0.3854113221168518
by O 0 0.00013469137775246054
deficiency O 1 0.9842570424079895
in O 0 8.388733476749621e-07
the O 0 2.7193757432542043e-06
antidiuretic O 0 0.006948560941964388
hormone O 0 1.4707839000038803e-05
arginine O 0 4.104621893930016e-06
vasopressin O 0 2.8775270948244724e-06
( O 0 1.6672527181071928e-07
AVP O 0 8.506031917931978e-06
) O 0 1.9733844780489562e-08
encoded O 0 1.1901185814622295e-08
by O 0 8.530478545765163e-09
the O 0 3.683625848793781e-08
AVP O 0 5.259943281998858e-05
- O 0 0.00069948541931808
neurophysin O 0 0.003814211580902338
II O 0 0.0002150707587134093
( O 0 1.147066200246627e-06
AVP O 0 0.00027468084590509534
- O 0 0.0011102046119049191
NPII O 0 0.0030931425280869007
) O 0 8.210225814764271e-07
gene O 0 1.392796207255742e-06
on O 0 7.244034918585385e-07
chromosome O 0 0.0001377764856442809
20p13 O 0 0.0004427836975082755
. O 0 7.861039193812758e-06

In O 0 8.106397217488848e-06
this O 0 7.17847512987646e-07
study O 0 1.6335166037606541e-06
, O 0 2.0980046144813969e-07
we O 0 7.578822192044754e-08
analyzed O 0 2.412422475117637e-07
two O 0 1.8604222162821316e-08
families O 0 2.0472579365105048e-07
with O 0 1.844969972353283e-07
FNDI B-Disease 0 0.02686234936118126
using O 0 3.575833318336663e-08
direct O 0 2.731190384963611e-08
automated O 0 3.1809827305551153e-07
fluorescent O 0 5.895743697692524e-07
, O 0 3.94585271124015e-08
solid O 0 1.4541315351834783e-07
phase O 0 2.2553686562787334e-07
, O 0 1.927094217535341e-08
single O 0 5.750859699560351e-08
- O 0 7.321947578020627e-06
stranded O 0 1.528812163087423e-06
DNA O 0 2.5702988182274566e-07
sequencing O 0 1.6201600772092206e-07
of O 0 2.3918753200291576e-08
PCR O 0 1.4976332067817566e-06
- O 0 9.42352107813349e-06
amplified O 0 6.563612714671763e-06
AVP O 0 0.00016913427680265158
- O 0 0.0005641316529363394
NPII O 0 0.002034219680353999
DNA O 0 4.828537566936575e-05
. O 0 7.3316732596140355e-06

In O 0 4.540788268059259e-06
one O 0 2.6000364528044884e-07
of O 0 1.0692603069628603e-07
the O 0 3.0967518682700756e-07
families O 0 3.6103576803725446e-06
, O 0 1.3326962289283983e-06
affected O 0 4.151825578446733e-06
individuals O 0 9.524248412162706e-08
presented O 0 9.219182572905993e-08
a O 0 5.192080365645779e-08
novel O 0 1.1246451094848453e-06
nonsense O 0 1.2651461474888492e-05
mutation O 0 9.470571171732445e-07
in O 0 2.0834788116985692e-08
exon O 0 4.001883098680992e-06
3 O 0 1.012179637882582e-07
of O 0 9.149650814777033e-09
the O 0 2.7396739099572187e-08
gene O 0 1.7297067245181097e-07
, O 0 1.3716926261508888e-08
consisting O 0 1.9630421732586e-08
in O 0 1.125024873260827e-08
a O 0 4.026964006698108e-08
G O 0 7.497831393266097e-05
to O 0 6.063861235361401e-08
T O 0 7.286587788257748e-05
transition O 0 2.2530277021814982e-07
at O 0 7.892597153613679e-08
nucleotide O 0 8.799503916634421e-07
2101 O 0 1.5097641153261065e-05
, O 0 1.7590959799917982e-08
which O 0 5.681310089045155e-09
produces O 0 1.8018560865584732e-08
a O 0 1.1581584580255821e-08
stop O 0 5.868436403488886e-08
signal O 0 5.575019557113592e-08
in O 0 2.078953365014513e-08
codon O 0 8.530951731700043e-07
82 O 0 2.0745981146319536e-06
( O 0 5.339217636901594e-07
Glu O 0 0.0013259314000606537
) O 0 3.2339366384803725e-07
of O 0 3.728622743892629e-07
NPII O 0 0.0009619054035283625
. O 0 5.702107955585234e-06

The O 0 2.7564383344724774e-05
premature O 0 0.0025952786672860384
termination O 0 0.0003074638661928475
eliminates O 0 2.8102822398068383e-05
part O 0 2.840314436980407e-07
of O 0 6.20437106135796e-08
the O 0 1.6286635684537032e-07
C O 0 4.7836132580414414e-05
- O 0 0.00021154803107492626
terminal O 0 1.1715203982021194e-05
domain O 0 1.4016049476595072e-07
of O 0 4.386512486576066e-08
NPII O 0 0.00025004774215631187
, O 0 3.6878933684647563e-08
including O 0 1.695097395781886e-08
a O 0 1.3356027395161618e-08
cysteine O 0 1.4508431434023805e-07
residue O 0 2.7467200425235205e-07
in O 0 1.749662992267531e-08
position O 0 4.1850004350862946e-08
85 O 0 2.1286732021508215e-07
, O 0 3.151391325673103e-08
which O 0 1.658036374863059e-08
could O 0 2.0776374398678854e-08
be O 0 3.625000299933845e-09
involved O 0 1.2626337309029623e-08
in O 0 1.3122353870187453e-08
the O 0 3.8206749763958214e-08
correct O 0 6.964327781133761e-07
folding O 0 5.661760951625183e-06
of O 0 1.4165641459840117e-07
the O 0 1.2727983857985237e-06
prohormone O 0 0.004480251111090183
. O 0 1.2334209714026656e-05

In O 0 6.4219093474093825e-06
the O 0 9.72354882833315e-07
second O 0 1.3627306998387212e-06
family O 0 8.914734053178108e-07
, O 0 5.204524100577146e-08
a O 0 2.9262968936905054e-08
G279A O 0 3.7668294226023136e-06
substitution O 0 3.599406639409608e-08
at O 0 2.9731223705198317e-08
position O 0 2.7902478549890475e-08
- O 0 1.159895873570349e-06
1 O 0 3.487280864078457e-08
of O 0 8.31776869603118e-09
the O 0 1.729842935560555e-08
signal O 0 1.1358372375980252e-07
peptide O 0 3.680346765122522e-07
was O 0 3.892554900630785e-08
observed O 0 9.869255990224701e-08
in O 0 3.037011353512753e-08
all O 0 6.870835989047919e-08
affected O 0 4.4902794797963e-06
individuals O 0 1.7051730765160755e-06
. O 0 5.419913577497937e-06

This O 0 1.5432618965860456e-05
missense O 0 0.00244751013815403
mutation O 0 0.00014994446246419102
, O 0 6.43141902401112e-07
which O 0 2.7054178985963517e-07
replaces O 0 2.1662579456460662e-05
Ala O 0 0.0041897473856806755
with O 0 2.0463846794882556e-06
Thr O 0 0.1387844830751419
, O 0 6.23943890332157e-07
is O 0 1.0780742343285965e-07
frequent O 0 3.6247197385819163e-06
among O 0 4.067614099767525e-06
FNDI B-Disease 1 0.999687910079956
patients O 0 0.0006367850583046675
and O 0 2.339638882631334e-07
is O 0 4.876252290841876e-08
thought O 0 8.56538946436558e-08
to O 0 2.0387663113297094e-08
reduce O 0 1.5233240446832497e-07
the O 0 1.3735069082088103e-08
efficiency O 0 1.3024536826833355e-07
of O 0 4.194702185600363e-08
cleavage O 0 9.718238288769498e-05
by O 0 3.02259621776102e-07
signal O 0 1.6766999806350213e-06
peptidases O 0 4.467485268833116e-05
. O 0 7.77817945163406e-07
. O 0 3.751757958525559e-06

Genetic O 0 0.0027367621660232544
heterogeneity O 0 0.0017746977973729372
of O 0 2.199802293034736e-05
Saethre B-Disease 1 0.9183798432350159
- I-Disease 1 0.9982435703277588
Chotzen I-Disease 1 0.9997522234916687
syndrome I-Disease 1 0.9999474287033081
, O 0 2.119847522408236e-06
due O 0 1.6499718640261563e-06
to O 0 2.445225391056738e-07
TWIST O 0 4.678665573010221e-05
and O 0 4.691742105933372e-06
FGFR O 0 0.34930258989334106
mutations O 0 0.0002774452150333673
. O 0 7.303675374714658e-06

Thirty O 0 7.557367644039914e-05
- O 0 0.0015925399493426085
two O 0 3.4711601983872242e-06
unrelated O 0 0.00029686623020097613
patients O 0 0.00016107759438455105
with O 0 2.3149848971115716e-07
features O 0 1.1557563084352296e-06
of O 0 1.7837691075328621e-06
Saethre B-Disease 1 0.9645788073539734
- I-Disease 1 0.9995635151863098
Chotzen I-Disease 1 0.9999185800552368
syndrome I-Disease 1 0.999962329864502
, O 0 4.707567768491572e-06
a O 0 2.2538968096341705e-06
common O 0 0.0001173757846117951
autosomal B-Disease 0 0.22532573342323303
dominant I-Disease 0 0.0013258075341582298
condition I-Disease 0 0.0006279288209043443
of O 0 3.2841417123563588e-06
craniosynostosis B-Disease 1 0.9987891316413879
and O 0 4.8740883357822895e-05
limb B-Disease 1 0.9890495538711548
anomalies I-Disease 0 0.18329419195652008
, O 0 2.384976482971979e-07
were O 0 3.583309649002331e-08
screened O 0 8.354125498044596e-07
for O 0 7.57681348773076e-08
mutations O 0 1.8791671436702018e-06
in O 0 6.850160616522771e-08
TWIST O 0 1.6291498468490317e-05
, O 0 9.389336810272653e-07
FGFR2 O 0 0.0037688156589865685
, O 0 6.290990768320626e-07
and O 0 1.4397546692634933e-06
FGFR3 O 0 0.003181520150974393
. O 0 1.0292860679328442e-05

Nine O 0 2.4134697014233097e-05
novel O 0 2.0324752767919563e-05
and O 0 1.2719090136670275e-06
three O 0 1.4495419691229472e-06
recurrent O 0 0.03826679289340973
TWIST O 0 0.003925246652215719
mutations O 0 0.0001595892827026546
were O 0 1.262626909692699e-07
found O 0 1.8253928146805265e-07
in O 0 1.8932306034002977e-07
12 O 0 2.267146101075923e-06
families O 0 1.4677600120194256e-05
. O 0 1.4106800335866865e-05

Seven O 0 1.782561230356805e-05
families O 0 7.673201253055595e-06
were O 0 2.361557989161156e-07
found O 0 1.2825472595068277e-07
to O 0 3.661560299406119e-08
have O 0 2.9741944018724098e-08
the O 0 8.266323447969626e-08
FGFR3 O 0 0.0031962881330400705
P250R O 0 0.000594562035985291
mutation O 0 4.062222160428064e-06
, O 0 4.0812533796952266e-08
and O 0 2.043180735711303e-08
one O 0 1.0531163496807494e-08
individual O 0 2.4741877879819185e-08
was O 0 3.111873780881069e-08
found O 0 2.835766643727311e-08
to O 0 2.1229029201208505e-08
have O 0 2.4372928564275753e-08
an O 0 7.232163312664852e-08
FGFR2 O 0 0.000998882343992591
VV269 O 0 0.0003118683525826782
- O 0 0.00012482274905778468
270 O 0 1.3061509889666922e-05
deletion O 0 7.87268509157002e-05
. O 0 6.660116468992783e-06

To O 0 8.378856364288367e-06
date O 0 4.895593974652002e-06
, O 0 3.098619174579653e-07
our O 0 1.4038403151062084e-07
detection O 0 1.9503365820128238e-06
rate O 0 2.1116242976404465e-07
for O 0 4.7434390637590695e-08
TWIST O 0 1.5934310795273632e-05
or O 0 1.1392331771276076e-06
FGFR O 0 0.06153464689850807
mutations O 0 7.063968496368034e-06
is O 0 2.3367704216070706e-08
68 O 0 2.66519720071301e-07
% O 0 2.982795166417418e-08
in O 0 3.1412074719128213e-08
our O 0 4.440221914592257e-07
Saethre B-Disease 0 0.25535911321640015
- I-Disease 1 0.999152660369873
Chotzen I-Disease 1 0.9999681711196899
syndrome I-Disease 1 0.9999927282333374
patients O 0 0.002962476573884487
, O 0 1.9594814659740223e-07
including O 0 1.6416987591583165e-07
our O 0 3.0848349297230016e-07
five O 0 6.920234341123432e-07
patients O 0 9.416295506525785e-05
elsewhere O 0 1.5766922842885833e-06
reported O 0 1.5860953226365382e-06
with O 0 1.468313712393865e-06
TWIST O 0 0.0007042213110253215
mutations O 0 0.00015599990729242563
. O 0 1.1526704838615842e-05

More O 0 1.547597662465705e-06
than O 0 2.5823453597695334e-07
35 O 0 3.9966477061170735e-07
different O 0 9.367007436367203e-08
TWIST O 0 5.5103726481320336e-05
mutations O 0 2.2210741008166224e-05
are O 0 3.412923632595266e-08
now O 0 9.218654639653323e-08
known O 0 1.3546397781283304e-07
in O 0 4.629529470889793e-08
the O 0 1.5222637728129484e-07
literature O 0 1.6333078747265972e-06
. O 0 4.436219114722917e-06

The O 0 9.998949280998204e-06
most O 0 1.0907807563853567e-06
common O 0 1.2151281225669663e-06
phenotypic O 0 9.157035492535215e-06
features O 0 1.1321833426336525e-06
, O 0 2.487371091319801e-07
present O 0 7.489126119253342e-08
in O 0 1.6028975480253393e-08
more O 0 4.117570728823239e-09
than O 0 4.415554144543421e-09
a O 0 8.71264216328882e-09
third O 0 7.682609037829025e-08
of O 0 3.8009702052477223e-08
our O 0 7.512724664593406e-07
patients O 0 1.701561086520087e-05
with O 0 3.007979785252246e-07
TWIST O 0 0.0002447540464345366
mutations O 0 1.806230648071505e-05
, O 0 6.091160287269304e-08
are O 0 3.537255466312672e-08
coronal B-Disease 0 0.00017885562556330115
synostosis I-Disease 0 0.0004433764552231878
, O 0 3.548913696249656e-07
brachycephaly B-Disease 0 0.0001842785277403891
, O 0 4.99020018196461e-07
low B-Disease 0 2.0146382667007856e-05
frontal I-Disease 0 0.13338571786880493
hairline I-Disease 1 0.9994257688522339
, O 0 1.949908801179845e-05
facial B-Disease 0 0.38816386461257935
asymmetry I-Disease 0 0.01911316066980362
, O 0 2.5210871172021143e-05
ptosis B-Disease 1 0.995845377445221
, O 0 1.1103179531346541e-05
hypertelorism B-Disease 0 0.22534942626953125
, O 0 1.0056529617941123e-06
broad B-Disease 0 1.0701009159674868e-05
great I-Disease 0 1.7636348275118507e-05
toes I-Disease 0 0.000323706422932446
, O 0 6.433253361137758e-07
and O 0 2.4744599613768514e-06
clinodactyly B-Disease 0 0.003630561288446188
. O 0 1.2703470929409377e-05

Significant O 0 2.6523153792368248e-05
intra O 0 0.00023626959591638297
- O 0 0.0014466390712186694
and O 0 4.205094228382222e-06
interfamilial O 0 0.008829789236187935
phenotypic O 0 0.0001371026155538857
variability O 0 0.00037666247226297855
is O 0 1.161707672281409e-07
present O 0 9.616026375169895e-08
for O 0 5.059622409930853e-08
either O 0 3.6464720665208006e-07
TWIST O 0 0.0002776704204734415
mutations O 0 0.0001962137030204758
or O 0 7.641194315510802e-06
FGFR O 0 0.37868210673332214
mutations O 0 0.0002957760007120669
. O 0 8.866939424478915e-06

The O 0 1.1960135452682152e-05
overlap O 0 2.7349255105946213e-05
in O 0 1.7341460534225916e-06
clinical O 0 0.0001231611386174336
features O 0 1.218061242980184e-06
and O 0 1.592104297287733e-07
the O 0 7.141282765132928e-08
presence O 0 2.1713242404075572e-07
, O 0 2.984320701671095e-08
in O 0 1.6235466304692636e-08
the O 0 1.9563438868885896e-08
same O 0 2.9746596297286487e-08
genes O 0 1.7932133289377816e-07
, O 0 2.4859142300215353e-08
of O 0 3.2225450752321194e-08
mutations O 0 9.83176164481847e-07
for O 0 6.653472439666075e-09
more O 0 3.186615860073516e-09
than O 0 9.428053893145716e-09
one O 0 7.1463787776338e-08
craniosynostotic B-Disease 0 0.006778702139854431
condition I-Disease 0 9.484323527431116e-06
- O 0 1.7509202734800056e-05
such O 0 5.476623599065533e-08
as O 0 8.353561753438044e-08
Saethre B-Disease 0 0.0005542563740164042
- I-Disease 0 0.0005944770528003573
Chotzen I-Disease 0 0.0007829242385923862
, I-Disease 0 3.1411062195729755e-07
Crouzon I-Disease 0 0.000179987313458696
, I-Disease 0 2.802997300932475e-07
and I-Disease 0 1.298948518524412e-06
Pfeiffer I-Disease 0 0.15338367223739624
syndromes I-Disease 1 0.885364830493927
- O 0 0.0002485659206286073
support O 0 2.3098706947166647e-07
the O 0 5.548942993982564e-08
hypothesis O 0 7.144483333831886e-07
that O 0 2.118283859431358e-08
TWIST O 0 2.1019552605139324e-06
and O 0 7.62288081546103e-08
FGFRs O 0 2.9829157938365825e-05
are O 0 6.587091760934527e-09
components O 0 2.0125325406183947e-08
of O 0 6.585094247668621e-09
the O 0 1.0678862238933107e-08
same O 0 1.99871514894312e-08
molecular O 0 1.9958617940574186e-06
pathway O 0 4.2621454099389666e-07
involved O 0 3.0636812198281405e-08
in O 0 1.604959543044515e-08
the O 0 3.9752382718916124e-08
modulation O 0 2.375110398133984e-06
of O 0 4.718552304439072e-07
craniofacial O 1 0.9982852339744568
and O 0 2.4100289010675624e-05
limb O 1 0.6898788213729858
development O 0 5.357934242056217e-06
in O 0 9.789666819415288e-07
humans O 0 4.660431841330137e-06
. O 0 7.651576083844702e-07
. O 0 3.7209999845799757e-06

Mutation O 0 0.001019228482618928
analysis O 0 6.959559686947614e-05
of O 0 4.0545557567384094e-05
UBE3A O 1 0.9835582375526428
in O 0 0.44648754596710205
Angelman B-Disease 1 0.9999918937683105
syndrome I-Disease 1 0.9999973773956299
patients O 1 0.9956210255622864
. O 0 0.0002465755969751626

Angelman B-Disease 1 0.9999899864196777
syndrome I-Disease 1 0.9999949932098389
( O 0 0.005502247251570225
AS B-Disease 0 0.0001890404528239742
) O 0 6.695199772366323e-06
is O 0 4.4638707663580135e-07
caused O 0 1.2604108633240685e-05
by O 0 2.2793705056756153e-07
chromosome O 0 5.3419353207573295e-05
15q11 O 0 0.0002997303381562233
- O 0 0.00023673883697483689
q13 O 0 7.084422395564616e-05
deletions O 0 1.7505327605249477e-06
of O 0 7.976255034236601e-08
maternal O 0 1.9913763026124798e-05
origin O 0 2.3356859912837535e-07
, O 0 1.0169845410246126e-07
by O 0 3.3530974974382843e-07
paternal O 0 0.00012887839693576097
uniparental B-Disease 1 0.6444241404533386
disomy I-Disease 0 0.44448816776275635
( O 0 6.313580797723262e-06
UPD B-Disease 1 0.7261056303977966
) O 0 2.0615445350813388e-07
15 O 0 6.325402068796393e-08
, O 0 3.640647960878596e-08
by O 0 1.397671240965792e-07
imprinting O 0 0.00556686706840992
defects O 0 0.12293665111064911
, O 0 1.63430669886111e-07
and O 0 8.022348652048095e-08
by O 0 1.2881687894150673e-07
mutations O 0 3.8283092180790845e-06
in O 0 1.3185406544380385e-07
the O 0 8.56773965551838e-07
UBE3A O 0 0.005843923892825842
gene O 0 2.1892148652113974e-05
. O 0 6.313363883236889e-06

UBE3A O 0 0.005925471428781748
encodes O 0 5.9091726143378764e-05
a O 0 5.366520781535655e-06
ubiquitin O 0 6.984791252762079e-05
- O 0 0.00016937730833888054
protein O 0 4.327466285758419e-06
ligase O 0 2.0791097995243035e-05
and O 0 6.505071041829069e-07
shows O 0 3.9870083128334954e-06
brain O 0 0.0010008495301008224
- O 0 0.000281065033050254
specific O 0 3.932021172659006e-06
imprinting O 0 0.0007553451578132808
. O 0 1.684426206338685e-05

Here O 0 2.6803638320416212e-05
we O 0 3.503078914945945e-06
describe O 0 2.4136881620506756e-05
UBE3A O 0 0.0035144209396094084
coding O 0 0.000714553170837462
- O 0 0.004933284595608711
region O 0 5.2963085181545466e-05
mutations O 0 5.054392750025727e-05
detected O 0 1.4796801224292722e-06
by O 0 9.161459502138314e-08
SSCP O 0 0.00013925832172390074
analysis O 0 1.7444421018808498e-07
in O 0 5.209798104033325e-08
13 O 0 5.090681156616483e-07
AS B-Disease 0 1.2621902669707197e-06
individuals O 0 3.392564451587532e-07
or O 0 8.174567369678698e-07
families O 0 1.1234830708417576e-05
. O 0 1.1403384633013047e-05

Two O 0 4.689590241468977e-06
identical O 0 5.766154117736733e-06
de O 0 8.730486115382519e-06
novo O 0 9.563980711391196e-06
5 O 0 1.0712337825680152e-06
- O 0 3.296943395980634e-05
bp O 0 2.4434531951555982e-05
duplications O 0 6.310300250333967e-06
in O 0 1.733374261903009e-07
exon O 0 1.4413603821594734e-05
16 O 0 7.08731647591776e-07
were O 0 1.3058964043466403e-07
found O 0 1.3159193485989817e-06
. O 0 4.268159045750508e-06

Among O 0 1.6748919733799994e-05
the O 0 1.1595751630011364e-06
other O 0 2.682196793557523e-07
11 O 0 1.28618421513238e-06
unique O 0 7.415879395011871e-07
mutations O 0 8.276692824438214e-06
, O 0 6.797034046712724e-08
8 O 0 2.2020476819761825e-07
were O 0 1.5727044555546854e-08
small O 0 7.879346242134488e-08
deletions O 0 2.598462288005976e-06
or O 0 2.014714794995598e-07
insertions O 0 3.26278131979052e-05
predicted O 0 2.6123516363441013e-05
to O 0 2.83967807490626e-07
cause O 0 1.0617612133501098e-05
frameshifts O 0 0.00032373014255426824
, O 0 6.513979400324388e-08
1 O 0 9.9440057965694e-08
was O 0 1.951126904486955e-08
a O 0 2.2547895994762257e-08
mutation O 0 3.150012730657181e-07
to O 0 1.1438645586281382e-08
a O 0 1.1967471458262935e-08
stop O 0 1.0249101478621014e-07
codon O 0 1.3586557656708464e-07
, O 0 1.428352103260977e-08
1 O 0 4.26150705834516e-08
was O 0 1.804910532143822e-08
a O 0 3.164963047197489e-08
missense O 0 3.910551095032133e-05
mutation O 0 1.789308043953497e-06
, O 0 3.090785583026445e-08
and O 0 3.7452757339906384e-08
1 O 0 3.8510933109137113e-07
was O 0 2.3602160581503995e-07
predicted O 0 1.2305541531532072e-05
to O 0 9.690855051758263e-08
cause O 0 9.786735972738825e-07
insertion O 0 4.6865937974871485e-07
of O 0 1.2856228970292705e-08
an O 0 2.0328252858803353e-08
isoleucine O 0 1.988990516110789e-05
in O 0 2.863060188929012e-08
the O 0 4.330019720555356e-08
hect O 0 3.0288223570096307e-05
domain O 0 8.315630850574962e-08
of O 0 1.1003606026349644e-08
the O 0 2.937985676965127e-08
UBE3A O 0 4.30521322414279e-05
protein O 0 8.454014022163392e-08
, O 0 7.944504609724845e-09
which O 0 4.592159097427384e-09
functions O 0 9.818276858197805e-09
in O 0 2.5842318507329765e-08
E2 O 0 5.966092885500984e-06
binding O 0 2.151024887098174e-07
and O 0 1.4406964510271791e-07
ubiquitin O 0 8.559592060919385e-06
transfer O 0 1.5604721284034895e-06
. O 0 4.8970323405228555e-06

Eight O 0 8.860050002112985e-06
of O 0 1.0263103149554809e-06
the O 0 9.613786460249685e-07
cases O 0 3.639687065515318e-06
were O 0 5.21723563906562e-07
familial O 0 0.2031155824661255
, O 0 7.191061968114809e-07
and O 0 2.195584869468803e-07
five O 0 2.5940079240172054e-07
were O 0 3.463623272637051e-07
sporadic O 0 2.3313774363487028e-05
. O 0 1.1009800800820813e-05

In O 0 1.7670256056590006e-05
two O 0 8.32487057778053e-06
familial O 1 0.8110028505325317
cases O 0 2.2251357222558e-05
and O 0 4.7115642587414186e-07
one O 0 1.9671225004458393e-07
sporadic O 0 8.97597783477977e-06
case O 0 1.9864526166202268e-06
, O 0 4.4296945134192356e-07
mosaicism O 0 0.0038235862739384174
for O 0 8.079708777586347e-07
UBE3A O 0 0.1563931107521057
mutations O 0 3.148704854538664e-05
was O 0 1.0619879731166293e-07
detected O 0 4.3177604425181926e-07
in O 0 1.298452190212629e-08
the O 0 3.31415854759598e-08
mother O 0 1.3098868976157974e-06
of O 0 1.73711356410422e-08
three O 0 6.47221867211556e-08
AS B-Disease 0 2.4860576104401844e-06
sons O 0 0.0001070800717570819
, O 0 7.341738239574624e-08
in O 0 2.3790626357822475e-08
the O 0 7.211225749870209e-08
maternal O 0 1.5191896636679303e-05
grandfather O 0 3.516615151966107e-06
of O 0 9.7389722952812e-09
two O 0 1.398090709869848e-08
AS B-Disease 0 3.674903439332411e-07
first O 0 1.9428611608418578e-07
cousins O 0 1.340301605523564e-05
, O 0 7.074891783531712e-08
and O 0 2.6702846156467785e-08
in O 0 3.3783965847078434e-08
the O 0 9.354276642170589e-08
mother O 0 4.389041350805201e-06
of O 0 7.279271585503011e-08
an O 0 3.2557997542426165e-07
AS B-Disease 0 3.135918086627498e-05
daughter O 0 0.003524662461131811
. O 0 1.8461667423252948e-05

The O 0 5.6765475164866075e-06
frequencies O 0 3.5233688322477974e-06
with O 0 4.143007288348599e-07
which O 0 1.7901274418363755e-07
we O 0 2.061377415429888e-07
detected O 0 4.4715152398566715e-06
mutations O 0 2.277026851515984e-06
were O 0 2.4947871324343396e-08
5 O 0 1.9305252862977795e-07
( O 0 7.730380247039648e-08
14 O 0 1.2362798429421673e-07
% O 0 2.5044508689120448e-08
) O 0 1.2531041981844737e-08
of O 0 5.15423836944251e-09
35 O 0 4.097938344216345e-08
in O 0 2.3941666427163e-08
sporadic O 0 1.3165570180717623e-06
cases O 0 2.0673682854521758e-07
and O 0 7.42802512831986e-08
8 O 0 6.80963353261177e-07
( O 0 8.995423428359572e-08
80 O 0 4.309569945348812e-08
% O 0 2.3807922744367715e-08
) O 0 1.8283122571460808e-08
of O 0 9.228186215182177e-09
10 O 0 1.085910241727106e-07
in O 0 4.6008807430553134e-07
familial O 0 0.2692985534667969
cases O 0 1.3145373486622702e-05
. O 0 2.788848860291182e-06
. O 0 8.948481081461068e-06

The O 0 0.00011303673818474635
hemochromatosis B-Disease 1 0.9974507689476013
845 O 0 0.02392491325736046
G O 0 0.008851629681885242
- O 0 0.0006226273835636675
- O 0 0.0005067013553343713
> O 0 2.957474316644948e-05
A O 0 6.884255299155484e-08
and O 0 2.640650187402116e-08
187 O 0 3.791832341448753e-07
C O 0 3.601574462663848e-06
- O 0 4.743528916151263e-05
- O 0 0.0014401799999177456
> O 0 0.0022994864266365767
G O 0 0.015461630187928677
mutations O 0 2.2383013856597245e-05
: O 0 8.15472731119371e-07
prevalence O 0 1.4755913980479818e-05
in O 0 5.960895776979669e-08
non O 0 1.5397642982861726e-06
- O 0 0.0010237576207146049
Caucasian O 0 0.0008187391213141382
populations O 0 7.018376345513389e-05
. O 0 8.688682100910228e-06

Hemochromatosis B-Disease 1 0.9978000521659851
, O 0 0.0008672096882946789
the O 0 0.00079471489880234
inherited B-Disease 1 0.9998050332069397
disorder I-Disease 1 0.9998027682304382
of I-Disease 0 1.08170124804019e-05
iron I-Disease 0 0.3192237317562103
metabolism I-Disease 0 0.004472319036722183
, O 0 2.709755563046201e-06
leads O 0 5.329585474100895e-05
, O 0 2.026484025918762e-06
if O 0 2.210306774941273e-06
untreated O 0 0.0013501490466296673
, O 0 2.3368491497421928e-07
to O 0 3.237720136439748e-07
progressive O 0 0.00014760211342945695
iron B-Disease 0 0.25592586398124695
overload I-Disease 1 0.6388526558876038
and O 0 1.1236717000429053e-05
premature B-Disease 0 0.006928374525159597
death I-Disease 0 4.8901973059400916e-05
. O 0 1.2970611351192929e-05

The O 0 0.000201570350327529
hemochromatosis B-Disease 1 0.9994884729385376
gene O 0 0.0020785091910511255
, O 0 1.7222733731614426e-05
HFE O 0 0.39188382029533386
, O 0 1.6574410892644664e-06
recently O 0 3.3299186270596692e-06
has O 0 1.1272958033714531e-07
been O 0 5.816839987460298e-08
identified O 0 2.2367589735949878e-07
, O 0 4.898569372357997e-08
and O 0 3.479825849694862e-08
characterization O 0 2.2294232167041628e-06
of O 0 2.0401042633011457e-08
this O 0 3.4768007139973633e-08
gene O 0 7.01048747941968e-07
has O 0 3.781712720751784e-08
shown O 0 3.557879324489477e-08
that O 0 6.145515651923006e-09
it O 0 3.910740620227671e-09
contains O 0 1.0068821332254174e-08
two O 0 1.8115738242840962e-08
mutations O 0 6.72451847094635e-07
that O 0 6.735510815758516e-09
result O 0 2.0468823080932452e-08
in O 0 9.448144488999333e-09
amino O 0 2.984013036666511e-08
acid O 0 8.432868270347171e-08
substitutions O 0 4.5867430742418946e-08
- O 0 5.145680574969447e-07
cDNA O 0 2.610770195587975e-07
nucleotides O 0 4.7229639221768593e-07
845 O 0 2.944442258012714e-06
G O 0 2.345026223338209e-05
- O 0 3.347108213347383e-05
- O 0 0.0001619480171939358
> O 0 2.8516851671156473e-05
A O 0 9.136505241258419e-08
( O 0 6.728463830540932e-08
C282Y O 0 2.225987827841891e-06
) O 0 1.7196613910641645e-08
and O 0 1.0823964835537936e-08
187 O 0 2.317452185707225e-07
C O 0 3.31751243720646e-06
- O 0 3.387249671504833e-05
- O 0 0.0006230693543329835
> O 0 0.0008652167744003236
G O 0 0.005413183476775885
( O 0 3.2004072636482306e-06
H63D O 0 0.0007433369173668325
) O 0 2.3605791739100823e-06
. O 0 3.4826759929273976e-06

Although O 0 0.0009127880912274122
hemochromatosis B-Disease 1 0.9995104074478149
is O 0 9.744382623466663e-06
common O 0 5.016662726120558e-06
in O 0 6.302322503870528e-07
Caucasians O 0 7.984025432961062e-05
, O 0 8.172821708285483e-07
affecting O 0 1.1422943316574674e-05
> O 0 0.0014492569025605917
= O 0 0.0001830226246966049
1 O 0 6.474385259025439e-07
/ O 0 1.443617838958744e-05
300 O 0 4.314652457537704e-08
individuals O 0 1.0928663307652187e-08
of O 0 5.629254395955741e-09
northern O 0 5.5686854238956585e-08
European O 0 1.0680312811928161e-07
origin O 0 8.044458610356742e-08
, O 0 6.830473608943066e-08
it O 0 1.3974909229830246e-08
has O 0 2.4175601964770976e-08
not O 0 1.1696132062866127e-08
been O 0 1.738817445584573e-08
recognized O 0 5.823478588240505e-08
in O 0 6.832219412444829e-08
other O 0 3.09701761125325e-07
populations O 0 1.907272235257551e-05
. O 0 7.699411980865989e-06

The O 0 5.758439328928944e-06
present O 0 1.5323475963668898e-06
study O 0 7.127177923393901e-07
used O 0 1.163519272040503e-07
PCR O 0 1.6784326817287365e-06
and O 0 4.687639787448461e-08
restriction O 0 2.2170466706938896e-07
- O 0 4.340687155490741e-05
enzyme O 0 3.4290976600459544e-06
digestion O 0 6.204635155881988e-06
to O 0 2.959340328345661e-08
analyze O 0 1.581518631610379e-07
the O 0 4.203509984535003e-09
frequency O 0 8.540426144065805e-09
of O 0 3.5485117066968996e-09
the O 0 1.2292466600172247e-08
845 O 0 6.0184852372913156e-06
G O 0 6.173520523589104e-05
- O 0 2.2468046154244803e-05
- O 0 3.990282129961997e-05
> O 0 5.508998583536595e-06
A O 0 2.305374025013407e-08
and O 0 1.6100553779097027e-08
187 O 0 1.930904431901581e-07
C O 0 1.5081001265571103e-06
- O 0 1.2789168977178633e-05
- O 0 0.00015578794409520924
> O 0 0.00011128031474072486
G O 0 0.0002644059422891587
mutations O 0 1.1212865729248733e-06
in O 0 3.838175288706225e-08
HLA O 0 8.572693332098424e-05
- O 0 5.5860473366919905e-06
typed O 0 2.9077318686177023e-07
samples O 0 5.949333115040645e-08
from O 0 1.1363080254511715e-08
non O 0 9.737824768762948e-08
- O 0 2.1503681637113914e-05
Caucasian O 0 5.7109173212666065e-05
populations O 0 1.7895214341479004e-06
, O 0 4.4900215101506546e-08
comprising O 0 1.1256661736069873e-07
Australian O 0 4.531896706794214e-07
Aboriginal O 0 4.827437010135327e-07
, O 0 2.504293483696074e-08
Chinese O 0 2.9280947444476624e-08
, O 0 8.01159885099878e-08
and O 0 4.070712407155952e-07
Pacific O 0 6.040580046828836e-05
Islanders O 0 0.000222390255657956
. O 0 7.033255315036513e-06

Results O 0 8.546279423171654e-05
showed O 0 1.0057986401079688e-05
that O 0 2.0074209317044733e-07
the O 0 2.2237591679186153e-07
845 O 0 0.00011883771367138252
G O 0 0.0005516296369023621
- O 0 0.0006337420199997723
- O 0 0.0015893044183030725
> O 0 0.0002757553302217275
A O 0 6.027595986779488e-07
mutation O 0 4.0737554627412464e-06
was O 0 5.8315478668191645e-08
present O 0 2.4897813588609097e-08
in O 0 2.008195920666367e-08
these O 0 2.0232784336826626e-08
populations O 0 3.224694751224888e-07
( O 0 3.60934748755426e-08
allele O 0 7.000085844310888e-08
frequency O 0 4.3149569250999775e-08
0 O 0 1.1259280796593885e-07
. O 0 1.039244246214821e-08
32 O 0 5.115466805705182e-08
% O 0 2.4475790283418064e-08
) O 0 3.935405246124901e-08
, O 0 1.6949421421941224e-08
and O 0 4.309487522391464e-08
, O 0 9.318785743062108e-08
furthermore O 0 3.8431792859228153e-07
, O 0 2.6706871381065866e-08
it O 0 8.744622803646962e-09
was O 0 2.3028249529488676e-08
always O 0 3.2984182496420544e-08
seen O 0 3.834780315514763e-08
in O 0 1.7514960148901082e-08
conjunction O 0 8.805766924524505e-07
with O 0 5.115427939017536e-07
HLA O 0 0.26718586683273315
haplotypes O 0 0.00033800568780861795
common O 0 5.371940119403007e-07
in O 0 1.0441562636742674e-07
Caucasians O 0 1.7828449927037582e-05
, O 0 1.4942236248316476e-07
suggesting O 0 5.635562843053776e-07
that O 0 3.509728685457958e-08
845 O 0 4.139496013522148e-05
G O 0 0.0005638385191559792
- O 0 0.0006963543710298836
- O 0 0.0032557903323322535
> O 0 0.00023770191182848066
A O 0 4.785774194715486e-07
may O 0 4.812806082554744e-07
have O 0 1.6442614381162457e-08
been O 0 1.0955336193774201e-08
introduced O 0 4.940455866631055e-08
into O 0 3.5135865772417674e-08
these O 0 6.564054899627081e-08
populations O 0 1.1652209650492296e-06
by O 0 5.308591539687768e-07
Caucasian O 0 0.00021623952488880605
admixture O 0 0.0018176757730543613
. O 0 2.3534455976914614e-05

187 O 0 0.00022318301489576697
C O 0 0.0003123923670500517
- O 0 0.0010861067567020655
- O 0 0.012631977908313274
> O 0 0.004484565928578377
G O 0 0.002052323194220662
was O 0 1.1151169587719778e-07
present O 0 3.824743188829416e-08
at O 0 3.534679038352806e-08
an O 0 1.0821281648532022e-08
allele O 0 1.5281023024726892e-07
frequency O 0 1.0298992947355146e-07
of O 0 7.400563362125467e-08
2 O 0 2.3559325654787244e-06
. O 0 3.6064070627617184e-06

68 O 0 0.00015736407658550888
% O 0 1.6389311667808215e-06
in O 0 1.4944045290121721e-07
the O 0 1.0338276723587114e-07
two O 0 1.1243346165201729e-07
populations O 0 5.257300472294446e-06
analyzed O 0 3.948604444303783e-06
( O 0 3.2181048936763545e-07
Australian O 0 4.826802069146652e-07
Aboriginal O 0 1.023282493406441e-06
and O 0 1.6757890364260675e-07
Chinese O 0 7.286647019100201e-07
) O 0 2.676075155250146e-06
. O 0 4.207047823001631e-06

In O 0 9.61211208050372e-06
the O 0 1.4539973562932573e-06
Australian O 0 1.7750634242474916e-06
Aboriginal O 0 2.3969139419932617e-06
samples O 0 3.958204501941509e-07
, O 0 5.0405699170141816e-08
187 O 0 6.956236688893114e-07
C O 0 6.898884748807177e-06
- O 0 7.814403215888888e-05
- O 0 0.003464269684627652
> O 0 0.0017277027945965528
G O 0 0.0016361932503059506
was O 0 8.363413428469357e-08
found O 0 1.9939479400932214e-08
to O 0 1.5112496143387943e-08
be O 0 6.113738848512185e-09
associated O 0 6.860412327114318e-08
with O 0 2.731954396040237e-07
HLA O 0 0.4264160394668579
haplotypes O 0 0.00023947398585733026
common O 0 3.6600425801225356e-07
in O 0 9.969301117962459e-08
Caucasians O 0 2.6627390980138443e-05
, O 0 2.894926467433834e-07
suggesting O 0 7.854480372770922e-07
that O 0 1.3082418703902476e-08
it O 0 7.878981911346727e-09
was O 0 3.486662336626978e-08
introduced O 0 8.700157394514463e-08
by O 0 1.3967490986033226e-07
recent O 0 2.3315162707149284e-06
admixture O 0 0.00029138088575564325
. O 0 1.2654827514779754e-05

In O 0 3.004424115715665e-06
the O 0 3.228387015496992e-07
Chinese O 0 2.6731314051176014e-07
samples O 0 3.7498870142371743e-07
analyzed O 0 3.1532948696622043e-07
, O 0 4.014540166963343e-08
187 O 0 3.865716280415654e-07
C O 0 5.482975211634766e-06
- O 0 7.69578546169214e-05
- O 0 0.0007243269355967641
> O 0 0.00040965256630443037
G O 0 0.0003498967853374779
was O 0 5.451028428637983e-08
present O 0 1.7179205613615522e-08
in O 0 1.1035596436670403e-08
association O 0 1.1432858570969984e-07
with O 0 1.884231259907665e-08
a O 0 2.0256802457652157e-08
wide O 0 1.3246800278921e-07
variety O 0 6.912055994234834e-08
of O 0 1.9257699079844315e-07
HLA O 1 0.557897686958313
haplotypes O 0 0.000724218727555126
, O 0 1.8125577128103032e-07
showing O 0 8.084071509983914e-07
this O 0 2.985424885082466e-08
mutation O 0 1.0094936442328617e-06
to O 0 4.000201059284336e-08
be O 0 1.3829599687653626e-08
widespread O 0 3.0939651196604245e-07
and O 0 7.996668216492253e-08
likely O 0 1.519954366813181e-07
to O 0 3.3446909242229594e-08
predate O 0 7.347023256443208e-06
the O 0 1.8720122341164824e-08
more O 0 1.0335039490882991e-08
genetically O 0 2.169378632288499e-07
restricted O 0 1.3858863212590222e-07
845 O 0 3.929368904209696e-05
G O 0 0.00037504654028452933
- O 0 0.0003845755709335208
- O 0 0.0013892865972593427
> O 0 0.00025764110614545643
A O 0 2.4243470306828385e-06
mutation O 0 3.101975016761571e-05
. O 0 4.98685903949081e-06

Genotype O 0 0.035079531371593475
- O 0 0.31747302412986755
phenotype O 0 0.034478142857551575
correlations O 0 0.007433701306581497
in O 0 0.00021894548262935132
attenuated B-Disease 1 0.9001636505126953
adenomatous I-Disease 1 0.999835729598999
polyposis I-Disease 1 0.9999133348464966
coli I-Disease 1 0.9986659288406372
. O 0 0.00023981533013284206

Germ O 0 0.03868198022246361
- O 0 0.008551260456442833
line O 0 7.437210297212005e-05
mutations O 0 3.420788925723173e-05
of O 0 2.5705193706926366e-07
the O 0 2.965306748592411e-06
tumor B-Disease 0 0.06470655649900436
suppressor O 0 0.00020243608742021024
APC O 0 4.753785833599977e-05
are O 0 2.2876325544984866e-07
implicated O 0 7.089117571013048e-05
in O 0 2.2374390027835034e-05
attenuated B-Disease 1 0.9415450692176819
adenomatous I-Disease 1 0.9999831914901733
polyposis I-Disease 1 0.9999898672103882
coli I-Disease 1 0.9998136162757874
( O 0 0.00016406309441663325
AAPC B-Disease 1 0.9973684549331665
) O 0 9.234402682523069e-07
, O 0 1.6839948102642666e-07
a O 0 5.123996515976614e-07
variant O 0 8.01505011622794e-05
of O 0 9.142988710664213e-05
familial B-Disease 1 0.9999746084213257
adenomatous I-Disease 1 0.9999892711639404
polyposis I-Disease 1 0.9999923706054688
( O 0 0.001505086780525744
FAP B-Disease 0 0.2630324959754944
) O 0 1.4331011698232032e-05
. O 0 8.089430593827274e-06

AAPC B-Disease 1 0.9967387318611145
is O 0 1.6955207684077322e-05
recognized O 0 3.245608013457968e-06
by O 0 2.5901763933688926e-07
the O 0 1.3906485207826336e-07
occurrence O 0 4.556087333185133e-06
of O 0 1.21901948091363e-07
< O 0 0.00037412589881569147
100 O 0 6.596838488803769e-07
colonic B-Disease 0 0.0849074125289917
adenomas I-Disease 0 0.002558331238105893
and O 0 1.0585905130255924e-07
a O 0 2.077041898473908e-07
later O 0 6.805239081586478e-06
onset O 1 0.927532970905304
of O 0 0.008099050261080265
colorectal B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999918937683105
( O 0 4.991228706785478e-05
age O 0 1.0363105502619874e-05
> O 0 0.00013849211973138154
40 O 0 6.792924978071824e-07
years O 0 1.7986066040975857e-06
) O 0 2.719796157180099e-06
. O 0 4.0334780351258814e-06

The O 0 7.459952485078247e-06
aim O 0 8.573636478104163e-06
of O 0 2.6649783535503957e-07
this O 0 1.2150117356668488e-07
study O 0 4.532977300186758e-07
was O 0 1.706157490843907e-07
to O 0 2.457417167534004e-07
assess O 0 5.776572652393952e-05
genotype O 0 0.00023296386643778533
- O 0 0.002117578871548176
phenotype O 0 0.0006350776529870927
correlations O 0 7.885983359301463e-05
in O 0 5.891623004572466e-06
AAPC B-Disease 1 0.9825544953346252
families O 0 5.639754090225324e-05
. O 0 1.7328602552879602e-05

By O 0 7.179726253525587e-06
protein O 0 7.037469003989827e-06
- O 0 9.03255058801733e-05
truncation O 0 0.00015465670730918646
test O 0 3.4092167879862245e-06
( O 0 2.4410596211055235e-07
PTT O 0 8.559436537325382e-06
) O 0 1.6774184530277125e-07
assay O 0 6.378801344908425e-07
, O 0 1.5894501714797116e-08
the O 0 6.299213151095273e-09
entire O 0 3.545577698105262e-08
coding O 0 1.5581745174131356e-06
region O 0 9.594188554729044e-08
of O 0 1.092530865776098e-08
the O 0 4.4966032675120005e-08
APC B-Disease 0 9.099407179746777e-06
gene O 0 5.801072688882414e-07
was O 0 4.567893796547651e-08
screened O 0 2.7090504772786517e-07
in O 0 4.843623813144404e-08
affected O 0 9.15555176561611e-07
individuals O 0 6.769488436475513e-08
from O 0 9.02561936300117e-08
11 O 0 5.943094492977252e-06
AAPC B-Disease 1 0.9815401434898376
kindreds O 0 0.00024286021653097123
, O 0 1.2330418996953085e-07
and O 0 4.2335809524729484e-08
their O 0 8.325978484435836e-08
phenotypic O 0 6.6485858951637056e-06
differences O 0 4.515396540227812e-06
were O 0 1.2058339962095488e-06
examined O 0 8.622623136034235e-05
. O 0 1.4590685168514028e-05

Five O 0 2.358964047743939e-05
novel O 0 3.238836507080123e-05
germ O 0 0.0037984915543347597
- O 0 0.0027218833565711975
line O 0 3.7989502743585035e-05
APC B-Disease 0 0.0003158865147270262
mutations O 0 2.2352469386532903e-05
were O 0 1.516485355068653e-07
identified O 0 6.866577564323961e-07
in O 0 3.7914671224825724e-07
seven O 0 3.6547478430293268e-06
kindreds O 0 0.000979627831839025
. O 0 1.882923061202746e-05

Mutations O 0 0.0019321596482768655
were O 0 1.7244441323782667e-06
located O 0 8.540280873603479e-07
in O 0 7.532059242976175e-08
three O 0 2.123769604622794e-08
different O 0 5.320529794516915e-09
regions O 0 6.108378869384978e-08
of O 0 1.2711685037913867e-08
the O 0 7.498231013869372e-08
APC B-Disease 0 2.274004145874642e-05
gene O 0 1.213059022120433e-06
( O 0 5.396243096811304e-08
1 O 0 6.570807187245009e-08
) O 0 2.386771136286825e-08
at O 0 1.2892892087279506e-08
the O 0 5.590669704957918e-09
5 O 0 2.9156224101711814e-08
end O 0 3.1961317148443413e-08
spanning O 0 3.995523627509101e-07
exons O 0 2.441306833134149e-06
4 O 0 1.9649476712402247e-07
and O 0 2.857168546199773e-08
5 O 0 1.5056225777243526e-07
, O 0 2.8189251821686412e-08
( O 0 2.611464289259402e-08
2 O 0 5.381175327556775e-08
) O 0 1.939839044950986e-08
within O 0 9.066783768219011e-09
exon O 0 2.074368921967107e-06
9 O 0 2.9907170073784073e-07
, O 0 3.758471933679175e-08
and O 0 2.5761902833210115e-08
( O 0 3.6997789720771834e-08
3 O 0 7.251252043261047e-08
) O 0 2.706186208456529e-08
at O 0 1.6785250522843853e-08
the O 0 1.2630142265379618e-08
3 O 0 1.535040325961745e-07
distal O 0 1.7207630662596785e-05
end O 0 2.0004664236239478e-07
of O 0 7.331775009333796e-08
the O 0 5.047550075687468e-07
gene O 0 1.337361209152732e-05
. O 0 5.389107172959484e-06

Variability O 0 0.00545461056753993
in O 0 4.0147729123418685e-06
the O 0 8.859710760589223e-07
number O 0 6.786812605241721e-07
of O 0 2.523455987102352e-05
colorectal B-Disease 1 0.9999958276748657
adenomas I-Disease 1 0.9999525547027588
was O 0 7.047052804409759e-06
most O 0 2.683343041098851e-07
apparent O 0 1.3883583051210735e-05
in O 0 1.8194435824625543e-07
individuals O 0 2.3773236534907483e-07
with O 0 3.721858661265287e-07
mutations O 0 7.681445822527166e-06
in O 0 6.479259440084206e-08
region O 0 6.083323569328059e-07
1 O 0 3.078595511851745e-07
, O 0 1.691785769253329e-07
and O 0 5.20230116762832e-07
upper O 0 0.006407514214515686
- O 1 0.993046224117279
gastrointestinal O 1 0.995553195476532
manifestations O 0 0.0004387969383969903
were O 0 2.319437726328033e-07
more O 0 2.0286678648062662e-07
severe O 0 0.00037617984344251454
in O 0 3.819903326984786e-07
them O 0 5.527135158445162e-07
. O 0 4.45351861344534e-06

In O 0 2.2367223209585063e-05
individuals O 0 6.809829301346326e-06
with O 0 2.2040301246306626e-06
mutations O 0 1.9913801224902272e-05
in O 0 1.2351685541034385e-07
either O 0 8.969330167474254e-08
region O 0 4.7647441192566475e-07
2 O 0 6.379549972734821e-07
or O 0 9.470266348898804e-08
region O 0 5.424905680229131e-07
3 O 0 3.531085042141058e-07
, O 0 4.6750056270639107e-08
the O 0 2.432184409428828e-08
average O 0 1.659448258806151e-07
number O 0 1.2241344826691147e-08
of O 0 4.683403886929227e-08
adenomas B-Disease 0 0.0016178871737793088
tended O 0 1.4369891232490772e-06
to O 0 2.027551104788472e-08
be O 0 4.1406145179223586e-09
lower O 0 8.759334235719507e-08
than O 0 6.873310365307361e-09
those O 0 1.453118958494315e-08
in O 0 3.6700626537822245e-08
individuals O 0 5.5518860619940824e-08
with O 0 2.3694559558862238e-07
mutations O 0 6.583454251085641e-06
in O 0 5.601581420933144e-08
region O 0 6.984095080042607e-07
1 O 0 7.226743150567927e-07
, O 0 3.6499130828815396e-07
although O 0 8.11838162917411e-07
age O 0 5.125148163642734e-06
at O 0 1.1485940376587678e-05
diagnosis O 0 0.049872029572725296
was O 0 1.2395446447044378e-06
similar O 0 2.66857978203916e-06
. O 0 8.385506589547731e-06

In O 0 1.2601464732142631e-05
all O 0 3.664191581265186e-06
AAPC B-Disease 1 0.9701675176620483
kindreds O 0 0.0016986237606033683
, O 0 6.009917115079588e-07
a O 0 1.7650587835760234e-07
predominance O 0 1.4001174349687062e-05
of O 0 2.7893253218280734e-07
right O 0 1.5737232388346456e-05
- O 1 0.7427676320075989
sided O 1 0.9985249638557434
colorectal B-Disease 1 0.9999953508377075
adenomas I-Disease 1 0.999947190284729
and O 0 0.0014422305393964052
rectal B-Disease 1 0.9997884631156921
polyp I-Disease 1 0.997911274433136
sparing O 0 0.0010629056487232447
was O 0 7.2711086431809235e-06
observed O 0 1.9622410036390647e-05
. O 0 8.86851194081828e-06

No O 0 0.0015591245610266924
desmoid B-Disease 1 0.9969478249549866
tumors I-Disease 1 0.9994468092918396
were O 0 2.1330677100195317e-06
found O 0 1.2932330264447955e-06
in O 0 8.401535183111264e-07
these O 0 2.146702172467485e-06
kindreds O 0 0.001479892642237246
. O 0 1.8599737813929096e-05

Our O 0 2.676460826478433e-05
data O 0 9.227966074831784e-06
suggest O 0 4.659694241126999e-06
that O 0 1.608927817642325e-07
, O 0 1.6169387606623786e-07
in O 0 7.284048137989885e-07
AAPC B-Disease 1 0.9949743747711182
families O 0 2.3391285139950924e-06
, O 0 8.585261923599319e-08
the O 0 2.360845918758514e-08
location O 0 8.011338792357492e-08
of O 0 2.5017822480322138e-08
the O 0 2.699783863135963e-07
APC B-Disease 0 0.00022545566025655717
mutation O 0 4.679709309129976e-05
may O 0 2.800308948280872e-06
partially O 0 1.6599116861470975e-05
predict O 0 1.613790482224431e-05
specific O 0 3.6299979910836555e-07
phenotypic O 0 9.242752639693208e-06
expression O 0 4.790510047314456e-06
. O 0 5.402233455242822e-06

This O 0 4.219701622787397e-06
should O 0 1.1740744412236381e-06
help O 0 6.434505053221073e-07
in O 0 3.7253627738209616e-08
the O 0 2.484188676987742e-08
design O 0 9.399006017929423e-08
of O 0 4.1907675552010915e-08
tailored O 0 1.693345620878972e-05
clinical O 0 0.00020150633645243943
- O 0 0.007398855872452259
management O 0 5.446302384370938e-05
protocols O 0 1.3468580618791748e-05
in O 0 7.850872663084374e-08
this O 0 3.802840708999611e-08
subset O 0 3.7458660244737985e-06
of O 0 2.8511967684607953e-06
FAP B-Disease 1 0.9290692210197449
patients O 0 0.0012277569621801376
. O 0 2.8522058528324123e-06
. O 0 8.208666258724406e-06

Wilms B-Disease 1 0.9954594969749451
' I-Disease 0 0.06601730734109879
tumor I-Disease 0 0.016961773857474327
1 O 0 1.4331611737361527e-06
and O 0 2.6743094849734916e-07
Dax O 0 0.0003027568745892495
- O 0 2.2555661416845396e-05
1 O 0 3.342456125210447e-07
modulate O 0 5.540029633266386e-06
the O 0 1.2694718520833703e-07
orphan O 0 6.76512427162379e-05
nuclear O 0 3.176806785631925e-06
receptor O 0 5.1971710490761325e-06
SF O 0 0.0008292477577924728
- O 0 1.0160158126382157e-05
1 O 0 8.939339579683292e-08
in O 0 4.179815249472085e-08
sex O 0 4.121879726426414e-07
- O 0 2.685079198272433e-05
specific O 0 4.2522634657871095e-07
gene O 0 2.8997144454478985e-06
expression O 0 3.083036972384434e-06
. O 0 3.646761115305708e-06

Products O 0 3.670717705972493e-05
of O 0 4.816345608560368e-06
steroidogenic O 0 0.01371402945369482
factor O 0 1.2580162547237705e-05
1 O 0 1.2809693998860894e-06
( O 0 9.13293149551464e-07
SF O 0 0.02936648204922676
- O 0 0.00012531314860098064
1 O 0 9.087249281947152e-07
) O 0 4.4149797417958325e-07
and O 0 2.2691535832564114e-06
Wilms B-Disease 1 0.9941239953041077
tumor I-Disease 0 0.010196268558502197
1 O 0 1.3019511015954777e-06
( O 0 9.933899036695948e-07
WT1 O 0 0.0006430257926695049
) O 0 1.1990609039003175e-07
genes O 0 6.516663120237354e-08
are O 0 5.8726432605737955e-09
essential O 0 3.7289527909933895e-08
for O 0 3.544725402093718e-08
mammalian O 0 3.2107923289004248e-06
gonadogenesis O 0 0.00028266856679692864
prior O 0 5.278297408040089e-07
to O 0 2.6245302819916105e-07
sexual O 0 3.4879842587542953e-06
differentiation O 0 3.472941170912236e-05
. O 0 1.1012614777428098e-05

In O 0 2.1325478883227333e-05
males O 0 2.638634032336995e-05
, O 0 3.8811112972325645e-06
SF O 0 0.11181022971868515
- O 0 0.00011784680100390688
1 O 0 5.931589157626149e-07
participates O 0 1.0511205346119823e-06
in O 0 7.09490493022713e-08
sexual O 0 4.450723167792603e-07
development O 0 1.1804138466686709e-07
by O 0 3.7449758849561476e-08
regulating O 0 7.294656256817689e-07
expression O 0 1.1512796049828466e-07
of O 0 3.4768540047025454e-08
the O 0 2.0098939046420128e-07
polypeptide O 0 0.00013321114238351583
hormone O 0 5.339362905942835e-05
Mullerian O 0 0.005130938719958067
inhibiting O 0 6.486794882221147e-05
substance O 0 1.0563184332568198e-05
( O 0 3.7167937989579514e-06
MIS O 0 0.005858779884874821
) O 0 2.0265479179215617e-06
. O 0 3.512432158458978e-06

Here O 0 1.8348335288465023e-05
, O 0 1.756136043695733e-06
we O 0 4.996967390979989e-07
show O 0 5.338062010196154e-07
that O 0 1.9953030516717263e-07
WT1 O 0 0.0006596306338906288
- O 0 0.00035374853177927434
KTS O 0 0.012014288455247879
isoforms O 0 7.866827331781678e-07
associate O 0 5.866214678462711e-07
and O 0 1.1529178323144151e-07
synergize O 0 0.000447173195425421
with O 0 8.753628435442806e-07
SF O 0 0.28741830587387085
- O 0 0.0002046381850959733
1 O 0 1.1233672694288543e-06
to O 0 4.3183121078982367e-07
promote O 0 4.548585366137559e-06
MIS O 0 0.0036313997115939856
expression O 0 9.060994671017397e-06
. O 0 7.126449418137781e-06

In O 0 2.252275044156704e-05
contrast O 0 4.874339356319979e-05
, O 0 1.3213218153396156e-05
WT1 O 0 0.22232317924499512
missense O 0 0.006342599168419838
mutations O 0 0.00035796742304228246
, O 0 4.1336184608553594e-07
associated O 0 4.65045957298571e-07
with O 0 1.7191931078741618e-07
male B-Disease 0 6.972422852413729e-06
pseudohermaphroditism I-Disease 1 0.5819216966629028
in O 0 4.358824753580848e-06
Denys B-Disease 1 0.9698724150657654
- I-Disease 1 0.9967569708824158
Drash I-Disease 1 0.9997884631156921
syndrome I-Disease 1 0.9999234676361084
, O 0 1.5720228248028434e-06
fail O 0 1.0995331649610307e-05
to O 0 1.3141180943421205e-07
synergize O 0 0.0005741548957303166
with O 0 1.3216822480899282e-06
SF O 0 0.41476738452911377
- O 0 0.0003025450569111854
1 O 0 9.119406058744062e-06
. O 0 1.0090729119838215e-05

Additionally O 0 6.165884406073019e-05
, O 0 1.5280775187420659e-06
the O 0 5.791024477730389e-07
X O 0 0.00022293842630460858
- O 0 0.000392824033042416
linked O 0 8.310766133945435e-06
, O 0 9.80914691695034e-08
candidate O 0 1.4679773130410467e-07
dosage O 0 1.233238776876533e-06
- O 0 6.196889444254339e-06
sensitive O 0 4.815730676455132e-07
sex O 0 3.425347756547126e-07
- O 0 4.0000963053898886e-05
reversal O 0 5.024960501032183e-06
gene O 0 3.0202363632270135e-07
, O 0 4.061010372424789e-08
Dax O 0 7.148632721509784e-05
- O 0 5.539453923120163e-06
1 O 0 1.1780622344303993e-07
, O 0 3.903670275917648e-08
antagonizes O 0 3.3798644381022314e-06
synergy O 0 1.2136607665524934e-06
between O 0 2.0405525447131367e-07
SF O 0 0.010715470649302006
- O 0 2.8150463549536653e-05
1 O 0 2.050853424861998e-07
and O 0 1.551423451928713e-07
WT1 O 0 0.0004254599043633789
, O 0 3.7365499139241365e-08
most O 0 9.792710642386737e-09
likely O 0 2.099999996119095e-08
through O 0 6.865644941456139e-09
a O 0 1.1847824943345131e-08
direct O 0 2.8096659221432674e-08
interaction O 0 1.2417673644904426e-07
with O 0 2.9360816711232474e-07
SF O 0 0.11995475739240646
- O 0 0.00040478393202647567
1 O 0 6.70966483085067e-06
. O 0 5.2201653488737065e-06

We O 0 1.5510284356423654e-05
propose O 0 3.255043338867836e-05
that O 0 6.596033017558511e-07
WT1 O 0 0.0003273142210673541
and O 0 6.923455657670274e-07
Dax O 0 0.002740380121394992
- O 0 0.0001447248796466738
1 O 0 6.512842674055719e-07
functionally O 0 2.064813998003956e-06
oppose O 0 2.2248961784043786e-07
each O 0 8.555147701372334e-09
other O 0 8.292645681251543e-09
in O 0 5.870876762514854e-08
testis O 0 0.00012246784172020853
development O 0 1.345390501228394e-07
by O 0 5.559791560472149e-08
modulating O 0 1.87758487300016e-05
SF O 0 0.00268415454775095
- O 0 1.3366904568101745e-05
1 O 0 3.900586023064534e-07
- O 0 2.5604036636650562e-05
mediated O 0 2.3890359443612397e-05
transactivation O 0 0.00017071887850761414
. O 0 1.7727880958773312e-06
. O 0 5.0264561650692485e-06

A O 0 6.842697621323168e-05
mouse O 0 0.00026348591200076044
model O 0 2.8316801035543904e-05
for O 0 3.2721422030590475e-05
Prader B-Disease 1 0.9998286962509155
- I-Disease 1 0.9998737573623657
Willi I-Disease 1 0.9999877214431763
syndrome I-Disease 1 0.9999775886535645
imprinting O 1 0.8268327713012695
- O 0 0.49702370166778564
centre O 0 0.001034567249007523
mutations O 0 0.0005180797888897359
. O 0 1.3207927622715943e-05

Imprinting O 0 0.0010641933185979724
in O 0 4.129770331928739e-06
the O 0 2.014277924899943e-06
15q11 O 0 0.00036327377893030643
- O 0 0.000985130202025175
q13 O 0 0.00040378456469625235
region O 0 2.592556256786338e-06
involves O 0 1.2135634506194037e-06
an O 0 9.763414965391348e-08
imprinting O 0 5.3712399676442146e-05
centre O 0 3.248562279623002e-06
( O 0 3.4541233162599383e-07
IC O 0 2.4289163775392808e-05
) O 0 4.988957869045407e-08
, O 0 1.440021524246049e-08
mapping O 0 1.6586886886216234e-07
in O 0 8.475111279437897e-09
part O 0 1.816923678177318e-08
to O 0 1.3788985064877579e-08
the O 0 2.956784506125132e-08
promoter O 0 5.305778813635698e-06
and O 0 4.843402123810847e-08
first O 0 1.0798316907312255e-07
exon O 0 1.084765335690463e-05
of O 0 1.0534466809986043e-06
SNRPN O 0 0.00902965385466814
. O 0 1.3448211575450841e-05

Deletion O 0 0.0006391012575477362
of O 0 1.959042037924519e-06
this O 0 8.567624831812282e-07
IC O 0 0.0001837642485043034
abolishes O 0 6.750747706973925e-05
local O 0 1.027144548970682e-06
paternally O 0 7.40419200155884e-05
derived O 0 1.0309345270798076e-06
gene O 0 8.45475312871713e-07
expression O 0 2.414843720544013e-07
and O 0 1.1460083726433368e-07
results O 0 2.4817650228214916e-06
in O 0 1.9051687559112906e-05
Prader B-Disease 1 0.9999637603759766
- I-Disease 1 0.9999666213989258
Willi I-Disease 1 0.9999966621398926
syndrome I-Disease 1 0.9999940395355225
( O 0 0.002126309322193265
PWS B-Disease 1 0.9991757273674011
) O 0 2.4584520360804163e-05
. O 0 1.3307657354744151e-05

We O 0 7.701821232330985e-06
have O 0 5.811760388496623e-07
created O 0 6.12918825027009e-07
two O 0 2.0052664240211016e-07
deletion O 0 9.96267917798832e-05
mutations O 0 2.490240876795724e-05
in O 0 3.337713394557795e-07
mice O 0 9.129571844823658e-05
to O 0 3.577256109110749e-07
understand O 0 1.2186073035991285e-05
PWS B-Disease 1 0.9062610864639282
and O 0 1.1286640955177063e-07
the O 0 5.186409524071678e-08
mechanism O 0 2.1983400699809863e-07
of O 0 6.074916569787092e-08
this O 0 3.7358230997597275e-07
IC O 0 0.0005281858611851931
. O 0 1.0326750270905904e-05

Mice O 0 0.044550951570272446
harbouring O 0 0.010411491617560387
an O 0 7.70210044720443e-06
intragenic O 0 0.045723751187324524
deletion O 0 0.0004860269546043128
in O 0 1.1899072660526144e-06
Snrpn O 0 0.0012326361611485481
are O 0 1.4959960026317276e-07
phenotypically O 0 2.708492502279114e-05
normal O 0 1.1279038290012977e-06
, O 0 2.6309430722903926e-07
suggesting O 0 2.134148189725238e-06
that O 0 1.037683858839955e-07
mutations O 0 2.81856523542956e-06
of O 0 1.253856538596665e-07
SNRPN O 0 0.006339918822050095
are O 0 5.49663212723317e-08
not O 0 5.657156165739252e-08
sufficient O 0 5.393077913140587e-07
to O 0 7.439169280587521e-07
induce O 0 0.0005057691014371812
PWS B-Disease 1 0.9864211082458496
. O 0 2.066401793854311e-05

Mice O 0 0.002057582139968872
with O 0 2.200262315454893e-06
a O 0 4.744592843053397e-07
larger O 0 1.4041485201232717e-06
deletion O 0 5.7882742112269625e-05
involving O 0 1.6662972939229803e-06
both O 0 1.8580557537006825e-07
Snrpn O 0 0.0003046730998903513
and O 0 1.9915256643798784e-07
the O 0 2.433046120131621e-07
putative O 0 0.00014582127914763987
PWS O 1 0.9393194913864136
- O 0 0.0010508423438295722
IC O 0 0.0005658347508870065
lack O 0 9.920617003444931e-07
expression O 0 8.473272572473434e-08
of O 0 1.6960999715820435e-08
the O 0 1.1608315730882168e-07
imprinted O 0 3.4752196370391175e-05
genes O 0 1.60308002250531e-06
Zfp127 O 0 0.00010205033322563395
( O 0 1.4574150952739728e-07
mouse O 0 9.533768547953514e-07
homologue O 0 1.0017361091740895e-06
of O 0 5.807228831145039e-08
ZNF127 O 0 0.0005616146954707801
) O 0 1.9182090227332083e-07
, O 0 1.331340513388568e-07
Ndn O 0 0.00011664271733025089
and O 0 1.5651878015887633e-07
Ipw O 0 5.1781771617243066e-05
, O 0 1.2701269724857411e-07
and O 0 1.490820267235904e-07
manifest O 0 4.157320745434845e-06
several O 0 2.4597875381004997e-07
phenotypes O 0 0.0002389088476775214
common O 0 1.0984871551045217e-05
to O 0 2.0039766241097823e-05
PWS B-Disease 1 0.9989731311798096
infants O 0 0.019333846867084503
. O 0 3.372377614141442e-05

These O 0 7.560278845630819e-06
data O 0 8.631770469946787e-06
demonstrate O 0 3.945291609852575e-06
that O 0 7.96236250266702e-08
both O 0 2.700632784069512e-08
the O 0 1.6143880898766838e-08
position O 0 3.0675401774260536e-08
of O 0 1.3172933854832536e-08
the O 0 4.996004676627308e-08
IC O 0 1.665037234488409e-05
and O 0 2.609542448794855e-08
its O 0 1.4117488511544707e-08
role O 0 5.298667815623048e-08
in O 0 1.1229261076550756e-08
the O 0 1.5702285693919293e-08
coordinate O 0 4.6093435912553105e-07
expression O 0 3.86056875356644e-08
of O 0 1.3552104327629877e-08
genes O 0 8.575507592922804e-08
is O 0 4.677161768995575e-09
conserved O 0 2.9638311360713487e-08
between O 0 4.165743661133092e-08
mouse O 0 5.180856078368379e-06
and O 0 7.23991959716841e-08
human O 0 1.0853056409132478e-07
, O 0 2.6487466442404184e-08
and O 0 3.0337343304154274e-08
indicate O 0 2.425986167509109e-07
that O 0 1.1650177711430842e-08
the O 0 2.617088945555679e-08
mouse O 0 3.1348715765489032e-06
is O 0 1.2770494883795891e-08
a O 0 1.704154861670304e-08
suitable O 0 1.3267155907215056e-07
model O 0 1.274798933081911e-07
system O 0 1.1388948450985481e-07
in O 0 2.076056837552187e-08
which O 0 2.4964483813505467e-08
to O 0 3.7211659531521946e-08
investigate O 0 4.861306592829351e-07
the O 0 3.0132621731127074e-08
molecular O 0 2.28684598369e-06
mechanisms O 0 3.3435560453654034e-07
of O 0 1.9865456835077566e-08
imprinting O 0 1.7962813217309304e-05
in O 0 5.1492691000021296e-08
this O 0 1.9230917303048045e-08
region O 0 1.9288965802388702e-07
of O 0 3.361011025049265e-08
the O 0 1.8551997982285684e-07
genome O 0 8.702431841811631e-06
. O 0 7.645354003216198e-07
. O 0 2.9373550205491483e-06

Mutations O 0 0.0005524062435142696
of O 0 2.6787331535160774e-06
the O 0 1.2856152125095832e-06
ATM O 0 0.0001288138737436384
gene O 0 1.2717617210000753e-05
detected O 0 4.775894467456965e-06
in O 0 2.9999239359312924e-07
Japanese O 0 0.00013548809511121362
ataxia B-Disease 1 0.999957799911499
- I-Disease 1 0.9999277591705322
telangiectasia I-Disease 1 0.9999920129776001
patients O 0 0.36729055643081665
: O 0 9.850476999417879e-06
possible O 0 8.559360367144109e-07
preponderance O 0 4.5825610868632793e-05
of O 0 3.874170673157096e-08
the O 0 7.496171861021139e-08
two O 0 1.9526875405517785e-07
founder O 0 0.00024523920728825033
mutations O 0 8.991739014163613e-05
4612del165 O 0 0.0001673738588578999
and O 0 2.4179905722121475e-06
7883del5 O 0 0.0006479917792603374
. O 0 8.112569048535079e-06

The O 0 2.518551809771452e-05
ATM O 0 0.00036893642391078174
( O 0 4.613618784787832e-06
A O 0 1.0950950127153192e-05
- O 0 0.22391055524349213
T O 1 0.9957451224327087
, O 0 3.1718541322334204e-06
mutated O 0 2.0816232790821232e-05
) O 0 4.963000606039714e-07
gene O 0 8.859508398018079e-07
on O 0 2.9550488989116275e-07
human O 0 2.9319928671611706e-06
chromosome O 0 0.00020972783386241645
11q22 O 0 0.0008572523365728557
. O 0 8.314571459777653e-06

3 O 0 8.159150456776842e-05
has O 0 3.2798129723232705e-06
recently O 0 7.156893843784928e-06
been O 0 2.5841782758107e-07
identified O 0 3.6310299833530735e-07
as O 0 2.945594168579646e-08
the O 0 8.68596501391039e-08
gene O 0 1.4251075981519534e-06
responsible O 0 5.401834073381906e-07
for O 0 1.94526563745967e-07
the O 0 3.180735802743584e-06
human O 0 0.0006927185459062457
recessive B-Disease 1 0.9985798597335815
disease I-Disease 1 0.9998070597648621
ataxia B-Disease 1 0.9999772310256958
- I-Disease 1 0.9994521737098694
telangiectasia I-Disease 1 0.9999035596847534
( O 0 2.4385202777921222e-05
A B-Disease 0 3.9973932871362194e-05
- I-Disease 0 0.39104753732681274
T I-Disease 1 0.9857207536697388
) O 0 1.2810971384169534e-05
. O 0 8.552549843443558e-06

In O 0 7.88844954513479e-06
order O 0 2.0107368072785903e-06
to O 0 2.493700606009952e-07
define O 0 1.4378213109011995e-06
the O 0 1.0423355689681557e-07
types O 0 7.261936616487219e-07
of O 0 1.7066632835849305e-06
disease O 1 0.6992418766021729
- O 0 0.1820932775735855
causing O 0 0.0003853557864204049
ATM O 0 0.000193158644833602
mutations O 0 4.90553475174238e-06
in O 0 5.930820634603151e-08
Japanese O 0 1.5401710697915405e-06
A B-Disease 0 1.916980545502156e-05
- I-Disease 1 0.9863640666007996
T I-Disease 1 0.9999468326568604
patients O 0 0.00029205757891759276
as O 0 2.4928176856064965e-08
well O 0 1.4731812214563433e-08
as O 0 9.512407750378316e-09
to O 0 1.5992146273902108e-08
look O 0 1.2592502685038198e-07
for O 0 2.3046133890147757e-08
possible O 0 1.4071001430693286e-07
mutational O 0 3.8777045119786635e-05
hotspots O 0 1.5119421732379124e-06
, O 0 2.732013548722989e-08
reverse O 0 3.9381805549965065e-07
- O 0 4.488832473725779e-06
transcribed O 0 5.920467174291844e-07
RNA O 0 1.7875773039577325e-07
derived O 0 3.7968760580042726e-08
from O 0 1.863661402978778e-08
ten O 0 1.299810605814855e-07
patients O 0 5.323655841493746e-06
belonging O 0 2.4986235303003923e-07
to O 0 1.6927710788650074e-08
eight O 0 3.880597532202046e-08
unrelated O 0 6.260729605855886e-07
Japanese O 0 1.0736895319496398e-06
A B-Disease 0 9.008846973301843e-06
- I-Disease 1 0.7564204335212708
T I-Disease 1 0.9987087249755859
families O 0 4.799609996553045e-06
was O 0 2.2659911280697997e-07
analyzed O 0 6.555353593284963e-07
for O 0 5.26249941401602e-08
mutations O 0 9.112746397477167e-07
by O 0 2.399565701693973e-08
the O 0 4.7733713870456995e-08
restriction O 0 8.864595884006121e-07
endonuclease O 0 5.172580131329596e-05
fingerprinting O 0 2.5375589757459238e-05
method O 0 3.4732461244857404e-06
. O 0 4.117001935810549e-06

As O 0 9.794497600523755e-06
has O 0 1.6235070461334544e-06
been O 0 2.5087570065807085e-07
reported O 0 1.2847583548136754e-06
by O 0 1.3413013277840946e-07
others O 0 3.780130555242067e-07
, O 0 4.324316478232504e-07
mutations O 0 4.024725058116019e-06
that O 0 2.0743192052918857e-08
lead O 0 2.1353952206482063e-07
to O 0 3.355182442987825e-08
exon O 0 5.138298547535669e-06
skipping O 0 3.654779220596538e-06
or O 0 3.807965924806922e-07
premature O 0 3.1126099202083424e-05
protein O 0 6.737279818480602e-07
truncation O 0 9.581453923601657e-06
were O 0 3.450283614370164e-08
also O 0 4.1799747663162634e-08
predominant O 0 3.9319471056842303e-07
in O 0 1.6872485275598592e-07
our O 0 1.1008381761712371e-06
mutants O 0 8.798578346613795e-05
. O 0 5.167109065951081e-06

Six O 0 1.1517518942127936e-05
different O 0 1.1127092420792906e-06
mutations O 0 3.431793811614625e-05
were O 0 1.1224490492622863e-07
identified O 0 1.877621542689667e-07
on O 0 3.004745252610519e-08
12 O 0 7.593885698042868e-08
of O 0 2.5328853681116925e-08
the O 0 1.7521584538826573e-07
16 O 0 2.2674878437101142e-06
alleles O 0 1.357110795652261e-05
examined O 0 4.155316491960548e-05
. O 0 7.810164788679685e-06

Four O 0 1.0822873264260124e-05
were O 0 1.2340799457888352e-06
deletions O 0 4.266488031134941e-05
involving O 0 4.6777131501585245e-06
a O 0 7.408160058730573e-07
loss O 0 6.162191857583821e-05
of O 0 5.935165958703692e-08
a O 0 5.923833157339686e-08
single O 0 1.0213896217692309e-07
exon O 0 1.1670309504552279e-05
exon O 0 2.4344173652934842e-05
7 O 0 5.39738493898767e-07
, O 0 4.7767596100811716e-08
exon O 0 3.7703480302297976e-06
16 O 0 1.2890670575416152e-07
, O 0 5.1809909251687714e-08
exon O 0 6.121248588897288e-06
33 O 0 7.60255090881401e-07
or O 0 2.3318246178405388e-07
exon O 0 2.2912359781912528e-05
35 O 0 3.7120539673196618e-06
. O 0 4.439033546077553e-06

The O 0 4.901419288216857e-06
others O 0 1.0270435950587853e-06
were O 0 1.3179133873109095e-07
minute O 0 3.6743952591677953e-07
deletions O 0 3.7008276194683276e-06
, O 0 1.927892441244694e-07
4649delA O 0 2.2600335796596482e-05
in O 0 1.1133168698052032e-07
exon O 0 1.655594132898841e-05
33 O 0 1.2710759165202035e-06
and O 0 3.0241389481489023e-07
7883del5 O 0 5.80388332309667e-05
in O 0 6.513345738312637e-07
exon O 0 8.990675996756181e-05
55 O 0 1.128874282585457e-05
. O 0 7.924068086140323e-06

The O 0 2.620153099996969e-05
mutations O 0 0.000321186293149367
4612del165 O 0 0.00047462646034546196
and O 0 1.0457054031576263e-06
7883del5 O 0 0.00012777587107848376
were O 0 6.048279033166182e-08
found O 0 2.2416251965751144e-08
in O 0 7.229980614198439e-09
more O 0 4.017433496983358e-09
than O 0 6.376287053910801e-09
two O 0 1.6837869765140567e-08
unrelated O 0 9.306553465648904e-07
families O 0 4.2493769569773576e-07
; O 0 4.343345665347442e-07
44 O 0 2.9566896841970447e-07
% O 0 8.625869440948009e-08
( O 0 6.312446032552543e-08
7 O 0 9.040315518404896e-08
of O 0 1.2696515838683808e-08
16 O 0 1.2754689748817327e-07
) O 0 2.241676533287773e-08
of O 0 6.422780085557633e-09
the O 0 1.815797645576822e-08
mutant O 0 2.2669298687105766e-06
alleles O 0 2.8338155289020506e-07
had O 0 2.0151713187033238e-08
one O 0 4.676242504331185e-09
of O 0 1.4777713275293536e-08
the O 0 7.400026902359969e-08
two O 0 5.603204726867261e-07
mutations O 0 7.247585745062679e-05
. O 0 4.950859420205234e-06

The O 0 2.8774431484634988e-05
4612del165 O 0 0.004005462396889925
mutations O 0 8.150564099196345e-05
in O 0 1.8682673896819324e-07
three O 0 4.743031922771479e-08
different O 0 1.809142879949377e-08
families O 0 2.014687794371639e-07
were O 0 1.2432574969523102e-08
all O 0 8.658007644157806e-09
ascribed O 0 4.5487752231565537e-07
to O 0 9.710740656032613e-09
the O 0 7.648451649799881e-09
same O 0 2.748561378496106e-08
T O 0 0.00015921129670459777
- O 0 6.141155608929694e-05
- O 0 0.00010559668589849025
> O 0 5.022411642130464e-06
A O 0 2.917803421098597e-08
substitution O 0 6.03113718966597e-08
at O 0 5.5494723483207054e-08
the O 0 4.7489066901107435e-08
splice O 0 2.2432850528275594e-05
donor O 0 3.598093371692812e-06
site O 0 1.0625740287650842e-06
in O 0 5.206534865465073e-07
intron O 0 0.0005783428205177188
33 O 0 1.276636976399459e-05
. O 0 7.984100193425547e-06

Microsatellite O 0 0.005374880041927099
genotyping O 0 0.0011381653603166342
around O 0 5.02975035487907e-06
the O 0 1.8550489357949118e-06
ATM O 0 0.000159528135554865
locus O 0 7.497423212043941e-05
also O 0 4.475832042771799e-07
indicated O 0 1.2891289316030452e-06
that O 0 3.66255221706524e-08
a O 0 8.052932543023417e-08
common O 0 2.0531010704871733e-06
haplotype O 0 0.0004743704339489341
was O 0 1.672386815698701e-07
shared O 0 1.2621573830529087e-07
by O 0 6.020000853368401e-08
the O 0 9.314947391203532e-08
mutant O 0 7.341853688558331e-06
alleles O 0 9.9848273293901e-07
in O 0 1.0201318190183883e-07
both O 0 6.931370535312453e-07
mutations O 0 3.602339347708039e-05
. O 0 3.3070250538003165e-06

This O 0 1.1373712368367705e-05
suggests O 0 2.7022075300919823e-05
that O 0 4.883755195805861e-07
these O 0 1.217809852960272e-07
two O 0 2.848023257229215e-07
founder O 0 0.0007538329809904099
mutations O 0 0.0007078031776472926
may O 0 1.619086447135487e-06
be O 0 2.5247823387530843e-08
predominant O 0 3.3916879260686983e-07
among O 0 2.4821480337777757e-07
Japanese O 0 3.5025645956920926e-06
ATM O 0 0.0002622100873850286
mutant O 0 0.00015191374404821545
alleles O 0 2.9590202757390216e-05
. O 0 8.392788004130125e-06

W474C O 0 0.0013396419817581773
amino O 0 2.2873344278195873e-05
acid O 0 9.268447684007697e-06
substitution O 0 1.4814394262430142e-06
affects O 0 1.329441602138104e-06
early O 0 9.388686095235244e-08
processing O 0 7.873126151025645e-08
of O 0 7.746021601917619e-09
the O 0 1.0955649720756355e-08
alpha O 0 8.887435853921488e-08
- O 0 5.116564807394752e-07
subunit O 0 9.753158991543387e-08
of O 0 1.193221077500084e-08
beta O 0 3.9365511383948615e-07
- O 0 6.185812526382506e-05
hexosaminidase O 0 0.00022369151702150702
A O 0 7.823681613672306e-08
and O 0 5.4375291824726446e-08
is O 0 5.878272091308645e-08
associated O 0 3.922333462469396e-07
with O 0 1.1595330988711794e-06
subacute O 1 0.9938490986824036
G B-Disease 0 0.32638800144195557
( I-Disease 0 4.115471256227465e-06
M2 I-Disease 0 0.0002376132906647399
) I-Disease 0 3.649648760983837e-06
gangliosidosis I-Disease 0 0.00041232185321860015
. O 0 6.9826096478209365e-06

Mutations O 0 0.0015447094338014722
in O 0 2.8844372081948677e-06
the O 0 1.175837041955674e-06
HEXA O 0 0.004588918760418892
gene O 0 1.5705422811151948e-06
, O 0 6.675784192111678e-08
encoding O 0 4.744008919033149e-08
the O 0 1.1274049249720974e-08
alpha O 0 6.876748415152178e-08
- O 0 5.344215310287836e-07
subunit O 0 1.102646933759388e-07
of O 0 2.4813758159325516e-08
beta O 0 6.777472663088702e-07
- O 0 0.00012452043301891536
hexosaminidase O 0 0.00027489697095006704
A O 0 1.275833767522272e-07
( O 0 1.0971923103397785e-07
Hex O 0 4.223799805913586e-06
A O 0 5.324349672264361e-08
) O 0 3.878325927075821e-08
, O 0 1.2572314744829782e-08
that O 0 1.1073126415794832e-08
abolish O 0 4.944801617057237e-07
Hex O 0 4.769149200001266e-06
A O 0 1.2871250021362357e-07
enzyme O 0 2.7425267035141587e-06
activity O 0 2.172630274799303e-06
cause O 0 0.0003643613890744746
Tay B-Disease 1 0.9999405145645142
- I-Disease 1 0.999863862991333
Sachs I-Disease 1 0.9999661445617676
disease I-Disease 1 0.9794486165046692
( O 0 8.378121492569335e-06
TSD B-Disease 0 0.17069001495838165
) O 0 4.1288549823548237e-07
, O 0 1.5792369367773063e-07
the O 0 3.762586118227773e-07
fatal O 0 0.0074602412059903145
infantile B-Disease 0 0.010391024872660637
form I-Disease 0 5.337323614185152e-07
of I-Disease 0 2.445391089622717e-07
G I-Disease 0 0.012919796630740166
( I-Disease 0 1.3847463833371876e-06
M2 I-Disease 0 0.00013502829824574292
) I-Disease 0 6.749981480425049e-07
gangliosidosis I-Disease 0 7.111373270163313e-05
, I-Disease 0 2.534696079692367e-07
Type I-Disease 0 2.3553914161311695e-06
1 I-Disease 0 2.5580795863788808e-06
. O 0 4.205335244478192e-06

Less O 0 0.00030652323039248586
severe O 1 0.5684634447097778
, O 0 3.8474739994853735e-05
subacute O 1 0.9911255240440369
( O 0 0.00011402665404602885
juvenile O 0 0.4391816556453705
- O 1 0.9857327938079834
onset O 1 0.9987071752548218
) O 0 3.803267463808879e-05
and O 0 4.0902064938563854e-05
chronic O 1 0.9996994733810425
( O 0 5.590433829638641e-06
adult O 0 7.748662028461695e-06
- O 0 0.22496920824050903
onset O 1 0.6311475038528442
) O 0 4.77790308650583e-07
variants O 0 3.4971066042999155e-07
are O 0 2.8231275095436104e-08
characterized O 0 2.147703526134137e-06
by O 0 1.847297070867171e-08
a O 0 2.610747174003336e-08
broad O 0 8.119667427308741e-07
spectrum O 0 1.0979559874613187e-06
of O 0 2.833307632954529e-07
clinical O 0 0.0003447400813456625
manifestations O 0 5.312039502314292e-05
and O 0 1.9548936336377665e-07
are O 0 2.994515213572413e-08
associated O 0 2.1763847257716407e-07
with O 0 6.49750049319664e-08
residual O 0 1.1316381460346747e-05
levels O 0 1.833320339983402e-07
of O 0 4.1601062150675716e-08
Hex O 0 2.054490141745191e-05
A O 0 5.821401600769605e-07
enzyme O 0 8.352240911335684e-06
activity O 0 3.8030332234484376e-06
. O 0 4.466022801352665e-06

We O 0 2.0900934032397345e-05
identified O 0 8.175009497790597e-06
a O 0 1.256095060853113e-06
1422 O 0 0.004042407963424921
G O 0 0.0009568663081154227
- O 0 0.0004969792207702994
- O 0 0.002365092048421502
> O 0 0.0003778662357944995
C O 0 1.8343540432397276e-05
( O 0 9.599094141776732e-08
amino O 0 7.98217598685369e-08
acid O 0 4.5609033350046957e-07
W474C O 0 2.2101232843851903e-06
) O 0 8.927800720925916e-09
substitution O 0 7.084786979305591e-09
in O 0 3.097369916105208e-09
the O 0 3.76842601568228e-09
first O 0 7.45679695768331e-09
position O 0 9.203156459136608e-09
of O 0 7.258485368311085e-09
exon O 0 2.0682964532170445e-06
13 O 0 9.456693561560314e-08
of O 0 1.8639884302729115e-08
HEXA O 0 0.0002797665074467659
of O 0 1.5939219721872178e-08
a O 0 2.144881250387698e-08
non O 0 3.9160613596322946e-07
- O 0 0.00019598580547608435
Jewish O 0 1.1401122719689738e-05
proband O 0 0.008213763125240803
who O 0 1.6826717228468624e-06
manifested O 0 8.41946621221723e-06
a O 0 3.7562614352282253e-07
subacute O 0 0.16874465346336365
variant O 0 1.0378356819273904e-05
of O 0 5.71278633287875e-07
G B-Disease 0 0.011319056153297424
( I-Disease 0 3.837926669802982e-06
M2 I-Disease 0 0.00036080871359445155
) I-Disease 0 3.957418357458664e-06
gangliosidosis I-Disease 0 0.00035661275614984334
. O 0 5.670514383382397e-06

On O 0 9.122613846557215e-06
the O 0 2.5242102310585324e-06
second O 0 8.471496585116256e-06
maternally O 0 0.0005815809709019959
inherited O 0 0.01402558758854866
allele O 0 9.98751238512341e-06
, O 0 3.7336468494686414e-07
we O 0 1.2154613671100378e-07
identified O 0 4.790103389495926e-07
the O 0 3.052441854833887e-07
common O 0 5.381325536291115e-05
infantile O 1 0.9991421699523926
disease O 1 0.971656084060669
- O 0 0.04343739524483681
causing O 0 6.304724956862628e-05
4 O 0 1.3314297575561795e-06
- O 0 0.00020327765378169715
bp O 0 6.59715078654699e-05
insertion O 0 3.735228347068187e-06
, O 0 3.05966096902921e-07
+ O 0 1.863123179646209e-05
TATC O 0 0.0007451968849636614
1278 O 0 0.00022994060418568552
, O 0 1.983222261969786e-07
in O 0 2.3006241178791242e-07
exon O 0 3.148191171931103e-05
11 O 0 7.80398022470763e-06
. O 0 5.316695023793727e-06

Pulse O 0 0.0008025022107176483
- O 0 0.0012466551270335913
chase O 0 0.00029795561567880213
analysis O 0 2.6254740532749565e-06
using O 0 5.961498459328141e-07
proband O 0 0.0004340016166679561
fibroblasts O 0 4.4623844587476924e-05
revealed O 0 1.4887502857163781e-06
that O 0 1.6498720611934914e-08
the O 0 2.1431473484767594e-08
W474C O 0 5.430768396763597e-06
- O 0 1.8397462326902314e-06
containing O 0 7.306897487069364e-08
alpha O 0 2.274554162795539e-07
- O 0 3.1199556360661518e-06
subunit O 0 4.0809936763253063e-07
precursor O 0 3.001406128078088e-07
was O 0 2.5054495367271556e-08
normally O 0 1.960669848699581e-08
synthesized O 0 1.0155191887406545e-07
, O 0 1.4295893357996192e-08
but O 0 8.894520675539752e-09
not O 0 8.272361462502431e-09
phosphorylated O 0 3.2855751896931906e-07
or O 0 2.736832804828282e-08
secreted O 0 1.7980116240323696e-07
, O 0 1.7348321890153784e-08
and O 0 1.8884119157291934e-08
the O 0 4.834578604118178e-08
mature O 0 2.166311787732411e-06
lysosomal O 0 0.0005023707053624094
alpha O 0 1.7725616316965898e-06
- O 0 1.608218008186668e-05
subunit O 0 2.935319344032905e-06
was O 0 3.616459878230671e-07
not O 0 3.5535330766833795e-07
detected O 0 1.1851171620946843e-05
. O 0 3.4172276173194405e-06

When O 0 7.168239335442195e-06
the O 0 6.223594937182497e-07
W474C O 0 2.264931572426576e-05
- O 0 6.0428696997405495e-06
containing O 0 2.4087395900096453e-07
alpha O 0 3.9542692320537753e-07
- O 0 3.6316087062004954e-06
subunit O 0 6.619500254601007e-07
was O 0 8.963088049540602e-08
transiently O 0 2.8430347356334096e-06
co O 0 2.9534926397900563e-06
- O 0 4.564115442917682e-06
expressed O 0 4.4418687394909284e-08
with O 0 8.887754532338477e-09
the O 0 1.0189627808188106e-08
beta O 0 7.817536129550717e-08
- O 0 3.2369962355005555e-06
subunit O 0 2.559646077315847e-07
to O 0 1.683924999440478e-08
produce O 0 2.356041584050672e-08
Hex O 0 1.329233668911911e-06
A O 0 5.254475610172449e-08
( O 0 1.2239947011494223e-07
alphabeta O 0 1.5822859495528974e-05
) O 0 3.143592763876768e-08
in O 0 2.8702446641659662e-08
COS O 0 0.0004940517246723175
- O 0 3.601064963731915e-05
7 O 0 6.663977956122835e-07
cells O 0 2.52734395189691e-07
, O 0 1.182010755940155e-08
the O 0 7.708761629032779e-09
mature O 0 9.26844450077624e-08
alpha O 0 1.2412085936830408e-07
- O 0 5.431803401734214e-06
subunit O 0 5.028168175158498e-07
was O 0 3.779275559168127e-08
present O 0 1.871026888977667e-08
, O 0 7.90423904106774e-09
but O 0 4.929571861822524e-09
its O 0 5.964236660105371e-09
level O 0 2.6653388829345204e-08
was O 0 1.1802580246467187e-08
much O 0 1.2449660857782874e-08
lower O 0 9.300992331873204e-08
than O 0 5.519479540083694e-09
that O 0 4.626119931572248e-09
from O 0 6.673974262128013e-09
normal O 0 3.943324955457683e-08
alpha O 0 2.4105091256387823e-07
- O 0 1.4211855159373954e-05
subunit O 0 1.8568084669823293e-06
transfections O 0 0.00010561894305283204
, O 0 3.020858230229351e-08
although O 0 7.959519265909876e-09
higher O 0 8.181491928382911e-09
than O 0 3.4020615213847805e-09
in O 0 9.918561971744566e-09
those O 0 2.83573413639715e-08
cells O 0 6.336849764920771e-07
transfected O 0 1.1129745871585328e-05
with O 0 1.8258729639342164e-08
an O 0 1.844797026251399e-08
alpha O 0 7.730430411356792e-07
- O 0 8.41307919472456e-05
subunit O 0 9.593595677870326e-06
associated O 0 4.688874469138682e-06
with O 0 4.558112777885981e-06
infantile O 0 0.20296317338943481
TSD B-Disease 1 0.6946672797203064
. O 0 3.142282002954744e-05

Furthermore O 0 7.191915210569277e-05
, O 0 1.130201667365327e-06
the O 0 2.5087186372729775e-07
precursor O 0 5.852216986568237e-07
level O 0 6.349335279765e-08
of O 0 1.460301302103062e-08
the O 0 3.031345485737802e-08
W474C O 0 6.8397557697608136e-06
alpha O 0 2.6405049879940634e-07
- O 0 2.88327646558173e-06
subunit O 0 2.868795263566426e-07
was O 0 2.0579491888383927e-08
found O 0 1.216196032771677e-08
to O 0 1.1745628469839176e-08
accumulate O 0 1.1998174613836454e-06
in O 0 1.1294496005120891e-08
comparison O 0 5.349635401330488e-08
to O 0 5.292533966638757e-09
the O 0 7.1219643515973985e-09
normal O 0 4.4397090448455856e-08
alpha O 0 2.2436361746258626e-07
- O 0 6.14788405073341e-06
subunit O 0 1.941843720487668e-06
precursor O 0 4.531267222773749e-06
levels O 0 2.524501496736775e-06
. O 0 2.96911002806155e-06

We O 0 1.906364741444122e-05
conclude O 0 2.3611471988260746e-05
that O 0 4.068201349127776e-07
the O 0 3.633905123479053e-07
1422 O 0 0.0017163489246740937
G O 0 0.001466229441575706
- O 0 0.0019326608162373304
- O 0 0.016748744994401932
> O 0 0.005703978706151247
C O 0 0.0002852915204130113
mutation O 0 3.658856030597235e-06
is O 0 2.7813264580345276e-08
the O 0 2.6875911274260034e-08
cause O 0 3.841783211555594e-07
of O 0 3.794153968783576e-08
Hex B-Disease 0 0.0002829711011145264
A I-Disease 0 1.667589276621584e-05
enzyme I-Disease 1 0.5320447683334351
deficiency I-Disease 1 0.9873002171516418
in O 0 5.709981110157969e-07
the O 0 1.909988895931747e-06
proband O 0 0.006556069944053888
. O 0 1.4389130228664726e-05

The O 0 1.0666958587535191e-05
resulting O 0 7.98231121734716e-06
W474C O 0 4.7384557547047734e-05
substitution O 0 6.100776772655081e-07
clearly O 0 3.8481047681671043e-07
interferes O 0 7.461265454367094e-07
with O 0 3.852198204867818e-08
alpha O 0 2.5624521526879107e-07
- O 0 1.9140604763379088e-06
subunit O 0 2.9175538429626613e-07
processing O 0 1.480583335933261e-07
, O 0 2.4812905508042604e-08
but O 0 9.612942442061012e-09
because O 0 8.461510603297029e-09
the O 0 5.591160423534802e-09
base O 0 4.268551734298853e-08
substitution O 0 6.035763533418503e-08
falls O 0 1.8912360246758908e-06
at O 0 1.6468664654212262e-08
the O 0 4.5964880790450025e-09
first O 0 7.223942777301318e-09
position O 0 1.3555284006372403e-08
of O 0 1.5789622054285246e-08
exon O 0 5.1729025472013745e-06
13 O 0 2.3012977123926248e-07
, O 0 1.0614493106686496e-07
aberrant O 0 3.913555246981559e-06
splicing O 0 4.623551376425894e-06
may O 0 3.724617272382602e-07
also O 0 4.4085712858077386e-08
contribute O 0 1.8046512195724063e-07
to O 0 1.0999581689929983e-07
Hex B-Disease 0 0.0001071328588295728
A I-Disease 0 9.595782103133388e-06
deficiency I-Disease 0 0.24745109677314758
in O 0 2.2445971126217046e-07
this O 0 3.7065282754156215e-07
proband O 0 0.001717225881293416
. O 0 2.1707933228753973e-06
. O 0 6.213013875822071e-06

Two O 0 4.505808465182781e-05
frequent O 0 0.0006139989127404988
missense O 0 0.08774522691965103
mutations O 0 0.06817842274904251
in O 0 0.0009736884967423975
Pendred B-Disease 1 0.9997968077659607
syndrome I-Disease 1 0.9999855756759644
. O 0 0.0003377223911229521

Pendred B-Disease 1 0.9998652935028076
syndrome I-Disease 1 0.9999868869781494
is O 0 0.011962879449129105
an O 0 0.05082818493247032
autosomal B-Disease 1 0.9999871253967285
recessive I-Disease 1 0.9999961853027344
disorder I-Disease 1 0.999998927116394
characterized O 1 0.987146258354187
by O 0 0.00015097713912837207
early O 0 0.004880646709352732
childhood O 1 0.9985674619674683
deafness B-Disease 1 0.9999916553497314
and O 0 0.12237001955509186
goiter B-Disease 1 0.9999635219573975
. O 0 0.0006022648303769529

A O 0 1.4116019883658737e-05
century O 0 1.0323777132725809e-05
after O 0 1.4980860214564018e-06
its O 0 1.8917867805612332e-07
recognition O 0 7.30686224414967e-07
as O 0 4.4929470277565997e-07
a O 0 1.449524916097289e-05
syndrome O 1 0.9997493624687195
by O 0 2.9791135602863505e-06
Vaughan O 0 0.003322478150948882
Pendred O 0 0.06232485547661781
, O 0 2.1903952074353583e-06
the O 0 4.164272922935197e-06
disease O 0 0.32998669147491455
gene O 0 1.4293884305516258e-05
( O 0 9.340840279037366e-07
PDS O 0 8.912169869290665e-05
) O 0 7.907242860483166e-08
was O 0 5.08372828278425e-08
mapped O 0 1.1085065807492356e-06
to O 0 1.9292811259674636e-07
chromosome O 0 3.6040913983015344e-05
7q22 O 0 0.00023047464492265135
- O 0 0.0004000073531642556
q31 O 0 0.0006970416288822889
. O 0 6.244729320314946e-06

1 O 0 2.7649628464132547e-05
and O 0 1.91448953046347e-06
, O 0 6.276871999943978e-07
recently O 0 1.563795763104281e-06
, O 0 1.1862244519988963e-07
found O 0 7.044419447765904e-08
to O 0 5.076306663909236e-08
encode O 0 5.593961986960494e-07
a O 0 4.653454368508392e-07
putative O 0 0.00018514310067985207
sulfate O 0 0.002399792894721031
transporter O 0 0.0018682237714529037
. O 0 1.3672967725142371e-05

We O 0 2.2881220502313226e-05
performed O 0 1.3200950888858642e-05
mutation O 0 6.681651939288713e-06
analysis O 0 2.268349987843976e-07
of O 0 4.615087689785469e-08
the O 0 2.392685871654976e-07
PDS B-Disease 0 0.0037945888470858335
gene O 0 9.950759704224765e-06
in O 0 6.249812827263668e-07
patients O 0 1.5674309906898998e-05
from O 0 6.802338248235174e-08
14 O 0 7.196503020168166e-07
Pendred B-Disease 0 0.0003170078853145242
families O 0 2.9709434556934866e-07
originating O 0 1.0172173858791211e-07
from O 0 1.8462403161834118e-08
seven O 0 5.655343571220328e-08
countries O 0 2.783321839672226e-08
and O 0 1.4908771106547647e-07
identified O 0 1.4720612853125203e-06
all O 0 5.523694426301518e-07
mutations O 0 7.666231249459088e-05
. O 0 8.791268555796705e-06

The O 0 2.8351822038530372e-05
mutations O 0 0.00012731578317470849
include O 0 1.2102844948458369e-06
three O 0 1.6363701149657572e-07
single O 0 2.1988410026096972e-07
base O 0 6.195999162628141e-07
deletions O 0 4.2039960135298315e-06
, O 0 9.739811446252133e-08
one O 0 8.101399373572349e-08
splice O 0 5.826836786582135e-05
site O 0 3.1638694508728804e-06
mutation O 0 2.37317453866126e-06
and O 0 3.1342625561592286e-07
10 O 0 1.7784660713004996e-06
missense O 0 0.0002550713543314487
mutations O 0 8.806418190943077e-05
. O 0 7.417558663291857e-06

One O 0 5.56976483494509e-05
missense O 0 0.031317491084337234
mutation O 0 0.0019116181647405028
( O 0 2.0070137907168828e-05
L236P O 0 0.0018956889398396015
) O 0 1.1378150475138682e-06
was O 0 1.2907339907997084e-07
found O 0 3.968647277474702e-08
in O 0 1.8825895509166912e-08
a O 0 4.535069919597845e-08
homozygous O 0 7.678212341488688e-07
state O 0 1.8616221453271464e-08
in O 0 1.502145607901184e-08
two O 0 3.264495163080028e-08
consanguineous O 0 0.00034633977338671684
families O 0 4.776190394295554e-07
and O 0 3.7662367446955614e-08
in O 0 1.997541509979328e-08
a O 0 1.9721015931395414e-08
heterozygous O 0 8.518190242057244e-08
state O 0 8.11005396172959e-09
in O 0 7.252686895498073e-09
five O 0 1.544923478036253e-08
additional O 0 4.956274324285914e-08
non O 0 7.225247600217699e-07
- O 0 0.0011350730201229453
consanguineous O 0 0.018984083086252213
families O 0 2.501563540135976e-05
. O 0 1.0252126230625436e-05

Another O 0 6.736785871908069e-05
missense O 0 0.014393606223165989
mutation O 0 0.0017409669235348701
( O 0 1.0155818017665297e-05
T416P O 0 0.0009880535071715713
) O 0 4.567179701098212e-07
was O 0 5.966605698404237e-08
found O 0 2.0998598415644665e-08
in O 0 1.0774859227069555e-08
a O 0 2.7565414839614277e-08
homozygous O 0 9.45019905884692e-07
state O 0 3.0671074568999757e-08
in O 0 3.38613794781395e-08
one O 0 2.6042917156132717e-08
family O 0 4.813870759790007e-07
and O 0 3.8805012536613503e-08
in O 0 2.6929839691547386e-08
a O 0 4.429457689525407e-08
heterozygous O 0 3.1218885965245136e-07
state O 0 3.888970567800243e-08
in O 0 5.3690165202624485e-08
four O 0 2.4252295816040714e-07
families O 0 5.349662842490943e-06
. O 0 6.751327418896835e-06

Pendred B-Disease 1 0.9396651387214661
patients O 0 0.00433654710650444
in O 0 6.279386184360192e-07
three O 0 1.690224706862864e-07
non O 0 1.4348008789966116e-06
- O 0 0.0012412515934556723
consanguineous O 0 0.04344030097126961
families O 0 3.3338017146888888e-06
were O 0 6.118920481412715e-08
shown O 0 1.2004269933640899e-07
to O 0 4.455351643173344e-08
be O 0 3.258293190810946e-08
compound O 0 1.2767434327543015e-06
heterozygotes O 0 2.18012082768837e-05
for O 0 3.348604593611526e-07
L236P O 0 0.0001680831628618762
and O 0 2.3928530481498456e-06
T416P O 0 0.000638360099401325
. O 0 1.075763429980725e-05

In O 0 6.997669061092893e-06
total O 0 2.1690384528483264e-06
, O 0 4.575851164645428e-07
one O 0 6.438126121111054e-08
or O 0 4.3012018835497656e-08
both O 0 1.2678366800855656e-08
of O 0 2.3696792084137996e-08
these O 0 6.329771196078582e-08
mutations O 0 3.78712661586178e-06
were O 0 1.2034492513635087e-08
found O 0 2.024035161696247e-08
in O 0 9.005719725507788e-09
nine O 0 2.4975388868142545e-08
of O 0 1.9459870159721504e-08
the O 0 9.80998819954948e-08
14 O 0 1.5468569927179487e-06
families O 0 5.839773621119093e-06
analyzed O 0 2.5204642952303402e-05
. O 0 8.457854164589662e-06

The O 0 5.577142019319581e-06
identification O 0 2.1736082089773845e-06
of O 0 2.840891397681844e-07
two O 0 4.1563080799278396e-07
frequent O 0 3.64908883057069e-05
PDS B-Disease 0 0.02349868230521679
mutations O 0 4.723689562524669e-05
will O 0 1.7451326073114615e-07
facilitate O 0 1.411166863363178e-06
the O 0 7.8282101867444e-07
molecular O 0 0.0021130091045051813
diagnosis O 1 0.823614776134491
of O 0 0.0003040776355192065
Pendred B-Disease 1 0.9999101161956787
syndrome I-Disease 1 0.9999769926071167
. O 0 0.0002018115046666935

Insertional O 0 0.07906945049762726
mutation O 0 0.00024653729633428156
by O 0 2.3551913272967795e-06
transposable O 0 0.00019184919074177742
element O 0 1.9758833786909236e-06
, O 0 6.338294156194024e-07
L1 O 0 0.0004723007732536644
, O 0 2.2580373126857012e-07
in O 0 1.1851355452563439e-07
the O 0 8.273152047877375e-07
DMD B-Disease 1 0.9975726008415222
gene O 0 2.0016312191728503e-05
results O 0 1.7582323152964818e-06
in O 0 4.5016022909294406e-07
X B-Disease 0 0.01226088311523199
- I-Disease 0 0.4732573926448822
linked I-Disease 0 0.07551813125610352
dilated I-Disease 1 0.994450569152832
cardiomyopathy I-Disease 1 0.9996684789657593
. O 0 6.626412505283952e-05

X B-Disease 1 0.7084220051765442
- I-Disease 1 0.956464409828186
linked I-Disease 1 0.9003034234046936
dilated I-Disease 1 0.9996649026870728
cardiomyopathy I-Disease 1 0.9999709129333496
( O 0 0.00032635018578730524
XLDCM B-Disease 0 0.4139110743999481
) O 0 1.2387115475576138e-06
is O 0 8.72099192861242e-08
a O 0 2.217067702758868e-07
clinical O 0 9.267256245948374e-05
phenotype O 0 6.892364763189107e-05
of O 0 1.9004664864041843e-07
dystrophinopathy B-Disease 0 0.0034538533072918653
which O 0 1.2537478255580936e-07
is O 0 8.391248229600023e-08
characterized O 0 1.0239356015517842e-05
by O 0 6.315504492704349e-07
preferential O 0 0.0001692681689746678
myocardial B-Disease 1 0.9986701011657715
involvement I-Disease 0 2.586720984254498e-05
without O 0 2.4268794618365064e-07
any O 0 1.0744899725523283e-07
overt O 0 6.353318440233124e-06
clinical O 0 0.00028955427114851773
signs O 0 3.987733362009749e-05
of O 0 1.938136301760096e-05
skeletal B-Disease 1 0.9997058510780334
myopathy I-Disease 1 0.9999361038208008
. O 0 0.0005248689558357

To O 0 1.1449675184849184e-05
date O 0 6.669613412668696e-06
, O 0 6.076203931115742e-07
several O 0 2.3138106541864545e-07
mutations O 0 1.1211133823962882e-05
in O 0 3.395510077552899e-07
the O 0 5.3459602895600256e-06
Duchenne B-Disease 1 0.9998487234115601
muscular I-Disease 1 0.9997233748435974
dystrophy I-Disease 1 0.9999485015869141
gene O 0 0.003027498023584485
, O 0 2.0576704628183506e-05
DMD O 1 0.9998345375061035
, O 0 2.6518457616475644e-06
have O 0 2.0269872891276464e-07
been O 0 1.230783794881063e-07
identified O 0 1.5012811900305678e-06
in O 0 9.188581202579371e-07
patients O 0 0.0004485085664782673
with O 0 1.980240995180793e-06
XLDCM B-Disease 1 0.5033677220344543
, O 0 5.58395811367518e-07
but O 0 6.536818375479925e-08
a O 0 5.090539900720614e-08
pathogenic O 0 7.171420293161646e-07
correlation O 0 3.937865074021829e-07
of O 0 2.8349177227937616e-08
these O 0 1.5734401870304282e-07
cardiospecific O 0 0.01216100063174963
mutations O 0 2.0833967937505804e-05
in O 0 4.807741333934246e-07
DMD O 1 0.9698382019996643
with O 0 8.787863521320105e-07
the O 0 1.8810120536727482e-06
XLDCM B-Disease 1 0.6280949711799622
phenotype O 0 0.0002881074615288526
has O 0 1.0884006229616716e-07
remained O 0 1.9201090140086308e-07
to O 0 8.512246552072611e-08
be O 0 1.4874871112624533e-07
elucidated O 0 4.981851452612318e-05
. O 0 5.352265361580066e-06

We O 0 1.8755754354060628e-05
report O 0 3.223869043722516e-06
here O 0 1.928392521222122e-07
the O 0 6.405068830872551e-08
identification O 0 6.956005194069803e-08
of O 0 1.6857985229989936e-08
a O 0 3.208090504358552e-08
unique O 0 8.413556429331948e-08
de O 0 1.165810090242303e-06
novo O 0 2.1208788894000463e-06
L1 O 0 2.757842230494134e-05
insertion O 0 9.02890462839423e-07
in O 0 2.6053845303408707e-08
the O 0 4.127936747977401e-08
muscle O 0 6.161989858810557e-06
exon O 0 4.6578506953665055e-06
1 O 0 3.472725609299232e-07
in O 0 2.511306433916616e-07
DMD O 1 0.9763398170471191
in O 0 6.36211268556508e-07
three O 0 1.836184537751251e-06
XLDCM B-Disease 1 0.8393436074256897
patients O 0 8.079101826297119e-05
from O 0 5.3614638062526865e-08
two O 0 1.0160926677826865e-07
unrelated O 0 6.273332473938353e-06
Japanese O 0 8.4368921307032e-06
families O 0 1.3673097782884724e-05
. O 0 9.965316166926641e-06

The O 0 6.781527645216556e-06
insertion O 0 2.9271534003783017e-05
was O 0 3.8713719163752103e-07
a O 0 1.1241073849532768e-07
5 O 0 3.3172042890328157e-07
- O 0 1.872938810265623e-05
truncated O 0 1.7461344441471738e-06
form O 0 8.121372729874565e-08
of O 0 2.0993352833897916e-08
human O 0 1.397057047825001e-07
L1 O 0 2.2041007468942553e-05
inversely O 0 5.936733487033052e-07
integrated O 0 1.367675253050038e-07
in O 0 1.0421959295570105e-08
the O 0 1.2960522433047572e-08
5 O 0 1.2369793012112495e-07
- O 0 1.835015427786857e-05
untranslated O 0 0.00017127404862549156
region O 0 3.630718197200622e-07
in O 0 2.0477491702308726e-08
the O 0 4.027716826726646e-08
muscle O 0 1.3087582374282647e-05
exon O 0 9.664652679930441e-06
1 O 0 2.918310713084793e-07
, O 0 5.1441247705952264e-08
which O 0 1.8981438643095316e-08
affected O 0 8.949114516099144e-08
the O 0 1.5048813750695444e-08
transcription O 0 1.1306975693514687e-06
or O 0 1.9386035887691833e-08
the O 0 1.030563012704988e-08
stability O 0 9.450742055605588e-08
of O 0 9.319600202672973e-09
the O 0 2.8013822372940922e-08
muscle O 0 4.188397269899724e-06
form O 0 2.857430025926533e-08
of O 0 1.847148922706765e-08
dystrophin O 0 0.00011790941789513454
transcripts O 0 1.5012195717645227e-06
but O 0 2.228159168282673e-08
not O 0 4.938625508543737e-09
that O 0 3.409967863632346e-09
of O 0 6.48892806154322e-09
the O 0 6.439022826043583e-08
brain O 0 6.575619772775099e-05
or O 0 3.2441613484479603e-07
Purkinje O 0 0.007455158047378063
cell O 0 2.7714255338651128e-05
form O 0 7.233859378175111e-07
, O 0 2.701684422845574e-07
probably O 0 3.035688393993041e-07
due O 0 8.274273710640045e-08
to O 0 7.979265248536649e-09
its O 0 1.3225979422770706e-08
unique O 0 4.60283366976455e-08
site O 0 2.1302756181285076e-07
of O 0 1.2775251434504753e-07
integration O 0 9.743081136548426e-06
. O 0 8.312747922900598e-06

We O 0 1.565768434375059e-05
speculate O 0 1.5925970728858374e-05
that O 0 1.2806356153305387e-07
this O 0 2.7870351360093082e-08
insertion O 0 5.029679641666007e-07
of O 0 1.6647099698730017e-08
an O 0 3.0454746280383915e-08
L1 O 0 0.0001437356258975342
sequence O 0 7.749836186121684e-07
in O 0 7.446167273883475e-07
DMD O 1 0.9992107152938843
is O 0 3.184321428761905e-07
responsible O 0 1.2809837812710612e-07
for O 0 6.4235763375108945e-09
some O 0 3.303232798401723e-09
of O 0 1.0383546467096494e-08
the O 0 2.8356151204889102e-08
population O 0 3.981969243227468e-08
of O 0 4.744542891899073e-08
Japanese O 0 2.315985329914838e-05
patients O 0 0.00015091669047251344
with O 0 3.048455255338922e-06
XLDCM B-Disease 0 0.1367369443178177
. O 0 2.864496991605847e-06
. O 0 6.333089459076291e-06

Severe O 1 0.7763004302978516
early O 0 0.0009097305010072887
- O 1 0.9968724846839905
onset O 1 0.9998916387557983
obesity B-Disease 1 0.9999293088912964
, O 0 0.008367783389985561
adrenal B-Disease 1 0.9998574256896973
insufficiency I-Disease 1 0.99982750415802
and O 0 4.999241718905978e-05
red O 0 0.08013980835676193
hair O 1 0.9304313659667969
pigmentation O 1 0.9958693385124207
caused O 0 0.00664086127653718
by O 0 7.473639016097877e-06
POMC O 1 0.9212444424629211
mutations O 0 0.0001374391431454569
in O 0 1.2180194062239025e-06
humans O 0 1.1127888683404308e-05
. O 0 5.346067155187484e-06

Sequential O 0 0.00013588181172963232
cleavage O 0 0.00021189989638514817
of O 0 5.592415277533291e-07
the O 0 2.512805963306164e-07
precursor O 0 1.2206380688439822e-06
protein O 0 2.8939325602550525e-07
pre O 0 1.8778073354042135e-06
- O 0 2.814391154970508e-05
pro O 0 3.294920816188096e-06
- O 0 0.0014902671100571752
opiomelanocortin O 0 0.003934897016733885
( O 0 1.1974752851529047e-06
POMC O 0 0.00020982864953111857
) O 0 8.300418130602338e-08
generates O 0 1.2151426176387758e-07
the O 0 7.198610063596789e-08
melanocortin O 0 0.0001777210709406063
peptides O 0 7.62168929213658e-06
adrenocorticotrophin O 0 0.0002767509431578219
( O 0 4.915336830890737e-07
ACTH O 0 8.643144610687159e-06
) O 0 7.364936749354456e-08
, O 0 4.941190923091199e-08
melanocyte O 0 5.7187316997442394e-05
- O 0 9.490775119047612e-05
stimulating O 0 1.5732146493974142e-05
hormones O 0 3.934350843337597e-06
( O 0 1.9294557773719134e-07
MSH O 0 8.605626499047503e-05
) O 0 3.824991523515564e-08
alpha O 0 8.02880819605889e-08
, O 0 1.0044691300947761e-08
beta O 0 3.725583397340415e-08
and O 0 9.645449772222037e-09
gamma O 0 2.312447264785078e-07
as O 0 4.529466135494431e-09
well O 0 4.757281235612254e-09
as O 0 5.183953710741207e-09
the O 0 2.7558423099094398e-08
opioid O 0 4.199808245175518e-05
- O 0 0.00011906489817192778
receptor O 0 6.0764223235310055e-06
ligand O 0 5.160643013368826e-06
beta O 0 4.6773566282354295e-06
- O 0 0.00028881014441139996
endorphin O 0 0.002619406906887889
. O 0 6.353888238663785e-06

While O 0 8.632601748104207e-06
a O 0 1.4760719295736635e-06
few O 0 1.0572038036116282e-06
cases O 0 2.6466866529517574e-06
of O 0 4.711236670118524e-06
isolated O 0 0.4531829059123993
ACTH B-Disease 1 0.9982469081878662
deficiency I-Disease 1 0.9981212019920349
have O 0 5.833761633766699e-07
been O 0 3.394969496639533e-07
reported O 0 7.0127139224496204e-06
( O 0 5.140886514709564e-06
OMIM O 1 0.8398796319961548
201400 O 0 0.007510996423661709
) O 0 8.85317376742023e-07
, O 0 3.1750394668961235e-07
an O 0 6.579629143743659e-07
inherited O 0 0.2851329743862152
POMC O 1 0.9985400438308716
defect O 0 0.028378639370203018
has O 0 2.8168031462882936e-07
not O 0 5.1698364700314414e-08
been O 0 9.206846129927726e-08
described O 0 1.1997614137726487e-06
so O 0 2.542617778544809e-07
far O 0 9.558422107147635e-07
. O 0 4.28499106419622e-06

Recent O 0 5.440821041702293e-05
studies O 0 7.5393772931420244e-06
in O 0 4.823493213734764e-07
animal O 0 1.7372396996506723e-06
models O 0 6.420945624086016e-07
elucidated O 0 4.300190539652249e-06
a O 0 2.99608089449066e-08
central O 0 3.947584303887197e-08
role O 0 5.143693115883252e-08
of O 0 2.178109603789835e-08
alpha O 0 1.469395101594273e-06
- O 0 0.000214299070648849
MSH O 0 0.0021652954164892435
in O 0 3.524863245729648e-08
the O 0 2.073243443589945e-08
regulation O 0 1.9154927599629445e-07
of O 0 1.4702310480174674e-08
food O 0 1.1298789104330353e-07
intake O 0 2.2440941904733336e-07
by O 0 1.688392181620202e-08
activation O 0 2.2352600126396283e-07
of O 0 2.0670285039159353e-08
the O 0 9.110455323479982e-08
brain O 0 2.2574595277546905e-05
melanocortin O 0 0.00014895916683599353
- O 0 1.3606746506411582e-05
4 O 0 4.948967671225546e-07
- O 0 4.2014864447992295e-05
receptor O 0 3.0658345622214256e-06
( O 0 1.4623685729020508e-07
MC4 O 0 7.658799586351961e-05
- O 0 1.0266459867125377e-05
R O 0 2.2246415028348565e-05
; O 0 1.0999917776643997e-07
refs O 0 1.7357691604047432e-06
3 O 0 1.1926060494715784e-07
- O 0 7.206858299468877e-06
5 O 0 1.1953889611504565e-07
) O 0 2.3600895460162974e-08
and O 0 5.763121979640573e-09
the O 0 1.305509922389092e-08
linkage O 0 2.6278839868609793e-06
of O 0 7.859188144720974e-08
human O 0 4.381146482046461e-06
obesity B-Disease 0 0.2579262852668762
to O 0 2.640797163167008e-07
chromosome O 0 9.668331585999113e-06
2 O 0 1.6405280689468782e-07
in O 0 2.616155470036574e-08
close O 0 1.5822293164546863e-07
proximity O 0 3.9844960042501043e-07
to O 0 2.6927837737389382e-08
the O 0 6.340888347722284e-08
POMC O 0 0.002334873890504241
locus O 0 3.021727934537921e-06
, O 0 2.8304873112006135e-08
led O 0 5.585247109252123e-08
to O 0 6.663569696030436e-09
the O 0 6.563414256532951e-09
proposal O 0 4.915866114174605e-08
of O 0 1.6601502395019452e-08
an O 0 3.373264689798816e-08
association O 0 1.7418317383999238e-06
of O 0 6.942776167306874e-07
POMC O 1 0.7774852514266968
with O 0 7.512885076721432e-06
human O 0 0.00010221063712378964
obesity B-Disease 1 0.9369401931762695
. O 0 3.602140350267291e-05

The O 0 3.567377007129835e-06
dual O 0 2.8834635941166198e-06
role O 0 5.394842332862027e-07
of O 0 1.0398633776276256e-07
alpha O 0 2.8926131108164554e-06
- O 0 0.00046735230716876686
MSH O 0 0.017819464206695557
in O 0 1.511756266836528e-07
regulating O 0 2.41951283896924e-06
food O 0 2.872195068448491e-07
intake O 0 7.933904839774186e-07
and O 0 1.5663853503156133e-07
influencing O 0 7.929163075459655e-06
hair O 0 0.01512586697936058
pigmentation O 0 0.38572150468826294
predicts O 0 0.010486987419426441
that O 0 2.5112200319199474e-07
the O 0 3.137687087928498e-07
phenotype O 0 0.00011513850768096745
associated O 0 4.698923419255152e-07
with O 0 9.374979015319695e-08
a O 0 3.886438548761362e-07
defect O 0 0.0005071029299870133
in O 0 1.0813987501023803e-06
POMC O 0 0.15018199384212494
function O 0 9.24401547308662e-07
would O 0 1.1870369576172379e-07
include O 0 4.8831261665327474e-06
obesity B-Disease 1 0.7686439752578735
, O 0 2.6310538032703334e-06
alteration O 0 0.00021711172303184867
in O 0 9.560542821418494e-06
pigmentation O 1 0.9108431935310364
and O 0 0.0009941780008375645
ACTH B-Disease 1 0.9885686635971069
deficiency I-Disease 1 0.9975797533988953
. O 0 2.333681914024055e-05

The O 0 7.281962098204531e-06
observation O 0 1.6437274098279886e-05
of O 0 6.607081672882487e-07
these O 0 1.0049195680039702e-06
symptoms O 0 0.0007795598939992487
in O 0 1.5620668136762106e-07
two O 0 2.064241613197737e-07
probands O 0 0.012892212718725204
prompted O 0 1.02283565865946e-05
us O 0 2.235912290871056e-07
to O 0 3.5599565961774715e-08
search O 0 1.4350524679684895e-07
for O 0 6.467751489935836e-08
mutations O 0 1.9421752313064644e-06
within O 0 1.1689279233451089e-07
their O 0 6.131971304057515e-07
POMC O 0 0.027361948043107986
genes O 0 1.3069347915006801e-05
. O 0 5.233938281890005e-06

Patient O 0 0.03227439522743225
1 O 0 2.502964525774587e-05
was O 0 1.4186449561748304e-06
found O 0 1.825196136451268e-07
to O 0 3.627014422136199e-08
be O 0 6.849335321135186e-09
a O 0 2.5389313762502752e-08
compound O 0 6.281387072704092e-07
heterozygote O 0 1.68338228831999e-05
for O 0 2.0589386195979387e-08
two O 0 2.3625622347367425e-08
mutations O 0 8.397378223889973e-07
in O 0 2.61055799199994e-08
exon O 0 1.541578967589885e-05
3 O 0 1.445782459086331e-06
( O 0 5.253493782220175e-07
G7013T O 0 7.233141514007002e-05
, O 0 2.2851686765079648e-07
C7133delta O 0 9.712800238048658e-05
) O 0 3.081779098579318e-08
which O 0 6.656912798774783e-09
interfere O 0 4.432804345810837e-08
with O 0 9.965875236161992e-09
appropriate O 0 1.5327019653454954e-08
synthesis O 0 6.056497880990719e-08
of O 0 4.865939473575054e-08
ACTH O 0 2.27140753850108e-05
and O 0 4.148384391555737e-07
alpha O 0 1.1104789336968679e-05
- O 0 0.0006623611552640796
MSH O 0 0.012772515416145325
. O 0 8.670785973663442e-06

Patient O 0 0.07951761782169342
2 O 0 5.2610768761951476e-05
was O 0 3.872704837704077e-06
homozygous O 0 6.624921297770925e-06
for O 0 1.0657379334588768e-07
a O 0 1.3053771397153469e-07
mutation O 0 2.5141966943920124e-06
in O 0 1.5957888876982906e-07
exon O 0 3.942979674320668e-05
2 O 0 5.446805516839959e-06
( O 0 1.631081886444008e-06
C3804A O 0 0.00010433782153995708
) O 0 5.057205498815165e-07
which O 0 3.877327969803446e-07
abolishes O 0 7.096132321748883e-05
POMC O 0 0.005843496881425381
translation O 0 1.2539570889202878e-05
. O 0 8.927835551730823e-06

These O 0 1.4294497304945253e-05
findings O 0 7.1344393290928565e-06
represent O 0 4.365495556157839e-07
the O 0 7.584447558883767e-08
first O 0 8.288616015761363e-08
examples O 0 1.728371188391975e-07
of O 0 8.390048122919325e-08
a O 0 2.390246208960889e-06
genetic B-Disease 0 0.08613202720880508
defect I-Disease 0 0.2423495352268219
within O 0 1.80909694336151e-07
the O 0 3.3569722290849313e-07
POMC O 0 0.016304995864629745
gene O 0 1.1409728131184238e-06
and O 0 5.692897531162089e-08
define O 0 8.350700113624043e-07
a O 0 2.2144347155972355e-07
new O 0 1.1288969290035311e-05
monogenic B-Disease 1 0.9968355298042297
endocrine I-Disease 1 0.9994731545448303
disorder I-Disease 1 0.8776413202285767
resulting O 0 2.4504106477252208e-06
in O 0 2.724892738115159e-07
early O 0 6.576557552762097e-06
- O 1 0.9416954517364502
onset O 1 0.9997592568397522
obesity B-Disease 1 0.9999144077301025
, O 0 0.001550778397358954
adrenal B-Disease 1 0.9995558857917786
insufficiency I-Disease 1 0.999386191368103
and O 0 3.514567652018741e-05
red O 0 0.011936148628592491
hair O 0 0.29643380641937256
pigmentation O 1 0.6253941655158997
. O 0 3.3072835776692955e-06
. O 0 6.1595806073455606e-06

A O 0 4.3524090870050713e-05
European O 0 4.340736995800398e-05
multicenter O 0 0.16639213263988495
study O 0 2.4518960344721563e-05
of O 0 5.637779395328835e-06
phenylalanine B-Disease 1 0.9839180707931519
hydroxylase I-Disease 1 0.9991534948348999
deficiency I-Disease 1 0.9999076128005981
: O 0 1.1853354408231098e-05
classification O 0 2.287798997713253e-05
of O 0 6.6681486998732e-08
105 O 0 2.9864841053495184e-06
mutations O 0 3.4128306651837192e-06
and O 0 2.3799341164476573e-08
a O 0 1.7102962601711624e-08
general O 0 6.633998594907098e-08
system O 0 1.3760326567080483e-07
for O 0 3.866176356837059e-08
genotype O 0 1.6379735825466923e-05
- O 0 9.372990461997688e-05
based O 0 1.890096541501407e-06
prediction O 0 1.8371867554378696e-05
of O 0 1.174007138615707e-06
metabolic O 0 0.018696123734116554
phenotype O 0 0.001661366899497807
. O 0 1.1855015145556536e-05

Phenylketonuria B-Disease 1 0.9905260801315308
( O 0 0.0007688982877880335
PKU B-Disease 1 0.577251136302948
) O 0 2.703308200580068e-05
and O 0 8.743984835746232e-06
mild B-Disease 0 0.055210601538419724
hyperphenylalaninemia I-Disease 1 0.9994176626205444
( O 0 0.000134035391965881
MHP B-Disease 1 0.959525465965271
) O 0 3.643361196736805e-06
are O 0 8.446597234978981e-07
allelic B-Disease 1 0.7778094410896301
disorders I-Disease 1 0.999819815158844
caused O 0 0.0007870892877690494
by O 0 4.131328523726552e-07
mutations O 0 2.4445753297186457e-06
in O 0 3.8379337041760664e-08
the O 0 7.212711494730684e-08
gene O 0 1.270639586437028e-06
encoding O 0 2.0935767679475248e-06
phenylalanine O 0 0.0003221556544303894
hydroxylase O 0 0.006193752866238356
( O 0 2.5001325411722064e-05
PAH O 1 0.9960829019546509
) O 0 7.605983228131663e-06
. O 0 5.150166089151753e-06

Previous O 0 8.934873039834201e-05
studies O 0 1.188873102364596e-05
have O 0 8.384735110666952e-07
suggested O 0 1.1265149169048527e-06
that O 0 6.765590399027133e-08
the O 0 9.309955828484817e-08
highly O 0 1.336839773102838e-06
variable O 0 6.900354492245242e-05
metabolic O 0 0.4981379806995392
phenotypes O 0 0.06537360697984695
of O 0 0.0002521864662412554
PAH B-Disease 1 0.9999918937683105
deficiency I-Disease 1 0.9997696280479431
correlate O 0 0.003073800355195999
with O 0 0.00020364043302834034
PAH O 1 0.9998241066932678
genotypes O 0 0.04480541869997978
. O 0 3.1035844585858285e-05

We O 0 3.6872461350867525e-05
identified O 0 1.663075636315625e-05
both O 0 1.9113117559754755e-06
causative O 0 0.01045175176113844
mutations O 0 0.0002924867148976773
in O 0 2.4928285711212084e-06
686 O 0 0.11465106904506683
patients O 0 0.00031911200494505465
from O 0 1.357575598603944e-07
seven O 0 5.405575507211324e-07
European O 0 2.4698179004190024e-06
centers O 0 1.217973021994112e-05
. O 0 6.365423814713722e-06

On O 0 3.89180468118866e-06
the O 0 3.95750987536303e-07
basis O 0 1.6961023163730715e-07
of O 0 5.4563336959745357e-08
the O 0 9.607849449366768e-08
phenotypic O 0 2.591671318441513e-06
characteristics O 0 4.976873242412694e-07
of O 0 1.0604092182120439e-07
297 O 0 9.042616875376552e-05
functionally O 0 0.0003937545989174396
hemizygous O 1 0.7820414304733276
patients O 0 0.0001002736680675298
, O 0 5.029986027693667e-08
105 O 0 1.315379591915189e-07
of O 0 1.943597993658841e-08
the O 0 9.030423342437643e-08
mutations O 0 3.2036930406320607e-06
were O 0 2.071978322248924e-08
assigned O 0 8.934413386896267e-08
to O 0 9.436077696989287e-09
one O 0 6.703751331826879e-09
of O 0 1.9315983479373244e-08
four O 0 1.1394055121627389e-07
arbitrary O 0 2.1272455796861323e-06
phenotype O 0 0.00013409087841864675
categories O 0 6.148623469925951e-06
. O 0 5.7289089454570785e-06

We O 0 1.0973491043841932e-05
proposed O 0 5.895613867323846e-06
and O 0 8.491366543239565e-07
tested O 0 1.0054400263470598e-06
a O 0 5.683003934109365e-08
simple O 0 2.0241149911726097e-07
model O 0 1.5005238651610853e-07
for O 0 3.593630637510614e-08
correlation O 0 1.299982159252977e-06
between O 0 5.34564719600894e-07
genotype O 0 4.915946556138806e-05
and O 0 6.54973518976476e-07
phenotypic O 0 1.6682894056430086e-05
outcome O 0 9.179279004456475e-06
. O 0 5.948554644419346e-06

The O 0 2.684326136659365e-05
observed O 0 6.862275040475652e-05
phenotype O 0 0.0007567103602923453
matched O 0 2.4129703888320364e-05
the O 0 6.569553647750581e-07
predicted O 0 5.269884059089236e-05
phenotype O 0 5.262130798655562e-05
in O 0 1.3456472913730977e-07
79 O 0 2.8038039090461098e-06
% O 0 4.01674604688651e-08
of O 0 1.3160853740146194e-08
the O 0 6.794610385441047e-08
cases O 0 2.6447034429111227e-07
, O 0 4.719956336884934e-08
and O 0 2.6445615475267914e-08
in O 0 2.0154214297463113e-08
only O 0 8.586076738481552e-09
5 O 0 1.2402466609273688e-07
of O 0 1.0456131604996699e-07
184 O 0 0.00015207665273919702
patients O 0 0.00011846806592075154
was O 0 1.1524846854626958e-07
the O 0 7.695499704141184e-08
observed O 0 9.248292371921707e-07
phenotype O 0 3.4037036584777525e-06
more O 0 4.954542109913973e-09
than O 0 5.009322290305818e-09
one O 0 1.0417626761238807e-08
category O 0 8.98911096669508e-08
away O 0 8.99377639029808e-08
from O 0 4.827483124358878e-08
that O 0 1.2310127317505248e-07
expected O 0 1.283118876926892e-06
. O 0 2.7231026251683943e-06

Among O 0 2.440002208459191e-05
the O 0 1.703653310869413e-06
seven O 0 1.5664795682823751e-06
contributing O 0 4.442273166205268e-06
centers O 0 1.4473523606284289e-06
, O 0 1.1560170776192535e-07
the O 0 6.399072560725472e-08
proportion O 0 8.155194564096746e-07
of O 0 5.389427997215535e-07
patients O 0 0.00015147996600717306
for O 0 1.702963174921024e-07
whom O 0 2.2355400233209366e-06
the O 0 1.7461347567859775e-07
observed O 0 1.670292249400518e-06
phenotype O 0 3.718266452779062e-05
did O 0 6.466296298412999e-08
not O 0 5.256477919601821e-09
match O 0 5.6852154983744185e-08
the O 0 4.9928228662565743e-08
predicted O 0 1.2019226232951041e-05
phenotype O 0 8.539550435671117e-06
was O 0 3.431565787082036e-08
4 O 0 1.285208952594985e-07
% O 0 5.8631776767015253e-08
- O 0 4.3482523324200884e-05
23 O 0 7.442270089086378e-07
% O 0 1.6188721474463819e-07
( O 0 4.007544305295596e-07
P O 0 0.0007038443582132459
< O 0 0.00018584138888400048
. O 0 1.5950023168898042e-07
0001 O 0 7.701467984588817e-05
) O 0 8.281442376301129e-08
, O 0 3.1140647394067855e-08
suggesting O 0 1.3786163322038192e-07
that O 0 7.845286198460144e-09
differences O 0 8.231615566955952e-08
in O 0 2.1185101672926976e-08
methods O 0 6.265245389158736e-08
used O 0 3.5256231711855435e-08
for O 0 7.570255178279695e-08
mutation O 0 7.45611168895266e-06
detection O 0 1.9919538317481056e-05
or O 0 3.192594022038975e-06
phenotype O 0 0.007373904809355736
classification O 0 0.00026827710098586977
may O 0 7.672408059988811e-07
account O 0 5.453337337257835e-08
for O 0 1.012401185107592e-08
a O 0 2.125398523844524e-08
considerable O 0 2.812991226619488e-07
proportion O 0 5.316398414834111e-07
of O 0 2.7211427777729114e-07
genotype O 0 0.0006051172968000174
- O 0 0.0556032732129097
phenotype O 0 0.003113366896286607
inconsistencies O 0 0.0003468056384008378
. O 0 1.0922412911895663e-05

Our O 0 2.245797986688558e-05
data O 0 9.600980774848722e-06
indicate O 0 5.185354439163348e-06
that O 0 3.805036214998836e-07
the O 0 1.2201981007819995e-06
PAH O 1 0.9997414946556091
- O 0 0.04051561653614044
mutation O 0 3.7667970900656655e-05
genotype O 0 7.476262453565141e-06
is O 0 1.908705016262502e-08
the O 0 1.668339955074316e-08
main O 0 8.33638651442925e-08
determinant O 0 2.6472166609892156e-06
of O 0 2.2567026292108494e-07
metabolic O 0 0.023339081555604935
phenotype O 0 0.0005084533477202058
in O 0 7.44075805414468e-07
most O 0 3.906198344338918e-06
patients O 0 0.08109964430332184
with O 0 0.0032071492169052362
PAH B-Disease 1 0.9999932050704956
deficiency I-Disease 1 0.9997325539588928
. O 0 6.807844329159707e-05

In O 0 8.224023986258544e-06
the O 0 1.2027605862385826e-06
present O 0 6.237184493329551e-07
study O 0 6.134814043434744e-07
, O 0 1.1832663915356534e-07
the O 0 6.595467283432299e-08
classification O 0 1.0232913155050483e-05
of O 0 3.29650987396235e-07
105 O 0 0.00042957847472280264
PAH O 1 0.9999749660491943
mutations O 0 0.00032264870242215693
may O 0 3.302428979168326e-07
allow O 0 3.1980828651967386e-08
the O 0 1.9894047298407713e-08
prediction O 0 4.2141891753999516e-07
of O 0 9.799792088927006e-09
the O 0 3.5524276853493575e-08
biochemical O 0 1.1514071047713514e-05
phenotype O 0 1.1377130249456968e-05
in O 0 7.002155655300157e-08
> O 0 1.718540988804307e-05
10 O 0 1.0391931937192567e-07
, O 0 8.313283927918746e-08
000 O 0 6.452085017372156e-07
genotypes O 0 3.421539440751076e-05
, O 0 1.0993415600069056e-07
which O 0 5.303510874909989e-08
may O 0 1.1105407793365885e-07
be O 0 4.550777088496716e-09
useful O 0 1.7854144829243523e-08
for O 0 1.2053422260294155e-08
the O 0 6.16782926954329e-08
management O 0 3.4937836517201504e-06
of O 0 6.764312274754047e-07
hyperphenylalaninemia B-Disease 1 0.9868272542953491
in O 0 1.9671331756399013e-05
newborns O 0 0.01839299313724041
. O 0 1.5142023585212883e-05

Somatic O 0 0.0015932029346004128
instability O 0 0.00045507895993068814
of O 0 2.3749246338411467e-06
the O 0 2.074400299534318e-06
CTG O 0 0.0032223800662904978
repeat O 0 4.403443381306715e-05
in O 0 3.494366183076636e-07
mice O 0 1.286141650780337e-05
transgenic O 0 4.302848992665531e-06
for O 0 3.045466314688383e-07
the O 0 1.4432614079851191e-05
myotonic B-Disease 1 0.9999740123748779
dystrophy I-Disease 1 0.9999890327453613
region O 0 0.0006070998497307301
is O 0 1.4284222515925649e-06
age O 0 2.5815795652306406e-06
dependent O 0 8.412792453782458e-07
but O 0 3.79117359727843e-08
not O 0 1.8594858985920837e-08
correlated O 0 4.4574346702574985e-07
to O 0 1.520719372649637e-08
the O 0 3.2999786014897836e-08
relative O 0 6.525133926515991e-07
intertissue O 0 0.00015190914564300328
transcription O 0 6.8857848418701906e-06
levels O 0 8.259686978817626e-07
and O 0 9.522773893877456e-07
proliferative O 0 0.059006690979003906
capacities O 0 5.9327907365513965e-05
. O 0 1.5143627024372108e-05

A O 0 4.670435737352818e-05
( O 0 2.0600069547072053e-05
CTG O 0 0.0014625054318457842
) O 0 1.745525082696986e-06
nexpansion O 0 3.444604226388037e-05
in O 0 5.9177580169489374e-08
the O 0 4.2120834820025266e-08
3 O 0 5.390563728724374e-07
- O 0 0.00013928207044955343
untranslated O 0 0.0013590939342975616
region O 0 6.145340194052551e-06
( O 0 6.318528562587744e-07
UTR O 0 0.0001419854670530185
) O 0 5.160556071359679e-08
of O 0 2.3880460275904625e-08
the O 0 1.9463531941710244e-07
DM O 1 0.9824844002723694
protein O 0 6.781217052775901e-06
kinase O 0 9.752085315994918e-05
gene O 0 5.057127054897137e-06
( O 0 5.057905241301341e-07
DMPK O 0 0.0003424773458391428
) O 0 1.4395085656815354e-07
is O 0 5.238095113213603e-08
responsible O 0 7.286160439434752e-07
for O 0 3.0194264581950847e-06
causing O 0 0.22226466238498688
myotonic B-Disease 1 0.999974250793457
dystrophy I-Disease 1 0.9999884366989136
( O 0 0.0036460005212575197
DM B-Disease 1 0.9996987581253052
) O 0 4.675823947764002e-05
. O 0 1.29409454530105e-05

Major O 0 0.0003447512863203883
instability O 0 0.0011723825009539723
, O 0 1.0731470183600322e-06
with O 0 2.0904174391489505e-07
very O 0 7.04119571537376e-08
large O 0 1.3873807347408729e-07
expansions O 0 9.564136234985199e-06
between O 0 1.8289476599875343e-07
generations O 0 8.408052281083656e-07
and O 0 4.2929240606781605e-08
high O 0 1.9205704404612334e-07
levels O 0 8.365599057924555e-08
of O 0 3.719548047342869e-08
somatic O 0 3.4342952858423814e-05
mosaicism O 0 0.04705328121781349
, O 0 5.680537924490636e-07
is O 0 2.1576219921826123e-07
observed O 0 1.6517998346898821e-06
in O 0 1.1974889275734313e-06
patients O 0 0.00029688121867366135
. O 0 9.694219443190377e-06

There O 0 1.0943350389425177e-05
is O 0 5.351182039703417e-07
a O 0 1.5060693669965985e-07
good O 0 3.100566914326919e-07
correlation O 0 1.218425950355595e-06
between O 0 4.3532108406907355e-07
repeat O 0 5.682158007402904e-05
size O 0 1.6351937119907234e-06
( O 0 1.8083794373069395e-07
at O 0 1.141223791023549e-07
least O 0 2.8568525323180438e-08
in O 0 1.3682975463780167e-07
leucocytes O 0 0.007784560788422823
) O 0 1.1180244428032893e-06
, O 0 1.0788235158543102e-06
clinical O 0 0.00036618855665437877
severity O 0 0.000548776239156723
and O 0 4.7633398025936913e-07
age O 0 2.6778338906296995e-06
of O 0 1.5475754935323494e-06
onset O 0 0.30697911977767944
. O 0 2.8763375667040236e-05

The O 0 9.646415855968371e-05
trinucleotide O 1 0.6917617321014404
repeat O 0 0.017792917788028717
instability O 0 0.0038195925299078226
mechanisms O 0 4.354427073849365e-05
involved O 0 3.6495619042398175e-06
in O 0 6.318749001366086e-06
DM B-Disease 1 0.9998557567596436
and O 0 1.487646750319982e-05
other O 0 5.986816631775582e-06
human O 0 0.0032541844993829727
genetic B-Disease 1 0.9984492063522339
diseases I-Disease 1 0.9997493624687195
are O 0 2.9389043447736185e-06
unknown O 0 2.9534183340729214e-05
. O 0 1.4913073755451478e-05

We O 0 1.735403566271998e-05
studied O 0 1.3169918020139448e-05
somatic O 0 9.094260167330503e-05
instability O 0 0.00012308514851611108
by O 0 5.81151653022971e-07
measuring O 0 3.877826384268701e-05
the O 0 3.440949001287663e-07
CTG O 0 0.0012224066304042935
repeat O 0 1.523125138191972e-05
length O 0 6.25791813035903e-07
at O 0 8.407429419321488e-08
several O 0 2.0907878095499655e-08
ages O 0 2.974680342049396e-07
in O 0 1.7415555220168244e-08
various O 0 2.1880445899569168e-08
tissues O 0 1.4652446225227322e-06
of O 0 4.476801152009102e-08
transgenic O 0 1.3408040103968233e-05
mice O 0 6.941365882084938e-06
carrying O 0 4.096266081887734e-08
a O 0 7.198829621302139e-08
( O 0 5.405926231105695e-07
CTG O 0 0.00036191524122841656
) O 0 3.011168132616149e-07
55expansion O 0 1.2186630556243472e-05
surrounded O 0 3.760741833502834e-07
by O 0 1.9032482256875483e-08
45 O 0 4.334547654138987e-08
kb O 0 6.3575917010894045e-06
of O 0 2.624567052578186e-08
the O 0 1.4930670033663773e-07
human O 0 1.8130173202735023e-06
DM B-Disease 1 0.8735122680664062
region O 0 1.0539068853177014e-06
, O 0 5.019654381044347e-08
using O 0 4.7133799085941064e-08
small O 0 2.2237166774630168e-07
- O 0 9.714383486425504e-05
pool O 0 6.330322503345087e-05
PCR O 0 4.863057256443426e-05
. O 0 4.583359441312496e-06

These O 0 3.3775857446016744e-05
mice O 0 0.0006449296488426626
have O 0 5.416541171143763e-07
been O 0 1.581503568104381e-07
shown O 0 1.485207832274682e-07
to O 0 8.449853794445517e-08
reproduce O 0 1.269961217076343e-06
the O 0 5.8723326645804264e-08
intergenerational O 0 1.6565449186600745e-05
and O 0 1.6737430996727198e-07
somatic O 0 4.152233486820478e-06
instability O 0 2.7695064090949018e-06
of O 0 2.8714165267729186e-08
the O 0 7.77838948806675e-08
55 O 0 1.0287384384355391e-06
CTG O 0 0.0009289723820984364
repeat O 0 1.6471278286189772e-05
suggesting O 0 3.965046175835596e-07
that O 0 1.499483381905975e-08
surrounding O 0 1.283926422956938e-07
sequences O 0 8.428735043253255e-08
and O 0 1.9394136074879498e-08
the O 0 3.4545507787697716e-08
chromatin O 0 6.550206308020279e-06
environment O 0 1.5195703326753573e-06
are O 0 3.898788847322976e-08
involved O 0 1.828755671340332e-07
in O 0 6.397241918421059e-07
instability O 0 0.00022420099412556738
mechanisms O 0 3.273702532169409e-05
. O 0 8.992145012598485e-06

As O 0 6.564896011695964e-06
observed O 0 3.8011951346561546e-06
in O 0 1.0188892929363647e-07
some O 0 2.634145879198968e-08
of O 0 4.600428482604002e-08
the O 0 2.26109960976828e-07
tissues O 0 3.670304795377888e-05
of O 0 7.651125997654162e-06
DM B-Disease 1 0.9999923706054688
patients O 0 0.0782151147723198
, O 0 4.874151500189328e-07
there O 0 4.266313524681209e-08
is O 0 1.4929481650938214e-08
a O 0 2.5747363352479624e-08
tendency O 0 7.295943760254886e-07
for O 0 2.5366952982608382e-08
repeat O 0 3.056658897548914e-06
length O 0 2.4208321747209993e-07
and O 0 6.152836817818752e-08
somatic O 0 6.5307135628245305e-06
mosaicism O 0 0.0011795058380812407
to O 0 5.8013725379169045e-08
increase O 0 1.0424131602349007e-07
with O 0 5.662705149234171e-08
the O 0 6.844206268397102e-08
age O 0 2.5358662014696165e-07
of O 0 8.591519673473158e-08
the O 0 7.680116596020525e-07
mouse O 0 8.773686568019912e-05
. O 0 5.395087555370992e-06

Furthermore O 0 0.00029337118030525744
, O 0 3.302263166915509e-06
we O 0 4.240814632794354e-07
observed O 0 4.100456862943247e-07
no O 0 6.336149027674765e-08
correlation O 0 3.590767505556869e-07
between O 0 8.463161549343567e-08
the O 0 7.958809788988219e-08
somatic O 0 2.085231608361937e-05
mutation O 0 1.3531057447835337e-05
rate O 0 1.5428083770530066e-06
and O 0 1.110076595978171e-06
tissue O 0 0.0011976577807217836
proliferation O 0 0.00010317499254597351
capacity O 0 5.761317424912704e-06
. O 0 4.4083717511966825e-06

The O 0 1.1977702342846896e-05
somatic O 0 0.000330751616274938
mutation O 0 0.00012614252045750618
rates O 0 3.3765268199204e-06
in O 0 7.195480833388501e-08
different O 0 2.6880679016016984e-08
tissues O 0 2.8518738872662652e-06
were O 0 2.4435022893953828e-08
also O 0 2.7428372462168227e-08
not O 0 1.0699434227490201e-08
correlated O 0 3.015890115420916e-07
to O 0 1.3036635770902194e-08
the O 0 1.7399287344233016e-08
relative O 0 1.6187902929232223e-07
inter O 0 4.845554940402508e-06
- O 0 0.002499818569049239
tissue O 0 0.00012871761282440275
difference O 0 2.1009019235407322e-07
in O 0 2.4329269265876974e-08
transcriptional O 0 6.263022669372731e-07
levels O 0 3.5774842643832017e-08
of O 0 6.324760271070318e-09
the O 0 1.6039434669323782e-08
three O 0 3.5581916080218434e-08
genes O 0 4.038436713926785e-07
( O 0 2.5169214268316864e-07
DMAHP O 0 0.0001411489356542006
, O 0 1.3834618073360616e-07
DMPK O 0 0.00011636166163953021
and O 0 1.0605670297536562e-07
59 O 0 9.796933682082454e-07
) O 0 1.0227542190932581e-07
surrounding O 0 5.237900495558279e-07
the O 0 1.8724321648733167e-07
repeat O 0 2.1835165171069093e-05
. O 0 1.05700212316151e-06
. O 0 4.658112629840616e-06

A O 0 5.021416291128844e-05
novel O 0 9.458889689994976e-05
missense O 0 0.009429240599274635
mutation O 0 0.0006715552299283445
in O 0 6.3439456425840035e-06
patients O 0 0.00019338511629030108
from O 0 2.3153889117111248e-07
a O 0 7.780464557072264e-07
retinoblastoma B-Disease 0 0.046375714242458344
pedigree O 0 0.0004537909117061645
showing O 0 3.031628693861421e-06
only O 0 6.574354927124659e-08
mild O 0 1.0823874617926776e-05
expression O 0 2.584370690783544e-07
of O 0 2.128855953742459e-07
the O 0 6.991771442699246e-06
tumor B-Disease 0 0.4821169376373291
phenotype O 0 0.00199839542619884
. O 0 9.56079747993499e-06

We O 0 1.0253700565954205e-05
have O 0 4.0714692772780836e-07
used O 0 1.6638836086713127e-07
single O 0 1.222303325221219e-07
strand O 0 1.176064529317955e-06
conformation O 0 9.19766421247914e-07
polymorphism O 0 1.1986795698248898e-06
analysis O 0 1.0827768903709512e-07
to O 0 1.5721823842795857e-08
study O 0 3.181164132115555e-08
the O 0 1.2543596383807198e-08
27 O 0 1.2483586431244476e-07
exons O 0 6.578098350473738e-07
of O 0 3.6026484906415135e-08
the O 0 2.498139792805887e-07
RB1 O 0 0.004679188132286072
gene O 0 8.837432687869295e-07
in O 0 3.6163765315677665e-08
individuals O 0 3.145686022776317e-08
from O 0 1.8115530409090752e-08
a O 0 6.138044028602962e-08
family O 0 1.3504505886885454e-06
showing O 0 5.244981366558932e-06
mild O 0 2.3349173716269433e-05
expression O 0 3.630752871686127e-07
of O 0 2.092306203849148e-07
the O 0 3.0931621495255968e-06
retinoblastoma B-Disease 0 0.1853262186050415
phenotype O 0 0.003988900687545538
. O 0 1.8604545402922668e-05

In O 0 1.393716229358688e-05
this O 0 4.006346898677293e-06
family O 0 4.905671448796056e-05
affected O 0 3.907117934431881e-05
individuals O 0 2.8181675588712096e-06
developed O 0 7.912785076769069e-05
unilateral B-Disease 0 0.0020661514718085527
tumors I-Disease 1 0.9995461106300354
and O 0 9.578972139934194e-07
, O 0 1.3714512192564143e-07
as O 0 2.0318523752393958e-08
a O 0 2.8107162819424047e-08
result O 0 9.316653404312092e-08
of O 0 2.7052468709598543e-08
linkage O 0 2.9149441616027616e-05
analysis O 0 1.383641574648209e-06
, O 0 4.766629899677355e-07
unaffected O 0 7.922426448203623e-05
mutation O 0 1.552810317662079e-05
carriers O 0 4.08440700994106e-06
were O 0 4.178667367682465e-08
also O 0 1.0125059191068431e-07
identified O 0 3.0407909434870817e-07
within O 0 1.3762858941390732e-07
the O 0 6.079234822209401e-07
pedigree O 0 0.0002311813150299713
. O 0 7.019719305390026e-06

A O 0 8.945836270868313e-06
single O 0 1.9174788121745223e-06
band O 0 2.353747504457715e-06
shift O 0 1.6976475762930932e-06
using O 0 5.234479658611235e-07
SSCP O 0 0.000497068278491497
was O 0 2.3739140431189298e-07
identified O 0 2.441397271013557e-07
in O 0 6.380413708484411e-08
exon O 0 2.7044350645155646e-05
21 O 0 6.542543360410491e-07
which O 0 4.946264198224526e-08
resulted O 0 2.6579579071039916e-07
in O 0 2.4623757255426426e-08
a O 0 5.3763024254749325e-08
missense O 0 1.2115571735193953e-05
mutation O 0 2.6645491857379966e-07
converting O 0 4.7148994042345294e-08
a O 0 4.3155907292202755e-08
cys O 0 0.0012783189304172993
- O 0 0.00021823895804118365
- O 0 0.000617543060798198
> O 0 0.00020990791381336749
arg O 0 8.99419974302873e-05
at O 0 1.2058944776072167e-07
nucleotide O 0 5.427990004136518e-07
position O 0 6.61916033095622e-08
28 O 0 1.2984824593331723e-07
in O 0 6.920565454038297e-08
the O 0 3.1544587386633793e-07
exon O 0 9.494792902842164e-05
. O 0 1.101062025554711e-05

The O 0 6.18133635725826e-05
mutation O 0 0.000371620204532519
destroyed O 0 3.591232962207869e-05
an O 0 1.5387499843200203e-06
NdeI O 0 0.0008668929222039878
restriction O 0 9.811888048716355e-06
enzyme O 0 2.5915678634191863e-05
site O 0 1.1185886251041666e-05
. O 0 9.712162864161655e-06

Analysis O 0 1.251929370482685e-05
of O 0 6.379707997439255e-07
all O 0 2.020959328774552e-07
family O 0 1.1307903378110495e-06
members O 0 9.470049633364397e-08
demonstrated O 0 4.585728277106682e-07
that O 0 1.8502731791159022e-08
the O 0 3.0826843300246765e-08
missense O 0 1.9896791854989715e-05
mutation O 0 4.441214514372405e-06
co O 0 6.119805766502395e-05
- O 0 0.000805067247711122
segregated O 0 5.517449608305469e-05
with O 0 2.0730138203362003e-05
patients O 0 0.026755833998322487
with O 0 0.00017598990234546363
tumors B-Disease 1 0.9999270439147949
or O 0 2.9349359920161078e-06
who O 0 5.486351710715098e-07
, O 0 8.34407032357376e-08
as O 0 1.6644877476323927e-08
a O 0 3.8307593541730967e-08
result O 0 1.1478274331011562e-07
of O 0 4.060925107296498e-08
linkage O 0 3.03675278701121e-05
analysis O 0 7.383036972896662e-07
had O 0 1.421890090114175e-07
been O 0 5.8923596668591927e-08
predicted O 0 1.3897114286010037e-06
to O 0 5.0584450406176984e-08
carry O 0 1.5672520703446935e-07
the O 0 6.30462466233439e-07
predisposing O 0 0.0008250679820775986
mutation O 0 4.062439256813377e-05
. O 0 7.339732746913796e-06

These O 0 5.061435786046786e-06
observations O 0 8.23304071673192e-06
point O 0 6.924895501470019e-07
to O 0 5.839751082703515e-08
another O 0 4.5131180570479046e-08
region O 0 1.4805650039306784e-07
of O 0 3.5241171758571e-08
the O 0 3.501083938317606e-07
RB1 O 0 0.02337712235748768
gene O 0 3.1588108413416194e-06
where O 0 2.7955542236668407e-07
mutations O 0 9.278186325900606e-07
only O 0 5.90138871103818e-09
modify O 0 1.5585312951316155e-07
the O 0 6.821565090575632e-09
function O 0 1.2100459301223054e-08
of O 0 4.916060891702045e-09
the O 0 1.8705346604974693e-08
gene O 0 2.8197811730024114e-07
and O 0 3.774708545734029e-08
raise O 0 3.9634321069570433e-07
important O 0 3.209093790701445e-08
questions O 0 1.4051087759980874e-07
for O 0 8.207346979816066e-08
genetic O 0 4.459559204406105e-05
counseling O 0 2.6109293685294688e-05
in O 0 2.45422938860429e-07
families O 0 1.3970477539260173e-06
with O 0 3.9737872725709167e-07
these O 0 2.8978931254641793e-07
distinctive O 0 4.3476054997881874e-05
phenotypes O 0 0.0008076375816017389
. O 0 1.7631841728871223e-06
. O 0 5.663704541802872e-06

Maternal B-Disease 0 0.21336938440799713
disomy I-Disease 1 0.8004496097564697
and O 0 0.001792263356037438
Prader B-Disease 1 0.9999207258224487
- I-Disease 1 0.999940037727356
Willi I-Disease 1 0.9999936819076538
syndrome I-Disease 1 0.9999855756759644
consistent O 0 3.6131350498180836e-05
with O 0 1.3667511211679084e-06
gamete O 0 0.00018219348567072302
complementation O 0 0.0028510047122836113
in O 0 1.443200687845092e-07
a O 0 1.0955862705941399e-07
case O 0 3.6722761365126644e-07
of O 0 2.9489623898371065e-07
familial O 1 0.5356113314628601
translocation O 0 0.002066617598757148
( O 0 7.362534120147757e-07
3 O 0 5.919355317018926e-07
; O 0 2.695297212085279e-07
15 O 0 1.6778407996298483e-07
) O 0 1.7891801462610601e-07
( O 0 2.144648476587463e-07
p25 O 0 1.1751480087696109e-05
; O 0 3.82989071567863e-07
q11 O 0 2.0329962353571318e-05
. O 0 1.4389101465894782e-07
2 O 0 1.4380653965417878e-06
) O 0 1.972392738025519e-06
. O 0 2.9518564588215668e-06

Maternal B-Disease 0 0.36282575130462646
uniparental I-Disease 1 0.9918850660324097
disomy I-Disease 1 0.966609537601471
( I-Disease 0 0.00044531008461490273
UPD I-Disease 1 0.9832682013511658
) I-Disease 0 5.800232429464813e-06
for I-Disease 0 3.9800943341106176e-07
chromosome I-Disease 0 0.00015246274415403605
15 I-Disease 0 4.4704057700073463e-07
is O 0 5.1182972526930826e-08
responsible O 0 1.3801303566651768e-07
for O 0 2.5568590800162383e-08
an O 0 2.320541092615258e-08
estimated O 0 2.0298251968142722e-07
30 O 0 7.851456729213169e-08
% O 0 5.28077954697892e-08
of O 0 5.5202090010197935e-08
cases O 0 1.5616526525263907e-06
of O 0 2.096573189191986e-05
Prader B-Disease 1 0.9999892711639404
- I-Disease 1 0.999988317489624
Willi I-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.9999971389770508
( O 0 0.003348912578076124
PWS B-Disease 1 0.9993649125099182
) O 0 2.62772537098499e-05
. O 0 1.1050096873077564e-05

We O 0 1.2387148672132753e-05
report O 0 2.3739553398627322e-06
on O 0 1.6328890239947214e-07
an O 0 5.881793541107072e-08
unusual O 0 2.6177633571933256e-07
case O 0 3.6942262227057654e-07
of O 0 2.8417966291272023e-07
maternal B-Disease 0 0.0011003032559528947
disomy I-Disease 0 0.05830054357647896
15 I-Disease 0 1.4368082474902621e-06
in O 0 1.450266495339747e-06
PWS B-Disease 1 0.9949927926063538
that O 0 1.7629677984132286e-07
is O 0 1.996985155017228e-08
most O 0 8.355883984734191e-09
consistent O 0 3.522618285956014e-08
with O 0 1.1218535433954457e-08
adjacent O 0 3.70978170849412e-07
- O 0 1.3499570741259959e-05
1 O 0 1.286219344365236e-07
segregation O 0 6.08531991019845e-07
of O 0 1.711784491931212e-08
a O 0 9.795105171406249e-08
paternal O 0 7.958104833960533e-05
t O 0 0.010994769632816315
( O 0 2.2424276835408818e-07
3 O 0 2.774531822069548e-07
; O 0 1.6790748702533165e-07
15 O 0 1.1323415805009063e-07
) O 0 9.14436810717234e-08
( O 0 8.043967625326331e-08
p25 O 0 4.086008175363531e-06
; O 0 1.005673340159774e-07
q11 O 0 5.836070613440825e-06
. O 0 1.5290696708802898e-08
2 O 0 4.613996296143341e-08
) O 0 1.9577512944124464e-08
with O 0 2.113586283769564e-08
simultaneous O 0 4.095989538654976e-07
maternal O 0 4.531157901510596e-05
meiotic O 0 0.0012146257795393467
nondisjunction O 0 0.006632102653384209
for O 0 6.360323254739342e-07
chromosome O 0 8.10437195468694e-05
15 O 0 3.6592259675671812e-06
. O 0 6.146963642095216e-06

The O 0 7.411369006149471e-05
patient O 0 0.003221874823793769
( O 0 8.521076779288705e-06
J O 0 0.014284920878708363
. O 0 4.6756696292504785e-07
B O 0 7.401899438264081e-06
. O 0 3.111220792106906e-08
) O 0 2.599249526724634e-08
, O 0 9.74664704500583e-09
a O 0 1.278409378357992e-08
17 O 0 1.0774986236583572e-07
- O 0 2.3602939108968712e-05
year O 0 2.9960781944282644e-07
- O 0 0.0002584229805506766
old O 0 5.6408782256767154e-05
white O 0 7.033136353129521e-05
male O 0 6.485555331892101e-06
with O 0 5.47780109627638e-06
PWS B-Disease 1 0.9990718364715576
, O 0 7.105264216988871e-07
was O 0 1.0576459175126729e-07
found O 0 2.120919795345344e-08
to O 0 2.1708432385025844e-08
have O 0 2.0900301933579613e-08
47 O 0 4.3058480514446273e-07
chromosomes O 0 6.320022976069595e-07
with O 0 3.4307674923184095e-08
a O 0 1.0975899300547098e-07
supernumerary O 0 0.00017311460396740586
, O 0 6.86286568907235e-07
paternal O 0 0.00012147131928941235
der O 0 0.0014568169135600328
( O 0 1.505990354644382e-07
15 O 0 2.4147581711986277e-08
) O 0 8.797639949875702e-09
consisting O 0 6.839204758080086e-09
of O 0 5.14298381659728e-09
the O 0 2.065326043521054e-08
short O 0 3.6878444120702625e-07
arm O 0 4.351439656602452e-06
and O 0 4.804903852573261e-08
the O 0 8.123820549599259e-08
proximal O 0 0.00034778701956383884
long O 0 1.5331032045651227e-05
arm O 0 3.214975367882289e-05
of O 0 1.3427846567992674e-07
chromosome O 0 3.447611379669979e-05
15 O 0 2.6351241899646993e-07
, O 0 1.7980664779315703e-07
and O 0 5.463101615532651e-07
distal O 0 0.002043311018496752
chromosome O 0 0.0016989795258268714
arm O 0 0.0008723529754206538
3p O 0 0.036351487040519714
. O 0 1.8226706743007526e-05

The O 0 2.2827824068372138e-05
t O 0 0.02180119976401329
( O 0 2.783847776299808e-06
3 O 0 1.0400970040791435e-06
; O 0 2.555160847350635e-07
15 O 0 1.4658145630619401e-07
) O 0 4.9649599986878457e-08
was O 0 1.407243210849174e-08
present O 0 1.0562020591464716e-08
in O 0 5.933985303130385e-09
the O 0 9.610301887619244e-09
balanced O 0 6.024698961937247e-08
state O 0 5.3186855808462496e-08
in O 0 1.163379508284379e-07
the O 0 9.281336588173872e-07
patients O 0 0.00012086773494957015
father O 0 7.517214271501871e-06
and O 0 4.193702523025422e-07
a O 0 1.1314646144455764e-06
sister O 0 0.000271060795057565
. O 0 1.2224973033880815e-05

Fluorescent O 0 0.00028078703326173127
in O 0 4.119625828025164e-06
situ O 0 8.616087143309414e-05
hybridization O 0 1.6920350390137173e-05
analysis O 0 1.7636366465012543e-06
demonstrated O 0 1.2269041462786845e-06
that O 0 1.311615278609679e-07
the O 0 4.273419449418725e-07
PWS B-Disease 1 0.9044604301452637
critical O 0 2.0564855276461458e-06
region O 0 1.2359325864963466e-06
resided O 0 1.2287554227441433e-06
on O 0 2.5433859462964392e-08
the O 0 2.7279105196953424e-08
derivative O 0 2.9259063012432307e-06
chromosome O 0 2.8189791919430718e-05
3 O 0 3.827488228580478e-07
and O 0 5.25040810828159e-08
that O 0 2.40052226985199e-08
there O 0 2.311670499466345e-08
was O 0 4.3998017673629874e-08
no O 0 2.8426983433860187e-08
deletion O 0 1.2177661119494587e-06
of O 0 3.0047793586618354e-08
the O 0 3.880968222347292e-07
PWS B-Disease 1 0.9704315066337585
region O 0 1.080010406440124e-06
on O 0 3.2427504237375615e-08
the O 0 2.2499779817053422e-08
normal O 0 1.2206433552819362e-07
pair O 0 2.478394094396208e-07
of O 0 9.825868119150982e-08
15s O 0 4.095768235856667e-05
present O 0 6.116529220889788e-07
in O 0 1.7009406292345375e-06
J O 0 0.0045087398029863834
. O 0 9.177107131108642e-06

B O 0 0.009285520762205124
. O 0 0.0005800033104605973

Methylation O 0 0.00015380301920231432
analysis O 0 6.1425862440955825e-06
at O 0 6.580287958968256e-07
exon O 0 7.466999250027584e-06
alpha O 0 8.459237506031059e-07
of O 0 4.1908474912588645e-08
the O 0 6.108635375312588e-08
small O 0 1.49889046952012e-07
nuclear O 0 3.947768618672853e-06
ribonucleoprotein O 0 0.0004396727017592639
- O 0 0.00013126240810379386
associated O 0 1.077407773664163e-06
polypeptide O 0 1.149705258285394e-05
N O 0 3.670220758067444e-05
( O 0 3.905189771558071e-07
SNRPN O 0 0.00023818964837118983
) O 0 1.1824193535403538e-07
gene O 0 2.546940152114985e-07
showed O 0 1.1073552741436288e-07
a O 0 1.808908400846576e-08
pattern O 0 8.970610565484094e-07
characteristic O 0 2.9013662583565747e-07
of O 0 2.3141099703138934e-08
only O 0 2.005512556024769e-08
the O 0 1.5098933658919123e-07
maternal O 0 6.102066254243255e-05
chromosome O 0 6.823170406278223e-05
15 O 0 8.883052942110226e-07
in O 0 1.7912083194460138e-06
J O 0 0.009537735022604465
. O 0 8.704399078851566e-06

B O 0 0.013661730103194714
. O 0 0.0006789822946302593

Maternal B-Disease 0 0.15116742253303528
disomy I-Disease 0 0.11461883038282394
was O 0 4.975453521183226e-06
confirmed O 0 1.3357603165786713e-06
by O 0 1.2241909530530393e-07
polymerase O 0 1.2293811778363306e-05
chain O 0 4.7990702114475425e-06
reaction O 0 1.6509385147855937e-07
analysis O 0 6.38318908841029e-08
of O 0 2.2426942081210655e-08
microsatellite O 0 9.443574526812881e-06
repeats O 0 8.570166301069548e-07
at O 0 5.667935099040733e-08
the O 0 3.327409103803802e-08
gamma O 0 3.2081568406283623e-06
- O 0 0.00020791482529602945
aminobutyric O 0 0.0016585212433710694
acid O 0 1.7889524315251037e-05
receptor O 0 7.64230117056286e-06
beta3 O 0 9.000858699437231e-05
subunit O 0 5.476599199027987e-06
( O 0 1.7696378336040652e-06
GABRB3 O 0 0.0003766594163607806
) O 0 1.6617777873761952e-06
locus O 0 2.1283967726049013e-05
. O 0 4.047797574457945e-06

A O 0 9.535078424960375e-05
niece O 0 0.014123023487627506
( O 0 1.2835452253057156e-05
B O 0 7.380618626484647e-05
. O 0 2.1285046614138992e-07
B O 0 2.966251486213878e-06
. O 0 2.230706286354689e-08
) O 0 1.2823313966237038e-08
with O 0 7.599388673895646e-09
45 O 0 2.6081988124815325e-08
chromosomes O 0 1.8831700288046704e-07
and O 0 8.794502015518901e-09
the O 0 8.96380303316846e-09
derivative O 0 4.946750209455786e-07
3 O 0 1.6146474024480995e-07
but O 0 1.9134253292918402e-08
without O 0 1.617254241637056e-08
the O 0 3.6148456672435714e-08
der O 0 6.179045158205554e-05
( O 0 8.639338489047077e-08
15 O 0 6.721089107486478e-08
) O 0 6.380876271805391e-08
demonstrated O 0 1.7443704791730852e-07
a O 0 7.165132132058716e-08
phenotype O 0 2.44235125137493e-05
consistent O 0 1.819594643848177e-07
with O 0 4.04010407351052e-08
that O 0 7.036832272433458e-08
reported O 0 5.413628514361335e-07
for O 0 8.440479604132634e-08
haploinsufficiency O 0 0.0002476728695910424
of O 0 5.05189859723032e-07
distal O 0 0.0018860900308936834
3 O 0 4.402926788316108e-05
p O 0 0.0023710974492132664
. O 0 1.4606693184759934e-05

Uniparental B-Disease 1 0.9969812035560608
disomy I-Disease 1 0.9927069544792175
associated O 0 0.00010402011685073376
with O 0 1.8166155086873914e-06
unbalanced O 0 8.051069744396955e-05
segregation O 0 2.3053728000377305e-05
of O 0 2.841837272171688e-07
non O 0 8.041932233027183e-06
- O 0 0.0795457661151886
Robertsonian O 0 0.37197601795196533
translocations O 0 0.0017926959553733468
has O 0 5.900845394535281e-07
been O 0 1.1709384750702156e-07
reported O 0 4.187427862234472e-07
previously O 0 1.175123500729569e-07
but O 0 2.746580207713123e-08
has O 0 1.981701558406712e-08
not O 0 1.0659814364544218e-08
, O 0 1.4728048114420744e-08
to O 0 1.1924112364170014e-08
our O 0 2.2084341466666046e-08
knowledge O 0 9.811522261315986e-08
, O 0 4.238792428168381e-08
been O 0 3.350443833483041e-08
observed O 0 1.1171436398171863e-07
in O 0 2.7860519224987e-08
a O 0 9.768872644144722e-08
case O 0 1.502947270637378e-06
of O 0 3.96992300011334e-06
PWS B-Disease 1 0.9970672726631165
. O 0 2.8991393264732324e-05

Furthermore O 0 0.00026104168500751257
, O 0 4.520096808846574e-06
our O 0 1.1413678748795064e-06
findings O 0 1.636419824535551e-06
are O 0 4.521320207118151e-08
best O 0 1.438014294308232e-07
interpreted O 0 1.7221236703335308e-07
as O 0 5.018419457769596e-08
true O 0 5.585459348367294e-07
gamete O 0 2.204994234489277e-05
complementation O 0 0.0009304724517278373
resulting O 0 4.706005256593926e-06
in O 0 2.075987367788912e-06
maternal B-Disease 0 0.0027117955032736063
UPD I-Disease 1 0.9708051681518555
15 I-Disease 0 2.5331439246656373e-05
and O 0 5.116988904774189e-05
PWS B-Disease 1 0.9932119846343994

Schwartz B-Disease 1 0.6064066886901855
- I-Disease 1 0.994361400604248
Jampel I-Disease 1 0.9992191791534424
syndrome I-Disease 1 0.9999006986618042
type I-Disease 0 0.00013322994345799088
2 I-Disease 0 6.324210971797584e-06
and O 0 4.99698035127949e-06
Stuve B-Disease 1 0.8977023959159851
- I-Disease 1 0.9996975660324097
Wiedemann I-Disease 1 0.999945878982544
syndrome I-Disease 1 0.9999517202377319
: O 0 3.4403065001242794e-06
a O 0 1.9391404748603236e-07
case O 0 7.641578463335463e-07
for O 0 1.5215120185985143e-07
" O 0 1.8226459133074968e-06
lumping O 0 0.00017546460730955005
" O 0 4.702533260569908e-06
. O 0 6.374268195941113e-06

Recent O 0 0.0001080672736861743
studies O 0 1.3759773537458386e-05
demonstrated O 0 5.218910700932611e-06
the O 0 1.8648459843007004e-07
existence O 0 7.900268315097492e-07
of O 0 4.566203770650645e-08
a O 0 1.4422388971979672e-07
genetically O 0 1.0042124358733417e-06
distinct O 0 2.675697317044978e-07
, O 0 1.931987725356521e-07
usually O 0 1.1967578927851719e-07
lethal O 0 1.6936131430611567e-07
form O 0 2.719162672804032e-08
of O 0 3.684792559965899e-08
the O 0 8.199145895559923e-07
Schwartz B-Disease 0 0.011514313519001007
- I-Disease 1 0.9863523244857788
Jampel I-Disease 1 0.9996252059936523
syndrome I-Disease 1 0.9999498128890991
( O 0 4.621685729944147e-05
SJS B-Disease 1 0.981285810470581
) O 0 4.700846432115213e-07
of O 0 4.5698240569436166e-07
myotonia B-Disease 1 0.9554054737091064
and O 0 1.680157038208563e-05
skeletal B-Disease 1 0.9344804883003235
dysplasia I-Disease 1 0.9994213581085205
, O 0 8.40234520183003e-07
which O 0 9.127360556249187e-08
we O 0 2.636516569509695e-07
called O 0 1.1638666364888195e-05
SJS B-Disease 1 0.9787035584449768
type I-Disease 0 2.109565684804693e-05
2 I-Disease 0 5.5878376770124305e-06
. O 0 5.336719823390013e-06

This O 0 0.00045319178025238216
disorder O 1 0.9514325857162476
is O 0 1.2662544577324297e-06
reminiscent O 0 2.6615280148689635e-05
of O 0 5.296495260154188e-07
another O 0 2.059011194432969e-06
rare O 0 4.589217496686615e-05
condition O 0 6.043864050297998e-05
, O 0 3.39840312335582e-07
the O 0 1.4219051536201732e-06
Stuve B-Disease 1 0.8658578395843506
- I-Disease 1 0.99977046251297
Wiedemann I-Disease 1 0.99997878074646
syndrome I-Disease 1 0.9999871253967285
( O 0 8.140163845382631e-05
SWS B-Disease 1 0.7197216749191284
) O 0 2.8843743393736077e-07
, O 0 3.4787639435762685e-08
which O 0 2.7106805688958957e-08
comprises O 0 2.981572606586269e-07
campomelia B-Disease 0 0.0009376102243550122
at O 0 2.1932860363449436e-06
birth O 0 3.143391222693026e-05
with O 0 1.3072164620098192e-05
skeletal B-Disease 1 0.993233859539032
dysplasia I-Disease 1 0.999901294708252
, O 0 2.695526200113818e-05
contractures B-Disease 1 0.9040895104408264
, O 0 8.667526003591774e-07
and O 0 6.406162356142886e-07
early B-Disease 0 3.5538621432351647e-06
death I-Disease 0 2.288933865202125e-05
. O 0 8.990386959339958e-06

To O 0 1.5798370441189036e-05
test O 0 4.8060314838949125e-06
for O 0 4.091554615115456e-07
possible O 0 1.3187184322305257e-06
nosologic O 0 0.0006047182832844555
identity O 0 3.1183196824713377e-06
between O 0 1.8121201037502033e-06
these O 0 2.340453875149251e-06
disorders O 0 0.4414725601673126
, O 0 2.4137801801771275e-07
we O 0 4.5698371309299546e-08
reviewed O 0 1.0882013157242909e-07
the O 0 9.993323502044404e-09
literature O 0 2.0996235861048262e-08
and O 0 1.4589203622961122e-08
obtained O 0 2.435856849558604e-08
a O 0 9.723826188690055e-09
follow O 0 4.239972994923846e-08
- O 0 4.119036475458415e-06
up O 0 3.6048209750561e-08
of O 0 8.418417074551598e-09
the O 0 1.4873631215550631e-08
only O 0 1.1042629033397589e-08
two O 0 1.5394603281038144e-07
surviving O 0 0.0005951072089374065
patients O 0 0.00011176535190315917
, O 0 1.1392968701784412e-07
one O 0 4.792017449517516e-08
with O 0 1.195931076836132e-06
SJS B-Disease 1 0.9936904907226562
type I-Disease 0 8.306281415570993e-06
2 I-Disease 0 3.8003253166607465e-07
at O 0 1.7371010585520708e-07
age O 0 2.0231480846177874e-07
10 O 0 4.6789480734332756e-08
years O 0 5.502296573922649e-08
and O 0 3.705753570670822e-08
another O 0 8.521571004393991e-08
with O 0 1.1517104212543927e-06
SWS B-Disease 1 0.6400123238563538
at O 0 1.9948779481637757e-06
age O 0 2.432055907775066e-06
7 O 0 3.3542503388162004e-06
years O 0 3.7035181321698474e-06
. O 0 5.6522872000641655e-06

Patients O 0 0.4771813452243805
reported O 0 9.27821165532805e-05
as O 0 9.403360650139803e-07
having O 0 2.7456383122625994e-06
either O 0 5.183094799576793e-06
neonatal O 1 0.9998005032539368
SJS B-Disease 1 0.9999189376831055
or O 0 3.224844112992287e-05
SWS B-Disease 0 0.3319951295852661
presented O 0 3.883100703205855e-07
a O 0 7.454083572611125e-08
combination O 0 7.60607520078338e-07
of O 0 8.387824124156396e-08
a O 0 2.9247653401398566e-06
severe O 0 0.08885900676250458
, O 0 2.0473140466492623e-05
prenatal O 1 0.990388810634613
- O 1 0.9998819828033447
onset O 1 0.9999812841415405
neuromuscular B-Disease 1 0.9999942779541016
disorder I-Disease 1 0.9998490810394287
( O 0 3.316361835459247e-05
with O 0 7.987033313838765e-05
congenital B-Disease 1 0.9999852180480957
joint I-Disease 0 0.4780048429965973
contractures I-Disease 1 0.9999579191207886
, O 0 0.001995257567614317
respiratory O 1 0.9943200349807739
and O 0 1.0205565558862872e-05
feeding O 0 0.00022529323177877814
difficulties O 0 0.00026947041624225676
, O 0 1.0202091971223126e-06
tendency O 0 1.3532478078559507e-05
to O 0 5.077503146821982e-07
hyperthermia B-Disease 0 0.020383154973387718
, O 0 3.736204234883189e-07
and O 0 3.143140929751098e-07
frequent O 0 7.221325631689979e-06
death O 0 3.7897748370596673e-06
in O 0 4.0424328062727e-07
infancy O 0 0.00030886352760717273
) O 0 1.280561150451831e-07
with O 0 2.881962224421386e-08
a O 0 7.889256181670135e-08
distinct O 0 1.572166752339399e-06
campomelic B-Disease 0 0.12978747487068176
- I-Disease 1 0.7653602957725525
metaphyseal I-Disease 1 0.955045759677887
skeletal I-Disease 1 0.9508005380630493
dysplasia I-Disease 1 0.9985368251800537
. O 0 6.78897849866189e-05

The O 0 4.385656211525202e-06
similarity O 0 1.293595960305538e-05
of O 0 3.6805960235142265e-07
the O 0 8.038029477575037e-07
clinical O 0 9.079346637008712e-05
and O 0 1.479674438087386e-06
radiographic O 0 0.0458439402282238
findings O 0 1.3245439731690567e-05
is O 0 1.0465169708595567e-07
so O 0 7.702798399122912e-08
extensive O 0 1.5164346223173197e-06
that O 0 2.1630714286402508e-07
these O 0 5.118502599543717e-07
disorders O 1 0.5208570957183838
appear O 0 5.63240860174119e-07
to O 0 3.747291188460622e-08
be O 0 1.0795883298442277e-08
a O 0 4.84052087301734e-08
single O 0 3.94906464862288e-07
entity O 0 6.743052381352754e-06
. O 0 6.2733679442317225e-06

The O 0 2.6914183308690554e-06
follow O 0 1.8130137959815329e-06
- O 0 2.103595033986494e-05
up O 0 2.802858034556266e-07
observation O 0 4.981474717169476e-07
of O 0 2.0527195943031984e-08
an O 0 1.4883420718092566e-08
identical O 0 1.479434530438084e-07
and O 0 4.953023591269812e-08
unique O 0 1.202993047400014e-07
pattern O 0 4.7096596063056495e-06
of O 0 9.439849577574932e-07
progressive O 0 0.09506402909755707
bone B-Disease 1 0.9992017149925232
dysplasia I-Disease 1 0.9997507929801941
in O 0 1.0879653018491808e-06
the O 0 5.128396196596441e-07
two O 0 1.309875642618863e-06
patients O 0 0.00017603319429326802
( O 0 3.691507401981653e-07
one O 0 5.538654690440126e-08
with O 0 2.294036903549568e-06
SJS B-Disease 1 0.9977868795394897
type I-Disease 0 8.17894033389166e-06
2 I-Disease 0 6.082819368202763e-07
, O 0 5.875391195786506e-08
one O 0 3.034023521308882e-08
with O 0 6.860502708150307e-07
SWS B-Disease 0 0.4670334458351135
) O 0 6.036904096617945e-07
surviving O 0 4.245036961947335e-06
beyond O 0 4.572636100874661e-07
infancy O 0 1.6435125871794298e-05
adds O 0 8.396673933930288e-07
to O 0 3.308764462417457e-08
the O 0 1.874513166910674e-08
evidence O 0 8.01847832576641e-08
in O 0 3.2747355049878024e-08
favor O 0 1.8194072026744834e-07
of O 0 2.3160866646776412e-07
identity O 0 1.227396660397062e-05
. O 0 1.0595074854791164e-05

The O 0 1.4689700037706643e-05
hypothesis O 0 6.4750638557598e-05
that O 0 2.3082179723132867e-06
SWS B-Disease 0 0.17283077538013458
and O 0 6.168009804241592e-06
SJS B-Disease 1 0.9965638518333435
type I-Disease 0 1.3182330803829245e-05
2 I-Disease 0 3.9558082676194317e-07
are O 0 2.3680119198843386e-08
the O 0 1.2377533664675866e-07
same O 0 1.814158849811065e-06
disorder O 0 0.1678028404712677
should O 0 1.2709956820344814e-07
be O 0 1.8930242262626962e-08
testable O 0 5.609374511550413e-07
by O 0 7.509939337069227e-08
molecular O 0 6.6484021772339474e-06
methods O 0 1.0472651865711669e-06
. O 0 6.767203331037308e-07
. O 0 3.775259528993047e-06

A O 0 5.068317477707751e-05
mouse O 0 0.0006494025583378971
model O 0 5.693922867067158e-05
of O 0 7.180136162787676e-05
severe O 1 0.9995633959770203
von B-Disease 1 0.9999877214431763
Willebrand I-Disease 1 0.9999924898147583
disease I-Disease 1 0.999985933303833
: O 0 0.01700815185904503
defects O 1 0.9348573684692383
in O 0 4.369880480226129e-05
hemostasis O 1 0.997238278388977
and O 0 0.00021376111544668674
thrombosis B-Disease 1 0.9991282820701599
. O 0 6.084320921218023e-05

von B-Disease 1 0.9957196116447449
Willebrand I-Disease 1 0.9979708790779114
factor I-Disease 0 0.013068705797195435
( I-Disease 0 0.0006555776344612241
vWf I-Disease 1 0.9757230281829834
) I-Disease 0 0.048769086599349976
deficiency I-Disease 1 0.9998984336853027
causes O 1 0.9921751618385315
severe O 1 0.9999269247055054
von B-Disease 1 0.9999926090240479
Willebrand I-Disease 1 0.9999864101409912
disease I-Disease 1 0.9997801184654236
in O 0 1.444350436941022e-05
humans O 0 5.6539487559348345e-05
. O 0 1.1075228030676953e-05

We O 0 6.11620680501801e-06
generated O 0 1.6753446061557042e-06
a O 0 3.367894123584847e-07
mouse O 0 1.227815755555639e-05
model O 0 6.867507522656524e-07
for O 0 2.1108129999447556e-07
this O 0 6.62423644826049e-07
disease O 0 0.0016465818043798208
by O 0 1.631863284501378e-07
using O 0 3.603893219406018e-07
gene O 0 3.83266751668998e-06
targeting O 0 3.7452232390933204e-06
. O 0 5.019916898163501e-06

vWf B-Disease 1 0.5059046745300293
- I-Disease 1 0.5957901477813721
deficient I-Disease 1 0.6714770197868347
mice O 0 0.0018503942992538214
appeared O 0 5.5471718951594085e-06
normal O 0 2.287880079165916e-06
at O 0 1.3322795666681486e-06
birth O 0 2.0160874555585906e-05
; O 0 6.020460432409891e-07
they O 0 6.034359500972641e-08
were O 0 7.003745139400053e-08
viable O 0 1.237508399754006e-06
and O 0 1.0033011221821653e-06
fertile O 0 0.0001753209508024156
. O 0 1.0830844075826462e-05

Neither O 0 0.0013631577603518963
vWf O 0 0.06489384919404984
nor O 0 0.0007941342191770673
vWf O 0 0.09528195112943649
propolypeptide O 1 0.5443766117095947
( O 0 0.00022363118478097022
von B-Disease 1 0.8661327958106995
Willebrand I-Disease 1 0.9944474697113037
antigen O 0 0.01320529356598854
II O 0 0.0001947230484802276
) O 0 1.612566933317794e-07
were O 0 1.622964695968676e-08
detectable O 0 2.212262728562564e-07
in O 0 1.9852462784797353e-08
plasma O 0 1.1173241318829241e-06
, O 0 1.563376770263858e-07
platelets O 0 8.09361445135437e-05
, O 0 1.3538404175506003e-07
or O 0 3.602401932312205e-07
endothelial O 0 0.00029938394436612725
cells O 0 7.901783192210132e-07
of O 0 4.205532988521554e-08
the O 0 2.646671646289178e-07
homozygous O 0 2.2115878891781904e-05
mutant O 0 6.228857819223776e-05
mice O 0 0.0001256673422176391
. O 0 3.89837623515632e-06

The O 0 5.3345225751399994e-05
mutant O 0 0.0015598188620060682
mice O 0 0.007001848891377449
exhibited O 0 0.00021216858294792473
defects O 0 0.09217943996191025
in O 0 2.1459611616592156e-06
hemostasis O 0 0.08687017858028412
with O 0 6.045984264346771e-07
a O 0 7.837808766453236e-07
highly O 0 2.4493885575793684e-05
prolonged O 1 0.7188903093338013
bleeding O 1 0.5154751539230347
time O 0 7.746718893031357e-07
and O 0 1.125439098359493e-06
spontaneous O 0 6.277822831179947e-05
bleeding O 0 0.011145779862999916
events O 0 9.450454285797605e-08
in O 0 2.8528720719123157e-08
approximately O 0 7.28528632976122e-08
10 O 0 1.0743957545855665e-07
% O 0 1.9900200243228028e-07
of O 0 8.292164466183749e-07
neonates O 0 0.02161537855863571
. O 0 1.1441979950177483e-05

As O 0 8.845038792060222e-06
in O 0 2.4129340090439655e-06
the O 0 4.247316610417329e-06
human O 0 0.00010778879368444905
disease O 0 0.1979895383119583
, O 0 4.0861652905732626e-07
the O 0 2.7332157515047584e-07
factor O 0 4.181628355581779e-06
VIII O 0 0.00017366746033076197
level O 0 1.5745854398119263e-07
in O 0 2.7153015835779115e-08
these O 0 3.3517157049800517e-08
mice O 0 1.2284705007914454e-05
was O 0 4.107853257551142e-08
reduced O 0 7.854003314378133e-08
strongly O 0 3.90740204636586e-08
as O 0 9.521029298298345e-09
a O 0 2.1456996179836096e-08
result O 0 8.89761295752578e-08
of O 0 1.4524844438312812e-08
the O 0 9.068119766197924e-08
lack O 0 9.326686836175213e-07
of O 0 1.0680495421411251e-07
protection O 0 1.5561665350105613e-05
provided O 0 1.5636690022802213e-06
by O 0 2.1070027287350968e-06
vWf O 0 0.0014889558078721166
. O 0 1.0366179594711866e-05

Defective O 1 0.9702085852622986
thrombosis B-Disease 1 0.9994561076164246
in O 0 3.70095694961492e-05
mutant O 0 0.0016525137471035123
mice O 0 0.0008989901980385184
was O 0 6.397053198270441e-07
also O 0 9.617475882350845e-08
evident O 0 2.6990215928890393e-07
in O 0 2.8391708539743377e-08
an O 0 2.7129358315391983e-08
in O 0 1.917179588417639e-07
vivo O 0 0.000248679454671219
model O 0 3.7656909626093693e-06
of O 0 1.0450748959556222e-05
vascular B-Disease 1 0.9997393488883972
injury I-Disease 0 0.10486896336078644
. O 0 3.108628879999742e-05

In O 0 5.394017534854356e-06
this O 0 6.081328365326044e-07
model O 0 9.122102255787468e-07
, O 0 1.8083828479120712e-07
the O 0 2.0132740985445707e-07
exteriorized O 0 0.0005779950879514217
mesentery O 0 0.0004996929201297462
was O 0 5.632655870613235e-07
superfused O 0 6.858625420136377e-05
with O 0 2.539479737606598e-07
ferric O 0 0.0009423766168765724
chloride O 0 8.01177247922169e-06
and O 0 5.318432272360951e-08
the O 0 4.76796664372614e-08
accumulation O 0 2.892858674385934e-06
of O 0 1.1473315453258692e-07
fluorescently O 0 0.0007391004473902285
labeled O 0 3.62588616553694e-05
platelets O 0 0.00013066871906630695
was O 0 2.106646093125164e-07
observed O 0 3.277216649166803e-07
by O 0 2.6457681201463856e-07
intravital O 0 0.0003187647380400449
microscopy O 0 2.805572330544237e-05
. O 0 6.064519311621552e-06

We O 0 4.77180874440819e-05
conclude O 0 0.00012289598817005754
that O 0 1.1137686897200183e-06
these O 0 5.259288968773035e-07
mice O 0 7.126403943402693e-05
very O 0 9.629890200812952e-07
closely O 0 8.644274203106761e-05
mimic O 1 0.9030351638793945
severe O 1 0.9773041605949402
human O 0 0.04885905608534813
von B-Disease 1 0.9999932050704956
Willebrand I-Disease 1 0.9999905824661255
disease I-Disease 1 0.9995371103286743
and O 0 8.482293765155191e-07
will O 0 1.0027045505012211e-07
be O 0 8.538910911681796e-09
very O 0 1.4257825142749425e-08
useful O 0 1.544905892103543e-08
for O 0 9.255473720770624e-09
investigating O 0 3.4984108765456767e-07
the O 0 2.251690922605576e-08
role O 0 1.0641576153602728e-07
of O 0 5.709513217766471e-08
vWf O 0 0.0001763606269378215
in O 0 1.1312202019553297e-07
normal O 0 1.1162442206114065e-06
physiology O 0 2.5154982722597197e-05
and O 0 6.455833272411837e-07
in O 0 5.0661246859817766e-06
disease O 0 0.0462038516998291
models O 0 3.76613252228708e-06
. O 0 1.2906234587717336e-06
. O 0 4.825430551136378e-06

Oral O 0 0.05246556177735329
contraceptives O 0 0.010116659104824066
and O 0 1.753890137479175e-05
the O 0 1.2287576282687951e-05
risk O 0 0.0014024749398231506
of O 0 0.00027875235537067056
hereditary B-Disease 1 0.9999167919158936
ovarian I-Disease 1 0.9999966621398926
cancer I-Disease 1 0.9999303817749023
. O 0 0.0004714412207249552

Hereditary B-Disease 1 0.9996304512023926
Ovarian I-Disease 1 0.9999685287475586
Cancer I-Disease 1 0.9997223019599915
Clinical O 0 0.2891312539577484
Study O 0 0.00017487400327809155
Group O 0 9.126299119088799e-05
. O 0 4.1566403524484485e-05

BACKGROUND O 0 0.0004329618823248893
Women O 0 3.2874744647415355e-05
with O 0 3.2386174098064657e-06
mutations O 0 4.310220538172871e-05
in O 0 9.659778044124323e-08
either O 0 8.070153256767298e-08
the O 0 1.3982686652980192e-07
BRCA1 O 0 0.00010274154192302376
or O 0 1.943776481994064e-07
the O 0 3.0035968734409835e-07
BRCA2 O 0 0.00019887549569830298
gene O 0 1.4954895277696778e-06
have O 0 4.141927689715885e-08
a O 0 8.497744374835747e-08
high O 0 1.1053312846343033e-05
lifetime O 0 0.0007833271520212293
risk O 0 0.0013725608587265015
of O 0 0.000278748368145898
ovarian B-Disease 1 0.9999935626983643
cancer I-Disease 1 0.9997190833091736
. O 0 0.00013031843991484493

Oral O 0 0.3767600655555725
contraceptives O 1 0.9377807378768921
protect O 1 0.5155256986618042
against O 1 0.9721916317939758
ovarian B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999439716339111
in O 0 3.4151782983826706e-06
general O 0 3.920417839253787e-06
, O 0 3.429545074595808e-07
but O 0 4.949236753759578e-08
it O 0 1.7998912582584126e-08
is O 0 1.7636246241181652e-08
not O 0 1.6959251780690465e-08
known O 0 1.4858906638437475e-07
whether O 0 5.9151396669676615e-08
they O 0 3.783718227623467e-08
also O 0 1.195593171132714e-07
protect O 0 7.110929800546728e-06
against O 0 7.848670975363348e-06
hereditary B-Disease 0 0.016139592975378036
forms I-Disease 0 5.823548053740524e-05
of I-Disease 0 0.0021375378128141165
ovarian I-Disease 1 0.9999949932098389
cancer I-Disease 1 0.9997579455375671
. O 0 0.00015648826956748962

METHODS O 0 6.062023385311477e-05
We O 0 3.7760155464638956e-06
enrolled O 0 8.350536518264562e-06
207 O 0 0.00017235973791684955
women O 0 6.814482185291126e-05
with O 0 0.005183331202715635
hereditary B-Disease 1 0.9999854564666748
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.999942421913147
and O 0 1.718633939162828e-06
161 O 0 3.5250191103841644e-06
of O 0 4.8654012374527156e-08
their O 0 1.1351029627348908e-07
sisters O 0 2.9767803425784223e-05
as O 0 2.6042867418141213e-08
controls O 0 1.1294824986407548e-07
in O 0 2.1977482944635085e-08
a O 0 9.83201715598625e-08
case O 0 2.0008376395708183e-06
- O 0 0.0007249459158629179
control O 0 1.302583495998988e-05
study O 0 9.163526556221768e-06
. O 0 6.374006716214353e-06

All O 0 7.3886972131731454e-06
the O 0 6.14277996646706e-06
patients O 0 0.00014186635962687433
carried O 0 5.92582239278272e-07
a O 0 3.3667541288195935e-07
pathogenic O 0 7.92929859017022e-06
mutation O 0 2.7508251605468104e-06
in O 0 1.1917352082946309e-07
either O 0 4.280140899481921e-07
BRCA1 O 0 0.00020710003445856273
( O 0 5.75547858261416e-07
179 O 0 5.770896223111777e-06
women O 0 9.593288723408477e-07
) O 0 3.577450513603253e-07
or O 0 5.193695074012794e-07
BRCA2 O 0 0.00020803537336178124
( O 0 6.321482146631752e-07
28 O 0 1.0587312999632559e-06
women O 0 1.4074613545744796e-06
) O 0 1.790970941328851e-06
. O 0 2.6930770218314137e-06

The O 0 1.9069793779635802e-05
control O 0 1.4815518625255208e-05
women O 0 2.2411607005778933e-06
were O 0 1.4611210019666032e-07
enrolled O 0 1.0680388413675246e-06
regardless O 0 1.477301339036785e-07
of O 0 4.480140702867175e-08
whether O 0 2.0636139197449666e-07
or O 0 1.3783323993266094e-07
not O 0 4.246658491524613e-08
they O 0 5.272405445566619e-08
had O 0 3.173480536133866e-07
either O 0 5.712366828447557e-07
mutation O 0 2.0694995328085497e-05
. O 0 4.611045824276516e-06

Lifetime O 0 0.0005960691487416625
histories O 0 0.00016904542280826718
of O 0 1.720001250760106e-06
oral O 0 0.0006283733528107405
- O 0 0.1098407730460167
contraceptive O 0 0.008680334314703941
use O 0 2.0579713577717484e-07
were O 0 3.027791706244898e-08
obtained O 0 5.0790472272410625e-08
by O 0 2.765441031726823e-08
interview O 0 6.134878276498057e-07
or O 0 2.5773994494215913e-08
by O 0 1.7613787761661115e-08
written O 0 1.1899329166453754e-07
questionnaire O 0 2.504241820133757e-06
and O 0 4.182351176496013e-08
were O 0 2.6957387433412805e-08
compared O 0 1.073634280146507e-06
between O 0 5.071427494840464e-06
patients O 0 0.0001916873879963532
and O 0 4.62081317209595e-07
control O 0 2.3783857159287436e-06
women O 0 9.261248692382651e-07
, O 0 1.4852926710773318e-07
after O 0 5.318970011103374e-07
adjustment O 0 1.8979412743647117e-06
for O 0 2.933080800460175e-08
year O 0 1.0070572642462139e-07
of O 0 8.080935742782458e-08
birth O 0 1.954127219505608e-05
and O 0 1.1795826821980882e-06
parity O 0 5.484944995259866e-05
. O 0 8.734908078622539e-06

RESULTS O 0 0.00018292179447598755
The O 0 4.4454009184846655e-06
adjusted O 0 0.000293889082968235
odds O 0 0.007637282833456993
ratio O 0 0.002011550823226571
for O 0 0.012482238933444023
ovarian B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999744892120361
associated O 0 1.4045867828826886e-05
with O 0 1.0309645404049661e-07
any O 0 2.0421598634356997e-08
past O 0 9.246619470104633e-08
use O 0 3.909146784053519e-08
of O 0 1.1892794304912968e-07
oral O 0 0.0001746373891364783
contraceptives O 0 0.0008680318132974207
was O 0 2.962226062663831e-06
0 O 0 3.5073691833531484e-05
. O 0 7.221545729407808e-06

5 O 0 2.379631405347027e-05
( O 0 2.304962208654615e-06
95 O 0 1.0635097851263708e-06
percent O 0 5.859828888787888e-07
confidence O 0 1.7502155742477044e-06
interval O 0 1.5326324955822201e-06
, O 0 5.189466634192286e-08
0 O 0 7.184981996033457e-07
. O 0 2.4409587240370456e-08
3 O 0 1.2140955618633598e-07
to O 0 5.891831378335155e-08
0 O 0 1.2174190260338946e-06
. O 0 1.3115652564010816e-07
8 O 0 1.3716345392822404e-06
) O 0 1.8214087731394102e-06
. O 0 3.996634859504411e-06

The O 0 6.167607352836058e-05
risk O 0 0.0003124835202470422
decreased O 0 1.8230148270959035e-05
with O 0 3.135763506634248e-07
increasing O 0 5.014109092371655e-07
duration O 0 1.2191943596917554e-06
of O 0 2.799096421313152e-08
use O 0 1.0716532017340796e-07
( O 0 2.4636116791043605e-07
P O 0 3.421389192226343e-05
for O 0 2.925895081773433e-08
trend O 0 5.357631494007364e-07
, O 0 4.0142190016467794e-08
< O 0 1.5776453437865712e-05
0 O 0 9.103374054575397e-07
. O 0 2.683007238601931e-08
001 O 0 8.1766011135187e-06
) O 0 2.7820588499594123e-08
; O 0 1.4127239822414595e-08
use O 0 3.5242631035714567e-09
for O 0 3.40542438692637e-09
six O 0 1.9943474427464025e-08
or O 0 1.7889801640080805e-08
more O 0 6.2135705469756886e-09
years O 0 1.1724122828127292e-07
was O 0 8.074896129528497e-08
associated O 0 1.2003229699075746e-07
with O 0 2.0366636377389113e-08
a O 0 3.5501585671227076e-08
60 O 0 1.524821016118949e-07
percent O 0 1.081395566870924e-06
reduction O 0 5.191756827116478e-06
in O 0 2.547698386479169e-06
risk O 0 0.00016514289018232375
. O 0 1.1791579709097277e-05

Oral O 0 0.005322121549397707
- O 0 0.15538114309310913
contraceptive O 0 0.21143466234207153
use O 0 2.8679120077867992e-05
protected O 0 0.003889701562002301
against O 0 0.3941282331943512
ovarian B-Disease 1 0.9999978542327881
cancer I-Disease 1 0.9995201826095581
both O 0 3.3700081303322804e-07
for O 0 1.1271259836576064e-07
carriers O 0 1.931038468683255e-06
of O 0 5.843885020340167e-08
the O 0 7.102939889591653e-07
BRCA1 O 0 0.001967123942449689
mutation O 0 1.4939791981305461e-05
( O 0 4.1986967858065327e-07
odds O 0 8.175953553291038e-06
ratio O 0 3.8293060811156465e-07
, O 0 2.5106542622665984e-08
0 O 0 1.7690848608253873e-07
. O 0 1.012795181054571e-08
5 O 0 3.298286088693203e-08
; O 0 2.5260732172682765e-08
95 O 0 4.649900731124035e-08
percent O 0 8.833659848050956e-08
confidence O 0 2.537000796110078e-07
interval O 0 2.1721049847656104e-07
, O 0 1.6421113357978356e-08
0 O 0 1.2982719965748402e-07
. O 0 5.556650695126564e-09
3 O 0 2.136934718066641e-08
to O 0 1.0995550248082964e-08
0 O 0 2.4607118120911764e-07
. O 0 1.0481146617280501e-08
9 O 0 1.2396684212490072e-07
) O 0 2.2677458133557593e-08
and O 0 8.921587024701694e-09
for O 0 8.906233972538757e-09
carriers O 0 1.9098071390999394e-07
of O 0 2.8042958177820765e-08
the O 0 4.0223892483481904e-07
BRCA2 O 0 0.0007413437706418335
mutation O 0 5.971443897578865e-06
( O 0 1.8660610123788501e-07
odds O 0 5.932725343882339e-06
ratio O 0 2.0863008387550508e-07
, O 0 2.0757598306886393e-08
0 O 0 1.9978411103238614e-07
. O 0 9.203437123517233e-09
4 O 0 3.823430461125099e-08
; O 0 3.215889066154887e-08
95 O 0 5.3374964892327625e-08
percent O 0 9.85266694897291e-08
confidence O 0 3.2830223517521517e-07
interval O 0 4.998296958547144e-07
, O 0 2.4796444009211882e-08
0 O 0 3.6002003866997256e-07
. O 0 8.750913771393698e-09
2 O 0 6.163642751744192e-08
to O 0 1.886647638116301e-08
1 O 0 1.6172795369584492e-07
. O 0 1.0525042171138921e-07
1 O 0 8.977063430393173e-07
) O 0 2.790178996292525e-06
. O 0 3.978446784458356e-06

CONCLUSIONS O 0 0.0003741523250937462
Oral O 0 0.000923730491194874
- O 0 0.047319911420345306
contraceptive O 0 0.014076192863285542
use O 0 3.370080094100558e-06
may O 0 8.041779437917285e-06
reduce O 0 1.941695882123895e-05
the O 0 1.3457079148793127e-06
risk O 0 0.0005412872997112572
of O 0 0.0002915870863944292
ovarian B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999351501464844
in O 0 4.503969648794737e-06
women O 0 6.108948582550511e-06
with O 0 2.5537601686664857e-06
pathogenic O 0 0.0001315087138209492
mutations O 0 2.331352879991755e-05
in O 0 2.280975195390056e-07
the O 0 1.3243103467175388e-06
BRCA1 O 0 0.0012056211708113551
or O 0 1.540147786727175e-05
BRCA2 O 0 0.003252733964473009
gene O 0 0.00020578909607138485

A O 0 3.849290806101635e-05
Japanese O 0 5.116842658026144e-05
family O 0 4.122721657040529e-05
with O 0 6.257087534322636e-06
adrenoleukodystrophy B-Disease 1 0.9984277486801147
with O 0 5.947857744104112e-07
a O 0 1.9095193692919565e-07
codon O 0 3.662580866148346e-06
291 O 0 1.0507795195735525e-05
deletion O 0 3.201842991984449e-05
: O 0 8.458559932478238e-07
a O 0 2.6841286171475076e-07
clinical O 0 6.220483192009851e-05
, O 0 6.8583574375225e-07
biochemical O 0 6.552634295076132e-05
, O 0 1.6081821740954183e-06
pathological O 0 0.0020729603711515665
, O 0 1.2112278682252509e-06
and O 0 2.3770273855916457e-06
genetic O 0 0.0002275149163324386
report O 0 1.1118118891317863e-05
. O 0 7.087870017130626e-06

We O 0 1.3306566870596725e-05
report O 0 3.6146227557765087e-06
a O 0 5.140456664776138e-07
Japanese O 0 7.366927547991509e-06
family O 0 3.1372223020298406e-05
with O 0 9.637203038437292e-05
adrenoleukodystrophy B-Disease 1 0.9999862909317017
( O 0 0.0036429392639547586
ALD B-Disease 1 0.9999392032623291
) O 0 4.936080699735612e-07
with O 0 3.0171037224135944e-08
a O 0 2.307767310583131e-08
three O 0 2.2344579519995023e-08
base O 0 3.377366510903812e-07
pair O 0 2.6804912067746045e-06
deletion O 0 4.288122363504954e-05
( O 0 6.757761639164528e-07
delGAG O 0 0.00010133835894521326
291 O 0 4.495969733397942e-06
) O 0 1.3915347096826736e-07
in O 0 1.2808506255623797e-07
the O 0 1.7914132968144258e-06
ALD B-Disease 1 0.9987443685531616
gene O 0 7.51857296563685e-05
. O 0 7.55431847210275e-06

A O 0 1.085136773326667e-05
variety O 0 2.7779392439697403e-06
of O 0 1.4484502344203065e-06
phenotypes O 0 0.0003545581712387502
were O 0 2.3840145502163068e-07
observed O 0 4.953174652655434e-07
within O 0 1.3228697071099305e-07
this O 0 2.2710534608449962e-07
family O 0 8.500664080202114e-06
. O 0 5.99444365434465e-06

While O 0 1.3931275134382304e-05
the O 0 5.050798790762201e-06
proband O 0 0.097696952521801
( O 0 1.3522597328119446e-05
patient O 0 0.00017590215429663658
1 O 0 1.0949695479212096e-06
) O 0 2.564114538472495e-07
was O 0 8.849984567405045e-08
classified O 0 8.050473638832045e-07
as O 0 2.3478770927454207e-08
having O 0 8.780813232078799e-08
a O 0 5.505813405193294e-08
rare O 0 1.1715242180798668e-06
intermediate O 0 1.4326022892419132e-06
type O 0 1.6699370917194756e-06
of O 0 1.0608017220192778e-07
adult O 0 5.3225135161483195e-06
cerebral O 0 0.012344270944595337
and O 0 1.5649087572455755e-06
cerebello O 0 0.10084458440542221
- O 0 0.3083307147026062
brain O 0 0.024520114064216614
stem O 0 4.423228165251203e-05
forms O 0 2.9274843882376445e-07
, O 0 1.471069026592886e-07
his O 0 6.313348421826959e-07
younger O 0 2.508001125534065e-05
brother O 0 8.712266571819782e-05
( O 0 2.234843123005703e-06
patient O 0 1.625095319468528e-05
2 O 0 7.239255523927568e-07
) O 0 2.2683045131088875e-07
and O 0 3.5906577977584675e-07
nephew O 0 0.0012927515199407935
( O 0 3.522693532431731e-06
patient O 0 2.8240159736014903e-05
3 O 0 9.042115038937482e-07
) O 0 4.6469881453958806e-07
had O 0 5.705740591110953e-07
a O 0 3.3415046800655546e-06
childhood O 1 0.5163090825080872
ALD B-Disease 1 0.9998962879180908
type O 0 0.0012429890921339393
. O 0 1.8282853488926776e-05

Another O 0 0.00014474296767730266
nephew O 0 0.062176961451768875
( O 0 7.236508099595085e-05
patient O 0 0.0006766961305402219
4 O 0 5.814643373014405e-06
) O 0 4.2983316461686627e-07
of O 0 1.820660457951817e-07
patient O 0 6.627316179219633e-05
1 O 0 1.431655732631043e-06
was O 0 2.804119958454976e-07
classified O 0 2.6224010980513413e-06
as O 0 1.0412407647208965e-07
having O 0 8.146146797116671e-07
an O 0 5.693287903341115e-07
adolescent O 0 0.001893842127174139
form O 0 7.82134520704858e-06
. O 0 1.0116938028659206e-05

The O 0 8.229892955569085e-06
tau O 0 5.9193524066358805e-05
level O 0 1.8407852167001693e-06
in O 0 2.197300261741475e-07
the O 0 3.453632189120981e-07
cerebrospinal O 0 0.003423401853069663
fluid O 0 0.00018526919302530587
( O 0 3.626974148573936e-06
CSF O 0 0.019122453406453133
) O 0 2.854652620953857e-07
in O 0 7.861617490334538e-08
patient O 0 1.189292743219994e-05
1 O 0 2.0195508909637283e-07
was O 0 3.6336828657113074e-08
as O 0 1.5492080507328865e-08
high O 0 1.6901473998132133e-07
as O 0 2.08237427301583e-08
that O 0 4.1195679756356185e-08
of O 0 4.523368772879621e-07
patients O 0 0.011227386072278023
with O 0 0.0015872219810262322
Alzheimers B-Disease 1 0.9999959468841553
disease I-Disease 1 0.9930144548416138
( O 0 9.398355359735433e-06
AD B-Disease 0 3.353392457938753e-05
) O 0 3.992680831288453e-06
. O 0 5.354578206606675e-06

His O 0 0.00012061846791766584
brain O 0 0.004903059918433428
magnetic O 0 5.0736365665216e-05
resonance O 0 0.00011792426084866747
image O 0 9.314246563008055e-05
( O 0 1.0772591849672608e-05
MRI O 0 0.006456527393311262
) O 0 1.8792997025229852e-06
showed O 0 7.106523298716638e-06
abnormalities B-Disease 0 0.00020863325335085392
in I-Disease 0 3.658537650608196e-08
the I-Disease 0 6.656229345480824e-08
bilateral I-Disease 0 4.199996510578785e-06
cerebellar I-Disease 0 0.06473712623119354
hemispheres I-Disease 0 0.00016355450497940183
and O 0 1.3625353858515155e-05
brain O 0 0.09521658718585968
stem O 0 0.0002433186600683257
, O 0 1.7171873878396582e-07
but O 0 3.29589013858822e-08
not O 0 9.736167427831788e-09
in O 0 2.3675738702877425e-08
the O 0 2.2267599320002773e-07
cerebral O 0 0.011868325062096119
white O 0 1.851832348620519e-05
matter O 0 1.5971683353654953e-07
, O 0 5.460852392502602e-08
where O 0 5.521620138893013e-08
marked O 0 2.4894401917663345e-07
reductions O 0 4.944330385114881e-07
of O 0 4.6531656749948525e-08
the O 0 7.026176831459452e-07
cerebral O 0 0.10294841229915619
blood O 0 5.008279185858555e-05
flow O 0 1.0419128102512332e-06
and O 0 1.1522835308142021e-07
oxygen O 0 3.6055334931006655e-06
metabolism O 0 4.000471108156489e-06
were O 0 3.012526761381196e-08
clearly O 0 1.6558358595375466e-07
demonstrated O 0 2.1724508769693784e-07
by O 0 7.867136986305923e-08
positron O 0 3.6795037885895e-05
emission O 0 4.445460035640281e-06
tomography O 0 4.004310176242143e-05
( O 0 1.1517796565385652e-06
PET O 0 3.7201109080342576e-05
) O 0 1.808151523619017e-06
. O 0 3.492973974061897e-06

In O 0 7.865150837460533e-05
patients O 0 0.0009944759076461196
2 O 0 5.314058853400638e-06
and O 0 5.280815003061434e-07
3 O 0 1.7865405652628397e-06
, O 0 2.1609332634398015e-07
the O 0 2.152032436697482e-07
autopsy O 0 0.00010290057252859697
findings O 0 4.530813384917565e-06
showed O 0 5.768629307567608e-06
massive O 0 0.0003619211202021688
demyelination B-Disease 1 0.9925083518028259
of I-Disease 0 3.686476475195377e-07
the I-Disease 0 1.3206150697442354e-06
cerebral I-Disease 0 0.009503436274826527
white I-Disease 0 4.053932116221404e-06
matter I-Disease 0 4.42032543901405e-08
with O 0 1.8803859802574152e-08
sparing O 0 2.625601780437137e-07
of O 0 9.172313575334101e-09
the O 0 3.424034034082979e-08
U O 0 0.00011505838483572006
- O 0 0.0008083516731858253
fibers O 0 0.00020105055591557175
, O 0 9.635726172518844e-08
compatible O 0 1.3665865594703064e-07
with O 0 5.291062876722208e-08
the O 0 1.4648615831447387e-07
findings O 0 2.9990021630510455e-06
of O 0 2.9015259315201547e-06
childhood O 1 0.7291274666786194
ALD B-Disease 1 0.9997863173484802
. O 0 9.93281792034395e-05

Oleic O 0 0.00451858201995492
and O 0 2.81839857052546e-05
erucic O 0 0.04652903601527214
acids O 0 5.606759441434406e-05
( O 0 2.1223984276730334e-06
Lorenzos O 0 0.00013988207501824945
Oil O 0 7.658635468033026e-07
) O 0 1.1688175050039717e-07
were O 0 3.365270373478779e-08
administered O 0 3.8194698959159723e-07
to O 0 2.9860916583857033e-07
patients O 0 1.4780139281356242e-05
1 O 0 3.628004492384207e-07
and O 0 1.9596440381519642e-07
4 O 0 1.3511345287042786e-06
, O 0 1.8585804184567678e-07
but O 0 1.0429182850657526e-07
sufficient O 0 5.19412139965425e-07
effectiveness O 0 1.291166427108692e-06
was O 0 9.461762573437227e-08
not O 0 8.555771557894332e-08
obtained O 0 1.0577483635643148e-06
. O 0 3.10856898977363e-06

The O 0 1.793512092262972e-05
findings O 0 1.8851440472644754e-05
in O 0 4.0976499349199e-07
this O 0 1.7494001269824366e-07
family O 0 1.951099420693936e-06
suggest O 0 1.8175461491409806e-06
that O 0 1.2331101117979415e-07
delGAG291 O 0 7.819622260285541e-05
is O 0 2.9370220033797523e-08
part O 0 2.9235856402465288e-08
of O 0 2.4441130008767686e-08
the O 0 1.9014164820418955e-07
cause O 0 3.654998863567016e-06
of O 0 3.7557529708465154e-07
Japanese O 0 0.0001164980058092624
ALD B-Disease 1 0.9997841715812683
with O 0 1.175003399112029e-05
phenotypic O 0 0.00023467444407287985
variations O 0 5.5995882576098666e-05
. O 0 1.0976264093187638e-05

Moreover O 0 0.00020056824723724276
, O 0 2.151992703147698e-06
although O 0 2.905508722506056e-07
the O 0 6.797552742909829e-08
scale O 0 1.7328748072031885e-06
of O 0 5.8395620783358027e-08
the O 0 1.0292531982258879e-07
study O 0 4.381436724543164e-07
is O 0 3.757124389380806e-08
limited O 0 1.7740977398261748e-07
, O 0 1.1443255232279625e-07
there O 0 3.0001409356827935e-08
is O 0 2.0822868762593316e-08
a O 0 4.516872564863661e-08
possibility O 0 1.4363014315676992e-06
that O 0 4.92593756007409e-07
PET O 0 0.0004990403540432453
can O 0 1.9375834199308883e-06
detect O 0 0.00021201731578912586
an O 0 3.101471861555183e-07
insidious B-Disease 0 0.012544459663331509
lesion I-Disease 0 0.3332803547382355
which O 0 1.4205699017111328e-07
is O 0 9.196158856639158e-08
undetectable O 0 4.34394405601779e-06
by O 0 5.0903263826285183e-08
computed O 0 1.0605341458358453e-06
tomogram O 0 0.00044769232044927776
( O 0 9.567178267388954e-07
CT O 0 0.011245081201195717
) O 0 3.435243627336604e-07
or O 0 1.3725201597480918e-07
MRI O 0 4.438583709998056e-05
analysis O 0 1.1420773660120176e-07
, O 0 2.238685326005907e-08
and O 0 1.0982513565238605e-08
that O 0 4.455349422727295e-09
the O 0 6.1131322226515294e-09
higher O 0 1.997305076884004e-08
level O 0 1.738840538223485e-08
of O 0 9.559296465511125e-09
tau O 0 2.697490344871767e-06
reflects O 0 1.7556475029323337e-07
the O 0 1.501417834504082e-08
process O 0 4.9962523007707205e-08
of O 0 1.8131282786271186e-07
neuronal B-Disease 0 0.0017505551222711802
degeneration I-Disease 1 0.9890885949134827
in O 0 0.00013192015467211604
ALD B-Disease 1 0.9996763467788696
. O 0 5.774816600023769e-05

Lorenzos O 0 0.015572378411889076
Oil O 0 3.1757728720549494e-05
should O 0 7.94252002833673e-07
be O 0 5.476132614035123e-08
given O 0 2.7605086216908603e-08
in O 0 2.414946997930656e-08
the O 0 4.468006054025864e-08
early O 0 3.809298902979208e-07
stage O 0 4.835523668589303e-06
. O 0 9.340697033621836e-07
. O 0 3.832320089713903e-06

Nonsense O 0 0.002528880024328828
mutation O 0 0.00030771640012972057
in O 0 1.7975039554585237e-06
exon O 0 7.757752609904855e-05
4 O 0 1.7756765373633243e-06
of O 0 1.7621945858081745e-07
human O 0 5.819469492962526e-07
complement O 0 2.1376354197855107e-06
C9 O 0 0.026852896437048912
gene O 0 5.688425972039113e-06
is O 0 5.3882828865425836e-08
the O 0 8.306737697694189e-08
major O 0 1.0786702659970615e-06
cause O 0 2.122372052326682e-06
of O 0 1.6250966439201875e-07
Japanese O 0 1.697682455414906e-05
complement B-Disease 0 0.00020968966418877244
C9 I-Disease 1 0.9937536120414734
deficiency I-Disease 1 0.9958785772323608
. O 0 3.298317824373953e-05

Deficiency B-Disease 1 0.9949835538864136
of I-Disease 0 3.437331997702131e-06
the I-Disease 0 9.68340486906527e-07
ninth I-Disease 0 1.1999733033007942e-05
component I-Disease 0 1.326887968389201e-06
of I-Disease 0 1.2148032624281768e-07
human I-Disease 0 4.664998414227739e-07
complement I-Disease 0 1.8698623307500384e-06
( O 0 9.182572284771595e-07
C9 O 0 0.01281087938696146
) O 0 2.4424264211120317e-07
is O 0 2.6328599744829262e-08
the O 0 2.748126171070453e-08
most O 0 5.5351488725818854e-08
common O 0 6.412759830709547e-06
complement B-Disease 0 0.030459348112344742
deficiency I-Disease 1 0.9994716048240662
in O 0 6.240759944375895e-07
Japan O 0 6.218378530320479e-06
but O 0 1.3362402739858226e-07
is O 0 5.888697174327717e-08
rare O 0 4.194162386284006e-07
in O 0 7.135496105092898e-08
other O 0 9.969567571488369e-08
countries O 0 7.385882554444834e-07
. O 0 5.641984898829833e-06

We O 0 7.3246014835604e-06
studied O 0 1.8553356539996457e-06
the O 0 1.9309764809349872e-07
molecular O 0 2.2197577891347464e-06
basis O 0 1.2352674616522563e-07
of O 0 6.188900556480803e-07
C9 B-Disease 1 0.9737571477890015
deficiency I-Disease 1 0.8342484831809998
in O 0 1.174304529172332e-07
four O 0 1.7041881505974743e-07
Japanese O 0 1.7049638699973002e-05
C9 B-Disease 1 0.9804081916809082
- I-Disease 1 0.9930724501609802
deficient I-Disease 1 0.9968926310539246
patients O 0 0.03667806088924408
who O 0 1.778652222128585e-05
had O 0 6.0053942434024066e-05
suffered O 1 0.675342857837677
from O 0 5.524294465431012e-05
meningococcal B-Disease 1 0.9988351464271545
meningitis I-Disease 1 0.9957590699195862
. O 0 6.883543392177671e-05

Direct O 0 1.3083164958516136e-05
sequencing O 0 1.283460824197391e-05
of O 0 8.678675840201322e-07
amplified O 0 1.1185779840161558e-05
C9 O 0 0.00034222195972688496
cDNA O 0 5.107105153001612e-06
and O 0 4.1159444208460627e-07
DNA O 0 3.2460509373777313e-06
revealed O 0 8.400806450481468e-07
a O 0 4.00725745919317e-08
nonsense O 0 7.900065384092159e-07
substitution O 0 9.073552575955546e-08
( O 0 5.9400580454394e-08
CGA O 0 1.0792115290314541e-06
- O 0 2.602187123557087e-05
- O 0 0.00012238622002769262
> O 0 5.8916284615406767e-05
TGA O 0 0.00016769110516179353
) O 0 4.1012931717432366e-08
at O 0 1.7232567373071106e-08
codon O 0 7.218491759886092e-08
95 O 0 2.117807085255663e-08
in O 0 6.3295026997423065e-09
exon O 0 4.882376742898487e-07
4 O 0 5.4167433205520865e-08
in O 0 1.1294367219250034e-08
the O 0 3.639196677340806e-08
four O 0 3.703584923187009e-07
C9 B-Disease 0 0.39702725410461426
- I-Disease 0 0.20885559916496277
deficient I-Disease 0 0.07028093934059143
individuals O 0 6.245205440791324e-06
. O 0 7.251622264448088e-06

An O 0 7.828225534467492e-06
allele O 0 2.2666688892059028e-05
- O 0 0.00010345488408347592
specific O 0 9.998891528084641e-07
polymerase O 0 8.833888568915427e-05
chain O 0 2.708011925278697e-05
reaction O 0 1.0246711781292106e-06
system O 0 5.12472524860641e-07
designed O 0 1.0181786365137668e-06
to O 0 9.589103200369209e-08
detect O 0 5.0998146434722e-06
exclusively O 0 2.1224250801310518e-08
only O 0 3.787615998618321e-09
one O 0 3.1391573784844695e-09
of O 0 4.6701278400007595e-09
the O 0 1.74787171403068e-08
normal O 0 1.0257627991450136e-07
and O 0 5.24524317313535e-08
mutant O 0 5.337992661225144e-06
alleles O 0 8.945306717578205e-07
indicated O 0 2.4591329861323175e-07
that O 0 5.823219684231162e-09
all O 0 4.0881698026851154e-09
the O 0 2.3636664181481137e-08
four O 0 2.1896859436765226e-07
patients O 0 1.1611759873630945e-05
were O 0 1.749379130444595e-08
homozygous O 0 4.014468117929937e-07
for O 0 8.07309064043693e-09
the O 0 2.5346832188688495e-08
mutation O 0 3.888381456818024e-07
in O 0 2.452611980174879e-08
exon O 0 1.1180041838088073e-05
4 O 0 4.295208952953544e-07
and O 0 3.1015691348557084e-08
that O 0 1.868584043052124e-08
the O 0 4.466566139171846e-08
parents O 0 5.940335654486262e-07
of O 0 1.3695482437015016e-07
patient O 0 5.551528374780901e-05
2 O 0 1.6279519741146942e-06
were O 0 4.345885429302143e-07
heterozygous O 0 1.2032323866151273e-05
. O 0 6.174413101689424e-06

The O 0 1.5255021025950555e-05
common O 0 7.5021316661150195e-06
mutation O 0 6.343534550978802e-06
at O 0 2.5586501806174056e-07
codon O 0 9.934827858160133e-07
95 O 0 2.4468795345455874e-07
in O 0 5.5921017150240004e-08
exon O 0 1.2148384485044517e-05
4 O 0 1.801896019060223e-06
might O 0 3.3619062378420494e-07
be O 0 1.2893506706745939e-08
responsible O 0 8.168631637772705e-08
for O 0 4.3115512937674794e-08
most O 0 2.829006575666426e-07
Japanese O 0 0.000397296593291685
C9 B-Disease 1 0.9996567964553833
deficiency I-Disease 1 0.9993661046028137
. O 0 5.885384325665655e-06
. O 0 1.2246584446984343e-05

BRCA1 O 0 0.009944969788193703
required O 0 6.7661462708201725e-06
for O 0 1.1565556405912503e-06
transcription O 0 7.908003317425027e-05
- O 0 0.008289465680718422
coupled O 0 0.0007637870730832219
repair O 0 0.012524995021522045
of O 0 2.012672666751314e-06
oxidative O 0 0.0680241659283638
DNA O 0 0.0008408896974287927
damage O 0 0.0012402263237163424
. O 0 1.7753036445355974e-05

The O 0 0.0021703671663999557
breast B-Disease 1 0.9992220401763916
and I-Disease 1 0.8720507025718689
ovarian I-Disease 1 0.9999964237213135
cancer I-Disease 1 0.9999725818634033
susceptibility O 1 0.9838457107543945
gene O 0 0.000543913512956351
BRCA1 O 0 0.0007452423451468349
encodes O 0 3.3815056212915806e-06
a O 0 5.405797196544881e-07
zinc O 0 0.0014563160948455334
finger O 0 7.695066597079858e-05
protein O 0 7.242038577714993e-07
of O 0 1.444737449673994e-07
unknown O 0 2.497059085726505e-06
function O 0 3.6322981031844392e-06
. O 0 4.4520575102069415e-06

Association O 0 4.806889410247095e-05
of O 0 7.91467243743682e-07
the O 0 7.44387421036663e-07
BRCA1 O 0 0.00015570773393847048
protein O 0 4.487936564601114e-07
with O 0 5.687796544862067e-08
the O 0 7.937918411471401e-08
DNA O 0 6.129625489847967e-06
repair O 0 0.0006540006143040955
protein O 0 1.2015350421279436e-06
Rad51 O 0 0.00014233872934710234
and O 0 2.572522461719018e-08
changes O 0 2.1670290450970242e-08
in O 0 4.773824002768379e-09
the O 0 4.295173994250945e-09
phosphorylation O 0 4.596595459815944e-08
and O 0 1.3722657676851213e-08
cellular O 0 3.2095690016831213e-07
localization O 0 1.6431225446922326e-07
of O 0 8.466677137164424e-09
the O 0 1.9260211203686595e-08
protein O 0 1.465740524508874e-07
after O 0 2.292349847721198e-07
exposure O 0 5.425818926596548e-06
to O 0 6.023400800359013e-08
DNA O 0 6.3155198404274415e-06
- O 0 0.0011462965048849583
damaging O 0 4.492178049986251e-05
agents O 0 1.9654724781048571e-07
are O 0 1.1052616599727116e-08
consistent O 0 5.59257102850097e-08
with O 0 1.2790337677870411e-08
a O 0 3.481551758000023e-08
role O 0 2.3430840201399405e-07
for O 0 2.6238694772473536e-07
BRCA1 O 0 0.00011844976688735187
in O 0 8.02481736172922e-07
DNA O 0 0.00016832885739859194
repair O 0 0.0762920007109642
. O 0 1.9653274648590013e-05

Here O 0 1.7649726942181587e-05
, O 0 1.3195764267948107e-06
it O 0 1.1433523638970655e-07
is O 0 6.780317818311232e-08
shown O 0 1.2976555296972947e-07
that O 0 1.0590994747872173e-07
mouse O 0 2.603631764941383e-05
embryonic O 0 9.719906665850431e-05
stem O 0 0.000394705799408257
cells O 0 3.158369872835465e-05
deficient B-Disease 0 0.0001643792202230543
in I-Disease 0 1.5082410698141757e-07
BRCA1 I-Disease 0 3.100457615801133e-05
are O 0 3.049049013270633e-08
defective O 0 1.6240257991739782e-06
in O 0 1.5540290831950188e-08
the O 0 1.5158686750282868e-08
ability O 0 4.8368935523512846e-08
to O 0 5.513576706306367e-09
carry O 0 9.633995823321584e-09
out O 0 7.425529524596186e-09
transcription O 0 6.108904244683799e-07
- O 0 6.642235530307516e-05
coupled O 0 2.7940486688748933e-05
repair O 0 0.0010368915973231196
of O 0 2.5676334303170734e-07
oxidative O 0 0.010697157122194767
DNA O 0 0.0003396956599317491
damage O 0 0.00012133252312196419
, O 0 9.669695799630063e-08
and O 0 6.018359499648795e-08
are O 0 5.059680319163817e-08
hypersensitive O 0 0.00016689306357875466
to O 0 5.462632657327049e-07
ionizing O 0 0.00035328679950907826
radiation O 0 2.693632268346846e-05
and O 0 2.437644468500366e-07
hydrogen O 0 5.325189249560935e-06
peroxide O 0 0.00022782597807236016
. O 0 8.387530215259176e-06

These O 0 1.133413752540946e-05
results O 0 1.4288050806499086e-05
suggest O 0 1.0674843906599563e-05
that O 0 6.530076461785939e-07
BRCA1 O 0 0.0002963250153698027
participates O 0 5.415407940745354e-06
, O 0 1.3999498094108276e-07
directly O 0 4.7588084584049284e-08
or O 0 7.022673287337966e-08
indirectly O 0 3.046950780571933e-07
, O 0 2.6272315878372865e-08
in O 0 3.734576026204195e-08
transcription O 0 1.3185550415073521e-05
- O 0 0.006165733095258474
coupled O 0 0.0004312775854486972
repair O 0 0.0066071683540940285
of O 0 1.3510521057469305e-06
oxidative O 0 0.029108604416251183
DNA O 0 0.0006741301040165126
damage O 0 0.0009184254449792206
. O 0 1.7997904251387808e-06
. O 0 6.952715011721011e-06

Truncation O 0 0.007900837808847427
mutations O 0 0.0005564905004575849
in O 0 1.4685209634990315e-06
the O 0 6.206477678460942e-07
transactivation O 0 0.00014766657841391861
region O 0 2.0456761831155745e-06
of O 0 3.563992834187957e-07
PAX6 O 0 0.013547892682254314
result O 0 6.844616109447088e-07
in O 0 1.1325672488737837e-07
dominant O 0 3.8935681914153975e-06
- O 0 0.0014660743763670325
negative O 0 1.1209294825675897e-05
mutants O 0 0.00012063100439263508
. O 0 4.6986328925413545e-06

PAX6 O 0 0.0866670086979866
is O 0 5.237068762653507e-06
a O 0 1.062140427166014e-06
transcription O 0 1.806446016416885e-05
factor O 0 1.0141541224584216e-06
with O 0 4.196742864337466e-08
two O 0 3.1522869647915286e-08
DNA O 0 1.5279317722161068e-06
- O 0 4.3622072553262115e-05
binding O 0 6.796709044465388e-07
domains O 0 1.4894490050210152e-06
( O 0 1.3310612700934144e-07
paired O 0 8.241204341175035e-07
box O 0 1.2031276810375857e-06
and O 0 1.4240340817650576e-07
homeobox O 0 0.00010223801655229181
) O 0 5.021923854542365e-08
and O 0 9.824478119924152e-09
a O 0 1.4638093404073516e-08
proline O 0 1.9903666270693066e-06
- O 0 1.2118670383642893e-05
serine O 0 1.6525576711501344e-06
- O 0 2.8120999559178017e-05
threonine O 0 1.2310353667999152e-05
( O 0 3.3703906865412137e-07
PST O 0 3.516300785122439e-05
) O 0 2.1389128335158603e-07
- O 0 1.6029247490223497e-05
rich O 0 4.806769538845401e-06
transactivation O 0 0.000156232577865012
domain O 0 8.356097168871202e-06
. O 0 7.287436346814502e-06

PAX6 O 1 0.9107539653778076
regulates O 0 0.019653553143143654
eye O 0 0.033454254269599915
development O 0 1.3213596503192093e-05
in O 0 8.729027172194037e-07
animals O 0 9.369649092150212e-07
ranging O 0 1.1965025805693585e-06
from O 0 3.172723666011734e-07
jellyfish O 0 2.1961006495985202e-05
to O 0 1.3581400537532318e-07
Drosophila O 0 1.5693834711782984e-06
to O 0 4.044842683015304e-07
humans O 0 2.9904056191298878e-06
. O 0 3.662458766484633e-06

Heterozygous O 0 0.0015788399614393711
mutations O 0 0.0010419045574963093
in O 0 2.2721440018358408e-06
the O 0 9.951991160050966e-07
human O 0 3.432483708820655e-06
PAX6 O 0 0.061470843851566315
gene O 0 1.8587343220133334e-05
result O 0 3.904549430444604e-07
in O 0 4.944867981748757e-08
various O 0 6.332378887918821e-08
phenotypes O 0 4.742624150821939e-05
, O 0 3.1816321666156e-07
including O 0 2.19841672333132e-06
aniridia B-Disease 1 0.995873749256134
, O 0 4.253747101756744e-05
Peters B-Disease 1 0.9553630352020264
anomaly I-Disease 1 0.9748240113258362
, O 0 6.698816287098452e-05
autosomal B-Disease 0 0.21986621618270874
dominant I-Disease 0 0.001494410214945674
keratitis I-Disease 1 0.9602996110916138
, O 0 1.55824855028186e-05
and O 0 0.0001016319656628184
familial B-Disease 1 0.9994372725486755
foveal I-Disease 1 0.9993200302124023
dysplasia I-Disease 1 0.9997697472572327
. O 0 0.0001499342906754464

It O 0 1.0114603355759755e-05
is O 0 1.2562112488012644e-06
believed O 0 8.557352089155756e-07
that O 0 7.782930566690993e-08
the O 0 6.324606260932342e-08
mutated O 0 1.450969307370542e-06
allele O 0 2.825649403348507e-07
of O 0 6.570431310137792e-08
PAX6 O 0 0.0003375210799276829
produces O 0 2.0608251816156553e-07
an O 0 2.6675664344111283e-08
inactive O 0 1.1677140037136269e-06
protein O 0 6.066933337933733e-07
and O 0 9.133210028267058e-07
aniridia B-Disease 1 0.9326493144035339
is O 0 1.3547563639804139e-06
caused O 0 3.16174809995573e-05
due O 0 2.3980571768333903e-06
to O 0 1.0743409575297846e-06
genetic O 0 0.00018995290156453848
haploinsufficiency O 0 0.01628740504384041
. O 0 1.4803385056438856e-05

However O 0 2.546868381614331e-05
, O 0 1.6527609432159807e-06
several O 0 7.760575044812867e-07
truncation O 0 0.00045256366138346493
mutations O 0 0.00015702727250754833
have O 0 2.0068658557192975e-07
been O 0 5.620031018338523e-08
found O 0 5.5371657481373404e-08
to O 0 3.0052266453139964e-08
occur O 0 4.27150013138089e-08
in O 0 7.929577883203365e-09
the O 0 2.5609637077650405e-08
C O 0 1.017846807371825e-05
- O 0 4.6610122808488086e-05
terminal O 0 5.441136181616457e-06
half O 0 4.166808409422629e-08
of O 0 6.778041949928593e-08
PAX6 O 0 0.012499730102717876
in O 0 1.039341327668808e-06
patients O 0 3.804308653343469e-05
with O 0 5.280124923956464e-07
Aniridia B-Disease 0 0.45057913661003113
resulting O 0 5.184841711525223e-07
in O 0 1.963012330463698e-08
mutant O 0 7.315305765587254e-07
proteins O 0 5.1084853680549713e-08
that O 0 6.6975012202874495e-09
retain O 0 7.092266685049253e-08
the O 0 1.3303500523420553e-08
DNA O 0 5.844486850037356e-07
- O 0 2.1528981960727833e-05
binding O 0 3.125740306586522e-07
domains O 0 7.777393307151215e-07
but O 0 3.640863255327531e-08
have O 0 3.513104118724186e-08
lost O 0 1.4988377188274171e-06
most O 0 2.1987084153352043e-08
of O 0 5.8809185077279835e-08
the O 0 6.211640766196069e-07
transactivation O 0 0.000568008457776159
domain O 0 2.3485399651690386e-05
. O 0 1.0114853466802742e-05

It O 0 6.6724378484650515e-06
is O 0 6.548786473103974e-07
not O 0 7.359516018823342e-08
clear O 0 1.2385882541821047e-07
whether O 0 7.555800607406127e-08
such O 0 7.719506811554311e-08
mutants O 0 4.0715342038311064e-05
really O 0 1.0071184988191817e-06
behave O 0 3.1139668976720714e-07
as O 0 2.0718438520361815e-08
loss O 0 6.398873665602878e-06
- O 0 1.4375263162946794e-05
of O 0 7.37263832206736e-08
- O 0 0.0004035655583720654
function O 0 1.4899519555910956e-06
mutants O 0 1.3897159988118801e-05
as O 0 1.2694100348653592e-07
predicted O 0 4.348374659457477e-06
by O 0 6.695466936434968e-07
haploinsufficiency O 0 0.0010380831081420183
. O 0 7.779020052112173e-06

Contrary O 0 4.160233220318332e-05
to O 0 1.6207766293518944e-06
this O 0 9.906900544365271e-08
theory O 0 1.9519147542723658e-07
, O 0 5.8689174409209954e-08
our O 0 6.038791866558313e-08
data O 0 1.6848734674113075e-07
showed O 0 2.729113361965574e-07
that O 0 1.594451148889675e-08
these O 0 1.5493794691678886e-08
mutants O 0 8.818212791084079e-07
are O 0 9.345624718548606e-09
dominant O 0 4.1302214981442376e-07
- O 0 5.788903217762709e-05
negative O 0 2.142119939207987e-07
in O 0 5.065706076834431e-08
transient O 0 1.3918234799348284e-05
transfection O 0 0.00042660904000513256
assays O 0 2.8767453841282986e-06
when O 0 8.375002380489605e-08
they O 0 1.5200784631019815e-08
are O 0 1.7468517299334962e-08
coexpressed O 0 5.292022615321912e-05
with O 0 2.6958679200106417e-07
wild O 0 1.8365597497904673e-05
- O 0 0.00290117459371686
type O 0 0.00014023292169440538
PAX6 O 0 0.008935513906180859
. O 0 1.6801650417619385e-05

We O 0 1.5108875231817365e-05
found O 0 1.795836851670174e-06
that O 0 1.4303086004474608e-07
the O 0 1.0513746673268543e-07
dominant O 0 2.0294837668188848e-06
- O 0 0.0006196011672727764
negative O 0 5.126121322973631e-06
effects O 0 2.991626615767018e-06
result O 0 8.935095507922597e-08
from O 0 8.49245740397464e-09
the O 0 1.5185078083845838e-08
enhanced O 0 6.434486863327038e-07
DNA O 0 1.7038840951499878e-06
binding O 0 2.7412272629590007e-07
ability O 0 1.6524789714367216e-07
of O 0 6.020483311885982e-08
these O 0 2.8605199986486696e-07
mutants O 0 4.865520168095827e-05
. O 0 4.3521331463125534e-06

Kinetic O 0 4.8276997404173017e-05
studies O 0 4.046006779390154e-06
of O 0 2.3024503548185749e-07
binding O 0 8.751048881094903e-07
and O 0 3.1871135774963477e-07
dissociation O 0 0.00013075981405563653
revealed O 0 4.218373760522809e-06
that O 0 1.523951098647558e-08
various O 0 1.396888560378784e-08
truncation O 0 4.2660103645175695e-06
mutants O 0 1.6424015711891116e-06
have O 0 9.190210370491059e-09
3 O 0 4.6714308865603016e-08
- O 0 2.5475283109699376e-06
5 O 0 1.0027313379623592e-07
- O 0 2.958425966426148e-06
fold O 0 3.538163753091794e-07
higher O 0 3.8236784405398794e-08
affinity O 0 9.762800345924916e-08
to O 0 8.23679435768554e-09
various O 0 7.83413067750871e-09
DNA O 0 4.223209373321879e-07
- O 0 7.426207957905717e-06
binding O 0 1.057462384324026e-07
sites O 0 6.215481107574305e-08
when O 0 2.0849020287982967e-08
compared O 0 4.885999871362401e-08
with O 0 2.5199808462161855e-08
the O 0 9.654546317960921e-08
wild O 0 9.602500540495384e-06
- O 0 0.0023351237177848816
type O 0 0.00014998920960351825
PAX6 O 0 0.012465539388358593
. O 0 1.0113387361343484e-05

These O 0 6.734460839652456e-06
results O 0 7.01992621543468e-06
provide O 0 5.228542931945412e-07
a O 0 9.032697079192076e-08
new O 0 8.345805468934486e-08
insight O 0 5.939695597589889e-07
into O 0 2.8495763970681764e-08
the O 0 2.613427518838307e-08
role O 0 9.279163037945182e-08
of O 0 8.623204195146172e-08
mutant O 0 5.828892972203903e-05
PAX6 O 0 0.010058082640171051
in O 0 2.518019300623564e-06
causing O 0 0.00047375811845995486
aniridia B-Disease 1 0.8422418832778931
. O 0 5.1006468311243225e-06
. O 0 1.1170609468535986e-05

Reversal O 0 0.1368461549282074
of O 0 0.004643328953534365
severe O 1 0.9997430443763733
hypertrophic B-Disease 1 0.999968409538269
cardiomyopathy I-Disease 1 0.9999774694442749
and O 0 3.214337266399525e-05
excellent O 0 4.011740384157747e-05
neuropsychologic O 0 0.002568220952525735
outcome O 0 1.2726163731713314e-06
in O 0 7.263044921046458e-08
very B-Disease 0 7.520202416344546e-08
- I-Disease 0 4.6671593736391515e-05
long I-Disease 0 6.964501153561287e-06
- I-Disease 0 0.00017713266424834728
chain I-Disease 0 7.908229599706829e-05
acyl I-Disease 0 0.00015449030615855008
- I-Disease 0 0.0018673542654141784
coenzyme I-Disease 0 0.0007163136033341289
A I-Disease 0 8.972526848083362e-05
dehydrogenase I-Disease 1 0.8662506341934204
deficiency I-Disease 1 0.9888872504234314
. O 0 2.1776666471851058e-05

Very B-Disease 0 9.742904694576282e-06
- I-Disease 0 0.00012783752754330635
long I-Disease 0 1.6124995454447344e-05
- I-Disease 0 0.0001684203598415479
chain I-Disease 0 5.139876520843245e-05
acyl I-Disease 0 7.136945350794122e-05
- I-Disease 0 0.00027929662610404193
coenzyme I-Disease 0 3.356607703608461e-05
A I-Disease 0 2.254188984807115e-06
dehydrogenase I-Disease 0 0.002891676966100931
( I-Disease 0 2.0956276785000227e-05
VLCAD I-Disease 1 0.8726714253425598
) I-Disease 0 8.659876039018854e-05
deficiency I-Disease 1 0.7529464960098267
is O 0 1.1943419053750404e-07
a O 0 3.980561302796559e-07
disorder O 0 0.002625188557431102
of O 0 7.914032806866089e-08
fatty O 0 2.0818813936784863e-05
acid O 0 2.5690001166367438e-06
beta O 0 4.1006171613844344e-07
oxidation O 0 2.283964477101108e-06
that O 0 3.900611034168833e-08
reportedly O 0 4.6099503947516496e-07
has O 0 3.917379132190035e-08
high O 0 3.534666461746383e-07
rates O 0 7.087350581969076e-07
of O 0 4.5169329609962006e-07
morbidity O 0 0.03174891322851181
and O 0 7.791642019583378e-06
mortality O 0 0.0016106717521324754
. O 0 1.693568628979847e-05

We O 0 1.1611915397224948e-05
describe O 0 7.747568815830164e-06
the O 0 2.1312672515705344e-07
outcome O 0 2.620228656269319e-07
of O 0 1.6804118985191963e-08
a O 0 2.3306633067932125e-08
5 O 0 1.456384097764385e-07
- O 0 3.895937334164046e-05
year O 0 8.195971759050735e-07
- O 0 0.0012519408483058214
old O 0 0.0001892095897346735
girl O 0 0.002401631325483322
with O 0 0.000269423151621595
VLCAD B-Disease 1 0.999990701675415
deficiency I-Disease 1 0.9999774694442749
who O 0 1.417383259649796e-06
was O 0 7.712427674277933e-08
first O 0 3.12372527844218e-08
seen O 0 8.78996146980171e-08
at O 0 9.065991690704323e-08
5 O 0 2.44809541527502e-07
months O 0 3.046843346510286e-07
of O 0 1.4596433572933165e-07
age O 0 3.9741313230479136e-05
with O 0 0.00046360542182810605
severe O 1 0.9998297691345215
hypertrophic B-Disease 1 0.9999920129776001
cardiomyopathy I-Disease 1 0.9999960660934448
, O 0 0.005837311968207359
hepatomegaly B-Disease 1 0.9999798536300659
, O 0 0.0008251144317910075
encephalopathy B-Disease 1 0.9959398508071899
, O 0 7.131629445211729e-06
and O 0 1.2177255484857596e-05
hypotonia B-Disease 1 0.6331484317779541
. O 0 5.306191815179773e-05

Biochemical O 0 0.02303425967693329
studies O 0 0.0033730310387909412
indicated O 1 0.8547656536102295
VLCAD B-Disease 1 0.9999748468399048
deficiency I-Disease 1 0.9999901056289673
caused O 0 0.010074799880385399
by O 0 6.543429549310531e-07
a O 0 4.927445615976467e-07
stable O 0 9.675442015577573e-06
yet O 0 2.031670192081947e-06
inactive O 0 2.723208672250621e-05
enzyme O 0 5.223976040724665e-05
. O 0 7.549032943643397e-06

Molecular O 0 0.0038661430589854717
genetic O 0 0.0006539937458001077
analysis O 0 4.28102066507563e-06
of O 0 6.090621127441409e-07
her O 0 2.1584221030934714e-05
VLCAD O 0 0.3493939936161041
gene O 0 3.8382058846764266e-05
revealed O 0 1.2319703273533378e-05
a O 0 6.340549134620233e-07
T1372C O 0 0.001160932588391006
( O 0 2.0629736354749184e-06
F458L O 0 0.00015871274808887392
) O 0 6.479629632849537e-07
missense O 0 4.027495378977619e-05
mutation O 0 2.9936900318716653e-06
and O 0 1.8540519874932215e-07
a O 0 1.4907448075973662e-06
1668 O 0 0.10031868517398834
ACAG O 0 0.27948129177093506
1669 O 0 0.005554819945245981
splice O 0 0.0007894645677879453
site O 0 3.494481643429026e-05
mutation O 0 6.118895544204861e-05
. O 0 8.921146218199283e-06

After O 0 0.00010836509318323806
initial O 0 6.44445390207693e-05
treatment O 0 5.943929863860831e-05
with O 0 1.3763110473519191e-06
intravenous O 0 7.70128463045694e-05
glucose O 0 4.560828165267594e-05
and O 0 8.267836051345512e-07
carnitine O 0 0.041616130620241165
, O 0 5.623102197205299e-07
the O 0 5.421156288321072e-07
patient O 0 4.261376307113096e-05
has O 0 8.201525503181983e-08
thrived O 0 2.892955080824322e-06
on O 0 3.9079836255950795e-08
a O 0 4.1192691924152314e-08
low O 0 5.234899163042428e-07
- O 0 1.7744674551067874e-05
fat O 0 2.274873850183212e-06
diet O 0 4.826889608011697e-07
supplemented O 0 8.130285067409204e-08
with O 0 1.3779125396240488e-08
medium O 0 2.4307010448865185e-07
- O 0 5.185428562981542e-06
chain O 0 2.2977765183895826e-06
triglyceride O 0 2.186202436860185e-06
oil O 0 2.6873200908994477e-07
and O 0 1.6152371529187803e-07
carnitine O 0 0.00017241529712919146
and O 0 2.1261411120576668e-07
avoidance O 0 2.5278832254116423e-05
of O 0 8.679486995788466e-07
fasting O 0 5.3221097914502025e-05
. O 0 9.800067346077412e-06

Her O 0 0.005162096116691828
ventricular O 1 0.9812431931495667
hypertrophy O 1 0.6759006977081299
resolved O 0 7.001838821452111e-05
significantly O 0 3.962989467254374e-06
over O 0 4.613120836438611e-07
1 O 0 8.673512752466195e-07
year O 0 2.8082308745069895e-07
, O 0 1.319343141403806e-07
and O 0 4.17844830735703e-07
cognitively O 0 0.0007358479779213667
, O 0 4.144378351611522e-07
she O 0 2.182077025736362e-07
is O 0 9.139865753127197e-09
in O 0 2.057666570465244e-08
the O 0 6.184438916534418e-08
superior O 0 2.076506007142598e-06
range O 0 2.3016291095245833e-07
for O 0 2.2594052495605865e-07
age O 0 7.55985365685774e-06
. O 0 8.161573532561306e-06

Clinical O 0 0.011472445912659168
recognition O 0 0.00015212627477012575
of O 0 0.000689424283336848
VLCAD B-Disease 1 0.9999841451644897
deficiency I-Disease 1 0.9999880790710449
is O 0 3.013514970007236e-06
important O 0 5.088443231215933e-07
because O 0 2.87725328007582e-07
it O 0 1.778538560870402e-08
is O 0 7.367349841302939e-09
one O 0 5.738671760013858e-09
of O 0 1.4263182634977056e-08
the O 0 1.0437580755251474e-07
few O 0 8.658999490762653e-07
directly O 0 1.2875530046585482e-05
treatable O 1 0.9956436157226562
causes O 0 0.0004451466666068882
of O 0 1.3681772543350235e-05
cardiomyopathy B-Disease 1 0.9999064207077026
in O 0 3.959056812163908e-06
children O 0 9.922718163579702e-06
. O 0 2.0709767341031693e-06
. O 0 1.0467227184562944e-05

Cloning O 0 8.053410419961438e-05
of O 0 7.88637976256723e-07
a O 0 4.930246859657927e-07
novel O 0 9.298382792621851e-07
member O 0 7.897807563495007e-08
of O 0 2.5726450303409365e-08
the O 0 5.761102528367701e-08
low O 0 1.8038732605418772e-06
- O 0 0.000283419038169086
density O 0 3.6929854104528204e-05
lipoprotein O 0 0.20085464417934418
receptor O 0 0.00014951385674066842
family O 0 2.241416041215416e-05
. O 0 9.58818054641597e-06

A O 0 1.9978891941718757e-05
gene O 0 1.2540287571027875e-05
encoding O 0 2.9396389891189756e-06
a O 0 5.563350100601383e-07
novel O 0 5.225439963396639e-06
transmembrane O 0 0.00036436261143535376
protein O 0 1.246914621333417e-06
was O 0 7.143843561152607e-08
identified O 0 5.419017057306519e-08
by O 0 1.0521928217599452e-08
DNA O 0 1.4835656259037933e-07
sequence O 0 4.217437776787847e-08
analysis O 0 2.671583843039116e-08
within O 0 1.1721480674964369e-08
the O 0 9.99950486857415e-08
insulin B-Disease 0 0.00013234464859124273
- I-Disease 1 0.5962997078895569
dependent I-Disease 0 0.38760554790496826
diabetes I-Disease 1 0.9999920129776001
mellitus I-Disease 1 0.9999459981918335
( O 0 2.8535325327538885e-05
IDDM B-Disease 0 0.024134356528520584
) O 0 1.2020725534966914e-06
locus O 0 1.6705660527804866e-05
IDDM4 O 0 0.0002586958871688694
on O 0 6.243403163352923e-07
chromosome O 0 9.73622445599176e-05
11q13 O 0 0.0002154067187802866
. O 0 7.025726063147886e-06

Based O 0 1.6884918295545503e-05
on O 0 1.1870114349221694e-06
its O 0 8.496940040458867e-07
chromosomal O 0 0.0007578535587526858
position O 0 7.876241170379217e-07
, O 0 1.3210882343628327e-07
this O 0 3.863456399244569e-08
gene O 0 3.2943947303465393e-07
is O 0 2.631639972605626e-08
a O 0 3.365655487641561e-08
candidate O 0 1.0490870749890746e-07
for O 0 1.3008933308356063e-07
conferring O 0 9.207436960423365e-05
susceptibility O 0 0.042744286358356476
to O 0 3.6083969462197274e-05
diabetes B-Disease 1 0.97807776927948
. O 0 2.6450177756487392e-05

The O 0 6.127042070147581e-06
gene O 0 1.0942952940240502e-05
, O 0 4.4063440896024986e-07
termed O 0 5.034976766182808e-06
low O 0 4.0151212488126475e-06
- O 0 0.0002555350656621158
density O 0 1.3419142305792775e-05
lipoprotein O 0 0.024213839322328568
receptor O 0 6.102858151280088e-06
related O 0 4.2592034787958255e-07
protein O 0 3.812267834746308e-07
5 O 0 3.762589528832905e-07
( O 0 3.203978451438161e-07
LRP5 O 0 0.00025881698820739985
) O 0 5.17524298970784e-08
, O 0 1.3085139194402018e-08
encodes O 0 4.8511310524190776e-08
a O 0 9.950016810478246e-09
protein O 0 3.387307145885643e-08
of O 0 1.8077253471915355e-08
1615 O 0 1.1215988706680946e-05
amino O 0 8.133449114211544e-08
acids O 0 3.4948584470839705e-08
that O 0 2.9682423186017104e-09
contains O 0 5.39082956052539e-09
conserved O 0 2.0379731680009172e-08
modules O 0 7.823413028518189e-08
which O 0 4.954882282248718e-09
are O 0 2.687589706340532e-09
characteristic O 0 2.465336201851187e-08
of O 0 6.58243237694478e-09
the O 0 3.030715234331183e-08
low O 0 2.2944548163650325e-06
- O 0 0.000705457350704819
density O 0 3.804471998591907e-05
lipoprotein O 1 0.5681748986244202
( O 0 8.071929187281057e-06
LDL O 0 0.009374705143272877
) O 0 2.7432015485828742e-06
receptor O 0 1.1244562301726546e-05
family O 0 8.718148819752969e-06
. O 0 6.377156296366593e-06

These O 0 4.8856131797947455e-06
modules O 0 6.84077986079501e-06
include O 0 6.610870286749559e-07
a O 0 1.5239473327710584e-07
putative O 0 3.813507646555081e-06
signal O 0 3.6703187333841925e-07
peptide O 0 3.4577945484670636e-07
for O 0 1.7911549576865582e-08
protein O 0 7.65493481935664e-08
export O 0 7.370178423116158e-08
, O 0 6.999699309062635e-08
four O 0 1.8294412029717932e-07
epidermal O 0 0.00225743162445724
growth O 0 1.6665209841448814e-05
factor O 0 2.9937500585219823e-06
( O 0 4.523114398580219e-07
EGF O 0 0.0001148577721323818
) O 0 6.858488887928615e-08
repeats O 0 2.0366758235468296e-07
with O 0 1.4108605839169286e-08
associated O 0 9.00838657003078e-08
spacer O 0 5.226531357038766e-06
domains O 0 6.302286124082457e-07
, O 0 4.8535099494984024e-08
three O 0 8.081336488885427e-08
LDL O 0 0.003838508389890194
- O 0 0.0013313066447153687
receptor O 0 2.2452817574958317e-05
( O 0 3.6516016166388e-07
LDLR O 0 9.69318498391658e-05
) O 0 7.794116640980064e-08
repeats O 0 2.2353088979798486e-07
, O 0 9.693476243910482e-09
a O 0 1.5363781358246342e-08
single O 0 5.8870909924735315e-08
transmembrane O 0 6.990278507146286e-06
spanning O 0 1.41905763939576e-06
domain O 0 2.753234298324969e-07
, O 0 3.9645165372803604e-08
and O 0 5.389896529095495e-08
a O 0 2.4594379510745057e-07
cytoplasmic O 0 2.355425567657221e-05
domain O 0 1.4332227692648303e-05
. O 0 6.867121555842459e-06

The O 0 4.003264621132985e-06
encoded O 0 1.7283362012676662e-06
protein O 0 1.4600277609133627e-06
has O 0 9.043522908314117e-08
a O 0 3.37003633887889e-08
unique O 0 6.310953182264711e-08
organization O 0 1.4193064146184042e-07
of O 0 7.016581804464295e-08
EGF O 0 0.004886523354798555
and O 0 8.405863809457514e-07
LDLR O 0 0.017823604866862297
repeats O 0 1.4228685358830262e-05
; O 0 4.7058432528501726e-07
therefore O 0 9.16090030500527e-08
, O 0 1.218947431880224e-07
LRP5 O 0 0.00041948151192627847
likely O 0 1.7859329659586365e-07
represents O 0 8.609104185097749e-08
a O 0 2.0789018506661705e-08
new O 0 4.837585620975915e-08
category O 0 1.46807394685311e-07
of O 0 5.6359393596494556e-08
the O 0 9.209996392200992e-07
LDLR O 0 0.023666178807616234
family O 0 4.0050548705039546e-05
. O 0 9.318390766566154e-06

Both O 0 1.1616567462624516e-05
human O 0 5.6580906857561786e-06
and O 0 1.6524157899766578e-06
mouse O 0 0.0003563368518371135
LRP5 O 0 0.20976202189922333
cDNAs O 0 0.0019130761502310634
have O 0 1.9122201422305807e-07
been O 0 5.373073364012271e-08
isolated O 0 4.816676550944976e-07
and O 0 1.5837942513030612e-08
the O 0 1.222806655931663e-08
encoded O 0 4.533807285156399e-08
mature O 0 3.274173820955184e-07
proteins O 0 2.8374007143838753e-08
are O 0 4.482412219175558e-09
95 O 0 5.105865241716856e-08
% O 0 3.2169385377756043e-08
identical O 0 1.736627268655866e-07
, O 0 5.2665161121012716e-08
indicating O 0 2.6391504093226104e-07
a O 0 2.234799012512667e-08
high O 0 1.3805122023313743e-07
degree O 0 1.4465615549852373e-07
of O 0 1.2522851022822579e-07
evolutionary O 0 1.384706047247164e-05
conservation O 0 1.6049407349782996e-05
. O 0 1.7440243027522229e-06
. O 0 6.033466434018919e-06

The O 0 1.620228613319341e-05
APC B-Disease 0 0.00017023594409693033
variants O 0 1.3022381608607247e-05
I1307K O 0 0.0006348737515509129
and O 0 2.3117293039831566e-06
E1317Q O 0 0.0011928383028134704
are O 0 5.372078817345027e-07
associated O 0 6.804345321143046e-05
with O 0 0.01767311617732048
colorectal B-Disease 1 0.9999996423721313
tumors I-Disease 1 0.9999990463256836
, O 0 1.3134534128766973e-05
but O 0 2.992546228597348e-07
not O 0 4.564592970268677e-08
always O 0 9.105382048346655e-08
with O 0 6.396864193902729e-08
a O 0 3.1139165912463795e-07
family O 0 1.0535056389926467e-05
history O 0 1.8172175259678625e-05
. O 0 1.0600714631436858e-05

Classical O 0 0.18642079830169678
familial B-Disease 1 0.9998818635940552
adenomatous I-Disease 1 0.9999555349349976
polyposis I-Disease 1 0.9999853372573853
( O 0 0.016115639358758926
FAP B-Disease 1 0.7517275214195251
) O 0 3.404872586543206e-06
is O 0 1.3609458449082013e-07
a O 0 1.89016375884421e-07
high O 0 6.0181810113135725e-06
- O 1 0.5135331749916077
penetrance O 1 0.9826750159263611
autosomal B-Disease 1 0.9649659395217896
dominant I-Disease 0 0.25745347142219543
disease I-Disease 1 0.7779326438903809
that O 0 1.1706508757924894e-06
predisposes O 0 0.0010417804587632418
to O 0 1.2163519613750395e-07
hundreds O 0 2.400987852979597e-07
or O 0 2.086052290906082e-07
thousands O 0 2.6871277896134416e-06
of O 0 3.4062250051647425e-05
colorectal B-Disease 1 0.9999982118606567
adenomas I-Disease 1 0.9999871253967285
and I-Disease 0 0.005777607671916485
carcinoma I-Disease 1 0.99998939037323
and O 0 2.760161805781536e-06
that O 0 1.8807864421432896e-07
results O 0 9.88631313703081e-07
from O 0 1.5645161965949228e-07
truncating O 0 0.0014019955415278673
mutations O 0 1.2345942195679527e-05
in O 0 1.3958995737084479e-07
the O 0 7.127076173674141e-07
APC B-Disease 0 0.00012435988173820078
gene O 0 1.7580314306542277e-05
. O 0 4.83235180581687e-06

A O 0 4.2140578443650156e-05
variant O 0 0.00019800894369836897
of O 0 1.1422506759117823e-05
FAP B-Disease 1 0.6554099917411804
is O 0 9.789157775230706e-05
attenuated B-Disease 1 0.802707314491272
adenomatous I-Disease 1 0.9999599456787109
polyposis I-Disease 1 0.9999765157699585
coli I-Disease 1 0.9973905682563782
, O 0 2.0115078314120183e-06
which O 0 1.5272456721504568e-07
results O 0 3.6375388390297303e-07
from O 0 6.276751918221635e-08
germ O 0 0.0002279922046000138
- O 0 0.0005716419545933604
line O 0 4.1689659155963454e-06
mutations O 0 1.8589964838611195e-06
in O 0 1.2917604763629242e-08
the O 0 1.4473184428709374e-08
5 O 0 7.924364098244041e-08
and O 0 2.1714892994850743e-08
3 O 0 1.141264007742393e-07
regions O 0 1.017939368352927e-07
of O 0 3.3936380816612655e-08
the O 0 2.939452201644599e-07
APC B-Disease 0 5.63043613510672e-05
gene O 0 2.0747422240674496e-05
. O 0 4.973697741661454e-06

Attenuated B-Disease 1 0.9947603344917297
adenomatous I-Disease 1 0.9999357461929321
polyposis I-Disease 1 0.9999719858169556
coli I-Disease 1 0.9999514818191528
patients O 1 0.9920668601989746
have O 0 4.158685987931676e-05
" O 0 4.5107353798812255e-05
multiple O 0 0.00024849342298693955
" O 0 0.0034764197189360857
colorectal B-Disease 1 0.9999929666519165
adenomas I-Disease 1 0.9999563694000244
( O 0 3.151008422719315e-05
typically O 0 1.0522278444113908e-06
fewer O 0 8.296050424405621e-08
than O 0 2.0779861387154597e-08
100 O 0 2.9248630184497415e-08
) O 0 5.0799773276821725e-08
without O 0 3.220701927375558e-08
the O 0 1.0852869536392973e-07
florid O 0 0.0005678455345332623
phenotype O 0 6.768757884856313e-05
of O 0 4.5415407612381387e-07
classical O 0 1.6105326722026803e-05
FAP B-Disease 0 0.01315251924097538
. O 0 1.792274088074919e-05

Another O 0 4.1534429328748956e-05
group O 0 5.0244190788362175e-05
of O 0 5.391754257288994e-06
patients O 0 0.003679753514006734
with O 0 5.105269337946083e-06
multiple O 0 0.0001412521960446611
adenomas B-Disease 1 0.9057800769805908
has O 0 1.8749532273432123e-06
no O 0 4.4461751258495497e-07
mutations O 0 3.3133671877294546e-06
in O 0 3.138308812822288e-08
the O 0 7.11878911374697e-08
APC B-Disease 0 2.039279934251681e-05
gene O 0 1.092253683054878e-06
, O 0 4.093750760603143e-08
and O 0 4.2084138840436935e-08
their O 0 1.1082892825697854e-07
phenotype O 0 6.413237861124799e-05
probably O 0 1.654894958846853e-07
results O 0 7.720110062336971e-08
from O 0 7.742653629350116e-09
variation O 0 2.2085653483827627e-07
at O 0 9.123566258040228e-08
a O 0 5.362486987792181e-08
locus O 0 7.612412900925847e-06
, O 0 1.5159648114604352e-07
or O 0 1.3260995501696016e-07
loci O 0 1.2641201010410441e-06
, O 0 7.830892911897536e-08
elsewhere O 0 1.308510633180049e-07
in O 0 7.077483132889029e-08
the O 0 3.030282300642284e-07
genome O 0 2.2001673642080277e-05
. O 0 5.996450454404112e-06

Recently O 0 0.00030788799631409347
, O 0 5.4691040531906765e-06
however O 0 7.958131504892663e-07
, O 0 1.7729188073190016e-07
a O 0 1.915037870503511e-07
missense O 0 6.285820563789457e-05
variant O 0 5.293437880027341e-06
of O 0 2.6839572342396423e-07
APC B-Disease 0 9.115974535234272e-05
( O 0 1.413251652593317e-06
I1307K O 0 0.0002844615373760462
) O 0 1.8843449822725233e-07
was O 0 3.5041228585441786e-08
described O 0 1.829839106903819e-07
that O 0 3.0002095030567943e-08
confers O 0 1.0899218523263698e-06
an O 0 1.1328578608527096e-07
increased O 0 7.519479822803987e-06
risk O 0 0.00026125332806259394
of O 0 0.0001912121952045709
colorectal B-Disease 1 0.9999994039535522
tumors I-Disease 1 0.9999974966049194
, O 0 1.0480393029865809e-05
including O 0 2.754061370069394e-06
multiple O 0 2.5501081836409867e-05
adenomas B-Disease 0 0.3700989782810211
, O 0 1.972581003428786e-06
in O 0 2.2309886844595894e-06
Ashkenazim O 0 0.0013813611585646868
. O 0 1.4314128748083021e-05

We O 0 8.949488801590633e-06
have O 0 5.715281758966739e-07
studied O 0 6.458487291638448e-07
a O 0 8.390256311940902e-08
set O 0 1.4868162168113486e-07
of O 0 2.6894812776845356e-07
164 O 0 0.00026985121075995266
patients O 0 0.0011956635862588882
with O 0 1.200861697725486e-05
multiple O 0 0.03956814482808113
colorectal B-Disease 1 0.9999982118606567
adenomas I-Disease 1 0.9999690055847168
and I-Disease 0 0.00016658571257721633
/ I-Disease 0 0.2688712477684021
or I-Disease 0 3.936202483600937e-05
carcinoma I-Disease 1 0.9999105930328369
and O 0 1.0710683682191302e-06
analyzed O 0 5.674528438248672e-06
codons O 0 1.2747730579576455e-05
1263 O 0 0.00014943447604309767
- O 0 7.18043083907105e-05
1377 O 0 0.00032944214763119817
( O 0 2.70280281711166e-07
exon O 0 5.581633104156936e-06
15G O 0 1.3788840988127049e-05
) O 0 2.1095264202131148e-08
of O 0 6.170321587006811e-09
the O 0 2.068898119489404e-08
APC B-Disease 0 2.111754156430834e-06
gene O 0 3.124947625110508e-07
for O 0 9.234933884272323e-08
germ O 0 0.00011717415327439085
- O 0 9.037582640303299e-05
line O 0 6.9563629949698225e-06
variants O 0 9.500780834059697e-06
. O 0 6.654111075476976e-06

Three O 0 8.542238356312737e-05
patients O 0 0.0010905592935159802
with O 0 1.329370547864528e-06
the O 0 1.0220926469628466e-06
I1307K O 0 0.0007130647427402437
allele O 0 2.9186494430177845e-06
were O 0 1.252500112514099e-07
detected O 0 1.1134501392007223e-06
, O 0 4.269382358756957e-08
each O 0 3.517515523299153e-08
of O 0 3.810988289387751e-07
Ashkenazi O 0 0.0003723574918694794
descent O 0 0.00011526075832080096
. O 0 1.292926481255563e-05

Four O 0 7.632167398696765e-05
patients O 0 0.000579090672545135
had O 0 9.634961770643713e-07
a O 0 2.5675868187136075e-07
germ O 0 0.00036642709164880216
- O 0 0.00029048803844489157
line O 0 7.325299975491362e-06
E1317Q O 0 0.00021522154565900564
missense O 0 3.63552535418421e-05
variant O 0 1.6249429108938784e-06
of O 0 7.570659477096342e-08
APC O 0 2.5035778890014626e-05
that O 0 5.662154123342589e-08
was O 0 3.743462073657611e-08
not O 0 6.922859618896382e-09
present O 0 1.4181855689798795e-08
in O 0 1.547666350631971e-08
controls O 0 2.8111270466979477e-07
; O 0 7.609312291378956e-08
one O 0 7.332037643692502e-09
of O 0 1.3354906513995957e-08
these O 0 4.1388322102875463e-08
individuals O 0 1.1115070464029486e-07
had O 0 1.1163341895326084e-07
an O 0 2.720086023089152e-08
unusually O 0 3.0690878247696673e-06
large O 0 2.505536258468055e-07
number O 0 6.547649178401116e-08
of O 0 4.536796041065827e-07
metaplastic B-Disease 0 0.34791067242622375
polyps I-Disease 0 0.010058244690299034
of I-Disease 0 3.7672569419555657e-07
the I-Disease 0 2.5318383904959774e-06
colorectum I-Disease 0 0.0071556842885911465
. O 0 1.4469162124441937e-05

There O 0 2.17241067730356e-05
is O 0 1.4730907196280896e-06
increasing O 0 2.3567124571854947e-06
evidence O 0 1.2934674487041775e-06
that O 0 9.262593891889992e-08
there O 0 7.111921718205849e-08
exist O 0 2.851458589248068e-07
germ O 0 9.815685916692019e-05
- O 0 3.851086148642935e-05
line O 0 4.5591156094815233e-07
variants O 0 9.174766546493629e-08
of O 0 1.4809822701522535e-08
the O 0 5.868951191700944e-08
APC B-Disease 0 7.062553777359426e-06
gene O 0 6.792471367589314e-07
that O 0 4.424247990186814e-08
predispose O 0 4.395601081341738e-06
to O 0 1.542870897708326e-08
the O 0 1.3566250345320441e-08
development O 0 1.0508033199130296e-07
of O 0 4.217240814341494e-07
multiple O 0 0.003787367371842265
colorectal B-Disease 1 0.9999978542327881
adenomas I-Disease 1 0.999990701675415
and I-Disease 0 0.04192044585943222
carcinoma I-Disease 1 0.9999971389770508
, O 0 1.0485001439519692e-05
but O 0 1.833495133496399e-07
without O 0 7.077078123529645e-08
the O 0 7.574183058522976e-08
florid O 0 0.00060275784926489
phenotype O 0 1.4794960407016333e-05
of O 0 3.114409352633629e-08
classical O 0 1.1006723070750013e-06
FAP B-Disease 0 0.0010866676457226276
, O 0 1.391241539749899e-07
and O 0 8.152429131769168e-08
possibly O 0 3.2654048709446215e-07
with O 0 2.1885146850308956e-07
importance O 0 5.89400005992502e-05
for O 0 0.017511697486042976
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999927282333374
risk O 0 0.000621544721070677
in O 0 2.4591284386588086e-07
the O 0 2.1758430079898972e-07
general O 0 1.1955513627981418e-06
population O 0 9.915489727063687e-07
. O 0 6.678993713649106e-07
. O 0 4.533194896794157e-06

Genomic O 0 0.0009625674574635923
structure O 0 3.956245564040728e-05
of O 0 1.9447757040325087e-06
the O 0 1.5522817193414085e-05
human O 0 0.011636540293693542
congenital B-Disease 1 0.999991774559021
chloride I-Disease 1 0.999681830406189
diarrhea I-Disease 1 0.9999912977218628
( O 0 0.0019155360059812665
CLD B-Disease 1 0.9912447333335876
) O 0 1.140204676630674e-05
gene O 0 1.87898021977162e-05
. O 0 7.872968126321211e-06

Congenital B-Disease 1 0.9999613761901855
chloride I-Disease 1 0.9994353652000427
diarrhea I-Disease 1 0.9999781847000122
( O 0 0.1338839828968048
CLD B-Disease 1 0.9991769194602966
) O 0 7.132862810976803e-05
is O 0 1.8617110981722362e-06
caused O 0 2.913193566200789e-05
by O 0 2.9320190719772654e-07
mutations O 0 5.15663850819692e-06
in O 0 4.1639008685478984e-08
a O 0 8.324787614810703e-08
gene O 0 1.1662248198263114e-06
which O 0 1.0457986121537033e-07
encodes O 0 2.931335984612815e-06
an O 0 2.039606215475942e-06
intestinal O 1 0.822771430015564
anion O 0 0.001134557998739183
transporter O 0 0.001070807222276926
. O 0 9.200382010021713e-06

We O 0 1.6429061361122876e-05
report O 0 3.3003868793457514e-06
here O 0 4.567872338157031e-07
the O 0 1.6956009574187192e-07
complete O 0 9.480158382757509e-07
genomic O 0 6.311365723377094e-06
organization O 0 1.6663594237797952e-07
of O 0 2.729898973541367e-08
the O 0 1.0966608243734299e-07
human O 0 1.1090754696851945e-06
CLD B-Disease 0 0.012230279855430126
gene O 0 8.61490775605489e-07
which O 0 4.27873310115956e-08
spans O 0 1.421375145582715e-06
approximately O 0 2.1319543463960144e-07
39kb O 0 7.432940765284002e-05
, O 0 8.093152104038381e-08
and O 0 8.748465063490585e-08
comprises O 0 1.4090514923736919e-06
21 O 0 3.2799159725982463e-06
exons O 0 5.682829942088574e-05
. O 0 6.95182689014473e-06

All O 0 8.378536222153343e-06
exon O 0 0.00035626787575893104
/ O 0 0.0004156866925768554
intron O 0 0.000814588216599077
boundaries O 0 5.259085810394026e-06
conform O 0 4.500427166931331e-06
to O 0 2.798080345201015e-07
the O 0 3.393561200937256e-07
GT O 0 0.00017394173482898623
/ O 0 0.0012084218906238675
AG O 1 0.5469797253608704
rule O 0 2.66591232502833e-05
. O 0 1.3253728866402525e-05

An O 0 3.927258148905821e-06
analysis O 0 1.6904871245060349e-06
of O 0 1.76454051370456e-07
the O 0 2.476497229508823e-07
putative O 0 2.017320366576314e-05
promoter O 0 4.127127249375917e-05
region O 0 9.192078209707688e-07
sequence O 0 3.111159116997442e-07
shows O 0 1.0156315255471782e-07
a O 0 1.0889156243365505e-07
putative O 0 1.0357483915868215e-05
TATA O 0 0.000756861874833703
box O 0 4.860703029407887e-06
and O 0 2.939239323040965e-07
predicts O 0 2.986917934322264e-05
multiple O 0 7.922579357000359e-07
transcription O 0 7.756359082122799e-06
factor O 0 1.175822376353608e-06
binding O 0 1.116946009460662e-06
sites O 0 2.6458135380380554e-06
. O 0 4.085992713953601e-06

The O 0 1.2912333659187425e-05
genomic O 0 6.72931200824678e-05
structure O 0 9.70012024481548e-06
was O 0 4.374697937237215e-07
determined O 0 3.633856522355927e-07
using O 0 4.1178708443112555e-08
DNA O 0 3.5644009699353774e-07
from O 0 1.2476189859000897e-08
several O 0 9.77416192426972e-09
sources O 0 2.1633741908999582e-08
including O 0 2.9515668131807615e-08
multiple O 0 1.0728025756634452e-07
large O 0 2.3697883477780124e-07
- O 0 0.00016257664537988603
insert O 0 3.4912511182483286e-05
libaries O 0 0.00025796753470785916
and O 0 1.7533402285607735e-07
genomic O 0 5.227423571341205e-06
DNA O 0 2.995926479343325e-06
from O 0 3.3457314430052065e-07
Finnish O 0 0.0022010751999914646
CLD B-Disease 1 0.9947512745857239
patients O 0 0.0004705536412075162
and O 0 1.4873710370011395e-06
controls O 0 1.3078300071356352e-05
. O 0 6.625502010138007e-06

Exon O 0 0.0009438440320082009
- O 0 0.0008881458779796958
specific O 0 3.254441708122613e-06
primers O 0 5.1833696488756686e-05
developed O 0 2.176080670324154e-06
in O 0 7.456372941305744e-08
this O 0 2.7466535712505902e-08
study O 0 1.2519650738340715e-07
will O 0 3.946665927401227e-08
facilitate O 0 8.205763606383698e-07
mutation O 0 4.126770818402292e-06
screening O 0 2.4514999950042693e-06
studies O 0 4.1711592757565086e-07
of O 0 3.315110461699078e-07
patients O 0 0.00021544079936575145
with O 0 4.170270130998688e-06
the O 0 4.6205495891626924e-05
disease O 1 0.6267922520637512
. O 0 1.5923158571240492e-05

Genomic O 0 0.0003104479401372373
sequencing O 0 3.4561173379188403e-05
of O 0 1.0170695077249547e-06
a O 0 2.115590405082912e-06
BAC O 0 0.0006120509933680296
clone O 0 0.016787473112344742
H O 1 0.986344575881958
_ O 0 2.4434837541775778e-05
RG364P16 O 0 0.0005279266042634845
revealed O 0 3.349410690134391e-06
the O 0 3.181983387889886e-08
presence O 0 4.397217878704396e-08
of O 0 1.3517845509625204e-08
another O 0 4.981465195896817e-08
, O 0 4.313237411679438e-08
highly O 0 1.0131221728215678e-07
homologous O 0 2.945970436485368e-06
gene O 0 3.637504164544225e-07
3 O 0 6.593153045741929e-08
of O 0 2.589748326897734e-08
the O 0 2.850278519872518e-07
CLD B-Disease 0 0.149825319647789
gene O 0 2.1144223865121603e-06
, O 0 3.5627145678063243e-08
with O 0 2.2145545841567582e-08
a O 0 2.911254703974464e-08
similar O 0 7.139348667806189e-08
genomic O 0 4.171407908870606e-06
structure O 0 1.3483490874932613e-06
, O 0 2.020456406626181e-07
recently O 0 3.00270835396077e-06
identified O 0 1.3671174201590475e-06
as O 0 3.923713904896431e-07
the O 0 4.1028015402844176e-05
Pendred B-Disease 1 0.9999746084213257
syndrome I-Disease 1 0.9999958276748657
gene O 0 0.000396015151636675
( O 0 6.283283255470451e-06
PDS B-Disease 0 0.0010609697783365846
) O 0 8.920848699744965e-07
. O 0 5.822017783430056e-07
. O 0 2.3502886961068725e-06

The O 0 7.035437010927126e-05
APCI1307K O 0 0.4617261290550232
allele O 0 0.0010963858803734183
and O 0 0.00036319514038041234
cancer B-Disease 1 0.945957601070404
risk O 0 2.3345277440967038e-05
in O 0 5.202598885034604e-08
a O 0 5.0540283069722136e-08
community O 0 2.4707432544346375e-07
- O 0 0.00010100735380547121
based O 0 1.022341166390106e-06
study O 0 7.659351126676484e-07
of O 0 4.074600212788937e-07
Ashkenazi O 0 0.0003052976680919528
Jews O 0 2.5639907107688487e-05
. O 0 1.069098107109312e-05

Mutations O 0 0.010216564871370792
in O 0 2.0158222469035536e-05
APC O 0 0.0008862193208187819
are O 0 5.5731543397996575e-06
classically O 0 0.07237611711025238
associated O 0 0.00027941144071519375
with O 0 0.001207616413012147
familial B-Disease 1 0.9999901056289673
adenomatous I-Disease 1 0.9999955892562866
polyposis I-Disease 1 0.9999970197677612
( O 0 0.01330932043492794
FAP B-Disease 1 0.6063830256462097
) O 0 2.225949856438092e-06
, O 0 2.213704277664874e-07
a O 0 3.7416600662254496e-07
highly O 0 3.03353135677753e-05
penetrant O 1 0.9763216972351074
autosomal B-Disease 1 0.9997562766075134
dominant I-Disease 1 0.9843331575393677
disorder I-Disease 1 0.9999911785125732
characterized O 1 0.7554567456245422
by O 0 0.00010254930384689942
multiple O 0 0.09490985423326492
intestinal O 1 0.999950647354126
polyps B-Disease 1 0.8698510527610779
and O 0 1.1772608559112996e-06
, O 0 8.634080472802452e-07
without O 0 5.731504302275425e-07
surgical O 0 0.0027225823141634464
intervention O 0 3.5213599858252564e-06
, O 0 1.1821509815490572e-07
the O 0 8.592470379653605e-08
development O 0 5.626628080790397e-06
of O 0 0.0004608516173902899
colorectal B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999728202819824
( O 0 0.00010497272160137072
CRC B-Disease 0 0.02145381271839142
) O 0 6.194827165018069e-06
. O 0 8.206974598579109e-06

APC B-Disease 0 0.0017550253542140126
is O 0 4.525549229583703e-06
a O 0 5.2090108511038125e-06
tumour O 1 0.9316715002059937
- O 0 0.002935464959591627
suppressor O 0 0.0002081119455397129
gene O 0 2.090645693897386e-06
, O 0 1.0950138573662116e-07
and O 0 2.1999716182108386e-07
somatic O 0 8.095141674857587e-05
loss O 0 0.011524009518325329
occurs O 0 2.9038292268523946e-05
in O 0 1.3783766007691156e-05
tumours B-Disease 1 0.9960578680038452
. O 0 4.536545020528138e-05

The O 0 2.6236739358864725e-05
germline O 0 0.029256194829940796
T O 0 0.30632078647613525
- O 0 0.0023631250951439142
to O 0 1.1617469226621324e-06
- O 0 0.00010777121497085318
A O 0 8.121285759443708e-07
transversion O 0 0.0006803555297665298
responsible O 0 2.213459282529584e-07
for O 0 1.4787581825714824e-08
the O 0 3.3378846353571134e-08
APC O 0 3.831483354588272e-06
I1307K O 0 8.600652108725626e-06
allele O 0 1.156774658284121e-07
converts O 0 3.3570387358849985e-08
the O 0 7.934070289650208e-09
wild O 0 1.2262029258636176e-07
- O 0 6.930485596967628e-06
type O 0 2.6889736659541086e-07
sequence O 0 5.368125854943173e-08
to O 0 2.4851555480154275e-08
a O 0 1.492924610602131e-07
homopolymer O 0 0.060665279626846313
tract O 0 0.03289587050676346
( O 0 9.018319815368159e-07
A8 O 0 0.0036790454760193825
) O 0 1.664459858830014e-07
that O 0 2.650302910467417e-08
is O 0 5.993089757794223e-08
genetically O 0 2.690910378078115e-06
unstable O 0 0.0001684443122940138
and O 0 1.1752159707612009e-06
prone O 0 0.00034833731479011476
to O 0 8.352117220056243e-07
somatic O 0 6.645105895586312e-05
mutation O 0 5.84939552936703e-05
. O 0 7.413386356347473e-06

The O 0 3.2732903491705656e-05
I1307K O 0 0.0022272078786045313
allele O 0 4.3420826841611415e-05
was O 0 2.097461674566148e-06
found O 0 7.253422609210247e-07
in O 0 8.691571906638274e-07
6 O 0 1.8409678887110204e-05
. O 0 1.2576492736116052e-05

1 O 0 3.801472848863341e-05
% O 0 2.660991185621242e-06
of O 0 7.494369924643252e-07
unselected O 0 0.002183613833039999
Ashkenazi O 0 0.0010071953292936087
Jews O 0 6.643141659878893e-06
and O 0 3.6844136275249184e-07
higher O 0 6.945147106307559e-07
proportions O 0 1.117603369493736e-05
of O 0 1.4012105964411603e-07
Ashkenazim O 0 0.00022333349625114352
with O 0 9.041908128892828e-07
family O 0 5.37027335667517e-06
or O 0 2.4793115471766214e-07
personal O 0 9.425087910130969e-07
histories O 0 1.517056989541743e-05
of O 0 3.358887283866352e-07
CRC B-Disease 0 0.003946377895772457
( O 0 3.3882879506563768e-06
ref O 0 0.040124278515577316
. O 0 2.003192633992512e-07
2 O 0 1.5526594552284223e-06
) O 0 1.7332945390080567e-06
. O 0 3.3975677524722414e-06

To O 0 1.160464216809487e-05
evaluate O 0 2.5752189685590565e-05
the O 0 4.431363720414083e-07
role O 0 4.166042799624847e-07
of O 0 3.6121031143920845e-07
I1307K O 0 0.003132960293442011
in O 0 7.514096523664193e-06
cancer B-Disease 0 0.055309753865003586
, O 0 2.8354673986541457e-07
we O 0 2.0142766743447282e-07
genotyped O 0 0.00020785095694009215
5 O 0 6.342937695080764e-07
, O 0 4.7220274268511275e-07
081 O 0 0.002055589808151126
Ashkenazi O 0 6.791283522034064e-05
volunteers O 0 6.779386012567556e-07
in O 0 8.476020241232618e-08
a O 0 2.833512837696617e-07
community O 0 1.6270596461254172e-06
survey O 0 1.9633831470855512e-05
. O 0 6.894491434650263e-06

Risk O 0 0.003244664752855897
of O 0 1.5161155715759378e-05
developing O 0 0.018839646130800247
colorectal B-Disease 1 0.9999450445175171
, I-Disease 0 0.0006420368445105851
breast I-Disease 1 0.9220094680786133
and I-Disease 0 9.801366104511544e-06
other I-Disease 0 1.464065690015559e-06
cancers I-Disease 0 0.10355675220489502
were O 0 7.50562847429137e-08
compared O 0 3.42587696877672e-07
between O 0 5.146259809407638e-07
genotyped O 0 0.0067704725079238415
I1307K O 0 0.00028201122768223286
carriers O 0 1.2113526963730692e-06
and O 0 2.398366838463062e-08
non O 0 1.0251876858546893e-07
- O 0 1.2519675692601595e-05
carriers O 0 4.874555656897428e-07
and O 0 1.555588902135696e-08
their O 0 1.4579690343907714e-08
first O 0 1.0210136736077402e-07
- O 0 7.058237679302692e-05
degree O 0 4.670888756663771e-06
relatives O 0 3.470911178737879e-05
. O 0 9.106422112381551e-06

Sperm O 0 0.000855876540299505
DNA O 0 8.535700180800632e-05
analysis O 0 6.379041224136017e-06
in O 0 9.87728412837896e-07
a O 0 4.150938821112504e-06
Friedreich B-Disease 1 0.952604353427887
ataxia I-Disease 1 0.9985901713371277
premutation O 1 0.8592198491096497
carrier O 0 0.00023372319992631674
suggests O 0 2.3624259029020322e-06
both O 0 1.3180000735246722e-07
meiotic O 0 4.544460534816608e-05
and O 0 3.5967786971013993e-07
mitotic O 0 4.4823147618444636e-05
expansion O 0 4.295161943446146e-06
in O 0 3.505825247884786e-07
the O 0 1.138023435487412e-06
FRDA B-Disease 0 0.01567676104605198
gene O 0 4.2361865780549124e-05
. O 0 1.1181396075699013e-05

Friedreich B-Disease 1 0.9971776008605957
ataxia I-Disease 1 0.999237060546875
is O 0 0.00037067977245897055
usually O 0 7.369738887064159e-05
caused O 0 0.00010227585880784318
by O 0 1.2865150722518592e-07
an O 0 3.338852394563219e-08
expansion O 0 4.298495355214982e-07
of O 0 4.564575561971651e-08
a O 0 2.2671387966965995e-07
GAA O 0 0.00013114330067764968
trinucleotide O 0 0.026771144941449165
repeat O 0 1.9880098989233375e-05
in O 0 1.8769483745018078e-07
intron O 0 8.192096720449626e-05
1 O 0 2.0790513133306376e-07
of O 0 1.346246705224985e-07
the O 0 1.083301071957976e-06
FRDA B-Disease 0 0.005177752114832401
gene O 0 2.7564197807805613e-05
. O 0 5.962901923339814e-06

Occasionally O 0 0.00012316618813201785
, O 0 2.1302298591763247e-06
a O 0 4.2486271922825836e-07
fully O 0 4.6582186996602104e-07
expanded O 0 5.186004159440927e-07
allele O 0 1.0510232186788926e-06
has O 0 7.231445664501734e-08
been O 0 3.263623682414618e-08
found O 0 4.626775051974619e-08
to O 0 5.152058690782724e-08
arise O 0 5.313398219186638e-07
from O 0 1.2864911802523693e-08
a O 0 4.488634530730451e-08
premutation O 0 5.130034332978539e-05
of O 0 3.2486745737969613e-08
100 O 0 6.963465182252548e-08
or O 0 1.166667189522741e-07
less O 0 5.192699745748541e-07
triplet O 0 0.0038821138441562653
repeats O 0 0.00015421624993905425
. O 0 1.0698957339627668e-05

We O 0 1.8640526832314208e-05
have O 0 1.3147164281690493e-06
examined O 0 6.020137789164437e-06
the O 0 1.5767419370149582e-07
sperm O 0 3.8618577491433825e-06
DNA O 0 1.4986077303547063e-06
of O 0 1.0739449152197267e-07
a O 0 1.1878710211021826e-06
premutation O 0 0.00927518866956234
carrier O 0 0.00021123321494087577
. O 0 1.1381362128304318e-05

This O 0 8.018330845516175e-06
mans O 0 0.00013228166790213436
leucocyte O 0 0.004492795094847679
DNA O 0 5.725694791181013e-05
showed O 0 2.0581376247719163e-06
one O 0 6.619337256097424e-08
normal O 0 2.898412674312567e-07
allele O 0 2.928928211076709e-07
and O 0 2.8632458182187293e-08
one O 0 1.8948231428339568e-08
allele O 0 8.952819285923397e-08
of O 0 2.5261021718847587e-08
approximately O 0 1.577885058168249e-07
100 O 0 3.9061475831658754e-07
repeats O 0 1.2830140803998802e-05
. O 0 4.680203346651979e-06

His O 0 3.246642154408619e-05
sperm O 0 8.61239168443717e-05
showed O 0 4.143305432080524e-06
an O 0 8.871871415294663e-08
expanded O 0 2.613505500903557e-07
allele O 0 3.544171534031193e-07
in O 0 2.5134429648687728e-08
a O 0 3.267684789420855e-08
tight O 0 1.0427238521515392e-06
range O 0 1.0514588666410418e-07
centering O 0 6.098513836150232e-07
on O 0 3.6054533580909265e-08
a O 0 3.470943354955125e-08
size O 0 1.6059370011589635e-07
of O 0 6.910171634899598e-08
approximately O 0 8.032206437746936e-07
320 O 0 1.7683825717540458e-05
trinucleotide O 0 0.007902205921709538
repeats O 0 8.050309406826273e-05
. O 0 7.619879397680052e-06

His O 0 0.0001089493598556146
affected O 0 0.0002832056488841772
son O 0 0.0002465337747707963
has O 0 1.284141035284847e-06
repeat O 0 2.7477297408040613e-05
sizes O 0 2.0096708794881124e-06
of O 0 4.589618072259327e-07
1040 O 0 0.0002173443353967741
and O 0 2.155408083126531e-06
540 O 0 5.659780072164722e-05
. O 0 1.1241967513342388e-05

These O 0 5.672591214533895e-06
data O 0 4.471689862839412e-06
suggest O 0 3.121595682387124e-06
that O 0 8.160222364494985e-08
expansion O 0 1.2933686548421974e-06
occurs O 0 1.8672092494398385e-07
in O 0 1.5266858000018146e-08
two O 0 1.8097711773634728e-08
stages O 0 1.0012823850047425e-06
, O 0 2.6738828040606677e-08
the O 0 1.323304577027784e-08
first O 0 3.164938533473105e-08
during O 0 2.1715042919367988e-07
meiosis O 0 3.482503416307736e-06
followed O 0 1.7575942479197693e-07
by O 0 2.4309183999093875e-08
a O 0 5.0884239044535207e-08
second O 0 6.633479188167257e-07
mitotic O 0 8.089924813248217e-05
expansion O 0 2.9507522413041443e-05
. O 0 7.724167517153546e-06

We O 0 1.2597318345797248e-05
also O 0 1.103649083233904e-06
show O 0 6.709483955091855e-07
that O 0 2.9317943628370813e-08
in O 0 1.8303149218468207e-08
all O 0 9.975098969050578e-09
informative O 0 5.329200689629943e-07
carrier O 0 2.3164491722127423e-05
father O 0 2.3593886453454616e-06
to O 0 1.5733532165995712e-07
affected O 0 1.3227084991740412e-06
child O 0 1.0202159046457382e-06
transmissions O 0 7.000239179433265e-07
, O 0 3.645546797770294e-08
with O 0 1.8841699755967056e-08
the O 0 2.6920186968482085e-08
notable O 0 1.7165390886475507e-07
exception O 0 8.421906017019865e-08
of O 0 2.3431081075386828e-08
the O 0 1.540132927857485e-07
premutation O 0 0.0019383305916562676
carrier O 0 1.027825510391267e-05
, O 0 5.524021773339882e-08
the O 0 3.050724473041555e-08
expansion O 0 7.89513990184787e-07
size O 0 2.694459226404433e-06
decreases O 0 8.332893230544869e-06
. O 0 7.373488415396423e-07
. O 0 2.5253875719499774e-06

The O 0 2.0590230633388273e-05
R496H O 0 0.0016462180064991117
mutation O 0 5.8731278841150925e-05
of O 0 1.6513020000274992e-06
arylsulfatase O 0 0.00890412274748087
A O 0 4.74966782348929e-06
does O 0 4.066958808834897e-06
not O 0 2.066251909127459e-06
cause O 0 0.0004993310431018472
metachromatic B-Disease 1 0.9875730872154236
leukodystrophy I-Disease 1 0.9981185793876648
. O 0 6.413360097212717e-05

Deficiency B-Disease 1 0.9971977472305298
of I-Disease 0 2.4382017727475613e-05
arylsulfatase I-Disease 0 0.033396560698747635
A I-Disease 0 1.1926329534617253e-05
( O 0 1.1223169167351443e-05
ARSA O 0 0.09868719428777695
) O 0 2.9902146252425155e-06
enzyme O 0 1.4138315236777999e-05
activity O 0 1.0923788977379445e-05
causes O 0 0.0008728327811695635
metachromatic B-Disease 1 0.9951257109642029
leukodystrophy I-Disease 1 0.9995208978652954
( O 0 0.00018867471953853965
MLD B-Disease 1 0.9706413745880127
) O 0 1.4735397598997224e-05
. O 0 7.238590569613734e-06

A O 0 1.2077273822796997e-05
number O 0 2.5815550088736927e-06
of O 0 3.698968157550553e-06
ARSA O 1 0.9293727874755859
gene O 0 0.0004113193426746875
mutations O 0 0.00023450444859918207
responsible O 0 3.4213751405332005e-06
for O 0 1.2776508810929954e-06
MLD B-Disease 1 0.9875723123550415
have O 0 7.885033710408607e-07
been O 0 7.034932991700771e-07
identified O 0 6.373459655151237e-06
. O 0 6.978262263146462e-06

Recently O 0 0.000128494793898426
, O 0 4.45316982222721e-06
the O 0 9.748646334628575e-07
R496H O 0 0.0002104331215377897
mutation O 0 5.181691449251957e-06
of O 0 2.0940369438449125e-07
ARSA O 0 0.031095251441001892
was O 0 2.0737483907851129e-07
proposed O 0 2.6827470378520957e-07
to O 0 5.8380699385907064e-08
be O 0 1.840010810383319e-08
a O 0 1.1490693907489913e-07
cause O 0 6.377156296366593e-06
of O 0 5.092933861305937e-07
MLD B-Disease 1 0.9985380172729492
( O 0 6.829288395238109e-06
Draghia O 0 0.012717006728053093
et O 0 0.0001513825118308887
al O 0 1.654542938922532e-05
. O 0 9.009519885694317e-08
, O 0 1.7920851291819417e-07
1997 O 0 2.4845926418493036e-06
) O 0 1.2906222082165186e-06
. O 0 2.5953170279535698e-06

We O 0 2.7615791623247787e-05
have O 0 2.594644001874258e-06
investigated O 0 1.147106468124548e-05
the O 0 7.3689687951628e-07
R496H O 0 0.0016841094475239515
mutation O 0 1.6939820852712728e-05
and O 0 1.9515798044267285e-07
found O 0 1.542857006597842e-07
this O 0 2.7132307067745387e-08
mutation O 0 6.222052206794615e-07
at O 0 5.5823718980718695e-08
a O 0 2.164236789781171e-08
relatively O 0 3.455031816201881e-08
high O 0 6.927247397925385e-08
frequency O 0 4.324407143485587e-08
in O 0 1.0400572847402145e-08
an O 0 6.647625117039979e-09
African O 0 1.1411997746790803e-07
American O 0 2.2929775411739683e-07
population O 0 1.2239281943493552e-07
( O 0 1.9461879219306866e-07
f O 0 1.238479762832867e-05
= O 0 1.4120193554845173e-05
0 O 0 3.843831564154243e-07
. O 0 2.6653793838704587e-08
09 O 0 1.1069494121329626e-06
, O 0 9.304861237069417e-08
n O 0 1.4546251804858912e-05
= O 0 3.4503278584452346e-05
61 O 0 1.5570039977319539e-06
subjects O 0 1.3509683185475296e-06
) O 0 1.5018812291600625e-06
. O 0 2.457843947922811e-06

The O 0 3.158321851515211e-05
ARSA O 0 0.017613478004932404
enzyme O 0 2.7885940653504804e-05
activity O 0 1.370736299577402e-06
in O 0 1.2328044363130175e-07
subjects O 0 3.3577950375729415e-07
with O 0 7.526573853056107e-08
and O 0 7.226426390616325e-08
without O 0 5.536151803653411e-08
the O 0 1.3290608080751554e-07
R496H O 0 0.00041145566501654685
mutation O 0 6.403940915333806e-06
was O 0 1.214683891248569e-07
determined O 0 1.8885170049998123e-07
and O 0 3.386622537959738e-08
found O 0 7.116453559774527e-08
to O 0 7.781743249779538e-08
be O 0 9.399436606827294e-08
normal O 0 2.6309030545235146e-06
. O 0 4.262606580596184e-06

It O 0 4.339571205491666e-06
is O 0 8.010343321984692e-07
therefore O 0 3.945635000945913e-07
concluded O 0 1.544790052321332e-06
that O 0 4.24605062221417e-08
the O 0 1.1553161272104262e-07
R496H O 0 0.00031641818350180984
mutation O 0 3.487824642434134e-06
of O 0 1.6720710505069292e-07
ARSA O 0 0.048651933670043945
does O 0 1.2886295053249341e-07
not O 0 1.0329481270332508e-08
negatively O 0 5.3242480646531476e-08
influence O 0 1.7410043184895585e-08
the O 0 7.627618536787395e-09
activity O 0 4.246990314982213e-08
of O 0 6.784392780900816e-08
ARSA O 0 0.04578709602355957
and O 0 1.4536989567659475e-07
is O 0 6.493907989124637e-08
not O 0 6.506740390932464e-08
a O 0 4.876601451542228e-07
cause O 0 1.8327908037463203e-05
of O 0 1.2390894880809356e-05
MLD B-Disease 1 0.9949327111244202

Down O 0 5.909882020205259e-05
- O 0 0.00011849586007883772
regulation O 0 1.2104324014217127e-05
of O 0 8.185918431991013e-07
transmembrane O 0 0.001179241226054728
carbonic O 0 0.0029985099099576473
anhydrases O 0 0.071613609790802
in O 0 3.222222221666016e-05
renal B-Disease 1 0.9998468160629272
cell I-Disease 1 0.7145950794219971
carcinoma I-Disease 1 0.9999773502349854
cell O 0 0.00025463031488470733
lines O 0 6.210436822584597e-06
by O 0 4.5726488906439045e-07
wild O 0 1.9734803572646342e-05
- O 0 0.018048657104372978
type O 0 0.0007488966803066432
von B-Disease 0 0.457203209400177
Hippel I-Disease 1 0.7103473544120789
- I-Disease 0 0.031909894198179245
Lindau I-Disease 0 0.39443692564964294
transgenes O 0 0.0016442803898826241
. O 0 2.9672602977370843e-05

To O 0 6.0761627537431195e-05
discover O 0 0.00025379631551913917
genes O 0 9.67583036981523e-06
involved O 0 1.6575959307374433e-06
in O 0 2.6516586331126746e-06
von B-Disease 1 0.6806452870368958
Hippel I-Disease 1 0.9782589673995972
- I-Disease 0 0.35979920625686646
Lindau I-Disease 1 0.9425725340843201
( O 0 4.182653356110677e-06
VHL B-Disease 0 0.0006869117496535182
) O 0 3.565227189028519e-07
- O 0 2.812840284605045e-05
mediated O 0 2.2285848899628036e-05
carcinogenesis O 0 0.00045677507296204567
, O 0 2.0815411971852882e-07
we O 0 1.4286250404893508e-07
used O 0 2.0593606677721255e-06
renal B-Disease 1 0.9970147609710693
cell I-Disease 0 0.07160042226314545
carcinoma I-Disease 1 0.9999432563781738
cell O 0 0.0001268501946469769
lines O 0 8.360976607946213e-06
stably O 0 4.02006262447685e-05
transfected O 0 8.399956277571619e-05
with O 0 2.4102195084196865e-07
wild O 0 5.742726443713764e-06
- O 0 0.0010076186154037714
type O 0 6.750876491423696e-05
VHL O 0 0.010556812398135662
- O 0 0.0006391978240571916
expressing O 0 2.883065644709859e-05
transgenes O 0 0.00038968821172602475
. O 0 1.1465082025097217e-05

Large O 0 1.8559674572316e-05
- O 0 6.55711701256223e-05
scale O 0 9.591043635737151e-06
RNA O 0 2.4845217012625653e-06
differential O 0 2.440087428112747e-06
display O 0 3.3848633052002697e-07
technology O 0 4.12188342124864e-07
applied O 0 5.964625415799674e-08
to O 0 2.1300250452327418e-08
these O 0 1.5232680894428086e-08
cell O 0 1.3921188610765967e-06
lines O 0 7.979182896633574e-07
identified O 0 1.6203580344154034e-07
several O 0 2.4548539201418862e-08
differentially O 0 2.494238515282632e-06
expressed O 0 1.722204245879766e-07
genes O 0 1.8035707682884095e-07
, O 0 3.276815974118108e-08
including O 0 4.5072507504073656e-08
an O 0 8.32532762728988e-08
alpha O 0 6.4093605942616705e-06
carbonic O 0 0.00023853240418247879
anhydrase O 0 0.000600565574131906
gene O 0 5.160929049452534e-06
, O 0 1.1884510513482383e-06
termed O 0 4.0245617128675804e-05
CA12 O 0 0.002096386393532157
. O 0 1.0208641469944268e-05

The O 0 6.216890142241027e-06
deduced O 0 1.270204120373819e-05
protein O 0 1.2074497135472484e-06
sequence O 0 4.829016688745469e-07
was O 0 7.631274456798565e-08
classified O 0 1.7185242029427172e-07
as O 0 9.613951412745791e-09
a O 0 1.2834227014479893e-08
one O 0 1.6994288642990796e-08
- O 0 0.0001655442756600678
pass O 0 3.8732732718926854e-06
transmembrane O 0 0.0007244790904223919
CA O 0 2.7844856958836317e-05
possessing O 0 2.344503400308895e-07
an O 0 2.9404858992165828e-08
apparently O 0 1.8139913038339728e-07
intact O 0 5.495960522239329e-07
catalytic O 0 4.6668759523527115e-07
domain O 0 2.0512857190624345e-07
in O 0 3.513908097829699e-08
the O 0 1.3388539343850425e-07
extracellular O 0 1.4088152965996414e-05
CA O 0 8.337947656400502e-05
module O 0 0.000126699946122244
. O 0 6.4361279328295495e-06

Reintroduced O 0 0.0003244237741455436
wild O 0 0.0002659187885001302
- O 0 0.015214976854622364
type O 0 0.00044525874545797706
VHL B-Disease 0 0.03573174402117729
strongly O 0 2.3299025997403078e-06
inhibited O 0 4.180993983027292e-06
the O 0 1.0613886303190156e-07
overexpression O 0 2.7045043680118397e-06
of O 0 3.730198017137809e-08
the O 0 1.565099694289529e-07
CA12 O 0 0.0017797413747757673
gene O 0 1.390425950376084e-06
in O 0 1.5081261039995297e-07
the O 0 6.933862550795311e-07
parental O 0 0.0016169161535799503
renal B-Disease 1 0.9997643828392029
cell I-Disease 1 0.6115161776542664
carcinoma I-Disease 1 0.9999599456787109
cell O 0 0.002193397842347622
lines O 0 0.00015661874203942716
. O 0 1.6947884432738647e-05

Similar O 0 2.3863489332143217e-05
results O 0 9.87913335848134e-06
were O 0 2.606302302865515e-07
obtained O 0 3.525953218286304e-07
with O 0 3.982007967806567e-07
CA9 O 0 0.01856604963541031
, O 0 2.84745567569189e-07
encoding O 0 4.292072333100805e-07
another O 0 5.905951638851548e-07
transmembrane O 0 0.0011150605278089643
CA O 0 3.145130176562816e-05
with O 0 7.029119331036782e-08
an O 0 9.642216980410012e-08
intact O 0 5.7107608881779015e-06
catalytic O 0 1.0632426892698277e-05
domain O 0 1.3314690477272961e-05
. O 0 6.2724707277084235e-06

Although O 0 1.36619537443039e-05
both O 0 1.2017069366265787e-06
domains O 0 1.952644197444897e-06
of O 0 1.3514964791738748e-07
the O 0 3.125120429103845e-07
VHL B-Disease 0 0.0020919202361255884
protein O 0 7.142780873437005e-07
contribute O 0 2.655882838098478e-07
to O 0 3.540401039003882e-08
regulation O 0 2.1383378623340832e-07
of O 0 6.196187740670211e-08
CA12 O 0 0.0009025476756505668
expression O 0 2.753544379174855e-07
, O 0 5.342823783394124e-08
the O 0 4.68894540972542e-08
elongin O 0 3.952670158469118e-05
binding O 0 3.0680411100547644e-07
domain O 0 4.357971192803234e-07
alone O 0 4.4941211285731697e-07
could O 0 1.8833765125236823e-07
effectively O 0 1.0706476132327225e-06
regulate O 0 2.952328577521257e-05
CA9 O 0 0.006339029408991337
expression O 0 9.395273082191125e-06
. O 0 6.089835096645402e-06

We O 0 8.391565643250942e-05
mapped O 0 0.00041928383870981634
CA12 O 0 0.011037377640604973
and O 0 9.10373819351662e-06
CA9 O 0 0.07631654292345047
loci O 0 6.779630348319188e-05
to O 0 9.818503485803376e-07
chromosome O 0 4.92372055305168e-05
bands O 0 1.2317306754994206e-05
15q22 O 0 0.00044817139860242605
and O 0 2.582303523013252e-06
17q21 O 0 0.0004954708274453878
. O 0 1.4375304999703076e-05

2 O 0 4.841628106078133e-05
respectively O 0 1.6660251276334748e-05
, O 0 1.5383654954348458e-06
regions O 0 6.077204943721881e-06
prone O 0 0.0001898232731036842
to O 0 2.5137936177088704e-07
amplification O 0 2.3251095626619644e-05
in O 0 2.8829774123551033e-07
some O 0 4.639987025711889e-07
human O 0 8.31071229185909e-05
cancers B-Disease 0 0.3193170130252838
. O 0 1.958089524123352e-05

Additional O 0 1.5294439435820095e-05
experiments O 0 1.9944514860981144e-05
are O 0 3.379444422080269e-07
needed O 0 6.30905162779527e-07
to O 0 6.249920403433862e-08
define O 0 4.140767373428389e-07
the O 0 3.032693030036171e-08
role O 0 1.1630345397861674e-07
of O 0 1.8502173304568714e-07
CA O 0 0.0003354815416969359
IX O 0 0.0007401718175970018
and O 0 8.387709726775938e-07
CA O 0 0.00023524256539531052
XII O 0 0.0019772902596741915
enzymes O 0 8.414116337007727e-07
in O 0 1.2333400967179386e-08
the O 0 1.0640760272906391e-08
regulation O 0 9.761347996573022e-08
of O 0 2.0948712986523788e-08
pH O 0 5.922538548475131e-06
in O 0 2.1247542392188734e-08
the O 0 2.5758168931133696e-08
extracellular O 0 1.5688327721363748e-06
microenvironment O 0 3.780273982556537e-05
and O 0 4.166180644915585e-08
its O 0 5.360676880172832e-08
potential O 0 1.304227680520853e-06
impact O 0 2.833333837770624e-06
on O 0 2.7978690013696905e-06
cancer B-Disease 0 0.11767281591892242
cell O 0 0.00015108745719771832
growth O 0 2.7316933483234607e-05
. O 0 8.068750503298361e-06

A O 0 2.068767571472563e-05
gene O 0 1.7902035324368626e-05
encoding O 0 3.984609520557569e-06
a O 0 1.2994837561564054e-06
transmembrane O 0 0.00031992894946597517
protein O 0 3.94831067751511e-06
is O 0 2.957408753445634e-07
mutated O 0 2.653524097695481e-05
in O 0 6.355894129228545e-06
patients O 0 0.048142626881599426
with O 0 0.009414905682206154
diabetes B-Disease 1 0.9999967813491821
mellitus I-Disease 1 0.9999898672103882
and O 0 0.13755545020103455
optic B-Disease 1 0.9999879598617554
atrophy I-Disease 1 0.9999829530715942
( O 1 0.8477463126182556
Wolfram B-Disease 1 0.9999654293060303
syndrome I-Disease 1 0.9999936819076538
) O 0 0.00011239163723075762
. O 0 3.2805219234433025e-05

Wolfram B-Disease 1 0.9995232820510864
syndrome I-Disease 1 0.9999796152114868
( O 0 0.0082071702927351
WFS B-Disease 1 0.9987492561340332
; O 0 0.003081211354583502
OMIM O 1 0.9987518787384033
222300 O 0 0.2611064314842224
) O 0 3.859475782519439e-06
is O 0 6.281794071583136e-07
an O 0 4.633965090761194e-06
autosomal B-Disease 1 0.9949471354484558
recessive I-Disease 1 0.9998615980148315
neurodegenerative I-Disease 1 0.9999910593032837
disorder I-Disease 1 0.9976837635040283
defined O 0 5.869942015124252e-06
by O 0 3.758988782465167e-07
young O 0 5.192207026993856e-06
- O 0 0.011766431853175163
onset O 0 0.3200254738330841
non O 0 3.5107888834318146e-05
- O 1 0.6205567121505737
immune O 0 0.2535902261734009
insulin B-Disease 0 0.0014812767039984465
- I-Disease 1 0.7434799671173096
dependent I-Disease 0 0.11816907674074173
diabetes I-Disease 1 0.9999774694442749
mellitus I-Disease 1 0.9997709393501282
and O 0 0.00011684946366585791
progressive O 0 0.06535341590642929
optic B-Disease 1 0.9995390176773071
atrophy I-Disease 1 0.9973776340484619
. O 0 0.00014734631986357272

Linkage O 0 0.0013037924654781818
to O 0 9.883995517157018e-06
markers O 0 0.00011782635556301102
on O 0 4.276728304830613e-06
chromosome O 0 0.0019840127788484097
4p O 1 0.800957202911377
was O 0 1.0425637810840271e-06
confirmed O 0 5.685848805114802e-07
in O 0 8.939544215991191e-08
five O 0 3.3013833444783813e-07
families O 0 6.017848136252724e-06
. O 0 7.87801491242135e-06

On O 0 3.7106806303199846e-06
the O 0 6.100346467974305e-07
basis O 0 4.4361922846292146e-07
of O 0 2.568394847912714e-07
meiotic O 0 0.018726127222180367
recombinants O 1 0.8982446789741516
and O 0 0.00023713393602520227
disease O 1 0.9084338545799255
- O 0 0.07995810359716415
associated O 0 4.4235988752916455e-05
haplotypes O 0 0.0005563314189203084
, O 0 3.3495595630483876e-07
the O 0 2.911458523158217e-07
WFS B-Disease 0 0.17599721252918243
gene O 0 2.671704351087101e-06
was O 0 7.968804283109421e-08
localized O 0 6.873449933664233e-07
to O 0 2.8691502507172117e-08
a O 0 6.797332474661744e-08
BAC O 0 3.3722040825523436e-05
/ O 0 3.6944577004760504e-05
P1 O 0 0.00013451142876874655
contig O 0 4.4765045458916575e-05
of O 0 2.476005356299993e-08
less O 0 2.712521762759934e-08
than O 0 4.144804677252978e-08
250 O 0 5.610947937384481e-07
kb O 0 0.0004419451579451561
. O 0 7.492221357097151e-06

Mutations O 0 0.001589131192304194
in O 0 2.968764647448552e-06
a O 0 1.3638606333188363e-06
novel O 0 8.514911314705387e-06
gene O 0 9.370039151690435e-06
( O 0 5.545852559407649e-07
WFS1 O 0 5.861713725607842e-05
) O 0 4.3148499884182456e-08
encoding O 0 4.8061593815873493e-08
a O 0 4.483303683855411e-08
putative O 0 9.51156016526511e-06
transmembrane O 0 4.1653267544461414e-05
protein O 0 2.0457804339457653e-07
were O 0 1.8714551686116465e-08
found O 0 2.0955946311573825e-08
in O 0 9.533841272002519e-09
all O 0 1.3379637842092507e-08
affected O 0 6.970607273615315e-07
individuals O 0 3.552387184413419e-08
in O 0 5.055744622950442e-08
six O 0 8.887519129530119e-07
WFS B-Disease 1 0.8768905997276306
families O 0 3.262851123508881e-06
, O 0 1.6026322668949433e-07
and O 0 1.4249619084694132e-07
these O 0 8.692328634651858e-08
mutations O 0 6.4972050495271105e-06
were O 0 6.49693063792256e-08
associated O 0 1.1158375627928763e-06
with O 0 1.8240161807625555e-06
the O 0 4.179327515885234e-05
disease O 1 0.9719630479812622
phenotype O 0 0.011989335529506207
. O 0 1.3896205928176641e-05

WFS1 O 0 0.05168427154421806
appears O 0 3.617030961322598e-05
to O 0 9.720341722641024e-07
function O 0 4.4821067035627493e-07
in O 0 1.1530178767316102e-07
survival O 0 1.0519796887820121e-05
of O 0 1.3079042560093512e-07
islet O 0 0.0005520809208974242
beta O 0 7.514081517001614e-06
- O 0 0.0008476675138808787
cells O 0 1.5905145119177178e-05
and O 0 6.098234734963626e-07
neurons O 0 1.7934744391823187e-05
. O 0 9.082302199203696e-07
. O 0 5.301682904246263e-06

Stable O 0 6.253146420931444e-05
interaction O 0 5.644218163070036e-06
between O 0 5.962829163763672e-07
the O 0 1.1428553392534013e-07
products O 0 1.8247540367610782e-07
of O 0 5.2489262714061624e-08
the O 0 4.822707069251919e-07
BRCA1 O 0 0.0033113048411905766
and O 0 1.1461900612630416e-05
BRCA2 O 0 0.06911558657884598
tumor B-Disease 0 0.005523530766367912
suppressor O 0 7.459532753273379e-06
genes O 0 2.548181612382905e-07
in O 0 6.684728504069426e-08
mitotic O 0 9.980675713450182e-06
and O 0 1.0220730928267585e-06
meiotic O 0 0.0011757871834561229
cells O 0 6.917043356224895e-05
. O 0 1.007199170999229e-05

BRCA1 O 0 0.3540067672729492
and O 0 5.046672231401317e-05
BRCA2 O 0 0.010530178435146809
account O 0 5.527701432583854e-06
for O 0 2.0858631444298226e-07
most O 0 1.2391647885579005e-07
cases O 0 4.563905235954735e-07
of O 0 3.7501871474887594e-07
familial O 1 0.5842617154121399
, O 0 1.1439186891948339e-05
early O 0 0.00012855987006332725
onset O 1 0.9976580142974854
breast B-Disease 1 0.9811034202575684
and I-Disease 0 0.0001422384666511789
/ I-Disease 1 0.9989797472953796
or I-Disease 1 0.5831027030944824
ovarian I-Disease 1 0.9999990463256836
cancer I-Disease 1 0.99912029504776
and O 0 6.795672788939555e-07
encode O 0 1.2175199799457914e-06
products O 0 2.7121268431073986e-07
that O 0 2.996058157123116e-08
each O 0 2.9172245064046365e-08
interact O 0 4.872534304922738e-07
with O 0 8.828284876472026e-07
hRAD51 O 0 0.0010196797084063292
. O 0 6.997308901190991e-06

Results O 0 7.091126462910324e-05
presented O 0 5.6977919484779704e-06
here O 0 1.5982365084710182e-06
show O 0 1.457495727663627e-06
that O 0 4.5425107941809983e-07
BRCA1 O 0 0.0003080219030380249
and O 0 1.5517875908699352e-06
BRCA2 O 0 0.00035735502024181187
coexist O 0 4.854426151723601e-06
in O 0 5.1877350415452383e-08
a O 0 5.9204676716717586e-08
biochemical O 0 4.339417955634417e-06
complex O 0 1.0153686389458016e-06
and O 0 1.8731537920757546e-07
colocalize O 0 0.00013866191147826612
in O 0 2.0544592871374334e-07
subnuclear O 0 0.00036554428515955806
foci O 0 1.3110706277075224e-05
in O 0 8.371234372361869e-08
somatic O 0 4.148924290348077e-06
cells O 0 9.081903726837481e-07
and O 0 1.944654925978284e-08
on O 0 1.965222651278964e-08
the O 0 2.991843572885955e-08
axial O 0 5.060645662524621e-07
elements O 0 5.9484367653794834e-08
of O 0 1.0655407578497034e-07
developing O 0 1.2552947737276554e-05
synaptonemal O 0 0.005618944298475981
complexes O 0 0.0003340198891237378
. O 0 1.264740785700269e-05

Like O 0 0.00023269881785381585
BRCA1 O 0 0.00845955777913332
and O 0 1.4665135495306458e-05
RAD51 O 0 0.1092626079916954
, O 0 7.241407274705125e-06
BRCA2 O 0 0.0003647393605206162
relocates O 0 6.991976260906085e-05
to O 0 7.795846954650187e-07
PCNA O 0 0.0004031770513392985
+ O 0 1.8635104424902238e-05
replication O 0 5.85177076573018e-06
sites O 0 2.4541148491152853e-07
following O 0 1.2470997035052278e-07
exposure O 0 1.749017542351794e-06
of O 0 6.144134800933898e-08
S O 0 7.939201168483123e-05
phase O 0 1.0124677828571294e-05
cells O 0 3.942677722079679e-06
to O 0 3.579091867322859e-07
hydroxyurea O 0 0.00019630427414085716
or O 0 3.6324054235592484e-06
UV O 0 0.003250369569286704
irradiation O 0 8.780013740761206e-05
. O 0 5.913644145039143e-06

Thus O 0 4.3565993109950796e-05
, O 0 6.834090072516119e-06
BRCA1 O 0 0.00042430596658959985
and O 0 1.7225950159627246e-06
BRCA2 O 0 0.0001315569825237617
participate O 0 2.677777786175284e-07
, O 0 9.077083262809538e-08
together O 0 7.942431778928949e-08
, O 0 3.249759217283099e-08
in O 0 1.7839235866290437e-08
a O 0 6.292514598271737e-08
pathway O 0 6.957955065445276e-06
( O 0 1.7968509382626507e-06
s O 0 0.0001522400270914659
) O 0 1.2346350786174298e-07
associated O 0 3.6609460352110546e-08
with O 0 6.494586646255129e-09
the O 0 6.829050658296865e-09
activation O 0 1.211714959481469e-07
of O 0 9.242314469304347e-09
double O 0 7.566248427792743e-07
- O 0 9.249200957128778e-05
strand O 0 4.0577855543233454e-05
break O 0 1.0859038411581423e-05
repair O 0 0.00030803304980508983
and O 0 4.872501335739798e-07
/ O 0 6.404895248124376e-05
or O 0 1.054470999406476e-06
homologous O 0 4.001073102699593e-05
recombination O 0 5.546734246308915e-05
. O 0 8.144009370880667e-06

Dysfunction O 1 0.7256937623023987
of O 0 4.237970188114559e-06
this O 0 7.697502155679103e-07
pathway O 0 1.6688079995219596e-05
may O 0 7.507761665692669e-07
be O 0 1.0929518623470358e-08
a O 0 2.1691876739282634e-08
general O 0 1.8097492215929378e-07
phenomenon O 0 3.0568571673939005e-06
in O 0 2.142689403683562e-08
the O 0 1.8336624663106704e-08
majority O 0 1.254537096428976e-07
of O 0 5.4288452844275525e-08
cases O 0 8.317517199429858e-07
of O 0 1.8869628775064484e-06
hereditary B-Disease 1 0.991657555103302
breast I-Disease 1 0.9981587529182434
and I-Disease 0 0.0005614717956632376
/ I-Disease 1 0.9986298084259033
or I-Disease 1 0.7062875032424927
ovarian I-Disease 1 0.9999972581863403
cancer I-Disease 1 0.9998779296875
. O 0 1.3857445082976483e-05
. O 0 1.679034176049754e-05

A O 0 2.454020250297617e-05
novel O 0 3.183869193890132e-05
Arg362Ser O 0 0.0013625898864120245
mutation O 0 9.519191735307686e-06
in O 0 1.3947047250439937e-07
the O 0 1.0144970730152636e-07
sterol O 0 3.096683576586656e-05
27 O 0 1.923693616845412e-06
- O 0 0.00022432865807786584
hydroxylase O 0 0.0018784040585160255
gene O 0 4.3500463107193355e-06
( O 0 3.630870537563169e-07
CYP27 O 0 8.18664557300508e-05
) O 0 5.479078879488952e-08
: O 0 2.387508679646544e-08
its O 0 1.1920359810346781e-08
effects O 0 6.990826051378463e-08
on O 0 1.4458672481509893e-08
pre O 0 5.964870410934964e-07
- O 0 3.0944895570428343e-06
mRNA O 0 3.2350286005566886e-07
splicing O 0 1.1113338587165345e-06
and O 0 2.2532445598244522e-07
enzyme O 0 3.0868557132635033e-06
activity O 0 1.94801850739168e-06
. O 0 4.023558176413644e-06

A O 0 3.6893387004965916e-05
novel O 0 4.719731805380434e-05
C O 0 5.672596671502106e-05
to O 0 2.0124659272369172e-07
A O 0 1.2556969863908307e-07
mutation O 0 5.545176122723205e-07
in O 0 2.857811587375636e-08
the O 0 5.2735622091404366e-08
sterol O 0 2.5608578653191216e-05
27 O 0 2.2586953036807245e-06
- O 0 0.0002534360100980848
hydroxylase O 0 0.003047256963327527
gene O 0 8.099689694063272e-06
( O 0 3.8301865856738004e-07
CYP27 O 0 0.00020953756757080555
) O 0 9.390279842591553e-08
was O 0 2.9653802968709897e-08
identified O 0 3.732888131935397e-08
by O 0 1.655148551549246e-08
sequencing O 0 3.6867331232315337e-07
amplified O 0 2.092173417622689e-06
CYP27 O 0 0.00012735633936244994
gene O 0 4.281827159502427e-07
products O 0 6.734947533004743e-08
from O 0 4.41741789813932e-08
a O 0 2.810963621868723e-07
patient O 0 0.00010525638936087489
with O 0 8.940198313212022e-06
cerebrotendinous B-Disease 1 0.9983265995979309
xanthomatosis I-Disease 1 0.9972845315933228
( O 0 4.966051346855238e-05
CTX B-Disease 1 0.5659669637680054
) O 0 6.302439487626543e-06
. O 0 5.65234086025157e-06

The O 0 3.46198576153256e-05
mutation O 0 6.957907316973433e-05
changed O 0 2.2653048290521838e-06
the O 0 3.379551003490633e-07
adrenodoxin O 0 4.9698559450916946e-05
cofactor O 0 3.009608917636797e-06
binding O 0 8.600075034337351e-07
residue O 0 2.773312417048146e-06
362Arg O 0 5.1618430006783456e-05
to O 0 3.2063320531960926e-07
362Ser O 0 7.619890675414354e-05
( O 0 5.251390007288137e-07
CGT O 0 0.0001799221063265577
362Arg O 0 7.70234182709828e-05
to O 0 3.7205523994998657e-07
AGT O 0 0.007391214836388826
362Ser O 0 0.00029607510077767074
) O 0 1.4319819285901758e-07
, O 0 2.4518495678194085e-08
and O 0 2.989390779362111e-08
was O 0 6.457311485519313e-08
responsible O 0 3.786693696383736e-07
for O 0 2.8718966404994717e-07
deficiency O 0 0.03532012924551964
in O 0 3.098730871897715e-08
the O 0 3.746547605487649e-08
sterol O 0 2.600257175799925e-05
27 O 0 6.399677090485056e-07
- O 0 5.357914051273838e-05
hydroxylase O 0 0.00011329098197165877
activity O 0 2.731032395786315e-07
, O 0 4.087259597440607e-08
as O 0 1.433997098843065e-08
confirmed O 0 4.926491570245162e-08
by O 0 9.246404530927066e-09
expression O 0 1.5582378054546098e-08
of O 0 1.0343518042077449e-08
mutant O 0 4.249988876381394e-07
cDNA O 0 2.841956359134201e-07
into O 0 7.391675183043844e-08
COS O 0 0.0004962719394825399
- O 0 0.0001291091466555372
1 O 0 6.127521373855416e-06
cells O 0 2.266772571601905e-05
. O 0 3.80753340323281e-06

Quantitative O 0 0.00016908974794205278
analysis O 0 9.800776751944795e-06
showed O 0 2.875335439966875e-06
that O 0 5.5261295983655145e-08
the O 0 3.8497450560726065e-08
expression O 0 7.114309852340739e-08
of O 0 5.621242138431626e-08
CYP27 O 0 0.00016174832126125693
gene O 0 3.1996304983294976e-07
mRNA O 0 1.1162980229073582e-07
in O 0 2.6078605941393107e-08
the O 0 1.0735722355548205e-07
patient O 0 1.0443955034133978e-05
represented O 0 6.34174682545563e-07
52 O 0 5.601250904874178e-06
. O 0 6.080074399505975e-06

5 O 0 3.186673347954638e-05
% O 0 1.69476163591753e-06
of O 0 3.5887646276933083e-07
the O 0 6.346587042571628e-07
normal O 0 3.004040081577841e-06
level O 0 5.923623120906996e-06
. O 0 8.966172572399955e-06

As O 0 6.2698873080080375e-06
the O 0 1.6042484958234127e-06
mutation O 0 1.2234630958118942e-05
occurred O 0 1.2580154589159065e-06
at O 0 8.347190316726483e-08
the O 0 2.113723063246198e-08
penultimate O 0 8.953841756920156e-07
nucleotide O 0 3.780332349379023e-07
of O 0 2.384800801280562e-08
exon O 0 5.6712442528805695e-06
6 O 0 6.019186002959032e-07
( O 0 4.21218011581459e-08
- O 0 9.6481005584792e-07
2 O 0 3.244519675149604e-08
position O 0 7.4255579463056165e-09
of O 0 3.905485268518305e-09
exon O 0 1.0866162938327761e-06
6 O 0 5.68639677567262e-07
- O 0 4.1071660234592855e-05
intron O 0 0.000546324416063726
6 O 0 1.021261482492264e-06
splice O 0 1.4453495168709196e-05
site O 0 2.221300405835791e-07
) O 0 1.8649414457172497e-08
of O 0 5.68171110160165e-09
the O 0 2.5865396935387253e-08
gene O 0 5.426685447673663e-07
, O 0 5.2790067428531984e-08
we O 0 4.581759327493273e-08
hypothesized O 0 2.9222533157735597e-06
that O 0 2.2619399686618635e-08
the O 0 5.661819457714046e-08
mutation O 0 6.150728495413205e-06
may O 0 5.292794185152161e-07
partially O 0 5.034516448176873e-07
affect O 0 6.289814535875848e-08
the O 0 9.394558020403565e-09
normal O 0 3.9667252593744706e-08
splicing O 0 3.758325419767061e-07
efficiency O 0 3.492197322430002e-07
in O 0 3.325454756009094e-08
exon O 0 1.631866325624287e-05
6 O 0 1.4812472954872646e-06
and O 0 1.6316063522481272e-07
cause O 0 6.501424536509148e-07
alternative O 0 5.30401678133785e-08
splicing O 0 5.005056209483882e-07
elsewhere O 0 1.2420646555710846e-07
, O 0 2.0730851701955544e-08
which O 0 1.6261997970445918e-08
resulted O 0 1.3889136596390017e-07
in O 0 4.0115704535992336e-08
decreased O 0 2.8676458896370605e-06
transcript O 0 4.115722276765155e-06
in O 0 2.708601130052557e-07
the O 0 1.7228891238119104e-06
patient O 0 0.00021619828476104885
. O 0 1.306876220041886e-05

Transfection O 0 0.010861774906516075
of O 0 8.847975550452247e-06
constructed O 0 9.396526002092287e-05
minigenes O 0 0.0052758450619876385
, O 0 6.326602601802733e-07
with O 0 1.5493387195419928e-07
or O 0 8.344373014779194e-08
without O 0 2.8842499943948496e-08
the O 0 3.5714776913664537e-08
mutation O 0 4.32529816407623e-07
, O 0 1.9154482444605492e-08
into O 0 3.9754660008384235e-08
COS O 0 0.010493556037545204
- O 0 0.0002931164635811001
1 O 0 1.6087375342976884e-06
cells O 0 2.770890660031e-06
confirmed O 0 7.843075167102143e-08
that O 0 8.453735489410974e-09
the O 0 2.3757163347681853e-08
mutant O 0 3.398332410142757e-06
minigene O 0 0.00010602460679365322
was O 0 4.9185015171815394e-08
responsible O 0 3.626516331678431e-08
for O 0 4.6853667612367644e-09
a O 0 1.009632111248493e-08
mRNA O 0 7.150578085202142e-08
species O 0 2.919328423445222e-08
alternatively O 0 1.0456869148356418e-07
spliced O 0 6.278403930082277e-07
at O 0 4.376416740115019e-08
an O 0 1.3457212233447535e-08
activated O 0 1.5605957059960929e-06
cryptic O 0 2.7094663437310373e-06
5 O 0 1.2127334514389077e-07
splice O 0 3.9318265407928266e-06
site O 0 2.2303453306449228e-07
88 O 0 2.8080674496777647e-07
bp O 0 1.6961830624495633e-06
upstream O 0 1.6478365694183594e-07
from O 0 6.2145422141668405e-09
the O 0 9.416767809966586e-09
3 O 0 6.712991762469755e-08
end O 0 7.375353305860699e-08
of O 0 7.073151664371835e-08
exon O 0 8.62930974108167e-05
6 O 0 1.7490345271653496e-05
. O 0 5.654675987898372e-06

Our O 0 1.3825236237607896e-05
data O 0 5.92709329794161e-06
suggest O 0 1.1186099300175556e-06
that O 0 5.6969060580058795e-08
the O 0 6.957120035622211e-08
C O 0 4.685955445893342e-06
to O 0 4.417257670752406e-08
A O 0 6.652904005477467e-08
mutation O 0 3.098645322552329e-07
at O 0 2.533585963249152e-08
the O 0 1.314780728733922e-08
penultimate O 0 8.666179382998962e-07
nucleotide O 0 2.2082282669089182e-07
of O 0 1.5480146942081774e-08
exon O 0 2.7740661607822403e-06
6 O 0 1.4664115610685258e-07
of O 0 1.6601314101194475e-08
the O 0 1.3389548314535205e-07
CYP27 O 0 0.011051571927964687
gene O 0 1.9213139239582233e-06
not O 0 2.1957999862820543e-08
only O 0 2.4150022426283613e-08
causes O 0 7.352266038651578e-06
the O 0 1.2158177469245857e-06
deficiency B-Disease 0 0.044850412756204605
in I-Disease 0 3.243195578761515e-08
the I-Disease 0 5.1049305227479636e-08
sterol I-Disease 0 1.4112587450654246e-05
27 I-Disease 0 5.639476512442343e-07
- I-Disease 0 5.0309012294746935e-05
hydroxylase I-Disease 0 0.00010185288556385785
activity I-Disease 0 1.6981707062768692e-07
, O 0 2.614085659047305e-08
but O 0 1.4384569091419053e-08
also O 0 2.010760091764041e-08
partially O 0 4.3648921632666315e-07
leads O 0 1.76077520563922e-07
to O 0 8.987496080692381e-09
alternative O 0 1.722671605364212e-08
pre O 0 3.1256686838787573e-07
- O 0 1.8256155271956231e-06
mRNA O 0 1.4778044032937032e-07
splicing O 0 3.5632589856504637e-07
of O 0 6.347567449438429e-08
the O 0 2.9325755690479127e-07
gene O 0 7.832885785319377e-06
. O 0 4.109325800527586e-06

To O 0 7.613981324539054e-06
our O 0 1.3979221193949343e-06
knowledge O 0 1.0814626421051798e-06
, O 0 1.9514533278197632e-07
this O 0 2.6618941717515554e-08
is O 0 1.8538020896130547e-08
the O 0 2.5224093036513295e-08
first O 0 6.497277382777611e-08
report O 0 9.77935030732624e-08
regarding O 0 7.150359948582263e-08
effects O 0 1.6466802321701834e-07
on O 0 1.0713667286665896e-08
pre O 0 4.808497919839283e-07
- O 0 7.792025940034364e-07
mRNA O 0 3.434368522903242e-08
splicing O 0 6.067667612796868e-08
of O 0 5.348694376294816e-09
a O 0 1.7304566668485677e-08
mutation O 0 2.4387654207203013e-07
at O 0 1.7251970518827875e-08
the O 0 1.3519755093227559e-08
- O 0 7.543210813309997e-06
2 O 0 1.7430734544632287e-07
position O 0 2.6817586373795166e-08
of O 0 1.659840087597786e-08
a O 0 9.479790463728932e-08
5 O 0 1.2913573073092266e-06
splice O 0 0.00013744556054007262
site O 0 1.2315650565142278e-05
. O 0 5.4641777751385234e-06

ATM O 0 0.01107182539999485
germline O 0 0.4011543095111847
mutations O 0 0.0014468608424067497
in O 0 5.75528747503995e-06
classical O 0 0.00038322529871948063
ataxia B-Disease 1 0.9999681711196899
- I-Disease 1 0.999903678894043
telangiectasia I-Disease 1 0.9999819993972778
patients O 0 0.1540391892194748
in O 0 6.910941579008067e-07
the O 0 7.850541123843868e-07
Dutch O 0 6.95228372933343e-05
population O 0 7.143937182263471e-06
. O 0 7.790171366650611e-06

Germline O 1 0.7286257147789001
mutations O 0 0.002787721110507846
in O 0 2.2940610051591648e-06
the O 0 5.442981318992679e-07
ATM O 0 0.00012584900832735002
gene O 0 5.6919639064290095e-06
are O 0 7.740928964494742e-08
responsible O 0 8.779989002505317e-07
for O 0 1.44670661939017e-06
the O 0 0.00037749772309325635
autosomal B-Disease 1 0.9999808073043823
recessive I-Disease 1 0.9999964237213135
disorder I-Disease 1 0.9999996423721313
ataxia B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999723434448242
telangiectasia I-Disease 1 0.9999812841415405
( O 0 8.027196599869058e-05
A B-Disease 0 8.390301081817597e-05
- I-Disease 1 0.8384130001068115
T I-Disease 1 0.9982578158378601
) O 0 2.08265792025486e-05
. O 0 8.75579280545935e-06

In O 0 5.158606199984206e-06
our O 0 1.6873207187018124e-06
study O 0 1.2507209703471744e-06
, O 0 1.502752269288976e-07
we O 0 3.91146599554304e-08
have O 0 1.959787354621767e-08
determined O 0 6.068061253472479e-08
the O 0 2.6403681019360192e-08
ATM O 0 5.950654212938389e-06
mutation O 0 6.462443025156972e-07
spectrum O 0 1.2555521777812828e-07
in O 0 1.301040430945477e-08
19 O 0 8.523228700596519e-08
classical O 0 2.260135687492948e-07
A B-Disease 0 1.4672576980956364e-05
- I-Disease 1 0.9920338988304138
T I-Disease 1 0.9999716281890869
patients O 0 0.0024949563667178154
, O 0 1.7237340443898574e-07
including O 0 8.45519068093381e-08
some O 0 4.042162160544649e-08
immigrant O 0 2.0567935280269012e-05
populations O 0 3.500343609630363e-06
, O 0 6.098693461353832e-08
as O 0 9.016719815235774e-09
well O 0 1.1295401947108985e-08
as O 0 1.0792136073689562e-08
12 O 0 4.1567037811773844e-08
of O 0 3.3382665520775845e-08
Dutch O 0 2.081834054479259e-06
ethnic O 0 8.198942396120401e-07
origin O 0 4.011833425465738e-06
. O 0 1.0344720067223534e-05

Both O 0 7.4638805926952045e-06
the O 0 2.3648310616408708e-06
protein O 0 3.006780389114283e-06
truncation O 0 6.65163533994928e-05
test O 0 2.2634646938968217e-06
( O 0 2.7476605168885726e-07
PTT O 0 8.198721843655221e-06
) O 0 6.615386638486598e-08
and O 0 1.65222768799822e-08
the O 0 2.4096696193964817e-08
restriction O 0 3.230136087495339e-07
endonuclease O 0 3.9109836507122964e-05
fingerprinting O 0 2.487985693733208e-05
( O 0 9.72423549683299e-07
REF O 0 0.0156631488353014
) O 0 5.5673258003707815e-08
method O 0 1.4598640518670436e-08
were O 0 3.276682924990837e-09
used O 0 6.055271839500165e-09
and O 0 1.069064214931359e-08
compared O 0 4.0159953584861796e-08
for O 0 6.175254974039035e-09
their O 0 2.8424057774145695e-08
detection O 0 2.223372121079592e-06
efficiency O 0 5.536272169592849e-07
, O 0 6.36490398164824e-08
identifying O 0 4.260881212303502e-07
76 O 0 1.3327013448360958e-06
% O 0 3.303259887843524e-08
and O 0 1.66995732797659e-08
60 O 0 4.2501671515537964e-08
% O 0 2.2574015545728798e-08
of O 0 1.5709835210486744e-08
the O 0 2.71028852694144e-07
mutations O 0 1.6013311324059032e-05
, O 0 5.692652393918252e-07
respectively O 0 6.0310503613436595e-06
. O 0 5.1683168749150354e-06

Most O 0 0.00014644747716374695
patients O 0 0.007189879193902016
were O 0 7.230044616335363e-07
found O 0 5.192967478251376e-07
to O 0 2.124102422840224e-07
be O 0 1.8786120392633165e-07
compound O 0 1.8160932086175308e-05
heterozygote O 0 0.0008029772434383631
. O 0 1.3001757906749845e-05

Seventeen O 0 0.00028299589757807553
mutations O 0 0.0007022403297014534
were O 0 6.476028033830517e-07
distinct O 0 5.59337536287785e-07
, O 0 9.313668414279164e-08
of O 0 3.51925386610219e-08
which O 0 5.702276340002754e-08
10 O 0 8.345853075297782e-08
were O 0 3.921049795962972e-08
not O 0 8.137142515352025e-08
reported O 0 2.033734517681296e-06
previously O 0 2.607244596219971e-06
. O 0 6.559589110111119e-06

Mutations O 0 0.002918361220508814
are O 0 1.745521785778692e-06
small O 0 1.6274026393148233e-06
deletions O 0 4.245544914738275e-05
or O 0 1.5794734053997672e-06
point O 0 6.964753538341029e-06
mutations O 0 8.059510582825169e-05
frequently O 0 3.1599734029441606e-06
affecting O 0 1.0606620890030172e-05
splice O 0 0.00033898474066518247
sites O 0 1.1029032066289801e-05
. O 0 1.0363886758568697e-05

Moreover O 0 0.00028827894129790366
, O 0 1.353961579297902e-05
a O 0 7.638687748112716e-06
16 O 0 3.01346317428397e-05
. O 0 2.381947160756681e-05

7 O 0 0.00010237909737043083
- O 0 0.0005359146161936224
kb O 0 0.001523590530268848
genomic O 0 5.943176074652001e-05
deletion O 0 1.7121070413850248e-05
of O 0 4.899129990576512e-08
the O 0 3.473155274491546e-08
3 O 0 1.0427591945472159e-07
end O 0 5.2380652704187014e-08
of O 0 1.241371361260235e-08
the O 0 5.5016883493408386e-08
gene O 0 8.666798976264545e-07
, O 0 4.220060745296905e-08
most O 0 1.4711988960414146e-08
likely O 0 4.084820304228742e-08
a O 0 1.176448449768941e-08
result O 0 3.1640574604807625e-08
of O 0 6.120879803006574e-09
recombination O 0 7.630152367710252e-07
between O 0 2.9490962560885237e-08
two O 0 1.7663042584104005e-08
LINE O 0 3.6662325442193833e-07
elements O 0 1.1163789537249613e-07
, O 0 1.914491889465353e-07
was O 0 5.123009714225191e-07
identified O 0 4.333797733124811e-06
. O 0 5.130699264555005e-06

The O 0 1.1064839782193303e-05
most O 0 1.4983761502662674e-06
frequently O 0 2.8693500553345075e-06
found O 0 1.0795871503432863e-06
mutation O 0 9.073212822841015e-06
, O 0 1.62706299988713e-07
identified O 0 2.0727736682601972e-07
in O 0 2.9025775560853617e-08
three O 0 3.476787568956752e-08
unrelated O 0 1.1778716952903778e-06
Turkish O 0 7.14821851488523e-07
A B-Disease 0 2.3837719709263183e-05
- I-Disease 1 0.9492953419685364
T I-Disease 1 0.9998012185096741
individuals O 0 1.3740618669544347e-06
, O 0 1.2255131309757417e-07
was O 0 9.140008927488452e-08
previously O 0 1.6246565337496577e-07
described O 0 3.4304085261283035e-07
to O 0 1.7663108309307063e-08
be O 0 4.145427112689504e-09
a O 0 1.3077379179549098e-08
Turkish O 0 2.410984905054647e-07
A B-Disease 0 3.3968424304475775e-06
- I-Disease 0 0.23518840968608856
T I-Disease 1 0.9973527193069458
founder O 0 0.0036124810576438904
mutation O 0 0.00013096984184812754
. O 0 1.002506360237021e-05

The O 0 9.384221812069882e-06
presence O 0 3.4691545351961395e-06
of O 0 2.8406068963704456e-07
a O 0 4.727835687390325e-07
founder O 0 5.598045026999898e-05
mutation O 0 8.728712600714061e-06
among O 0 8.952050478683304e-08
relatively O 0 8.584443378367723e-08
small O 0 4.616223492348581e-08
ethnic O 0 6.03706453716768e-08
population O 0 6.03175891455976e-08
groups O 0 1.927888249042553e-08
in O 0 1.3571737511597348e-08
Western O 0 1.5539748687842803e-07
Europe O 0 2.404468375516444e-07
could O 0 6.578606814855448e-08
indicate O 0 1.1581148129380381e-07
a O 0 1.3585929714565737e-08
high O 0 1.704327985407872e-07
carrier O 0 2.632343694131123e-06
frequency O 0 1.1516640086028929e-07
in O 0 5.295525440374149e-08
such O 0 2.072149101195464e-07
communities O 0 5.4063566494733095e-06
. O 0 7.2397228905174416e-06

In O 0 4.071522562298924e-05
patients O 0 0.0003019209543708712
of O 0 4.0320756511391664e-07
Dutch O 0 8.520337360096164e-06
ethnic O 0 6.885409788992547e-07
origin O 0 9.933993396771257e-07
, O 0 5.959167879154847e-07
however O 0 2.1555385387728165e-07
, O 0 1.6305455119436374e-07
no O 0 1.7259448270579014e-07
significant O 0 4.3696735474441084e-07
founder O 0 4.154872658546083e-05
effect O 0 2.274322696393938e-06
could O 0 4.589919910813478e-07
be O 0 1.8086950603901641e-07
identified O 0 3.9816768548917025e-06
. O 0 6.130297606432578e-06

The O 0 2.9741730031673796e-05
observed O 0 3.953431951231323e-05
genetic O 0 7.586726860608906e-05
heterogeneity O 0 0.00010870954429265112
including O 0 3.7836866795259994e-07
the O 0 1.0087855883966768e-07
relative O 0 4.443822660959995e-07
high O 0 2.1876384437291563e-07
percentage O 0 2.1618050993765792e-07
of O 0 3.152768002223638e-08
splice O 0 0.00019018487364519387
- O 0 0.0017306010704487562
site O 0 9.423996743862517e-06
mutations O 0 5.223571406531846e-06
had O 0 5.90358659735557e-08
no O 0 4.8426816334767864e-08
reflection O 0 8.218490279432444e-07
on O 0 1.7814252828429744e-07
the O 0 9.14868280688097e-07
phenotype O 0 0.0002975221141241491
. O 0 9.066042366612237e-06

All O 0 2.610379124234896e-05
patients O 0 0.001100007677450776
manifested O 0 3.029472463822458e-05
classical O 0 3.2754342100815848e-06
A B-Disease 0 8.799748684396036e-06
- I-Disease 0 0.03456613048911095
T I-Disease 1 0.818091094493866
and O 0 7.460596407327102e-07
increased O 0 1.6611581941106124e-06
cellular O 0 0.00010789974476210773
radioresistant O 0 0.0024260079953819513
DNA O 0 4.0214930777437985e-05
synthesis O 0 1.3908787877880968e-05
. O 0 7.5945822572975885e-06

Determination O 0 8.388028800254688e-05
of O 0 1.4086349438002799e-06
the O 0 6.795477816012863e-07
genomic O 0 6.209714229044039e-06
structure O 0 7.292723012142233e-07
of O 0 6.875083613522293e-08
the O 0 2.450422016408993e-07
COL4A4 O 0 0.006405997090041637
gene O 0 2.0542645415844163e-06
and O 0 1.2392368375913065e-07
of O 0 6.233824478840688e-07
novel O 0 0.0007231591735035181
mutations O 0 0.08307640254497528
causing O 0 0.48588666319847107
autosomal B-Disease 1 0.999091386795044
recessive I-Disease 1 0.9997641444206238
Alport I-Disease 1 0.9999616146087646
syndrome I-Disease 1 0.9999468326568604
. O 0 0.000247161922743544

Autosomal B-Disease 1 0.9993948936462402
recessive I-Disease 1 0.999860405921936
Alport I-Disease 1 0.9999768733978271
syndrome I-Disease 1 0.9999785423278809
is O 0 3.307458609924652e-05
a O 0 9.882439371722285e-06
progressive O 0 0.006655516102910042
hematuric B-Disease 1 0.997261643409729
glomerulonephritis I-Disease 1 0.9999357461929321
characterized O 0 0.05196472257375717
by O 0 2.1553612896241248e-05
glomerular B-Disease 1 0.9943786263465881
basement I-Disease 0 0.46357840299606323
membrane I-Disease 0 0.022458912804722786
abnormalities I-Disease 1 0.702970564365387
and O 0 1.0166176025450113e-06
associated O 0 1.7229006061825203e-06
with O 0 5.117989871905593e-07
mutations O 0 7.338290743064135e-06
in O 0 4.088460414664041e-08
either O 0 5.858940710368188e-08
the O 0 1.2234836788138637e-07
COL4A3 O 0 0.0013392918044701219
or O 0 9.338322115581832e-08
the O 0 8.802796003237745e-08
COL4A4 O 0 0.00045660525211133063
gene O 0 5.093599497740797e-07
, O 0 1.6137938985139044e-08
which O 0 7.505196464308028e-09
encode O 0 5.071370878795278e-08
the O 0 3.251359004252663e-08
alpha3 O 0 4.034861194668338e-05
and O 0 2.2707330060711683e-07
alpha4 O 0 0.0011834950419142842
type O 0 2.9650027499883436e-05
IV O 0 0.0007461790228262544
collagen O 0 0.00030030697234906256
chains O 0 2.559263703005854e-05
, O 0 7.641031629646022e-07
respectively O 0 3.8422481338784564e-06
. O 0 5.376166427595308e-06

To O 0 2.1038600607425906e-05
date O 0 1.0003212082665414e-05
, O 0 1.123412289416592e-06
mutation O 0 9.133539606409613e-06
screening O 0 2.0710419903480215e-06
in O 0 4.4035040502876655e-08
the O 0 2.9727537764756562e-08
two O 0 5.6188735442219695e-08
genes O 0 1.038729919855541e-06
has O 0 9.161861669326754e-08
been O 0 1.295702958259426e-07
hampered O 0 0.00010504182137083262
by O 0 6.26916616397466e-08
the O 0 4.525668728661003e-08
lack O 0 3.7057682789054525e-07
of O 0 1.0761061730590882e-07
genomic O 0 4.318952051107772e-05
structure O 0 6.846667474746937e-06
information O 0 2.940836111520184e-06
. O 0 6.251551894820295e-06

We O 0 1.2942414286953863e-05
report O 0 2.1393097995314747e-06
here O 0 2.5775818812689977e-07
the O 0 5.7473506842598e-08
complete O 0 2.0818647783471533e-07
characterization O 0 6.783919843655895e-07
of O 0 1.553178563540314e-08
the O 0 2.857473724304782e-08
48 O 0 1.1422734047528138e-07
exons O 0 6.472786822087073e-07
of O 0 1.73015965998502e-08
the O 0 5.68456499649983e-08
COL4A4 O 0 0.00038104719715192914
gene O 0 3.559893002602621e-07
, O 0 1.344520494939161e-08
a O 0 1.004810101790099e-08
comprehensive O 0 3.3831980772447423e-07
gene O 0 3.910568011633586e-07
screen O 0 3.2843971098373004e-07
, O 0 1.78088424007683e-08
and O 0 1.209279965053156e-08
the O 0 1.4706714068779547e-08
subsequent O 0 1.6340776198831009e-07
detection O 0 5.5654300012975e-07
of O 0 2.084051153872224e-08
10 O 0 2.1292295571129216e-07
novel O 0 4.117111984669464e-06
mutations O 0 1.3593024050351232e-05
in O 0 8.52236439641274e-07
eight O 0 0.00015833351062610745
patients O 1 0.9502496123313904
diagnosed O 1 0.9996289014816284
with O 0 0.03562069684267044
autosomal B-Disease 1 0.9998819828033447
recessive I-Disease 1 0.9999152421951294
Alport I-Disease 1 0.9999855756759644
syndrome I-Disease 1 0.9999688863754272
. O 0 0.00035577171365730464

Furthermore O 0 0.0002336839825147763
, O 0 3.502100071273162e-06
we O 0 3.002276400820847e-07
identified O 0 2.1747186451648304e-07
a O 0 3.3308950264654413e-08
glycine O 0 1.918395355460234e-06
to O 0 3.790811931025928e-08
alanine O 0 1.038804271047411e-06
substitution O 0 5.899703126033273e-08
in O 0 2.1242719583369762e-08
the O 0 3.03559239966944e-08
collagenous O 0 0.00032646191539242864
domain O 0 4.126111434743507e-07
that O 0 1.7780603656092353e-08
is O 0 1.937413429686785e-08
apparently O 0 1.3984953284307267e-07
silent O 0 1.0532427268117317e-06
in O 0 3.82973652790497e-08
the O 0 6.13031048146695e-08
heterozygous O 0 1.0751414265541825e-06
carriers O 0 1.2967676639163983e-06
, O 0 9.844401915870549e-08
in O 0 2.452111971251725e-07
11 O 0 4.219737547828117e-06
. O 0 4.869096301263198e-06

5 O 0 2.482418858562596e-05
% O 0 9.116936325881397e-07
of O 0 1.5687355414684134e-07
all O 0 8.996761380331009e-08
control O 0 1.5733230611658655e-06
individuals O 0 1.704427177173784e-07
, O 0 5.5959429090535195e-08
and O 0 2.797345644012239e-08
in O 0 4.2049720150316716e-08
one O 0 3.657979519289256e-08
control O 0 3.1070493378138053e-07
individual O 0 4.4698044376900725e-08
homozygous O 0 4.2103209807464737e-07
for O 0 2.8424761211454097e-08
this O 0 6.657587903191597e-08
glycine O 0 9.711996426631231e-06
substitution O 0 3.2888867735891836e-06
. O 0 4.966199867340038e-06

There O 0 1.7502790797152556e-05
has O 0 1.129709175984317e-06
been O 0 1.6679429393207101e-07
no O 0 5.696895044593475e-08
previous O 0 7.162781656688821e-08
finding O 0 4.320194690876633e-08
of O 0 6.949875341888401e-09
a O 0 2.4343657756276116e-08
glycine O 0 4.4105581764597446e-06
substitution O 0 1.5321079160912632e-07
that O 0 3.420887750849033e-08
is O 0 2.8559373532743848e-08
not O 0 2.5965343652956108e-08
associated O 0 1.467668084842444e-07
with O 0 5.93733986420375e-08
any O 0 1.5433882083470962e-07
obvious O 0 9.098868758883327e-06
phenotype O 0 0.00010597587242955342
in O 0 8.012436296667147e-07
homozygous O 0 3.154405567329377e-05
individuals O 0 2.9183236165408744e-06
. O 0 5.246741693554213e-06

Founder O 0 0.0064446148462593555
BRCA1 O 0 0.09527827054262161
and O 0 6.722006946802139e-05
BRCA2 O 0 0.03771410882472992
mutations O 0 0.00026795349549502134
in O 0 1.3733387049796875e-06
French O 0 8.860860543791205e-05
Canadian O 0 0.0017610739450901747
breast B-Disease 1 0.9996374845504761
and I-Disease 1 0.6526350378990173
ovarian I-Disease 1 0.9999980926513672
cancer I-Disease 1 0.999924898147583
families O 0 0.0008668007212691009
. O 0 4.948952482664026e-05

We O 0 1.5123189768928569e-05
have O 0 1.4414608813240193e-06
identified O 0 1.0469666449353099e-06
four O 0 1.7540827457196428e-07
mutations O 0 2.8550305160024436e-06
in O 0 2.7212898601192137e-08
each O 0 1.0646322934348973e-08
of O 0 1.1534324784179262e-07
the O 0 1.6839410818647593e-05
breast B-Disease 1 0.9983964562416077
cancer I-Disease 1 0.9785475730895996
- O 1 0.527117908000946
susceptibility O 0 0.13797159492969513
genes O 0 4.236652785039041e-06
, O 0 4.832545528188348e-07
BRCA1 O 0 7.846332300687209e-05
and O 0 3.481542876215826e-07
BRCA2 O 0 4.9601927457842976e-05
, O 0 6.939414021189805e-08
in O 0 9.58718260335445e-08
French O 0 9.723940820549615e-06
Canadian O 0 0.0004436428425833583
breast B-Disease 1 0.9992291927337646
cancer I-Disease 1 0.9963292479515076
and O 0 0.006054470781236887
breast B-Disease 1 0.9999570846557617
/ I-Disease 1 0.9999842643737793
ovarian I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999256134033203
families O 0 5.545745443669148e-05
from O 0 3.5262528399471194e-06
Quebec O 0 0.00017005503468681127
. O 0 1.5477893612114713e-05

To O 0 4.889348929282278e-05
identify O 0 0.0001597276859683916
founder O 0 0.00048738211626186967
effects O 0 0.00012692692689597607
, O 0 8.443311116934638e-07
we O 0 2.4711863488846575e-07
examined O 0 4.873946636507753e-06
independently O 0 2.41605789597088e-07
ascertained O 0 3.0517333016177872e-06
French O 0 3.4987283470400143e-06
Canadian O 0 4.524987161858007e-05
cancer B-Disease 0 0.04611608758568764
families O 0 4.5081540633873374e-07
for O 0 1.715104858135419e-08
the O 0 1.4132576886538573e-08
distribution O 0 4.398374997549581e-08
of O 0 4.094672334531424e-08
these O 0 1.2300199614401208e-07
eight O 0 1.139669961958134e-06
mutations O 0 3.952161569031887e-05
. O 0 6.822530849603936e-06

Mutations O 0 0.005319592077285051
were O 0 3.601079924919759e-06
found O 0 8.914886961974844e-07
in O 0 1.759084966579394e-07
41 O 0 7.14749546659732e-07
of O 0 1.5754972082504537e-07
97 O 0 1.239429820998339e-05
families O 0 1.0444911822560243e-05
. O 0 1.150397292803973e-05

Six O 0 9.042899364430923e-06
of O 0 1.5440979268532828e-06
eight O 0 3.6899239148624474e-06
mutations O 0 4.6875928092049435e-05
were O 0 1.8588178818390588e-07
observed O 0 9.03989018752327e-07
at O 0 3.613498336108023e-07
least O 0 3.3361348528160306e-07
twice O 0 2.8605029456230113e-06
. O 0 5.66223616260686e-06

The O 0 8.098176476778463e-05
BRCA1 O 0 0.24762223660945892
C4446T O 0 0.056970611214637756
mutation O 0 0.00023103083367459476
was O 0 4.0246956700684677e-07
the O 0 7.360387144217384e-08
most O 0 5.890056442581226e-08
common O 0 1.2600831951203872e-06
mutation O 0 7.939453098515514e-06
found O 0 1.5491170302084356e-07
, O 0 7.51051203451425e-08
followed O 0 3.1882717621556367e-07
by O 0 1.8622334607698576e-07
the O 0 1.193575940305891e-06
BRCA2 O 0 0.0016015429282560945
8765delAG O 0 0.00732808094471693
mutation O 0 5.3458541515283287e-05
. O 0 5.830129794048844e-06

Together O 0 3.346964149386622e-05
, O 0 2.6444788545632036e-06
these O 0 3.064084808102052e-07
mutations O 0 8.929777322919108e-06
were O 0 3.86652310169211e-08
found O 0 3.6567378458585154e-08
in O 0 3.1515174470087004e-08
28 O 0 2.0550294266286073e-07
of O 0 4.6742918868858396e-08
41 O 0 4.675488071370637e-06
families O 0 2.3474774479836924e-06
identified O 0 7.809010185155785e-07
to O 0 8.562644637777339e-08
have O 0 8.959703734490176e-08
a O 0 6.258467237785226e-07
mutation O 0 4.03285666834563e-05
. O 0 5.5079635785659775e-06

The O 0 2.0602466975105926e-05
odds O 0 0.00016541978402528912
of O 0 5.590506475527945e-07
detection O 0 4.980580797564471e-06
of O 0 4.896887872973821e-08
any O 0 1.7944035590744534e-08
of O 0 1.5748987891583965e-08
the O 0 7.944674251803008e-08
four O 0 1.034624119711225e-06
BRCA1 O 0 0.010850679129362106
mutations O 0 5.0091104640159756e-05
was O 0 5.976652346362243e-07
18 O 0 2.0817844870180124e-06
. O 0 4.8598271860100795e-06

7x O 0 0.11858002841472626
greater O 0 7.151224417611957e-05
if O 0 3.4680629141803365e-06
one O 0 3.922845621673332e-07
or O 0 3.782791679896036e-07
more O 0 1.2662952997288812e-07
cases O 0 1.9606866771937348e-05
of O 0 0.005301294382661581
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999568462371826
were O 0 7.475653092114953e-07
also O 0 2.760704091997468e-07
present O 0 1.6789851997600636e-07
in O 0 1.2547536698548356e-07
the O 0 5.190125307308335e-07
family O 0 2.1460005882545374e-05
. O 0 1.0198083145951387e-05

The O 0 1.2917063031636644e-05
odds O 0 0.00012049120414303616
of O 0 5.298223300087557e-07
detection O 0 4.703152171714464e-06
of O 0 5.3497881680186765e-08
any O 0 2.2404794464137012e-08
of O 0 2.935006016002717e-08
the O 0 1.0339223166511147e-07
four O 0 8.357989713658753e-07
BRCA2 O 0 0.007785577327013016
mutations O 0 3.1352959922514856e-05
was O 0 6.914060008966771e-07
5 O 0 4.506203367782291e-06
. O 0 5.444873750093393e-06

3x O 0 0.005305751226842403
greater O 0 5.1143251766916364e-05
if O 0 1.371087932966475e-06
there O 0 1.4285760130405833e-07
were O 0 3.9446035771106835e-08
at O 0 1.0795804428198608e-07
least O 0 2.6977343026146627e-08
five O 0 9.03100882965191e-08
cases O 0 1.9030542262044037e-06
of O 0 1.3687618775293231e-05
breast B-Disease 1 0.999625563621521
cancer I-Disease 1 0.7783132195472717
in O 0 1.2214043181302259e-06
the O 0 2.518132077966584e-06
family O 0 5.994843377266079e-05
. O 0 2.379418037889991e-05

Interestingly O 0 0.00026855990290641785
, O 0 2.3996310574148083e-06
the O 0 3.2179974596147076e-07
presence O 0 6.859920631541172e-07
of O 0 3.591548249914922e-07
a O 0 3.5557713999878615e-05
breast B-Disease 1 0.9996342658996582
cancer I-Disease 1 0.9801335334777832
case O 0 2.895025500038173e-05
< O 0 0.0028275102376937866
36 O 0 1.252057359124592e-06
years O 0 1.6292786142457771e-07
of O 0 3.413196836277166e-08
age O 0 3.7808945307915565e-07
was O 0 6.285305431674715e-08
strongly O 0 1.0479890732995045e-07
predictive O 0 4.461610956241202e-07
of O 0 9.856910843097921e-09
the O 0 1.5228236449615906e-08
presence O 0 3.9216406122477565e-08
of O 0 7.076386587812067e-09
any O 0 7.837194893056676e-09
of O 0 1.6850977502258502e-08
the O 0 1.1869441607359477e-07
eight O 0 1.3045437299297191e-06
mutations O 0 3.0032184440642595e-05
screened O 0 1.606222394912038e-05
. O 0 4.849622655456187e-06

Carriers O 0 0.00011690238898154348
of O 0 1.4190725323715014e-06
the O 0 4.931558805765235e-07
same O 0 3.256675427110167e-07
mutation O 0 4.749183517560596e-06
, O 0 6.883546177505195e-08
from O 0 1.795817539118616e-08
different O 0 1.1537862221189243e-08
families O 0 2.8498192250481225e-07
, O 0 8.969655596047232e-08
shared O 0 2.666875218437781e-07
similar O 0 2.813444552884903e-07
haplotypes O 0 6.644719542236999e-05
, O 0 1.5581225909500063e-07
indicating O 0 5.409954155766172e-07
that O 0 1.3451951552667651e-08
the O 0 2.341874960620771e-08
mutant O 0 1.5107444824025151e-06
alleles O 0 2.477869713857217e-07
were O 0 1.533093829664267e-08
likely O 0 3.4916268987217336e-08
to O 0 7.831173043371109e-09
be O 0 2.704053869706513e-09
identical O 0 2.6390841512125007e-08
by O 0 1.722287201744166e-08
descent O 0 5.323450977812172e-07
for O 0 1.9944652152048548e-08
a O 0 1.0478971290694972e-07
mutation O 0 1.5189095847745193e-06
in O 0 5.435476069237666e-08
the O 0 2.8988495159865124e-07
founder O 0 6.956845754757524e-05
population O 0 2.9801080927427392e-06
. O 0 4.327578153606737e-06

The O 0 7.0950509325484745e-06
identification O 0 4.34018375017331e-06
of O 0 7.11805512310093e-07
common O 0 8.983145562524442e-06
BRCA1 O 0 0.0036979829892516136
and O 0 9.233538548869547e-06
BRCA2 O 0 0.005136233288794756
mutations O 0 9.15746386453975e-06
will O 0 5.513348355634662e-08
facilitate O 0 5.365320134842477e-07
carrier O 0 7.951425686769653e-06
detection O 0 2.5815893422986846e-06
in O 0 2.0738352191074227e-07
French O 0 2.4584778657299466e-05
Canadian O 0 0.0008549869526177645
breast B-Disease 1 0.9995476603507996
cancer I-Disease 1 0.9987711310386658
and O 0 0.041970863938331604
breast B-Disease 1 0.9999786615371704
/ I-Disease 1 0.9999802112579346
ovarian I-Disease 1 0.9999985694885254
cancer I-Disease 1 0.999929666519165
families O 0 0.0006304925191216171
. O 0 5.141514338902198e-05

Are O 0 2.554487218731083e-05
Dp71 O 0 0.005932779051363468
and O 0 3.0265153327491134e-05
Dp140 O 0 0.009726639837026596
brain O 0 0.0102149723097682
dystrophin O 0 0.000924537016544491
isoforms O 0 6.465349088102812e-06
related O 0 6.880074124637758e-06
to O 0 3.4306772249692585e-06
cognitive B-Disease 0 0.0015683217206969857
impairment I-Disease 0 0.29335278272628784
in O 0 0.00047527471906505525
Duchenne B-Disease 1 0.99983811378479
muscular I-Disease 1 0.999757707118988
dystrophy I-Disease 1 0.9997944235801697
? O 0 0.015372861176729202

Molecular O 0 0.0008656716090627015
study O 0 1.950827572727576e-05
and O 0 1.2628572676476324e-06
neuropsychological O 0 0.00020929436141159385
analysis O 0 4.818703018827364e-07
were O 0 4.375382189891752e-08
performed O 0 1.705168557464276e-07
concurrently O 0 9.211834850475498e-08
on O 0 1.8602578677473502e-07
49 O 0 2.869737181754317e-05
patients O 0 0.000470655009848997
with O 0 0.00010725195170380175
Duchenne B-Disease 1 0.9999819993972778
muscular I-Disease 1 0.999950647354126
dystrophy I-Disease 1 0.9999816417694092
( O 0 0.0017794042360037565
DMD B-Disease 1 0.9999104738235474
) O 0 6.797487230869592e-07
in O 0 5.270113234701057e-08
order O 0 8.284096253419193e-08
to O 0 3.510759327696178e-08
find O 0 7.345534669411791e-08
a O 0 2.5590592755975194e-08
molecular O 0 1.7215177194884745e-06
explanation O 0 1.6782840361884155e-07
for O 0 2.652032549121941e-08
the O 0 1.9273629447980056e-07
cognitive B-Disease 0 0.00017044904234353453
impairment I-Disease 0 0.0036237817257642746
observed O 0 5.281452104100026e-06
in O 0 1.8340389260629308e-06
most O 0 1.6332971426891163e-05
DMD B-Disease 1 0.9999263286590576
patients O 0 0.1662244200706482
. O 0 3.248209031880833e-05

Complete O 0 2.412047797406558e-05
analysis O 0 2.767011437754263e-06
of O 0 2.5218133714588475e-07
the O 0 4.407651488236297e-07
dystrophin O 0 0.0010831697145476937
gene O 0 7.704972631472629e-06
was O 0 1.8729413397977623e-07
performed O 0 2.3530668613602757e-07
to O 0 1.82820762972824e-08
define O 0 1.5514739004629519e-07
the O 0 1.0548934170628854e-08
localization O 0 2.931197116140538e-07
of O 0 2.8840958066211897e-08
deletions O 0 3.138359261356527e-06
and O 0 1.3176004642900807e-07
duplications O 0 7.518146503571188e-06
in O 0 1.2433612539552996e-07
relation O 0 1.1085435289714951e-06
to O 0 1.2538446014787041e-07
the O 0 2.3045899411044957e-07
different O 0 8.470765919810219e-07
DMD B-Disease 1 0.9969848990440369
promoters O 0 0.0026742215268313885
. O 0 1.5909879948594607e-05

Qualitative O 0 9.394160588271916e-05
analysis O 0 4.614318640960846e-06
of O 0 3.9443185073650966e-07
the O 0 2.958221045901155e-07
Dp71 O 0 0.00015015290409792215
transcript O 0 4.1955372580559924e-06
and O 0 8.688019903502209e-08
testing O 0 1.6672161962105747e-07
for O 0 7.512228172856794e-09
the O 0 7.822634096044112e-09
specific O 0 9.162032021947653e-09
first O 0 2.643215069042526e-08
exon O 0 1.8392357787888614e-06
of O 0 6.192985324560141e-08
Dp140 O 0 4.595484278979711e-05
were O 0 4.3714365460800764e-08
also O 0 6.55773533253523e-08
carried O 0 1.9567980302781507e-07
out O 0 5.760657018072379e-07
. O 0 3.7719557894888567e-06

Neuropsychological O 0 0.010788831859827042
analysis O 0 5.0358459702692926e-05
assessed O 0 2.4207191017922014e-05
verbal O 0 1.1272821211605333e-05
and O 0 1.3908795608585933e-06
visuospatial O 0 0.0014315246371552348
intelligence O 0 7.407845259876922e-06
, O 0 5.018912929699582e-07
verbal O 0 3.11584062728798e-06
memory O 0 1.8957245629280806e-05
, O 0 2.9475339147211344e-07
and O 0 3.4872351761805476e-07
reading O 0 4.7937915041984525e-06
skills O 0 2.0901650714222342e-05
. O 0 1.3334793038666248e-05

Comparison O 0 7.039663614705205e-05
of O 0 2.9889799861848587e-06
molecular O 0 6.635023601120338e-05
and O 0 2.346147994103376e-06
psychometric O 0 0.0008806855184957385
findings O 0 1.0662573913577944e-05
demonstrated O 0 1.294323624279059e-06
that O 0 3.867917186539671e-08
deletions O 0 1.6139620129251853e-06
and O 0 8.785704608271772e-08
duplications O 0 9.846269676927477e-06
that O 0 3.837282491758742e-08
were O 0 1.888386691462074e-08
localized O 0 1.103767999666161e-06
in O 0 2.4793509467713193e-08
the O 0 3.58572975756033e-08
distal O 0 2.38657885347493e-05
part O 0 7.034537929939688e-08
of O 0 1.9119914540510763e-08
the O 0 4.992041979789974e-08
gene O 0 4.2478129103074025e-07
seemed O 0 1.444679611495303e-07
to O 0 2.3735058363172357e-08
be O 0 2.0452938898074535e-08
preferentially O 0 1.2788260619345238e-06
associated O 0 1.000460542854853e-06
with O 0 1.181616084977577e-06
cognitive B-Disease 0 0.0008261308539658785
impairment I-Disease 0 0.08451861143112183
. O 0 2.328733171452768e-05

Two O 0 7.624466434208443e-06
altered O 0 2.675302494026255e-05
Dp71 O 0 0.00016848879749886692
transcripts O 0 6.1000941968814e-06
and O 0 1.5467360015009035e-07
two O 0 5.62543611692945e-08
deleted O 0 1.5294830291168182e-06
Dp140 O 0 2.86136146314675e-05
DNA O 0 1.3386552382144146e-06
sequences O 0 2.677392103578313e-07
were O 0 3.373316204147159e-08
found O 0 8.104552762233652e-08
in O 0 1.2294805173951318e-07
four O 0 3.6418189210962737e-06
patients O 0 0.02981194667518139
with O 0 0.0024178377352654934
severe O 1 0.9996871948242188
cerebral B-Disease 1 0.9997650980949402
dysfunction I-Disease 1 0.9992823004722595
. O 0 0.00011218080908292904

These O 0 2.533926635805983e-05
findings O 0 4.99075285915751e-05
suggest O 0 3.7125707876839442e-06
that O 0 5.592677609911334e-08
some O 0 1.3846386259785959e-08
sequences O 0 1.0707052666703021e-07
located O 0 8.549606178576141e-08
in O 0 1.687905992753258e-08
the O 0 2.250982333862339e-08
distal O 0 1.4597225344914477e-05
part O 0 6.691592346896869e-08
of O 0 1.621723910716355e-08
the O 0 3.7265710517431216e-08
gene O 0 4.757923477427539e-07
and O 0 3.45501192100528e-08
, O 0 2.8582370248386724e-08
in O 0 2.0264069533482143e-08
particular O 0 2.8880206670578445e-08
, O 0 2.5759348432075058e-08
some O 0 2.9183263805521165e-08
DMD B-Disease 1 0.7707706093788147
isoforms O 0 5.526429163182911e-07
expressed O 0 1.927614761143559e-07
in O 0 1.2620394329587725e-07
the O 0 2.0722827684949152e-06
brain O 0 0.09335561096668243
may O 0 2.4405667318205815e-06
be O 0 1.7064772706021358e-08
related O 0 2.116505442018024e-07
to O 0 7.947114255557608e-08
the O 0 3.267619774760533e-07
cognitive B-Disease 0 0.0007184226415120065
impairment I-Disease 0 0.059180185198783875
associated O 0 3.344820288475603e-05
with O 0 2.68598050752189e-05
DMD B-Disease 1 0.9996950626373291
. O 0 9.620017408451531e-06
. O 0 1.3425965335045476e-05

I1307K O 0 0.01448885165154934
APC O 0 0.001328463084064424
and O 0 1.3658045645570382e-05
hMLH1 O 0 0.006207975093275309
mutations O 0 3.732178083737381e-05
in O 0 1.2929194781463593e-07
a O 0 8.235038961856844e-08
non O 0 7.838945066396263e-07
- O 0 0.00028993410523980856
Jewish O 0 5.500058250618167e-06
family O 0 6.777952421543887e-06
with O 0 4.232133960613282e-06
hereditary B-Disease 0 0.250908762216568
non I-Disease 0 0.01189999096095562
- I-Disease 1 0.9999129772186279
polyposis I-Disease 1 0.9999905824661255
colorectal I-Disease 1 0.9999972581863403
cancer I-Disease 1 0.9998952150344849
. O 0 0.0001765182678354904

We O 0 1.801177131710574e-05
describe O 0 1.7691889297566377e-05
a O 0 1.1182676189491758e-06
French O 0 6.711462901876075e-06
Canadian O 0 1.9989756765426137e-05
hereditary B-Disease 0 0.1184397041797638
non I-Disease 0 0.01584765315055847
- I-Disease 1 0.9999428987503052
polyposis I-Disease 1 0.9999977350234985
colorectal I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.999995231628418
( O 0 0.004358334932476282
HNPCC B-Disease 1 0.9975142478942871
) O 0 2.5239864953618962e-06
kindred O 0 4.157905277679674e-05
which O 0 6.36225792050027e-08
carries O 0 1.4472983878022205e-07
a O 0 1.2518289338459e-07
novel O 0 4.0742957025940996e-06
truncating O 0 0.00029453029856085777
mutation O 0 2.2300369892036542e-05
in O 0 1.9110564153379528e-06
hMLH1 O 0 0.0008958366233855486
. O 0 7.642367563676089e-06

Interestingly O 0 0.0005004656268283725
, O 0 3.3960877772187814e-06
the O 0 1.2795213706340292e-06
I1307K O 0 0.0004062261723447591
APC O 0 8.067322778515518e-05
polymorphism O 0 9.122175833908841e-05
, O 0 6.309797413450724e-07
associated O 0 5.27732083810406e-07
with O 0 1.1577889580394185e-07
an O 0 1.6219566134623165e-07
increased O 0 2.439327545289416e-05
risk O 0 0.0023782229982316494
of O 0 0.0011947157327085733
colorectal B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999855756759644
, O 0 9.903006684908178e-06
is O 0 3.2632726743031526e-07
also O 0 1.5207707804165693e-07
present O 0 1.1779251707366711e-07
in O 0 1.4601933173707948e-07
this O 0 3.0670932460452605e-07
family O 0 1.4558742805093061e-05
. O 0 8.73154385772068e-06

The O 0 1.541129131510388e-05
I1307K O 0 0.0014038593508303165
polymorphism O 0 9.051882807398215e-05
has O 0 9.107238270189555e-07
previously O 0 6.068906373002392e-07
only O 0 3.475726373380894e-08
been O 0 4.066994563345361e-08
identified O 0 1.1506890729151564e-07
in O 0 2.4926704256245102e-08
individuals O 0 4.084220606159761e-08
of O 0 5.0828173669970056e-08
self O 0 2.632696669024881e-05
- O 0 0.02004421129822731
reported O 0 6.286605639616027e-05
Ashkenazi O 0 0.00015587752568535507
Jewish O 0 9.190998753183521e-06
origins O 0 2.7064603273174725e-05
. O 0 6.557962478836998e-06

In O 0 4.7856287892500404e-06
addition O 0 1.4886268218106125e-06
, O 0 3.084667241637362e-07
in O 0 9.820977453500745e-08
this O 0 7.990050931994119e-08
family O 0 2.6766492737806402e-06
, O 0 2.2248664777180238e-07
there O 0 5.392045210328433e-08
appears O 0 2.2185504633398523e-07
to O 0 3.031490081184529e-08
be O 0 6.6534857623423704e-09
no O 0 1.7242692607055687e-08
relationship O 0 2.327490022935308e-07
between O 0 5.0374072912973133e-08
the O 0 5.1498975750519094e-08
I1307K O 0 9.794910147320479e-05
polymorphism O 0 3.982288490078645e-06
and O 0 6.113181427735981e-08
the O 0 4.7848750739376555e-08
presence O 0 2.8484984682108916e-07
or O 0 2.658824769241619e-07
absence O 0 7.5559109973255545e-06
of O 0 4.328040176915238e-06
cancer B-Disease 0 0.49350470304489136
. O 0 2.356514642087859e-06
. O 0 7.173724043241236e-06

Identification O 0 1.8014949091593735e-05
of O 0 8.578130632486136e-07
a O 0 6.361093483064906e-07
novel O 0 4.033812729176134e-06
mutation O 0 1.8253805365020526e-06
of O 0 3.6917992218832296e-08
the O 0 1.1192679494342883e-07
CPO O 0 5.019587479182519e-05
gene O 0 1.2267754527783836e-06
in O 0 5.687471116289089e-08
a O 0 2.9955810987303266e-07
Japanese O 0 1.9683153368532658e-05
hereditary B-Disease 0 0.031553901731967926
coproporphyria I-Disease 0 0.16066163778305054
family O 0 8.384590910281986e-05
. O 0 1.821164187276736e-05

Hereditary B-Disease 1 0.9877326488494873
coproporphyria I-Disease 1 0.9901026487350464
( O 0 0.0015411775093525648
HCP B-Disease 1 0.996631920337677
) O 0 1.676362080615945e-05
is O 0 9.731656973599456e-07
an O 0 2.714178435780923e-06
autosomal B-Disease 1 0.9028744101524353
dominant I-Disease 1 0.6806314587593079
disease I-Disease 1 0.9991281628608704
characterized O 0 0.004412645008414984
by O 0 3.537978500389727e-06
a O 0 1.424514084646944e-05
deficiency B-Disease 1 0.8548277616500854
of I-Disease 0 1.1324307251925347e-06
coproporphyrinogen I-Disease 1 0.5989712476730347
oxidase I-Disease 0 0.000877023150678724
( O 0 4.32794922744506e-06
CPO O 0 0.000745879951864481
) O 0 8.0910280075841e-07
caused O 0 2.374725227127783e-06
by O 0 3.6086042598526546e-08
a O 0 6.427757881510843e-08
mutation O 0 9.391674211656209e-07
in O 0 9.052342164750371e-08
the O 0 2.8972547738703724e-07
CPO O 0 0.00013695731468033046
gene O 0 1.53666187543422e-05
. O 0 5.240826340013882e-06

Only O 0 1.050342689268291e-05
11 O 0 1.1165657269884832e-05
mutations O 0 1.7934589777723886e-05
of O 0 1.6401588709413772e-07
the O 0 3.13634672011176e-07
gene O 0 3.2359066608478315e-06
have O 0 1.5311817946894735e-07
been O 0 2.4845661528161145e-07
reported O 0 7.67298843129538e-06
in O 0 1.9250926925451495e-05
HCP B-Disease 1 0.9989696741104126
patients O 0 0.02792365662753582
. O 0 3.5472767194733024e-05

We O 0 2.3517559384345077e-05
report O 0 6.4209239099000115e-06
another O 0 1.063488525687717e-06
mutation O 0 4.351108600531006e-06
in O 0 1.3071560545085958e-07
a O 0 4.3404844518590835e-07
Japanese O 0 1.184769189421786e-05
family O 0 3.0596853321185336e-05
. O 0 1.2149195754318498e-05

Polymerase O 0 0.0017860312946140766
chain O 0 0.00023969096946530044
reaction O 0 1.4228819964046124e-05
- O 0 5.2214611059753224e-05
single O 0 7.418630616484734e-07
strand O 0 7.021298642939655e-06
conformational O 0 6.127024335000897e-06
polymorphism O 0 1.0813563449119101e-06
and O 0 3.254945468711412e-08
direct O 0 3.065715148409254e-08
sequence O 0 1.103063382856817e-07
analyses O 0 2.147640856264843e-07
demonstrated O 0 7.624741726885986e-08
a O 0 2.0971139491621216e-08
C O 0 8.884061344360816e-07
to O 0 2.714260638470023e-08
T O 0 1.4027021279616747e-05
substitution O 0 2.6539350272969386e-08
in O 0 1.0207854117538773e-08
exon O 0 6.368674689838372e-07
1 O 0 2.2588013237623272e-08
of O 0 9.202207884584368e-09
the O 0 1.4285482130560467e-08
CPO O 0 3.046749043278396e-06
gene O 0 1.2103924973416724e-07
at O 0 1.71130469794889e-08
nucleotide O 0 2.0106034526179428e-07
position O 0 3.107040313921061e-08
85 O 0 7.2660242267375e-08
, O 0 1.877590527499251e-08
which O 0 1.1687189882536586e-08
lies O 0 1.5659267660339538e-07
in O 0 1.761936729849367e-08
the O 0 5.404607250625304e-08
putative O 0 9.952590517059434e-06
presequence O 0 7.622195698786527e-05
for O 0 7.03510067978641e-08
targeting O 0 5.967482366031618e-07
to O 0 4.031514322377916e-07
mitochondria O 0 4.2111096263397485e-05
. O 0 5.158729436516296e-06

This O 0 1.3476404092216399e-05
mutation O 0 2.1670495698344894e-05
changes O 0 5.972811436549819e-07
the O 0 1.0147950035843678e-07
codon O 0 7.187483106463333e-07
for O 0 4.072722958881059e-08
glutamine O 0 5.574109422923357e-07
to O 0 3.0831369457473556e-08
a O 0 5.178027251417916e-08
termination O 0 4.38242841482861e-06
codon O 0 1.0053163350676186e-06
at O 0 1.885779568056023e-07
amino O 0 3.133934001198213e-07
acid O 0 1.6057746279329876e-06
position O 0 6.550635021085327e-07
29 O 0 3.1336578558693873e-06
. O 0 2.9516511403926415e-06

MaeI O 0 0.013766448944807053
restriction O 0 6.178850890137255e-05
analysis O 0 1.0770086191769224e-05
showed O 0 2.1120160909049446e-06
two O 0 8.642354032417643e-08
other O 0 9.469146533547246e-08
carriers O 0 3.6560236367222387e-06
in O 0 3.3866942317217763e-07
the O 0 9.13946564651269e-07
family O 0 3.538985038176179e-05
. O 0 1.8408785763313062e-05

The O 0 1.7156866306322627e-05
C O 0 0.0008434929768554866
- O 0 0.1275574266910553
T O 1 0.8760613203048706
mutation O 0 5.214425254962407e-05
is O 0 8.93189238126979e-08
located O 0 1.3260337539122702e-07
within O 0 3.3687509670699e-08
a O 0 4.691155197633634e-08
recently O 0 4.1378896753485606e-07
proposed O 0 2.296982728466901e-07
putative O 0 1.177510171146423e-06
alternative O 0 7.687915370979681e-08
translation O 0 9.741874151814045e-08
initiation O 0 3.8292697013275756e-07
codon O 0 7.056656841086806e-07
( O 0 1.0137175365798612e-07
TIC O 0 5.5929172958713025e-05
- O 0 1.3720435163122602e-05
1 O 0 1.4730062503076624e-07
) O 0 4.158011890353919e-08
, O 0 1.4045295593234641e-08
supporting O 0 4.2804224165138294e-08
that O 0 3.1656512078370724e-08
TIC O 0 0.0002488184254616499
- O 0 2.0016406779177487e-05
1 O 0 1.3089898232010455e-07
is O 0 1.2989873177104982e-08
the O 0 1.7596931911612046e-08
real O 0 7.248070232890313e-07
TIC O 0 0.00021077768178656697
rather O 0 5.3018421652950565e-08
than O 0 5.7424525579108376e-08
TIC O 0 0.0005423376569524407
- O 0 4.023214933113195e-05
2 O 0 1.4830425243417267e-06
. O 0 6.498578954960976e-07
. O 0 3.5032592222705716e-06

Human B-Disease 0 0.0004998253425583243
complement I-Disease 0 0.0008913445053622127
factor I-Disease 0 0.025056302547454834
H I-Disease 1 0.9998412132263184
deficiency I-Disease 1 0.9998844861984253
associated O 0 0.1430409550666809
with O 1 0.7903439402580261
hemolytic B-Disease 1 0.9999942779541016
uremic I-Disease 1 0.9999971389770508
syndrome I-Disease 1 0.9999861717224121
. O 0 0.0010679796105250716

This O 0 9.211734322889242e-06
study O 0 4.756603175337659e-06
reports O 0 1.4282179563451791e-06
on O 0 3.0010568252691883e-07
six O 0 7.882710519879765e-07
cases O 0 3.3053506740543526e-06
of O 0 6.4833907345018815e-06
deficiency B-Disease 1 0.9901697039604187
in I-Disease 0 2.7362960963728256e-07
the I-Disease 0 9.419250091013964e-08
human I-Disease 0 2.732861332788161e-07
complement I-Disease 0 5.872236670256825e-07
regulatory I-Disease 0 4.759557214129018e-06
protein I-Disease 0 2.196337618443067e-06
Factor I-Disease 0 8.365936992049683e-06
H I-Disease 1 0.5164878368377686
( O 0 1.9034099523196346e-06
FH O 0 0.0006523839547298849
) O 0 4.222492577810044e-08
in O 0 1.1333340488306476e-08
the O 0 1.7068126467734146e-08
context O 0 2.0038537229538633e-07
of O 0 1.5835365729799378e-06
an O 0 0.00044985651038587093
acute B-Disease 1 0.9999632835388184
renal I-Disease 1 0.9999984502792358
disease I-Disease 1 0.9999645948410034
. O 0 0.00023090663307812065

Five O 0 4.740906661027111e-06
of O 0 1.0127432688022964e-06
the O 0 6.730331278959056e-07
cases O 0 1.5454074855369981e-06
were O 0 1.7813741237659997e-07
observed O 0 1.2750314226650517e-06
in O 0 4.4972253476771584e-07
children O 0 1.112745394493686e-05
presenting O 0 0.0003489171213004738
with O 1 0.8114982843399048
idiopathic O 1 0.999998927116394
hemolytic B-Disease 1 0.9999997615814209
uremic I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999988079071045
( O 0 0.10572734475135803
HUS B-Disease 1 0.9997535347938538
) O 0 9.386317833559588e-05
. O 0 2.4090475562843494e-05

Two O 0 3.600118589019985e-06
of O 0 9.527788051855168e-07
the O 0 1.0400920018582838e-06
children O 0 3.318268454677309e-06
exhibited O 0 3.3413707569707185e-05
a O 0 1.9890265321009792e-05
homozygous O 0 0.2485583871603012
deficiency O 1 0.9989499449729919
characterized O 0 7.688750338274986e-05
by O 0 9.279852974941605e-08
the O 0 3.54092755117108e-08
absence O 0 1.0132825423170289e-07
of O 0 4.121986751925988e-09
the O 0 8.520395944344727e-09
150 O 0 4.2052363369293744e-08
- O 0 4.035757592646405e-05
kD O 0 0.0009035432012751698
form O 0 1.0024061936064754e-07
of O 0 5.302701566733958e-08
Factor O 0 1.7619956906855805e-06
H O 0 0.006053782068192959
and O 0 2.2529238918878036e-08
the O 0 1.2691915962648181e-08
presence O 0 4.0391331168621036e-08
, O 0 1.6768961330626553e-08
upon O 0 3.6684809856524225e-08
immunoblotting O 0 2.5314102458651178e-05
, O 0 9.08289887746605e-09
of O 0 4.202564074518023e-09
the O 0 9.656936583724018e-09
42 O 0 1.752845264491043e-07
- O 0 3.214215030311607e-05
kD O 0 0.0016885654767975211
Factor O 0 1.3242989780337666e-06
H O 0 0.0007237468962557614
- O 0 2.8441493213904323e-06
like O 0 8.10950027130275e-08
protein O 0 7.733034834700447e-08
1 O 0 6.993840173663557e-08
( O 0 9.162210545810012e-08
FHL O 0 5.010448148823343e-05
- O 0 5.688149485649774e-06
1 O 0 1.1166174118670824e-07
) O 0 2.4028310008361586e-08
and O 0 1.349424927354903e-08
other O 0 4.751099069721931e-08
FH O 0 0.0024597137235105038
- O 0 0.0001952110615093261
related O 0 4.287313004169846e-06
protein O 0 2.813154196701362e-06
( O 0 1.4229103726393078e-06
FHR O 0 0.0005497353267855942
) O 0 1.0483385040060966e-06
bands O 0 4.64032427771599e-06
. O 0 3.6889703096676385e-06

Southern O 0 4.739314681501128e-05
blot O 0 0.0006687500281259418
and O 0 1.5019298871266074e-06
PCR O 0 8.748155778448563e-06
analysis O 0 2.710024773477926e-07
of O 0 4.145769239016772e-08
DNA O 0 1.3061894605925772e-06
of O 0 9.316777038748114e-08
one O 0 1.0308558557881042e-06
patient O 0 0.0011010612361133099
with O 0 1.6141859305207618e-05
homozygous O 0 0.032460883259773254
deficiency O 1 0.9387356042861938
ruled O 0 2.0278471311030444e-06
out O 0 3.085095912069846e-08
the O 0 1.6136983305159447e-08
presence O 0 2.99800149150542e-08
of O 0 6.073060720979129e-09
a O 0 1.1636741348297619e-08
large O 0 1.1396793553331008e-07
deletion O 0 3.693289500006358e-06
of O 0 3.047339802719762e-08
the O 0 4.3763378698713495e-07
FH O 0 0.2954942584037781
gene O 0 4.001803063147236e-06
as O 0 6.09806534157542e-08
the O 0 2.4531951225981175e-07
underlying O 0 0.0002113486552843824
defect O 0 0.003158176550641656
for O 0 1.291402895731153e-06
the O 0 3.164227746310644e-05
deficiency O 1 0.9803312420845032
. O 0 2.5601522793294862e-05

The O 0 4.774300577992108e-06
other O 0 2.673269250408339e-07
four O 0 3.065785847411462e-07
children O 0 7.786031801515492e-07
presented O 0 6.859744416942704e-07
with O 0 3.120056817351724e-06
heterozygous O 0 0.00041550485184416175
deficiency O 1 0.9081544280052185
and O 0 5.697752953892632e-07
exhibited O 0 1.9618539681687253e-06
a O 0 1.1878331207526571e-07
normal O 0 2.245428731839638e-06
immunoblotting O 0 0.0004492488515097648
pattern O 0 8.574948537898308e-07
of O 0 2.121571185398352e-08
proteins O 0 1.2636544965971552e-07
of O 0 7.75699575683575e-08
the O 0 1.232607360179827e-06
FH O 0 0.29238516092300415
family O 0 6.267833668971434e-05
. O 0 9.804142791836057e-06

Factor B-Disease 1 0.8873405456542969
H I-Disease 1 0.9998667240142822
deficiency I-Disease 1 0.9993029832839966
is O 0 2.725911144807469e-06
the O 0 9.220094625561615e-07
only O 0 1.0445780844747787e-06
complement B-Disease 0 0.09065137058496475
deficiency I-Disease 1 0.999821126461029
associated O 0 8.385733235627413e-05
with O 0 3.0669980333186686e-05
HUS B-Disease 1 0.9984599351882935
. O 0 5.413421968114562e-05

These O 0 1.2316848369664513e-05
observations O 0 2.39260643866146e-05
suggest O 0 4.614714725903468e-06
a O 0 2.6314674528293835e-07
role O 0 4.993208335690724e-07
for O 0 3.118130393886531e-07
FH O 0 0.05272385850548744
and O 0 1.6946808045759099e-06
/ O 0 0.0004061309155076742
or O 0 3.373665322214947e-06
FH O 0 0.27214881777763367
receptors O 0 1.7215412299265154e-05
in O 0 1.2543158334210602e-07
the O 0 8.043612638175546e-07
pathogenesis O 0 0.014401266351342201
of O 0 4.041873762616888e-05
idiopathic O 1 0.9999282360076904
HUS B-Disease 1 0.9997395873069763
. O 0 2.5779194402275607e-05
. O 0 1.6563726603635587e-05

Further O 0 2.27013006224297e-05
evidence O 0 6.320135071291588e-06
for O 0 2.8625859727071656e-07
a O 0 5.039781285631761e-07
major O 0 4.520907623373205e-06
ancient O 0 5.637307185679674e-05
mutation O 0 0.004665049724280834
underlying O 0 0.28865066170692444
myotonic B-Disease 1 0.9999716281890869
dystrophy I-Disease 1 0.9999778270721436
from O 0 7.428800927300472e-06
linkage O 0 0.0011922108242288232
disequilibrium O 0 0.006455193739384413
studies O 0 1.742411541272304e-06
in O 0 1.497660377935972e-07
the O 0 3.4148908412134915e-07
Japanese O 0 9.33410683501279e-06
population O 0 5.455976406665286e-06
. O 0 7.96198128227843e-06

The O 0 0.004881202708929777
myotonic B-Disease 1 0.9998902082443237
dystrophy I-Disease 1 0.9999732971191406
( O 0 0.15599344670772552
DM B-Disease 1 0.9999569654464722
) O 0 0.0001888833212433383
mutation O 0 8.034686470637098e-05
is O 0 1.7597157864202018e-07
an O 0 1.082789324868827e-07
unstable O 0 0.00012414364027790725
( O 0 9.372311637889652e-07
CTG O 0 0.00044161625555716455
) O 0 1.8266884183049115e-07
n O 0 5.321675871527987e-06
repeat O 0 3.270056595283677e-06
, O 0 1.773535274196547e-08
present O 0 8.895606029568626e-09
at O 0 1.0366153269103506e-08
a O 0 5.376545875179772e-09
copy O 0 2.7375429922926742e-08
number O 0 3.26626259372631e-09
of O 0 4.489342675384478e-09
5 O 0 8.162977849224262e-08
- O 0 1.0978284990414977e-05
37 O 0 2.6446707579452777e-07
repeats O 0 4.011043017726479e-07
on O 0 1.9352970781483236e-08
normal O 0 8.557828579114357e-08
chromosomes O 0 3.374198627170699e-07
but O 0 1.3083017336157354e-08
amplified O 0 1.6391689428019163e-07
to O 0 1.5583715651246166e-08
50 O 0 2.3584155073308466e-08
- O 0 1.8444014813212561e-06
3000 O 0 8.347984703505062e-07
copies O 0 2.088532511379526e-07
on O 0 1.2937659903400345e-06
DM B-Disease 1 0.9791892766952515
chromosomes O 0 0.0001296789268963039
. O 0 9.108610356634017e-06

Previous O 0 7.116013875929639e-05
findings O 0 3.10949471895583e-05
in O 0 7.940081445667602e-07
Caucasian O 0 0.00023201710428111255
populations O 0 1.2033574421366211e-05
of O 0 1.7815526121012226e-07
a O 0 4.225838893034961e-06
DM B-Disease 1 0.9999052286148071
founder O 0 0.011331849731504917
chromosome O 0 0.0006768425228074193
raise O 0 1.442303869225725e-06
a O 0 7.594653084197489e-08
question O 0 9.535172296182282e-08
about O 0 3.171404472368522e-08
the O 0 3.3625628503841654e-08
molecular O 0 2.1466223643074045e-06
events O 0 1.072708428750957e-07
involved O 0 8.81311166267551e-08
in O 0 7.143299285417015e-08
the O 0 1.9576343390781403e-07
expansion O 0 1.5342660844908096e-05
mutation O 0 5.507792593562044e-05
. O 0 7.335317150136689e-06

To O 0 2.887033042497933e-05
investigate O 0 5.895056528970599e-05
whether O 0 1.4914871826476883e-06
a O 0 5.663282536261249e-07
founder O 0 6.96142524247989e-05
chromosome O 0 0.00014664814807474613
for O 0 3.0538657824763504e-07
the O 0 3.879912583215628e-06
DM B-Disease 1 0.9999127388000488
mutation O 0 0.00015045332838781178
exists O 0 4.4489917172541027e-07
in O 0 2.8373465355002736e-08
the O 0 3.771225109971965e-08
Japanese O 0 9.439281711820513e-07
population O 0 1.1668429067412944e-07
, O 0 5.801814850769915e-08
we O 0 5.906717959192065e-08
genotyped O 0 5.2520230383379385e-05
families O 0 1.4909724654899037e-07
using O 0 7.923064515580336e-08
polymorphic O 0 9.15582222660305e-06
markers O 0 8.277103916043416e-06
near O 0 7.320539907595958e-07
the O 0 8.98797978265975e-08
( O 0 4.7206225417539827e-07
CTG O 0 0.00019504604279063642
) O 0 2.5988214247263386e-07
n O 0 7.1291883614321705e-06
repeat O 0 4.955124950356549e-06
region O 0 8.221539928854327e-07
and O 0 4.853824862038891e-07
constructed O 0 2.87408365693409e-05
haplotypes O 0 0.000927854678593576
. O 0 1.3647045307152439e-05

Six O 0 1.1726168850145768e-05
different O 0 1.4920805142537574e-06
haplotypes O 0 0.0003176889440510422
were O 0 4.07263058832541e-07
found O 0 8.330908940479276e-07
and O 0 3.5589837352745235e-06
DM B-Disease 1 0.9996296167373657
alleles O 0 3.4502292692195624e-05
were O 0 5.537159495361266e-07
always O 0 3.007437044288963e-06
haplotype O 0 0.00019864673959091306
A O 0 2.513947265470051e-06
. O 0 6.86530074744951e-06

To O 0 1.2617771062650718e-05
find O 0 4.301195531297708e-06
an O 0 1.5941614606163057e-07
origin O 0 1.1241780839554849e-07
of O 0 5.128626412442827e-08
the O 0 1.3890341676869866e-07
( O 0 5.886619192096987e-07
CTG O 0 0.00044914521276950836
) O 0 3.1626038321519445e-07
n O 0 1.0233283319394104e-05
repeat O 0 1.173144846688956e-05
mutation O 0 8.247769756053458e-07
and O 0 2.1070654554478097e-08
to O 0 1.3012737554163323e-08
investigate O 0 2.0041747461618797e-07
the O 0 8.220378155954222e-09
mechanism O 0 2.1298950159120977e-08
of O 0 2.9056668182647627e-09
the O 0 8.537054618784623e-09
expansion O 0 5.875945703337493e-07
mutation O 0 4.42433275793519e-07
in O 0 1.4884101950940476e-08
the O 0 2.456249426074919e-08
Japanese O 0 4.162587572409393e-07
population O 0 4.995785474193326e-08
we O 0 1.523799930680525e-08
have O 0 9.888283081238569e-09
studied O 0 7.51618642880203e-08
90 O 0 1.314645885486243e-07
Japanese O 0 3.71963756151672e-06
DM B-Disease 1 0.9686680436134338
families O 0 1.0937317256320966e-06
comprising O 0 6.195999162628141e-07
190 O 0 1.5987930055416655e-06
affected O 0 1.0891415058722487e-06
and O 0 1.931595221549287e-07
130 O 0 1.2110892839700682e-06
unaffected O 0 1.9444883946562186e-05
members O 0 1.096608230000129e-06
. O 0 4.793571861227974e-06

The O 0 1.838169919210486e-05
results O 0 3.150449265376665e-05
suggest O 0 9.228468115907162e-06
that O 0 1.4393603464668558e-07
a O 0 1.2222031386954768e-07
few O 0 2.0574377401771926e-07
common O 0 1.3475134892360074e-06
ancestral O 0 0.00020776379096787423
mutations O 0 1.01975774668972e-05
in O 0 4.984088519677243e-08
both O 0 4.865902525352794e-08
Caucasian O 0 1.6917801985982805e-05
and O 0 2.642522645146528e-07
Japanese O 0 2.693143869691994e-06
populations O 0 1.2886274589618552e-06
have O 0 1.6796972701627055e-08
originated O 0 4.758599558840615e-08
by O 0 9.815561696768782e-09
expansion O 0 1.066852348685643e-07
of O 0 9.670687362017816e-09
an O 0 1.9985590071769366e-08
ancestral O 0 1.5028660527605098e-05
n O 0 5.322119977790862e-05
= O 0 4.126418934902176e-05
5 O 0 2.820999611685693e-07
repeat O 0 1.1717053212123574e-06
to O 0 3.832608541642912e-08
n O 0 3.483988393782056e-06
= O 0 6.572061920451233e-06
19 O 0 2.848321969395329e-07
- O 0 1.0640897016855888e-05
37 O 0 1.2191966334285098e-06
copies O 0 9.924638106895145e-07
. O 0 3.1983017834136263e-06

These O 0 6.650818249909207e-06
data O 0 3.593008159441524e-06
support O 0 7.795125611664844e-07
multistep O 0 9.705273441795725e-06
models O 0 4.4308688984529e-07
of O 0 1.6036045735745574e-07
triplet O 0 0.007126454263925552
repeat O 0 0.0001533888280391693
expansion O 0 3.068812702622381e-06
that O 0 3.728853315010383e-08
have O 0 1.566806062669457e-08
been O 0 1.456954468181948e-08
proposed O 0 6.919482586908998e-08
for O 0 6.93478270363812e-08
both O 0 1.1029641200366314e-06
DM B-Disease 1 0.9996390342712402
and O 0 2.6703397452365607e-05
Friedreichs B-Disease 1 0.7938371896743774
ataxia I-Disease 1 0.9839690923690796
. O 0 6.1976156757737044e-06
. O 0 1.0238769391435198e-05

The O 0 1.3741951079282444e-05
molecular O 0 4.264889139449224e-05
basis O 0 2.2231281491258414e-06
of O 0 2.0052115360158496e-05
C6 B-Disease 1 0.9999521970748901
deficiency I-Disease 1 0.9999463558197021
in O 0 7.057699917822902e-07
the O 0 2.5417693905183114e-07
western O 0 1.6515241441084072e-06
Cape O 0 3.650241342256777e-05
, O 0 5.929411486249592e-07
South O 0 2.0655938897107262e-06
Africa O 0 7.606854069308611e-06
. O 0 6.8725917117262725e-06

Deficiency B-Disease 1 0.9919360876083374
of I-Disease 0 2.7102960302727297e-06
the I-Disease 0 9.655648227635538e-07
sixth I-Disease 0 5.340843927115202e-06
component I-Disease 0 9.87328235169116e-07
of I-Disease 0 8.341937984823744e-08
human I-Disease 0 5.488575425260933e-07
complement I-Disease 0 2.7953087737841997e-06
( O 0 2.0355760170787107e-06
C6 O 0 0.08319863677024841
) O 0 6.054165737623407e-07
has O 0 4.124537156258157e-08
been O 0 1.738926691530196e-08
reported O 0 9.739403594721807e-08
in O 0 6.8095533656276075e-09
a O 0 5.536138658612799e-09
number O 0 4.90268892150425e-09
of O 0 7.093251319645333e-09
families O 0 8.004328577726483e-08
from O 0 1.3393655073912214e-08
the O 0 3.818955462975282e-08
western O 0 3.932918275495467e-07
Cape O 0 1.0003699571825564e-05
, O 0 1.7163017673738068e-07
South O 0 1.0128050007551792e-06
Africa O 0 4.393526523926994e-06
. O 0 4.100662408745848e-06

Meningococcal B-Disease 1 0.9995877146720886
disease I-Disease 1 0.9996927976608276
is O 0 7.289373752428219e-05
endemic O 0 0.0012377126840874553
in O 0 6.309207947197137e-07
the O 0 2.505925920104346e-07
Cape O 0 9.315600436821114e-06
and O 0 3.1248696075181215e-08
almost O 0 1.3405078824746397e-08
all O 0 1.0685790030606768e-08
pedigrees O 0 6.984041192481527e-06
of O 0 2.1286265905473556e-07
total O 0 0.00010783813195303082
C6 B-Disease 1 0.9999896287918091
deficiency I-Disease 1 0.999993085861206
( O 0 6.31055299891159e-05
C6Q0 O 0 0.35711684823036194
) O 0 5.611653932646732e-07
have O 0 6.887170656000308e-08
been O 0 1.1151212220283924e-07
ascertained O 0 8.433836228505243e-06
because O 0 4.6456057134491857e-07
of O 0 2.2708895812684204e-06
recurrent O 1 0.9814292788505554
disease O 1 0.9316637516021729
. O 0 4.1099403460975736e-05

We O 0 1.0634707905410323e-05
have O 0 1.004571686280542e-06
sequenced O 0 2.4803005089779617e-06
the O 0 1.0453558729750512e-07
expressed O 0 1.5202921588297613e-07
exons O 0 2.0917364054184873e-06
of O 0 7.376451094387448e-08
the O 0 2.1089576307531388e-07
C6 O 0 0.006942529696971178
gene O 0 3.134491862510913e-06
from O 0 6.572587096798088e-08
selected O 0 7.000085844310888e-08
cases O 0 1.1223099249946245e-07
and O 0 6.126277440898775e-08
have O 0 4.792044805412843e-08
found O 0 7.936086632298611e-08
three O 0 2.02768717372237e-07
molecular O 0 0.003097489243373275
defects O 0 0.2702268362045288
leading O 0 4.56056932307547e-06
to O 0 4.5799112058375613e-07
total O 0 1.6336804037564434e-05
deficiency O 1 0.9846364259719849
879delG O 0 0.017199674621224403
, O 0 2.0673091682965605e-07
which O 0 2.2931036625095658e-08
is O 0 1.8653825151204728e-08
the O 0 3.973957163339037e-08
common O 0 8.328661351697519e-07
defect O 0 5.658457666868344e-05
in O 0 5.822812099154362e-08
the O 0 7.65008820735602e-08
Cape O 0 9.803105058381334e-06
and O 0 1.424194380206245e-07
hitherto O 0 4.115934189030668e-06
unreported O 0 3.1087229217519052e-06
, O 0 1.0318065335468418e-07
and O 0 2.329424120262047e-07
1195delC O 0 0.00015904256724752486
and O 0 3.619250890096737e-07
1936delG O 0 0.0005604302859865129
, O 0 1.2958659567630093e-07
which O 0 2.2118106457469366e-08
have O 0 1.4265877368302426e-08
been O 0 1.2472287203024734e-08
previously O 0 9.721308202870205e-08
reported O 0 2.118120789873501e-07
in O 0 7.020356918019388e-08
African O 0 1.1564629858185071e-06
- O 0 0.0006452189409174025
Americans O 0 1.477574187447317e-05
. O 0 1.0412559277028777e-05

We O 0 9.535274330119137e-06
also O 0 8.355639238288859e-07
show O 0 5.456587928165391e-07
that O 0 5.7952124876692324e-08
the O 0 1.1917272502159904e-07
879delG O 0 0.0005620527663268149
and O 0 5.015375791117549e-06
1195delC O 0 0.4105443060398102
defects O 0 0.056321948766708374
are O 0 6.621710468834863e-08
associated O 0 3.285064451574726e-07
with O 0 2.2614467809489724e-07
characteristic O 0 2.3135262381401844e-05
C6 O 0 0.296620637178421
/ O 0 0.004530102480202913
C7 O 0 0.033128511160612106
region O 0 8.716559932508972e-06
DNA O 0 2.2697642634739168e-05
marker O 0 5.98305014136713e-05
haplotypes O 0 0.00012438680278137326
, O 0 1.0013781093221041e-07
although O 0 6.768713944893534e-08
small O 0 1.9211564961096883e-07
variations O 0 2.088234623442986e-06
were O 0 3.5542583987080434e-07
observed O 0 3.57440239895368e-06
. O 0 4.782959422300337e-06

The O 0 7.250254566315562e-05
1936delG O 0 0.26561418175697327
defect O 0 0.033571772277355194
was O 0 2.0277736894058762e-06
observed O 0 1.012712345982436e-06
only O 0 2.7604137642356363e-08
once O 0 8.972735798806752e-08
in O 0 3.272162985012983e-08
the O 0 9.937824785311022e-08
Cape O 0 1.0937871593341697e-05
, O 0 7.583145844591854e-08
but O 0 2.916979724432167e-08
its O 0 6.893334614233027e-08
associated O 0 1.8503227465771488e-06
haplotype O 0 0.00016063585644587874
could O 0 4.757338274430367e-07
be O 0 1.944677734400102e-07
deduced O 0 1.2329929631960113e-05
. O 0 3.773412800001097e-06

The O 0 5.275385774439201e-06
data O 0 2.7780188247561455e-06
from O 0 2.009514474821117e-07
the O 0 2.0170774917005474e-07
haplotypes O 0 0.00019926746608689427
indicate O 0 2.1813352759636473e-06
that O 0 2.8004100371958884e-08
these O 0 1.8218235808831196e-08
three O 0 1.346707705351946e-07
molecular O 0 0.0010354991536587477
defects O 0 0.1700030118227005
account O 0 9.77103127297596e-07
for O 0 1.433275826911995e-07
the O 0 6.24420067651954e-07
defects O 0 0.005074473097920418
in O 0 3.841705620288849e-08
all O 0 9.986635518544063e-09
the O 0 5.555021687086992e-08
38 O 0 1.2078158988515497e-06
unrelated O 0 1.5856667232583277e-05
C6Q0 O 0 0.05376584082841873
individuals O 0 1.754599736614182e-07
we O 0 3.999209141625215e-08
have O 0 2.219146466586608e-08
studied O 0 1.3557111344653094e-07
from O 0 6.798551055453572e-08
the O 0 3.810639270795946e-07
Cape O 0 6.222043884918094e-05
. O 0 6.183558980410453e-06

We O 0 1.90856953850016e-05
have O 0 1.1403636790419114e-06
also O 0 3.650567634849722e-07
observed O 0 6.007435331412125e-07
the O 0 2.2645046726665896e-07
879delG O 0 0.00040608094423078
defect O 0 3.906432175426744e-05
in O 0 4.942510756222873e-08
two O 0 5.7278597864751646e-08
Dutch O 0 6.109891546657309e-05
C6 B-Disease 1 0.9977995753288269
- I-Disease 1 0.8643741011619568
deficient I-Disease 1 0.9423279166221619
kindreds O 0 0.0006629708805121481
, O 0 1.150540995809024e-07
but O 0 3.2059492838243386e-08
the O 0 6.646740047244748e-08
879delG O 0 0.00029775794246234
defect O 0 4.336855636211112e-05
in O 0 3.1659290300467546e-08
the O 0 5.444440986934751e-08
Cape O 0 2.5800272851483896e-05
probably O 0 4.5918508817521797e-07
did O 0 5.103294853370244e-08
not O 0 6.935388707773882e-09
come O 0 1.4295076233850068e-08
from O 0 1.2363620349731264e-08
The O 0 4.8039140665423474e-08
Netherlands O 0 3.3640658330114093e-06
. O 0 6.594397632397886e-07
. O 0 3.4684962884057313e-06

Complement B-Disease 0 0.2260223925113678
C7 I-Disease 1 0.9998408555984497
deficiency I-Disease 1 0.9999551773071289
: O 0 0.0002276435843668878
seven O 0 8.358241757377982e-06
further O 0 4.896831342193764e-06
molecular O 0 0.0024597756564617157
defects O 0 0.17420588433742523
and O 0 7.137203397178382e-07
their O 0 8.414838816861447e-07
associated O 0 2.380067053309176e-05
marker O 0 0.0003773081407416612
haplotypes O 0 0.0031214014161378145
. O 0 1.9362041712156497e-05

Seven O 0 2.1790878236060962e-05
further O 0 5.647438229061663e-06
molecular O 0 3.482485772110522e-05
bases O 0 6.45494992568274e-06
of O 0 1.7457934518461116e-05
C7 B-Disease 1 0.9999229907989502
deficiency I-Disease 1 0.9999496936798096
are O 0 6.567669970536372e-06
described O 0 7.304111204575747e-05
. O 0 1.890279963845387e-05

All O 0 3.64781135431258e-06
these O 0 1.1223114597669337e-06
new O 0 1.544744350212568e-06
molecular O 0 0.00026040582451969385
defects O 0 0.005390508100390434
involve O 0 6.400391043825948e-07
single O 0 1.5571880851439346e-07
- O 0 2.0233836039551534e-05
nucleotide O 0 1.4784105815124349e-06
events O 0 9.355294139368198e-08
, O 0 3.8659550227748696e-08
deletions O 0 5.442524297905038e-07
and O 0 3.0881338375365885e-08
substitutions O 0 1.3956280042748404e-07
, O 0 1.2455385167697841e-08
some O 0 4.1711718523629315e-09
of O 0 6.7316188179233905e-09
which O 0 3.85953811132822e-08
alter O 0 2.786057621051441e-06
splice O 0 1.5369696484412998e-05
sites O 0 2.2577961544811842e-07
, O 0 6.926269691120979e-08
and O 0 1.3497445650045847e-07
others O 0 8.380753797609941e-07
codons O 0 1.8910228391177952e-05
. O 0 5.259070348984096e-06

They O 0 6.484874575107824e-06
are O 0 2.703527286485041e-07
distributed O 0 1.630654509199303e-07
along O 0 2.2272163846537296e-07
the O 0 1.7196079227232985e-07
C7 O 0 0.010986590757966042
gene O 0 4.490938863455085e-06
, O 0 9.819703450375528e-08
but O 0 2.4409775534195433e-08
predominantly O 0 3.955663885335525e-08
towards O 0 9.36877597723651e-08
the O 0 1.26565666391798e-07
3 O 0 1.6058465917012654e-06
end O 0 5.180183961783769e-06
. O 0 8.887858712114394e-06

All O 0 6.253466381167527e-06
were O 0 1.272177087230375e-06
found O 0 8.249547249761235e-07
in O 0 5.972395911157946e-07
compound O 0 2.219050111307297e-05
heterozygous O 0 2.1238147382973693e-05
individuals O 0 3.2776588341221213e-06
. O 0 8.433144103037193e-06

The O 0 0.00010791610839078203
C6 O 0 0.4646664559841156
/ O 0 0.05205099657177925
C7 O 1 0.8935810327529907
marker O 0 0.004509846214205027
haplotypes O 0 0.021853554993867874
associated O 0 1.8570281099528074e-05
with O 0 1.9006093907592003e-06
most O 0 4.292106950742891e-06
C7 B-Disease 1 0.997071385383606
defects I-Disease 1 0.9061970114707947
are O 0 1.1006387694578734e-06
tabulated O 0 0.0001541709789307788
. O 0 2.5226124762411928e-06
. O 0 7.1367462624039035e-06

A O 0 1.0205741091340315e-05
genome O 0 3.384482261026278e-05
- O 0 0.0001268498454010114
wide O 0 1.9784363303188e-06
search O 0 7.742390266685106e-07
for O 0 1.7163900167815882e-07
chromosomal O 0 0.001420681132003665
loci O 0 4.92349972773809e-05
linked O 0 3.8916521589271724e-05
to O 0 3.3298013022431405e-06
mental O 0 0.24728357791900635
health O 0 0.00025812649982981384
wellness O 0 0.0005839053192175925
in O 0 5.030974534747656e-07
relatives O 0 2.4156801373464987e-05
at O 0 3.3670412449282594e-06
high O 0 9.028107888298109e-05
risk O 0 0.0008293991559185088
for O 0 0.00010834194108610973
bipolar B-Disease 1 0.9999940395355225
affective I-Disease 1 0.9999327659606934
disorder I-Disease 1 0.9925540089607239
among O 0 1.0584203664620873e-06
the O 0 2.8742914537360775e-07
Old O 0 9.304147170041688e-06
Order O 0 2.3780839910614304e-06
Amish O 0 0.00025004675262607634
. O 0 1.4511086192214862e-05

Bipolar B-Disease 1 0.9998946189880371
affective I-Disease 1 0.9997592568397522
disorder I-Disease 1 0.9997804760932922
( O 0 0.005106514319777489
BPAD B-Disease 1 0.9992328882217407
; O 0 0.013449521735310555
manic B-Disease 1 0.9998760223388672
- I-Disease 1 0.9999407529830933
depressive I-Disease 1 0.9999940395355225
illness I-Disease 1 0.9995905756950378
) O 0 6.148042757558869e-06
is O 0 1.5751065518543328e-07
characterized O 0 4.214320142637007e-06
by O 0 6.456067325188997e-08
episodes O 0 3.211785895018693e-07
of O 0 1.507079332441208e-07
mania B-Disease 0 0.16061978042125702
and O 0 1.346989279227273e-06
/ O 0 0.000282353168586269
or O 0 1.7986820921578328e-06
hypomania B-Disease 0 0.17002415657043457
interspersed O 0 3.83872575184796e-05
with O 0 8.281463692583202e-07
periods O 0 2.3960998078109697e-05
of O 0 5.325295660441043e-06
depression B-Disease 1 0.8857372999191284
. O 0 3.158020626869984e-05

Compelling O 0 0.00011097291280748323
evidence O 0 1.521165540907532e-05
supports O 0 4.310652457206743e-06
a O 0 6.472601512541587e-07
significant O 0 8.746184789742983e-07
genetic O 0 1.4433384421863593e-05
component O 0 1.2590464848472038e-06
in O 0 1.6880096609384054e-07
the O 0 5.702465841750382e-07
susceptibility O 0 0.0010436414740979671
to O 0 2.1936332359473454e-06
develop O 0 0.00012172514834674075
BPAD B-Disease 1 0.932036817073822
. O 0 3.6156619898974895e-05

To O 0 1.7009720977512188e-05
date O 0 1.0488561201782431e-05
, O 0 1.137405092777044e-06
however O 0 3.6633983313549834e-07
, O 0 2.8254581252440403e-07
linkage O 0 2.3537169909104705e-05
studies O 0 9.168772407974757e-07
have O 0 7.421228076509578e-08
attempted O 0 6.119347517596907e-07
only O 0 1.7391789342013908e-08
to O 0 1.1443135150557282e-07
identify O 0 4.255465682945214e-06
chromosomal O 0 0.005922584794461727
loci O 0 2.6966472432832234e-05
that O 0 3.9396641682287736e-07
cause O 0 7.243679647217505e-06
or O 0 1.3375355933931132e-07
increase O 0 5.021900051360717e-07
the O 0 2.775058760562388e-07
risk O 0 6.119637419033097e-06
of O 0 5.496285666595213e-07
developing O 0 0.00011727732635335997
BPAD B-Disease 1 0.9545256495475769
. O 0 2.5681607439764775e-05

To O 0 2.097377182508353e-05
determine O 0 9.503462933935225e-06
whether O 0 1.3312379678609432e-06
there O 0 2.535566352435126e-07
could O 0 2.2080324413309427e-07
be O 0 3.790074742937577e-08
protective O 0 1.777224497345742e-05
alleles O 0 2.0824477360292803e-06
that O 0 1.3378290475429822e-07
prevent O 0 2.8332638066785876e-06
or O 0 1.5289361954273772e-07
reduce O 0 5.154450718691805e-06
the O 0 1.8029979287348397e-07
risk O 0 1.6953840713540558e-06
of O 0 4.2925389465153785e-08
developing O 0 1.679117303865496e-05
BPAD B-Disease 1 0.927933394908905
, O 0 2.0738826833621715e-07
similar O 0 1.0279406836843918e-07
to O 0 2.717311708977377e-08
what O 0 2.6927169827217767e-08
is O 0 1.4606467146904833e-08
observed O 0 1.1892193185758515e-07
in O 0 1.221882683921649e-07
other O 0 3.39836469720467e-06
genetic B-Disease 1 0.9950156807899475
disorders I-Disease 1 0.9999547004699707
, O 0 3.7112324662302854e-06
we O 0 1.330651571151975e-06
used O 0 9.790855983737856e-06
mental O 1 0.833916425704956
health O 0 0.006749373860657215
wellness O 0 0.027034161612391472
( O 0 2.0294994556024903e-06
absence O 0 2.4202420263463864e-06
of O 0 2.909479519530578e-07
any O 0 5.219363629294094e-06
psychiatric B-Disease 1 0.9893504977226257
disorder I-Disease 1 0.9779157042503357
) O 0 7.722634336460033e-07
as O 0 3.0922304716796134e-08
the O 0 3.9357807679607504e-08
phenotype O 0 2.046103645625408e-06
in O 0 1.1451568582288019e-08
our O 0 3.73152850841052e-08
genome O 0 3.3400917232029315e-07
- O 0 6.322504759737058e-06
wide O 0 3.715765615197597e-07
linkage O 0 3.5961929825134575e-06
scan O 0 2.8023926006426336e-06
of O 0 1.3125005970948678e-08
several O 0 1.7651220929337796e-08
large O 0 1.847817401312568e-07
multigeneration O 0 0.0001084621690097265
Old O 0 2.5699337129481137e-06
Order O 0 2.751310432813625e-07
Amish O 0 4.1554947529220954e-05
pedigrees O 0 8.541945135220885e-05
exhibiting O 0 7.094719876477029e-06
an O 0 1.7762579318514327e-07
extremely O 0 4.437501047505066e-06
high O 0 7.304371592908865e-06
incidence O 0 0.0007542884559370577
of O 0 5.007613708585268e-06
BPAD B-Disease 1 0.9955047965049744
. O 0 3.9088768971851096e-05

We O 0 2.0568799300235696e-05
have O 0 1.1971874300797936e-06
found O 0 3.950518703277339e-07
strong O 0 3.577853249225882e-07
evidence O 0 1.1549482081818496e-07
for O 0 1.7145881159308374e-08
a O 0 5.359051513664781e-08
locus O 0 2.7026892439607764e-06
on O 0 2.2618414163844136e-07
chromosome O 0 2.447877704980783e-05
4p O 0 0.003822097321972251
at O 0 3.9685644992459856e-07
D4S2949 O 0 1.3317814591573551e-05
( O 0 6.045164724355345e-08
maximum O 0 8.521587346876913e-08
GENEHUNTER O 0 2.191861676692497e-05
- O 0 3.848218511848245e-06
PLUS O 0 5.868603807357431e-07
nonparametric O 0 1.8219925550511107e-06
linkage O 0 1.6423828128608875e-06
score O 0 1.1909511954399932e-07
= O 0 1.4815439044468803e-06
4 O 0 9.152569901971219e-08
. O 0 2.7013593140168268e-08
05 O 0 4.947650268150028e-06
, O 0 7.220254616413513e-08
P O 0 7.580775854876265e-05
= O 0 1.2961745596840046e-05
5 O 0 6.951866993176736e-08
. O 0 1.5357247917791028e-08
22 O 0 5.5270568566356815e-08
x O 0 1.0125181688636076e-06
10 O 0 2.3154390405011327e-08
( O 0 3.4320436270718346e-08
- O 0 5.647405487252399e-06
4 O 0 2.806134489219403e-07
) O 0 6.549085895812823e-08
; O 0 1.7416411424164835e-07
SIBPAL O 0 5.32877747900784e-05
Pempirical O 0 1.1881238606292754e-05
value O 0 3.300419493257323e-08
< O 0 2.367936303926399e-06
3 O 0 1.3084832062304486e-07
x O 0 1.9082553990301676e-06
10 O 0 3.711865304012463e-08
( O 0 5.928083623985003e-08
- O 0 2.3347392925643362e-05
5 O 0 6.481354262177774e-07
) O 0 8.496706271898802e-08
) O 0 3.501316925280662e-08
and O 0 2.061555548493743e-08
suggestive O 0 6.222705337677326e-07
evidence O 0 7.175634664235986e-08
for O 0 1.5690281074398627e-08
a O 0 4.8223483872789075e-08
locus O 0 3.7259994769556215e-06
on O 0 3.265753889536427e-07
chromosome O 0 0.00022212239855434746
4q O 0 0.32977530360221863
at O 0 7.047079861877137e-07
D4S397 O 0 2.5813511456362903e-05
( O 0 8.905865200858898e-08
maximum O 0 6.570606103650789e-08
GENEHUNTER O 0 1.0664568435458932e-05
- O 0 3.105617679466377e-06
PLUS O 0 4.5657512259822397e-07
nonparametric O 0 1.6071089703473262e-06
linkage O 0 1.3150537370165694e-06
score O 0 1.5391593422009464e-07
= O 0 2.475682777003385e-06
3 O 0 6.300813737425415e-08
. O 0 1.197948318321096e-08
29 O 0 9.680952217649974e-08
, O 0 5.3165560842671766e-08
P O 0 7.675023516640067e-05
= O 0 7.539420039393008e-06
2 O 0 7.396413792548628e-08
. O 0 1.4334830211737426e-08
57 O 0 3.168429998368083e-07
x O 0 2.1595005819108337e-06
10 O 0 4.5410427418346444e-08
( O 0 5.439707706500485e-08
- O 0 5.610783773590811e-06
3 O 0 2.964595466892206e-07
) O 0 1.1555717094324791e-07
; O 0 2.14041477875071e-07
SIBPAL O 0 0.00010910354467341676
Pempirical O 0 1.7601987565285526e-05
value O 0 3.293790840075417e-08
< O 0 3.0691519441461423e-06
1 O 0 1.2248391101365996e-07
x O 0 3.8496978049806785e-06
10 O 0 5.085561483042511e-08
( O 0 8.028960962747078e-08
- O 0 2.6407205950818025e-05
3 O 0 9.367254278913606e-07
) O 0 1.7745985303463385e-07
) O 0 5.7361472016737025e-08
that O 0 1.79747594586388e-08
are O 0 3.195400211097876e-08
linked O 0 1.6011876141419634e-05
to O 0 4.8172505557886325e-06
mental O 0 0.44437524676322937
health O 0 0.010563927702605724
wellness O 0 0.04488232359290123
. O 0 3.0109869840089232e-05

These O 0 1.3714967280975543e-05
findings O 0 2.0588522602338344e-05
are O 0 1.4809110382429935e-07
consistent O 0 4.426793509537674e-07
with O 0 6.994560663997618e-08
the O 0 9.75356897470192e-08
hypothesis O 0 1.4054239727556705e-06
that O 0 3.0378803472785876e-08
certain O 0 4.664433106427168e-08
alleles O 0 6.845406232969253e-07
could O 0 1.3511548502265214e-07
prevent O 0 7.300084803318896e-07
or O 0 6.696469512235126e-08
modify O 0 2.6998038720194018e-06
the O 0 3.360011930908513e-07
clinical O 0 9.535450953990221e-05
manifestations O 0 2.250679608550854e-05
of O 0 3.0950511131777603e-07
BPAD B-Disease 1 0.9845104813575745
and O 0 1.7280988231505034e-06
perhaps O 0 1.6982531860776362e-06
other O 0 9.802840850170469e-07
related O 0 0.00102239940315485
affective B-Disease 1 0.9994457364082336
disorders I-Disease 1 0.9995717406272888
. O 0 0.00012674972822424024

Segregation O 0 0.01236124150454998
distortion O 0 0.12787039577960968
in O 0 0.002981143072247505
myotonic B-Disease 1 0.999687671661377
dystrophy I-Disease 1 0.9998262524604797
. O 0 0.002890896052122116

Myotonic B-Disease 1 0.9998769760131836
dystrophy I-Disease 1 0.9999754428863525
( O 1 0.7694854736328125
DM B-Disease 1 0.9999525547027588
) O 0 0.0004049120470881462
is O 0 5.278631761029828e-06
an O 0 5.1502888709364925e-06
autosomal B-Disease 1 0.8999274373054504
dominant I-Disease 0 0.3285231292247772
disease I-Disease 1 0.8814064860343933
which O 0 2.854911542726768e-07
, O 0 1.0286311180607299e-07
in O 0 5.109869505304232e-08
the O 0 6.53782805670744e-08
typical O 0 1.386236817779718e-06
pedigree O 0 1.638123649172485e-05
, O 0 4.144757070889682e-08
shows O 0 4.8227896343178145e-08
a O 0 2.7396321655714928e-08
three O 0 9.12530708774284e-08
generation O 0 5.7177580856659915e-06
anticipation O 0 3.0658222385682166e-05
cascade O 0 0.0006701282109133899
. O 0 1.2511989552876912e-05

This O 0 3.485868364805356e-05
results O 0 0.0002971511275973171
in O 0 0.00015525540220551193
infertility B-Disease 1 0.999663233757019
and O 1 0.7425680756568909
congenital B-Disease 1 0.9999990463256836
myotonic I-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999986886978149
( O 0 0.008372792974114418
CDM B-Disease 0 0.1890672743320465
) O 0 8.668923783261562e-07
with O 0 1.158873814688377e-07
the O 0 2.1025074659064558e-07
disappearance O 0 5.264117498882115e-05
of O 0 1.8030477804131806e-06
DM B-Disease 1 0.9996114373207092
in O 0 1.6227422747761011e-06
that O 0 1.5218995486065978e-06
pedigree O 0 0.0005894826026633382
. O 0 8.095203156699426e-06

The O 0 5.161155513633275e-06
concept O 0 3.630480023275595e-06
of O 0 2.6797039254233823e-07
segregation O 0 5.5508080549770966e-05
distortion O 0 0.00016466519446112216
, O 0 3.6038758821632655e-07
where O 0 1.6546708536679944e-07
there O 0 3.349562049947963e-08
is O 0 2.473324123286602e-08
preferential O 0 4.6604313297393674e-07
transmission O 0 7.182378567449632e-07
of O 0 1.8168094584325445e-08
the O 0 2.9604525053628095e-08
larger O 0 1.1939717126097094e-07
allele O 0 2.8981389732507523e-07
at O 0 1.1158616075590544e-07
the O 0 3.0394429018087976e-07
DM B-Disease 1 0.9972990155220032
locus O 0 2.695366674743127e-05
, O 0 7.118137546058279e-08
has O 0 1.8173535565324528e-08
been O 0 7.3373396247689016e-09
put O 0 4.306217249450128e-08
forward O 0 6.607189817486869e-08
to O 0 4.62723406258192e-08
explain O 0 8.78488037869829e-07
partially O 0 7.780873261253873e-07
the O 0 5.6061555397945995e-08
maintenance O 0 8.861258720571641e-06
of O 0 4.7393652380378626e-07
DM B-Disease 1 0.9986316561698914
in O 0 8.3417455698509e-07
the O 0 7.697722708144283e-07
population O 0 3.0392072858376196e-06
. O 0 5.794675871584332e-06

In O 0 7.37723439669935e-06
a O 0 3.636182782429387e-06
survey O 0 1.776494536898099e-05
of O 0 1.001202122097311e-06
DM B-Disease 1 0.9887461066246033
in O 0 6.519759381262702e-07
Northern O 0 9.008400638776948e-07
Ireland O 0 1.0419236105008167e-06
, O 0 3.1175744652500725e-07
59 O 0 3.3766300475690514e-06
pedigrees O 0 7.355113484663889e-05
were O 0 8.454543376501533e-07
ascertained O 0 3.0496585168293677e-05
. O 0 4.352971245680237e-06

Sibships O 0 0.04978121072053909
where O 0 1.0152050890610553e-05
the O 0 4.991042601432127e-07
status O 0 2.439977322410414e-07
of O 0 4.021529775855015e-08
all O 0 1.9142101237434872e-08
the O 0 3.212621635384494e-08
members O 0 4.746769732832945e-08
had O 0 1.508724523091587e-07
been O 0 4.968711664332659e-08
identified O 0 1.8299316195680149e-07
were O 0 2.490204131788687e-08
examined O 0 1.4492294440060505e-06
to O 0 2.7598979102094745e-08
determine O 0 5.5910028606831474e-08
the O 0 1.1086440210306137e-08
transmission O 0 2.5964087058127916e-07
of O 0 2.260697762324071e-08
the O 0 1.993537921407551e-07
DM B-Disease 1 0.9758899807929993
expansion O 0 1.2050834811816458e-05
from O 0 3.04229644143561e-07
affected O 0 2.8943459255970083e-06
parents O 0 9.233240803041554e-07
to O 0 1.6859247864431381e-07
their O 0 5.177958541935368e-07
offspring O 0 2.7647492970572785e-05
. O 0 5.963959665677976e-06

Where O 0 3.211616785847582e-05
the O 0 4.337577138358029e-06
transmitting O 0 0.00019378568686079234
parent O 0 0.0001278519193874672
was O 0 2.3718891952739796e-06
male O 0 4.982751761417603e-06
, O 0 1.5364930732175708e-06
58 O 0 2.0508825400611386e-05
. O 0 1.3048887012701016e-05

3 O 0 4.472950240597129e-05
% O 0 1.156820417236304e-06
of O 0 1.5602874725573201e-07
the O 0 3.087539539592399e-07
offspring O 0 7.844525498512667e-06
were O 0 7.885314801114873e-08
affected O 0 9.165633514385263e-07
, O 0 6.84194745304012e-08
and O 0 2.7069193109241496e-08
in O 0 2.74470544070482e-08
the O 0 2.7329727814162652e-08
case O 0 1.0616659551487828e-07
of O 0 2.169212542924015e-08
a O 0 1.8765814502330613e-07
female O 0 3.5208931876695715e-06
transmitting O 0 5.3611078328685835e-05
parent O 0 2.5656392608652823e-05
, O 0 6.00965904595796e-07
68 O 0 1.073453404387692e-05
. O 0 5.162966772331856e-06

7 O 0 0.00013669846521224827
% O 0 1.4071274563320912e-05
were O 0 4.101651938981377e-06
affected O 0 4.928996349917725e-05
. O 0 2.422300894977525e-05

Studies O 0 3.4714706998784095e-05
on O 0 2.7840178518090397e-06
meiotic O 0 0.0004609658499248326
drive O 0 1.2716962373815477e-05
in O 0 2.0513514300546376e-06
DM B-Disease 1 0.9955264925956726
have O 0 2.9103063070579083e-07
shown O 0 1.3974900525681733e-07
increased O 0 8.17626926163939e-08
transmission O 0 2.273870904900832e-07
of O 0 7.969484627778911e-09
the O 0 1.6421864756921423e-08
larger O 0 9.538828749100503e-08
allele O 0 2.76875653071329e-07
at O 0 7.956077752169222e-08
the O 0 1.905135604829411e-07
DM B-Disease 1 0.9349386692047119
locus O 0 7.584094419144094e-06
in O 0 1.6316391793225193e-07
non O 0 2.632411451486405e-06
- O 0 0.0316954180598259
DM O 1 0.999043881893158
heterozygotes O 0 0.0012434578966349363
for O 0 3.841185844066786e-06
CTGn O 0 0.0026844418607652187
. O 0 1.4123829714662861e-05

This O 0 7.775207450322341e-06
study O 0 8.828217687550932e-06
provides O 0 1.3280805433169007e-06
further O 0 2.4913330776143994e-07
evidence O 0 2.434603345591313e-07
that O 0 5.750409570737247e-08
the O 0 3.5128132935824397e-07
DM B-Disease 1 0.9976813793182373
expansion O 0 2.768981721601449e-05
tends O 0 3.4015295113931643e-06
to O 0 1.4863908859297226e-07
be O 0 1.286854995896647e-07
transmitted O 0 5.389430953073315e-06
preferentially O 0 1.0948391718557104e-05
. O 0 4.329191597207682e-06

Diagnosis O 1 0.979568362236023
of O 0 0.0005182437016628683
hemochromatosis B-Disease 1 0.9989274144172668
. O 0 0.0011216311249881983

If O 0 0.0037102163769304752
untreated O 1 0.9894666075706482
, O 0 0.0010210438631474972
hemochromatosis B-Disease 1 0.999964714050293
can O 0 0.009295888245105743
cause O 0 0.30185404419898987
serious O 0 0.049762699753046036
illness O 1 0.6180921196937561
and O 0 1.7137483609985793e-06
early B-Disease 0 5.8183154578728136e-06
death I-Disease 0 3.170307900290936e-05
, O 0 1.3558019418269396e-06
but O 0 1.3857477370038396e-06
the O 0 8.24300241220044e-06
disease O 0 0.15878333151340485
is O 0 1.7768626037195645e-07
still O 0 5.057200951341656e-07
substantially O 0 5.55384167455486e-06
under O 0 8.808053280517925e-06
- O 1 0.9475553631782532
diagnosed O 1 0.9857392907142639
. O 0 3.105147334281355e-05

The O 0 6.737441253790166e-06
cornerstone O 0 2.9800583433825523e-05
of O 0 6.644521022280969e-07
screening O 0 7.796458703523967e-06
and O 0 4.7559728955093306e-07
case O 0 1.0993253454216756e-06
detection O 0 5.556957148655783e-06
is O 0 1.7857074041671694e-08
the O 0 1.8001660606614678e-08
measurement O 0 3.356885827088263e-07
of O 0 4.746099691033123e-08
serum O 0 1.2515629350673407e-05
transferrin O 0 9.930234227795154e-06
saturation O 0 6.474675728895818e-07
and O 0 6.116586348525743e-08
the O 0 1.649986103302581e-07
serum O 0 3.0030121706658974e-05
ferritin O 0 7.58364622015506e-05
level O 0 3.12841143568221e-06
. O 0 5.837362095917342e-06

Once O 0 0.0001583615958224982
the O 0 2.5460476535954513e-05
diagnosis O 0 0.3551744222640991
is O 0 1.2751177109748824e-06
suspected O 0 2.508508441678714e-05
, O 0 4.594645304223377e-07
physicians O 0 1.1174616702191997e-05
must O 0 7.72436692386691e-08
use O 0 9.532353573149521e-08
serum O 0 2.3034368496155366e-05
ferritin O 0 4.0180770156439394e-05
levels O 0 4.5518865476879e-07
and O 0 2.517913060273713e-07
hepatic O 0 0.004936239682137966
iron O 0 0.00028884923085570335
stores O 0 3.026547346962616e-06
on O 0 2.938142188213533e-06
liver O 1 0.59328293800354
biopsy O 0 0.12138292193412781
specimens O 0 2.5862966140266508e-05
to O 0 1.0267311836287263e-06
assess O 0 0.0002931120106950402
patients O 0 1.1203620488231536e-05
for O 0 2.354190797859701e-08
the O 0 4.5681638027872395e-08
presence O 0 2.0753093110670306e-07
of O 0 6.526820470753592e-07
iron B-Disease 0 0.061774201691150665
overload I-Disease 0 0.38676854968070984
. O 0 1.7009981092996895e-05

Liver O 1 0.9988980293273926
biopsy O 1 0.971950352191925
is O 0 2.3516809051216114e-06
also O 0 1.9253623406711995e-07
used O 0 6.021942056122498e-08
to O 0 3.173679985479794e-08
establish O 0 2.0620576890451048e-07
the O 0 4.451529278526323e-08
presence O 0 2.5830669869719713e-07
or O 0 1.3614365457215172e-07
absence O 0 3.8041760035412153e-06
of O 0 1.995899992834893e-06
cirrhosis B-Disease 1 0.964408814907074
, O 0 1.2153483339716331e-06
which O 0 3.5846255741489585e-07
can O 0 1.8091743640979985e-06
affect O 0 8.766486280364916e-05
prognosis O 1 0.7737544775009155
and O 0 6.59081024423358e-06
management O 0 0.0002607096394058317
. O 0 1.4182082850311417e-05

A O 0 1.568141124153044e-05
DNA O 0 4.2523843148956075e-05
- O 0 8.724554209038615e-05
based O 0 6.91607795033633e-07
test O 0 3.221829558697209e-07
for O 0 2.0850571047503763e-08
the O 0 7.173705540708397e-08
HFE O 0 0.0015735061606392264
gene O 0 7.545668836428376e-07
is O 0 1.2218018596854563e-08
commercially O 0 2.1012301232303798e-08
available O 0 4.913192075406414e-09
, O 0 5.536317626564369e-09
but O 0 2.8663700302189454e-09
its O 0 3.711254858984603e-09
place O 0 1.8678749214018353e-08
in O 0 4.529312747081349e-08
the O 0 9.074276476894738e-07
diagnosis O 0 0.08472279459238052
of O 0 4.805646312888712e-06
hemochromatosis B-Disease 1 0.9999716281890869
is O 0 2.432079099889961e-06
still O 0 1.7946468915397418e-06
being O 0 9.126914051194035e-07
evaluated O 0 1.964177135960199e-05
. O 0 6.543269591929857e-06

Currently O 0 1.3712260624743067e-05
, O 0 1.0764895250758855e-06
the O 0 1.515763727866215e-07
most O 0 2.954924127607228e-08
useful O 0 6.737851521165794e-08
role O 0 6.971518473619653e-08
for O 0 1.8761371123332538e-08
this O 0 1.2439311802836528e-08
test O 0 9.071994355736024e-08
is O 0 5.005711845029737e-09
in O 0 8.116243677136481e-09
the O 0 2.1099930691548252e-08
detection O 0 2.7239336759521393e-06
of O 0 2.6116890694538597e-07
hemochromatosis B-Disease 1 0.9994841814041138
in O 0 4.4081892269787204e-07
the O 0 2.5394868430339557e-07
family O 0 2.470847675795085e-06
members O 0 8.401642048738722e-08
of O 0 4.2263198452019424e-07
patients O 0 6.318163650576025e-05
with O 0 2.8824962328144466e-07
a O 0 8.220073937081906e-07
proven O 0 1.3251769814814907e-05
case O 0 1.0720063983171713e-06
of O 0 4.678693983350968e-07
the O 0 2.021265754592605e-05
disease O 0 0.3862631022930145
. O 0 1.6459218386444263e-05

It O 0 1.0675586963770911e-05
is O 0 3.3707005968608428e-06
crucial O 0 2.268714706588071e-05
to O 0 6.51693917461671e-05
diagnose O 1 0.9997596144676208
hemochromatosis B-Disease 1 0.9999579191207886
before O 0 0.010645578615367413
hepatic B-Disease 1 0.999841570854187
cirrhosis I-Disease 1 0.9998446702957153
develops O 0 0.06561650335788727
because O 0 8.750826236791909e-05
phlebotomy O 1 0.9762822985649109
therapy O 0 0.15267008543014526
can O 0 0.00021551210375037044
avert O 1 0.9938161373138428
serious O 1 0.9962390661239624
chronic O 1 0.9999979734420776
disease O 1 0.9995798468589783
and O 0 5.856756615685299e-06
can O 0 9.004681942315074e-07
even O 0 3.6091623201173206e-07
lead O 0 2.08428150472173e-06
to O 0 1.1407363587068176e-07
normal O 0 1.119119019676873e-06
life O 0 2.416897586954292e-06
expectancy O 0 7.911917055025697e-05
. O 0 1.2686175523413112e-06
. O 0 4.368579539004713e-06

Prevalence O 0 0.006640986539423466
of O 0 2.931660219473997e-06
the O 0 2.203080157414661e-06
I1307K O 0 0.0012402181746438146
APC B-Disease 0 0.00015863197040744126
gene O 0 6.071672487450996e-06
variant O 0 2.9279747195687378e-06
in O 0 6.564818733068023e-08
Israeli O 0 1.9028838948997873e-07
Jews O 0 1.0961966268041579e-07
of O 0 1.8974777304947565e-08
differing O 0 9.463477113058616e-08
ethnic O 0 1.564837077694392e-07
origin O 0 7.563795634268899e-07
and O 0 5.383476946008159e-06
risk O 0 0.0025131949223577976
for O 0 0.0011303084902465343
colorectal B-Disease 1 0.9999966621398926
cancer I-Disease 1 0.999920129776001
. O 0 0.00018582507618702948

BACKGROUND O 0 0.0003368972393218428
& O 0 0.0010246016317978501
AIMS O 0 3.3675383747322485e-05
Israeli O 0 3.097920853178948e-06
Jews O 0 1.112038944484084e-06
of O 0 1.092973107574835e-07
European O 0 6.192082082634442e-07
birth O 0 7.45253601053264e-06
, O 0 3.188296204825747e-07
i O 0 7.7420213528967e-07
. O 0 4.5699589890091374e-08
e O 0 2.140740662071039e-06
. O 0 1.990824216591136e-08
, O 0 3.977301332724892e-08
Ashkenazim O 0 1.1807333976321388e-05
, O 0 8.059939915483483e-08
have O 0 3.6017691940060104e-08
the O 0 7.052512387417664e-07
highest O 0 0.029981376603245735
colorectal B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999803304672241
incidence O 0 0.061413563787937164
of O 0 1.4431195438646682e-07
any O 0 6.446149569683257e-08
Israeli O 0 4.805311846212135e-07
ethnic O 0 8.886942737262871e-07
group O 0 1.103991235140711e-05
. O 0 6.230957296793349e-06

The O 0 5.873060581507161e-05
I1307K O 0 0.004123514052480459
APC B-Disease 0 0.0007868485990911722
gene O 0 6.892713281558827e-05
variant O 0 3.212593583157286e-05
was O 0 7.602209848300845e-07
found O 0 3.524211820149503e-07
in O 0 6.001125143484387e-07
6 O 0 1.4405690308194607e-05
. O 0 8.12052621768089e-06

1 O 0 1.4221032870409545e-05
% O 0 7.140062621147081e-07
of O 0 1.211140840950975e-07
American O 0 4.7409338321813266e-07
Jews O 0 1.1227889444853645e-06
, O 0 1.523870309938502e-07
28 O 0 2.871724120723229e-07
% O 0 6.307499234026182e-08
of O 0 2.174353710415744e-07
their O 0 0.00015657229232601821
familial O 1 0.9999964237213135
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999936819076538
cases O 0 7.028074469417334e-05
, O 0 1.0905238241321058e-06
but O 0 1.1093932528183359e-07
not O 0 1.740881394596272e-08
in O 0 3.9792361405943666e-08
non O 0 7.262033250299282e-07
- O 0 0.00015854593948461115
Jews O 0 1.2575797882163897e-05
. O 0 6.859751010779291e-06

We O 0 2.7008727556676604e-05
assessed O 0 2.5856208594632335e-05
the O 0 1.5073509302965249e-06
I1307K O 0 0.0013302129227668047
prevalence O 0 0.0002811164886225015
in O 0 2.106754521946641e-07
Israeli O 0 5.004660010854423e-07
Jews O 0 1.8420919900563604e-07
of O 0 2.533494303236239e-08
differing O 0 1.1860796433893483e-07
ethnic O 0 2.008589063962063e-07
origin O 0 1.023870140670624e-06
and O 0 9.699389011075255e-06
risk O 0 0.009832723997533321
for O 0 0.001109505072236061
colorectal B-Disease 1 0.9999969005584717
cancer I-Disease 1 0.9999020099639893
. O 0 0.0001728328934404999

METHODS O 0 5.3426130762090907e-05
DNA O 0 4.917722981190309e-05
samples O 0 1.7629974990995834e-06
from O 0 1.1123723453465573e-07
500 O 0 2.8426205744835897e-07
unrelated O 0 8.895082714843738e-07
Jews O 0 1.9457183952908963e-07
of O 0 2.234052942640119e-08
European O 0 1.0720007281861399e-07
or O 0 5.099597188973348e-08
non O 0 2.3709570484697906e-07
- O 0 6.420525460271165e-05
European O 0 2.6398123509352445e-07
origin O 0 5.906571587388498e-08
, O 0 3.3487637551843363e-08
with O 0 5.512654155381824e-08
or O 0 7.741564189700512e-08
without O 0 2.953312616682524e-08
a O 0 3.408617033073824e-08
personal O 0 1.219902628690761e-06
and O 0 5.296697622725333e-07
/ O 0 0.00033647031523287296
or O 0 2.792202167256619e-07
family O 0 1.2054672424710589e-06
history O 0 4.59695542076588e-07
of O 0 3.4480706290196395e-07
neoplasia B-Disease 1 0.593928337097168
, O 0 4.4974012780585326e-07
were O 0 5.156817195484109e-08
examined O 0 9.779915899343905e-07
for O 0 1.6159560800588224e-08
the O 0 5.835353178440528e-08
I1307K O 0 6.592830322915688e-05
variant O 0 7.115069138308172e-07
by O 0 1.591279286117242e-08
the O 0 1.4969343098414356e-08
allele O 0 1.844999815148185e-07
- O 0 5.0131666284869425e-06
specific O 0 1.1347718498200265e-07
oligonucleotide O 0 2.50821904046461e-05
( O 0 1.4415956002267194e-06
ASO O 0 0.00039008085150271654
) O 0 6.70966983307153e-07
method O 0 1.1267276249782299e-06
. O 0 2.0976656287530204e-06

RESULTS O 0 0.00019233732018619776
In O 0 3.07343429994944e-06
persons O 0 3.821746759058442e-06
at O 0 5.577609954343643e-06
average O 0 0.00018872780492529273
risk O 0 0.0018108660588040948
for O 0 0.00035814204602502286
colorectal B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999814033508301
, O 0 3.9086717151803896e-05
I1307K O 0 0.013542401604354382
was O 0 4.5053860731059103e-07
found O 0 1.7308337874055724e-07
in O 0 3.86558724585484e-07
5 O 0 7.556833224953152e-06
. O 0 6.878197837068001e-06

0 O 0 0.00012680691725108773
% O 0 1.75277955349884e-06
of O 0 3.0457741218015144e-07
120 O 0 8.934147217587451e-07
European O 0 7.238696184685978e-07
and O 0 5.62330569664482e-07
1 O 0 4.628117494576145e-06
. O 0 7.312247817026218e-06

6 O 0 3.531429683789611e-05
% O 0 1.0266196568409214e-06
of O 0 2.021402565333119e-07
188 O 0 1.734274974296568e-06
non O 0 1.3360023558561807e-06
- O 0 0.0001209773836308159
European O 0 1.0944016821667901e-06
Jews O 0 1.9805847841780633e-06
( O 0 1.1530083838806604e-06
P O 0 0.0005968612967990339
= O 0 3.8941914681345224e-05
0 O 0 2.0877746464975644e-06
. O 0 1.7989154343922564e-07
08 O 0 5.673733085131971e-06
) O 0 1.1768881904572481e-06
. O 0 1.9156675534759415e-06

It O 0 2.2141877707326785e-05
occurred O 0 3.412630030652508e-05
in O 0 3.6876335798297077e-06
15 O 0 9.943767508957535e-06
. O 0 1.6471325579914264e-05

4 O 0 3.4148637496400625e-05
% O 0 1.4838686865914497e-06
of O 0 3.1884755458122527e-07
52 O 0 6.847587883385131e-06
Ashkenazi O 0 0.00020593452791217715
Israelis O 0 1.3998784197610803e-05
with O 0 1.88873218576191e-05
familial O 1 0.9997095465660095
cancer B-Disease 1 0.9825579524040222
( O 0 8.813976819510572e-06
P O 0 0.022680900990962982
= O 0 0.0002514995285309851
0 O 0 2.2772505872126203e-06
. O 0 8.371760173986331e-08
02 O 0 8.367314148927107e-05
) O 0 5.644825762374239e-08
and O 0 1.9191197964119056e-08
was O 0 2.5397065783749895e-08
not O 0 1.282783923528541e-08
detected O 0 2.1226868796020426e-07
in O 0 1.1542066857828104e-08
51 O 0 2.6508877226660843e-07
non O 0 3.1786626664143114e-07
- O 0 5.7442786783212796e-05
European O 0 7.419005783049215e-07
Jews O 0 3.1297931855078787e-06
at O 0 7.085315701260697e-06
increased O 0 0.00013353406393434852
cancer B-Disease 1 0.5178769826889038
risk O 0 0.00014716124860569835
. O 0 7.603836365888128e-06

Colorectal B-Disease 1 0.9988330006599426
neoplasia I-Disease 1 0.9977794289588928
occurred O 0 0.0018159289611503482
personally O 0 0.00015332683688029647
or O 0 9.887652367979172e-07
in O 0 1.5078801141044096e-07
the O 0 8.111573635005698e-08
families O 0 1.8029584225587314e-07
of O 0 2.565647427843487e-08
13 O 0 1.8945183910545893e-07
of O 0 4.920087093296388e-08
20 O 0 6.611633125430671e-07
Ashkenazi O 0 0.0001640907721593976
I1307K O 0 0.0005566388135775924
carriers O 0 3.8327953006955795e-06
, O 0 5.623891397021907e-08
8 O 0 1.8457460271292803e-07
of O 0 6.299047328184315e-08
whom O 0 1.4851315199848614e-06
also O 0 1.0115716975178657e-07
had O 0 7.092063469826826e-08
a O 0 5.866735008908108e-08
personal O 0 1.6928134982663323e-06
or O 0 3.089353981522436e-07
family O 0 1.7917891454999335e-06
history O 0 1.785879703675164e-06
of O 0 2.472561163813225e-06
noncolonic O 1 0.5571953058242798
neoplasia B-Disease 1 0.8895142078399658
. O 0 2.9427577828755602e-05

CONCLUSIONS O 0 0.0001430111879017204
The O 0 9.105318895308301e-06
I1307K O 0 0.0020560915581882
APC O 0 0.0003670308506116271
variant O 0 9.154810686595738e-05
may O 0 1.630564042898186e-06
represent O 0 1.242424900738115e-07
a O 0 4.0973804971145e-07
susceptibility O 0 0.0012582929339259863
gene O 0 2.517370376153849e-05
for O 0 2.90953380499559e-06
colorectal B-Disease 1 0.9990185499191284
, I-Disease 0 1.7483438341514557e-06
or I-Disease 0 4.788143428413605e-07
other I-Disease 0 2.8383081485117145e-07
, I-Disease 0 9.516523277852684e-06
cancers I-Disease 0 0.15324635803699493
in O 0 6.853794047856354e-07
Ashkenazi O 0 0.0003402126021683216
Jews O 0 3.2710045161365997e-06
, O 0 2.253882911418259e-07
and O 0 1.7592829237855767e-07
partially O 0 6.027462404745165e-06
explains O 0 2.4704352199478308e-06
the O 0 1.0149034324058448e-07
higher O 0 3.247032054787269e-06
incidence O 0 0.14592255651950836
of O 0 0.00034781117574311793
colorectal B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9997820258140564
in O 0 2.349945816604304e-06
European O 0 5.953015261184191e-06
Israelis O 0 1.9578616047510877e-05
. O 0 1.4771796486456878e-05

Systematic O 0 0.0003262372629251331
analysis O 0 2.5254472348024137e-05
of O 0 4.3954541979474016e-06
coproporphyrinogen O 0 0.07331959158182144
oxidase O 0 0.003551982808858156
gene O 0 0.0011739771580323577
defects O 0 0.25030165910720825
in O 0 4.2249603211530484e-06
hereditary B-Disease 0 0.08676833659410477
coproporphyria I-Disease 0 0.16426968574523926
and O 0 7.087247922754614e-06
mutation O 0 7.916650065453723e-05
update O 0 0.00011938230454688892
. O 0 9.950255844159983e-06

Hereditary B-Disease 1 0.9714198708534241
coproporphyria I-Disease 1 0.9849386215209961
( O 0 0.0006848154589533806
HC B-Disease 1 0.9973228573799133
) O 0 8.084966975729913e-05
is O 0 5.1984848141728435e-06
an O 0 2.782508272503037e-05
acute O 1 0.9991338849067688
hepatic B-Disease 1 0.9999505281448364
porphyria I-Disease 1 0.9999566078186035
with O 0 0.0005546368774957955
autosomal O 1 0.9117900729179382
dominant O 0 0.003731888486072421
inheritance O 0 0.06959220767021179
caused O 0 0.0008334803278557956
by O 0 7.685524110456754e-07
deficient B-Disease 0 0.00019301523570902646
activity I-Disease 0 2.532437122226838e-07
of I-Disease 0 2.972476806917257e-07
coproporphyrinogen I-Disease 0 0.06495088338851929
III I-Disease 0 0.028560452163219452
oxidase I-Disease 0 0.00019532907754182816
( O 0 2.844062464646413e-06
CPO O 0 9.597300959285349e-05
) O 0 2.2005078790243715e-06
. O 0 2.921863142546499e-06

Clinical O 0 0.2898537814617157
manifestations O 0 0.010203317739069462
of O 0 2.143588790204376e-05
the O 0 0.00022744138550478965
disease O 1 0.9931822419166565
are O 0 4.972474471287569e-06
characterized O 0 0.07602196931838989
by O 0 0.00015919003635644913
acute O 1 0.9949980974197388
attacks O 0 0.0028193143662065268
of O 0 0.00047653180081397295
neurological B-Disease 1 0.9999878406524658
dysfunction I-Disease 1 0.9995393753051758
often O 0 4.788368823938072e-05
precipitated O 0 0.015576764941215515
by O 0 1.0697127663661377e-06
drugs O 0 2.0541881440294674e-06
, O 0 4.0171525483856385e-07
fasting O 0 1.08044960143161e-05
, O 0 2.6496061309444485e-06
cyclical O 0 0.37089458107948303
hormonal O 0 0.011732862330973148
changes O 0 5.344181317923358e-06
, O 0 6.376110377459554e-06
or O 0 0.00012284958211239427
infectious B-Disease 1 0.9833307862281799
diseases I-Disease 1 0.9604719281196594
. O 0 3.166334499837831e-05

Skin O 1 0.9987322688102722
photosensitivity O 1 0.9980431795120239
may O 0 0.0004526708507910371
also O 0 6.203937118698377e-06
be O 0 1.3468453516907175e-06
present O 0 4.566027200780809e-06
. O 0 1.1731615813914686e-05

The O 0 5.601822522294242e-06
seven O 0 1.5968257685017306e-06
exons O 0 1.4458899386227131e-05
, O 0 2.2292735479823023e-07
the O 0 8.575180743264355e-08
exon O 0 1.963014256034512e-05
/ O 0 2.7796624635811895e-05
intron O 0 5.243076157057658e-05
boundaries O 0 1.3744588045483397e-07
and O 0 1.6219591003618916e-08
part O 0 1.5551735899066443e-08
of O 0 1.14328440048439e-08
3 O 0 1.0756218671303941e-07
noncoding O 0 6.973028121137759e-06
sequence O 0 6.715207234719855e-08
of O 0 1.2352871614496053e-08
the O 0 3.8687215209165515e-08
CPO O 0 1.0103804925165605e-05
gene O 0 3.5973278045275947e-07
were O 0 2.7026786142414494e-08
systematically O 0 4.393214965148218e-07
analyzed O 0 1.2021513384752325e-07
by O 0 8.951261953882295e-09
an O 0 9.603430939364443e-09
exon O 0 1.545189434182248e-06
- O 0 4.369470843812451e-06
by O 0 8.620737901310349e-08
- O 0 2.328251321159769e-05
exon O 0 5.016682553105056e-05
denaturing O 0 0.0008830399601720273
gradient O 0 3.875475158565678e-05
gel O 0 0.0001389038225170225
electrophoresis O 0 0.00011179903958691284
( O 0 3.493239830731909e-07
DGGE O 0 4.499016358749941e-05
) O 0 3.968465733805715e-08
strategy O 0 5.955827475645492e-08
followed O 0 2.024876799566755e-08
by O 0 5.268914637923672e-09
direct O 0 1.2703952556591958e-08
sequencing O 0 1.0099927294504596e-07
in O 0 1.819722683649161e-08
seven O 0 1.9200612655367877e-07
unrelated O 0 1.1410236766096205e-05
heterozygous O 0 1.8471124349161983e-05
HC B-Disease 1 0.950127363204956
patients O 0 0.00019260213593952358
from O 0 1.1478612549353784e-07
France O 0 4.036721747979755e-06
, O 0 5.781643039881601e-07
Holland O 0 3.0178576707839966e-05
, O 0 2.4530081077500654e-07
and O 0 2.7010071335098473e-07
Czech O 0 2.509235855541192e-05
Republic O 0 1.2355966646282468e-05
. O 0 1.060492195392726e-05

Seven O 0 6.40526122879237e-05
novel O 0 6.970499089220539e-05
mutations O 0 6.357747042784467e-05
and O 0 2.3681637628669705e-07
two O 0 1.3860277192634385e-07
new O 0 7.700285209466529e-07
polymorphisms O 0 0.00020073259656783193
were O 0 8.022261681617238e-07
detected O 0 3.142995046800934e-05
. O 0 6.632051281485474e-06

Among O 0 2.810646765283309e-05
these O 0 2.4599428343208274e-06
mutations O 0 2.7678886908688582e-05
two O 0 1.5900330652129924e-07
are O 0 1.1125888477181434e-07
missense O 0 5.994180537527427e-05
( O 0 1.0062333331006812e-06
G197W O 0 0.0001174698190880008
, O 0 3.0777675874560373e-07
W427R O 0 7.314364484045655e-05
) O 0 6.974178035079603e-08
, O 0 9.635594544477044e-09
two O 0 5.625047094781621e-09
are O 0 1.1182645920371215e-08
nonsense O 0 1.527628683106741e-06
( O 0 1.745668640751319e-07
Q306X O 0 2.1354499040171504e-05
, O 0 9.882592877374918e-08
Q385X O 0 1.5142254596867133e-05
) O 0 2.7632321319970288e-08
, O 0 4.118505536609973e-09
two O 0 3.107032409133126e-09
are O 0 4.827554356268138e-09
small O 0 4.4935941190260564e-08
deletions O 0 1.6003580185497412e-06
( O 0 3.0141160323182703e-07
662de14bp O 0 3.643865784397349e-05
; O 0 3.659131380118197e-07
1168del3bp O 0 5.900377072975971e-05
removing O 0 3.1583329018758377e-07
a O 0 3.271888360245612e-08
glycine O 0 3.5649247820401797e-06
at O 0 8.314901123185336e-08
position O 0 8.465647738375992e-08
390 O 0 6.135609851298796e-07
) O 0 4.713514556442533e-08
, O 0 9.652075583233e-09
and O 0 9.033520598222822e-09
one O 0 6.894739001950256e-09
is O 0 5.349326759329642e-09
a O 0 1.5942079656383612e-08
splicing O 0 1.5011164578027092e-06
mutation O 0 1.3151415032552904e-06
( O 0 9.702932146637977e-08
IVS1 O 0 2.445758946123533e-05
- O 0 1.539795266580768e-05
15c O 0 1.1682624972308986e-05
- O 0 2.3526534278062172e-05
- O 0 0.00021041468426119536
> O 0 0.00014101533452048898
g O 0 9.04465196072124e-05
) O 0 5.516040957331825e-08
which O 0 1.1493867191347817e-08
creates O 0 1.1075855610442886e-07
a O 0 2.9682210467285586e-08
new O 0 1.7334123469936458e-07
acceptor O 0 6.738635875080945e-06
splice O 0 9.84520447673276e-05
site O 0 9.101576324610505e-06
. O 0 5.202611191634787e-06

The O 0 3.172213473590091e-05
pathological O 0 0.0013257404789328575
significance O 0 3.1880240385362413e-06
of O 0 2.7009090786123124e-07
the O 0 1.9764043202030734e-07
point O 0 1.3530984688259196e-06
mutations O 0 1.7903230400406756e-05
G197W O 0 7.316848495975137e-05
, O 0 1.8147372315979737e-07
W427R O 0 2.63177789747715e-05
, O 0 2.3906117974092922e-08
and O 0 6.8857759494278525e-09
the O 0 8.644641447119739e-09
in O 0 2.251136876907367e-08
- O 0 5.715695442631841e-05
frame O 0 4.9116679292637855e-05
deletion O 0 9.38692464842461e-05
390delGly O 0 0.00018501780868973583
were O 0 2.41581776805333e-08
assessed O 0 1.0145512163717285e-07
by O 0 7.399740820090983e-09
their O 0 5.59706059277687e-09
respective O 0 3.6929542091002077e-08
expression O 0 3.490222155733136e-08
in O 0 1.520029080381846e-08
a O 0 4.057835312210045e-08
prokaryotic O 0 9.75844159256667e-07
system O 0 1.8209868812846253e-07
using O 0 7.754007214089143e-08
site O 0 6.904742235747108e-07
- O 0 2.521738497307524e-05
directed O 0 4.905862169835018e-06
mutagenesis O 0 5.458354644360952e-05
. O 0 4.427575731824618e-06

These O 0 2.9721768441959284e-05
mutations O 0 0.00027671584393829107
resulted O 0 8.5021956692799e-06
in O 0 2.2071967009651416e-07
the O 0 1.8340583096687624e-07
absence O 0 1.6805340692371828e-06
or O 0 1.0982119391655942e-07
a O 0 1.3761966499714617e-07
dramatic O 0 6.73592467137496e-06
decrease O 0 8.685367902216967e-06
of O 0 5.907472200306074e-07
CPO O 0 0.00027643790235742927
activity O 0 1.0925298738584388e-05
. O 0 7.991413440322503e-06

The O 0 7.582387297588866e-06
two O 0 1.3695721463591326e-06
polymorphisms O 0 7.955920591484755e-05
were O 0 2.5862914299068507e-07
localized O 0 3.258152673879522e-06
in O 0 1.052733153983354e-07
noncoding O 0 3.3072599762817845e-05
part O 0 1.0022915120089237e-07
of O 0 2.2818818834480226e-08
the O 0 4.759479921290222e-08
gene O 0 5.625462335956399e-07
1 O 0 1.3114689068061125e-07
) O 0 6.459417534188105e-08
a O 0 6.017406661840141e-08
C O 0 3.7659567169612274e-05
/ O 0 0.00012330812751315534
G O 0 9.836337267188355e-05
polymorphism O 0 1.0890563544307952e-06
in O 0 3.04957232799552e-08
the O 0 5.5200931825538646e-08
promotor O 0 8.520418487023562e-05
region O 0 4.4906937546329573e-07
, O 0 5.60847652764096e-08
142 O 0 4.101884201190842e-07
bp O 0 3.157717401336413e-06
upstream O 0 1.6738037800223537e-07
from O 0 7.739568097520078e-09
the O 0 9.520013222186208e-09
transcriptional O 0 4.2722459170363436e-07
initiation O 0 5.376588774197444e-07
site O 0 4.1049798937820015e-07
( O 0 1.1717829551116665e-07
- O 0 3.9337599446298555e-05
142C O 0 0.0002592462406028062
/ O 0 7.29469393263571e-05
G O 0 6.31343646091409e-05
) O 0 3.723551600387509e-08
, O 0 6.879605773946196e-09
and O 0 5.8212319409278734e-09
2 O 0 6.252781759030768e-08
) O 0 2.002431820358197e-08
a O 0 1.4137429005245394e-08
6 O 0 3.786498439239949e-07
bp O 0 8.774817615631036e-06
deletion O 0 1.9751164472836535e-06
polymorphism O 0 4.6801088160464133e-07
in O 0 9.484706353646288e-09
the O 0 7.865723183897444e-09
3 O 0 6.24251015324262e-08
noncoding O 0 3.7251575122354552e-06
part O 0 2.32834853619579e-08
of O 0 1.2541515381769841e-08
the O 0 3.996174413600784e-08
CPO O 0 1.8700582586461678e-05
gene O 0 8.080764359874593e-07
, O 0 5.2674199224611584e-08
574 O 0 4.409796929394361e-06
bp O 0 4.340064151620027e-06
downstream O 0 1.837757821476771e-07
of O 0 5.027394056611456e-09
the O 0 6.955338971437186e-09
last O 0 3.170098139548827e-08
base O 0 4.385859497801903e-08
of O 0 9.85371606532226e-09
the O 0 3.8615631581251364e-08
normal O 0 3.818460925231193e-07
termination O 0 1.2375056940072682e-05
codon O 0 5.405031970440177e-06
( O 0 1.1457476603027317e-06
+ O 0 1.9097931726719253e-05
574 O 0 0.00010141868551727384
delATTCTT O 0 0.00020288731320761144
) O 0 2.3902505290607223e-06
. O 0 4.182741122349398e-06

Five O 0 5.514840086107142e-05
intragenic O 0 0.042997971177101135
dimorphisms O 0 0.012567338533699512
are O 0 6.509831678158662e-07
now O 0 4.905858190795698e-07
well O 0 1.5254204299708363e-07
characterized O 0 7.092312444001436e-06
and O 0 9.746743501182209e-08
the O 0 3.2827024654125125e-08
high O 0 1.688128890009466e-07
degree O 0 8.302366438783793e-08
of O 0 4.163170075344169e-08
allelic O 0 6.282824324443936e-05
heterogeneity O 0 0.00017221287998836488
in O 0 7.402221058327996e-07
HC B-Disease 1 0.6722895503044128
is O 0 2.504425538063515e-07
demonstrated O 0 4.298634905808285e-07
with O 0 3.563353345725773e-08
seven O 0 6.794351037342494e-08
new O 0 5.643878253636103e-08
different O 0 1.4130581149629506e-08
mutations O 0 8.089446623671392e-07
making O 0 9.115145083171683e-09
a O 0 7.774203503174704e-09
total O 0 1.3270250676100659e-08
of O 0 2.610259208779553e-08
nineteen O 0 2.313793856956181e-06
CPO O 0 0.0027175997383892536
gene B-Disease 0 0.00019564837566576898
defects I-Disease 0 0.24927504360675812
reported O 0 2.869771378755104e-06
so O 0 1.510734506382505e-07
far O 0 3.185235755154281e-07
. O 0 5.167564722796669e-07
. O 0 3.7392060221463908e-06

Coincidence O 0 0.00010491208377061412
of O 0 2.2893116238265065e-06
two O 0 9.065937547347858e-07
novel O 0 1.0571882739895955e-05
arylsulfatase O 0 0.0009567281231284142
A O 0 8.606195933680283e-07
alleles O 0 1.8447744878358208e-06
and O 0 1.9329790745814535e-07
mutation O 0 3.378208248250303e-06
459 O 0 1.9318476915941574e-05
+ O 0 1.7908643712871708e-05
1G O 0 0.00022508193796966225
> O 0 1.4492637092189398e-05
A O 0 4.393009334080489e-08
within O 0 2.1379785053454725e-08
a O 0 6.42989164134633e-08
family O 0 2.2606559468840715e-06
with O 0 5.029208296036813e-06
metachromatic B-Disease 1 0.9962759017944336
leukodystrophy I-Disease 1 0.9961193799972534
: O 0 2.0333275188022526e-06
molecular O 0 2.9404407086985884e-06
basis O 0 1.6003275504772319e-07
of O 0 4.392431662836316e-07
phenotypic O 0 5.8208162954542786e-05
heterogeneity O 0 0.0008410720620304346
. O 0 1.5603751307935454e-05

In O 0 7.303612619580235e-06
a O 0 2.387384711255436e-06
family O 0 4.487295882427134e-06
with O 0 6.20882246948895e-07
three O 0 8.206836241697602e-07
siblings O 0 0.0001752404059516266
, O 0 3.008387068348384e-07
one O 0 7.41398480386124e-08
developed O 0 1.0994731383107137e-06
classical O 0 1.84571410954959e-06
late O 0 4.389054811326787e-05
infantile O 1 0.994401752948761
metachromatic B-Disease 1 0.9998623132705688
leukodystrophy I-Disease 1 0.9999032020568848
( O 0 0.0001898411865113303
MLD B-Disease 1 0.9964377880096436
) O 0 3.124416252830997e-06
, O 0 8.039026511141856e-07
fatal O 0 0.00013972385204397142
at O 0 7.134584052437276e-07
age O 0 8.795451549303834e-07
5 O 0 3.600224260935647e-07
years O 0 2.2261272647483565e-07
, O 0 1.4718183649620187e-07
with O 0 8.084687692644366e-07
deficient O 0 0.009812494739890099
arylsulfatase O 0 0.002877636346966028
A O 0 5.549255206460657e-07
( O 0 7.745019274807419e-07
ARSA O 0 0.002096849260851741
) O 0 7.137633417642064e-08
activity O 0 9.090701524883116e-08
and O 0 6.155501353077852e-08
increased O 0 6.027872245795152e-07
galactosylsulfatide O 0 0.0011625881306827068
( O 0 4.3506270230864175e-06
GS O 0 0.08889306336641312
) O 0 2.310548097739229e-06
excretion O 0 1.8498642020858824e-05
. O 0 4.5158662942412775e-06

The O 0 6.435606337618083e-06
two O 0 1.0488024599908385e-06
other O 0 5.008737389289308e-07
siblings O 0 0.00013655293150804937
, O 0 9.939755045706988e-07
apparently O 0 1.4678781781185535e-06
healthy O 0 1.3818572597301682e-06
at O 0 1.0392923144308952e-07
12 O 0 9.356900676493751e-08
( O 0 5.3445255332462693e-08
1 O 0 1.2945838534506038e-07
/ O 0 7.169046057242667e-06
2 O 0 1.9999455957986356e-07
) O 0 3.2361391788526817e-08
and O 0 1.7410043184895585e-08
15 O 0 4.712903489689779e-08
years O 0 7.598811890829893e-08
, O 0 6.032770727415482e-08
respectively O 0 2.894310853207571e-07
, O 0 3.8254437839668753e-08
and O 0 4.0733755923838544e-08
their O 0 7.002503110697944e-08
father O 0 4.803145202458836e-06
, O 0 2.682949116206146e-07
apparently O 0 4.70159505994161e-07
healthy O 0 4.843101919504988e-07
as O 0 1.3014797239918607e-08
well O 0 2.008559718547076e-08
, O 0 5.312248063660263e-08
presented O 0 4.4833510060016124e-07
ARSA O 0 0.005641825497150421
and O 0 3.1156039881352626e-07
GS O 0 0.00820548553019762
values O 0 1.1022095236512541e-07
within O 0 4.076282422715849e-08
the O 0 5.1990870275631096e-08
range O 0 3.9071011315172655e-07
of O 0 3.0450644317170372e-06
MLD B-Disease 1 0.9988308548927307
patients O 0 0.0033818024676293135
. O 0 1.3054934242973104e-05

Mutation O 0 0.001065169577486813
screening O 0 5.94311895838473e-05
and O 0 9.275594266000553e-07
sequence O 0 1.0819568387887557e-06
analysis O 0 6.960317477933131e-07
disclosed O 0 4.553915459837299e-06
the O 0 5.1894371466687517e-08
involvement O 0 4.12299215213352e-07
of O 0 3.23405977553648e-08
three O 0 7.810799473872976e-08
different O 0 1.128345559209265e-07
ARSA O 1 0.6501421928405762
mutations O 0 1.3062744073977228e-05
being O 0 2.5851832674561592e-08
the O 0 2.0533773792408283e-08
molecular O 0 7.552666261290142e-07
basis O 0 6.932428675554547e-08
of O 0 4.267457143214415e-07
intrafamilial O 0 0.0028580431826412678
phenotypic O 0 7.655324588995427e-05
heterogeneity O 0 0.0004799223970621824
. O 0 1.4213142094376963e-05

The O 0 2.5563856979715638e-05
late O 0 0.00030907883774489164
infantile O 1 0.9980332255363464
patient O 0 0.454662561416626
inherited O 0 0.0700213834643364
from O 0 8.162135145539651e-07
his O 0 1.0975278428304591e-06
mother O 0 1.3325525287655182e-05
the O 0 6.994854118147487e-08
frequent O 0 1.122591925195593e-06
0 O 0 4.1545745261828415e-06
- O 0 0.0001948874705703929
type O 0 5.265102572593605e-06
mutation O 0 1.8581299627840053e-06
459 O 0 6.8465169533737935e-06
+ O 0 1.073429848474916e-05
1G O 0 9.705282718641683e-05
> O 0 1.2770399735018145e-05
A O 0 4.410270548760309e-08
, O 0 1.4705142881155098e-08
and O 0 1.0011983242463884e-08
from O 0 1.440246766293285e-08
his O 0 1.0240776759928849e-07
father O 0 8.308645647048252e-07
a O 0 5.313190243327881e-08
novel O 0 4.1583263055144926e-07
, O 0 4.409816511952158e-08
single O 0 1.1700934265945762e-07
basepair O 0 6.220833165571094e-05
microdeletion O 0 8.846380296745338e-06
of O 0 2.481508332152771e-08
guanine O 0 8.730117997401976e-07
at O 0 7.473387597656256e-08
nucleotide O 0 4.6919873852857563e-07
7 O 0 1.8328833562009095e-07
in O 0 5.776396960754937e-08
exon O 0 1.1437866305641364e-05
1 O 0 1.7415876527593355e-06
( O 0 1.5403238649014384e-06
7delG O 0 0.00022032887500245124
) O 0 2.5677827579784207e-06
. O 0 3.5310615658090683e-06

The O 0 1.3457384739012923e-05
two O 0 3.8022863009246066e-06
clinically O 0 0.0005046225269325078
unaffected O 0 0.00038774253334850073
siblings O 0 0.0001254115195479244
carried O 0 7.189958068920532e-07
the O 0 2.8025371534567967e-07
maternal O 0 6.598565960302949e-05
mutation O 0 8.530426384822931e-06
459 O 0 4.123385951970704e-05
+ O 0 4.434728543856181e-05
1G O 0 0.00018306434503756464
> O 0 1.5076591807883233e-05
A O 0 5.651267898088008e-08
and O 0 1.8432354309538823e-08
, O 0 1.4771935674673387e-08
on O 0 1.4535430636897217e-08
their O 0 2.820350353260892e-08
paternal O 0 4.734265075967414e-06
allele O 0 3.161246979743737e-07
, O 0 1.9146446206264045e-08
a O 0 1.1159314361464112e-08
novel O 0 1.093406822860743e-07
cytosine O 0 3.932502181669406e-07
to O 0 1.717494590991464e-08
thymidine O 0 1.0752972912086989e-06
transition O 0 1.211616762475387e-07
at O 0 3.035447804222713e-08
nucleotide O 0 4.898948304798978e-07
2435 O 0 1.534440161776729e-05
in O 0 2.9520847988351306e-08
exon O 0 3.474061031738529e-06
8 O 0 1.803758209462103e-07
, O 0 3.255715341765608e-08
resulting O 0 5.8033425176517994e-08
in O 0 1.4748709808998228e-08
substitution O 0 4.135375775149441e-08
of O 0 5.2415831675034497e-08
alanine O 0 2.6974495995091274e-05
464 O 0 1.9757042537094094e-05
by O 0 6.831671157669916e-07
valine O 0 0.00021056216792203486
( O 0 3.4547824725450482e-06
A464V O 0 0.00018128909869119525
) O 0 2.8923786885570735e-06
. O 0 3.4258223422511946e-06

The O 0 5.971347854938358e-05
fathers O 0 0.00029199241544120014
genotype O 0 0.0012041865848004818
thus O 0 1.150871321442537e-05
was O 0 7.669198566873092e-06
7delG O 0 0.0026164837181568146
/ O 0 0.0017962977290153503
A464V O 0 0.0020125294104218483
. O 0 2.6811308998730965e-05

Mutation O 0 0.007497604005038738
A464V O 0 0.012766066938638687
was O 0 3.830719833786134e-06
not O 0 2.0606226769359637e-07
found O 0 1.6475001984872506e-07
in O 0 1.9209733181924094e-07
18 O 0 6.626702543144347e-06
unrelated O 0 0.001861173426732421
MLD B-Disease 1 0.9999074935913086
patients O 0 0.0014259128365665674
and O 0 5.078665026303497e-07
50 O 0 9.329577892458474e-07
controls O 0 7.100006314431084e-06
. O 0 5.5577097555215005e-06

A464V O 0 0.008872189559042454
, O 0 1.3762109119852539e-05
although O 0 1.9707381397893187e-06
clearly O 0 2.1177702365093865e-06
modifying O 0 1.895852983579971e-05
ARSA O 0 0.1480693370103836
and O 0 5.357780992198968e-06
GS O 1 0.9774070978164673
levels O 0 1.220294780068798e-05
, O 0 4.89098397338239e-07
apparently O 0 1.4085959492149414e-06
bears O 0 6.550849775521783e-06
little O 0 1.0644859003150486e-06
significance O 0 1.5429054656124208e-06
for O 0 5.218385012994986e-07
clinical O 0 0.00015006073226686567
manifestation O 0 5.824181062052958e-05
of O 0 2.0562736153806327e-06
MLD B-Disease 1 0.9979567527770996
, O 0 2.1386613298091106e-06
mimicking O 0 6.853008380858228e-05
the O 0 1.3190026493248297e-06
frequent O 0 4.5013071940047666e-05
ARSA O 0 0.22341503202915192
pseudodeficiency O 0 0.0027318578213453293
allele O 0 3.7595695175696164e-05
. O 0 1.1328214895911515e-05

Our O 0 3.7639852962456644e-05
results O 0 1.9766976038226858e-05
demonstrate O 0 4.09597987527377e-06
that O 0 1.9693075614668487e-07
in O 0 1.2014074002308917e-07
certain O 0 3.718927814588824e-07
genetic O 0 0.00023262891045305878
conditions O 0 0.0009671535808593035
MLD B-Disease 1 0.9912864565849304
- O 0 0.005046158563345671
like O 0 1.5828352843527682e-05
ARSA O 0 0.0830308198928833
and O 0 6.10118945587601e-07
GS O 0 0.06552832573652267
values O 0 2.578858016022423e-07
need O 0 1.351174176988934e-07
not O 0 1.102722180235105e-08
be O 0 1.080869793668171e-08
paralleled O 0 7.144747996790102e-06
by O 0 3.025545993295964e-06
clinical O 0 0.16124534606933594
disease O 0 0.4307691752910614
, O 0 4.581247878832073e-07
a O 0 1.9905647263840365e-07
finding O 0 2.5486824597464874e-06
with O 0 3.2729174108681036e-06
serious O 0 0.00023646927729714662
diagnostic O 0 0.006275404244661331
and O 0 2.5194360205205157e-05
prognostic O 0 0.3899989724159241
implications O 0 0.0006418252014555037
. O 0 2.4615535949124023e-05

Moreover O 0 0.0002385737607255578
, O 0 7.754576472507324e-06
further O 0 5.818487352371449e-06
ARSA O 0 0.1726861447095871
alleles O 0 2.2682863345835358e-05
functionally O 0 9.64906212175265e-06
similar O 0 4.697480733284465e-07
to O 0 2.865653243588895e-07
A464V O 0 0.0001848654355853796
might O 0 3.847216589747404e-07
exist O 0 8.373501714231679e-08
which O 0 1.1567985680471793e-08
, O 0 1.2421885742242011e-08
together O 0 2.7780869160665134e-08
with O 0 9.732272587825719e-08
0 O 0 3.803489016718231e-05
- O 0 0.1442716419696808
type O 0 0.000433238543337211
mutations O 0 0.00011175245890626684
, O 0 1.110645143853617e-06
may O 0 9.440359463042114e-06
cause O 0 3.6261382774682716e-05
pathological O 0 0.0011588301276788116
ARSA O 1 0.6429550647735596
and O 0 3.1018676054372918e-06
GS O 1 0.9612598419189453
levels O 0 3.0412336400331696e-06
, O 0 1.4252610469611682e-07
but O 0 1.0683673679068306e-07
not O 0 2.1031692654105427e-07
clinical O 0 0.00019476354646030813
outbreak O 0 0.000218965535168536
of O 0 4.716576995633659e-07
the O 0 2.2314836314762942e-05
disease O 1 0.7579503655433655
. O 0 3.236638349335408e-06
. O 0 7.977615496201906e-06

Human O 0 0.18065495789051056
MLH1 O 1 0.9969542026519775
deficiency O 1 0.999617338180542
predisposes O 1 0.9908058047294617
to O 0 0.001573871704749763
hematological B-Disease 1 0.9982398748397827
malignancy I-Disease 1 0.9983394145965576
and O 0 0.0006842120201326907
neurofibromatosis B-Disease 1 0.9994195699691772
type I-Disease 0 0.0006546083022840321
1 I-Disease 0 3.892821405315772e-05
. O 0 2.2147982235765085e-05

Heterozygous O 0 0.0006787319434806705
germ O 0 0.009877821430563927
- O 0 0.002852702047675848
line O 0 3.3798471122281626e-05
mutations O 0 1.5960546079440974e-05
in O 0 1.8188295314303105e-07
the O 0 2.7060914931098523e-07
DNA O 0 4.4327418436296284e-05
mismatch O 1 0.5417728424072266
repair O 1 0.568515956401825
genes O 0 3.151940109091811e-05
lead O 0 3.1298346584662795e-05
to O 0 1.1633673238975462e-05
hereditary B-Disease 1 0.970355212688446
nonpolyposis I-Disease 1 0.9996925592422485
colorectal I-Disease 1 0.9999929666519165
cancer I-Disease 1 0.9997994303703308
. O 0 0.00013569432485383004

The O 0 0.0021265875548124313
disease O 1 0.9976671934127808
susceptibility O 0 0.06737005710601807
of O 0 1.4849714489173493e-06
individuals O 0 1.5643551023458713e-06
who O 0 6.112680921432911e-07
constitutionally O 0 1.1948742439926718e-06
lack O 0 7.824172598702717e-07
both O 0 1.4470832354618324e-07
wild O 0 3.209647911717184e-05
- O 0 0.02886880189180374
type O 0 7.185676804510877e-05
alleles O 0 3.3174583222717047e-06
is O 0 3.173943525780487e-07
unknown O 0 1.846048576226167e-06
. O 0 3.323792270748527e-06

We O 0 1.7881509847939014e-05
have O 0 1.5558165387119516e-06
identified O 0 1.5327772189266398e-06
three O 0 2.836781902715302e-07
offspring O 0 4.3754675971285906e-06
in O 0 4.176320942406164e-07
a O 0 1.1646527127595618e-05
hereditary B-Disease 1 0.997685432434082
nonpolyposis I-Disease 1 0.9999794960021973
colorectal I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999929666519165
family O 0 0.0035755764693021774
who O 0 4.356811405159533e-05
developed O 0 0.0007963363896124065
hematological B-Disease 1 0.9687429666519165
malignancy I-Disease 1 0.5337703824043274
at O 0 2.4427106382063357e-07
a O 0 2.4106533658141416e-08
very O 0 3.361850886562934e-08
early O 0 2.2292054779882164e-07
age O 0 4.616959188297187e-07
, O 0 4.373863404794065e-08
and O 0 2.0891016916380067e-08
at O 0 4.1042586218509314e-08
least O 0 4.59572513378248e-09
two O 0 2.662979614598271e-09
of O 0 6.614690128969869e-09
them O 0 1.803588922655308e-08
displayed O 0 2.2057110982132144e-07
signs O 0 3.7751874515379313e-06
of O 0 2.275639644722105e-06
neurofibromatosis B-Disease 1 0.9997873902320862
type I-Disease 0 0.00013820084859617054
1 I-Disease 0 9.178210348181892e-06
( O 0 1.2446676009858493e-05
NF1 B-Disease 0 0.0112144248560071
) O 0 3.879320502164774e-06
. O 0 4.616154001269024e-06

DNA O 0 0.00010715554526541382
sequence O 0 8.640063242637552e-06
analysis O 0 1.2051120847900165e-06
and O 0 1.1639688324294184e-07
allele O 0 7.194923909992212e-07
- O 0 1.8446815374772996e-05
specific O 0 9.308730852808367e-08
amplification O 0 2.4324106107087573e-06
in O 0 4.0105454957028996e-08
two O 0 8.629819348016099e-08
siblings O 0 5.590000728261657e-05
revealed O 0 7.662210009584669e-06
a O 0 1.8551503444541595e-07
homozygous O 0 1.1717650522768963e-05
MLH1 O 0 0.0040651424787938595
mutation O 0 4.726307452074252e-06
( O 0 2.5353247679049673e-07
C676T O 0 2.2088754121796228e-05
- O 0 0.00015266450645867735
- O 0 0.0008182228193618357
> O 0 0.0006808932521380484
Arg226Stop O 0 0.0008685609791427851
) O 0 2.7436751679488225e-06
. O 0 2.7108208087156527e-06

Thus O 0 1.9723272998817265e-05
, O 0 1.9123090169159696e-06
a O 0 6.448099156841636e-07
homozygous O 0 1.4970169104344677e-05
germ O 0 0.0005557672120630741
- O 0 0.0005099075497128069
line O 0 2.5195367925334722e-05
MLH1 O 0 0.009743357077240944
mutation O 0 2.3018204956315458e-05
and O 0 3.1613328701496357e-06
consequent O 0 0.19397127628326416
mismatch O 1 0.9995608925819397
repair O 1 0.9998692274093628
deficiency O 1 0.9996681213378906
results O 0 8.021459507290274e-06
in O 0 2.098162781294377e-07
a O 0 1.6049677924456773e-06
mutator O 1 0.8872474431991577
phenotype O 0 0.04788108915090561
characterized O 0 0.002697403309866786
by O 0 4.561841342365369e-05
leukemia B-Disease 1 0.999806821346283
and O 0 6.630394636886194e-05
/ O 1 0.897374153137207
or O 0 0.0063336859457194805
lymphoma B-Disease 1 0.9999979734420776
associated O 0 0.0005317201721481979
with O 0 9.403633157489821e-05
neurofibromatosis B-Disease 1 0.9999173879623413
type I-Disease 0 0.00018078692664857954
1 I-Disease 0 4.821309175895294e-06
. O 0 1.8347403738516732e-06
. O 0 5.347541446099058e-06

Missense O 0 0.3052327036857605
mutations O 0 0.0037969942204654217
in O 0 1.5485160247408203e-06
the O 0 1.988016862242148e-07
most O 0 4.386353325003256e-08
ancient O 0 2.0550746171466017e-07
residues O 0 3.0820677920928574e-07
of O 0 2.911160201790608e-08
the O 0 1.2498297508045653e-07
PAX6 O 0 0.0022387774661183357
paired O 0 9.526784197078086e-06
domain O 0 1.0377349326518015e-06
underlie O 0 2.8906089937663637e-05
a O 0 1.9542692086815805e-07
spectrum O 0 7.434966846631141e-06
of O 0 9.151125595963094e-06
human O 0 0.047042738646268845
congenital B-Disease 1 0.9999911785125732
eye I-Disease 1 0.9997976422309875
malformations I-Disease 1 0.9997734427452087
. O 0 0.00014574314991477877

Mutations O 0 0.0007314225076697767
of O 0 1.7664679035078734e-06
the O 0 1.167963432635588e-06
human O 0 6.389087502611801e-06
PAX6 O 0 0.30521583557128906
gene O 0 0.0005147021729499102
underlie O 1 0.7764217257499695
aniridia B-Disease 1 0.9998613595962524
( O 0 0.0020452078897506
congenital B-Disease 1 0.9998805522918701
absence I-Disease 0 1.2262735253898427e-05
of I-Disease 0 2.552493754137686e-07
the I-Disease 0 2.1585781269095605e-06
iris I-Disease 1 0.5211272835731506
) O 0 2.294435034855269e-06
, O 0 2.9939076284790644e-07
a O 0 2.4196552317334863e-07
rare O 0 1.841642369981855e-05
dominant O 0 0.00042511450010351837
malformation B-Disease 1 0.9922637939453125
of I-Disease 0 7.988989523255441e-07
the I-Disease 0 5.377356046665227e-06
eye I-Disease 0 0.017445867881178856
. O 0 1.541449637443293e-05

The O 0 6.9031561906740535e-06
spectrum O 0 1.1809236639237497e-05
of O 0 2.6819564027391607e-06
PAX6 O 1 0.8758625984191895
mutations O 0 0.0013174294726923108
in O 0 2.8674745408352464e-05
aniridia B-Disease 1 0.9997606873512268
patients O 0 0.001848852727562189
is O 0 8.478898649855182e-08
highly O 0 7.93563259549046e-08
biased O 0 3.744483478840266e-07
, O 0 2.8835126286708146e-08
with O 0 3.358857725288544e-08
92 O 0 1.234300157193502e-06
% O 0 2.911032481733855e-08
of O 0 1.3922921482389938e-08
all O 0 3.547850369045591e-08
reported O 0 4.921776508126641e-06
mutations O 0 1.091641479433747e-05
leading O 0 8.302166634166497e-07
to O 0 1.1783566122858247e-07
premature O 0 1.5482943126698956e-05
truncation O 0 2.648514737302321e-06
of O 0 1.546905004090604e-08
the O 0 3.2201306510160066e-08
protein O 0 2.8583193056874734e-07
( O 0 4.224747840453347e-08
nonsense O 0 2.970957666548202e-07
, O 0 1.4345387988612401e-08
splicing O 0 1.9721039734577062e-07
, O 0 2.0330967132053956e-08
insertions O 0 6.282171511884371e-07
and O 0 2.6281437470743185e-08
deletions O 0 8.099435717667802e-07
) O 0 2.6156117272080337e-08
and O 0 6.709737210286448e-09
just O 0 9.224174313260392e-09
2 O 0 6.936132024293329e-08
% O 0 2.030453849499736e-08
leading O 0 4.722639346255164e-08
to O 0 6.384854867036438e-09
substitution O 0 1.1063753468931736e-08
of O 0 6.526326590261533e-09
one O 0 1.6037231986842926e-08
amino O 0 1.0672655292864874e-07
acid O 0 9.794355264602927e-07
by O 0 4.107226914129569e-08
another O 0 1.7729628609686188e-07
( O 0 8.034979828153155e-07
missense O 0 2.7789841624326073e-05
) O 0 1.5940884168230696e-06
. O 0 2.0558600226650015e-06

The O 0 7.872667083574925e-06
extraordinary O 0 1.1961891686951276e-05
conservation O 0 2.5201165954058524e-06
of O 0 1.356232246507716e-07
the O 0 1.7787310468975193e-07
PAX6 O 0 0.0003724002745002508
protein O 0 4.235843107380788e-07
at O 0 5.857968687905668e-08
the O 0 2.2641586383542744e-08
amino O 0 9.611076023929854e-08
acid O 0 4.859243745158892e-07
level O 0 8.355856095931813e-08
amongst O 0 2.2486014472633542e-07
vertebrates O 0 6.495657089544693e-06
predicts O 0 5.99309969402384e-05
that O 0 1.6467463126446091e-07
pathological O 0 0.00023925442656036466
missense O 0 0.0005378189962357283
mutations O 0 1.576784961798694e-05
should O 0 2.3788130576463118e-08
in O 0 2.487251471450236e-08
fact O 0 9.822045399232593e-08
be O 0 1.2830678741693191e-08
common O 0 1.7948694619462913e-07
even O 0 9.690540281326321e-08
though O 0 6.02368785962426e-08
they O 0 1.5772856798434987e-08
are O 0 2.0687007662445467e-08
hardly O 0 6.765738476133265e-07
ever O 0 4.933374384563649e-07
seen O 0 1.3383820487433695e-06
in O 0 3.925247256120201e-06
aniridia B-Disease 1 0.9986045956611633
patients O 0 0.01211363822221756
. O 0 1.4022111827216577e-05

This O 0 1.3466769814840518e-05
indicates O 0 2.61448494711658e-05
that O 0 2.083831276422643e-07
there O 0 6.427439558365222e-08
is O 0 2.4395903963636556e-08
a O 0 6.067470792459062e-08
heavy O 0 1.6772897652117535e-05
ascertainment O 0 0.00023007768322713673
bias O 0 9.195998700306518e-07
in O 0 1.902123258901156e-08
the O 0 1.765283741406165e-08
selection O 0 4.373646689259658e-08
of O 0 1.4689267402445694e-07
patients O 0 4.8324258386855945e-05
for O 0 5.07401239246974e-07
PAX6 O 0 0.16741253435611725
mutation O 0 8.14338000054704e-06
analysis O 0 1.543333780773537e-07
and O 0 2.1299316088629894e-08
that O 0 1.8391476785950545e-08
the O 0 9.749272322778779e-08
missing O 0 1.2563403288368136e-05
PAX6 O 0 0.3005397319793701
missense O 0 0.012754274532198906
mutations O 0 0.0002657732693478465
frequently O 0 4.728128715214552e-06
may O 0 5.107041943119839e-06
underlie O 0 0.0006647981936112046
phenotypes O 0 8.714493014849722e-05
distinct O 0 7.069778575896635e-07
from O 0 7.644500783499097e-07
textbook O 0 0.00028053467394784093
aniridia B-Disease 1 0.8010660409927368
. O 0 2.81214015558362e-05

Here O 0 1.92331281141378e-05
we O 0 1.4763803619644023e-06
present O 0 4.730496243610105e-07
four O 0 4.336772860824567e-07
novel O 0 9.371307896799408e-06
PAX6 O 0 0.02166394330561161
missense O 0 0.001228974317200482
mutations O 0 3.461401502136141e-05
, O 0 8.678943430595609e-08
two O 0 3.0200055789464386e-08
in O 0 1.595964107536929e-07
association O 0 5.598917141469428e-06
with O 0 3.0290248105302453e-06
atypical O 0 0.03579135239124298
phenotypes O 0 0.021467411890625954
ectopia B-Disease 0 0.4379265010356903
pupillae I-Disease 0 0.12592431902885437
( O 0 2.5970475689973682e-06
displaced B-Disease 0 6.410411515389569e-06
pupils I-Disease 0 4.126447947783163e-06
) O 0 2.740596983130672e-06
and O 0 1.9013101336895488e-05
congenital B-Disease 1 0.9999606609344482
nystagmus I-Disease 1 0.8448551297187805
( O 0 3.1715699151391163e-06
searching B-Disease 0 2.2575345610675868e-06
gaze I-Disease 0 1.1398817150620744e-05
) O 0 4.3091667123462685e-08
, O 0 1.1843576785963705e-08
and O 0 7.693823356191842e-09
two O 0 7.233318832788882e-09
in O 0 3.48064901345424e-08
association O 0 7.606343501720403e-07
with O 0 2.024474099471263e-07
more O 0 3.743216154816764e-07
recognizable O 0 0.000183162817847915
aniridia B-Disease 1 0.9936766028404236
phenotypes O 0 0.005704890005290508
. O 0 1.6640053217997774e-05

Strikingly O 0 0.0006012184894643724
, O 0 4.043025001010392e-06
all O 0 2.1657341164882382e-07
four O 0 3.7327214386095875e-07
mutations O 0 6.360793122439645e-06
are O 0 1.5431917077535218e-08
located O 0 6.363131177522519e-08
within O 0 3.036350904039864e-08
the O 0 9.981896909039278e-08
PAX6 O 0 0.0008253558189608157
paired O 0 2.063445890598814e-06
domain O 0 3.4398891557430034e-07
and O 0 5.148110204800105e-08
affect O 0 1.847769652840725e-07
amino O 0 7.231390242168345e-08
acids O 0 8.850829402717864e-08
which O 0 8.193297595937565e-09
are O 0 4.101877504325557e-09
highly O 0 2.085164396703476e-08
conserved O 0 5.831792648791634e-08
in O 0 2.0419651747261014e-08
all O 0 2.7440826499969262e-08
known O 0 5.24301299265062e-07
paired O 0 3.3248827548959525e-06
domain O 0 3.341424871905474e-06
proteins O 0 3.4131107895518653e-06
. O 0 4.7106209422054235e-06

Our O 0 1.5078591786732432e-05
results O 0 5.551268259296194e-06
support O 0 5.980426180940412e-07
the O 0 1.4033062711860111e-07
hypothesis O 0 1.159611656476045e-06
that O 0 1.3375809793103599e-08
the O 0 1.4390550973075733e-08
under O 0 2.0761005359304363e-08
- O 0 3.1588529054715764e-06
representation O 0 1.1174867609042849e-07
of O 0 2.451029672556615e-07
missense O 0 0.0036600029561668634
mutations O 0 8.098709804471582e-05
is O 0 2.543381754094298e-07
caused O 0 5.978726221655961e-06
by O 0 1.065010408751732e-07
ascertainment O 0 0.00018996647850144655
bias O 0 5.0546777856652625e-06
and O 0 1.44261449008809e-07
suggest O 0 5.371099973672244e-07
that O 0 2.4563993505921644e-08
a O 0 4.9430195048216774e-08
substantial O 0 1.2154746400483418e-06
burden O 0 1.7022506654029712e-05
of O 0 7.48270736039558e-07
PAX6 B-Disease 1 0.9746645092964172
- I-Disease 1 0.9709949493408203
related I-Disease 0 0.09326176345348358
disease I-Disease 1 0.8676192760467529
remains O 0 2.248568080176483e-06
to O 0 2.0032595671182207e-07
be O 0 1.0169245001634408e-07
uncovered O 0 2.1691914298571646e-05
. O 0 9.497977089267806e-07
. O 0 5.166222308616852e-06

The O 0 1.3181123904359993e-05
chromosomal O 0 0.001756981248036027
order O 0 1.6672605624989956e-06
of O 0 1.830324265483796e-07
genes O 0 2.395771161900484e-06
controlling O 0 6.409250090655405e-06
the O 0 2.0973324410533678e-07
major O 0 3.187267338944366e-06
histocompatibility O 0 0.05521153658628464
complex O 0 4.276230356481392e-06
, O 0 6.897674325045955e-07
properdin O 0 0.005239497404545546
factor O 0 7.3894580054911785e-06
B O 0 1.916814289870672e-05
, O 0 2.9561314818238316e-07
and O 0 1.0738020819189842e-06
deficiency B-Disease 0 0.0027422283310443163
of I-Disease 0 1.1670372224159564e-08
the I-Disease 0 1.7965302134825833e-08
second I-Disease 0 8.890793168347955e-08
component I-Disease 0 3.2808441119414056e-07
of I-Disease 0 1.53141698433501e-07
complement I-Disease 0 5.673365194525104e-06
. O 0 5.45432158105541e-06

The O 0 1.1058668860641774e-05
relationship O 0 1.2575894288602285e-05
of O 0 3.9377599136969366e-07
the O 0 2.96917590958401e-07
genes O 0 1.0378676051914226e-06
coding O 0 7.774340701871552e-06
for O 0 1.4986046892317972e-07
HLA O 0 0.0016399964224547148
to O 0 4.639889539248543e-08
those O 0 3.099351530977401e-08
coding O 0 1.2521004464360885e-06
for O 0 8.164129638998929e-08
properdin O 0 0.0003837424155790359
Factor O 0 1.3851637277184636e-06
B O 0 1.0871285667235497e-05
allotypes O 0 9.248918649973348e-05
and O 0 1.1763714979906581e-07
for O 0 3.3453807191108353e-07
deficiency B-Disease 0 0.008545735850930214
of I-Disease 0 1.1927228094066322e-08
the I-Disease 0 1.4512161250479494e-08
second I-Disease 0 4.06963245325187e-08
component I-Disease 0 8.419689123684293e-08
of I-Disease 0 2.061304016365284e-08
complement I-Disease 0 8.701350679984898e-07
( O 0 4.946504645886307e-07
C2 O 0 0.0004976693890057504
) O 0 1.0683002216183013e-07
was O 0 3.134659465331424e-08
studied O 0 9.986219851043643e-08
in O 0 5.419306248199973e-08
families O 0 1.5843976370888413e-06
of O 0 1.7595826875549392e-06
patients O 0 0.010770336724817753
with O 0 0.0002420855307718739
connective O 1 0.999896764755249
tissue O 1 0.999451220035553
disorders O 1 0.999234676361084
. O 0 0.00010138687503058463

Patients O 0 0.011668352410197258
were O 0 1.8329408248973778e-06
selected O 0 6.424596108445257e-07
because O 0 2.614275729229121e-07
they O 0 6.615474035243096e-08
were O 0 7.483229325089269e-08
heterozygous O 0 1.5164143860602053e-06
or O 0 7.756594300190045e-07
homozygous O 0 4.258293120074086e-05
for O 0 2.98243230645312e-05
C2 B-Disease 1 0.9998103976249695
deficiency I-Disease 1 0.9998456239700317
. O 0 5.874769340152852e-05

12 O 0 3.6162447941023856e-05
families O 0 6.584634775208542e-06
with O 0 1.077473484656366e-06
15 O 0 1.6167010699064122e-06
matings O 0 0.0002473352069500834
informative O 0 3.2893971365410835e-05
for O 0 6.315080099739134e-05
C2 B-Disease 1 0.9999253749847412
deficiency I-Disease 1 0.9999091625213623
were O 0 4.122793598071439e-06
found O 0 1.110938592319144e-05
. O 0 1.7293439668719657e-05

Of O 0 5.997262633172795e-06
57 O 0 1.4182947779772803e-05
informative O 0 1.0270367056364194e-05
meioses O 0 0.000629043614026159
, O 0 2.1358961532769172e-07
two O 0 4.49754686826509e-08
crossovers O 0 9.881524647425977e-07
were O 0 5.324024598962751e-08
noted O 0 1.7933433582584257e-07
between O 0 2.3216639988277166e-07
the O 0 6.932838459761115e-06
C2 B-Disease 1 0.9999221563339233
deficiency I-Disease 1 0.9998595714569092
gene O 0 4.999397333449451e-06
and O 0 8.604343548768156e-08
the O 0 1.9692662078796275e-07
HLA O 0 0.06864538043737411
- O 0 0.004360934719443321
B O 0 6.206528632901609e-05
gene O 0 4.940677058584697e-07
, O 0 1.6264076307948017e-08
with O 0 1.8247760635858867e-08
a O 0 4.005897125125557e-08
recombinant O 0 1.7200504771608394e-06
fraction O 0 5.487366934175952e-07
of O 0 2.260517248942051e-07
0 O 0 1.5157092093431856e-05
. O 0 5.860013516212348e-06

035 O 1 0.6762365698814392
. O 0 0.002677725860849023

A O 0 2.8465281502576545e-05
lod O 0 0.0018426846945658326
score O 0 1.722190972941462e-06
of O 0 1.2475659616484336e-07
13 O 0 4.3190701148887456e-07
was O 0 5.969906879954578e-08
calculated O 0 8.9425626015327e-08
for O 0 2.9659517508662248e-08
linkage O 0 1.5777974113007076e-05
between O 0 2.3510719984187745e-05
C2 B-Disease 1 0.9998959302902222
deficiency I-Disease 1 0.9998562335968018
and O 0 4.344905391917564e-06
HLA O 1 0.5806418061256409
- O 0 0.0025665690191090107
B O 0 1.6500711353728548e-05
at O 0 4.69481591380827e-08
a O 0 1.0217203971762956e-08
maximum O 0 2.0712748849405216e-08
likelihood O 0 7.201040830295824e-08
value O 0 5.102601008388774e-09
of O 0 6.541243102731187e-09
the O 0 2.4308025814434586e-08
recombinant O 0 8.538439715266577e-07
fraction O 0 3.05115833043601e-07
of O 0 1.3903037654472428e-07
0 O 0 1.4954731341276783e-05
. O 0 4.724477548734285e-06

04 O 0 0.09410367161035538
. O 0 0.0013306323671713471

18 O 0 3.605453093769029e-05
families O 0 6.548363671754487e-06
with O 0 5.902634825361019e-07
21 O 0 8.822544828035461e-07
informative O 0 1.4013445479577058e-06
matings O 0 2.3806254830560647e-05
for O 0 1.0399228500546087e-07
both O 0 2.016558227069254e-07
properdin O 0 0.0004358378064353019
Factor O 0 1.9414585494814673e-06
B O 0 6.758607014489826e-06
allotype O 0 5.368582787923515e-05
and O 0 3.879691519159678e-07
HLA O 0 0.012887273915112019
- O 0 0.0009662160882726312
B O 0 2.6022713427664712e-05
were O 0 2.3390298053982406e-07
found O 0 1.3517287698050495e-06
. O 0 4.745909791381564e-06

Of O 0 5.207987214816967e-06
72 O 0 1.573261215526145e-05
informative O 0 8.475068170810118e-06
meioses O 0 0.0010418746387585998
, O 0 5.086425289846375e-07
three O 0 2.7421947379480116e-07
recombinants O 0 0.0008022941765375435
were O 0 9.292694613804997e-08
found O 0 7.365020593397276e-08
, O 0 3.35243157678633e-08
giving O 0 6.09611134905208e-08
a O 0 4.6069967396533684e-08
recombinant O 0 2.3914135454106145e-06
fraction O 0 7.934321502034436e-07
of O 0 4.123597818761482e-07
0 O 0 3.3134980185423046e-05
. O 0 7.962937161209993e-06

042 O 0 0.13368161022663116
. O 0 0.0014320891350507736

A O 0 2.3008133211988024e-05
lod O 0 0.0007591820904053748
score O 0 7.243751838359458e-07
of O 0 5.93978661811434e-08
16 O 0 1.5268379627286777e-07
between O 0 2.226460509291428e-07
HLA O 0 0.009605360217392445
- O 0 0.0009356666705571115
B O 0 2.1045381799922325e-05
and O 0 1.452514197808341e-07
Factor O 0 8.91803324520879e-07
B O 0 1.0087966984428931e-05
allotypes O 0 7.031908171484247e-05
was O 0 6.324292201043136e-08
calculated O 0 5.030370076042345e-08
at O 0 1.1417785827916305e-08
a O 0 8.804589057831436e-09
maximum O 0 2.7681220871045298e-08
likelihood O 0 1.0244527004488191e-07
value O 0 7.921716616010599e-09
of O 0 7.47690620528374e-09
the O 0 2.5122925961795772e-08
recombinant O 0 9.655454960011411e-07
fraction O 0 3.915176591817726e-07
of O 0 2.7055804707742936e-07
0 O 0 1.6842896002344787e-05
. O 0 3.772373020183295e-06

04 O 0 0.05355053395032883
. O 0 0.0009370378102175891

A O 0 7.235995781229576e-06
crossover O 0 8.896593499230221e-06
was O 0 1.0803009899973404e-06
shown O 0 2.6095676730619743e-07
to O 0 6.174433053729445e-08
have O 0 2.130394882726705e-08
occurred O 0 8.709588428246207e-08
between O 0 4.022350452714818e-08
genes O 0 1.0847654152712494e-07
for O 0 1.589659426315393e-08
Factor O 0 2.8948215913260356e-07
B O 0 1.4096212908043526e-06
and O 0 1.1705599689548762e-07
HLA O 0 0.00832611508667469
- O 0 0.0005747023387812078
D O 0 0.0006286638672463596
, O 0 3.3046525516056136e-08
in O 0 1.7090961534904636e-08
which O 0 6.833288068719412e-08
HLA O 0 0.0010818770388141274
- O 0 0.0008311126730404794
D O 0 0.013655736111104488
segregared O 0 0.00015574975986965
with O 0 2.875840721117129e-07
HLA O 0 0.010560020804405212
- O 0 9.853065421339124e-05
A O 0 4.171493230842316e-07
and O 0 7.470543437193555e-07
B O 0 5.875660281162709e-05
. O 0 5.6256676543853246e-06

These O 0 1.0847507837752346e-05
studies O 0 8.771035936661065e-06
suggest O 0 3.1657921226724284e-06
that O 0 5.803563496442621e-08
the O 0 5.008140036011355e-08
genes O 0 2.2770130669869104e-07
for O 0 7.646266197980367e-08
Factor O 0 4.334826826379867e-06
B O 0 0.0002398363867541775
and O 0 3.383794683031738e-05
C2 B-Disease 1 0.9999278783798218
deficiency I-Disease 1 0.999771773815155
are O 0 4.4887542571814265e-08
located O 0 1.4729177166827867e-07
outside O 0 3.2970973506962764e-08
those O 0 1.4059687636347462e-08
for O 0 6.605425539873977e-08
HLA O 0 0.04407888650894165
, O 0 7.921099864915959e-08
that O 0 8.521517713688809e-09
the O 0 8.298736808853846e-09
order O 0 2.6162901178850007e-08
of O 0 2.1075315714824683e-08
genese O 0 0.00011579175043152645
is O 0 9.74750591353768e-08
HLA O 0 0.000283512519672513
- O 0 8.006715688679833e-06
A O 0 4.301611866708299e-08
, O 0 2.9022785952292907e-08
- O 0 1.0911388017120771e-05
B O 0 2.9514033030864084e-06
, O 0 5.4375291824726446e-08
- O 0 3.574429138097912e-05
D O 0 0.0009549909154884517
, O 0 2.0409923706665722e-07
Factor O 0 9.976413366530323e-07
B O 0 2.7111336748930626e-05
allotype O 0 0.004478751681745052
, O 0 2.081293860101141e-05
C2 B-Disease 1 0.9998151659965515
deficiency I-Disease 1 0.997776448726654
, O 0 9.29820771489176e-08
that O 0 1.0464168198609514e-08
the O 0 1.9785819205253574e-08
genes O 0 2.4926782771217404e-07
coding O 0 3.143942740280181e-05
for O 0 6.754096830263734e-06
C2 B-Disease 1 0.9999103546142578
deficiency I-Disease 1 0.9998028874397278
and O 0 8.838537155497761e-07
Factor O 0 2.2837903088657185e-06
B O 0 5.130385943630245e-06
allotypes O 0 1.981102286663372e-05
are O 0 5.806860325918706e-09
approximately O 0 2.0937727995828936e-08
3 O 0 5.8873606434417525e-08
- O 0 1.3490833225660026e-05
- O 0 1.9878887542290613e-05
5 O 0 3.152371732539905e-07
centimorgans O 0 1.4184435713104904e-05
from O 0 1.3730668158018489e-08
the O 0 2.8416087261007306e-08
HLA O 0 0.00022136257030069828
- O 0 1.1870388334500603e-05
A O 0 7.976468907600065e-08
and O 0 1.6590176699082804e-07
HLA O 0 0.011314432136714458
- O 0 0.0007041294011287391
B O 0 3.53524083038792e-05
loci O 0 1.0154528808925534e-06
, O 0 1.441120556222586e-08
and O 0 1.2590601450312988e-08
that O 0 9.259287558904816e-09
the O 0 1.87233357706873e-08
apparent O 0 8.863953553372994e-07
lack O 0 1.554100776957057e-07
of O 0 2.1385085702263495e-08
recombinants O 0 0.0001776685385266319
between O 0 8.952853391974713e-08
the O 0 8.461063316644868e-08
Factor O 0 9.369497320221853e-07
B O 0 2.6932442779070698e-05
gene O 0 8.623987014289014e-06
and O 0 3.438962085056119e-05
C2 B-Disease 1 0.9999412298202515
deficiency I-Disease 1 0.9999517202377319
gene O 0 2.470817526045721e-05
suggests O 0 8.734115226616268e-07
that O 0 1.1791824405804618e-08
these O 0 5.068157893362013e-09
two O 0 1.462143561781204e-08
genes O 0 3.6491334753918636e-07
lie O 0 4.241431270202156e-06
in O 0 3.8128348478494445e-08
close O 0 2.7117414447275223e-07
proximity O 0 1.273782004318491e-06
to O 0 8.822176766898338e-08
one O 0 1.1695802726308102e-07
another O 0 7.3369642450416e-07
. O 0 4.149497726757545e-06

Distribution O 0 1.848488682298921e-05
of O 0 2.2516110220749397e-06
emerin O 0 0.0017722143093124032
and O 0 2.271353196192649e-06
lamins O 0 0.0018644328229129314
in O 0 3.561213759439852e-07
the O 0 4.148585901475599e-07
heart O 0 7.081037620082498e-05
and O 0 2.6245902517985087e-07
implications O 0 5.543343377212295e-06
for O 0 4.880816959484946e-07
Emery B-Disease 0 0.030865000560879707
- I-Disease 1 0.9768837094306946
Dreifuss I-Disease 1 0.9996161460876465
muscular I-Disease 1 0.9996758699417114
dystrophy I-Disease 1 0.9997918009757996
. O 0 0.00010569813457550481

Emerin O 0 0.006027585361152887
is O 0 2.3303871330426773e-06
a O 0 3.6704449257740634e-07
nuclear O 0 2.686992047529202e-06
membrane O 0 2.884260993596399e-06
protein O 0 3.65286950909649e-07
which O 0 3.453865460301131e-08
is O 0 2.4271146870091798e-08
missing O 0 3.5086515026705456e-07
or O 0 1.6733584118355793e-07
defective O 0 1.7328833564533852e-05
in O 0 1.1091685792052886e-06
Emery B-Disease 0 0.024621685966849327
- I-Disease 1 0.9932430386543274
Dreifuss I-Disease 1 0.9998162388801575
muscular I-Disease 1 0.9997840523719788
dystrophy I-Disease 1 0.9999145269393921
( O 0 0.00042382997344247997
EDMD B-Disease 1 0.9957879185676575
) O 0 1.2260899893590249e-05
. O 0 8.377250196645036e-06

It O 0 4.360088496468961e-06
is O 0 3.572786795302818e-07
one O 0 5.089753685183496e-08
member O 0 6.100368921124755e-08
of O 0 2.3217808120534755e-08
a O 0 9.12241802097924e-08
family O 0 4.862855007559119e-07
of O 0 2.768231013305922e-07
lamina O 1 0.6350224018096924
- O 0 0.023525744676589966
associated O 0 3.2328375709766988e-06
proteins O 0 1.0955382379052025e-07
which O 0 2.1138683692356608e-08
includes O 0 1.3482728888902784e-07
LAP1 O 0 0.0006897547864355147
, O 0 4.5609161247739394e-07
LAP2 O 0 0.0005427762516774237
and O 0 9.55917926148686e-07
lamin O 0 0.0708659216761589
B O 0 0.0007400375325232744
receptor O 0 0.00012634825543500483
( O 0 7.394272870442364e-06
LBR O 0 0.23925450444221497
) O 0 6.379327714967076e-06
. O 0 6.295057119132252e-06

A O 0 2.1915086108492687e-05
panel O 0 1.3293019947013818e-05
of O 0 1.7894702750709257e-06
16 O 0 1.1049054592149332e-05
monoclonal O 0 0.000364576349966228
antibodies O 0 3.3190357498824596e-05
( O 0 7.843148068786832e-07
mAbs O 0 0.00012147607776569203
) O 0 9.573970771725726e-08
has O 0 1.57780917220407e-08
been O 0 1.0334802347244931e-08
mapped O 0 2.043002069740396e-07
to O 0 9.659459898614386e-09
six O 0 1.322996556751832e-08
specific O 0 7.612299235404407e-09
sites O 0 1.4213865640044787e-08
throughout O 0 7.67081864694319e-09
the O 0 1.1257547782861366e-08
emerin O 0 2.8157498945802217e-06
molecule O 0 6.574881439291858e-08
using O 0 1.681784134177633e-08
phage O 0 6.565569492522627e-07
- O 0 1.8200404383605928e-06
displayed O 0 7.769122589706967e-08
peptide O 0 1.6111680167796294e-07
libraries O 0 4.9407386626398875e-08
and O 0 1.6338697506057542e-08
has O 0 1.3060079240290179e-08
been O 0 7.403919699555672e-09
used O 0 1.8448110594704303e-08
to O 0 6.047724809832289e-08
localize O 0 4.655228622141294e-05
emerin O 0 0.0005751216085627675
in O 0 2.7106864308734657e-07
human O 0 1.1257567393840873e-06
and O 0 2.7367968868929893e-06
rabbit O 0 0.013154363259673119
heart O 0 0.0015244190581142902
. O 0 1.0030266821559053e-05

Several O 0 2.5759951313375495e-05
mAbs O 0 0.000842435983940959
against O 0 6.0988199948042165e-06
different O 0 5.432578404906963e-07
emerin O 0 0.0018807592568919063
epitopes O 0 0.0005850674351677299
did O 0 7.84549683885416e-07
not O 0 5.5615945626641405e-08
recognize O 0 5.151577511242067e-07
intercalated O 0 5.255510768620297e-05
discs O 0 4.565595645544818e-06
in O 0 1.8816547253663884e-07
the O 0 6.534399972224492e-07
heart O 0 0.00021659568301402032
, O 0 1.8145605906738638e-07
though O 0 9.53489944777175e-08
they O 0 2.9129710199526926e-08
recognized O 0 1.7550449626924092e-07
cardiomyocyte O 0 0.00012793326459359378
nuclei O 0 1.909307684400119e-06
strongly O 0 7.003451685250184e-08
, O 0 1.421589868044748e-08
both O 0 7.043906791182053e-09
at O 0 2.309793067922783e-08
the O 0 1.4850187746162646e-08
rim O 0 4.061307663505431e-06
and O 0 4.406461329153899e-08
in O 0 1.0132980321486684e-07
intranuclear O 0 0.0002495137741789222
spots O 0 2.1009852844144916e-06
or O 0 3.477395011941553e-07
channels O 0 2.465085799485678e-06
. O 0 3.5527709769667126e-06

A O 0 0.00014408334391191602
polyclonal O 0 0.008182166144251823
rabbit O 0 0.00809496734291315
antiserum O 0 0.005520775448530912
against O 0 3.1977997423382476e-05
emerin O 0 0.0014144063461571932
did O 0 1.1537299542396795e-06
recognize O 0 4.079697930592374e-07
both O 0 3.9383191818842533e-08
nuclear O 0 3.6869687392027117e-07
membrane O 0 5.424755613603338e-07
and O 0 3.8212437658557974e-08
intercalated O 0 6.533205578307388e-06
discs O 0 1.323341962233826e-06
but O 0 3.099239265225151e-08
, O 0 2.1739674949117216e-08
after O 0 4.55151756284522e-08
affinity O 0 3.176259895099065e-07
purification O 0 1.2868173371316516e-06
against O 0 5.157702531732866e-08
a O 0 1.2593338816202504e-08
pure O 0 1.1441191816174978e-07
- O 0 5.1578175771282986e-05
emerin O 0 6.975646101636812e-05
band O 0 1.804654630177538e-07
on O 0 1.1286851453462532e-08
a O 0 1.1694504031822817e-08
western O 0 1.2032788276883366e-07
blot O 0 5.92271208006423e-05
, O 0 4.6203901149510784e-08
it O 0 2.312283520211622e-08
stained O 0 9.368127393827308e-06
only O 0 2.4980247204098305e-08
the O 0 1.4719671526108868e-07
nuclear O 0 8.31286706670653e-06
membrane O 0 3.499881495372392e-05
. O 0 6.3632510318711866e-06

These O 0 1.0707644833019003e-05
results O 0 9.858315024757758e-06
would O 0 2.481400258602662e-07
not O 0 3.8250497880198964e-08
be O 0 1.3290438971580443e-08
expected O 0 8.796267536581581e-08
if O 0 6.777860761530974e-08
immunostaining O 0 7.434259896399453e-05
at O 0 2.5338721343359794e-07
intercalated O 0 4.239613190293312e-05
discs O 0 4.6014120016479865e-06
were O 0 4.866069502895698e-08
due O 0 1.3792067932172358e-07
to O 0 9.377049359216016e-09
a O 0 8.314675170595365e-09
product O 0 2.3678854432773733e-08
of O 0 9.988521121329086e-09
the O 0 8.485596225682457e-08
emerin O 0 0.0007364211487583816
gene O 0 1.926313416333869e-06
and O 0 9.859660110578261e-08
, O 0 6.836755517269921e-08
therefore O 0 2.6177678691396977e-08
, O 0 1.939025295882857e-08
cast O 0 6.759657367183536e-08
some O 0 8.386060734721923e-09
doubt O 0 2.0272928225040232e-07
upon O 0 2.993829895103772e-08
the O 0 8.878591728489482e-08
hypothesis O 0 2.4271683287224732e-05
that O 0 5.4135903155838605e-06
cardiac B-Disease 1 0.9498370885848999
defects I-Disease 1 0.6889956593513489
in O 0 1.2395196790748741e-05
EDMD B-Disease 1 0.99953293800354
are O 0 9.879950084723532e-07
caused O 0 2.578630119387526e-05
by O 0 1.3267825238472142e-07
absence O 0 1.0740715197243844e-06
of O 0 3.0170494369485823e-07
emerin O 0 0.000977837946265936
from O 0 1.1888307653862284e-06
intercalated O 0 0.00040942206396721303
discs O 0 5.981857611914165e-05
. O 0 1.1379300303815398e-05

Although O 0 5.767408583778888e-05
emerin O 0 0.0031015907879918814
was O 0 1.497186303822673e-06
abundant O 0 6.28481416242721e-07
in O 0 5.3106980146822025e-08
the O 0 4.22937596056272e-08
membranes O 0 3.2022328468883643e-06
of O 0 1.0804950534293312e-07
cardiomyocyte O 0 0.0016229485627263784
nuclei O 0 1.2597763088706415e-05
, O 0 9.60799653171307e-08
it O 0 1.3505784934864096e-08
was O 0 1.6585994799811488e-08
absent O 0 6.789169759713332e-08
from O 0 9.512371335063108e-09
many O 0 1.1910223918221163e-08
non O 0 5.199974566494348e-07
- O 0 0.0022902546916157007
myocyte O 0 0.06895213574171066
cells O 0 5.765356945630629e-06
in O 0 1.7897673387778923e-07
the O 0 7.992974815351772e-07
heart O 0 0.000442594027845189
. O 0 9.840899110713508e-06

This O 0 3.5830644264933653e-06
distribution O 0 3.004627842528862e-06
of O 0 5.777481533186801e-07
emerin O 0 0.0008248707163147628
was O 0 2.2937823018764902e-07
similar O 0 1.0172252018492145e-07
to O 0 3.217325073023858e-08
that O 0 1.744035316164627e-08
of O 0 4.166204448097233e-08
lamin O 0 0.0010874029248952866
A O 0 3.5871906334250525e-07
, O 0 9.882856488729885e-08
a O 0 7.44516057693545e-08
candidate O 0 3.1134771916185855e-07
gene O 0 5.941066092418623e-07
for O 0 5.122388913036957e-08
an O 0 1.9518087412961904e-07
autosomal O 0 0.00013887548993807286
form O 0 1.0121890454684035e-06
of O 0 2.748719225564855e-06
EDMD B-Disease 1 0.9844129681587219
. O 0 2.9292674298631027e-05

In O 0 1.7725156794767827e-05
contrast O 0 5.296126983012073e-05
, O 0 8.693937161297072e-06
lamin O 0 0.3100700378417969
B1 O 1 0.7086106538772583
was O 0 1.073086650649202e-06
absent O 0 9.01887062809692e-07
from O 0 1.4163654782350932e-07
cardiomyocyte O 0 0.0007071266300044954
nuclei O 0 1.1233631084905937e-05
, O 0 2.0812136369841028e-07
showing O 0 1.453144818697183e-06
that O 0 3.9333122003881726e-07
lamin O 0 0.19292111694812775
B1 O 0 0.30881208181381226
is O 0 6.177742761792615e-08
not O 0 1.1390160814528372e-08
essential O 0 1.680264460901526e-08
for O 0 8.647181637400081e-09
localization O 0 3.5052835301030427e-07
of O 0 9.447894910863397e-08
emerin O 0 0.00038237645640037954
to O 0 2.161380479037689e-07
the O 0 4.42092073171807e-07
nuclear O 0 1.9653143681352958e-05
lamina O 0 0.010504508391022682
. O 0 1.6076506653917022e-05

Lamin O 1 0.9824778437614441
B1 O 1 0.9939129948616028
is O 0 7.513759555877186e-06
also O 0 9.665008064985159e-07
almost O 0 3.78413773205466e-07
completely O 0 1.2143959793320391e-06
absent O 0 5.8916289162880275e-06
from O 0 1.9101307771052234e-06
skeletal O 0 0.22754819691181183
muscle O 0 0.016015764325857162
nuclei O 0 0.0006106868968345225
. O 0 2.496332672308199e-05

In O 0 4.6564451622543857e-05
EDMD B-Disease 1 0.8509396910667419
, O 0 1.4074880709813442e-06
the O 0 1.6593041607393388e-07
additional O 0 1.2363977930363035e-07
absence O 0 6.23606581484637e-07
of O 0 2.689268683297996e-07
lamin O 1 0.7719585299491882
B1 O 1 0.9729573726654053
from O 0 4.007512416137615e-06
heart O 0 0.0025666237343102694
and O 0 4.558921318675857e-06
skeletal O 0 0.2651183605194092
muscle O 0 0.0033944130409508944
nuclei O 0 3.906607162207365e-05
which O 0 1.5381351659016218e-07
already O 0 6.514719075312314e-07
lack O 0 3.7258998872857774e-06
emerin O 0 0.005282445810735226
may O 0 5.643258873533341e-07
offer O 0 4.9362547827058734e-08
an O 0 1.1691181356354718e-08
alternative O 0 4.357409721933436e-08
explanation O 0 1.0005476269725477e-07
of O 0 3.608934662224783e-08
why O 0 8.937547590903705e-07
these O 0 6.184250622709442e-08
tissues O 0 5.978738045087084e-06
are O 0 6.290559184662925e-08
particularly O 0 1.3019511015954777e-06
affected O 0 3.581134478736203e-06
. O 0 9.77192598838883e-07
. O 0 4.006648850918282e-06

Genetic O 0 0.0009156687883660197
mapping O 0 5.5383668950526044e-05
of O 0 1.4505181979984627e-06
the O 0 1.5849824421820813e-06
copper B-Disease 0 0.0005409216391853988
toxicosis I-Disease 0 0.1672024130821228
locus O 0 2.4897635739762336e-05
in O 0 4.1627703240010305e-07
Bedlington O 0 0.0009197008912451565
terriers O 0 0.0034055921714752913
to O 0 9.050941116583999e-07
dog O 0 7.807476504240185e-05
chromosome O 0 4.2731579014798626e-05
10 O 0 9.764104191845036e-08
, O 0 3.5106388907024666e-08
in O 0 2.6561329136143286e-08
a O 0 1.0060531252520377e-07
region O 0 8.727140084374696e-06
syntenic O 0 0.005347248632460833
to O 0 6.280793627411185e-07
human O 0 1.3924561699241167e-06
chromosome O 0 3.7507707020267844e-05
region O 0 5.203087766858516e-06
2p13 O 0 0.000258188258158043
- O 0 0.0004623137356247753
p16 O 0 0.00012332704500295222
. O 0 5.609981144516496e-06

Abnormal O 1 0.986407995223999
hepatic B-Disease 1 0.9986459612846375
copper I-Disease 1 0.8427443504333496
accumulation I-Disease 0 0.2473982870578766
is O 0 3.2398993425886147e-06
recognized O 0 2.121386614817311e-06
as O 0 1.1237734725000337e-06
an O 0 1.549425724078901e-05
inherited B-Disease 1 0.9999220371246338
disorder I-Disease 1 0.9999146461486816
in O 0 4.150906988797942e-06
man O 0 2.727866558416281e-05
, O 0 2.6096724923263537e-06
mouse O 0 0.0001549464650452137
, O 0 1.678365492807643e-06
rat O 0 0.0012619231129065156
and O 0 1.607873969078355e-06
dog O 0 0.0001631930936127901
. O 0 7.985174306668341e-06

The O 0 2.8969947379664518e-05
major O 0 7.612751505803317e-05
cause O 0 0.00011391928273951635
of O 0 2.6814448119694134e-06
hepatic B-Disease 1 0.9720921516418457
copper I-Disease 0 0.17238616943359375
accumulation I-Disease 0 0.006362856365740299
in O 0 6.100759151195234e-07
man O 0 4.495344001043122e-06
is O 0 1.0484090040563387e-07
a O 0 4.419360664087435e-07
dysfunctional O 0 0.028640050441026688
ATP7B O 1 0.7679170966148376
gene O 0 0.00014960512635298073
, O 0 1.0179905075347051e-05
causing O 0 0.011603254824876785
Wilson B-Disease 0 0.157944455742836
disease I-Disease 1 0.9468831419944763
( O 0 4.0198981878347695e-05
WD B-Disease 1 0.9871830940246582
) O 0 5.293215508572757e-06
. O 0 5.196724941924913e-06

Mutations O 0 0.0027420290280133486
in O 0 3.370208787600859e-06
the O 0 1.502869736214052e-06
ATP7B O 0 0.011506825685501099
genes O 0 3.7722650176874595e-06
have O 0 8.317629607290655e-08
also O 0 5.714394646361143e-08
been O 0 4.629264083177986e-08
demonstrated O 0 4.1915754422916507e-07
in O 0 2.3017236117084394e-07
mouse O 0 6.1212238506414e-05
and O 0 3.910917712346418e-06
rat O 0 0.011579856276512146
. O 0 9.647525075706653e-06

The O 0 3.548176755430177e-05
ATP7B O 0 0.09021920710802078
gene O 0 6.723732076352462e-05
has O 0 3.871951435030496e-07
been O 0 8.967260356484985e-08
excluded O 0 1.7544692809678963e-07
in O 0 2.9177197546914613e-08
the O 0 4.8220723414260647e-08
much O 0 1.907138909018613e-07
rarer O 0 7.251499482663348e-05
human O 0 1.7520595065434463e-05
copper B-Disease 1 0.6451160311698914
overload I-Disease 1 0.9960783123970032
disease O 0 0.3523375689983368
non B-Disease 0 6.5709591581253335e-06
- I-Disease 0 0.04743412509560585
Indian I-Disease 0 0.0011508611496537924
childhood I-Disease 1 0.8850032687187195
cirrhosis I-Disease 1 0.9963735938072205
, O 0 9.444375791645143e-06
indicating O 0 0.0001291719381697476
genetic O 0 0.0005096634849905968
heterogeneity O 0 0.0018766248831525445
. O 0 2.226810647698585e-05

By O 0 4.2259052861481905e-05
investigating O 0 0.00030068657360970974
the O 0 1.7035108612617478e-05
common O 0 0.0006331666954793036
autosomal O 1 0.9805994033813477
recessive O 1 0.9893584251403809
copper B-Disease 1 0.9846104383468628
toxicosis I-Disease 1 0.9991673231124878
( O 0 4.745325350086205e-05
CT B-Disease 0 0.1903361678123474
) O 0 3.384217563962011e-07
in O 0 1.3145091770638828e-07
Bedlington O 0 0.0005419671651907265
terriers O 0 0.0018987256335094571
, O 0 2.2685878775519086e-07
we O 0 4.929123420538417e-08
have O 0 2.56059760062044e-08
identified O 0 7.703753368559774e-08
a O 0 2.7986157391524102e-08
new O 0 1.7859500189842947e-07
locus O 0 1.0580596608633641e-05
involved O 0 1.41866394187673e-06
in O 0 1.689134478510823e-05
progressive O 1 0.880757749080658
liver B-Disease 1 0.9999529123306274
disease I-Disease 1 0.9996365308761597
. O 0 6.123728235252202e-05

We O 0 3.2926356652751565e-05
examined O 0 5.08501470903866e-05
whether O 0 2.7938056064158445e-06
the O 0 1.6887598803805304e-06
WD B-Disease 1 0.9761945009231567
gene O 0 7.269277557497844e-05
ATP7B O 0 0.00918104499578476
was O 0 3.3352122841279197e-07
also O 0 1.1908001340543706e-07
causative O 0 2.7748312277253717e-05
for O 0 1.1267916733004313e-07
CT B-Disease 0 0.005767709109932184
by O 0 8.936834205997002e-08
investigating O 0 1.0982660114677856e-06
the O 0 1.3177023561183887e-07
chromosomal O 0 0.0004093274474143982
co O 0 6.502091855509207e-05
- O 0 3.780277620535344e-05
localization O 0 3.197063733750838e-06
of O 0 1.1454009296585355e-07
ATP7B O 0 0.0007143393740989268
and O 0 2.3418577654865658e-07
C04107 O 0 2.5759090931387618e-05
, O 0 3.055114916605817e-08
using O 0 3.9755871483748706e-08
fluorescence O 0 1.0298045935996925e-06
in O 0 1.9036281173612224e-07
situ O 0 1.4118416402197909e-05
hybridization O 0 5.549997695197817e-06
( O 0 8.523746259925247e-07
FISH O 0 2.597231059553451e-06
) O 0 1.6584276636422146e-06
. O 0 3.0075891572778346e-06

C04107 O 0 0.04882918298244476
is O 0 1.0571327948127873e-05
an O 0 1.5958194126142189e-06
anonymous O 0 8.596060979471076e-06
microsatellite O 0 0.0003678305074572563
marker O 0 5.2155981393298134e-05
closely O 0 7.302616722881794e-06
linked O 0 1.7057463992387056e-05
to O 0 2.265490593345021e-06
CT B-Disease 0 0.0843287780880928
. O 0 1.0647819181031082e-05

However O 0 2.0751322153955698e-05
, O 0 3.2241857752524083e-06
BAC O 0 0.00012158373283455148
clones O 0 4.531603190116584e-05
containing O 0 1.4204034641807084e-06
ATP7B O 0 0.00043806980829685926
and O 0 3.703789843712002e-07
C04107 O 0 6.155878509161994e-05
mapped O 0 2.205871851401753e-06
to O 0 5.013722059743486e-08
the O 0 4.9768971166486153e-08
canine O 0 3.6472622014116496e-05
chromosome O 0 2.0900535673717968e-05
regions O 0 1.071474002856121e-06
CFA22q11 O 0 0.0001815014984458685
and O 0 2.596482886474405e-07
CFA10q26 O 0 0.00012981540930923074
, O 0 8.606591705984101e-08
respectively O 0 1.6501309119121288e-07
, O 0 5.759586585440957e-08
demonstrating O 0 1.0727089829742908e-06
that O 0 4.943731255480088e-07
WD B-Disease 1 0.8486692309379578
cannot O 0 8.629964440842741e-07
be O 0 7.673587987255814e-08
homologous O 0 1.2040060937579256e-05
to O 0 1.7891049992613262e-06
CT B-Disease 0 0.053827591240406036
. O 0 1.4079597349336836e-05

The O 0 2.1747946448158473e-05
copper O 0 0.0004890140844509006
transport O 0 5.135055471328087e-05
genes O 0 1.7290767573285848e-05
CTR1 O 0 0.0029066866263747215
and O 0 1.3892092738387873e-06
CTR2 O 0 0.0018711452139541507
were O 0 7.577189364837977e-08
also O 0 4.1134907036166624e-08
excluded O 0 2.0803048528250656e-07
as O 0 2.383095676350422e-08
candidate O 0 8.315758037724663e-08
genes O 0 2.3211902089315117e-07
for O 0 7.148273795110072e-08
CT B-Disease 0 0.027272453531622887
since O 0 3.375810990746686e-07
they O 0 2.6285647436452564e-08
both O 0 5.029544425383392e-08
mapped O 0 3.076815801250632e-06
to O 0 6.283064521994675e-07
canine O 0 0.0011759995250031352
chromosome O 0 0.0004702222940977663
region O 0 4.858574175159447e-05
CFA11q22 O 0 0.009642081335186958
. O 0 1.359673206025036e-05

2 O 0 0.00022999016800895333
- O 0 0.002625951776280999
22 O 0 0.00012062685709679499
. O 0 5.502747080754489e-05

5 O 0 0.001103237853385508
. O 0 0.000324531109072268

A O 0 1.3150388440408278e-05
transcribed O 0 3.8581179978791624e-05
sequence O 0 5.2535660870489664e-06
identified O 0 5.841700954078988e-07
from O 0 3.4656842728963966e-08
the O 0 6.503179150740834e-08
C04107 O 0 7.05722050042823e-05
- O 0 5.459750536829233e-05
containing O 0 6.449525926655042e-07
BAC O 0 2.9594999432447366e-05
was O 0 6.294063581435694e-08
found O 0 2.8732792145547137e-08
to O 0 8.066949774843124e-09
be O 0 8.705100640327146e-09
homologous O 0 4.2737332250908366e-07
to O 0 1.1962632662232409e-08
a O 0 2.6202053859947227e-08
gene O 0 3.371126808815461e-07
expressed O 0 6.233324967297449e-08
from O 0 4.731439418037553e-08
human O 0 4.156209172379022e-07
chromosome O 0 2.0994884835090488e-05
2p13 O 0 0.0001816892036003992
- O 0 0.0003839817363768816
p16 O 0 1.4359576198330615e-05
, O 0 3.55236693394545e-08
a O 0 2.12827071521815e-08
region O 0 1.5900876348950987e-07
devoid O 0 3.246271944590262e-07
of O 0 2.005156929385521e-08
any O 0 6.536656371736171e-08
positional O 0 5.1348401939321775e-06
candidate O 0 2.353646550545818e-06
genes O 0 6.112609298725147e-06
. O 0 4.515379259828478e-06

Molecular O 0 0.00018960800662171096
analysis O 0 5.443783265945967e-06
of O 0 3.6506685319181997e-07
the O 0 2.0618807639039005e-07
APC B-Disease 0 8.363113011000678e-06
gene O 0 8.211125646084838e-07
in O 0 5.821967974384279e-08
205 O 0 4.547504204310826e-07
families O 0 1.3970048939881963e-07
: O 0 1.3640773488532432e-07
extended O 0 7.143025868572295e-07
genotype O 0 5.052074266131967e-05
- O 0 0.0006663059466518462
phenotype O 0 0.0001290120417252183
correlations O 0 1.2185817467980087e-05
in O 0 1.6768025545843557e-07
FAP B-Disease 0 0.0001894238666864112
and O 0 6.012484732309531e-08
evidence O 0 4.968200073562912e-08
for O 0 5.5495963380280955e-09
the O 0 8.552798469452227e-09
role O 0 3.2327090337958e-08
of O 0 2.9394653822123473e-08
APC B-Disease 0 9.71381177805597e-06
amino O 0 5.275081775835133e-07
acid O 0 9.101411706069484e-06
changes O 0 4.8599149522488005e-06
in O 0 0.00025853709666989744
colorectal B-Disease 1 0.9999961853027344
cancer I-Disease 1 0.9999617338180542
predisposition O 1 0.9035699367523193
. O 0 6.681412196485326e-05

BACKGROUND O 0 0.000555771985091269
/ O 0 0.0010980531806126237
AIMS O 0 2.9812435968779027e-05
The O 0 1.2687264643318485e-06
development O 0 8.282891940325499e-06
of O 0 0.00024154671700671315
colorectal B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9998830556869507
and O 0 9.436960226594238e-07
a O 0 1.465915318021871e-07
variable O 0 9.536351512906549e-07
range O 0 1.785061272130406e-07
of O 0 2.0590236715634092e-07
extracolonic O 0 0.050906021147966385
manifestations O 0 0.002239558147266507
in O 0 0.00013372249668464065
familial B-Disease 1 0.9999854564666748
adenomatous I-Disease 1 0.9999945163726807
polyposis I-Disease 1 0.999996542930603
( O 0 0.001044918317347765
FAP B-Disease 0 0.3210136294364929
) O 0 6.201341875566868e-07
is O 0 2.491415607153158e-08
the O 0 2.6066670599789177e-08
result O 0 7.068808827170869e-08
of O 0 2.43482105588555e-08
the O 0 1.5487123050661467e-07
dominant O 0 1.2724071893899236e-05
inheritance O 0 0.0005746564129367471
of O 0 0.0003409499768167734
adenomatous B-Disease 1 0.9999912977218628
polyposis I-Disease 1 0.9999878406524658
coli I-Disease 1 0.9996899366378784
( O 0 3.506432767608203e-05
APC B-Disease 0 0.000246577023062855
) O 0 3.065583314310061e-06
gene O 0 1.6391673852922395e-05
mutations O 0 3.673820538097061e-05
. O 0 4.212508429191075e-06

In O 0 7.659193215658888e-06
this O 0 8.928781198846991e-07
study O 0 1.3376061360759195e-06
, O 0 1.469677926024815e-07
direct O 0 1.454540807799276e-07
mutation O 0 1.1659179790513008e-06
analysis O 0 4.9693941406303566e-08
of O 0 1.4246679391760608e-08
the O 0 6.206465741342981e-08
APC B-Disease 0 1.666320713411551e-05
gene O 0 8.595171721026418e-07
was O 0 5.753745213610273e-08
performed O 0 1.0366809277684297e-07
to O 0 2.300792267817542e-08
determine O 0 2.255129913919518e-07
genotype O 0 6.555923846462974e-06
- O 0 0.00010773031681310385
phenotype O 0 1.571389839227777e-05
correlations O 0 2.564072929089889e-06
for O 0 3.5352996974324924e-08
nine O 0 3.3070014637814893e-07
extracolonic O 0 0.003280381439253688
manifestations O 0 2.0886825950583443e-05
and O 0 1.0885916168490439e-07
to O 0 7.275523472571876e-08
investigate O 0 2.3239533675223356e-06
the O 0 1.866993812882356e-07
incidence O 0 9.712234896142036e-05
of O 0 2.2178862479904637e-07
APC B-Disease 0 0.00025154772447422147
mutations O 0 1.4486570762528572e-05
in O 0 4.667152211368375e-07
non O 0 4.807604636880569e-05
- O 1 0.996893048286438
FAP O 1 0.9997113347053528
colorectal B-Disease 1 0.9999938011169434
cancer I-Disease 1 0.9996436834335327
. O 0 0.00010265321179758757

METHODS O 0 4.7075409383978695e-05
The O 0 2.333582870051032e-06
APC B-Disease 0 5.013009285903536e-05
gene O 0 5.120267815073021e-06
was O 0 2.0418237056674116e-07
analysed O 0 8.248745189121109e-07
in O 0 7.892295883493716e-08
190 O 0 1.1572584526220453e-06
unrelated O 0 7.492814802390058e-06
FAP B-Disease 0 0.0005315585876815021
and O 0 3.5727049407796585e-07
15 O 0 1.327370227954816e-06
non O 0 6.0907121223863214e-05
- O 1 0.9989895224571228
FAP O 1 0.999927282333374
colorectal B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999673366546631
patients O 0 0.0010229586623609066
using O 0 6.462325927714119e-07
denaturing O 0 0.0004875912272837013
gradient O 0 4.4433054426917806e-05
gel O 0 4.4916640035808086e-05
electrophoresis O 0 9.668183338362724e-06
, O 0 1.9857727906469336e-08
the O 0 1.1451197323708584e-08
protein O 0 9.05569237374948e-08
truncation O 0 2.9353445825108793e-06
test O 0 1.7240728311662679e-07
, O 0 3.53232039174145e-08
and O 0 3.6205729969651657e-08
direct O 0 1.8101910370660335e-07
sequencing O 0 4.562183221423766e-06
. O 0 3.255214323871769e-06

RESULTS O 0 0.0003356155939400196
Chain O 0 0.00012965344649273902
terminating O 0 5.5826811149017885e-05
signals O 0 5.170638814888662e-06
were O 0 1.7068215640847484e-07
only O 0 7.167072624270077e-08
identified O 0 1.0946960173896514e-06
in O 0 7.99922815986065e-07
patients O 0 9.704708645585924e-05
belonging O 0 2.8030901830788935e-06
to O 0 1.8913483756932692e-07
the O 0 5.026993790124834e-07
FAP B-Disease 0 0.014661801047623158
group O 0 1.626791708986275e-05
( O 0 3.33357911586063e-06
105 O 0 1.7995271264226176e-05
patients O 0 0.00011716800509020686
) O 0 4.036379323224537e-06
. O 0 5.398288521973882e-06

Amino O 0 0.00010382113396190107
acid O 0 0.00017946686421055347
changes O 0 1.7870535202746396e-06
were O 0 1.2173268260085024e-07
identified O 0 4.412807754761161e-07
in O 0 9.537099998624399e-08
four O 0 1.255848360415257e-06
patients O 0 9.796432277653366e-05
, O 0 7.245845523584649e-08
three O 0 2.735674264897625e-08
of O 0 4.117368490597073e-08
whom O 0 1.1523982266226085e-06
belonged O 0 1.3281438668855117e-06
to O 0 4.286051336066521e-08
the O 0 4.627286642744366e-08
non O 0 1.4112798680798733e-06
- O 0 0.012116961181163788
FAP O 0 0.10084563493728638
group O 0 0.00019473754218779504
of O 0 0.00046247243881225586
colorectal B-Disease 1 0.9999982118606567
cancer I-Disease 1 0.999984860420227
patients O 1 0.6979511976242065
. O 0 7.830149843357503e-05

Genotype O 0 0.22995790839195251
- O 0 0.47243234515190125
phenotype O 0 0.11961177736520767
correlations O 0 0.0017487825825810432
identified O 0 1.4480826393992174e-05
significant O 0 5.840786911903706e-07
differences O 0 1.3101517879476887e-06
in O 0 1.1820065992651507e-07
the O 0 8.955380792485812e-08
nature O 0 6.864102601866762e-07
of O 0 1.0215220669351766e-07
certain O 0 7.877044936321909e-07
extracolonic O 0 0.12769781053066254
manifestations O 0 0.000827874056994915
in O 0 1.0297661901859101e-05
FAP B-Disease 1 0.8795104622840881
patients O 0 0.0006028411444276571
belonging O 0 2.847859605026315e-06
to O 0 2.1299200625435333e-07
three O 0 5.591530225501629e-07
mutation O 0 3.722360634128563e-05
subgroups O 0 0.00017467518046032637
. O 0 1.2420306120475288e-05

CONCLUSIONS O 0 0.00013660869444720447
Extended O 0 4.33042150689289e-05
genotype O 0 0.0019288428593426943
- O 0 0.012975930236279964
phenotype O 0 0.0009021555306389928
correlations O 0 4.648432513931766e-05
made O 0 1.4491615729639307e-07
in O 0 5.8322374485442197e-08
this O 0 3.2196513899407364e-08
study O 0 6.672906920357491e-07
may O 0 4.96095594826329e-07
have O 0 2.4121250774555847e-08
the O 0 3.102409351640745e-08
potential O 0 2.1807602479384514e-07
to O 0 2.204061821942105e-08
determine O 0 3.945687154782718e-08
the O 0 5.861833241027625e-09
most O 0 8.24392998310941e-09
appropriate O 0 3.042467255909287e-08
surveillance O 0 9.065410608855018e-07
and O 0 5.146112584952789e-07
prophylactic O 0 0.0015220228815451264
treatment O 0 0.00020601287542376667
regimens O 0 0.0004006699309684336
for O 0 6.052907224329829e-07
those O 0 2.911416004280909e-06
patients O 0 0.0002991046058014035
with O 0 6.02203226662823e-06
mutations O 0 0.0005026015569455922
associated O 0 6.059171937522478e-06
with O 0 1.3541325643018354e-06
life O 0 0.00010569651931291446
threatening O 0 0.007154478225857019
conditions O 0 0.0006000212160870433
. O 0 1.67404577950947e-05

This O 0 9.399556802236475e-06
study O 0 8.216310561692808e-06
also O 0 4.1248443949370994e-07
provided O 0 2.904140217196982e-07
evidence O 0 2.805749375056621e-07
for O 0 4.2291823376672255e-08
the O 0 1.7485145065165852e-07
pathological O 0 8.893010090105236e-05
nature O 0 7.218918085527548e-07
of O 0 3.2605004918195846e-08
amino O 0 3.244616095798847e-07
acid O 0 2.1935788936389145e-06
changes O 0 1.1121772303113175e-07
in O 0 7.796867151910192e-08
APC O 0 1.0429384929011576e-05
associated O 0 2.676314920790901e-07
with O 0 5.495426691481953e-08
both O 0 1.5709856882040185e-07
FAP B-Disease 0 0.00033739127684384584
and O 0 1.1804671657955623e-06
non O 0 0.00011032170004909858
- O 1 0.999546468257904
FAP O 1 0.9999524354934692
colorectal B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.999984622001648
patients O 0 0.11483602970838547
. O 0 7.1975309765548445e-06
. O 0 1.607031299499795e-05

Inherited B-Disease 1 0.9994907379150391
colorectal I-Disease 1 0.9999669790267944
polyposis I-Disease 1 0.9999721050262451
and O 1 0.7456242442131042
cancer B-Disease 1 0.9996140599250793
risk O 0 0.00019125486142002046
of O 0 4.250779284120654e-07
the O 0 1.488616817368893e-06
APC O 0 0.00042405040585435927
I1307K O 0 0.0012184347724542022
polymorphism O 0 0.0001233530492754653
. O 0 1.0453570212121122e-05

Germ O 0 0.008509363047778606
- O 0 0.0005597854033112526
line O 0 1.1289539543213323e-05
and O 0 1.2057535059284419e-06
somatic O 0 4.706836261902936e-05
truncating O 0 0.0014638520078733563
mutations O 0 1.8320322851650417e-05
of O 0 5.938608182987082e-08
the O 0 9.475434126215987e-08
APC B-Disease 0 6.463561476266477e-06
gene O 0 3.9642296201236604e-07
are O 0 2.1204828115628516e-08
thought O 0 1.2412286309881893e-07
to O 0 3.6798658697989595e-07
initiate O 0 0.00032320775790140033
colorectal B-Disease 1 0.9999030828475952
tumor I-Disease 1 0.9577304720878601
formation O 0 0.00226734671741724
in O 0 0.0037409700453281403
familial B-Disease 1 0.9999920129776001
adenomatous I-Disease 1 0.9999983310699463
polyposis I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999960660934448
and O 0 0.000533486541826278
sporadic O 0 0.39334893226623535
colorectal O 1 0.9999668598175049
carcinogenesis O 1 0.9432388544082642
, O 0 5.531240276468452e-06
respectively O 0 1.8024486053036526e-05
. O 0 1.312193853664212e-05

Recently O 0 6.465648766607046e-05
, O 0 2.533749011490727e-06
an O 0 3.930335026325338e-07
isoleucine O 0 0.00013641758414451033
- O 0 0.00017732767446432263
- O 0 0.00028296923846937716
> O 0 8.801298099569976e-05
lysine O 0 1.0598855624266434e-05
polymorphism O 0 3.3454105050623184e-06
at O 0 3.1018950608086016e-07
codon O 0 3.1905640298646176e-06
1307 O 0 0.00015754648484289646
( O 0 4.131202615553775e-07
I1307K O 0 1.1235141755605582e-05
) O 0 3.775860335508696e-08
of O 0 8.379313243267461e-09
the O 0 4.3902286250840916e-08
APC B-Disease 0 6.567707714566495e-06
gene O 0 5.140393000147014e-07
has O 0 1.795728366005278e-08
been O 0 1.0630616387174996e-08
identified O 0 3.7846351830239655e-08
in O 0 1.1634944563354566e-08
6 O 0 3.640995487330656e-07
% O 0 6.082198211743162e-08
- O 0 4.62092793895863e-05
7 O 0 5.921223760196881e-07
% O 0 3.419700433937578e-08
of O 0 3.1915995180042955e-08
the O 0 4.357609668659279e-07
Ashkenazi O 0 0.00014176224067341536
Jewish O 0 6.764674708392704e-06
population O 0 3.216253162463545e-06
. O 0 4.92023718834389e-06

To O 0 5.3728486818727106e-05
assess O 0 0.0005320669733919203
the O 0 2.1612477212329395e-06
risk O 0 1.2533845620055217e-05
of O 0 1.5964161548254197e-07
this O 0 1.5722402224582765e-07
common O 0 1.6312001207552385e-06
APC B-Disease 0 9.325462451670319e-05
allelic O 0 0.00031057585147209466
variant O 0 9.90676780929789e-05
in O 0 1.1156238542753272e-05
colorectal O 1 0.9996236562728882
carcinogenesis O 0 0.34249359369277954
, O 0 5.10399559061625e-07
we O 0 5.0867448919689195e-08
have O 0 1.560906071063073e-08
analyzed O 0 1.0222139934512597e-07
a O 0 1.3238599549936225e-08
large O 0 7.34627718657066e-08
cohort O 0 8.128057743306272e-06
of O 0 1.6264439750557358e-07
unselected O 0 0.00033919926499947906
Ashkenazi O 0 5.21795627719257e-05
Jewish O 0 1.0209839729213854e-06
subjects O 0 1.885034635051852e-06
with O 0 1.5190215890470427e-05
adenomatous B-Disease 1 0.999846339225769
polyps I-Disease 1 0.9695435166358948
and O 0 8.634108780825045e-06
. O 0 2.9164068109821528e-05
or O 0 0.009993350133299828
colorectal B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9998944997787476
, I-Disease 0 9.246439844901033e-07
for O 0 1.4867779896121647e-07
the O 0 5.94575965351396e-07
APC O 0 0.00015097267169039696
I1307K O 0 0.0007710735080763698
polymorphism O 0 0.00010277475666953251
. O 0 7.165553142840508e-06

The O 0 1.9535887986421585e-05
APC O 0 0.00032124476274475455
I1307K O 0 0.0007698180270381272
allele O 0 1.612239793757908e-05
was O 0 4.576186825033801e-07
identified O 0 2.282224187410975e-07
in O 0 3.073256138463876e-08
48 O 0 2.6070605940731184e-07
( O 0 4.655740326597879e-08
10 O 0 1.8410885260777832e-08
. O 0 1.1814156763989558e-08
1 O 0 7.983454963778058e-08
% O 0 6.486047254838923e-08
) O 0 1.9257132066741178e-07
of O 0 4.145263687860279e-07
476 O 0 0.0018729495350271463
patients O 0 0.0022370684891939163
. O 0 1.2056537343596574e-05

Compared O 0 1.9639897800516337e-05
with O 0 5.274754926176684e-07
the O 0 1.1190715554221242e-07
frequency O 0 1.430552742931468e-07
in O 0 1.608680122444639e-08
two O 0 1.1486503304070084e-08
separate O 0 7.181728278737864e-08
population O 0 8.13748357586519e-08
control O 0 1.3644833529724565e-07
groups O 0 2.2506259966803555e-08
, O 0 3.088522504413049e-08
the O 0 4.994384994461143e-08
APC O 0 1.651763523113914e-05
I1307K O 0 9.891267109196633e-05
allele O 0 5.62976651963254e-07
is O 0 2.858116943116329e-08
associated O 0 9.284969593181813e-08
with O 0 2.9269667578546432e-08
an O 0 3.687379646066802e-08
estimated O 0 1.0267458492307924e-06
relative O 0 3.0848250389681198e-06
risk O 0 1.830338078434579e-06
of O 0 1.2628714785023476e-07
1 O 0 5.029040494264336e-06
. O 0 9.174893421004526e-06

5 O 0 0.0003101181355305016
- O 0 0.0017182602314278483
1 O 0 0.0001233382208738476
. O 0 5.9916768805123866e-05

7 O 0 0.0006622952641919255
for O 0 0.00011082486162194982
colorectal B-Disease 1 0.9997103810310364
neoplasia I-Disease 1 0.9974815249443054
( O 0 1.3449096513795666e-05
both O 0 2.156142272724537e-06
P O 0 0.1126079186797142
= O 0 0.0015754490159451962
. O 0 1.6056397953434498e-06
01 O 0 0.0008239103481173515
) O 0 3.3740934668458067e-06
. O 0 4.675791387853678e-06

Furthermore O 0 0.00011995733075309545
, O 0 3.0340870580403134e-06
compared O 0 1.9725093807210214e-06
with O 0 7.675488973291067e-07
noncarriers O 0 0.0012197908945381641
, O 0 8.696372901795257e-07
APC O 0 5.1923827413702384e-05
I1307K O 0 0.0004558125219773501
carriers O 0 4.665328106057132e-06
had O 0 1.1305116487392297e-07
increased O 0 7.562837112118359e-08
numbers O 0 7.760783660160087e-08
of O 0 2.4024924982768425e-07
adenomas B-Disease 1 0.8433874845504761
and O 0 0.0005798228085041046
colorectal B-Disease 1 0.9999946355819702
cancers I-Disease 1 0.9979415535926819
per O 0 2.8619219847314525e-06
patient O 0 0.0002667928347364068
( O 0 3.347146730448003e-06
P O 0 0.0914015993475914
= O 0 0.0005002390826120973
. O 0 2.3354010636467137e-07
03 O 0 0.00012491454253904521
) O 0 5.400711700076499e-08
, O 0 1.583498132617933e-08
as O 0 6.166791965966922e-09
well O 0 1.1242849318193748e-08
as O 0 1.697718232662737e-08
a O 0 1.202892150331536e-07
younger O 0 1.0457887583470438e-05
age O 0 7.780697160342243e-06
at O 0 1.4833543900749646e-05
diagnosis O 0 0.0668669193983078
. O 0 1.5920244550216012e-05

We O 0 2.3039245206746273e-05
conclude O 0 5.5710501328576356e-05
that O 0 8.811125553620514e-07
the O 0 6.181397225191176e-07
APC O 0 9.308386506745592e-05
I1307K O 0 0.0006961958715692163
variant O 0 2.53266825893661e-05
leads O 0 7.480326985387364e-06
to O 0 3.9405435359185503e-07
increased O 0 4.723793153971201e-06
adenoma B-Disease 1 0.8888205885887146
formation O 0 1.2455391697585583e-05
and O 0 9.438025472263689e-08
directly O 0 4.636740058572286e-08
contributes O 0 1.2337535792994458e-07
to O 0 1.5716787871156157e-08
3 O 0 5.1183651095243476e-08
% O 0 3.877208953895206e-08
- O 0 7.940483556012623e-06
4 O 0 2.3076314903391903e-07
% O 0 3.6325392471781015e-08
of O 0 4.7533291080981144e-08
all O 0 5.055932774666871e-07
Ashkenazi O 0 0.019738025963306427
Jewish O 0 0.11148550361394882
colorectal B-Disease 1 0.9999904632568359
cancer I-Disease 1 0.9997841715812683
. O 0 9.765486174728721e-05

The O 0 2.0375051462906413e-05
estimated O 0 3.252958049415611e-05
relative O 0 5.5658991186646745e-05
risk O 0 9.26996799535118e-05
for O 0 7.336656722145563e-07
carriers O 0 7.57378147682175e-05
may O 0 4.1928815335268155e-06
justify O 0 5.196368420001818e-06
specific O 0 1.1122980936306703e-07
clinical O 0 5.38398535354645e-06
screening O 0 3.81996500209425e-07
for O 0 7.771445709181535e-09
the O 0 9.98299753973697e-09
360 O 0 6.651482920005947e-08
, O 0 2.5273164894201727e-08
000 O 0 1.4481283017175883e-07
Americans O 0 1.2167846819011174e-07
expected O 0 9.695845903934242e-08
to O 0 7.772931098770641e-08
harbor O 0 1.181046445708489e-05
this O 0 1.6701386940098928e-08
allele O 0 1.6869073249381472e-07
, O 0 2.983318836413673e-08
and O 0 6.823884035611627e-08
genetic O 0 2.591868906165473e-06
testing O 0 1.0987147902596917e-07
in O 0 9.299730763245861e-09
the O 0 6.993757573070525e-09
setting O 0 2.6074577164081347e-08
of O 0 1.3523055564235165e-08
long O 0 4.911091764370212e-07
- O 0 7.45824581827037e-05
term O 0 3.005152166224434e-06
- O 0 0.0002941458369605243
outcome O 0 3.862852281599771e-06
studies O 0 1.6250141925411299e-06
may O 0 1.8690119532038807e-06
impact O 0 4.246619937475771e-06
significantly O 0 5.051539483247325e-05
on O 0 0.0018859968986362219
colorectal B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999898672103882
prevention O 0 0.029590263962745667
in O 0 1.1798820196418092e-06
this O 0 4.7563540306327923e-07
population O 0 2.9160146368667483e-06
. O 0 7.958428795973305e-06

Localization O 0 0.00020900419622194022
of O 0 4.1785665416682605e-06
human O 0 9.205894457409158e-06
BRCA1 O 0 0.00045092168147675693
and O 0 2.051424559113002e-07
its O 0 1.2981779207166255e-07
loss O 0 2.1943631509202532e-05
in O 0 7.902779941559857e-08
high O 0 7.754937882964441e-07
- O 0 9.391061757924035e-05
grade O 0 1.4532469322148245e-05
, O 0 6.170189408294391e-07
non B-Disease 0 1.5226401046675164e-05
- I-Disease 1 0.8824557662010193
inherited I-Disease 1 0.9923391342163086
breast I-Disease 1 0.9956639409065247
carcinomas I-Disease 1 0.9993785619735718
. O 0 9.5985276857391e-05

Although O 0 1.0067372386401985e-05
the O 0 1.1861616258102003e-06
link O 0 7.337212991842534e-06
between O 0 1.6107329656733782e-06
the O 0 2.541549065426807e-06
BRCA1 O 0 0.1302482634782791
tumour B-Disease 1 0.9973061084747314
- O 0 0.03545619174838066
suppressor O 0 0.0014398234197869897
gene O 0 2.9728344088653103e-05
and O 0 1.966383024409879e-05
hereditary B-Disease 1 0.9895205497741699
breast I-Disease 1 0.9998843669891357
and I-Disease 1 0.886345624923706
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999077320098877
is O 0 5.955134270152485e-07
established O 0 4.5835946593797416e-07
, O 0 6.242914452059267e-08
the O 0 3.756493782702819e-08
role O 0 1.5330914493461023e-07
, O 0 4.4124750075980046e-08
if O 0 1.8970869319900885e-08
any O 0 5.376658673839074e-09
, O 0 1.1884943695861239e-08
of O 0 3.623681621434116e-08
BRCA1 O 0 4.097378041478805e-05
in O 0 2.696587841910514e-07
non B-Disease 0 2.885717185563408e-05
- I-Disease 1 0.9880286455154419
familial I-Disease 1 0.999829888343811
cancers I-Disease 1 0.9910973310470581
is O 0 3.32027229887899e-06
unclear O 0 1.0256086170556955e-05
. O 0 9.419342859473545e-06

BRCA1 O 1 0.9145069718360901
mutations O 0 0.00820448063313961
are O 0 1.6860064988577506e-06
rare O 0 1.1905750398000237e-05
in O 0 2.2517997422255576e-06
sporadic B-Disease 0 0.01128812599927187
cancers I-Disease 1 0.9806174635887146
, O 0 3.0093851819401607e-06
but O 0 6.288794907050033e-07
loss O 0 0.0001790894166333601
of O 0 5.410727794696868e-07
BRCA1 O 0 0.0013348145876079798
resulting O 0 1.3538846133087645e-06
from O 0 5.062740271455368e-08
reduced O 0 1.9979364651590004e-07
expression O 0 1.1332933524954569e-07
or O 0 4.5182424912582064e-08
incorrect O 0 1.1240130248779678e-07
subcellular O 0 6.994379759817093e-07
localization O 0 6.120788498265028e-07
is O 0 1.9984941701522985e-08
postulated O 0 7.843117373340647e-07
to O 0 1.4899781852761862e-08
be O 0 3.6554528293208932e-09
important O 0 9.419965252277507e-09
in O 0 4.806599207540785e-08
non B-Disease 0 1.0076284524984658e-05
- I-Disease 1 0.9741008877754211
familial I-Disease 1 0.9999265670776367
breast I-Disease 1 0.9999147653579712
and I-Disease 0 0.45556578040122986
ovarian I-Disease 1 0.9999949932098389
cancers I-Disease 1 0.9999216794967651
. O 0 0.0001912871521199122

Epigenetic O 1 0.5641535520553589
loss O 0 0.24027274549007416
, O 0 1.2049180440953933e-05
however O 0 9.618519243304036e-07
, O 0 2.575758628609037e-07
has O 0 8.940209283991862e-08
not O 0 1.842697550102912e-08
received O 0 3.606471210559903e-08
general O 0 1.115789274308554e-07
acceptance O 0 1.4321105936687673e-06
due O 0 4.026400119983009e-07
to O 0 3.968874295878777e-08
controversy O 0 2.508921852495405e-07
regarding O 0 6.22394011884353e-08
the O 0 1.5610847725611166e-08
subcellular O 0 5.537037850444904e-07
localization O 0 3.7817528664163547e-07
of O 0 8.71254570711244e-08
BRCA1 O 0 0.00022803482715971768
proteins O 0 4.424809390002338e-07
, O 0 4.535537456717975e-08
reports O 0 3.4406628657279725e-08
of O 0 7.257558110040918e-09
which O 0 1.1704411662094572e-08
have O 0 1.0594829014110019e-08
ranged O 0 1.708484234086427e-07
from O 0 1.243172143006177e-08
exclusively O 0 4.286255617103052e-08
nuclear O 0 2.995455474774644e-07
, O 0 1.7880999791941576e-08
to O 0 1.4788795077436134e-08
conditionally O 0 4.181812869319401e-07
nuclear O 0 3.3120420539489714e-07
, O 0 2.0009732537573655e-08
to O 0 1.655337911188326e-08
the O 0 7.74374981915571e-08
ER O 0 0.0020523008424788713
/ O 0 0.0001503456151112914
golgi O 0 0.00038472370943054557
, O 0 7.404855040249458e-08
to O 0 3.706481876974976e-08
cytoplasmic O 0 1.7636332358961226e-06
invaginations O 0 9.774156751518603e-06
into O 0 8.771706205834562e-08
the O 0 2.0580695547778305e-07
nucleus O 0 7.58565693104174e-06
. O 0 6.191702141222777e-06

In O 0 4.6814661800453905e-06
an O 0 6.276285375861335e-07
attempt O 0 1.7941147234523669e-06
to O 0 1.622479572915836e-07
resolve O 0 3.5166115139873e-06
this O 0 2.3859243469814828e-08
issue O 0 6.243153194418483e-08
, O 0 4.523079866203261e-08
we O 0 3.29455787095867e-08
have O 0 4.852195445437246e-08
comprehensively O 0 2.0320661860750988e-05
characterized O 0 7.921506949060131e-06
19 O 0 1.5550733678537654e-06
anti O 0 1.8292113963980228e-05
- O 0 0.052259400486946106
BRCA1 O 0 0.03254752606153488
antibodies O 0 6.553190178237855e-05
. O 0 4.9915456656890456e-06

These O 0 1.0785101949295495e-05
reagents O 0 0.00014534291403833777
detect O 0 3.166231908835471e-05
a O 0 2.2454534587268427e-07
220 O 0 4.941539373248816e-07
- O 0 3.169249976053834e-05
kD O 0 0.0006599767948500812
protein O 0 6.022694947205309e-07
localized O 0 6.001388328513713e-07
in O 0 2.641778706902187e-08
discrete O 0 1.924115906604129e-07
nuclear O 0 6.994233103796432e-07
foci O 0 2.7948074148298474e-06
in O 0 2.5025887140373015e-08
all O 0 2.3393525339088228e-08
epithelial O 0 5.757435064879246e-05
cell O 0 3.100545200140914e-06
lines O 0 5.622024445983698e-07
, O 0 5.291608218271904e-08
including O 0 5.497848576396791e-08
those O 0 1.6110020339965558e-07
derived O 0 1.3544101875595516e-06
from O 0 5.559426881518448e-06
breast B-Disease 1 0.7013018727302551
malignancies I-Disease 0 0.48854273557662964
. O 0 3.5610850318335e-05

Immunohistochemical O 0 0.08133895695209503
staining O 0 0.006206410937011242
of O 0 1.9546901967260055e-05
human O 0 0.00023489067098125815
breast O 1 0.7060211896896362
specimens O 0 0.00014608458150178194
also O 0 1.3070579143459327e-06
revealed O 0 4.569077646010555e-05
BRCA1 O 0 0.00043463215115480125
nuclear O 0 3.713425394380465e-05
foci O 0 0.00047800803440622985
in O 0 1.3084088095638435e-05
benign O 1 0.8640847206115723
breast O 1 0.9914072155952454
, O 0 0.00028078112518414855
invasive B-Disease 1 0.895796537399292
lobular I-Disease 1 0.9999021291732788
cancers I-Disease 1 0.9720562100410461
and O 0 4.247211563779274e-06
low B-Disease 0 0.0001186172739835456
- I-Disease 0 0.1713826060295105
grade I-Disease 0 0.022606877610087395
ductal I-Disease 1 0.9992289543151855
carcinomas I-Disease 1 0.9996684789657593
. O 0 0.0001635262742638588

Conversely O 0 0.0015216548927128315
, O 0 2.1945828848402016e-05
BRCA1 O 0 0.0015193151775747538
expression O 0 3.328093271193211e-06
was O 0 3.3983056368924736e-07
reduced O 0 4.864283482675091e-07
or O 0 1.2156294815213187e-07
undetectable O 0 4.828090823139064e-06
in O 0 1.6985701734029135e-08
the O 0 1.3888865169064957e-08
majority O 0 3.2821013462580595e-08
of O 0 2.1751370482547827e-08
high O 0 1.4762395039724652e-06
- O 0 0.0012522604083642364
grade O 0 0.00015333225019276142
, O 0 1.0681351341190748e-05
ductal B-Disease 1 0.9996861219406128
carcinomas I-Disease 1 0.9999369382858276
, O 0 5.961775968899019e-06
suggesting O 0 4.109078872716054e-06
that O 0 4.621994520448425e-08
absence O 0 5.734412980018533e-07
of O 0 2.1045836717803468e-07
BRCA1 O 0 0.005806087050586939
may O 0 3.3226290270249592e-06
contribute O 0 3.827203158834891e-07
to O 0 3.633634193533908e-08
the O 0 4.3913342295809343e-08
pathogenesis O 0 2.7584523195400834e-05
of O 0 2.3007572735878057e-08
a O 0 6.415510256374546e-08
significant O 0 2.283447742001954e-07
percentage O 0 1.777616489562206e-06
of O 0 9.520412618257978e-07
sporadic B-Disease 0 0.03803182765841484
breast I-Disease 1 0.999455988407135
cancers I-Disease 1 0.9766645431518555
. O 0 9.206298273056746e-06
. O 0 1.4520541299134493e-05

